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Chronic obstructive pulmonary disease (COPD) has been and remains a major cause of morbidity and
mortality across the world. The studies reported in this thesis describe some of the important
concepts which have been tested and translated into routine clinical practice in the last 3 decades.
We have now clarified the reflex mechanisms underlying persistent cough in COPD, defined the non¬
specific nature of the sensation of breathlessness in COPD and established that sleep quality is poor
in hypoxaemic patients. Secondary polycythaemia is strongly related to carbon monoxide exposure
from cigarettes which can also impair exercise tolerance. However the principal reason for exercise
limitation in COPD patients is dynamic hyperinflation together with the response of the chest wall
muscles to changing lung volume. Defining bronchodilator responsive patients is difficult as the
chance of being classified as a responder varies with random fluctuations in baseline FE\A. Expiratory
flow limitation at rest is a useful descriptive variable in characterising COPD but is not a predictor of
response to bronchodilator drugs.
COPD exacerbations are still defined by symptom change which does not always agree with the use
of therapy, the commonest outcome reported in clinical trials. However events defined by health
care use show a consistent pattern over time and patients who exacerbate often in one year are
highly likely to do so in subsequently. Exacerbations are associated with worsening lung mechanics
and increased operating lung volume which decreases as the episode resolves. Oral corticosteroids
hasten the resolution of these episodes. However hyperglycaemia in patients with respiratory failure
is a poor prognostic sign despite non-invasive ventilation.
Long-acting inhaled bronchodilators like tiotropium have a sustained bronchodilator effect over the
24 hour day but this does not abolish the normal circadian variation in lung function. Anti¬
inflammatory therapy with inhaled corticosteroids can reduce exacerbation numbers and improve
health status. An effect on mortality has not been conclusively established but seems possible while
all treatments so far tested which ameliorate symptoms and reduce exacerbations seem to modify
decline in lung function. Another anti-inflammatory agent the PDEIV inhibitor roflumilast has similar
effects on exacerbation rate and lung function and may be additive in action. Other non-medical
therapy such as heliox can substantially increase exercise performance but are not yet practical for
routine use. Rehabilitation, by contrast, can dramatically improve exercise capacity without changing
daily activity levels. Despite concerns to the contrary all existing drug treatment is well tolerated and
safe.
Future studies will need to address earlier intervention not only with smoking cessation -a key
intervention of itself- but also with other probably anti-inflammatory therapy which can prevent
disease progression and potentially limit the development of co-morbidities. Improvement in
patients with more established disease is more likely to follow from the better delivery of the




The work in this thesis was conducted by the candidate or by members of his research
group under his direction or as part of clinical trials which he helped devise, lead and
analyse.
This thesis is the culmination of many years spent trying to conduct clinically relevant but
scientifically rigorous research. The work began with the example of the late Sir John
Crofton, was fired by the passion for applied science of the late Professor David Flenley and
always tried to keep its focus on the problems of patients inspired by the example of Dr
Andrew Douglas, the best clinical doctor I have known. I have been more than fortunate in
my teachers and what physiology I have understood is due to the time I spent with Drs
Joseph Milic -Emili and Peter Macklem in Montreal and Prof Neil Pride in the UK. I have
learnt an enormous amount about medicine and life from my colleagues in Edinburgh,
Liverpool and in the many centres around the world where I have developed such fruitful
collaborations. A special mention is due to my younger colleagues in Liverpool, Drs Lisa
Davies, Nikki Stevenson and Paul Walker who have worked tirelessly to deliver complex
clinical and physiological studies and also to my co-workers in Milan, Drs Andrea Aliverti and
Raffaele Dellaca for the energy and detailed knowledge of bioengineering. I am grateful to
my many co-workers for their enthusiasm and continuing insight into all aspects of what we
do together and in particular to ProfWisia Wedzicha for her commitment to understanding
COPD exacerbations, Prof Paul Jones who taught me what little I know about health status
measurement and how to critically evaluate statistical methods in clinical trials and Prof
Jorgen Vestbo who continues to struggle to get me to express complex ideas simply. To
these and my many other friends, thank you.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is now the preferred term for a range of
conditions formerly called among other things, chronic bronchitis, emphysema, chronic
bronchitis and emphysema, chronic airflow limitation and chronic obstructive lung disease.
Defining terminology in this condition has always been a vexatious task which still provokes
controversy. Although acceptable definitions exist for individual components of COPD many
physicians and investigators still hanker after the relative certainty offered by Burrows et al(1)
who identified clinical, physiological and potential pathological subgroups of what we now
define as COPD. This urge to define discrete phenotypes continues(2) and data in this thesis
have contributed to our current approaches to doing so. The recognition that simple clinically
defined characteristics did not predict disease progression led to the inclusion of persistent
airflow obstruction (FEVi/FVC < 0.7) in the definition of COPD although whether this is the
most appropriate threshold is the subject of heated debate.
The studies reported here began at a time when objective measurements such as
spirometry and even the measurement of arterial gas tensions in sick patients were viewed
with suspicion by clinicians while treatment was restricted to advice about smoking
cessation, regular oral xanthine derivatives and, in a minority of cases, inhaled non-selective
adrenergic drugs on a largely as needed basis. Exacerbations were managed with
antibiotics and controlled oxygen plus intravenous aminophylline if the patient was
hospitalised. There were few clinical trials to support these treatment choices and when
larger clinical trials were conducted the focus was on the ability to improve FE\A over 3
months of treatment. Through an accident of fate and a prior enthusiasm for respiratory
medicine I found myself working for the late Prof David Flenley on the MRC trial of long term
domiciliary oxygen therapy in hypoxaemic COPD patients, a project which I subsequently
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helped write up<3). Prof Flenley's firm belief that clinical medicine should be related to
objective measurement and that this would allow the formulation of testable hypotheses of
potential benefit to patients has had a lasting effect on me. As a result I have spent much of
the subsequent three decades trying to define the physiological basis of COPD, the
limitations and potential value of objective testing in classifying patients and in establishing
clear evidence for the role (or lack of it) of proposed treatments in disease management. The
success and failures that followed from this work, together with some observations on the
pitfalls of clinical trials in a chronic condition like COPD, form the basis of this thesis.
The thesis is grouped by theme rather than chronologically, in part because the work
presented was conducted in parallel with studies in other areas but also because the focus
of activity, particularly the clinical trials I developed and led, varied overtime. Data about
assessments and exacerbations began to merge in parallel with the clinical studies in an
iterative process, observations in one area feeding into thinking in another. For this reason,
and to anchor what follows, the original publications begin with the Executive Summary of
the Global initiative in Obstructive Lung Disease (GOLD) updated in 2007 which I helped to
found and where I wrote the section on the management of stable disease together with a
review from 2003 of emerging ideas in COPD which is still relevant, although superseded in
places by newer data. The work presented does not represent all those in which I have
contributed to this field and some of these other papers are referenced in the explanatory
narrative below. The selection here was based on those manuscripts which contributed most
to the field when published and where I played a substantial role in the development,
analysis and writing of the data. Clearly much of this work relies on the collaborative efforts
of many co-workers in my own research group and in the steering committees of the large
multicentre clinical trials from which I have learned so much.
After a general review the thesis focuses on papers which have improved our understanding
of COPD symptoms especially as these relate to exercise capacity and also considers which
physiological tests define clinically useful patient subgroups. The topic of COPD
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exacerbations merits specific attention, both for its importance to patients and as a clinical
trial outcome measure. The next section addresses studies which have created an evidence-
base for therapy, many of which also affected our understanding of the biological behaviour
of this disease. Finally a brief section updates the information presented in the light of
subsequent by our group and others.
BACKGROUND
COPD has been defined by GOLD as a common and treatable condition characterised by
progressive airflow limitation which is not fully reversible and results from an enhanced
inflammatory response to noxious inhaled particles and gases. Exacerbations and co¬
morbidities are commonly seen. This formulation represents the latest refinement of the
definition which has evolved since the first GOLD document was published in 2001(4). It is
currently available online and is also the first version that I have not contributed to directly
since I helped found this group. GOLD has proven to be an important catalyst to research in
the COPD field(5) but was always primarily directed to clinicians seeking advice on patient
management. The most recent published version is presented in paper A. As evidence has
accumulated, the initial recommendations have changed. Thus the early proposal for a
GOLD stage 0, a symptomatic pre-obstructive phase of the disease, was withdrawn in the
2007 version as it was not really sensitive or specific enough to apply to clinical practice.
Nonetheless there are data to suggest that symptomatic patients with airflow obstruction and
minimal spirometric abnormality do show faster loss of FE\A over time(6) so the concept of
early identification and intervention may yet be revisited. Until very recently treatment was
introduced in the GOLD scheme in a staged manner linked to the post-bronchodilaior FENA.
As data in this thesis has shown this is not an optimal approach and would deny helpful
therapy to groups of patients who might otherwise benefit. The reasons for the lack of
association of FE\A and treatment response are one of the topics considered in the review
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by Calverley and Walker(7) which gives an insight into the concepts current in the COPD field
in the early part of the last decade.
A major advantage of the GOLD scheme for classifying the severity of spirometric
impairment was that it provided a framework for expressing data in large epidemiological
studies. The Burden of Obstructive Lung Disease study used this approach to demonstrate
both wide geographic variation in the prevalence of COPD but also significant under¬
estimation of the magnitude of this problem in both developed and developing economies'8',
a finding confirmed in Latin America by the PLATINO group'9'. This points to a diversity of
causes for COPD and there are abundant data to support this idea. Tobacco exposure
remains the dominant factor worldwide but contrary to earlier European perceptions this is
not the only cause of COPD. Exposure to biomass fuels especially wood smoke contributes
to airflow obstruction in many rural communities'10' as does prior tuberculosis'11'.
Occupational factors such as organic dust exposure and welding are important but
unquantified risks'12' while low birth weight and childhood respiratory disease all play a
role'13'. Often several factors interact and this is the proposed explanation of the high levels
of COPD seen in areas like Cape Town in South Africa.
There is familial aggregation of COPD cases'14' pointing to a genetic factor(s) in the
aetiology. Alpha -1-antitrypsin deficiency is the best known and understood genetic risk
factor leading to predominantly lower lobe emphysema in patients with modest or even
absent tobacco exposure. The mechanisms underlying this have now been elucidated'15'
and replacement therapy is available in the US. Being heterozygous for this gene may
confirm a modest increase of risk of COPD'16' but other genetic variants, especially those
associated with polymorphisms of the alpha-nicotinic acid receptor gene and of hedgehog
interacting protein, have been consistently identified in large COPD populations'17'.
Candidate gene and gene-wide association studies point to variation in oxidant -related
genes and in those coding for matrix metalloproteinases as key factors favouring the
development of COPD and doubtless many more targets will be identified. The complexity of
9
these analyses and the potential for gene-gene interaction make this a challenging area of
study.
Mechanistically there is now some general agreement about the major processes involved,
although not about the sequence in which they operate and interact. Persistent inflammation
in all compartments of the lung has been observed with an early predominance of monocytic
cells and an increase in neutrophil transit to the airway lumen in more advance disease. This
form of inflammation is not controlled by even high doses of corticosteroids and a specific
abnormality of histone deacetylase 2 activation has been proposed to explain this(18).
Oxidative stress is a key process promoting inflammation and accelerating lung ageing an
idea supported by recent studies of telomere length in COPD and tobacco exposed
animals'19'. Emphysema seems to be driven by accelerated apoptosis of alveolar wall cells,
although how this relates to the enhanced numbers of inflammatory cells observed in the
remaining tissue or the studies suggesting a vascular origin for this process is yet to be
resolved.
The interaction between these destructive processes and the normal repair mechanisms
lung tissue are also complex. We do not know whether the processes leading to it are the
same in all cases, whether there is a dose response relationship with the initiating insult or
indeed if damage begins at a critical threshold after which other mechanisms lead to disease
progression. The hope of identifying a single critical pathway appears to be a forlorn one and
considering these processes as a dynamic network with multiple interactions at both the
cellular and tissue levels'20' offers the best chance of translating laboratory insights into
progress at a functional level. The terminal bronchiole has been identified as the site of the
earliest damage which can progress to established small airways disease and/or centriacinar
emphysema'21'. Further data about how such a process evolves would be a major advance
conceptually
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The lag between the onset of lung damage and the time when symptoms become apparent
or even until detectable spirometric abnormality appears remains a long one. The
assumption that all individuals progress at the same rate throughout the disease is unlikely
to be correct. This idea was driven by a simplified interpretation of the early data from
Fletcher and Peto(22> showing that the group mean FEXA fell progressively over time
irrespective of the presence of bronchitic symptoms. This concept has shaped our present
understanding and definition of COPD but as is clear from reading the original substantive
publication, not all subjects showed this pattern of loss in lung function. Studies which have
attempted to modify the rate of FEV1 decline are discussed in detail later but this outcome is
clearly a complex one. Although apparently healthy smokers show a decline in FEVt that is
modified when they stop smoking(23), only 40% of patients with established COPD (GOLD 2-
4) are rapid decliners (greater than 40ml per year) with 30% showing no decline or even
improvement in lung function over this period(24). Hence some individuals present with
COPD sooner than others, perhaps because they experience more exacerbations
contributing to their lung damage.
The focus of physiological abnormality has moved from seeing COPD as a disease primarily
of airflow obstruction to one where changes in lung volume secondary to this obstruction are
seen as the primary problem. Thus the FEVi/FVC defines a threshold for considering COPD
but the clinical severity thereafter depends on the impact on operating lung volumes. Loss
of elastic recoil secondary to emphysema together with thickening and fibrosis of the wall of
the small airways increases the closing capacity of the lung and eventually residual volume
rises, with a consequent reduction enforced vital capacity. Subsequently end expiratory lung
volume becomes dynamically regulated at rest and during exercise when patients hyper-
inflate dynamically rather than decreasing their end expiratory lung volume'25'. The resulting
hyperinflation compromises the ability of the respiratory muscles to generate force and
produces changes in chest wall volume which can further add to the overall work of
breathing and are discussed later. Ultimately the matching of ventilation and perfusion is
11
compromised and the arterial oxygen tension falls initially during exercise and subsequently
at rest. Depending upon the mechanical burden on the lungs, arterial C02 tension rises and
patients with sustained hypoxaemia and hypercapnea develop secondary maladaptive
changes which further compromise their clinical wellbeing. In most but not all patients, the
natural history of disease is punctuated by intermittent exacerbations of symptoms which
impair the individual's health for long periods'26' and which are now the focus of significant
research efforts described below.
Recently there has been renewed focus on the presence of co-morbid conditions which
occur in COPD more frequently than would be predicted from exposure to known risk
factors. Lung cancer and pneumonia are both common in COPD(27;28) and their presence
may reflect persistent pulmonary inflammation. Depression'29', metabolic syndrome,
diabetes, osteoporosis and gastrointestinal reflux'30'31' are all significantly associated with
COPD. Cardiovascular disease is one of the commonest associations'32' and there is a clear
relationship between an abnormal pulse-wave velocity and the presence of CT-defined
emphysema'33'. Possible explanations for this include over-spilling of inflammatory
mediators from within the lungs or a shared common previous disposition, either genetic or
acquired, to organ damage in people with COPD.
The remaining parts of this thesis offer a brief general review of the importance and context
of the papers presented.
ASSESSING THE STABLE COPD PATIENT
As outlined in the GOLD summary document (A) a clinical diagnosis of COPD requires a
combination of symptoms and/or appropriate risk factors, together with spirometrically
defined airflow obstruction, ideally recorded after a bronchodilator. The typical symptoms
and signs associated with COPD have been reviewed in detail'34' but there is general
agreement that cough, with or without the production of small amounts of initially mucoid
sputum is the earliest feature. This may be persistent and meet the epidemiological criteria
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for chronic bronchitis (3 months for 2 consecutive years) although the importance of this
definition remains unclear as many people with bronchitic symptoms do not have airflow
obstruction. Nonetheless, identifying patients with a bronchitic history does select a sub¬
group more likely to exacerbate and therefore potentially one more responsive to treatment
reference. The mechanisms underlying cough in COPD remain obscure and were initially
thought to represent a normal response to local increases in mucus production'35'. A more
plausible explanation has come from our studies of cough reflex in asthmatics and COPD
patients [B], We were the first to demonstrate that increased non-specific cough reflex
responses to capsaicin in COPD were similar to those seen in chronic asthma. Our data
suggests that persistent inflammation in the large and medium airways is likely to be a major
contributor to this symptom. The poor relationship of these objective measures to
subjectively reported cough highlights the difficulty in evaluating this troublesome complaint.
Although many other symptoms are reported by COPD patients, the most feared is
breathlessness, either at rest or during exacerbations. Several scales are available to grade
the intensity of this symptom, the most widely applied being the simple MRC dyspnoea scale
which tracks quality of life well in COPD patients'36'. This scale gives an insight into the
functional impact of COPD but some have argued that specific symptom qualities might be
associated with particular diseases. We conducted standardised questionnaires in patients
with COPD, bronchial asthma and idiopathic hyperventilation to provide a range of lung
problems that might test this hypothesis. Using principal component analysis to interrogate
the data, we found that whatever the disease causing the breathlessness the symptoms
complained of were very similar (C). More mechanistic insights of this process, in particular
the importance of reduced inspiratory reserve volume, have subsequently been published1'37'
and emphasise the importance of hyperinflation and a reduced inspiratory capacity in
generating this symptom in patients with lung disease.
Although COPD is defined in terms of airflow obstruction, there is substantial difference
between patient's variability in symptoms such as breathlessness and problems such as
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exacerbation-frequency and overall measures of quality of life which we have usually
evaluated using the St George's respiratory questionnaire (SGRQ). One of the major
purposes of the ECLIPSE (Evaluating COPD longitudinally In Pursuit of Surrogate
Endpoints) cohort study which I helped design and manage was to understand how variable
the clinical presentations of COPD were and whether they related to other objective markers
which evolved over time. This study has provided important insights into the heterogeneous
nature of COPD in hospital practice in the early 21st Century(38) and other papers arising from
it are referred to throughout this presentation.
Although ECLIPSE endeavoured to capture information about a wide range of COPD
phenotypes, all which were excluded for practical reasons were patients who were
hypoxaemic with a history of clinical cor pulmonale. Such patients appear to be less
frequent now than 25 years ago and this likely reflects the changing demographics of COPD
and the availability of better methods of identifying impaired left ventricular function.
Nonetheless, this form of COPD is still commonly seen in many developing countries and
when hypoxaemia is significant, usually below 8.0 kPa, the incidence of clinically important
pulmonary hypertension becomes significant. Work from the UK MRC oxygen trial which I
participated in at the beginning of my research career(3) and from the US nocturnal oxygen
treatment study(39) has established that long term domiciliary oxygen treatment is beneficial
in such patients. COPD patients like this experience significant nocturnal oxygen
desaturation<40) with associated increases in pulmonary artery pressure mainly due to
physiological hypoventilation which worsens their background degree of hypoxaemia during
sleep(41). There continues to be debate about the importance of sleep quality in hypoxaemia
and COPD. The study in Paper D was the first to objectively demonstrate that sleep quality
was poor in COPD and might be improved by giving oxygen. This has been challenged by
other subsequently but a recent met-analysis in less severe patients still found an
association between sleep quality and hypoxaemia, suggesting that this may be an
important factor affecting such patients (McSharry et al under-revision Respirology)_
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Secondary polycythaemia, defined by an increased in red cell mass rather than simply an
elevated packed cell volume, is seen in residents of high altitude where the arterial p02 is
reduced and was noted as part of the "blue and bloated" hypoxaemic COPD patients'
problems. However, there was not a simple relationship between arterial p02 and red cell
mass. The main factor accounting for the variability between patients proved to be the
extent of cigarette smoking and particularly carboxyhaemoglobin in the blood as described in
Paper E. Patients who continued to smoke did not show a fall in red cell mass when given
oxygen therapy, one of the few physiological pointers confirming the benefits of smoking
cessation on the immediate response to treatment in COPD. Once COPD patients had their
carbon monoxide levels raised to values equivalent to that seen during cigarette smoking,
there appeared to be a reduction in exercise performance, this measured by the 12 minute
walking distance (F). Rather surprisingly these studies have never been repeated and given
the modest number of patients studied, it would be reassuring if they had been. Possibly the
advice that all patients should stop smoking for the many other valid reasons is sufficient in
itself not to challenge these observations. Despite the relatively simple methodology, we
have been able to show important short term improvements in exercise, performance and
symptoms in a similar number of patients studied with a 6 minute walking test after
bronchodilator treatment and oxygen(42).
The assessment of COPD has proven controversial. Routine assessments of lung volumes
helps to characterise the patient but tends to be confined to specialist centres and provides
an overall impression of physiological disturbance rather than suggesting specific
interventions. For many years there has been enthusiasm for using the spirometric response
to short-acting inhaled bronchodilators to establish the 'reversibility' of the disease to
treatment and, by extrapolation, identify which patients will not get better. This approach
proved to be wrong, although my group initially promoted the idea and subsequently have
spent much time trying to correct the misconceptions to which we inadvertently contributed.
Our first aim was to establish in an unselected group of COPD patients how often
15
reversibility was seen(43) and to determine whether corticosteroid treatment improved lung
function in COPD. These results appeared to separate responders using the widely adopted
criteria of a percentage improvement from baseline and we found that those showing this
improvement were more likely to show increases in FEV-, after 2 weeks of oral
corticosteroids. At this time routine treatment for COPD did not include inhaled
corticosteroids and so we studied a relatively treatment naive population. As a result many
people accepted the value of bronchodilator testing in COPD, it was recommended as part
of routine assessment by the British Thoracic Society and ultimately became incorporated in
the Quality Outcomes Framework for payment of General Practitioners in England.
Unfortunately our data had been taken beyond its original purpose. Subsequent studies
particularly those we embedded in the Inhaled Steroids in Obstructive Lung DiseasE
(ISOLDE) study, showed that irrespective of the criteria used to define reversibility or the
dose of drug used to induce it, there was substantial day to day variation in patient
classification and using the initial response to two bronchodilator drugs did not identify
patients with different clinical outcomes [G]. These findings were confirmed in the UPLIFT
study population(44) where a decrease in the absolute FENA increase in more severe disease
accounted for the less frequent occurrence of reversibility in GOLD stage IV. We have
confirmed this in our ECLIPSE cohort which showed similar degrees of absolute spirometric
change post-salbutamol in a GOLD stage II patients and healthy smokers. The measures of
reversibility chosen are very sensitive to spontaneous, possibly physiological, fluctuations in
pre-test FEVi, a finding in both ISOLDE and ECLIPSE. Whether there is value in classifying
large groups of patients by their 'average' reversibility status remains unclear. There was
some evidence to support this as less reversible patients showed a slower decliners in FEVi
in ECLIPSE(24) but even in such well characterised patients it is hard to exclude the
confounding effect of baseline FEV-t entirely. Studies of the spirometric response to oral
corticosteroid in ISOLDE failed to identify a responsive asthmatic subgroup or indeed any
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relationship with subsequent clinical progress(45). As a result of these data reversibility
testing is no longer recommended for the routine assessment of COPD patients.
Identifying the best measure of response to treatment has been the topic of several of our
studies. Approximately 23% of COPD patients show a greater improvement in FVC than
FENA after a bronchodilator and this is particularly likely if they have emphysema or a low
pre-test FEV/46'.However FVC is a relatively effort-dependent test. Inspiratory capacity (IC)
has a better between test reproducibility than FVC(47) and we found IC to be more
responsive to high dose bronchodilators in severe COPD patients than was FEVt [H], This
improvement in lung volume was accompanied by changes in breathing pattern that
favoured better lung emptying. We did not see any change in the number of patients
showing expiratory flow limitation (EFL) during tidal breathing as identified by the negative
expiratory pressure test (NEP). EFL is an important determinant of dynamic hyperinflation
and impaired exercise capacity in COPD(48). Testing using the NEP method is relatively
complex and can only sample a limited number of breaths. Working with colleagues from the
Politecnico di Milano we developed a non-invasive method based on measurements of
forced oscillatory mechanics to establish whether a breath was flow limited [I]. This proved to
be very reliable when related to the 'gold standard' of invasive balloon catheterisation and
could be applied to multiple breaths therefore allowing an estimate of the patient's degree of
tidal EFL. This approach involved an analysis of each breath by its behaviour drug
inspiration and expiration. Previous studies using a related measurement of mechanics by
the impulse oscillation algorithm found that there was little change in measured resistance
after bronchodilator drug[(49). Using within breath analysis and allowing for the effects of tidal
EFL we could demonstrate much larger effects of bronchodilators at rest on COPD than had
been seen with alternative methods [J], Studies re-analysing the ECLIPSE data are now
underway in the hope of better defining a physiological phenotype based on the presence of
EFL at rest.
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As impairment of exercise capacity is one of the commonest findings in COPD it was
reasonable to consider whether this was a useful outcome measure to assess the effect of
treatment. One of the first studies to use self-paced walking tests as an outcome in COPD
research was our examination of the effects of oxitropium bromide, an anticholinergic drug,
in 24 patients with stable COPD [K], Not only did we see a positive effect on lung function
and exercise performance, a finding we and others have confirmed with other drugs in this
class(50), but this as the first occasion when we demonstrated that improvements in exercise
capacity were unrelated to the degree of change in FE\A. Subsequently a compelling body
of evidence has been presented for the central role of changes in operating lung volume as
reflected by reductions in IC during exercise as a central mechanism in exercise limitation in
COPD(51). We hypothesised that the adaptive response of the chest wall to these volume
changes might vary and explain some of the apparent discrepancies between lung function
and exercise capacity which have been frequently noted in COPD(52). Working with another
group of colleagues in Milan who developed a non-invasive method to measure chest wall
volume during exercise (optoelectronic plethysmography OEP), we undertook an
observational study of stable COPD patients recording how they partitioned any volume
change in the chest wall between the ribcage and abdominal compartments. Although most
patients showed the expected hyperinflation in the chest wall during exercise a minority tried
to retain the normal breathing pattern of decreasing operating volumes below the resting
end-expiratory volume as exercise began. In the face of fixed EFL this was a poor choice
and these euvolumic patients had a worse exercise performance than did the hyperinflators
[L], This behaviour is associated with thoracic gas compression and blood shifts away from
the central circulation, changes seen in all more severe patients including those who
hyperinflate their chest wall. The resultant reduction in oxygen delivery to exercising limb
skeletal muscle and impairment of diaphragm perfusion contribute significantly to exercise
impairment'53'. We extended our observations to look at whether changes in the behaviour of
the chest wall explained the variability in the response to bronchodilators noted in study K.
This proved to be the case as we saw that while almost all subjects improved tests of
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expiratory flow and decreased their operating lung volume after Salbutamol, a minority had
worse exercise performance because they changed their breathing pattern from a
hyperinflating to a euvolumic response'54'. This suggests that some of the ways that we cope
with changes in lung mechanics may be learned behaviours and that acute testing may lead
clinicians to incorrect conclusions about the benefits of treatment.
Clinical observations have long suggested that COPD patients may show paradoxical in-
drawing of their lower ribcage during inspiration and that these patients are more breathless
than others with similar spirometric abnormaility. We applied our OEP methodology to test
this idea objectively. Using an appropriate age-matched control group to determine the
normal chest wall behaviour in healthy older subjects we established values for the presence
of rib cage paradox, demonstrated that when present it persisted during upright exercise and
was associated with a pattern of early onset of dynamic chest wall inflation during exercise
[M], These patients were more likely to be limited by breathlessness thereby providing a
physiological rationale for a longstanding clinical observation.
Perhaps the most important insight into exercise testing in COPD has come from the belated
realisation that an improvement in exercise capacity is not the same as an improvement in
daily activity'55'. The reasons why this should be so are now being studied but observations
from study K may be relevant. In this and indeed all subsequent studies where the patient
could select the difference walked there is an individual variation in the degree to which
patients report improved dyspnoea at the end of exercise. Some will walk to the same
distance for less dyspnoea while others walk to the same symptom intensity but cover a
greater distance. Moreover these are tests conducted on the level not an incline as applies
to stairs where other factors like fatigue in exercising muscles with a compromised blood
supply may be more important. Future studies will have to look at these more challenging
endpoints if patient well being is to be improved more effectively.
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EXACERBATIONS
Although long recognised by patients as clinically significant episodes[] it was only in the
mid-1990's that exacerbation rate was included as a secondary endpoint in a major clinical
trial, the ISOLDE study which I developed together with Professor Sherwood Burge.
Although there were attractions in looking at a symptom-based endpoint as used in the
antibiotic trial of Anthonisen(56) and the comprehensive data arising from the London group
led by Prof Wedzicha(57) at the time of ISOLDE analysing and interpreting symptom data in a
large number of participants over a long period of follow up was technically daunting.
Operationally we defined significant exacerbations as those requiring treatment with
antibiotic and/or oral corticosteroids with severe episodes being those leading to
hospitalisation or death. A subsequent consensus conference in which I participated
supported this approach(58). Our data from ISOLDE showed that health status, both generic
and disease specific were impaired in COPD(59) and that both the baseline health status and
the rate at which it deteriorated over time were related to the number of exacerbations
reported by the patient(60).However deciding when exactly an exacerbation had occurred and
hence who might benefit from treatment proved more complex than we first thought.
In a post-hoc analysis of the ISOLDE data we found that treatment with inhaled
corticosteroids decreased the frequency of exacerbations in patients with an FE\A <50%
predicted [N], a value which subsequently became accepted as a treatment threshold. In fact
as the paper shows had a different metric (number of patients with >1 event per year) been
used then the apparent effect of the FENA, level was lost. These equivocal findings should
have alerted us to the dangers of interpreting exacerbation numbers in a clinical trial. When
symptom diary cards were used to determine the presence of an exacerbation the effect of
treatment with bronchodilators and corticosteroids were supported but there was
discordance between events identified by symptoms and those recorded as a health care
use event [O],
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Health care utilisation events were less common but more economically important and so
remain the primary outcome of clinical studies. However, exacerbations are not normally
distributed in time and are now known to exhibit clustering'61'. As a result, summary
statistics in clinical trials can be misleading as shown in a series of articles by Suissa(62> and
ourselves which led to the analysis published by Keene et al(63). As a result, when
expressing event rates we now apply appropriate statistical methods.
Our knowledge of exacerbations has grown rapidly in the last decade. In a post hoc
analysis of data from the TORCH (TOwards a Revolution in COPD Health) data, the largest
exacerbation data set reported so far, we identified a range of predictive factors including
baseline lung function, severity of breathlessness, prior history and body mass index. A
further major factor we noted was seasonal variation which tracked temperature changes in
both the Northern and Southern hemispheres (P). Exacerbation rate in the tropical climate
showed little variation over the year, although whether this reflected the smaller contribution
of centres in this area or a different driving factor such as changes in local pollution'64'
remains unclear. Using the large observational data set from the ECLIPSE study, we
established that 70% of patients have a stable pattern of exacerbations over time, either
tending to exacerbate frequently or not at all (Q). The prior history of exacerbations was the
dominant predictor of the likelihood of recurrence, although lung function health status and a
history of gastro oesophageal reflux were also important. This study is the clearest
demonstration that baseline lung function does not preclude either being a frequent
exacerbator or even being hospitalised as a result and this has had implications for our
approach to clinical management.
Defining the changes in lung mechanics that accompany exacerbation had largely been
confined to ventilated patients in intensive care units. We were the first to report detailed
studies of lung mechanics in non-ventilated but hospitalised COPD patients (R). We found
that changes in spirometry after admission minimal over the first 3 days while changes in
inspiratory capacity were larger, could be detected almost immediately after administration of
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a bronchodilator and track changes in patient-reported breathlessness. Respiratory system
reactance measures were equally sensitive and offer the potential of a non-volitional marker
to monitor the progress of exacerbations. Non-invasive ventilation has been a highly
effective life-saving treatment in the management of respiratory acidosis secondary to
hypercapnoea in COPD exacerbations(65). However, not all patients benefit and identifying
those at risk of NIV failure is important when planning management. In paper S, we
established that tachypnea and hyperglycaemia on admission independently predicted those
patients with a poor clinical outcome with some modest improvement in predictive power
when these simple clinical measurements were combined. These markers of lung function
and systemic response were better than previously recommended indices such as severity
of hypercapnea or acidosis when stratifying risk. Further work exploring these simple end
points appears merited.
Treatment of acute exacerbations has changed little over the course of this thesis, although
the principles of controlled oxygen are still not always appreciated by emergency room
staff(66). Antibiotics and bronchodilator drugs form the mainstays of management but for
many years there was uncertainty about the relative merits of supplementary aminophylline
and routine oral corticosteroids in the management of exacerbations. Two studies from our
group have resolved this. In one, patients admitted with uncomplicated exacerbations of
COPD were randomised to intravenous aminophylline or placebo in a double blind
fashion(67). There were no differences in clinical outcome, save for a clinically
inconsequential reduction in arterial C02 tension in the aminophylline group. Given the
toxicity and lack of effect of this therapy, it should not be used. The second study (T) was
published almost the same time as a multi-centre veteran study from the USA which drew
similar conclusions'68'. We randomised patients to either a course of 30mg of Prednisolone
for 10 days on admission or an identical placebo. We found that those treated with the oral
corticosteroid showed a more rapid improvement in FEN^, a shorter hospital stay but slightly
higher blood sugar values during the recovery phase. The magnitude of improvement we
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saw was similar to that seen in the US study which used much higher doses of
corticosteroids. Our data suggests that a shorter treatment period might be equally
beneficial but this has not been rigorously explored and is an area that needs investigation.
Our group also contributed to the move towards managing uncomplicated exacerbations of
COPD in the community. In one of the key randomised clinical trials, we showed that it was
both safe and acceptable to discharge patients from Accident & Emergency with support
who would otherwise have been hospitalised"69', a finding supported by other UK studies'70'.
Although changing the place of care has advantages for patients and potentially offers cost
saving, it does not diminish the impact of exacerbations themselves, nor decrease their
number, which remains an important goal in future management plans.
TREATMENT OF STABLE COPD
As noted earlier the treatment options open to COPD 30 years ago were very limited. The
MRC trial of domiciliary oxygen treatment, which I contributed to and helped author, was one
of the first studies to consider physiologically rational treatment in patients defined as having
COPD by spirometry. It achieved its goal of showing mortality difference between groups
and could now never be repeated for ethical reasons, which is perhaps as well as the
intervening years have seen an almost exponential rise in the complexity, regulation and
monitoring of clinical trials which has begun to limit their value as a tool to define routine
clinical practice. The substantial expense associated with this means that only
pharmaceutical companies have the resources to support investigations which produce
immediate changes in management, and inevitably this has meant that most studies have
looked at pharmacological solutions rather than examining the even more challenging area
of integrated care. Sadly the Medical Research Council has not funded a major clinical
study in COPD since the oxygen study of 1980's. Despite this we now have a much larger
evidence base on which to make clinical decisions and the main lessons which we have
learned, both from the outcomes of the studies and the process of doing them which is
summarised in a review published in 2007(71) which predated the UPLIFT trial'72' about which
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I have made further editorial comment(73). The heterogeneity of COPD which has already
been discussed means that large numbers of patients have to be studied for relatively long
periods of time if a generalisable conclusion is to be drawn from any treatment intervention.
Indeed looking at clinically important outcomes such as exacerbation rate, and even more so
when considering mortality, which is happily a relatively infrequent event, means that
substantial resources have to be committed to undertake an adequately powered study. A
further less appreciated methodological problem has been the impact of including a placebo
group when studying a drug broadly within the class of one which has been used off label to
manage the disease already. This often means changing the patient's medication at the
outset of the study, if the therapy is effective then the patients often become clinically less
stable and the patients treated with placebo are more likely to experience adverse events
and withdrawal from follow-up, leaving a 'healthy survivor' population among the placebo
treated patients. This problem was first described in paper U where patients who withdrew
from the placebo group had a worse health status and lung function, and showed a more
rapid deterioration in their clinical state over time than those who did not. As the same was
not true for those on the active treatment it was clear that the populations being compared at
the end of the study were not really the same. Similar findings are seen in other studies and
the sources of clinical bias are now well recognised by those in the field(74), but much less
appreciated by others who simply pool the data to estimate outcomes.
One of the major treatment changes of the last two decades is the development of long-
acting inhaled bronchodilators with relatively low side effect profiles. The data in paper V
was the first to show that the long-acting antimuscarinic drug tiotropium had a truly 24 hour
action, irrespective of its time of dosing and this was present after repeated treatments. Of
greater interest scientifically was the fact that this drug, which should have abolished the
action of cholinergic innervation on the airway smooth muscle, did not change the nocturnal
fall in lung function. The magnitude of this diurnal variation in airway calibre was similar in
the COPD patients who start from a lower baseline function, to that seen in health(75). These
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data provide further evidence that the airways move muscle is not abnormal in COPD and
the problems relate to changes in lung structure which produce the fixed airflow obstruction.
A second major theme has been to determine whether anti-inflammatory therapy, a rational
treatment for a disease associated with persistent pulmonary inflammation'76', has a clinical
role either as a monotherapy or in combination with another agent such as a long-acting
beta agonist. Initial reports of monotherapy with inhaled corticosteroids appeared to be very
encouraging'77' but there were concerns that the population study included many who would
be classed as having bronchial asthma rather than COPD. The large EUROSCOP study in
patients with COPD who continued to smoke (78) and the smaller Copenhagen City Lung
Study in patients with much milder disease'79', both failed to show any effect of inhaled
corticosteroids on the rate of decline of lung function, the most commonly used index of
disease progression. Individuals identified in these studies were largely drawn from
population studies or from volunteer investigations of patients who wished to stop smoking
but could not. Together with Professor Burge in Birmingham I developed a protocol
subsequently led the ISOLDE study which compared lOOOmcg of Fluticasone Propionate
inhaled daily over three years and an identical placebo in patients with significant COPD,
predominantly gold stages three and four (W). Again the primary outcome was the rate of
change in FENAi, and this was not modified by these drugs. However, as noted previously
data about the improvement in health status'59' and reduction in exacerbation rate [N] with
treatment did impact clinical practice but were not sufficient to lead to widespread licensing
of inhaled corticosteroids for this purpose.
The TRISTAN study described in paper X involved twice the number of patients as in
ISOLDE, but the study period was for one year. This was a four armed double blind placebo
controlled parallel group trial comparing fluticasone propionate, the long-acting beta agonist
salmeterol, the combination of the two drugs and placebo, all delivered in single inhalers, to
COPD patients with a history of prior exacerbations. Again there was evidence of differential
drop out with more people withdrawing from the placebo arm than from the active limbs of
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the study, meaning that estimates of the effects size, particularly in clinical variables, were
conservative. All the active treatments were associated with improvements in lung function
which seemed to be a more sensitive way of distinguishing between them, reflecting some of
the issues of statistical power already discussed. Moreover there was evidence of a
significant improvement in health status in those patients receiving placebo which made it
hard to achieve the minimally clinically important change in the active treatment groups,
even though all active treatments were statistically significantly better than placebo for this
outcome. More evidence of the benefits of inhaled steroids and long-acting bronchodilator
combination treatment came from another study (Y) which compared budesonide and
formoterol as the inhaled steroid and LABA drugs. In this study we tried to overcome the
problems with variable health status by optimising clinical management with a period of oral
corticosteroid treatment, as used in the ISOLDE study, and also regular long-acting
bronchodilators before the randomisation. The effects on health status were much more
dramatic here and the patients included were sicker and had more exacerbations than was
seen in the TRISTAN study. The effect of treatment with a combination inhaler was also
more clear cut, although interestingly the inhaled steroid alone reduced the number of
exacerbations treated with oral corticosteroids, a finding which seems to be the hallmark of
all anti-inflammatory therapies in COPD.
By far the largest and most ambitious study of this type was the TORCH study which I
designed and led (Z). Here the aim was not just to see if treatment modified health status or
exacerbations, but whether regular treatment with a long-acting beta agonist - inhaled
corticosteroid combination, could reduce mortality. In such a large study we also had much
more power to identify less frequent adverse events than was the case in any of the previous
trials. We studied over 6000 patients in multiple centres around the world, with
approximately 1500 in each limb of the study. These numbers were based on the estimates
mortality derived from pooling previous studies of inhaled corticosteroids'80', and in
retrospect were probably too optimistic given the steady improvement in mortality over time
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since patients were recruited into these earlier trials. The patients were followed on an
intention to treat basis over three years in this four arm study which mirrored the design of
the TRISTAN trial. We were the first pulmonary study to develop an independent clinical
end points committee whose approach to classifying causes of death has been published'81'.
The study also incorporated specific measures of bone mineral density and eye
examinations to evaluate the risk of osteoporosis and cataracts in patients with COPD taking
inhaled corticosteroids. We found that the mortality of patients randomised simply to short
acting bronchodilators and/or theophylline treatment was lower than we had anticipated, with
15% dying over the three year study compared to our estimate of 18%. This not only
reflected changes in overall disease management but the fact that many patients who
withdrew from the trial then went on to take one of the active treatment arms in an open label
fashion, but by the rules of the intention to treat analysis were still considered as belonging
to the placebo group. Moreover the operation of the data and safety monitoring committee
meant that the timing of the second analysis compromised the statistical ability of the study
to show a difference. Frustratingly, despite all these problems the difference between active
and placebo treatment approached significance very closely with a p value of 0.052. As we
had set our p value at 0.05 at the outset of the study, we had to concede that we had not
shown a conclusive benefit, although the assertion made by some that there was no
evidence for the mortality effect appeared to us to err in the opposite direction.
The abundant statistical power for other secondary end points did allow us to conclusively
establish that combination treatment was more likely to reduce exacerbation rates and
improve health status than placebo or the individual components. In a pre-planned analysis
conducted after the main results were published we found that all the active treatments
reduced but did not abolish the accelerated decline of lung function which had been the
primary goal in other clinical trials AA. Why this happened is not immediately apparent but a
reduction in exacerbation frequency is a plausible candidate mechanism. Once again the
importance of studying large patient numbers is clear. This effect on lung function decline of
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any active treatment may explain why tiotropium in the UPLIFT trial failed to modify lung
function decline in all except the treatment naive patients. The final major trial in this
sequence studying beta agonists and inhaled corticosteroids was the INSPIRE study in
which a combination of long-acting beta agonist and inhaled steroid was compared with
tiotropium monotherapy over a two year study in patients with a history of exacerbations'82'.
We did not see not see any difference in exacerbation rate, although intriguingly there were
significantly fewer exacerbations treated with oral corticosteroids in the combination arm,
and conversely more treated with antibiotics than was the case with tiotropium. Once more
we used a run-in period with oral corticosteroids, and this did seem to simplify the
interpretation of the health status data which were better on the combination treatment.
Rather surprisingly more patients withdrew on tiotropium than on combination, and again this
compromised the ability of the study to give us clear cut an answer on the exacerbation
issue as we had hoped.
Other approaches to anti-inflammatory treatment have been developed but most of these
failed to either be effective or tolerable in man. An exception has been the use of
phosphodiesterase IV inhibitors which exploit the wide distribution of this enzyme within
tissues to modify inflammation. Even here the majority of compounds have failed to
progress but one of them, roflumilast, has now undergone extensive clinical studies, many of
which I designed and directed. After a six month dose ranging study in COPD(83) we studied
500mcg roflumilast or placebo in patients with GOLD stage 3/4 disease without necessarily
having an exacerbation history over a one year period. These data were disappointingly
negative'84'. We saw small improvements in post-bronchodilator FEV! which was statistically
significant, but of themselves probably clinically unimportant. We did not see any difference
in the exacerbation rate but this was significantly lower than we had anticipated from earlier
studies with inhaled corticosteroids. There was evidence for a reduction in the number of
episodes treated with oral corticosteroids, and also positive impacts in patients with more
severe disease and in those with chronic bronchitis. When the data from this study were
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pooled with an identical but currently unpublished US trial, we were able to identify a
potentially responsive patient sub-group(85). This led to the construction of two replicate
studies of this post-hoc-defined population to confirm that the apparent effects seen initially
were present. The results of this clinical trial are described in paper BB where all patients
had a history of chronic bronchitis and prior exacerbations before receiving treatment. Our
original sub-group findings were confirmed in both studies with a significant reduction in
exacerbation rate amounting to around 20% of the baseline value. This was present
irrespective of the use of background inhaled bronchodilator treatment^6'. As an oral
therapy roflumilast had more adverse events particularly pharmacologically predictable
diarrhoea, nausea and headache. These were generally self-limiting, but roflumilast
treatment was associated with weight loss irrespective of the presence of these other
symptoms. This appeared beneficial in the most obese sub-group and largely consisted of
fat mass decreasing, but the use of this drug in patients who are already underweight must
be viewed with caution. A further large study is underway to determine the beneficial effects,
or otherwise, of roflumilast on top of maximal treatment with existing bronchodilators and
inhaled corticosteroids.
Not all treatments for symptomatic COPD need be pharmacological. Increasing the
concentration of inspired oxygen during exercise can improve six minute walking distance
and reduce breathlessness, although these effects are most evident in severe COPD and
supplement the similar actions seen after an acute bronchodilator<42). Oxygen administered
by tight face mask can increase endurance shuttle walking time in normoxemic COPD.
Reducing the gas density with heliox, which permits better lung emptying at high expiratory
flows can further increased shuttle walking distance as shown in paper CC. In this
adequately powered study the combination of increased oxygen concentration and helium
produced dramatic improvements in exercise performance, particularly in patients with low
baseline FEVv Unfortunately the limitations to the supply of helium and the need for tighter
fitting face masks still limit the general application of this promising and potentially dramatic
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treatment. Many patients, particularly in the UK, use oxygen to decrease breathlessness
either acutely during an exacerbation, or most commonly after exercise, an approach
advocated in earlier studies of this treatment'87'. A careful clinical and physiological study by
Stevenson presented in paper DD acute administration of oxygen by face mask after a
standardised exercise stimulus did not influence the rate at which breathlessness resolved
or its severity, whether the oxygen was administered through a mouth piece or a face mask.
There is clearly a significant placebo effect here, although there may be some effects from
cooling of the face which reduces the sensation of breathlessness. Given the expense and
inconvenience of having oxygen in the home we should focus on better patient education
rather than offering cylinders or concentrators in what appears to be an expensive placebo.
One of the major non-drug therapies is pulmonary rehabilitation which is very effective in
improving exercise capacity and health status, at least in those ho complete the
individualised programme without experiencing an exacerbation'88'. These effects are larger
and more noticeable to the patient than those seen with drug treatment but their magnitude
declines over time to values similar to those not undergoing rehabilitation. We confirmed that
significant improvement was possible after rehabilitation but although the capacity to perform
walking exercise increased this did not necessarily translate into more daily activity at home
(EE). The greatest change in daily activity occurred in patients with less severe airflow
obstruction highlighting the need to understand the individual patient's problems when
prescribing any therapy.
TREATMENT SAFETY
In general the drugs used to treat COPD are very safe and produce much less in the way of
side effects than agents employed in the 1960's and 70's reflecting the low absolute doses
delivered to the airways. Despite this there have been concerns about the risks of treatment
in COPD patients, which is understandable given the multiple co-morbidities which
accompany this disease. The problems associated with roflumilast have already been
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mentioned, but particular concerns are being raised about long-acting beta agonists and
inhaled corticosteroids. Concerns about long-acting beta agonist use continue to surface in
the USA where these drugs are perceived as being more dangerous than they are thought to
be in Europe or the rest of the world. The reasons for this are complex, but have indirectly
impacted the COPD field where one rather selective meta-analysis has proposed that LABA
use is dangerous in COPD. Although this study was inaccurate it did raise concerns about
the risks of treatment, and it was reassuring to see that not only was there no evidence for
increased cardiovascular death rate in the TORCH study but in fact patients receiving these
drugs singly or in combination with inhaled corticosteroids had a lower mortality, as shown in
paper FF. If anything, the benefits of treatment were larger in patients who had more
cardiovascular risk, and this has led to a very large international prospective trial to test this
hypothesis in patients with moderately severe COPD. The long-time course over which
some adverse events develop makes the study in clinical trials difficult, although database
information is also potentially confounded by disease severity and prescribing bias. TORCH
offered relatively long exposure to inhaled corticosteroids in a large number of subjects and
the results where reassuring as were the data from more detailed studies of bone mineral
density and cataract risk in the US sub-group(89). Although osteoporosis and osteopaenia
were common in COPD there was no relationship to prior inhaled or oral corticosteroid use.
Patients receiving inhaled corticosteroids did not have an accelerated loss of bone mineral
density and reported the same number of new cataracts. However there was clear evidence
that treatment with regimes including fluticasone propionate was accompanied by more
reports of pneumonia(90). Not all pneumonias were confirmed by a chest X-ray but the signal
was still present when the analysis was restricted to radiologically definite events.
Surprisingly mortality due to pneumonia was not increased and this has subsequently been
confirmed in observational studies of hospitalised patients using inhaled corticosteroids for
COPD(91). The INSPIRE trail confirmed the association of pneumonia and fluticasone
propionate but had the advantage of recording symptoms daily on a diary card which
allowed us to examine events in the weeks before the diagnosis of pneumonia was made.
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These data are presented in paper GG which shows that similar numbers of pneumonias in
the corticosteroid and tiotropium groups present after a few days of symptoms but the
excess of events during corticosteroid therapy is accounted for by episodes which would
count as symptomatic and/or treated events where symptoms do not resolve fully, often
persisting for many days before a diagnosis of pneumonia is made. This may be a specific
issue with fluticasone propionate as it was not seen when a large database of budesonide
trials were reported'92'. Whatever the mechanism the effect in patients appears to be less
serious than at first thought.
FUTURE DEVELOPMENTS
COPD remains a global problem that is likely to slowly decline among men in the developed
economies but will increase among women and in both sexes across the developing world.
The present BOLD surveys set a benchmark against which change can be assessed and will
need to be repeated periodically to chart the size of this global epidemic. In the UK non¬
smoking COPD, whether work-related, secondary to childhood respiratory disease
(especially of extreme prematurity) and to regular non-tobacco inhaled drug use, will become
more important. The interaction of COPD and obesity will need to be addressed as obesity
can have some protective effects on mortality and dynamic hyperinflation in COPD'93' but
carries its own risk of serious co-morbidity as well as a potential for misdiagnosis
spirometrically which can make it hard to know if similar severities of lung disease are being
compared. A greater understanding of early disease and the importance of respiratory
bronchiolitis, small airway loss and accelerated aging mechanisms'19' may allow us to
separate the effects of disease progression from those of the primary mechanisms causing
disease in the first place. The association of emphysema and cardiovascular disease
suggests that key co-morbidities may occur in specific patient subsets and lead us to
undertake CT scanning more readily than in the past Although no simple biomarker has yet
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proven itself in terms of patient stratification new methods of identifying flow-limitation and
recording lung mechanics noninvasively may be successfully adapted to patient care and
enable effective telemonitoring to identify exacerbations at an early stage in their natural
history.
Therapeutically we need to be sure that treatment is appropriate for non-smoking COPD all
the studies in this thesis recruited typical current or ex-smokers. Effective smoking cessation
remains a key goal and a general health care challenge. More specific approaches to
vaccination perhaps by targeting innate immunity may reduce exacerbations as well as
pneumonia episodes as well as decreasing lower airway colonisation. Expensive and
potentially highly potent biological may decrease exacerbations through a variety of
mechanisms but are only likely to be financially and clinically viable if they reduce re-
hospitalisation in severe disease. A range of interesting small molecules with anti¬
inflammatory potential including CXCR2 and p45 MAPkinase antagonists are in
development but translating these into a viable clinical endpoint remains a challenge given
the late stage at which COPD presents clinically. However these drugs should be easier to
test in clinical trials as they will need to be effective on top of standard therapy, at least
initially.
The same, sadly, is not the case for the next generation of once daily inhaled
bronchodilators and corticosteroids which multiple pharmaceutical companies, like blind men
fighting over combs, are now committed to bring to market. Hopefully some of the effort
going into this will generate more useful knowledge about COPD which can inform general
clinical practice. Improving the care of hospitalised COPD patients may involve further
technical developments in non-invasive ventilation but the major gains at present will flow
from better organised and more holistic care rather than new drugs.
COPD is still defined as a progressive disease but recent data from the ECLIPSE study has
challenged that paradigm. In a third of cases(24). Spirometry was stable or improved over the
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3 years of follow up. Whether this reflects better treatment, biological predisposition, a
pattern of intermittent rather than progressive deterioration or simply the many different
pathways by which each patient reaches that degree of airflow obstruction is not known.
However it does offer a more optimistic vision of what is possible for COPD sufferers in the
early part of the 21st century. The next generation of studies will need to understand these
data better and should focus on increasing the number of people who can live with rather
than die from chronic obstructive pulmonary disease.
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Chronic obstructive pulmonary disease (COPD) remains a major
public health problem. It is the fourth leading cause of chronic
morbidity and mortality in the United States, and is projected to rank
fifth in 2020 in burden of disease worldwide, according to a study
published by the World Bank/World Health Organization. Yet,
COPD remains relatively unknown or ignored by the public as well
as public health and government officials. In 1998, in an effort to
bring more attention to COPD, its management, and its prevention,
a committed group of scientists encouraged the U.S. National Heart,
Lung, and Blood Institute and the World Health Organization to
form the Global Initiative for Chronic Obstructive Lung Disease
(GOLD). Among the important objectives of GOLD are to increase
awareness of COPD and to help the millions of people who suffer
from this disease and die prematurely of it or its complications. The
first step in the GOLD program was to prepare a consensus report,
Global Strategy for the Diagnosis, Management, and Prevention of
COPD, published in 2001. The present, newly revised document
follows the same format as the original consensus report, but has
been updated to reflect the many publications on COPD that have
appeared. GOLD national leaders, a network of international
experts, have initiated investigations of the causes and prevalence
of COPD in their countries, and developed innovative approaches
for the dissemination and implementation of COPD management
guidelines. We appreciate the enormous amount of work the GOLD
national leaders have done on behalf of their patients with COPD.
Despite the achievements in the 5 years since the GOLD report was
originally published, considerable additional work is ahead of us if
we are to control this major public health problem. The GOLD
initiative will continue to bring COPD to the attention of govern¬
ments, public health officials, health care workers, and the general
public, but a concerted effort by all involved in health care will be
necessary.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major
cause of chronic morbidity and mortality throughout the world.
Many people suffer from this disease for years and die pre¬
maturely of it or its complications. The goals of the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) are to
improve prevention and management of COPD through a con¬
certed worldwide effort of people involved in all facets of health
care and health care policy, and to encourage an expanded level
of research interest in this highly prevalent disease.
One strategy to help achieve the objectives of GOLD is to
provide health care workers, health care authorities, and the
general public with state-of-the-art information about COPD
and specific recommendations on the most appropriate man¬
agement and prevention strategies. The GOLD report, Global
Strategy for the Diagnosis, Management, and Prevention of
COPD, is based on the best-validated current concepts of
COPD pathogenesis and the available evidence on the most
appropriate management and prevention strategies. A major
part of the GOLD report is devoted to the clinical management
of COPD and presents a management plan with four compo¬
nents: (1) assess and monitor disease, (2) reduce risk factors, (5)
manage stable COPD, and (4) manage exacerbations. A new
section at the end of the document will assist readers in
translating guideline recommendations to the context of (pri¬
mary) care.
GOLD is a partner organization in a program launched in
March 2006 by the World Health Organization's Global Alli¬
ance Against Chronic Respiratory Diseases (GARD). Through
the work of the GOLD committees, and in cooperation with
GARD initiatives, progress toward better care for all patients
with COPD should be substantial in the next decade.
Methodology and Summary of New Recommendations
After the release of the 2001 GOLD report, a science commit¬
tee was formed and charged with keeping the GOLD docu¬
ments up-to-date by reviewing published research, evaluating
the impact of this research on the management recommenda¬
tions in the GOLD documents, and posting yearly updates of
these documents on the GOLD website (www.goldcopd.org).
The methodology is described in each update (see, e.g., the 2005
update in Reference 3 and the Appendix in the online supple¬
ment).
In January 2005, the GOLD science committee initiated
preparation of this revised 2006 document on the basis of the
most current scientific literature. Multiple meetings were held,
including several with GOLD national leaders to discuss con¬
cepts and new recommendations. Before its publications, sev¬
eral reviewers were invited to submit comments.
A summary of the issues presented in this report include the
following:
1. Recognition that COPD is characterized by chronic
airflow limitation and a range of pathologic changes in
the lung, some significant extrapulmonary effects, and
important comorbidities that may contribute to the se¬
verity of the disease in individual patients.
2. In the definition of COPD, the phrase "preventable and
treatable" has been incorporated following the American
Thoracic Society/European Respiratory Society recom¬
mendations to recognize the need to present a positive
outlook for patients, to encourage the health care com¬
munity to take a more active role in developing programs
for COPD prevention, and to stimulate effective manage¬
ment programs to treat those with the disease.
3. The spirometric classification of severity of COPD now
includes four stages: stage I, mild; stage II, moderate;
stage III, severe; stage IV, very severe. A fifth category,
"stage 0, at risk," that appeared in the 2001 report is no
longer included as a stage of COPD, as there is in¬
complete evidence that the individuals who meet the
definition of "at risk" (chronic cough and sputum pro¬
duction, normal spirometry) necessarily progress on to
stage I. Nevertheless, the importance of the public health
message that chronic cough and sputum are not normal is
unchanged.
4. The spirometric classification of severity continues to
recommend use of the fixed ratio post-bronchodilator
FEVj/FVC < 0.7 to define airflow limitation. Using the
fixed ratio (FEVi/FVC) is particularly problematic in
patients with milder disease who are elderly because the
normal process of aging affects lung volumes. Post-
bronchodilator reference values in this population are
urgently needed to avoid potential overdiagnosis.
5. Section 2, Burden of COPD, provides references to
published data from prevalence surveys to estimate that
about 15 to 25% of adults aged 40 years and older may
have airflow limitation classified as stage I mild COPD or
higher and that the prevalence of COPD (stage I, mild
COPD and higher) is appreciably higher in smokers and
ex-smokers than in nonsmokers, in those over 40 years
compared with those younger than 40, and higher in men
than in women. The section also provides new data on
COPD morbidity and mortality.
6. Cigarette smoke is the most commonly encountered risk
factor for COPD and elimination of this risk factor is an
important step toward prevention and control of COPD.
However, other risk factors for COPD should be taken
into account where possible, including occupational
dusts and chemicals, and indoor air pollution from
biomass cooking and heating in poorly ventilated dwell¬
ings—the latter especially among women in developing
countries.
7. The section on pathology, pathogenesis, and pathophys¬
iology, continues with the theme that inhaled cigarette
smoke and other noxious particles cause lung inflamma¬
tion, a normal response which appears to be amplified in
patients who develop COPD. The section has been
considerably updated and revised.
8. Management of COPD continues to be presented in four
components: (7) assess and monitor disease, (2) reduce
risk factors, (3) manage stable COPD, and (4) manage
exacerbations. All components have been updated on the
basis of recently published literature. Throughout it is
emphasized that the overall approach to managing stable
COPD should be individualized to address symptoms and
improve quality of life.
9. In Component 4, Manage Exacerbations, a COPD
exacerbation is defined as "an event in the natural course
of the disease characterized by a change in the patient's
baseline dyspnea, cough, and/or sputum that is beyond
normal day-to-day variations, is acute in onset, and may
warrant a change in regular medication in a patient with
underlying COPD."
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10. It is widely recognized that a wide spectrum of health
care providers is required to ensure that COPD is
diagnosed accurately, and that individuals who have
COPD are treated effectively. The identification of
effective health care teams will depend on the local
health care system, and much work remains to identify
how best to build these health care teams. A section on
COPD implementation programs and issues for clinical
practice has been included but it remains a field that
requires considerable attention.
Levels of Evidence
Levels of evidence are assigned to management recommen¬
dations where appropriate in subsections of section 3 that
discuss COPD management, with the system used in previous
GOLD reports (Table 1). Evidence levels are enclosed
in parentheses after the relevant statement—for example,
(Evidence A).
1. DEFINITION, CLASSIFICATION OF SEVERITY, AND
MECHANISMS OF COPD
Definition
Chronic obstructive pulmonary disease (COPD) is a preventable and
treatable disease with some significant extrapulmonary effects that
may contribute to the severity in individual patients. Its pulmonary
component is characterized by airflow limitation that is not fully
reversible. The airflow limitation is usually progressive and associ¬
ated with an abnormal inflammatory response of the lung to noxious
particles or gases.
The chronic airflow limitation characteristic of COPD is
caused by a mixture of small airway disease (obstructive
bronchiolitis) and parenchymal destruction (emphysema), the
relative contributions of which vary from person to person.
Airflow limitation is best measured by spirometry, because this
is the most widely available, reproducible test of lung function.
Because COPD often develops in longtime smokers in
middle age, patients often have a variety of other diseases
related to either smoking or aging (4). COPD itself also has
significant extrapulmonary (systemic) effects that lead to
comorbid conditions (5). Thus, COPD should be managed with
careful attention also paid to comorbidities and their effect on
the patient's quality of life. A careful differential diagnosis and
comprehensive assessment of severity of comorbid conditions
should be performed in every patient with chronic airflow
limitation.
Spirometric Classification of Severity and Stages of COPD
For educational reasons, a simple spirometric classification of
disease severity into four stages is recommended (Table 2).
Spirometry is essential for diagnosis and provides a useful
description of the severity of pathologic changes in COPD.
Specific spirometric cut points (e.g., post-bronchodilator FEV,/
FVC ratio < 0.70 or FEV, < 80, 50, or 30% predicted) are used
for purposes of simplicity; these cut points have not been
clinically validated. A study in a random population sample
found that the post-bronchodilator FEV,/FVC exceeded 0.70 in
all age groups, supporting the use of this fixed ratio (6). Flow-
ever, because the process of aging does affect lung volumes, the
use of this fixed ratio may result in overdiagnosis of COPD in
the elderly, especially in those with mild disease.
The characteristic symptoms of COPD are chronic and
progressive dyspnea, cough, and sputum production. Chronic
cough and sputum production may precede the development of
airflow limitation by many years. This pattern offers a unique
opportunity to identify smokers and others at risk for COPD,
and to intervene when the disease is not yet a major health
problem. Conversely, significant airflow limitation may develop
without chronic cough and sputum production.
Stage I: mild COPD: Characterized by mild airflow limitation
(FEV,/FVC < 0.70, FEV, 2= 80% predicted). Symptoms of
chronic cough and sputum production may be present, but
not always. At this stage, the individual is usually unaware
that his or her lung function is abnormal.
Stage II: moderate COPD: Characterized by worsening airflow
limitation (FEV,/FVC < 0.70, 50% =£ FEV! < 80% pre¬
dicted), with shortness of breath typically developing on
exertion and cough and sputum production sometimes also
present. This is the stage at which patients typically seek
medical attention because of chronic respiratory symptoms
or an exacerbation of their disease.
Stage III: severe COPD: Characterized by further worsening of
airflow limitation (FEV,/FVC < 0.70, 30% =S FEVX < 50%
predicted), greater shortness of breath, reduced exercise
capacity, fatigue, and repeated exacerbations that almost
always have an impact on patients' quality of life.
TABLE 1. DESCRIPTION OF LEVELS OF EVIDENCE
Evidence
Category Sources of Evidence Definition
RCTs. Rich body of data.




Evidence is from endpoints of well-designed RCTs that provide a consistent pattern of findings
in the population for which the recommendation is made. Category A requires substantial numbers
of studies involving substantial numbers of participants.
Evidence is from endpoints of intervention studies that include only a limited number of patients,
post hoc or subgroup analysis of RCTs, or meta-analysis of RCTs. In general, category B pertains
when few randomized trials exist, they are small in size, they were undertaken in a population
that differs from the target population of the recommendation, or the results are somewhat
inconsistent.
Evidence is from outcomes of uncontrolled or nonrandomized trials or from observational studies.
This category is used only in cases where the provision of some guidance was deemed valuable but
the clinical literature addressing the subject was insufficient to justify placement in one of the
other categories. The panel consensus is based on clinical experience or knowledge that does not
meet the above-listed criteria.
Definition of abbreviation: RCT = randomized controlled trial.
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TABLE 2. SPIROMETRY CLASSIFICATION OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE SEVERITY BASED ON
POST-BRONCHODILATOR FEVt
Stage 1: mild FEVt/FVC < 0.70
FEVt ss 80% predicted
Stage II: moderate FEV]/FVC < 0.70
50% =£ FEV] < 80% predicted
Stage III: severe FEV,/FVC < 0.70
30% FEV] < 50% predicted
Stage IV: very severe FEV]/FVC < 0.70
FEV, < 30% predicted or FEV] < 50%
predicted plus chronic respiratory failure*
* Respiratory failure: arterial partial pressure of oxygen (Pa0j) < 8.0 kPa
(60 mm Hg) with or without arterial partial pressure of C02 (Paco,) >6.7 kPa
(50 mm Hg) while breathing air at sea level.
Stage IV: very severe COPD: Characterized by severe airflow
limitation (FEV]/FVC < 0.70, FEVi < 30% predicted or
FEVj 50 /o predicted plus the presence of chronic re-
spiratory failure). Respiratory failure is defined as an arterial
partial pressure of 02 (Pao,) less than 8.0 kPa (60 mm Hg),
with or without an arterial partial pressure of C02 (Paco2)
greater than 6.7 kPa (50 mm Hg) while breathing air at sea
level. Respiratory failure may also lead to effects on the heart
such as cor pulmonale (right heart failure). Clinical signs of
cor pulmonale include elevation of the jugular venous
pressure and pitting ankle edema. Patients may have stage
IV COPD even if their FEVj is greater than 30% predicted,
whenever these complications are present. At this stage,
quality of life is very appreciably impaired and exacerbations
may be life threatening.
Although asthma can usually be distinguished from COPD,
in some individuals with chronic respiratory symptoms and fixed
airflow limitation it remains difficult to differentiate the two
diseases. In many developing countries, both pulmonary tuber¬
culosis and COPD are common (7). In countries where tuber¬
culosis is very common, respiratory abnormalities may be too
readily attributed to this disease (8). Conversely, where the rate
of tuberculosis is greatly diminished, the possible diagnosis of
this disease is sometimes overlooked. Therefore, in all subjects
with symptoms of COPD, a possible diagnosis of tuberculosis
should be considered, especially in areas where this disease is
known to be prevalent (9).
Pathology, Pathogenesis, and Pathophysiology
Pathologic changes characteristic of COPD are found in the
proximal airways, peripheral airways, lung parenchyma, and
pulmonary vasculature (10). The pathologic changes include
chronic inflammation, with increased numbers of specific in¬
flammatory cell types in different parts of the lung, and struc¬
tural changes resulting from repeated injury and repair. In
general, the inflammatory and structural changes in the airways
increase with disease severity and persist on smoking cessation.
The inflammation in the respiratory tract of patients with
COPD appears to be an amplification of the normal inflamma¬
tory response of the respiratory tract to chronic irritants such as
cigarette smoke. The mechanisms for this amplification are not
yet understood but may be genetically determined. Some pa¬
tients develop COPD without smoking, but the nature of the
inflammatory response in these patients is unknown (11). Lung
inflammation is further amplified by oxidative stress and an
excess of proteinases in the lung. Together, these mechanisms
lead to the characteristic pathologic changes in COPD.
There is now a good understanding of how the underlying
disease process in COPD leads to the characteristic physiologic
abnormalities and symptoms. For example, decreased FEV,
primarily results from inflammation and narrowing of periph¬
eral airways and a dynamic airway collapse in more severe
emphysema, whereas decreased gas transfer arises from the
parenchymal destruction of emphysema. The extent of inflam¬
mation, fibrosis, and luminal exudates in small airways is
correlated with the reduction in FEVi and FEV|/FVC ratio,
and probably with the accelerated decline in FEVi character¬
istic of COPD (4). Gas exchange abnormalities result in hy¬
poxemia and hypercapnia, and have several mechanisms in
COPD. In general, gas transfer worsens as the disease pro¬
gresses. Mild to moderate pulmonary hypertension may develop
late in the course of COPD and is due to hypoxic vasoconstric¬
tion of small pulmonary arteries. It is increasingly recognized
that COPD involves several systemic features, particularly in
patients with severe disease, and that these have a major impact
on survival and comorbid diseases (12, 13).
2. BURDEN OF COPD
COPD prevalence, morbidity, and mortality vary across coun¬
tries and across different groups within countries but, in general,
are directly related to the prevalence of tobacco smoking,
although, in many countries, air pollution resulting from the
burning of wood and other biomass fuels has also been
identified as a COPD risk factor. The prevalence and burden
of COPD are projected to increase in the coming decades due
to continued exposure to COPD risk factors and the changing
age structure of the world's population.
Epidemiology
In the past, imprecise and variable definitions of COPD have
made it difficult to quantify prevalence, morbidity, and mortal¬
ity. Furthermore, the underrecognition and underdiagnosis of
COPD lead to significant underreporting. The extent of the
underreporting varies across countries and depends on the level
of awareness and understanding of COPD among health
professionals, the organization of health care services to cope
with chronic diseases, and the availability of medications for the
treatment of COPD (14).
Prevalence. Many sources of variation can affect estimates of
COPD prevalence, including sampling methods, response rates,
quality control of spirometry, and whether spirometry is per¬
formed pre- or post-bronchodilator. Despite these complexities,
data are emerging that enable some conclusions to be drawn
regarding COPD prevalence. A prevalence study in Latin
America (19), a systematic review and meta-analysis of studies
performed in 28 countries between 1990 and 2004 (15), and
an additional study from Japan (16) provide evidence that the
prevalence of COPD (stage I, mild COPD and higher) is
appreciably higher in smokers and ex-smokers compared with
nonsmokers, in those older than 40 years compared with those
younger than 40 years, and in men compared with women.
Morbidity. Morbidity measures traditionally include physi¬
cian visits, emergency department visits, and hospitalizations.
Although COPD databases for these outcome parameters are
less readily available and usually less reliable than mortality
databases, the limited data available indicate that morbidity due
to COPD increases with age and is greater in men than in
women (17, 18). COPD in its early stages (stages I and II) is
usually not recognized, diagnosed, or treated, and therefore
may not be included as a diagnosis in a patient's medical record.
Morbidity from COPD may be affected by other comorbid
chronic conditions (20) (e.g., musculoskeletal disease, diabetes
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mellitus) that are not directly related to COPD but nevertheless
may have an impact on the patient's health status, or may in¬
terfere with COPD management. In patients with more
advanced disease (stages III and IV), morbidity from COPD
may be misattributed to another comorbid condition.
Mortality. COPD is one of the most important causes of
death in most countries. The Global Burden of Disease Study
(2, 21, 22) has projected that COPD, which ranked sixth as the
cause of death in 1990, will become the third leading cause of
death worldwide by 2020. This increased mortality is driven by
the expanding epidemic of smoking and the changing demo¬
graphics in most countries, with more of the population living
longer.
Economic and Social Burden of COPD
COPD is a costly disease. In developed countries, exacerbations
of COPD account for the greatest burden on the health care
system. In the European Union, the total direct costs of
respiratory disease are estimated to be about 6% of the total
health care budget, with COPD accounting for 56% (€38.6
billion) of this cost of respiratory disease (23). In the United
States in 2002, the direct costs of COPD were $18 billion and
the indirect costs totaled $14.1 billion (1). Costs per patient will
vary across countries because these costs depend on how health
care is provided and paid (24). Not surprisingly, there is
a striking direct relationship between the severity of COPD
and the cost of care (25), and the distribution of costs changes as
the disease progresses.
Risk Factors
Identification of cigarette smoking as the most commonly
encountered risk factor for COPD has led to the incorporation
of smoking cessation programs as a key element of COPD
prevention, as well as an important intervention for patients
who already have the disease. However, although smoking is
the best-studied COPD risk factor, it is not the only one and
there is consistent evidence from epidemiologic studies that
nonsmokers may develop chronic airflow obstruction (26, 27)
(Figure 1).
Genes. As the understanding of the importance of risk
factors for COPD has grown, so has the recognition that
essentially all risk for COPD results from a gene-environment
interaction. The genetic risk factor that is best documented is
a severe hereditary deficiency of cq-antitrypsin (28), a major
circulating inhibitor of serine proteases. This rare recessive trait
is most commonly seen in individuals of northern European
origin (29).
Genetic association studies have implicated a variety of genes
in COPD pathogenesis. However, the results of these genetic
association studies have been largely inconsistent, and functional
genetic variants influencing the development of COPD (other
than cti-antitrypsin deficiency) have not been definitively identi¬
fied (30).
Inhalational exposures. Tobacco smoke. Cigarette smokers
have a higher prevalence of respiratory symptoms and lung
function abnormalities, a greater annual rate of decline in
FEV], and a greater COPD mortality rate than nonsmokers.
Pipe and cigar smokers have greater COPD morbidity and
mortality rates than nonsmokers, although their rates are lower
than those for cigarette smokers (31). Other types of tobacco
smoking popular in various countries are also risk factors for
COPD (32, 33). Not all smokers develop clinically significant
COPD, which suggests that genetic factors must modify each
individual's risk (34). Passive exposure to cigarette smoke may
also contribute to respiratory symptoms (35) and COPD (36) by
increasing the lungs' total burden of inhaled particles and gases
(37, 38). Smoking during pregnancy may also pose a risk for the
fetus, by affecting lung growth and development in utero and
possibly the priming of the immune system (39, 40).
Occupational dusts and chemicals. Occupational expo¬
sures include organic and inorganic dusts and chemical agents
and fumes. A statement published by the American Thoracic
Society concluded that occupational exposures account for 10 to
20% of either symptoms or functional impairment consistent
with COPD (41).
Indoor and outdoor air pollution. The evidence that
indoor pollution from biomass cooking and heating in poorly
ventilated dwellings is an important risk factor for COPD
(especially among women in developing countries) continues
to grow (42-48), with case-control studies (47, 48) and other
designed studies now available. High levels of urban air
pollution are harmful to individuals with existing heart or lung
disease, but the role of outdoor air pollution in causing COPD is
unclear.
Sex. Studies from developed countries (1, 49) show that
the prevalence of the disease is now almost equal in men and
Cigarette smoke
Enviromental tobacco smoke (ETS)
Indoor and outdoor air polution
Occupational dust and chemicals
Figure 7. Chronic obstructive pulmonary disease risk is
related to the total burden of inhaled particles.
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women, probably reflecting the changing patterns of tobacco
smoking. Some studies have suggested that women are more
susceptible to the effects of tobacco smoke than men (50-
52).
Infection. A history of severe childhood respiratory infec¬
tion has been associated with reduced lung function and
increased respiratory symptoms in adulthood (53-55). How¬
ever, susceptibility to viral infections may be related to
another factor, such as low birth weight, that itself is related
to COPD.
Socioeconomic status. There is evidence that the risk of
developing COPD is inversely related to socioeconomic status
(56). It is not clear, however, whether this pattern reflects
exposures to cigarette smoke, indoor and outdoor air pollutants,
crowding, poor nutrition, or other factors that are related to low
socioeconomic status (57, 58).
3. THE FOUR COMPONENTS OF COPD MANAGEMENT
Introduction
An effective COPD management plan includes four compo¬
nents: (7) assess and monitor disease, (2) reduce risk factors, (3)
manage stable COPD, and (4) manage exacerbations. Although
disease prevention is the ultimate goal, once COPD has been
diagnosed, effective management should be aimed at the
following goals:
• Relieve symptoms
• Prevent disease progression
• Improve exercise tolerance
• Improve health status
• Prevent and treat complications
• Prevent and treat exacerbations
• Reduce mortality
These goals should be reached with minimal side effects from
treatment, a particular challenge in patients with COPD
because they commonly have comorbidities. The extent to
which these goals can be realized varies with each individual,
and some treatments will produce benefits in more than one
area. In selecting a treatment plan, the benefits and risks to
the individual, and the costs, direct and indirect, to the
individual, his or her family, and the community must be
considered.
Patients should be identified as early in the course of the
disease as possible, and certainly before the end stage of the
illness when disability is substantial. Access to spirometry is key
to the diagnosis of COPD and should be available to health care
workers who care for patients with COPD. However, the
benefits of community-based spirometric screening, of either
the general population or smokers, are still unclear.
Educating patients, physicians, and the public to recognize
that cough, sputum production, and especially breathlessness
are not trivial symptoms is an essential aspect of the public
health care of this disease.
Reduction of therapy once symptom control has been achieved
is not normally possible in COPD. Further deterioration of lung
function usually requires the progressive introduction of more
treatments, both pharmacologic and nonpharmacologic, to at¬
tempt to limit the impact of these changes. Exacerbations of signs
and symptoms, a hallmark of COPD, impair patients' quality of
life and decrease their health status. Appropriate treatment and
measures to prevent further exacerbations should be imple¬
mented as quickly as possible.
Component 1: Assess and Monitor Disease
KEY POINTS
• A clinical diagnosis of COPD should be considered in
any patient who has dyspnea, chronic cough or sputum
production, and/or a history of exposure to risk factors
for the disease. The diagnosis should be confirmed by
spirometry.
• For the diagnosis and assessment of COPD, spirometry
is the gold standard because it is the most reproducible,
standardized, and objective way of measuring airflow
limitation. A post-bronchodilator FEV^FVC < 0.70
confirms the presence of airflow limitation that is not
fully reversible.
• Health care workers involved in the diagnosis and
management of patients with COPD should have access
to spirometry.
• Assessment of COPD severity is based on the patient's
level of symptoms, the severity of the spirometric abnor¬
mality, and the presence of complications.
• Measurement of arterial blood gas tensions should be
considered in all patients with FEV! < 50% predicted or
clinical signs suggestive of respiratory failure or right
heart failure.
• COPD is usually a progressive disease and lung function
can be expected to worsen over time, even with the best
available care. Symptoms and objective measures of
airflow limitation should be monitored to determine
when to modify therapy and to identify any complica¬
tions that may develop.
• Comorbidities are common in COPD and should be
actively identified. Comorbidities often complicate the
management of COPD, and vice versa.
Initial diagnosis. A clinical diagnosis of COPD should be
considered in any patient who has dyspnea, chronic cough or
sputum production, and/or a history of exposure to risk factors
for the disease (Table 3). The diagnosis should be confirmed by
spirometry.
Assessment of symptoms. Dyspnea, the hallmark symptom
of COPD, is the reason most patients seek medical attention
and is a major cause of disability and anxiety associated with the
disease. As lung function deteriorates, breathlessness becomes
more intrusive. Chronic cough, often the first symptom of
COPD to develop (59) and often predating the onset of dys¬
pnea, may be intermittent, but later is present every day, often
throughout the day. In some cases, significant airflow limitation
may develop without the presence of a cough. Patients with
COPD commonly raise small quantities of tenacious sputum
after coughing bouts. Wheezing and chest tightness are non¬
specific symptoms that may vary between days, and over the
course of a single day. An absence of wheezing or chest tight¬
ness does not exclude a diagnosis of COPD. Weight loss, an¬
orexia, and psychiatric morbidity, especially symptoms of de¬
pression and/or anxiety, are common problems in advanced
COPD (60, 61).
Medical history. A detailed medical history of a new pa¬
tient known or believed to have COPD should assess the
following:
• Exposure to risk factors
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TABLE 3. KEY INDICATORS FOR CONSIDERING A DIAGNOSIS
OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Consider COPD, and perform spirometry, if any of these indicators are
present in an individual. These indicators are not diagnostic themselves,
but the presence of multiple key indicators increases the probability
of a diagnosis of COPD. Spirometry is needed to establish a diagnosis of COPD.
Dyspnea that is Progressive (worsens over time)
Usually worse with exercise
Persistent (present every day)
Described by the patient as an "increased
effort to breathe," "heaviness," "air hunger,"
or "gasping
Chronic cough May be intermittent and may be unproductive
Chronic sputum production Any pattern of chronic sputum production
may indicate COPD
History of exposure Tobacco smoke
to risk factors, especially, Occupational dusts and chemicals
Smoke from home cooking and heating fuels
Definition of abbreviation: COPD = chronic obstructive pulmonary disease.
• Past medical history, including asthma, allergy, sinusitis, or
nasal polyps; respiratory infections in childhood; other
respiratory diseases
• Family history of COPD or other chronic respiratory
disease
• Pattern of symptom development
• History of exacerbations or previous hospitalizations for
respiratory disorder
• Presence of comorbidities, such as heart disease, malignan¬
cies, osteoporosis, and muscloskeletal disorders, which may
also contribute to restriction of activity (62)
• Appropriateness of current medical treatments
• Impact of disease on patient's life, including limitation of
activity, missed work and economic impact, effect on family
routines, feelings of depression or anxiety
• Social and family support available to the patient
• Possibilities for reducing risk factors, especially smoking
cessation
Physical examination. Although an important part of pa¬
tient care, a physical examination is rarely diagnostic in COPD.
Physical signs of airflow limitation are usually not present
until significant impairment of lung function has occurred (63,
64), and their detection has a relatively low sensitivity and
specificity.
Measurement of airflow limitation (spirometry). Spirom¬
etry should be undertaken in all patients who may have COPD.
Spirometry should measure the volume of air forcibly exhaled
from the point of maximal inspiration (FVC) and the volume of
air exhaled during the first second of this maneuver (FEVi), and
the ratio of these two measurements (FEVj/FVC) should be
calculated. Spirometry measurements are evaluated by compar¬
ison with reference values (65) based on age, height, sex, and
race (use appropriate reference values; e.g., see Reference 65).
Patients with COPD typically show a decrease in both FEVj
and FVC. The presence of airflow limitation is defined by
a post-bronchodilator FEVj/FVC < 0.70. This approach is
pragmatic in view of the fact that universally applicable
reference values for FEV] and FVC are not available. Where
possible, values should be compared with age-related normal
values to avoid overdiagnosis of COPD in the elderly (66).
Using the fixed ratio (FEVj/FVC) is particularly problematic in
patients with milder COPD who are elderly because the normal
process of aging affects lung volumes.
Assessment of COPD severity. Assessment of COPD
severity is based on the patient's level of symptoms, the severity
of the spirometric abnormality (Table 2), and the presence of
complications such as respiratory failure, right heart failure,
weight loss, and arterial hypoxemia.
Additional investigations. For patients diagnosed with
stage II, moderate, COPD and beyond, the following additional
investigations may be considered.
Bronchodilator reversibility testing. Despite earlier hopes,
neither bronchodilator nor oral glucocorticosteroid reversibility
testing predicts disease progression, whether judged by decline
in FEVi, deterioration of health status, or frequency of exac¬
erbations (67, 68) in patients with a clinical diagnosis of COPD
and abnormal spirometry (68). In some cases (e.g., a patient
with an atypical history such as asthma in childhood and regular
night waking with cough or wheeze), a clinician may wish to
perform a bronchodilator and/or glucocorticosteroid reversibil¬
ity test.
Chest X-ray. An abnormal chest X-ray is seldom diagnostic
in COPD unless obvious bullous disease is present, but it is
valuable in excluding alternative diagnoses and establishing
the presence of significant comorbidities, such as cardiac
failure. Computed tomography (CT) of the chest is not
routinely recommended. However, when there is doubt about
the diagnosis of COPD, high-resolution CT scanning might
help in the differential diagnosis. In addition, if a surgical
procedure such as lung volume reduction is contemplated,
a chest CT scan is necessary because the distribution of
emphysema is one of the most important determinants of
surgical suitability (69).
Arterial blood gas measurement. In advanced COPD, mea¬
surement of arterial blood gases while the patient is breathing
air is important. This test should be performed in stable patients
with FEVi < 50% predicted or with clinical signs suggestive of
respiratory failure or right heart failure.
oL]-Antitrypsin deficiency screening. In patients of Caucasian
descent who develop COPD at a young age (< 45 yr) or who
have a strong family history of the disease, it may be valuable to
identify coexisting c^-antitrypsin deficiency. This could lead to
family screening or appropriate counseling.
Differential diagnosis. In some patients with chronic
asthma, a clear distinction from COPD is not possible using
current imaging and physiologic testing techniques, and it is
assumed that asthma and COPD coexist in these patients. In
these cases, current management is similar to that of asthma.
Other potential diagnoses are usually easier to distinguish from
COPD (Table 4).
Ongoing monitoring and assessment. Monitor disease pro¬
gression and development of complications. COPD is USUally
a progressive disease. Lung function can be expected to worsen
over time, even with the best available care. Symptoms and
objective measures of airflow limitation should be monitored to
determine when to modify therapy and to identify any compli¬
cations that may develop.
Follow-up visits should include a physical examination and
discussion of symptoms, particularly any new or worsening
symptoms. Spirometry should be performed if there is a sub¬
stantial increase in symptoms or a complication. The develop¬
ment of respiratory failure is indicated by a Pao2 < 8.0 kPa (60
mm Hg) with or without PaCo2 > 6.7 kPa (50 mm Hg) in arterial
blood gas measurements made while breathing air at sea level.
Measurement of pulmonary arterial pressure is not recommen¬
ded in clinical practice as it does not add practical information
beyond that obtained from a knowledge of Pao2.
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Monitor pharmacotherapy and other medical treatment.
To adjust therapy appropriately as the disease progresses, each
follow-up visit should include a discussion of the current
therapeutic regimen. Dosages of various medications, adher¬
ence to the regimen, inhaler technique, effectiveness of the
current regime at controlling symptoms, and side effects of
treatment should be monitored.
Monitor exacerbation history. Frequency, severity, and
likely causes of exacerbations should be evaluated. Increased
sputum volume, acutely worsening dyspnea, and the presence of
purulent sputum should be noted. Severity can be estimated by
the increased need for bronchodilator medication or glucocor-
ticosteroids and by the need for antibiotic treatment. Hospital¬
izations should be documented, including the facility, duration
of stay, and any use of critical care or intubation.
Monitor comorbidities. Comorbidities are common in
COPD and may become harder to manage when COPD is
present, either because COPD adds to the total level of dis¬
ability or because COPD therapy adversely affects the comor-
bid disorder. Until more integrated guidance about disease
management for specific comorbid problems becomes available,
the focus should be on identification and management of these
individual problems.
Component 2: Reduce Risk Factors
KEY POINTS
• Reduction of total personal exposure to tobacco smoke,
occupational dusts and chemicals, and indoor and out¬
door air pollutants are important goals to prevent the
onset and progression of COPD.
• Smoking cessation is the single most effective—and cost-
effective—intervention in most people to reduce the risk of
developing COPD and stop its progression (Evidence A).
• Comprehensive tobacco control policies and programs
with clear, consistent, and repeated nonsmoking messages
should be delivered through every feasible channel.
• Efforts to reduce smoking through public health initia¬
tives should also focus on passive smoking to minimize
•risks for nonsmokers.
• Many occupationally induced respiratory disorders can
be reduced or controlled through a variety of strategies
aimed at reducing the burden of inhaled particles and
gases.
• Reducing the risk from indoor and outdoor air pollution
is feasible and requires a combination of public policy
and protective steps taken by individual patients.
TABLE 4. DIFFERENTIAL DIAGNOSIS OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
Diagnosis Suggestive Features
COPD Onset in midlife
Symptoms slowly progressive
Long history of tobacco smoking
Dyspnea during exercise
Largely irreversible airflow limitation
Asthma Onset early in life (often childhood)
Symptoms vary from day to day
Symptoms at night/early morning
Allergy, rhinitis, and/or eczema also present
Family history of asthma
Largely reversible airflow limitation
Congestive heart failure Nonspecific basilar crackles on auscultation
Chest X-ray shows dilated heart, pulmonary edema
Pulmonary function tests indicate volume
restriction, not airflow limitation
Bronchiectasis Large volumes of purulent sputum
Commonly associated with bacterial infection
Coarse crackles/clubbing on auscultation
Chest X-ray/CT shows bronchial dilation,
bronchial wall thickening
Tuberculosis Onset all ages
Chest X-ray shows lung infiltrate
Microbiological confirmation
High local prevalence of tuberculosis
Obliterative bronchiolitis Onset in younger age, nonsmokers
May have history of rheumatoid arthritis
or fume exposure
CT on expiration shows hypodense areas
Diffuse panbronchioiitis Most patients are male and nonsmokers
Almost all have chronic sinusitis
Chest X-ray and HRCT show diffuse small
centrilobular nodular opacities and hyperinflation
Definition of abbreviations: COPD = chronic obstructive pulmonary disease;
CT = computed tomography; HRCT = high-resolution computed tomography.
These features tend to be characteristic of the respective diseases, but do not
occur in every case. For example, a person who has never smoked may develop
COPD (especially in the developing world where other risk factors may be more
important than cigarette smoking); asthma may develop in adult and even
elderly patients.
Smoking prevention and cessation. Comprehensive tobacco
control policies and programs with clear, consistent, and re¬
peated nonsmoking messages should be delivered through every
feasible channel, including health care providers, community
activities, and schools, and radio, television, and print media.
Legislation to establish smoke-free schools, public facilities, and
work environments should be developed and implemented by
government officials and public health workers, and encouraged
by the public.
Smoking cessation intervention process. Smoking cessa¬
tion is the single most effective—and cost-effective—way to re¬
duce exposure to COPD risk factors. All smokers—including
those who may be at risk for COPD as well as those who already
have the disease—should be offered the most intensive smoking
cessation intervention feasible. Even a brief (3 min) period of
counseling to urge a smoker to quit results in smoking cessation
rates of 5 to 10% (70). At the very least, this should be done for
every smoker at every health care provider visit (70, 71).
Guidelines for smoking cessation entitled "Treating Tobacco
Use and Dependence: A Clinical Practice Guideline" were
published by the U.S. Public Health Service (72) and recom¬
mend a five-step program for intervention (Table 5), which
provides a strategic framework helpful to health care providers
interested in helping their patients stop smoking (72-75).
Pharmacotherapy. Numerous effective pharmacotherapies
for smoking cessation now exist (72, 73, 76) (Evidence A), and
pharmacotherapy is recommended when counseling is not
sufficient to help patients quit smoking. Numerous studies
indicate that nicotine replacement therapy in any form (nicotine
gum, inhaler, nasal spray, transdermal patch, sublingual tablet,
or lozenge) reliably increases long-term smoking abstinence
rates (72, 77).
The antidepressants bupropion (78) and nortriptyline have
also been shown to increase long-term quit rates (76,77,79), but
should always be used as one element in a supportive in¬
tervention program rather than on their own. The effectiveness
of the antihypertensive drug clonidine is limited by side effects
(77). Varenicline, a nicotinic acetylcholine receptor partial
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agonist that aids smoking cessation by relieving nicotine with¬
drawal symptoms and reducing the rewarding properties of
nicotine, has been demonstrated to be safe and efficacious (80-
82). Special consideration should be given before using phar¬
macotherapy in the following selected populations: people with
medical contraindications, light smokers (<10 cigarettes/d), and
pregnant and adolescent smokers.
Occupational exposures. Although it is not known how many
individuals are at risk of developing respiratory disease from
occupational exposures in either developing or developed
countries, many occupationally induced respiratory disorders
can be reduced or controlled through a variety of strategies
aimed at reducing the burden of inhaled particles and gases
(83-85).
The main emphasis should be on primary prevention, which
is best achieved by the elimination or reduction of exposures to
various substances in the workplace. Secondary prevention,
achieved through surveillance and early case detection, is also
of great importance.
Indoor and outdoor air pollution. Individuals experience di¬
verse indoor and outdoor environments throughout the day,
each of which has its own unique set of air contaminants and
particulates that cause adverse effects on lung function (86).
Although outdoor and indoor air pollution are generally
considered separately, the concept of total personal exposure
may be more relevant for COPD. Reducing the risk from
indoor and outdoor air pollution is feasible and requires
a combination of public policy and protective steps taken by
individual patients. At the national level, achieving a set level of
air quality standards should be a high priority; this goal will
normally require legislative action. Reduction of exposure to
smoke from biomass fuel, particularly among women and
children, is a crucial goal to reduce the prevalence of COPD
worldwide. Although efficient nonpolluting cooking stoves have
been developed, their adoption has been slow due to social
customs and cost.
The health care provider should consider COPD risk factors,
including smoking history, family history, exposure to indoor/
outdoor pollution, and socioeconomic status, for each individual
patient. Those who are at high risk should avoid vigorous
exercise outdoors during pollution episodes. Persons with
advanced COPD should monitor public announcements of air
quality and be aware that staying indoors when air quality is
poor may help reduce their symptoms. If various solid fuels are
used for cooking and heating, adequate ventilation should be
encouraged. Under most circumstances, vigorous attempts
should be made to reduce exposure through reducing workplace
TABLE 5. BRIEF STRATEGIES TO HELP THE PATIENT WHO IS
WILLING TO QUIT
1. ASK: Systematically identify all tobacco users at every visit.
Implement an officewide system that ensures that, for EVERY patient at
EVERY clinic visit, tobacco use status is queried and documented.
2. ADVISE: Strongly urge all tobacco users to quit.
In a clear, strong, and personalized manner, urge every tobacco user to quit.
3. ASSESS: Determine willingness to make a quit attempt.
Ask every tobacco user if he or she is willing to make a quit attempt at this
time (e.g., within the next 30 d).
4. ASSIST: Aid the patient in quitting.
Help the patient with a quit plan; provide practical counseling; provide
intratreatment social support; help the patient obtain extratreatment
social support; recommend use of approved pharmacotherapy except
in special circumstances; provide supplementary materials.
5. ARRANGE: Schedule follow-up contact.
Schedule follow-up contact, either in person or via telephone.
Data from References 72-75.
emissions and improving ventilation measures, rather than
simply using respiratory protection to reduce the risks of
ambient air pollution. Air cleaners have not been shown to
have health benefits, whether directed at pollutants generated
by indoor sources or at those brought in with outdoor air.
Component 3: Manage Stable COPD
KEY POINTS
• The overall approach to managing stable COPD should
be individualized to address symptoms and improve
quality of life.
• For patients with COPD, health education plays an
important role in smoking cessation (Evidence A) and
can also play a role in improving skills, ability to cope
with illness, and health status.
• None of the existing medications for COPD have been
shown to modify the long-term decline in lung function
that is the hallmark of this disease (Evidence A).
Therefore, pharmacotherapy for COPD is used to de¬
crease symptoms and/or complications.
• Bronchodilator medications are central to the symptom¬
atic management of COPD (Evidence A). They are
given on an as-needed basis or on a regular basis to
prevent or reduce symptoms and exacerbations.
• The principal bronchodilator treatments are (^-agonists,
anticholinergics, and methylxanthines used singly or in
combination (Evidence A).
■ Regular treatment with long-acting bronchodilators is
more effective and convenient than treatment with
short-acting bronchodilators (Evidence A).
• The addition of regular treatment with inhaled glucocor-
ticosteroids to bronchodilator treatment is appropriate for
symptomatic patients with COPD with an FEV, < 50%
predicted (stage III, severe COPD, and stage IV, very
severe COPD) and repeated exacerbations (Evidence A).
• Chronic treatment with systemic glucocorticosteroids
should be avoided because of an unfavorable benefit-
to-risk ratio (Evidence A).
• In patients with COPD, influenza vaccines can reduce
serious illness (Evidence A). Pneumococcal polysaccha¬
ride vaccine is recommended for patients with COPD
who are 65 years and older and for patients with COPD
who are younger than age 65 with an FEV, < 40%
predicted (Evidence B).
• All patients with COPD benefit from exercise training
programs, improving with respect to both exercise toler¬
ance and symptoms of dyspnea and fatigue (Evidence A).
• The long-term administration of oxygen (>15 h/d) to
patients with chronic respiratory failure has been shown
to increase survival (Evidence A).
Introduction. The overall approach to managing stable COPD
should be characterized by an increase in treatment, depending
on the severity of the disease and the clinical status of the patient.
Management of COPD is based on an individualized assessment
of disease severity and response to various therapies. The clas¬
sification of severity of stable COPD incorporates an individual¬
ized assessment of disease severity and therapeutic response into
the management strategy. The severity of airflow limitation
provides a general guide to the use of some treatments, but the
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selection of therapy is predominantly determined by the patient's
symptoms and clinical presentation. Treatment also depends on
the patient's educational level and willingness to apply the
recommended management, on cultural and local practice con¬
ditions, and on the availability of medications.
Education. Although patient education is generally regarded
as an essential component of care for any chronic disease, assess¬
ment of the value of education in COPD may be difficult because
of the relatively long time required to achieve improvements in
objective measurements of lung function. Patient education alone
does not improve exercise performance or lung function (87-90)
(Evidence B), but it can play a role in improving skills, ability to
cope with illness, and health status (91). Patient education re¬
garding smoking cessation has the greatest capacity to influence
the natural history of COPD (Evidence A). Education also im¬
proves patient response to exacerbations (92, 93) (Evidence B).
Prospective end-of-life discussions can lead to understanding of
advance directives and effective therapeutic decisions at the end
of life (94) (Evidence B).
Ideally, educational messages should be incorporated into all
aspects of care for COPD and may take place in many settings:
consultations with physicians or other health care workers,
home-care or outreach programs, and comprehensive pulmo¬
nary rehabilitation programs. Education should be tailored to
the needs and environment of the individual patient, interactive,
directed at improving quality of life, simple to follow, practical,
and appropriate to the intellectual and social skills of the
patient and the caregivers. The topics that seem most appro¬
priate for an education program include the following: smoking
cessation; basic information about COPD and pathophysiology
of the disease, general approach to therapy and specific aspects
of medical treatment, self-management skills, strategies to help
minimize dyspnea, advice about when to seek help, self-
management and decision making during exacerbations, and
advance directives and end-of-life issues.
Pharmacologic treatments. Pharmacologic therapy is used to
prevent and control symptoms (Figure 2), reduce the frequency
and severity of exacerbations, improve health status, and
improve exercise tolerance. None of the existing medications
(Table 6) for COPD have been shown to modify the long-term
decline in lung function that is the hallmark of this disease (51,
95-97) (Evidence A). However, this should not preclude efforts
to use medications to control symptoms.
Bronchodilators. Bronchodilator medications are central
to the symptomatic management of COPD (98-101) (Evidence
A) (Table 7). They are given either on an as-needed basis for
relief of persistent or worsening symptoms or on a regular basis
to prevent or reduce symptoms. The side effects of bronchodi¬
lator therapy are pharmacologically predictable and dose de¬
pendent. Adverse effects are less likely, and resolve more rap¬
idly after treatment withdrawal, with inhaled than with oral
treatment. When treatment is given by the inhaled route, atten¬
tion to effective drug delivery and training in inhaler technique
are essential.
Bronchodilator drugs commonly used in treating COPD in¬
clude p2-agonists, anticholinergics, and methylxanthines. The
choice depends on the availability of the medications and the
patient's response. All categories of bronchodilators have been
shown to increase exercise capacity in COPD, without necessarily
producing significant changes in FEVj (102-105) (Evidence A).
Regular treatment with long-acting bronchodilators is more
effective and convenient than treatment with short-acting bron¬
chodilators (106-109) (Evidence A). Regular use of a long-
acting p2-agonist (107) or a short- or long-acting anticholinergic
improves health status (106-108). Treatment with a long-acting
inhaled anticholinergic drug reduces the rate of COPD exacer¬
bations (110) and improves the effectiveness of pulmonary re¬
habilitation (111). Theophylline is effective in COPD, but, due
to its potential toxicity, inhaled bronchodilators are preferred
when available. All studies that have shown efficacy of theoph¬
ylline in COPD were done with slow-release preparations.
Combining bronchodilators with different mechanisms and
durations of action may increase the degree of bronchodilation
for equivalent or lesser side effects. A combination of a short-
acting p2-agonist and an anticholinergic produces greater and
more sustained improvements in FEVi than either drug alone
and does not produce evidence of tachyphylaxis over 90 days of
treatment (112-114) (Evidence A).
1 Hi Moderate i r II: Severe IV: Very Severe
FEVj/FVC < 0.70
FEVi - 80% predicted
• FEVi/FVC < 0.70
• 50% s FEVi <80%
predicted
• FEVi/FVC < 0.70
• 30%<FEVi<50%
predicted
• FEV,/FVC < 0.70




Active reduction of risk factor(s); influenza vaccination •
Add short-acting bronchodilator (when needed)
Add regular treatment with one ormore long-acting bronchodilators
(when needed); Add rehabilitation
Add inhaled glucocorticosteroids if
repeated exacerbations





Figure 2. Therapy at each stage of
chronic obstructive pulmonary disease
(COPD). Post-bronchodilator FEV] is rec¬
ommended for the diagnosis and assess¬
ment of severity of COPD.
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The combination of a p2-agonist, an anticholinergic, and/or
theophylline may produce additional improvements in lung
function (112-118) and health status (112, 119). Increasing the
number of drugs usually increases costs, and an equivalent
benefit may occur by increasing the dose of one bronchodilator
when side effects are not a limiting factor. Detailed assessments
of this approach have not been performed.
Dose-response relationships using the FEVi as the outcome
are relatively flat with all classes of bronchodilators (98-101).
Toxicity is also dose related. Increasing the dose of either
a p2-agonist or an anticholinergic by an order of magnitude,
especially when given by a wet nebulizer, appears to provide
subjective benefit in acute episodes (120) (Evidence B) but is
not necessarily helpful in stable disease (121) (Evidence C).
When treatment is given by the inhaled route, attention to
effective drug delivery and training in inhaler technique are
essential. The choice of inhaler device will depend on availabil¬
ity, cost, the prescribing physician, and the skills and ability of
the patient. Patients with COPD may have more problems in ef¬
fective coordination and find it harder to use a simple metered-
dose inhaler than do healthy volunteers or younger patients
with asthma. It is essential to ensure that inhaler technique is
correct and to recheck this at each visit.
Glucocorticosteroids. Regular treatment with inhaled
glucocorticosteroids does not modify the long-term decline of
FEVj in patients with COPD (95-97, 122). However, regular
treatment with inhaled glucocorticosteroids is appropriate for
symptomatic patients with COPD with an FEVi < 50% pre¬
dicted (stages III and IV) and repeated exacerbations (e.g.,
three in the last 3 yr) (123-126) (Evidence A). This treatment
has been shown to reduce the frequency of exacerbations and
thus improve health status (127) (Evidence A), and withdrawal
from treatment with inhaled glucocorticosteroids can lead to
exacerbations in some patients (128). Reanalysis of pooled
data from several longer studies of inhaled glucocorticoste¬
roids in COPD suggests that this treatment reduces all-cause
mortality (129), but this conclusion requires confirmation in pro¬
spective studies before leading to a change in current treatment
TABLE 7. BRONCHODILATORS IN STABLE CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
• Bronchodilator medications are central to symptom management in COPD.
• Inhaled therapy is preferred.
• The choice among 02-agonist, anticholinergic, theophylline, or
combination therapy depends on availability and individual response in
terms of symptom relief and side effects.
• Bronchodilators are prescribed on an as-needed or on a regular basis to
prevent or reduce symptoms.
• Long-acting inhaled bronchodilators are more effective and convenient.
• Combining bronchodilators may improve efficacy and decrease the risk of
side effects compared to increasing the dose of a single bronchodilator.
Definition of abbreviation: COPD = chronic obstructive pulmonary disease.
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recommendations. An inhaled glucocorticosteroid combined with
a long-acting (32-agonist is more effective than the individual
components (123,125,126, 130,131) (Evidence A). The dose-
response relationships and long-term safety of inhaled gluco-
corticosteroids in COPD are not known.
Long-term treatment with oral glucocorticosteroids is not
recommended in COPD (Evidence A). A side effect of long-
term treatment with systemic glucocorticosteroids is steroid
myopathy (132-134), which contributes to muscle weakness,
decreased functionality, and respiratory failure in subjects with
advanced COPD.
Other pharmacologic treatments. Vaccines. Influenza
vaccines can reduce serious illness (135) and death in patients
with COPD by approximately 50% (136, 137) (Evidence A).
Vaccines containing killed or live, inactivated viruses are re¬
commended (138) because they are more effective in elderly
patients with COPD (139). The strains are adjusted each year
for appropriate effectiveness and should be given once each
year (140). Pneumococcal polysaccharide vaccine is recommen¬
ded for patients with COPD who are 65 years and older (141,
142). In addition, this vaccine has been shown to reduce the
incidence of community-acquired pneumonia in patients with
COPD who are younger than 65 years with an FEV| < 40%
predicted (143) (Evidence B).
GLj-Antitrypsin augmentation therapy. Young patients with
severe hereditary otj-antitrypsin deficiency and established
emphysema may be candidates for ai-antitrypsin augmentation
therapy. However, this therapy is very expensive, not available
in most countries, and not recommended for patients with COPD
that is unrelated to ofrantitrypsin deficiency (Evidence C).
Antibiotics. Prophylactic, continuous use of antibiotics has
been shown to have no effect on the frequency of exacerbations
in COPD (144—146), and a study that examined the efficacy of
chemoprophylaxis undertaken in the winter months over a pe¬
riod of 5 years concluded that there was no benefit (147). There
is no current evidence that the use of antibiotics, other than for
treating infectious exacerbations of COPD and other bacterial
infections, is helpful (148, 149) (Evidence A).
Mucolytic (mucokinetic, mucoregulator) agents (ambroxol,
erdosteine, carbocysteine, iodinated glycerol). The regular use
of mucolytics in COPD has been evaluated in a number of long-
term studies with controversial results (150-152). Although
a few patients with viscous sputum may benefit from mucolytics
(153, 154), the overall benefits seem to be very small, and the
widespread use of these agents cannot be recommended at
present (Evidence D).
Antioxidant agents. Antioxidants, in particular N-acetylcys-
teine, have been reported in small studies to reduce the
frequency of exacerbations, leading to speculation that these
medications could have a role in the treatment of patients with
recurrent exacerbations (155-158) (Evidence B). However,
a large randomized controlled trial found no effect of N-
acetylcysteine on the frequency of exacerbations, except in
patients not treated with inhaled glucocorticosteroids (159).
Immunoregulators (immunostimulators, immunomodulators).
Studies using an immunoregulator in COPD show a decrease in
the severity and frequency of exacerbations (160, 161). How¬
ever, additional studies to examine the long-term effects of this
therapy are required before its regular use can be recommended
(162).
Antitussives. Cough, although sometimes a troublesome
symptom in COPD, has a significant protective role (163).
Thus, the regular use of antitussives is not recommended in
stable COPD (Evidence D).
Vasodilators. In patients with COPD, inhaled nitric oxide can
worsen gas exchange because of altered hypoxic regulation of
ventilation-perfusion balance (164,165). Therefore, based on the
available evidence, nitric oxide is not indicated in stable COPD.
Narcotics (morphine). Oral and parenteral opioids are ef¬
fective for treating dyspnea in patients with advanced COPD
disease. There are insufficient data to conclude whether nebu¬
lized opioids are effective (166). However, some clinical studies
suggest that morphine used to control dyspnea may have serious
adverse effects and its benefits may be limited to a few sensitive
subjects (167-171).
Others. Nedocromil, leukotriene modifiers, and alternative
healing methods (e.g., herbal medicine, acupunture, homeopa¬
thy) have not been adequately tested in patients with COPD
and thus cannot be recommended at this time.
Nonpharmacologic treatments. Rehabilitation. The princi¬
pal goals of pulmonary rehabilitation are to reduce symptoms,
improve quality of life, and increase physical and emotional
participation in everyday activities. To accomplish these goals,
pulmonary rehabilitation covers a range of nonpulmonary prob¬
lems that may not be adequately addressed by medical therapy
for COPD. Such problems, which especially affect patients with
stages II through IV COPD, include exercise deconditioning,
relative social isolation, altered mood states (especially de¬
pression), muscle wasting, and weight loss.
Although more information is needed on criteria for patient
selection for pulmonary rehabilitation programs, patients with
COPD at all stages of disease appear to benefit from exercise
training programs, improving with respect to both exercise
tolerance and symptoms of dyspnea and fatigue (172) (Evidence
A). Data suggest that these benefits can be sustained even after
a single pulmonary rehabilitation program (173-175). Benefit
does wane after a rehabilitation program ends, but if exercise
training is maintained at home, the patient's health status remains
above pre-rehabilitation levels (Evidence B). To date, there is no
consensus on whether repeated rehabilitation courses enable
patients to sustain the benefits gained through the initial course.
Benefits have been reported from rehabilitation programs con¬
ducted in inpatient, outpatient, and home settings (176-178).
Ideally, pulmonary rehabilitation should involve several
types of health professionals. The components of pulmonary re¬
habilitation vary widely from program to program, but a com¬
prehensive pulmonary rehabilitation program includes exercise
training, nutrition counseling, and education. Baseline and out¬
come assessments of each participant in a pulmonary rehabil¬
itation program should be made to quantify individual gains and
target areas for improvement. Assessments should include the
following:
• Detailed history and physical examination
• Measurement of spirometry before and after use of a bron-
chodilator drug
• Assessment of exercise capacity
• Measurement of health status and impact of breathlessness
• Assessment of inspiratory and expiratory muscle strength
and lower limb strength (e.g., quadriceps) in patients who
suffer from muscle wasting
The first two assessments are important for establishing
entry suitability and baseline status but are not used in outcome
assessment. The last three assessments are baseline and out¬
come measures.
Oxygen therapy The long-term administration of oxygen
(> 15 h/d) to patients with chronic respiratory failure has been
shown to increase survival (179, 180). It can also have a bene¬
ficial impact on hemodynamics, hematologic characteristics,
exercise capacity, lung mechanics, and mental state (181).
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Long-term oxygen therapy is generally introduced in
patients with stage IV COPD, who have
• Pao2 at or below 7.3 kPa (55 mm Hg) or Sa0l at or below
88%, with or without hypercapnia (Evidence B), or
• Pao2 between 7.3 kPa (55 mm Hg) and 8.0 kPa (60 mm Hg),
or Sa0; of 88%, if there is evidence of pulmonary hyperten¬
sion, peripheral edema suggesting congestive cardiac failure,
or polycythemia (hematocrit > 55%) (Evidence D).
The primary goal of oxygen therapy is to increase the
baseline Pa0, to at least 8.0 kPa (60 mm Hg) at sea level and
rest, and/or produce an Sa02 of at least 90%, which will preserve
vital organ function by ensuring adequate delivery of oxygen. A
decision about the use of long-term oxygen should be based on
the waking Pao2 values. The prescription should always include
the source of supplemental oxygen (gas or liquid), method of
delivery, duration of use, and flow rate at rest, during exercise,
and during sleep.
Ventilatory support. Although long-term noninvasive
positive-pressure ventilation (NIPPV) cannot be recommended
for the routine treatment of patients with chronic respiratory
failure due to COPD, the combination of NIPPV with long-term
oxygen therapy may be of some use in a selected subset of
patients, particularly in those with pronounced daytime hyper¬
capnia (182).
Surgical treatments. Bullectomy. In carefully selected
patients, this procedure is effective in reducing dyspnea and
improving lung function (183) (Evidence C). A thoracic CT
scan, arterial blood gas measurement, and comprehensive re¬
spiratory function tests are essential before making a decision
regarding suitability for resection of a bulla.
Lung volume reduction surgery. A large multicenter study
of 1,200 patients comparing lung volume reduction surgery
with medical treatment has shown that after 4.3 years, patients
with upper lobe emphysema and low exercise capacity who
received the surgery had a greater survival rate than similar
patients who received medical therapy (54 vs. 39.7%) (184). In
addition, the surgery patients experienced greater improvements
in their maximal work capacity and their health-related quality of
life. The advantage of surgery over medical therapy was less
significant among patients who had other emphysema distribution
or high exercise capacity before treatment. Although the results of
this study showed some very positive results of surgery in a select
group of patients (69, 184), lung volume reduction surgery is an
expensive palliative surgical procedure and can be recommended
only in carefully selected patients.
Lung transplantation. In appropriately selected patients with
very advanced COPD, lung transplantation has been shown to
improve quality of life and functional capacity (185-188)
(Evidence C). Criteria for referral for lung transplantation
include FEV! < 35% predicted, Pao2 < 7.3-8.0 kPa (55-60
mm Hg), PaCo2 > 6.7 kPa (50 mm Hg), and secondary
pulmonary hypertension (189, 190).
Special considerations. Surgery in COPD. Postoperative
pulmonary complications are as important and common as
postoperative cardiac complications and, consequently, are
a key component of the increased risk posed by surgery in
patients with COPD. The principal potential factors contribut¬
ing to the risk include smoking, poor general health status, age,
obesity, and COPD severity. A comprehensive definition of
postoperative pulmonary complications should include only
major pulmonary respiratory complications, namely lung infec¬
tions, atelectasis, and/or increased airflow obstruction, all
potentially resulting in acute respiratory failure and aggravation
of underlying COPD (191-196).
Component 4: Manage Exacerbations
KEY POINTS
• An exacerbation of COPD is defined as an event in the
natural course of the disease characterized by a change in
the patient's baseline dyspnea, cough, and/or sputum that
is beyond normal day-to-day variations, is acute in onset,
and may warrant a change in regular medication in
a patient with underlying COPD.
• The most common causes of an exacerbation are in¬
fection of the tracheobronchial tree and air pollution,
but the cause of about one-third of severe exacerbations
cannot be identified (Evidence B).
• Inhaled bronchodilators (particularly inhaled p2-agonists
with or without anticholinergics) and oral glucocorticos-
teroids are effective treatments for exacerbations of
COPD (Evidence A).
• Patients experiencing COPD exacerbations with clinical
signs of airway infection (e.g., increased sputum purulence)
may benefit from antibiotic treatment (Evidence B).
• Noninvasive mechanical ventilation in exacerbations
improves respiratory acidosis, increases pH, decreases
the need for endotracheal intubation, and reduces PaCo2,
respiratory rate, severity of breathlessness, the length of
hospital stay, and mortality (Evidence A).
• Medications and education to help prevent future exac¬
erbations should be considered as part of follow-up,
because exacerbations affect the quality of life and
prognosis of patients with COPD.
Introduction. COPD is often associated with exacerbations
of symptoms (197-201). An exacerbation of COPD is defined as
"an event in the natural course of the disease characterized by
a change in the patient's baseline dyspnea, cough, and/or
sputum that is beyond normal day-to-day variations, is acute
in onset, and may warrant a change in regular medication in
a patient with underlying COPD" (202, 203). Exacerbations are
categorized in terms of either clinical presentation (number of
symptoms [199]) and/or heath care resources utilization (202).
The impact of exacerbations is significant and a patient's
symptoms and lung function may both take several weeks to
recover to the baseline values (204).
The most common causes of an exacerbation are infection of
the tracheobronchial tree and air pollution (205), but the cause
of approximately one-third of severe exacerbations cannot be
identified. The role of bacterial infections is controversial, but
recent investigations have shown that at least 50% of patients
have bacteria in high concentrations in their lower airways
during exacerbations (206-208). Development of specific im¬
mune responses to the infecting bacterial strains, and the
association of neutrophilic inflammation with bacterial exacer¬
bations, also support the bacterial causation of a proportion of
exacerbations (209-212).
Diagnosis and assessment of severity. Medical history. In¬
creased breathlessness, the main symptom of an exacerbation, is
often accompanied by wheezing and chest tightness, increased
cough and sputum, change of the color and/or tenacity of
sputum, and fever. Exacerbations may also be accompanied
by a number of nonspecific complaints, such as tachycardia and
tachypnea, malaise, insomnia, sleepiness, fatigue, depression,
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and confusion. A decrease in exercise tolerance, fever, and/or
new radiologic anomalies suggestive of pulmonary disease may
herald a COPD exacerbation. An increase in sputum volume
and purulence points to a bacterial cause, as does prior history
of chronic sputum production (199, 212).
Assessment of severity. Assessment of the severity of an
exacerbation is based on the patient's medical history before the
exacerbation, preexisting comorbidities, symptoms, physical
examination, arterial blood gas measurements, and other labo¬
ratory tests. Physicians should obtain the results of previous
evaluations, where possible, to compare with the current clinical
data. Specific information is required on the frequency and
severity of attacks of breathlessness and cough, sputum volume
and color, and limitation of daily activities. When available,
prior arterial blood gas measurements are extremely useful for
comparison with those made during the acute episode, as an
acute change in these tests is more important than their absolute
values. Thus, where possible, physicians should instruct their
patients to bring the summary of their last evaluation when they
come to the hospital with an exacerbation. In patients with stage
IV COPD, the most important sign of a severe exacerbation is
a change in the mental status of the patient and this signals
a need for immediate evaluation in the hospital.
Spirometry and PEF. Even simple spirometric tests can be
difficult for a sick patient to perform properly. These measure¬
ments are not accurate during an acute exacerbation; therefore,
their routine use is not recommended.
Pulse oximetry and arterial blood gas measurement. Pulse
oximetry can be used to evaluate a patient's oxygen saturation
and need for supplemental oxygen therapy. For patients that
require hospitalization, measurement of arterial blood gases is
important to assess the severity of an exacerbation. A Pa02 <
8.0 kPa (60 mm Hg) and/or Sao2 < 90% with or without PaCo2
> 6.7 kPa (50 mm Hg) when breathing room air indicate
respiratory failure. In addition, moderate to severe acidosis
(pH < 7.36) plus hypercapnia (PaCo2 > 6-8 kPa, 45-60 mm Hg)
in a patient with respiratory failure is an indication for
mechanical ventilation (196, 213).
Chest X-ray and ECG. Chest radiographs (posterior/ante¬
rior plus lateral) are useful in identifying alternative diagnoses
that can mimic the symptoms of an exacerbation. An ECG aids
in the diagnosis of right heart hypertrophy, arrhythmias, and
ischemic episodes. Pulmonary embolism can be very difficult to
distinguish from an exacerbation, especially in advanced
COPD, because right ventricular hypertrophy and large pulmo¬
nary arteries lead to confusing ECG and radiographic results. A
low systolic blood pressure and an inability to increase the Pao2
above 8.0 kPa (60 mm Hg) despite high-flow oxygen also
suggest pulmonary embolism. If there are strong indications
that pulmonary embolism has occurred, it is best to treat for this
together with the exacerbation.
Other laboratory tests. The complete blood count may iden¬
tify polycythemia (hematocrit > 55%) or suggest bleeding.
White blood cell counts are usually not very informative. The
presence of purulent sputum during an exacerbation of symp¬
toms is sufficient indication for starting empirical antibiotic
treatment (33). Streptococcus pneumoniae, Plemophilus influen¬
zae, and Moraxella catarrhalis are the most common bacterial
pathogens involved in COPD exacerbations. If an infectious
exacerbation does not respond to the initial antibiotic treatment,
a sputum culture and an antibiogram should be performed.
Biochemical test abnormalities can be associated with an
exacerbation and include electrolyte disturbance(s) (e.g., hypo¬
natremia, hypokalemia), poor glucose control, or metabolic
acid-base disorder. These abnormalities can also be due to
associated comorbid conditions.
Differential diagnoses. Patients with apparent exacerba¬
tions of COPD who do not respond to treatment (204, 214)
should be reevaluated for other medical conditions that can
aggravate symptoms or mimic COPD exacerbations (153),
including pneumonia, congestive heart failure, pneumothorax,
pleural effusion, pulmonary embolism, and cardiac arrhythmia.
Noncompliance with the prescribed medication regimen can
also cause increased symptoms that may be confused with a true
exacerbation. Elevated serum levels of brain-type natriuretic
peptide, in conjunction with other clinical information, can
identify patients with acute dyspnea secondary to congestive
heart failure and enable them to be distinguished from patients
with COPD exacerbations (215, 216).
Home management. There is increasing interest in home care
for patients with end-stage COPD, although the exact criteria
for this approach as opposed to hospital treatment remain
uncertain and will vary by health care setting (217-220).
Bronchodilator therapy. Home management of COPD
exacerbations involves increasing the dose and/or frequency of
existing short-acting bronchodilator therapy, preferably with
a p2-agonist (Evidence A). If not already used, an anticholin¬
ergic can be added until the symptoms improve (Evidence D).
Glucocorticosteroids. Systemic glucocorticosteroids are
beneficial in the management of exacerbations of COPD. They
shorten recovery time, improve lung function (FEVj) and
hypoxemia (Pao2) (221-224) (Evidence A), and may reduce
the risk of early relapse, treatment failure, and length of
hospital stay (225). They should be considered in addition to
bronchodilators if the patient's baseline FEVi is less than 50%
predicted. A dose of 30 to 40 mg prednisolone per day for 7 to
10 days is recommended (221, 222, 226).
Antibiotics. The use of antibiotics in the management of
COPD exacerbations is discussed below in Hospital manage¬
ment.
Hospital management. The risk of dying of an exacerbation
of COPD is closely related to the development of respiratory
acidosis, the presence of significant comorbidities, and the need
for ventilatory support (227). Patients lacking these features are
not at high risk of dying, but those with severe underlying
COPD often require hospitalization in any case. Attempts at
managing such patients entirely in the community have met
with only limited success (228), but returning them to their
homes with increased social support and a supervised medical
care package after initial emergency room assessment has been
much more successful (229). Savings on inpatient expenditures
(230) offset the additional costs of maintaining a community-
based COPD nursing team. However, detailed cost-benefit
analyses of these approaches are awaited.
A range of criteria to consider for hospital assessment/
admission for exacerbations of COPD are shown in Table 8.
Some patients need immediate admission to an intensive care
unit (ICU) (Table 9). Admission of patients with severe COPD
exacerbations to intermediate or special respiratory care units
may be appropriate if personnel, skills, and equipment exist to
identify and manage acute respiratory failure successfully.
The first actions when a patient reaches the emergency
department are to provide supplemental oxygen therapy and
to determine whether the exacerbation is life threatening. If so,
the patient should be admitted to the ICU immediately. Other¬
wise, the patient may be managed in the emergency department
or hospital (Table 10).
Controlled oxygen therapy. Oxygen therapy is the cor¬
nerstone of hospital treatment of COPD exacerbations. Sup¬
plemental oxygen should be titrated to improve the patient's
hypoxemia. Adequate levels of oxygenation (Pao2 > 8.0 kPa, 60
mm Hg, or Sao2 > 90%) are easy to achieve in uncomplicated
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TABLE 8. INDICATIONS FOR HOSPITAL ASSESSMENT OR
ADMISSION FOR EXACERBATIONS OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE*
• Marked increase in intensity of symptoms, such as sudden development
of resting dyspnea, change in vital signs
• Severe underlying COPD
• Onset of new physical signs (e.g., cyanosis, peripheral edema)
• Failure of exacerbation to respond to initial medical management
• Significant comorbidities
• Frequent exacerbations
• Newly occurring arrhythmias
• Diagnostic uncertainty
• Older age
• Insufficient home support
Definition of abbreviation: COPD = chronic obstructive pulmonary disease.
* Local resources need to be considered.
exacerbations, but CO2 retention can occur insidiously with
little change in symptoms. Once oxygen is started, arterial blood
gases should be checked 30 to 60 minutes later to ensure
satisfactory oxygenation without C02 retention or acidosis.
Venturi masks (high-flow devices) offer more accurate delivery
of controlled oxygen than do nasal prongs but are less likely to
be tolerated by the patient (196).
Bronchodilator therapy. Short-acting inhaled (32-agonists
are usually the preferred bronchodilators for treatment of
exacerbations of COPD (153, 196, 231) (Evidence A). If
a prompt response to these drugs does not occur, the addition
of an anticholinergic is recommended, even though evidence
concerning the effectiveness of this combination is controver¬
sial. Despite its widespread clinical use, the role of methylxan-
thines in the treatment of exacerbations of COPD remains
controversial. Intravenous methylxanthines (theophylline or
aminohylline) are currently considered second-line therapy,
used when there is inadequate or insufficient response to
short-acting bronchodilators (232-236) (Evidence B). Possible
beneficial effects in terms of lung function and clinical end-
points are modest and inconsistent, whereas adverse effects are
significantly increased (237, 238). There are no clinical studies
that have evaluated the use of inhaled long-acting bronchodi¬
lators (either (32-agonists or anticholinergics) with or without
inhaled glucocorticosteroids during an acute exacerbation.
Glucocorticosteroids. Oral or intravenous glucocorticos¬
teroids are recommended as an addition to other therapies in
the hospital management of exacerbations of COPD (222, 223)
(Evidence A). The exact dose that should be recommended is
not known, but high doses are associated with a significant risk
of side effects. Thirty to 40 mg of oral prednisolone daily for
7 to 10 days is effective and safe (Evidence C). Prolonged treat¬
ment does not result in greater efficacy and increases the risk of
side effects.
TABLE 9. INDICATIONS FOR INTENSIVE CARE UNIT
ADMISSION OF PATIENTS WITH EXACERBATIONS
OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE*
• Severe dyspnea that responds inadequately to initial emergency therapy
• Changes in mental status (confusion, lethargy, coma)
• Persistent or worsening hypoxemia (Pao2 < 5.3 kPa, 40 mm Hg), and/or
severe/worsening hypercapnia (PaCO; > 8.0 kPa, 60 mm Hg), and/or
severe/worsening respiratory acidosis (pH < 7.25) despite supplemental
oxygen and noninvasive ventilation
• Need for invasive mechanical ventilation
• Hemodynamic instability—need for vasopressors
* Local resources need to be considered.
TABLE 10. MANAGEMENT OF SEVERE BUT NOT
LIFE-THREATENING EXACERBATIONS OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE IN THE EMERGENCY
DEPARTMENT OR THE HOSPITAL*
• Assess severity of symptoms, blood gases, chest X-ray
• Administer controlled oxygen therapy and repeat arterial blood gas
measurement after 30-60 min
• Bronchodilators:
- Increase doses and/or frequency
- Combine p2-agonists and anticholinergics
- Use spacers or air-driven nebulizers
- Consider adding intravenous methylxanthines, if needed
• Add oral or intravenous glucocorticosteroids
• Consider antibiotics (oral or occasionally intravenous) when there are
signs of bacterial infection
• Consider noninvasive mechanical ventilation
• At all times:
- Monitor fluid balance and nutrition
- Consider subcutaneous heparin
- Identify and treat associated conditions (e.g., heart failure, arrhythmias)
- Closely monitor condition of the patient
Data from Reference 226.
* Local resources need to be considered.
Antibiotics. On the basis of the current available evidence
(196, 62), antibiotics should be given to the following individuals:
• Patients with exacerbations of COPD with the following
three cardinal symptoms: increased dyspnea, increased spu¬
tum volume, and increased sputum purulence (Evidence B)
• Patients with exacerbations of COPD with two of the
cardinal symptoms, if increased purulence of sputum is
one of the two symptoms (Evidence C)
• Patients with a severe exacerbation of COPD that requires
mechanical ventilation (invasive or noninvasive) (Evidence B)
The infectious agents in COPD exacerbations can be viral or
bacterial (140, 239). The predominant bacteria recovered from
the lower airways of patients with COPD exacerbations are H.
influenzae, S. pneumoniae, and M. catarrhalis (140,206,207,240).
So-called atypical pathogens, such as Mycoplasma pneumoniae
and Chlamydia pneumoniae (240, 241), have been identified in
patients with COPD exacerbations, but because of diagnostic
limitations the true prevalence of these organisms is not known.
Respiratory stimulants. Respiratory stimulants are not
recommended for acute respiratory failure (231). Doxapram,
a nonspecific but relatively safe respiratory stimulant available
in some countries as an intravenous formulation, should be used
only when noninvasive intermittent ventilation is not available
or not recommended (242).
Ventilatory support. The primary objectives of mechani¬
cal ventilatory support in patients with COPD exacerbations are
to decrease mortality and morbidity and to relieve symptoms.
Ventilatory support includes both noninvasive intermittent
ventilation using either negative- or positive-pressure devices,
and invasive (conventional) mechanical ventilation by orotra¬
cheal tube or tracheostomy.
Noninvasive mechanical ventilation. Noninvasive intermit¬
tent ventilation (NIV) has been studied in several randomized
controlled trials in acute respiratory failure, consistently pro¬
viding positive results, with success rates of 80 to 85% (182,
243-245). These studies provide evidence that NIV improves
respiratory acidosis (increases pH, and decreases Paco,), and
decreases respiratory rate, severity of breathlessness, and length
of hospital stay (Evidence A). More importantly, mortality—or
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its surrogate, intubation rate—is reduced by this intervention
(245-248). However, NIV is not appropriate for all patients, as
summarized in Table 11 (182).
Invasive mechanical ventilation. The indications for initiat¬
ing invasive mechanical ventilation during exacerbations of
COPD are shown in Table 12 and include failure of an initial
trial of NIV (252). As experience is being gained with the
generalized clinical use of NIV in COPD, several of the
indications for invasive mechanical ventilation are being suc¬
cessfully treated with NIV.
The use of invasive ventilation in patients with end-stage
COPD is influenced by the likely reversibility of the precipitat¬
ing event, the patient's wishes, and the availability of intensive
care facilities. Major hazards include the risk of ventilator-
acquired pneumonia (especially when multiresistant organisms
are prevalent), barotrauma, and failure to wean to spontaneous
ventilation. Contrary to some opinions, acute mortality among
patients with COPD with respiratory failure is lower than
mortality among patients ventilated for non-COPD causes
(253). When possible, a clear statement of the patient's own
treatment wishes—an advance directive or "living will"—makes
these difficult decisions much easier to resolve.
Weaning or discontinuation from mechanical ventilation can
be particularly difficult and hazardous in patients with COPD
and the best method (pressure support or a T-piece trial)
remains a matter of debate (254-256). In patients with COPD
who fail weaning trials, noninvasive ventilation facilitates
extubation. It can also prevent reintubation in patients with
extubation failure and may reduce mortality.
Other measures. Further treatments that can be used in the
hospital include the following: fluid administration (accurate
monitoring of fluid balance is essential); nutrition (supplemen¬
tary when needed); deep venous thrombosis prophylaxis (me¬
chanical devices, heparins, etc.) in immobilized, polycythemic,
or dehydrated patients with or without a history of thrombo¬
embolic disease; and sputum clearance (by stimulating coughing
and low-volume forced expirations as in home management).
Manual or mechanical chest percussion and postural drainage
may be beneficial in patients with excessive sputum production
or with lobar atelectasis.
Hospital discharge and follow-up. Insufficient clinical data
exist to establish the optimal duration of hospitalization in
individual patients who develop an exacerbation of COPD (197,
257, 258). Consensus and limited data support the discharge
TABLE 11. INDICATIONS AND RELATIVE CONTRAINDICATIONS
FOR NONINVASIVE INTERMITTENT VENTILATION
Selection criteria
• Moderate to severe dyspnea with use of accessory muscles and
paradoxical abdominal motion
• Moderate to severe acidosis (pH =£ 7.35) and/or hypercapnia
(Paco, > 6.0 kPa, 45 mm Hg) (251)
• Respiratory frequency > 25 breaths/min
Exclusion criteria (any may be present)
• Respiratory arrest
• Cardiovascular instability (hypotension, arrhythmias, myocardial infarction)
• Change in mental status; uncooperative patient
• High aspiration risk
• Viscous or copious secretions
• Recent facial or gastroesophageal surgery
• Craniofacial trauma
• Fixed nasopharyngeal abnormalities
• Burns
• Extreme obesity
Data from References 196, 243, 249, and 250.
TABLE 12. INDICATIONS FOR INVASIVE
MECHANICAL VENTILATION
• Unable to tolerate NIV or NIV failure (or exclusion criteria, see Table 11)
• Severe dyspnea with use of accessory muscles and paradoxical
abdominal motion
• Respiratory frequency > 35 breaths/min
• Life-threatening hypoxemia
• Severe acidosis (pH < 7.25) and/or hypercapnia (PaCo2 > 8.0 kPa, 60 mm Hg)
• Respiratory arrest
• Worsening in mental status despite optimal therapy
• Cardiovascular complications (hypotension, shock)
• Other complications (metabolic abnormalities, sepsis, pneumonia,
pulmonary embolism, barotrauma, massive pleural effusion)
Definition of abbreviation: NIV = noninvasive intermittent ventilation.
criteria listed in Table 13. Table 14 provides items to include in
a follow-up assessment 4 to 6 weeks after discharge from the
hospital. Thereafter, follow-up is the same as for patients with
stable COPD, including supervising smoking cessation, moni¬
toring the effectiveness of each drug treatment, and monitoring
changes in spirometric parameters (229). Home visits by
a community nurse may permit earlier discharge of patients
hospitalized with an exacerbation of COPD, without increasing
readmission rates (153, 259-261).
In patients who are hypoxemic during a COPD exacerba¬
tion, arterial blood gases and/or pulse oximetry should be
evaluated before hospital discharge and in the following 3
months. If the patient remains hypoxemic, long-term supple¬
mental oxygen therapy may be required.
Opportunities for prevention of future exacerbations should
be reviewed before discharge, with particular attention to
smoking cessation, current vaccination (influenza, pneumococ¬
cal vaccines), knowledge of current therapy including inhaler
technique (32, 262, 263), and how to recognize symptoms of
exacerbations. Pharmacotherapy known to reduce the number
of exacerbations and hospitalizations and delay the time of first/
next hospitalization, such as long-acting inhaled bronchodilators,
inhaled glucocorticosteroids, and combination inhalers, should
be specifically considered. Social problems should be discussed
and principal caregivers identified if the patient has a significant
persisting disability.
4. TRANSLATING GUIDELINE RECOMMENDATIONS TO
THE CONTEXT OF (PRIMARY) CARE
KEY POINTS
• There is considerable evidence that management of
COPD is generally not in accordance with current guide¬
lines. Better dissemination of guidelines and their effec¬
tive implementation in a variety of health care settings are
urgently required.
• In many countries, primary care practitioners treat the
vast majority of patients with COPD and may be actively
involved in public health campaigns and in bringing
messages about reducing exposure to risk factors to both
patients and the public.
• Spirometric confirmation is a key component of the di¬
agnosis of COPD and primary care practitioners should
have access to high-quality spirometry.
• Older patients frequently have multiple chronic health
conditions. Comorbidities can magnify the impact of
COPD on a patient's health status, and can complicate
the management of COPD.
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TABLE 13. DISCHARGE CRITERIA FOR PATIENTS WITH
EXACERBATIONS OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
• Inhaled 02-agonist therapy is required no more frequently than every 4 h
• Patient, if previously ambulatory, is able to walk across room
• Patient is able to eat and sleep without frequent awakening by dyspnea
• Patient has been clinically stable for 12-24 h
• Arterial blood gases have been stable for 12-24 h
• Patient (or home caregiver) fully understands correct use of medications
• Follow-up and home care arrangements have been completed
(e.g., visiting nurse, oxygen delivery, meal provisions)
• Patient, family, and physician are confident patient can manage successfully
at home
The recommendations provided in sections 1 through 3
define—from a disease perspective—best practices in the di¬
agnosis, monitoring, and treatment of COPD. However, (pri¬
mary) medical care is based on an engagement with patients,
and this engagement determines the success or failure of
pursuing best practice. For this reason, medical practice
requires a translation of disease-specific recommendations to
the circumstances of individual patients—with regard to the
local communities in which they live, and the health systems
from which they receive medical care.
Diagnosis
In pursuing early diagnosis, a policy of identifying patients at
high risk of COPD, followed by watchful surveillance of these
patients, is advised.
Respiratory symptoms. Of the chronic symptoms character¬
istic of COPD (dyspnea, cough, sputum production), dyspnea is
the symptom that interferes most with a patient's daily life and
health status. When taking the medical history of the patient, it
is therefore important to explore the impact of dyspnea and
other symptoms on daily activities, work, and social activities,
and provide treatment accordingly.
Spirometry. High-quality spirometry in primary care is pos¬
sible (264, 265), provided that good skills training and an
ongoing quality assurance program are provided. An alternative
is to ensure that high-quality spirometry is available in the
community—for example, within the primary care practice
itself, in a primary care laboratory, or in a hospital setting,
depending on the structure of the local health care system (266).
Ongoing collaboration between primary care and respiratory
care also helps assure quality control.
Comorbidities
Older patients frequently have multiple chronic health condi¬
tions and the severity of comorbid conditions and their impact
on a patient's health status will vary between patients and in the
same patient over time. Comorbidities for patients with COPD
may include the following: other smoking-related diseases, such
TABLE 14. ITEMS TO ASSESS AT FOLLOW-UP VISIT 4-6 WEEKS
AFTER DISCHARGE FROM HOSPITAL FOR EXACERBATIONS OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
• Ability to cope in usual environment
• Measurement of FEVi
• Reassessment of inhaler technique
• Understanding of recommended treatment regimen
• Need for long-term oxygen therapy and/or home nebulizer (for patients
with stage IV, very severe COPD)
Definition of abbreviation: COPD = chronic obstructive pulmonary disease.
as ischemic heart disease and lung cancer; conditions that arise
as a complication of a specific preexisting disease, such as
pulmonary hypertension and consequent heart failure; coexist¬
ing chronic conditions with unrelated pathogenesis related to
aging, such as bowel or prostate cancer, depression, diabetes
mellitus, Parkinson's disease, dementia, and arthritis; or acute
illnesses that may have a more severe impact in patients with
a given chronic disease. For example, upper respiratory tract
infections are the most frequent health problem in all age
groups, but they may have a more severe impact or require
different treatment in patients with COPD.
Reducing Exposure to Risk Factors
Reduction of total personal exposure to tobacco smoke, occu¬
pational dusts and chemicals, and indoor and outdoor air
pollutants, including smoke from cooking over biomass-fueled
fires, is an important goal to prevent the onset and progression
of COPD. In many health care systems, primary care practi¬
tioners may be actively involved in public health campaigns and
can play an important part in bringing messages about reducing
exposure to risk factors to patients and the public. Primary care
practitioners can also play a very important role in reinforcing
the dangers of passive smoking and the importance of imple¬
menting smoke-free work environments.
Smoking cessation is the most effective intervention to
reduce the risk of developing COPD, and simple smoking
cessation advice from health care professionals has been shown
to make patients more likely to stop smoking. Primary care
practitioners often have many contacts with a patient over time,
which provides the opportunity to discuss smoking cessation,
enhance motivation for quitting, and identify the need for
supportive pharmacologic treatment. It is very important to
align the advice given by individual practitioners with public
health campaigns to send a coherent message to the public.
Implementation of COPD Guidelines
GOLD national leaders play an essential role in the dissemi¬
nation of information about prevention, early diagnosis, and
management of COPD in health systems around the world. A
major GOLD program activity that has helped to bring together
health care teams at the local level is World COPD Day, held
annually on the third Wednesday in November.* GOLD na¬
tional leaders, often in concert with local physicians, nurses, and
health care planners, have hosted many types of activities to
raise awareness of COPD. WONCA (the World Organization of
Family Doctors) is also an active collaborator in organizing World
COPD Day activities. Increased participation of a wide variety of
health care professionals in World COPD Day activities in many
countries would help to increase awareness of COPD.
GOLD is a partner organization in the World Health
Organization's GARD with the goal to raise awareness of the
burden of chronic respiratory diseases in all countries of the
world, and to disseminate and implement recommendations
from international guidelines.
Although awareness and dissemination of guidelines are
important goals, the actual implementation of a comprehensive
care system in which to coordinate themanagement ofCOPD will
be important to pursue. Evidence is increasing that a chronic
disease management program for patients with COPD that
incorporates a variety of interventions, includes pulmonary re¬
habilitation, and is implemented by primary care reduces hospital
admissions and bed days. Key elements are patient participation
and information sharing among health care providers (267).
•For further information on World COPD Day: http://www.goldcopd.org/WCDindex.
asp.
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Background—Chronic cough is associ¬
ated with an increased sensitivity to
inhaled capsaicin in a number of condi¬
tions but there are no data for patients
with more severe asthma or chronic
obstructive pulmonary disease (COPD).
Moreover, the relationships between the
capsaicin response (expressed as the con¬
centration of capsaicin provoking five
coughs, C5), self-reported cough, and
routine medication is not known.
Methods—The cough response to capsai¬
cin in 53 subjects with asthma, 56 subjects
with COPD, and 96 healthy individuals
was recorded and compared with a
number of subjective measures of self-
reported cough, measures of airway ob¬
struction, and prescribed medication. In
asthmatic subjects the relationships be¬
tween the cough response to capsaicin and
mean daily peak flow variability and non¬
specific bronchial hyperresponsiveness to
histamine were also examined.
Results—Subjects with asthma (median
C5 = 62 mM) and COPD (median C5 =
31 mM) were similarly sensitive to capsai¬
cin and both were more reactive than
normal subjects (median C5 >500 mM).
Capsaicin sensitivity was related to symp¬
tomatic cough as measured by the diary
card score in both asthma and COPD (r =
-0.38 and r = -0.44, respectively), but only
in asthma and not COPD when measured
using a visual analogue score (r = -0.32
and r = -0.05, respectively). Capsaicin
sensitivity was independent of the degree
of airway obstruction and in asthmatics
was not related to PEF variability or PC2I)
for histamine. The response to capsaicin
was not related to treatment with inhaled
corticosteroids but was increased in those
using anticholinergic agents in both con¬
ditions.
Conclusions—These data suggest that an
increased cough reflex, as measured by
capsaicin responsiveness, is an important
contributor to the presence of cough in
asthma and COPD, rather than cough
being simply secondary to excessive air¬
way secretions. The lack of any relation¬
ship between capsaicin responsiveness
and airflow limitation as measured by the
FEV, suggests that the mechanisms pro¬
ducing cough are likely to be different
from those causing airways obstruction, at
least in patients with COPD.
('Thorax 2000;55:643-649)
Keywords: asthma; chronic obstructive pulmonary dis¬
ease; cough reflex
Chronic cough is one of the commonest symp¬
toms of patients with persistent asthma1 and
may be the sole presenting feature of this
disease.2 Cough is frequently the first symptom
reported by patients with chronic obstructive
pulmonary disease (COPD)3 and a cough pro¬
ductive of sputum is the cardinal feature of the
subset of COPD patients defined as having
chronic bronchitis.4 However, sputum produc¬
tion is often scanty or absent as COPD
progresses, yet cough remains a troublesome
problem.5
Objective attempts to assess cough sensitiv¬
ity have yielded conflicting results. When
capsaicin, the pungent extract of red pepper, is
inhaled it induces cough reproducibly without
tachyphylaxis.6 Patients with asthma have an
increased sensitivity to capsaicin which is most
marked in those who complain of cough.7
When tested with citric acid, patients with
COPD also have an increased cough response
but this has not been reported with capsaicin.7 8
These differences could reflect the use of
different tussive agents, differing patterns of
symptoms, or differences in disease severity.
Unfortunately, there are few specific data on
spirometry or other symptoms available from
the original capsaicin study which examined
only 11 patients with COPD.7We hypothesised
that the presence of chronic airflow limitation,
whether due to asthma or COPD, would be
associated with an increased capsaicin cough
response, that the cough response would be
related to the degree ofairflow obstruction, and
that the sensitivity to capsaicin would be
altered by changing airway calibre. Moreover,
we anticipated that there would a relationship
between the capsaicin cough threshold and the
perceived severity of the cough.
In the absence of an agreed symptomatic
measure of cough severity, we have compared
several methods of assessing cough as a symp¬
tom to the capsaicin response measured in
groups of stable chronic asthmatic and COPD
patients and have compared the objective data




We recruited 53 patients with chronic asthma
and 56 with COPD from our outpatient clinics.
All the asthmatic patients met the conventional
diagnostic criteria,9 as did those with COPD'0
(table 1). The presence of a persistent cough
was not necessary for inclusion in the study. All
patients were clinically stable and any patient
with a history of respiratory tract infection
in the preceding four weeks, symptoms or
investigations suggestive of oesophageal reflux,
www. ihoraxjnl. com
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Table 1 Demographic features, medication, andphysiology of subjects studied
Normal subjects Asthma COPD
No. of subjects 96 53 57
Median (range) age (years) 38 (20-65) 51 (22-73) 65 (45-88)
Sex (% male) 34 62 75
Smoking habits (%)
Current smokers 17 17 40
Ex-smokers 20 40 60
Non-smokers 63 43 0
Drug treatment (%)
P agonists 0 100 100
Anticholinergics 0 21 83
Theophylline 0 8 19
Inhaled corticosteroids 0 100 35
Lung function
Mean (SE) FEV, (1) 3.7 (0.48) 2.1 (0.12) 1.1 (0.1)
Mean (SE) FVC (1) 4.4 (0.62) 3.4 (0.16) 2.6 (0.1)
% Predicted FEV, (SE) 107 (14) 71(3) 42(2)
Mean (SE) PEF variability (%) — 15.9 (1.2) 17.0 (1.8)
(n=53) (n=18)
Mean (SE) PC20 (mg/ml) — 1.9 (0.46) —
(n=43)
FEV, = forced expiratory volume in one second; FVC = forced vital capacity; PEF — peak expira¬
tory flow; PC20 = concentration of histamine provoking a fall in FEV, of 20% or more.
Values are numbers of subjects except when otherwise stated.
subjects taking angiotensin converting enzyme
inhibitors, or those less than 18 years of age
were excluded, although there was no upper
age limit. No patient had clinical or radio¬
graphic features suggestive of co-existing bron¬
chiectasis. We excluded patients with a history
of allergic rhinitis, post nasal drip, and those
being treated for nasal symptoms. The data
were compared with those derived from our
normal subject population recruited from hos¬
pital staff, free from respiratory disease, who
denied cough and were not receiving any
medication. All subjects gave written informed
consent to the study which was approved by
our institutional ethical committee.
PROCEDURES
Subjects omitted short acting inhaled p ago¬
nists and anticholinergic agents for six hours
before attendance and longer acting drugs such
as oral theophylline or inhaled long acting p
agonists for 12 hours on all test days. All
subjects underwent the following tests.
Spirometry
Spirometric parameters were recorded with a
wedge spirometer (Vitalograph, Maidenhead,
Berkshire, UK) and the best forced expiratory
volume in one second (FEV,) and forced vital
capacity (FVC) traces from three technically
satisfactory attempts were used. Data are
expressed as percentage predicted values."
Capsaicin cough challenge
Capsaicin (Sigma Chemical Co, St Louis, Mis¬
souri, USA) was dissolved in absolute ethanol
to make a stock solution of 1CT2 M which was
further diluted with 0.9% saline to produce
nine doubling concentrations from 2 to
500 pM. Doses were administered from an
Acorn nebuliser powered from a dosimeter
calibrated to deliver 0.009 ml in each inhala¬
tion at a maximum flow rate of 0.75 1/s and a
mass median particle diameter of 5.2 pm. Sub¬
jects were asked to take a single slow inhalation
from the dosimeter beginning with saline con¬
trol and then, with a minimum of 30 second
intervals, increasing strengths of capsaicin until
a given inhalation caused five coughs (C5).
This dose was repeated to ensure that a repro¬
ducible C5 response had been attained and, if
so, that the value was recorded as the patient's
value (C5 capsaicin).
COPD: additional tests
Subjects with COPD then completed the
following additional tests:
(1) Diary cards: these were completed at
home over a two week period during which the
subject recorded symptom scores or daily cough
on a five point scale ranging from 1 = no cough
to 5 = distressing cough most of the day. The
score over the 14 day recording period was used
to calculate the mean daily diary cough score.
Peak expiratory flow (PEF) was self-recorded
using a mini Wright peak flow meter four times
a day in a standard fashion, the best of three
measurements being taken. Peak flow variation
for any particular day was taken as the difference
between the highest and lowest peak flow
divided by the highest measure. For patients
with more than nine days of complete data the
mean daily PEF variability was calculated.
(2) Hospital questionnaire: a detailed history
of current respiratory medications was ob¬
tained with particular note of 'as needed'
inhaled P agonists, regular inhaled anticholin¬
ergic agents, and inhaled corticosteroids (table
1). Sputum production was recorded as nil,
occasional, or frequent. Symptoms of cough
were recorded in a number ofways:
(a) the presence or absence of cough on most
days;
(b) whether this cough was mild, moderate,
or severe;
(c) using a 10 cm visual analogue scale
(VAS) marked between no cough at one end
and worst imaginable cough at the other end.
Further tests
After the above, patients with asthma and
COPD were invited to perform further tests
including lung volume measurement, hista¬
mine challenge tests, and the effect of bron-
chodilators on the C5 response. Histamine
challenge tests were performed later the same
day while lung volume estimation and effect of
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Figure 1 Comparison of the cumulative frequency at which subjects reached the C5
response for asthma andfor subjects with COPD compared with normal subjects.
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study days during the following three weeks. In
those with asthma the subgroup studied
depended solely on the patient's willingness to
undergo these investigations. In those with
COPD some patients were unable to take a
further part as they were about to enrol in
another clinical trial, and others were only will¬
ing to some of the extra tests. There was no
difference in mean age, percentage predicted
FEV„ or median C5 response between the
subgroups who underwent additional tests and
their parent cohorts.
(1) Static lung volumes and flow-volume
loops: 38 patients with asthma and 20 with
COPD performed flow-volume loops and
measurement of static lung volumes while
seated using a rolling seal spirometer (PK
Morgan Ltd) with standard criteria for an
acceptable loop." After coaching, each subject
performed repeated loops until three techni¬
cally satisfactory traces were obtained. The
-0.38
loop with the largest sum of FEV, and FVC
was chosen and from this loop PEF, 25-75%
forced expiratory flow (FEF25_75), and peak
inspiratory flow (PIF) were derived. Static lung
volumes were measured using the helium dilu¬
tion technique.
(2) Histamine challenge: 43 asthmatic pa¬
tients performed histamine challenge testing
15 minutes after the capsaicin study, inhaling
from a dosimeter in a standard fashion. The
FEV, was recorded before the histamine
challenge to ensure that there was no change
from the pre-capsaicin baseline. The concen¬
tration ofhistamine provoking a fall in FEV, of
20% or more (PC20) was calculated by linear
interpolation from the logarithmic concentra¬
tion response curve.
(3) Effect of changing airway calibre on the
C5 response: 40 patients with asthma and 13
with COPD performed a capsaicin challenge
test and spirometric measurements both before
and 30 minutes after each 5 mg nebulised
salbutamol, 500 pg nebulised ipratropium bro¬
mide, and 3 ml 0.9% saline. All solutions were
given using a System 22 Acorn nebuliser on
separate days at the same time of the day in
random double blind order. For each disease
group and for each solution the C5 and FEV,
values before and after administration of the
nebulised agents were compared. Twenty three
asthmatics performed a capsaicin challenge
both before and immediately after the hista¬
mine challenge so that, at the time of the
second histamine challenge, their FEV, was
reduced by at least 20% from baseline. The
effects of bronchoconstriction were then stud¬
ied by comparing the difference between the
C5 before and after the histamine challenge
test with the difference between each subject's
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Figure 2 Scatterplots with Spearman correlation coefficients showing the relationship
between self-reported cough measured using the daily diary card cough scores and capsaicin
responsiveness (CS) for (A) asthma and (B) COPD.
STATISTICAL ANALYSIS
Median C5 values and the frequency distribu¬
tion were used to describe the normal range in
each disease group. These were then compared
using the Kruskal Wallis test followed, if
significant, by paired Mann-Whitney U tests
between the groups.
The relationship between symptoms and
sensitivity to capsaicin was examined in a
number of ways. The average daily diary card
cough score and the visual analogue score
derived from the questionnaire were each
related to the C5 of each subject using Spear¬
man rank correlation coefficient within each
disease group. Patients were grouped into
those who did and those did not cough on
most days and were then compared using
Mann-Whitney U tests. Subjects were also
divided into those who considered their cough
to be mild, moderate, or severe and these
groups were compared using the Kruskal Wal¬
lis test. Similarly, subjects with asthma and
COPD were subdivided into those who rarely
produced phlegm, those who occasionally
produced phlegm, and those who usually pro¬
duced phlegm and these groups were again
compared using the Kruskal Wallis test. Lung
function data are presented as mean (SE). The
relationship between capsaicin sensitivity and
www. thoraxjnl. com
646 Doherty, Mister; Pearson, et al
Table 2 Severity ofself-reported cough in subjects with asthma and COPD using a variety ofmeasures, and its
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PC20 for histamine was examined using Spear¬
man rank correlation coefficient as was that for
the C5 response and lung function. Both pre
and post nebuliser C5 and FEV, values as well
as pre and post histamine C5 and FEV, values
were compared using Mann-Whitney U tests.
inhaled corticosteroids taken. However, those
patients using an inhaled anticholinergic drug
did have a greater C5 sensitivity (p = 0.002; fig
3A). The C5 response of those patients not
treated in this way was still significantly greater
than that of the normal subjects.
Results
The clinical and physiological data at study
entry are given in table 1. The patients with
asthma were older than the normal subjects but
younger than the patients with COPD
(p<0.001) and almost 60% had been or were
cigarette smokers. The median C5 was reduced
in both asthma (62.5 pM) and COPD
(31.2 pM) compared with the healthy controls
(>500 pM, p<0.001, fig 1). There were no sig¬
nificant differences in the median or in the dis¬
tribution of the C5 responses between the
asthmatic and COPD patients.
ASTHMA SYMPTOMS AND LUNG FUNCTION
Diary card data for the 53 patients with asthma
showed a mean (SE) daily cough score of 1.96
(0.1) which was inversely correlated with the
C5 concentration (r = -0.38, p<0.05; fig 2A).
Hospital questionnaire data using the VAS
assessment of cough were correlated with the
mean diary cough score in the 43 patients for
whom both were available (r = 0.40, p<0.05).
The VAS scores were more variable than the
diary card scores, ranging from 0 to 8.5 cm,
but they showed a similarweak correlation with
the C5 values (r = -0.32, p<0.05).
The distribution of the responses to specific
questions about the perception of cough are
given in table 2. The presence of any cough, of a
productive cough, and the patient's assessment
ofcough severity were all related to an increased
cough response and to a lower percentage
predicted FEV,. However, overall there was no
significant correlation between either the abso¬
lute FEV, or the percentage predicted FEV, and
the measured C5 response (fig 3). The cough
response was not related to whether or not sub¬
jects were current smokers or to the dose of
COPD SYMPTOMS AND LUNG FUNCTION
Complete symptomatic data were available in
only 19 cases, the remaining patients having
been recruited into a study of inhaled cortico¬
steroids where treatment changes might have
affected the data. These patient groups did not
differ significantly in their smoking habit,
percentage predicted FEV,, or median C5.
They reported a higher daily cough score than
the asthmatic subjects (2.36 (0.18) versus 1.96
(0.1)) but this difference was not significant. As
for asthma, there was a correlation between the
cough score and the mean C5 response (r =
-0.44, p<0.05; fig 2B).
Data on the response ofCOPD patients to the
cough questionnaire are given in table 2. Apart
from a non-significant trend for the patients with
'severe' cough to have an increased sensitivity to
capsaicin (p = 0.1), there were no associations
between the presence or absence of symptoms
and either C5 or FEV, (fig 4). Similarly, there
was no association between the recorded C5 and
current smoking status or the use of inhaled
corticosteroids. However, those patients using
inhaled anticholinergic treatment had an in¬
creased C5 response compared with those not so
treated (p<0.03; fig 3C), the remaining subjects
still having a greater C5 response than the
healthy controls.
C5 AND THE EFFECTS OF RESTING LUNG
FUNCTION AND ACUTE CHANGES IN AIRWAY
CALIBRE
C5 values were independent of all the param¬
eters derived from the flow-volume loop and of
the static lung volumes. In patients with asthma
C5 was unrelated to the diurnal PEF variability
or to the baseline PC20 histamine. In the 40
patients tested before and after bronchodilators
www. thoraxjnl. com
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Figure 3 Comparison of the cumulative frequency at which subjects reached the C5 response by medication for both
asthma andfor COPD: (A) asthma: inhaled anticholinergics versus no inhaled anticholinergics; (B) asthma: low versus
moderate versus high dose inhaled corticosteroids; (C) COPD: inhaled anticholinergics versus no inhaled anticholinergics;
(D) COPD: inhaled corticosteroids versus no inhaled corticosteroids.
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a mean increase in FEV, of 0.37 (0.04) 1 after
salbutamol or 0.36 (0.04) 1 after ipratropium
from a baseline of 2.07 (0.13) 1 did not change
the median C5 response. Similarly, the median
C5 values were unchanged in the 23 asthmatic
patients measured before and after histamine
challenge, despite a fall in FEV, of a mean of
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Figure 4 Scatter plot showing the relationship between C5 response and percentage
predicted FEV, for both asthma and COPD
In the 13 patients with COPD tested before
and after bronchodilators the FEV, rose from
1.2 (0.12) 1 to 1.37 (0.13) 1 after salbutamol
and to 1.41 (0.14) 1 after ipratropium, but
without a significant effect on the measured C5
response.
Discussion
The capsaicin cough challenge test is a simple
and reproducible laboratory method for the
assessment of cough susceptibility in a wide
range of diseases.7 12 It tests the afferent limb of
the cough reflex which is thought to be
mediated by rapidly adapting receptors within
the airway wall. It can be increased by inhaling
prostanoids in normal subjects13 or by taking a
thromboxane antagonist in patients with
asthma.14
Studies in a range of conditions associated
with chronic cough have shown an increased
capsaicin sensitivity that falls with successful
treatment, which can be achieved in two thirds
of cases.12 However, it is difficult to extrapolate
data from these studies to patients with either
asthma or COPD as the numbers studied, par¬
ticularly in the latter group, are relatively small
and data about lung function and bronchial
reactivity are scanty. Our data in a large group
of chronic persistent asthmatic subjects extend
earlier observations in mild asthma that
suggested that a reduced C5 cough threshold is
a frequent finding which bears some relation¬
ship to the severity of the patient's symptoms.
Other measures such as percentage predicted
FEV, have recently been shown not to relate to
the severity of cough in asthmatic subjects.15
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Similar reductions in cough threshold were
seen in patients with moderate to severe
COPD, despite the significant differences in
the baseline spirometric values and the differ¬
ent mechanisms producing the disease.16
Several methodological problems should be
addressed. We performed our capsaicin chal¬
lenge as described previously7 with the addi¬
tional feature of repeating the last concentra¬
tion inhaled to confirm the C5 end point. We
did not report the concentration producing two
coughs (C2) as we have found this to be less
reproducible than the C5 response in normal
subjects and it does not add additional
information. Others using similar methods
have also found that C2 and C5 data yield
similar information in other diseases.18 As chal¬
lenge test dosimeters are not identical, we have
related changes in our patients to our laborato¬
ry's normal values rather than to those derived
from the literature, although our normal range
overlaps that described elsewhere. We used a
fixed inspiratory flow rate to minimise differ¬
ences in cough threshold between subjects.17 In
our laboratory we have found no evidence of
age, sex, or smoking effects, unlike other
reports.18
The reduced C5 in patients with chronic
stable asthma was not surprising in view of the
earlier reports in milder disease. A range of
possible mechanisms involving different in¬
flammatory mediators has been suggested to
explain the enhanced C5 response.13 19 20 How¬
ever, given the heterogeneity of FEV, and PC20
of the asthmatic populations in which this has
now been reported, it seems likely that
increased cough susceptibility is either pro¬
duced by very non-specific means or involves
an entirely different pharmacological pathway
from the mechanisms which determine the
severity of airways reactivity or resting airway
calibre. This has implications for the modifica¬
tion of cough as a symptom in asthma.
The reduction in C5 in the patients with
COPD was unexpected as previous reports had
suggested that the C5 response was normal in
COPD and that the cough was perhaps related
to increased sputum production and now
increased responsiveness of laryngeal
receptors.21
Studies in patients with chronic bronchitis or
COPD where lung function data are available
have examined less severe disease and/or a
population diagnosed as having chronic sinus
disease,22 neither being representative of unse-
lected COPD patients reported here. Our
patients met the conventional diagnostic crite¬
ria for COPD, had limited bronchodilator
reversibility and a history of past or current
smoking, making it unlikely that there was a
significant asthmatic element to their illness. In
these patients we found no association between
reported sputum production and either cough
severity or C5 threshold.
Induced sputum studies have shown levels of
pro-inflammatory cytokines in both asthma
and COPD.23 24 Persistent airway inflammation
may contribute to the enhanced C5 response
and merits further investigation.
The confounding effects of drug treatment
or smoking are unlikely to explain our findings.
Regular use of P agonists does not appear to
modify the C5 response, despite earlier reports
ofbenefit in cough induced in volunteers,25 and
our patients were asked to omit inhaled therapy
before attendance. Short term use of oral
corticosteroids and longer term use of inhaled
corticosteroids are associated with changes in
the frequency of symptomatic cough in
COPD.26 Specific data about the effect of these
drugs on cough threshold are lacking. We
found no relationship between smoking status
and C5, neither did the regular use of p
agonists or inhaled corticosteroids relate to the
recorded response. Likewise, there were no dif¬
ferences in the symptom severity of cough,
however assessed, and the presence of sputum
production or use of inhaled corticosteroids.
We found that the C5 cough threshold was sig¬
nificantly lower in both asthmatic and COPD
patients taking regular inhaled ipratropium,
although the patients not using these drugs
were still more responsive than the control
subjects. Whilst it is tempting to postulate that
this may be a pharmacological effect, it is more
likely to reflect selection of the more severe
patients among the asthmatic group' and the
widespread use of these drugs among COPD
patients.10 Indeed, anticholinergic agents have
been shown to decrease rather than increase
the nasal response to capsaicin.27 Prospective
studies of the capsaicin response before and
after the introduction of anticholinergic treat¬
ment would be needed entirely to exclude this
as an adverse reaction to treatment.
Whilst differences in the deposition of
capsaicin to more central airway receptors
might be hypothesised to explain some of the
apparent similarities in asthmatic and COPD
patients, the absence of any relationship
between C5 and the severity of airflow
limitation is a pointer against this. None of the
measures of airflow limitation were related to
C5 in either disease. Moreover, the C5 was
unaltered even when the airway calibre was
varied acutely, suggesting that neither airflow
limitation alone nor changes in capsaicin depo¬
sition explain the increased level of response in
our patients with asthma or COPD. A similar
lack of effect of smaller changes in airway cali¬
bre has been reported in normal subjects,25 but
our data confirm that this is true in established
disease when baseline FEV, is reduced.
C5 was not related to the level of bronchial
hyperreactivity or to the level of PEF variability
over two weeks, providing further evidence that
the mechanisms underlying cough production
are not necessarily related to those determining
airway calibre.
Unlike previous studies, our patients were
not selected because of their complaint of
cough1217 but were randomly drawn from our
outpatient clinics as we did not wish to bias
our data by patients self-selected by their
perception of a subjective complaint. Most
patients, whatever the diagnosis, rated their
cough as being of either mild or moderate
severity, but the capsaicin response did not dis¬
tinguish between these subjective grades. Other
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mechanisms may be important in milder
disease, but this discrepancy is more likely to
reflect the relative insensitivity of assessing
cough from a single interview. Perceptions
about coughing reported at the hospital visit
were poorly related to severity as assessed from
the diary card data. However, patients with the
most troublesome cough did have significantly
lower C5 responses. In general, the agreement
between symptom severity and the C5 re¬
sponse was somewhat better in the asthmatic
subjects than in those with COPD. We should
be cautious in interpreting group data showing
symptomatic and C5 improvements with treat¬
ment in these diseases as the subjective and
objective measurements may not necessarily
change in the same way in an individual. This is
in contrast to other forms of chronic cough
such as that induced by ACE inhibitors where
symptom severity and C5 are in good agree¬
ment in the individual before and after
withdrawal of the drug.28
Our data show that a reduced cough thresh¬
old is a frequent finding in airways disease,
whether associated with asthma or COPD.
Reliance on one measure of self-reported
coughing can be difficult to interpret, particu¬
larly in COPD. Use of the capsaicin challenge
gives objective information about cough sus¬
ceptibility which may prove more discrimina¬
tory than just questioning about the presence
or absence of cough or sputum production.
The relative role of this mechanism and its
relationship to the effects of other agents such
as citric acid or low CI" as the disease
progresses merits further study. The mecha¬
nisms producing increased capsaicin respon¬
siveness, whether inflammatory or mediator
driven, also require further exploration, par¬
ticularly in patients with COPD where an
abnormal cough threshold appears to be
relatively common.
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Background: Patients with respiratory disease use many
different expressions to describe the sensation they
experience as breathlessness. Although previous analyses
have identified multiple dimensions of breathlessness,
there is little agreement about their number and nature.
This study has applied a novel approach, principal
component analysis (PCA), to understanding descriptions
of breathlessness in health and disease and extracting
representative components.
Methods: 202 patients (asthma n = 60, chronic
obstructive pulmonary disease n = 65, interstitial lung
disease n = 41, idiopathic hyperventilation n = 36) and
30 healthy volunteers were studied. All subjects
performed spirometry and gave binary responses to 45
descriptions recalling their experience of breathlessness
at the end of exercise; patients repeated this for resting
breathlessness. PCA identified response patterns in the
questionnaire data and extracted discriminatory compo¬
nents. Component scores were calculated for each
individual using the regression method.
Results: PCA identified six distinct components of
breathlessness on exercise, explaining 62.8% of the
variance: (1) air hunger, (2) affective, (3) nociceptive, (4)
regulation, (5) attention and (6) miscellaneous qualities.
Rest components explaining 63.1% of variance were (1)
affective, (2) air hunger, (3) nociceptive, (4) wheeze, (5)
regulation and (6) miscellaneous. Components identified
on exercise differed significantly between disease groups
and controls and were related to percentage predicted
forced vital capacity.
Conclusion: This analysis suggests that air hunger is the
dominant sensation during exercise, while affective
distress characterises resting breathlessness in patients
with a range of respiratory disorders including idiopathic
hyperventilation where lung mechanics are normal. This
suggests that common mechanisms operate in qualitative
aspects of breathlessness.
Breathlessness is one of the most frequent and
distressing symptoms experienced by patients with
lung disease and is usually defined as an uncomfor¬
table awareness of breathing.1 Healthy subjects also
experience breathlessness during exercise and this
may be characterised as physiologically appropriate
breathlessness. The clinical assessment of breath¬
lessness usually focuses on the degree or intensity of
the symptom, and much scientific effort has been
dedicated to understanding the factors that deter¬
mine the severity of breathlessness.2"4 Less attention
has been paid to the quality of the sensation and
whether this differs between conditions, although
some believe this is the case.5 6
Patients with a respiratory disease use a wide
variety of terms to describe the sensations
experienced when they become breathless. These
sensations cannot be assessed objectively7 and,
instead, representative verbal descriptors have been
identified.8 Although previous analyses in health910
and disease5 811-13 have identified clusters of these
descriptors (using cluster analysis), there is little
consistency in their number and nature and,
moreover, they are not sufficiently robust to aid
in differential diagnosis.
An alternative approach to cluster analysis is to
use principal component analysis (PCA) which
uncovers the latent structure (dimensions) of a set
of variables—in this case, breathlessness descrip¬
tors—by identifying important sources of varia¬
tion. PCA has the advantage that it does not
assume that distinct groups of descriptions exist; a
variable can appear in two separate components
and components can be allowed to correlate with
each other. Differences in the interpretation of
descriptions by subjects can therefore be accom¬
modated while also avoiding the constraint of
generating a hierarchic classification. This has been
shown to be a useful technique for identifying
patterns of respiratory symptoms in children14 but
only one study has applied PCA to breathlessness,
analysing a mixture of symptoms and qualitative
descriptors in an attempt to identify subjects with
medically unexplained breathlessness.15
We have applied PCA to the responses of healthy
volunteers and discrete patient groups to descrip¬
tions of breathlessness. We chose our patient
groups to represent a range of mechanical abnorm¬
alities, both fixed and variable, that are applied to
the respiratory system, and our principal focus was
on the recall of the sensation of breathlessness
perceived at the end of exercise. We hypothesised
that the quality of breathlessness would differ
between healthy volunteers and patients with
respiratory disease and would also differ between
breathlessness recalled at end of exercise and that
experienced at rest, although this analysis was
confined to patients with disease where this might
occur. Finally, we have explored the relationship
between the components of breathlessness and




Consecutive patients attending the outpatient
clinic and the respiratory function laboratory of
University Hospital Aintree were recruited.
Healthy control subjects of a similar age were
identified from hospital staff and relatives of
patients.
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Diagnoses were confirmed by review of the medical records
and subjects categorised as chronic obstructive pulmonary
disease (COPD), asthma, interstitial lung disease (ILD) and
idiopathic hyperventilation (IHV) when they unequivocally
met the established diagnostic criteria for these disorders"5-13 (see
online supplement for details). Patients with more than one
condition causing breathlessness were excluded.
All patients performed spirometry using a wedge bellows
spirometer (Vitalograph-R, Vitalograph Ltd, Buckinghamshire,
UK); control subjects were tested using an ultrasonic portable
spirometer (Easy One, NDD Medical Technologies, Zurich,
Switzerland). The best of three manoeuvres has been reported,
measured to ATS/ERS standards."
Questionnaire
A questionnaire comprising 45 short phrases describing breath¬
lessness and previously shown to be valid and reliable3 was
completed by each subject twice. Patients were asked to think
about how they felt when breathless at rest and to respond to
all items (yes or no). Subjects were then asked to think about
how they felt when breathless at end of exercise and to respond
to the same set of items; healthy subjects completed only the
exercise section. Unless they requested assistance, subjects were
left alone and given as much time as they needed to complete
the questionnaires.
Data analysis
All statistical analyses were performed using SPSS 13.0 (SPSS
Inc, Chicago, Illinois, USA). PCA was used to identify response
patterns in the questionnaire data both at rest and on exercise.20
PCA is an exploratory technique for investigating patterns
within a set of variables—in the current analysis, responses to a
series of descriptions of breathlessness. The large numbers of
responses can be reduced to a much smaller number of
representative components based on the covariance among
responses. If subsets of symptoms are correlated, this suggests
they are measuring aspects of a common underlying process;
several components may suggest a series of underlying
processes. The steps involved in each analysis were as follows.
Item selection
Redundant questions were removed (ie, question responses
with partial correlation coefficients >0.4 to other question
responses). To maximise the informative content of the
analysis, items that correlated with several other variables were
removed first.
Component extraction
PCA was used to generate the components and the numbers of
components for analysis were selected based on the Eigenvalues
and scree plots.
Rotation
Component rotation is used to improve the interpretability of
the results. An oblique rotation was chosen (Promax), assuming
that the components of breathlessness were unlikely to be
entirely independent of one another. The loading of the items
onto each component is a measure of the relationship between
that item and the component—the greater the loading, the
purer a measure of that component the item is. Only items with
the conventional loading of 0.4 and above were interpreted.
Component scores
For each subject included in the analysis it is possible to
calculate scores for the individual components. These scores are
derived from the subjects' responses to the items comprising
each component and their loadings. Scores were calculated
using the regression method; for each component the scores
were standardised; each has a mean value of 0 and a standard
deviation of 1. The scores indicate the relative importance of
that qualitative component of breathlessness for each indivi¬
dual, not the intensity of breathlessness.
In addition, we applied agglomerative hierarchical cluster
analysis (using the squared Euclidean distance as the dissim¬
ilarity measure) to the data set in order to compare the
components with the clusters formed. This allowed comparison
of our result with those previously generated using this
questionnaire.3
There are no available criteria against which the solution in a
PCA can be tested. However, the solution can be assessed for
face validity of the components and by examining the relation¬
ships between the component scores generated and other
available variables. We therefore examined whether diagnostic
grouping and also spirometric abnormality significantly pre¬
dicted component scores using multivariate analysis of variance
(MANOVA). If the predictor terms were significantly related to
the component scores (according to the Pillai test), then
individual associations between predictors and components
were examined using specific tests. As patients with different
conditions will inevitably have differences in spirometry, the
relationships between component scores and spirometry were
adjusted for differences due to diagnosis.
RESULTS
A total of 310 patients and 35 normal subjects were approached
to fill in the questionnaire; 234 patients and 35 normal subjects
agreed to take part in the study. Thirty-two patients and 5
healthy volunteers were excluded, leaving 202 patients and 30
normal subjects for analysis. The main reasons for exclusion
were: inconsistency in answering the repeat questions (>1 item
answered differently) and failure to give a response to more
than 5 questions. Patient characteristics, diagnoses and spiro¬
metric data are shown in table 1.
Component extraction
Exercise
For the analysis, data were pooled for the control and patient
groups. Thirty-five items were included in the PCA (Kaiser-
Meyer-Olkin measure of sampling adequacy 0.95, Bartlett's test
of sphericity <0.001); item selection is summarised in table El
in the online supplement. Six components with Eigenvalues >1
were identified (fig El in the online supplement), explaining
62.8% of the variance in the data. The main break in the scree
plot was after one component as the first component explained
the majority of the variance; however, the inclusion of the
additional five components added a further 20% to the variance
explained. The questionnaire items loading >0.4 onto each
component are shown in table 2, along with the proportion of
variance explained by each component. We named each
component based on the theme represented by the most
strongly loading items. For the descriptions of breathlessness
on exercise, the dominant component was air hunger (items
referring to a need for more air). The other independent
components explaining smaller percentages of the total variance
were (in order of magnitude): affective; items suggesting
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Table 1 Characteristics of study subjects
Diagnosis Gender
Mean age
(years) FEVi% predicted FVC% predicted FEV,/FVC ratio
Asthma (n = 60) 19M/41F 48.2 (15.4) 80.6 (26.6) 93.3 (26.7) 71.6 (12.1)
COPD (n = 65) 32M/33F 67.9 (9.2) 42.0 (30.5-56.5)* 78.3 (21.3) 40.2 (33.0-55.5)*
Interstitial lung disease
(n = 41)




8M/28F 53.7 (15.2) 93.0 (88.0-104.5)* 99.3 (14.4) 79.1 (7.6)
Healthy controls
(n = 30)
11IW19F 53.8 (12.7) 106.5 (16.0) 113.3 (17.2) 77.2 (6.3)
Data are mean (SD) except for "median (interquartile range).
COPD, chronic obstructive pulmonary disease; FEV,, forced expiratory volume in 1 s; FVC, forced vital capacity,
emotional distress, nociceptive; descriptions of unpleasant Rest
sensations, regulation; perceptions of inappropriately regulated Only data for the patients was used for this analysis. Thirty-
breathing, attention; subjective awareness of breathing; and four items were included in the PCA (Kaiser-Meyer-Olkin
miscellaneous descriptions including sighing, air not tasting measure of sampling adequacy 0.92, Bartlett test of sphericity
right and breath stopping. Several descriptions featured in more <0.001); item selection is summarised in table E2 in the online
than one component (eg, air hunger loaded onto the air hunger supplement. Again, six components with Eigenvalues >1 were
and affective components). identified (fig E2 in the online supplement), explaining 63.1% of
Table 2 Pattern matrix: item loadings on exercise for patients and controls, six component solution with
Promax rotation
Component loadings
Components (% variance) items 1
(1) Air hunger component (42.6%)
Cannot breathe deeply enough 0.86
Need to take a deeper breath 0.83
Breathing too shallow 0.77
Not satisfied by my breathing 0.67
Can't get enough air into my chest 0.67
Cannot breathe enough 0.67
(2) Affective component (5.8%)
Desperate for breath 0.89
Suffocating 0.86
Gasping for breath 0.74
Hunger for more air 0.52 0.68
Fighting for breath 0.65
(3) Nociceptive component (4.6%)
Chest aches 0.82
Chest feels tight 0.77
Raw sensation in chest 0.74
Wheezy 0.65
Raw sensation in throat 0.50
Winded in my chest 0.41
(4) Regulation component (3.7%)
Breathing is too deep 0.88
Breathing is too fast 0.68
Breathing is too heavy 0.63
Breathing feels unpleasant 0.50
Can't control my breathing 0.41
(5) Attention component (3.1%)
Puffed 0.71
Aware of my breathing 0.66
Need breath 0.47 0.53
Short of breath 0.52
Out of breath 0.49
(6) Miscellaneous component (3.0%)
Want to sigh 0.42 0.61
Air does not taste right 0.48 0.59
My breath stops 0.47 0.55
The magnitude of the component loadings represents how good each item is as an indicator of the component.
All items shown load >0.40 onto PCA components.
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Figure 1 Comparison of diagnostic groups for each component score
on exercise. Mean and 95% confidence intervals are shown. COPD,
chronic obstructive pulmonary disease; ILD, interstitial lung disease; IHV,
idiopathic hyperventilation.
the variance in the descriptions. The questionnaire item
loadings are shown in table E3 in the online supplement. The
items in the components were either identical to or synon¬
ymous with those for exercise: (1) affective, (2) air hunger, (3)
nociceptive, (4) wheeze, (5) regulation and (6) miscellaneous
descriptions. An additional component representing wheeze
emerged, but the attention component was not present. At rest
the dominant component was the affective one.
To assess whether the absence of controls from the analysis
had produced this change in the components and the variance
explained, the PCA was repeated on the exercise data without
the healthy volunteers. This confirmed that the air hunger
component still explained most of the variance (see table E4 in
online supplement) and the nociceptive items split into two
components.
Agglomerative hierarchical cluster analysis
The exercise pooled control and patient data were analysed
using all 45 descriptions. This generated a complex dendrogram.
Using the criteria as previously applied by Elliott et ala (squared
Euclidean distance of 12.5), 17 clusters of descriptions were
produced (fig E3 and table E5 in online supplement). At a
Euclidean distance of 17.5 the cluster analysis gave six clusters.
However, these did not seem to represent coherent themes—for
example, the items in the air hunger and affective components
appeared in a single cluster.
Breathlessness component scores in health and disease
Using the scores generated by the regression method, we were
able to examine the validity of the components by assessing
their ability to discriminate between control subjects and those
with respiratory disease. Gender and age had no significant
effect on any component score but, for the regulation
component, there was a trend towards a significant gender
difference at rest (p = 0.06) and on exercise (p = 0.09).
Exercise component scores
The diagnostic category significantly influenced' the component
score for all six exercise components (air hunger p<0.001,
affective p<0.001, nociceptive p<0.001, regulation p<0.001,
attention p = 0.001 and miscellaneous p = 0.008). Post hoc
analyses (Bonferroni correction for multiple comparisons)
suggested that, compared with controls, the value of the
component scores was greater for the air hunger component
(p<0.001 for all diagnoses), the regulation component (p<0.001
for all diagnoses) and the nociceptive component (p<0.001 for
all diagnoses) (fig 1). There were also significantly different
scores compared with controls for the affective component in
asthma, COPD and ILD (p = 0.005, p<0.001 and p<0.001,
respectively) but not IHV (p = 0.125); a similar pattern occurred
for the attentive component (COPD p<0.001, ILD p = 0.001,
and borderline significance for IHV p = 0.06 and asthma
p = 0.082). In contrast, the miscellaneous component was
significantly higher in IHV than asthma or ILD (p = 0.03 and
p = 0.007, respectively).
Rest component scores
The only significant difference between the diagnostic groups at
rest was for the affective component (p = 0.04). Post hoc
analysis suggested a higher score in subjects with COPD than in
those with asthma (p = 0.04, fig E4 in online supplement).
Breathlessness component scores and spirometry
MANOVA models (exertion and rest) were generated with
component scores as the dependant variables and spirometry as
predictors. The ratio of forced expiratory volume in 1 s (FEVi)
to forced vital capacity (FVC) was used to indicate airflow
obstruction and FVC percentage predicted was used as a marker
of volume change. All models were adjusted for age, gender and
diagnosis.
In the multivariate model for exercise, FVC percentage
predicted independently predicted all the breathlessness com¬
ponent scores except for the miscellaneous component (air
hunger p<0.001, affective p<0.001, nociceptive p = 0.001,
regulation p<0.001 and attention p = 0.02). Post hoc analyses
suggested that FVC percentage predicted was significantly
related to air hunger, affective and nociceptive components,
independent of diagnosis (table 3). The FEVt/FVC ratio was not
significant in the model (p = 0.37).
At rest, the FEVi/FVC ratio and FVC percentage predicted did
not significantly influence the component scores when the
model was adjusted for age, gender and diagnosis.
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Table 3 Post hoc analyses for variables significantly predicting
breathlessness components on exercise in MAIMOVA
Components Independent variables p Values
Exercise air hunger FVC (% predicted) Diagnosis 0.02, <0.001
Exercise affective FVC (% predicted) 0.004
Exercise nociceptive FVC (% predicted) Diagnosis 0.02, 0.001
Exercise regulation Diagnosis <0.001
Exercise attentive Diagnosis <0.001
Exercise miscellaneous - -
Diagnosis reflects the independent impact of a specific diagnostic category.
FVC, forced vital capacity.
DISCUSSION
Although breathlessness is a cardinal symptom in respiratory
disease, relatively little attention has been paid to its qualitative
aspects. This reflects the difficulty in developing consistent
themes from the range of attributes associated with this
symptom. The replication of cluster analysis results in different
patient groups has seldom been shown, while the resulting
dendrograms are difficult to interpret. This is the first study to
demonstrate that PCA can be successfully applied as an
alternative to this approach and can identify different compo¬
nents of breathlessness experienced both at rest and end of
exercise. The variation in the description of breathlessness at
end of exercise was dominated by a single component relating
to air hunger whereas, at rest, descriptions with emotional
connotations (affective component) were the most important
discriminators. Much smaller contributions were made by other
components representing nociceptive sensations, attributes
related to how breathing is regulated, wheeziness and the
attention paid to the act of breathing. In general, the association
of these variables and the diagnosis was closer on exercise than
in the resting data. Gender and age had no significant effect on
any component score, suggesting that the differences seen in
perceived intensity of exertional breathlessness in older
women21 are not associated with differences in quality of
breathlessness.
To aid comparison with published data, we used the same list
of descriptions of breathlessness as those reported by Elliott
et a!." Like them, we obtained a relatively complex dendrogram
with a large number of clusters. This implies that breathlessness
is a complicated sensation with a large number of dimensions,
but we were not able to replicate the clusters formed and these
differed significantly from the components indicated by the
PCA. In contrast, PCA produced a smaller number of
components with good face validity. When a simpler structure
was derived from the cluster analysis (six clusters) it was
apparent that the items in the air hunger and affective
components from the PCA formed a single cluster (ie, were
not discriminated by this technique). Furthermore, the remain¬
ing clusters lacked consistent themes.
Although the terms used to describe each cluster and each
component are arbitrary and can be debated, the patients clearly
identified qualities of unsatisfied inspiration within the group¬
ing "air hunger" as the dominant perception of breathlessness
on exercise. By contrast, terms related to emotional distress,
"affective" attributes, were the ones most characteristic of
breathlessness perceived at rest, reflecting the frightening nature
of this sensation previously identified by patients such as those
with COPD.22
The validity of the PCA was confirmed by our analysis of the
derived component scores. We found that exercise components
clearly distinguished between breathlessness in health and
disease, but there were few significant differences between the
different conditions for both rest and exercise. However, there
was a difference in the affective component scores between
asthma and COPD which could reflect the reported prevalence
of depression in COPD, which is itself associated with chronic
breathlessness.23 24
The dominance of air hunger as the major quality of
breathlessness on exercise, irrespective of the differences in the
mechanical behaviour of the lungs and those reporting it, is
initially surprising. This may reflect a common mechanism
generating this sensation on exercise. Air hunger is equally
induced by both hypercapnia and hypoxia in health25 but is also
experienced by ventilated quadriplegic subjects,25 supporting a
model in which air hunger is mediated, at least in part, via the
chemoreceptors and is independent of respiratory muscle
contraction; this has been confirmed by studies in paralysed
non-sedated volunteers.27 However, the adequacy of pulmonary
inflation is also important in both inducing and relieving air
hunger,28 suggesting that the sensation results from a balance
between chemoreceptor and mechanoreceptor inputs.29 In
disease, the factors modulating this interaction are complex.
We speculate that mechanical limitation at end of exercise is a
possible unifying explanation for the dominance of air hunger
across our disease groups. Patients with significant airflow
obstruction who report breathlessness show dynamic hyper¬
inflation of their end-expiratory lung volume during exercise.30
Moreover, the degree of breathlessness increases significantly as
the end-inspiratory lung volume approaches the inspiratory
reserve volume.29 31 A similar situation may apply in ILD where
the absolute inspiratory reserve volume is reduced.32 Although
patients with IP1V do not have any mechanical limitation to
breathing at rest, they do show respiratory rather than
cardiovascular limitation on exercise and the large tidal volume
breathing they adopt at end of exercise is likely to encroach on
the inspiratory reserve volume and generate a dissimilar
sensation of unsatisfied inspiration.33 This interpretation is in
keeping with our limited physiological data which showed that
FVC rather than FEVi was related to the sensation of
breathlessness irrespective of the diagnosis. Thus, a common
mechanism may explain why seemingly different diseases at
rest produce qualitatively similar sensations.
Our study investigated respiratory diseases as a cause of
breathlessness and omitted other conditions such as congestive
heart failure where a mixture of cardiac and pulmonary
abnormalities contribute directly or indirectly to dyspnoea. Our
patient groups represent a spectrum of respiratory disease, all
causing breathlessness but characterised by different mechanical
abnormalities—the asthma and COPD groups representing vari¬
able and fixed airflow obstruction and the ILD group representing
a purer form of elastic respiratory loading. Previous reports have
not always included healthy controls in the same study as
patients,5 811 and have not studied subjectswith IHV. The subjects
with IHV acted as a "positive control" group—subjects with
symptoms of breathlessness but with normal spirometry, transfer
factor and resting lung volumes. Patients with IHV are often felt to
have psychological problems underlying their breathlessness, but
our data indicate that the sensation experienced is the same as in
patientswith structural lung disease. The association of air hunger
as the dominant exercise-related symptom was not different from
that where breathlessness was due to organic factors, nor was
there any stronger attribution of breathlessness to factors
associated with the affective or emotional components we
identified—something which might be expected if psychological
factors played a dominant role in this condition.
Thorax 2009;64:713-718. doi:10.1136/thx.2008.104869 717
Downloaded from thorax.bmj.com on March 21, 2012 - Published by group.bmj.com
Respiratory physiology
Our study has some limitations. We used a questionnaire
developed by others to try and reduce variability between our
datasets. However, the descriptions within this questionnaire
are not strongly representative of the work or effort of
breathing, an attribute previously described as being strongly
related to breathlessness.34 However, our main interest was to
identify the qualitative dimensions of breathlessness rather than
dimensions inextricably related to the intensity of respiratory
drive such as work and effort. It also would have been
interesting to establish objectively the exercise capacity of all
the participants, but PCA requires a large number of subjects
making this impractical, notwithstanding the difficulties in
identifying a suitable standardised test for all the disease groups
studied. The range of spirometric abnormalities in the selected
patient groups should be sufficient to encompass a wide range
of exercise performance. Finally, we related breathlessness to a
specific point during exercise—namely, maximum exercise
performance—and it is possible that mechanisms operating
earlier in exercise may be associated with a different quality of
respiratory sensation. However, given the number of individuals
questioned, identifying a specific point to consider made it
easier for them to focus on the wide range of attributes they
were asked to classify.
Our data suggest that the qualitative experience of breath¬
lessness involves a variety of unpleasant sensations which are
shared by a range of respiratory conditions irrespective of their
aetiology. .Whether the same is true for other conditions where
breathlessness limits exercise remains to be determined. We
have not identified significant differences in the qualitative
attributes of breathlessness which are disease-related, so the
present clinical practice of quantifying the intensity of the
sensation relative to the task which produces it appears to
capture the important attributes of breathlessness.
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Introduction
Impairment of cerebral function can
be induced by chronic hypoxia both ex¬
perimentally and clinically (1, 2). Re¬
current transient hypoxemia has been
shown to be particularly frequent and
profound during sleep in patients with
chronic bronchitis and emphysema
(3-5) but the frequency and duration
of such nocturnal hypoxemic episodes
vary considerably from patient to pa¬
tient. We have previously shown that
administration of oxygen improves
cerebral function in chronic bronchitis
and emphysema as assessed by the day¬
time electroencephalogram (EEG) (6).
We have now studied a similar group
of patients to see if their sleep is more
disturbed than that of healthy subjects
of similar age sleeping under the same
conditions. We have also examined the
relationship between the EEG pattern
and the severity of nocturnal hypox¬
emia, and the effects on the EEG of
improving oxygen saturation during
the night by nocturnal oxygen therapy.
Methods
We studied 20 patients with chronic bron¬
chitis and emphysema, 13 of whom were
>articipants in the Medical Research Coun¬
t's trial of domiciliary oxygen therapy (7).
these 13 were of the "blue and bloated''
ype (7 men, 6 women); the remaining 7
'ere of the-"pink and puffing" type (6 men,
woman). All the patients had severe irre-
ersible airflow obstruction. The "blue and
loated" patients showed significant day-
me hypoxemia and hypercapnia, whereas
ie "pink and puffing" patients were less
ypoxemic and did not retain carbon diox-
le (table 1). No patient had had an exacer-
ition of chronic bronchitis for 6 wk prior
1 study, none was receiving hypnotics,
datives, or stimulant drugs, and none was
ore than 20% above his or her desired
2ight. All were treated with beta2-sym-
cthomimetic agents given by aerosol. Our
ntrol group was comprised of 9 subjects
men and 4 women), all of whom were
:e from respiratory disease and had nor-
SUMMARY We recorded the electroencephalogram, electrooculogram, electromyogram, and
ear oxygen saturation (Sao,) during sleep in 20 patients with chronic bronchitis and emphysema,
13 of whom had a low arterial Po, and elevated Pco, ("blue and bloated") and 7 of whom had a
relatively normal arterial Po, and Pco, ("pink and putting"), and compared the findings in these
patients with 9 healthy subjects of similar age. All subjects slept for 2 nights and there was no
difference between the groups in the total sleep period. The patients had a lower stable Sao, than
the normal subjects, the "blue and bloated" patients having significantly more hypoxemic
episodes during sleep (p < 0.01). Transient nocturnal hypoxemia was commonest during REM
sleep in both patients and healthy subjects and its duration was not related to any sleep variable
examined. The patients had significantly shorter periods of sleep between the episodes of brief
arousal occurring during the night (p < 0.02). Six representative "blue and bloated" patients
(mean FEV„ 0.6 ± 0.2 L; mean Pao,, 48 ±7 mmHg; mean Paco,, 50 ± 6 mmHg) were studied for a
further night receiving either air or oxygen on successive study nights. When breathing oxygen
there were fewer hypoxemic episodes per night (mean, 3.7 breathing air; mean, 1.5 breathing ox¬
ygen) and the amount of sleep proper (Stages 2, 3, and 4) increased in 5 of 6 patients. Intervening
wakefulness and drowsiness was reduced by oxygen, and the amount of time spent in REM sleep
increased to 17% of total sleep. The total sleep period and distribution of sleep stages in the
"blue and bloated" patients breathing oxygen resembled that seen in normal subjects rather than
in the "pink and puffing" patients with a similar degree of airway obstruction, suggesting that dif¬
ferences in the ability to arouse from sleep may be related to the frequency and severity of noctur¬
nal hypoxia. AM REV RESPIR DIS 1982; 126:206-210
mal spirometric tests and a normal waking
ear oxygen saturation. These subjects were
drawn from hospital staff and a group of
healthy volunteers.
The subjects slept in a quiet darkened
room for 2 consecutive nights, the first
night serving to accustom them to the moni¬
toring equipment, and data were not col¬
lected until the second night of study. The
whole night's sleep was recorded on an
8-channel Galileo EEG apparatus with the
usual electrophysiologic technique includ¬
ing EEG (from 2 midline frontoparietal
electrodes), electro-oculogram (from 4
frontal electrodes outside and above the
outer canthi), and electromyogram (from 2
submental electrodes). Ear oxygen satura¬
tion was continuously recorded using a
Hewlett-Packard 47201A ear oximeter, air¬
flow at the mouth and nostrils was moni¬
tored by thermocouples mounted on nasal
prongs, and anteroposterior thoracic move¬
ments were measured using an induction
stethogram. These respiratory variables
were recorded on paper and analyzed off¬
line. We considered arterial oxygen satura¬
tion (Sao2) to be stable when it did not vary
by more than 5% over a 15-min period and
transient nocturnal hypoxemia to occur
when the Sao2 fell from its previously stable
level by more than 10% for longer than
1 min.
A computer-generated signal was re¬
corded on the EEG trace every 15 min to
provide a frame of synchronization for the
oxygen saturation, respiration, and EEG
sleep data. The sleep pattern was scored vi¬
sually according to the standard criteria (8),
except for the amplitude criteria of the slow
wave Stages 3 and 4, which were decreased
to 50microvolts. Themaximal amplitude of
the slow waves of Stages 3 and 4 was also
measured. All the EEGs were scored with¬
out knowledge of the type of subjects stud¬
ied or the severity of nocturnal hypoxemia
during that study.
Six of the "blue and bloated" patients (2
men and 4 women with a mean age of 60 ±
(Received in originalform July 21, 1981 and in
revised form February 16, 1982)
1 From the Departments of Medicine and Re¬
spiratory Medicine, University of Edinburgh,
and Scotland and Regional Clinical Neurophys¬
iology Service, Western General Hospital, Edin¬
burgh, Scotland.
2 Requests for reprints should be addressed to
Dr. Peter M. A. Calverley, Department of Medi¬
cine, Royal Infirmary, Lauriston Place, Edin¬
burgh EH3 9YW, Scotland.
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TABLE 1
CLINICAL DETAILS OF 20 PATIENTS WITH CHRONIC BRONCHITIS







Age, yr 57.4 ± 5.0 62.1 ± 7.0 53.0 ± 9.0
FEV„ L 0.58 ± 0.18 0.75 ± 0.20 2.70 1.0t
FVC, L 1.76 ± 0.67 1.95 ± 0.64 3.31 1.lt
Ear oxygen saturation
80.0 ± 9.2tawake, % 94.1 ,± 1.6t 97 -4- 1.0t
Paoj, mmHg 47.0 ± 6.8t 72.3 ± 4.8 —
Paco2, mmHg 51.4 ± 6.71 36.0 ± 5.6 —
Definition of abbreviations: FEVt = forced expiratory volume In one second; FVC = forced
vital capacity; Pao2 = arterial oxygen tension; Paco2 = arterial carbon dioxide tension.
" Values are expressed as mean ± SD.
t Significantly different (p < 0.001) from results In the other patients.
4 yr) who did not differ significantly from
the rest of the "blue and bloated" group in
the severity of their hypoxemia or airway
obstruction (mean FEVj, 0.6 + 0.2 L;
mean FVC, 1.5 ± 0.5 L; mean Pao2, 48 ±
7mmHg; mean Paco2, 50 ± 6 mmHg) were
studied on 3 nights using similar techniques.
On one of the nights after adaptation they
breathed 2 L of air, whereas on the other 2
nights they breathed 2 L of oxygen given
through nasal prongs on both occasions.
The order of the air or oxygen nights was
randomized and the subjects did not know
which gas mixture they were receiving. All
patients gave informed consent to the stud¬
ies, which were approved by the Hospital
Ethical Committee.
Statistical analysis was made using non-
parametric tests, differences between sub¬
jects being compared with the Mann-
Whitney U test and differences within sub¬
jects using Wilcoxon's signed rank test, as
previously described (9). The degree of sig¬
nificance is given as for the two-tailed t test
and all values are expressed as mean ± SD
throughout.
Results
Comparison of the 2 patients groups
n control subjects. The characteris¬tics of nocturnal oxygenation in the 2
o oups 0f patients chj-onio 0fc>-
ctive airway disease and in the
m normal subjects are sum-
tienr^A-S tab'e ®odl grouPS of pa-
norm i ed significantly from the
had n't contrcd subjects in that they
fation ?|Wer st£dde level of oxygen satu-
°f tran Un"g s*eeP' a greater number
greaterS1f^ .yP°xendc episodes, and a
s°des (allHtff1 Sa°2 durinS these ePi_
0-002) wti 6nces si&nificant at p <
Were Sn tbe ^ groups of patients
"k'ue an7ared each other the
si°nificanti iated" Patients showed a
sleeP, moreyiu°Wer StabIe Sa°2 durin§
ITl°re Drnm yP°xemic episodes, and a
b'POxSnf in Sa»" th«Pisodes, than did the "pink
and puffing" patients (all differences
significant at p < 0.01). Transient
hypoxemic episodes occurred predomi¬
nantly during periods of hypoventila¬
tion and there was no significant dif¬
ference in the incidence of hypoventila¬
tion in the 3 groups. No subject showed
evidence of a sleep apnea syndrome
when breathing air.
The sleep EEG. The time from the
onset of sleep to the final awakening
(total sleep period), the percentage of
this time the subjects spent in the vari¬
ous sleep stages or awake, the amount
of sleep proper (summed amount of
Stages 2, 3, and 4 and REM), and some
derived variables are shown in table 3.
The sleeping EEG of the patients
compared with that of the normal con¬
trol subjects was more disturbed, with
a tendency to a longer sleep onset la¬
tency, more intervening wakefulness
and drowsiness, less Stage 3 and 4
sleep, and less REM sleep. These dif¬
ferences, however, did not reach statis¬
tical significance because of the wide
TABLE 2
OXYGEN SATURATION DURING SLEEP IN 20 PATIENTS WITH CHRONIC BRONCHITIS










Stable Sao2 asleep, % 71 ± 14 92 ± 2 96 ± 1 p< 0.002 p< 0.002 p < 0.002
Lowest Sao2 asleep, % 39 ± 22 78 ± 14 86 ± 8 p< 0.002 nst p < 0.002
Hypoxemic episodes!
per night
Total 3.3 ± 2.0 0.9 + 1.1 0.3 ± 0.7 p < 0.005 ns p<0.01
In non-REM sleep 0.6 ± 1.0 0 0
In REM sleep 2.7 ± 1.9 0.9 ± 1.1 0.3 ± 0.7
Total duration of hypoxemic
episodes per night, min 79 ± 58 13 + 18 6 ± 15 p<0.01
Definition of abbreviations: BB = "blue and bloated" patients; PP = "pink and puffing" patients; Sao, = arterial oxy¬
gen saturation measured by ear oximeter.
* Values are expressed as mean ± SD.
- t A fall In Sao2 greater than 10% lasting longer than 1 mln.
t Insufficient data points for comparison.
TABLE 3
SLEEP PATTERN IN 20 PATIENTS WITH CHRONIC BRONCHITIS AND EMPHYSEMA










Sleep onset latency, mln 35 ± 44 62 + 46 20 ± 16 ns p < 0.02 p < 0.02
Total sleep period, mint 361 ± 66 343 ± 94 399 ± 43 ns ns ns
Sleep proper, mint 265 ± 89 219 106 307 ± 54 ns p< 0.05 ns
Total sleep period, %
awake (stage 0) 17 ± 16 25 19 14 ± 7 |
stage 1 10 ± 4 12 + 2 9 ± 5 j
stage 2 51 ± 15 40 11 49 ± 5 I
stage 3 7 ± 5 6 ± 3 7 ± 2 (
ns ns ns
stage 4 4 ± 5 2 ± 3 5 ± 4 I
stage REM 11 ± 7 15 7 16 ± 6 I
Mean duration of
uninterrupted sleep
episodes, min 6 ± 3 5 ± 2 10 ± 4 p < 0.02 p < 0.05 ns
For definition of abbreviations, see table 2.
* Values are mean ± SD.
t Time from sleep onset to final awakening.
1 Summed duration of Stages 2, 3, 4, and REM sleep.
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intersubject variability. Both groups of
patients differed significantly (p <
0.05) from the control subjects in
showing shorter duration periods of
sleep between the brief episodes of
arousal occurring during the night. The
group of "blue and bloated" patients
had less REM sleep than the normal
subjects, whereas the "pink and puff¬
ing" patients showed a significantly
longer sleep onset latency (p < 0.02)
and a shorter duration of sleep proper
(p < 0.05) than the healthy control
subjects.
Comparison between the level of ox¬
ygenation and the characteristics of
sleep. The transient falls in Sao2 were
commoner during periods of REM
sleep than during non-REM sleep in all
groups of subjects (table 2). In the
"blue and bloated" group the number
of hypoxemic episodes per night occur¬
ring during REM sleep averaged 2.7 ±
1.9 compared with 0.6 ± 1.0 hypox¬
emic episodes occurring during non-
REM sleep. The number, of hypoxemic
episodes was significantly higher in the
"blue and bloated" patients with a
greater amount of Stages 3 and 4 sleep
(p < 0.05), and a nonspecific trend in
the same direction was also seen in the
"pink and puffing" group (0.05 < p <
0.1). In the "pink and puffing" patients
the hypoxemic episodes were more fre¬
quent in those with a greater amount of
REM sleep (p < 0.05); this relationship
was not significant in the "blue and
bloated" group. In both groups of pa-
dents the number of hypoxemic epi¬
sodes was greater in those subjects
showing less intervening wakefulness
ind drowsiness and this relationship
vas significant at 2°7o in both groups
combined (figure 1).
The duration of hypoxemic episodes
'as not significantly related to any of
he sleep characteristics examined,
owever, the stable level of oxygen
duration during sleep was positively
orrelated with the amount of REM
eePJ patients with the lowest stable
•vel of nocturnal oxygen saturation
ad the fewest periods of REM sleep
»< 0.05).
The effect of correcting nocturnal
The 6 hypoxic "blue and
a ed patients studied breathing air
xygen at 2 L/min via nasal prongsWe a similar sleep disturbance to
group as a whole when breathing
> e only significant difference was











NUMBER OF HYPOXAEMIC EPISODES
(101 (71 (71 (31 (21
Fig. 1. Relationship between sleep disturbance
and number of hypoxemic episodes. The greater
number of hypoxemic episodes, the less disturbed
the patient's sleep. Figures in parentheses refer to
number of subjects with that frequency of hypox¬
emic episodes. Results given as mean ± SD.
breathing air, an average of 3.7 hypox¬
emic episodes were observed with a
mean duration of 31 min, the lowest
Sao2 reached varying from 74 to 10%.
When breathing oxygen all patients
showed an improvement in their level
of nocturnal oxygen saturation and
sleep pattern. The mean number of
hypoxemic episodes was reduced and
their duration consistently decreased
from 31 to 20 min. In 2 patients no
hypoxemic episodes occurred during
the oxygen treatment night.
Sleep onset latency fell during the
night breathing oxygen, whereas the
amount of sleep proper (Stages 2, 3, 4,
and REM) increased in 5 of the 6 pa¬
tients (0.05 < p < 0.1). The amount of
intervening wakefulness and drowsiness
decreased (p < 0.05) in all 6 patients
and averaged 15% of the total sleep.
The number of periods of REM sleep
increased significantly as did the
amount ofREM sleep. The duration of
Stages 3 and 4 reached an unusually
high level of 20% but this change was
not significant because of the wide va¬
riability within the subjects. The mean
duration of uninterrupted episodes of
sleep (Stages 2, 3, 4, and REM) in¬
creased in 5 of the 6 patients from a
group mean of 6.7 to 10.3 min while
breathing oxygen. The majority of the c
hypoxemic episodes occurred during
the period of REM sleep whether
breathing air or oxygen.
Discussion
Severe airway obstruction is known to
be associated with frequent and pro¬
found episodes of nocturnal oxygen
desaturation especially if the patient is
already hypoxic during the day (4, 5).
These episodes of additional hypox¬
emia are usually associated with peri¬
ods of relative hypoventilation (10), as
was the case in these studies, and can
increase the resting pulmonary artery
pressure (5).
Significant disturbances in the sleep¬
ing EEG have been reported in patients
with a similar degree of airway ob-
TABLE 4
THE EFFECTS OF IMPROVING OXYGENATION ON SLEEP IN 6 SUBJECTS
'
WITH HYPOXIC CHRONIC BRONCHITIS AND EMPHYSEMA*
Breathing Air Breathing Oxygen
Stable Sao, awake, % • 81 ± 6 97 ± 2 (p < 0.05)
Mean stable Sao2 asleep, % 53 ± 23 90 ± 9 (p < 0.05)
Lowest Sao, asleep, % 33 27 76 ± 17 (p < 0.05)
Hypoxemic episodest per night, n 3.7 ± 2.2 1.5 ± 1.6 (p< 0.05)
Sleep onset latency, min 52 60 20 ± 13 (0.05 < p< 0.1)
Total sleep period, mint 336 60 395 ± 40 ns
Sleep proper, min§ 247 + 82 334 ± 29 (0.05 < p< 0.1)
Total sleep period, %
Stage 0+1 27 ± 18 15 ± 8 (p< 0.05)
Stage 2 51 ± 17 49 ± 14 ns
Stage 3 + 4 11 ± 9 20 ± 11 ns
Stage REM 11 ± 7 17 ± 6 (p < 0.05)
Duration of uninterrupted sleep, min 6.8 ± 3.4 10.3 ± 3.9 (0.05 < p < 0.1)
REM periods, n 2.7 ± 1.0 4.2 ± 1.0 (p < 0.05)
For definition of abbreviations, see table 2.
* Values are expressed as mean ± SD.
t A fall in Sao2 greater than 10% lasting longer than 1 min.
tTIme from sleep onset to final awakening.
§ Summed duration of Stages 2, 3, 4, and REM sleep.
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struction, the sleep period time and
amount of sleep proper (summed
Stages 2, 3, 4, and REM) being reduced
when compared with control subjects
of similar age (4). However, in the
above studies the patients slept for only
one night study in unfamiliar sur¬
roundings, wearing a variable amount
of monitoring equipment. Further¬
more, the results of these single night
studies have been compared with retro¬
spective studies carried out with better
acclimatization and without the same
amount of monitoring apparatus. The
disturbance in sleep pattern that we
now report still had a nonspecific com¬
ponent to incomplete adaptation, as
shown by the lower percentage of REM
sleep in our control group (16%), when
contrasted with a normal value of ap¬
proximately 22% for similar age
groups (11, 12). Nevertheless, the total
sleep duration for our more severely
disabled "blue and bloated" patients
was 361 ± 66 min, considerably longer
than the 266 ± 136 min in the one
night study of similar patients reported
by Wynne and colleagues (4). Because
we were interested in the amount of
disturbed sleep shown by our groups of
patients and control subjects we con¬
centrated on the total sleep period
rather than on the total sleep time in
our analysis because the latter term ex¬
cludes the stages awake during the
night's sleep.
sleep. These results are supported by
the findings of Demarco and cowork¬
ers (13) who studied 6 "pink and puff¬
ing" and 4 "blue and bloated" patients
for one night only. The "pink and puff¬
ing" patients spent 43.4% of the total
sleep period in Stages 0 and 1 sleep com¬
pared with 36.7% in the 4 "blue and
bloated" patients who also spent more
of the night in Stages 3 and 4 sleep.
These results suggest that the distur¬
bance of sleep might have a protective
effect in preventing the development of
profound hypoxemia.
The 6 "blue and bloated" patients
who were studied without and during
nocturnal oxygen administration had
fewer episodes of transient nocturnal
hypoxemia when breathing oxygen,
probably reflecting their different
starting point on the oxygen dissocia¬
tion curve (10). When breathing ox¬
ygen there was a significant reduction
in the amount of Stages 0 and 1 sleep,
and an increase in REM sleep. The
total sleep, period and the distribution
of sleep stages in this group of "blue
and bloated" patients when breathing
oxygen resembles that seen in the con¬
trol subjects rather than that seen in
the normally better oxygenated "pink
and puffing" patients with an equiva¬
lent degree of airflow obstruction. This
objective evidence of more normal
sleep supports the frequent subjective
observations made by patients who
Although the total duration of sleep ' start nocturnal oxygen therapy that
was not significantly reduced when
compared with that of similarly aged
and acclimatized normal control sub¬
lets, there was evidence of more sleep
jsturbance in the patients with airway0 struction. They took longer to fallas eeP, had more intervening wakeful¬
ness, and less Stages 3 and 4 and REM
eep. However, other differences be-
n ?e,n groups emerged that could
wax e1attr'buted to the irreversible air-
spvs •? . ruc(aon that was of similar
"ninv y' j "hlue and bloated" and
the "uf Puffing" patients. Although" blue and bloated" had
■ptak ®eater faU in Sa°. >




tients "pink and puffing" pa-
as show ^ the most disturbed sleep
larly " ythcEEG recordings. Simi-
lients with ™lthinany group' the pa~
hypoxemia Tre fre(luent episodes of
Usua]]v no characteristics
e-g., iess ,s°CIated with "good sleep,"
clrow.si'nQ„,n ervening wakefulness andWsiness, and more Stages 3 and 4
they get a better night's sleep as a result
of this treatment and waken less fre¬
quently. It may also account for the
improved neuropsychologic function
observed in patients receiving long-
term domiciliary oxygen therapy (14).
It has been suggested that the varia¬
tion in the ventilatory response to hy¬
poxia and hypercapnia may account
for the variation in prevalence of
arousal from sleep in humans (15). Pa¬
tients with hypoxic chronic bronchitis
and emphysema have a reduced hypox¬
ic drive to breathing when studied
awake (16), and it is possible that this
reduction in the ventilatory response to
hypoxia contributes to the relatively •
"good" sleep quality of these patients.
Animal studies suggest that a reduced
C02 response occurs duringREM sleep
(17) but the significance of this in hu¬
mans is not clear because only small
changes in the directly measured
arterial C02 tension are seen during the
hypoxemic episode (10). Animal
experiments also suggest that the
hypoxic drive is preserved during REM
sleep but recent measurements in nor¬
mal human subjects have found it to be
diminished (18). It is possible that
some of the differences in the clinical
course of patients with chronic ob¬
structive airway disease may depend
upon the interplay of factors such as
the hypoxic and hypercapnic ventila¬
tory drives and the sleep arousal thres¬
hold, which determine whether sleep is
disturbed, while the arterial Po2 is
maintained relatively normal as in the
"pink and puffing" patients or whether
the quality of sleep is good but pro¬
found hypoxia develops as in the "blue
and bloated" patients.
References
1. Davidson LA, Jefferson JH. EEG studies in
respiratory failure. Br Med J 1959; 2:396-400.
2. Demedts M, Pillen E, van de Woestijne KP.
Comparative study of EEG changes, clinical en¬
cephalopathy and blood gas disturbances in
chronic obstructive lung disease. Acta Neurol
Belg 1973; 73:273-80.
3. Koo KY, Sax DS, Snider GL. Arterial blood
gases and pH during sleep in chronic obstructive
pulmonary disease. Am J Med 1975; 58:663-70.
4. Wynne JW, Block AJ, Hemenway J, Hunt
LA, Flick WR. Disordered breathing and oxygen
desaturation during sleep in patients with chronic
obstructive lung disease (COLD). Am J Med
1979; 66:573-9.
5. Douglas NJ, Calverley PMA, Leggett RJE,
Brash HM, Flenley DC, Brezinova V. Transient
hypoxemia during sleep in chronic bronchitis and
emphysema. Lancet 1979; 1:1-4.
6. Brezinova V, Calverley PMA, Flenley DC,
Townsend HRA. The effect of long term oxygen
therapy on the EEG in patients with chronic
stable ventilatory failure. Bull Physiopathol
Respir 1979; 15:603-9.
7. Report of the Medical Research Council
Working Party. Long term domiciliary oxygen
therapy in chronic hypoxic cor pulmonale com¬
plicating chronic bronchitis and emphysema.
Lancet 1981; 1:681-6.
8. Rechtschaffen A, Kales A, eds. A manual of
standardized terminology, techniques and scor¬
ing system for sleep stages of human subjects.
Washington, D.C.:USGPO 1968.
9. Siegel S. Non-parametric statistics for the
behavioral sciences. New York: McGraw Hill,
1956.
10. Catterall JR, Douglas NJ, Calverley PMA,
Shapiro C, Brezinova V, Flenley DC. Hypoventi¬
lation is common but sleep apnea rare in tran¬
sient nocturnal hypoxemia of "blue and bloated"
bronchitis (abstract). Am Rev Respir Dis 1981;
123:113.
11. Agnew HW, Webb WB, Williams RL. The
first night effect: an EEG study of sleep. Psycho-
physiology 1966; 2:263-6.
-12. Agnew HW, Webb WB, Williams RL.
Sleep patterns in late middle age males: an EEG
study. Electroencephalogr Clin Neurophysiol
1967; 23:168-71.
13. DeMarco FJ, Wynne JW, Block AJ,
Bousen PG, Taasan VC. Oxygen desaturation
210 CALVERLEY, BREZINOVA, DOUGLAS, CATTERALL, AND FLENLEY
during sleep as a determinant of the 'blue and
bloated'syndrome. Chest 1981; 79:621-5.
14. Nocturnal Oxygen Therapy Trial Group.
Continuous or nocturnal oxygen therapy in
hypoxemic chronic obstructive lung disease.'Ann
Intern Med 1980; 93:391-8.
15. Phillipson EA. Arousal: the forgotten re¬
sponse to respiratory stimuli. Am Rev Respir Dis
1978; 118:807-9.
16. Flenley DC, Franklin DH, Millar JS. The
hypoxic drive to breathing in chronic bronchitis
and emphysema. Clin Sci 1970; 38:503-18.
17. Phillipson EA. Controlled breathing during
sleep. Am Rev Respir Dis 1978; 118:909-39.
18. Douglas NJ, Wight DP, Pickett CK, Weil
JV, Zwillich CW. Hypoxic ventilatory response
decreases during sleep in man. Clin Sci 1981;
62:1-2.
E
Cigairs^® Smoking and SeoOTdairy Polycythemia
in hypoxic C@r Pylmonafl®"3'2
3£TER M. A. GALVERIEY, RAYMOND J. LEOGETT, LINDA McELDERRY, and DAVID G. FLENLEY
InSroduciion
Secondary polycythemia is well recog¬
nized as a physiologic response to the
reduced arterial oxygen saturation
(Sao2) occurring at high altitude (1).
However, the degree of polycythemia
at any degree of Sao2, as shown by red
cell mass (RCM) is much more variable
in patients who are hypoxic as a result
af chronic bronchitis and emphysema
[2-4). Secondary polycythemia has
ilso been described in heavy smokers
,vho had normal respiratory function,
and has been attributed to the raised
carboxyhemoglobin concentrations re¬
sulting from their inhalation of carbon
nonoxide (CO) in cigarette smoke,
furthermore, this secondary poly-
sythemia is partially corrected when
hese patients stopped smoking, thus
^storing their circulating carboxy-
lemoglobin concentrations to normal
.5).
We measured the carboxyhemoglo-bin concentration, arterial oxygen
duration, and RCM in patients with
^vere chronic bronchitis and emphyse¬
ma in an attempt to explain the vari-
! lty 'n extent of their secondary
r„„.yCytIlem^a- We also studied the ef¬fects of
by long-
correcting-arterial hypoxemia
1 <: . " term oxygen therapy, given for
Polycwh m- a 24'h0ur Period' on thePa.?ei?s reSP?.nSe in 15 of these
>moi<-» a ■ whom continued tooke during the time when they
Jd -eiving o3dv,ce to stop.
not recp- . - -- —- were
i tn :?8 oxy8en' despite repeated
For.w MethodsriV-seven no**
i"0na|e seconriVentS With hyP°xic cor pul-
^Physema w Fy chronic bronchitis and
^nicallystable ? -n'tially assessed when
hi 8ht. FEV I a Judsed bY constant body
eas tensimi measurements of arterial
andC 'hen bee from"' 4 wk (tabIe !)• AH
WPUlrtl°narV °, resP>ratory infectioniSSX^ 5?, had arterial' ^vhen breath; . ± 5.2 SD
n8 air, and severe irre¬
SUMMARY We have related the red cell mass (ROM) in 47 hypoxic patients with COPD (mean
P02, 52.5 ± 5.2 SD mmHg; mean Pco2, 151.7 ± 6.7 mmHg; meanlFEV,, 0.6 ± 0.2 L; mean FVC, 1.7 ±
0.6 L) to their smoking habits and outpatient carboxyhemoglobin concentrations. The mean RCM
was 42.5 ± 8.0 ml/kg in the 31 patients who still smoked, significantly (p < 0.01) higher than In the
16 who were currently nonsmokers (RCM, 29.7 ± 4.4 ml/kg). Measurements of arterial Po2, pH, PE0,
and COHb showed that the saturation of available hemoglobin (So2A) was less well correlated (r =
-0.36, p < 0.05) with RCM in the smokers, than was So2T (r = -0.58, p < 0.001), So2T including a
corrective term for COHb. The RCM correlated well with the mean outpatient COHb measured
repeatedly over 6 to 36 months in 40 of the patients but poorly with their average arterial oxygen
saturation (r = 0.15, p > 0.1). in 15 patients given long-term oxygen therapy (15 hours/24-hour
period) for 12 months RCM decreased significantly only in those who stopped smoking, as shown
by a decrease in COHb. We conclude that cigarette smoking may determine the severity of secon¬
dary polycythemia in patients with hypoxic COPD, and prevent its correction by long-term oxygen
therapy. AM REV RESPIR DIS 1982; 125:507-510
versible airway obstruction (FEVj, 0.6 ±
0.2 L). None had splenomegaly, a raised
platelet count, or a raised leukocyte count
to suggest that their polycythemia might be
primary. Red cell mass and plasma volume
were measured simultaneously by intrave¬
nously administered autologous [5lCR]eryth-
rocytes and [13'I]albumin (6). Arterial car¬
boxyhemoglobin concentrations (COHb)
were measured initially, and then at two
monthly intervals, with an IL182 Co-oxi-
meter (7). The patients were classified as
either smokers or nonsmokers on the basis
of their smoking history, and patients were
accepted as nonsmokers only if their cur¬
rent COHb was less than ,3%, and they also
stated that they had not smoked cigarettes
for the preceding 2 yr.
The oxygen tension at 50% hemoglobin
saturation (P5o) was measured by
tonometering blood with three different gas
mixtures, all of which had a Pco2 of 40
mmHg, but the Po2 was adjusted to give
oxygen saturations (So2) of 40, 50, and
60%. The P50 at pH 7.4 and zero base ex¬
cess was then obtained by interpolation on
Hill's logarithmic plot of the oxygen disso¬
ciation curve (ODC). Arterial oxygen satu¬
ration may be expressed as the saturation of
the total oxygen binding sites (Sao2T):
Sao2T =
Hbo2
Hb02 + Hb + Hbco
x 100,
which includes the binding sites occupied by
CO, Hbo2 being the concentration of oxy¬
genated hemoglobin, Hb being the concen¬
tration of reduced hemoglobin, and Hbco
being the concentration of hemoglobin
combined with carbon monoxide. An alter¬
native is to express saturation in terms of
those sites that are available for oxygen
binding (8), this term being Sao2A:
Sa°2A = Hbo2 +2Hb X 10°-
The Sao2A therefore ignores any hemoglo¬
bin that is combined with CO, and is the
expression used in figure 1. We have also
calculated Sao2A and Sao2T in 40 patients,
using the measured arterial Po2 when
breathing air, the directly measured P50,
and the average of that patient's carboxy¬
hemoglobin values, as measured at after¬
noon outpatient clinics, every two months,
over 4 to 36 months.
Red cell mass and plasma volume estima¬
tions were repeated in 15 patients who re¬
ceived long-term oxygen therapy for 15 h in
a 24-h period, over a period of at least 12
months (9, 10). Treatment compliance was
assessed by unannounced home visits and
monitoring reservoir weight in those pa¬
tients on liquid oxygen systems, and
(Received in original form May 28, 1981 and in
revised form October 27, 1981)
1 From the Departments of Medicine and
Respiratory Medicine, University of Edinburgh,
Edinburgh, Scotland.
2 Requests for reprints should be addressed to
Dr. Peter M. A. Calverley, Department of
Medicine, Royal Infirmary, Edinburgh, Scot¬
land.
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TABLE 1
RESPIRATORY FUNCTION, OXYGEN SATURATION, RED CELL MASS, AND PLASMA VOLUME
IN 47 PATIENTS WITH CHRONIC BRONCHITIS AND EMPHYSEMA
Num¬ FEV, FVC Po2 Pco2 RCM PV Pso
Group ber (/) (/) (mmHg) (mmHg) PH Sao2A Sao2T • (ml/kg) (ml) (mmHg)
All patients 47 0.6 ± 0.2 1.7 ± 0.6
'
52.5 ± 5.2 51.7 ± 6.7 7.38 =fc 0.04 86 ± 4.0 82 ± 5.5 37.6 ± 9.3 39.0 ± 6.0 25.4 + 2.35
All smokers 31 0.6 + 0.2 1.8 ± 0.6 52.5 ± 5.2 53.2 ± 6.0 7.38 ± 0.04 86 ± 4.0 80 ± 5.4 42.5 ± 8.0 41.5 ± 6.0 24.4 ± 1.8
All nonsmokers 16 0.56 ± 0.2 1.6 ± 0.5 53.5 ± 4.5 49.5 ± 7.5 7.39 ± 0.03 86 ± 3.7 85 ± 4.0 29.7 ± 4.4 35.5 ± 3.5 27.4 ± 1.9
All men 27 0.7 ± 0.2 1.9 ± 0.6 53.5 ± 5.2 51.0 ± 6.7 7.39 ± 0.04 86 ± 4.7 82 ± 6.0 40.0 ± 9.0 40.0 ± 6.0 25.1 + 2.4
All women 20 0.6 ± 0.2 1.3 ± 0.3 51.7 ± 4.5 53.5 ± 6.7 7.38 ± 0.03 85 ± 3.5 82 ± 4.8 34.5 ± 9.4 39.0 ± 6.0 26.0 ± 2.2
Definition of abbreviations: FEV, = forced expiratory volume in one second; FVC = forced vital capacity; Po2 and Pco, = arterial oxygen and arterial carbon dioxide tensions, re¬
spectively; RCM = red cell mass; PV = plasma volume; Ps0 = oxygen tension at 50% saturation.
cylinder usage in the other patients. Re¬
peated COHb measurements showed that 7
of these patients continued to smoke, for
the period in the day when they were not
taking oxygen despite our repeated advice
to stop, whereas the remaining 8 patients
stopped smoking during the 12 months of
long-term oxygen treatment.
The significance of difference of mean
values was determined by the unpaired t
test, multiple regression relationships, and
correlations being made by the least squares
method. The measurements of RCM before
and after long-term oxygen therapy was
compared by Wilcoxon's rank sum test, as
the normality of these distributions could
not be assumed. Values are given as mean
± 1 SD.
Results
There was no significant difference in
age, severity of airway obstruction,
resting P02, Pco2, pH, or Sao2A be¬
tween the 31 patients who smoked and

















HbQ2OXYGEN SATURATION (S02A= —— )
Hb +Hb02
Fl3-1. The relationship between red cell mass
and oxygen saturation in 47 patients with chronic
ronchltis and emphysema. Confidence limits
enved from normal data of Weil and coworkers
J- Solid circles = smokers; open circles = cur-
tent nonsmokers.
However, in the 31 smokers the RCM
(mean 42.5 ± 8.0 ml/kg) was signifi¬
cantly higher (p < 0.01) than in the 16
nonsmokers (mean RCM, 29.7 ± 4.4
ml/kg) (figure 1), and the plasma
volume in the smokers (41.5 ± 6.2
ml/kg) was significantly higher (p <
0.01) than in the nonsmokers (35.3 ±
3.5 ml/kg). As a result, the difference
in packed cell volume between smokers
and nonsmokers was less pronounced
than that seen in RCM measurements.
The relation between the RCM and
Sao2A was different in the smokers
from what it was in the nonsmokers,
the smokers tending to have a higher
value of RCM for any reduction in
Sao2A (figure 1). However, the corre¬
lation between RCM and Sao2A was
weak in both smokers (r = — 0.36, p <
0.05) and nonsmokers (r = — 0.24, p <
0.1). In contrast, the correlation be¬
tween RCM and Sao2T was more
significant in the 31 smokers (r =
-0.58, p < 0.01) but there was no
significant correlation between RCM
and either Sao2A or Sao2T in the 16
nonsmokers.
In 40 patients (24 men, 16 women),
repeated measurements of Pao2 and
COHb were made at an afternoon out¬
patient clinic over 6 to 36 months of
follow-up. Between 4 and 16 measure¬
ments of COHb were made in each pa¬
tient; these varied only by 1 to 2% in
any individual patient. There was a.sig¬
nificant relation between the average
of the COHb values in each patient,
and that patient's RCM (r = 0.73, p <
0.01) (figure 2). Once the carboxyhe-
moglobin concentration was taken into
account, the addition of Sao2A to a
multiple regression analysis of this data
did not add significantly to the predic¬
tion of RCM.
The RCM was higher in men (40.0 ±
9.0 ml/kg) than in women (34.5 ± 9.4
ml/kg), but as more of the men were
smokers, this may have accounted for
some of this difference. There was no
significant relation between the plasma
volume and either Sao2A or Sao2T, in
either smokers or nonsmokers, and
there was no difference in plasma
volume measurements between men
and women.
The physiologic variables recorded
in 15 patients who were restudied are
shown in table 2. There was no signifi¬
cant difference in the severity of hy¬
poxemia, C02 retention, pulmonary
hypertension, or polycythemia in either
group at the time of initial assessment,
and treatment compliance was good in
both the smoking and nonsmoking pa¬
tients. Despite receiving 12 months of
long-term oxygen therapy (given for 15.
h in a 24-hour period), there was no
significant change in RCM in the 7 pa¬
tients who continued to smoke, in
whom the COHb values remained high
(figure 3). In contrast, in the 8 patients
who stopped smoking, as confirmed by
a decrease in COHb to 1.8 ± 0.4%,
RCM decreased from a mean value of
43.4 ml/kg to 28.0 ml/kg during the
year when they were given long-term
oxygen therapy. This difference was
very significant (p < 0.001). Likewise,
packed cell volume and mean pulmo¬
nary artery pressure only decreased sig¬




















Fig. 2. The relationship between red cell mass
and mean outpatient carboxyhemoglobin concen¬
tration in 40 patients with chronic bronchitis and
emphysema.
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TABLE 2=
PHYSIOLOGIC MEASUREMENTS IN SMOKING AND NONSMOKING
PATIENTS WITH CHRONIC BRONCHITIS AND EMPHYSEMA
BEFORE AND AFTER 12 MONTHS OF DOMICILIARY OXYGEN THERAPY
Still Smoking Stopped Smoking
Initial 1 Year Initial 1 Year
(n = 7) (n = 7) = 8) (n = 8)
FEV„ L 0.66 + 0.15 0.61 0.1 0.53 ± 0.14 0.53 ± 0.13
FVC, L 1.69 ± 0.4 1.48 ± 0.4 1.56 0.6 1.49 ± 0.57
Pao2, mmHg 54.7 ± 4.0 51.5 ± 5.8 52.0 ± 4;0 48.6 -fi 5.8
Paco2, mmHg 53.0 ± 4.0 53.0 ± 4.4 53.6 ± 1.5 56.0 6.8
PCV, % 54.0 ± 4.7 51.0 -h 7.4 53.0 ± 3.8 43.6 + 2.8
PAP, mmHg 30.6 ± 4.5 29.4 ±: 9.4 38.7 ± 7.4 25.0 ± 4.6*
RCM, ml/kg 40.9 ± 8.0 39.1 10.4 43.4 ± 7.4 28.0 ± 5.4t
COHb, % 8.34 ± 3.0 10.0 ± 3.0 6.8 ± 1.3 1.8 ±2 0.41
Delinitlon of abbreviations: PCV = packed cell volume; PAP = mean pulmonary artery pres¬
sure; COHb = carboxyhemoglobin concentration. For other abbreviations, see table. 1.
* Initial and 1-year values differ significantly (p < 0.01).
t Initial and 1-year values differ significantly (p < 0.01).
Discussion
The decrease in arterial oxygenation in
healthy residents at high altitude is
iccompanied by a fairly predictable
ncrease in RCM(l). Whereas the rela-
ion between Pao2 and RCM was curvi-
inear in that study, the relation be-
ween Sao2A and RCM was linear (1).
Ne have therefore calculated correla-
ions between Sao2A (or Sao2T) and
ICM in this study, and not between
ICM and Pao2. As noted previously
2, 11) the variability of this relation-
hip in patients with hypoxemia caused
iy chronic bronchitis and emphysema
ras considerably greater than that seen
i healthy subjects (figure 1) although
he degree of airway obstruction, arte-
ial hypoxemia, and C02 retention
mong our patients was relatively simi-
ir (table 1) when they were breathing
ir at rest. It therefore appears reason-
ble to search for some other factor
ian arterial hypoxemia to account for
us greater variation in polycythemic
'-sponse.
Inhaled cigarette smoke contains
tfbon monoxide produced by incom-ete combustion of tobacco. In our
Terience, carboxyhemoglobin con¬
ic! Ki0nS commonly lie between 515% in our patients who continue
smoke, when measured at an after-
n °utpatient clinic. We thus sought
snn excessive polycythemic
tinJurj0 °Ur sm°king patients by re-
itio •^ t0 avera8e COHb concen-
eC£each patient, using the aver-
rnoo v.a'ues measured at these af-
]e Dt?v during several months,
e 2)Sl 1Ve correlation observed (fig-
3pjb SUggests that the increased
eventrations in the smokers
could indeed contribute to their poly¬
cythemic response, and this was sup¬
ported by the multiple regression rela¬
tionships between RCM, Sao2A, and
COHb, which implies that carboxyhe¬
moglobin was more important than the
degree of arterial oxygenation in terms
of effect on the RCM.
The greater polycythemic response
in our smokers
. may therefore arise
from impairment in delivery of oxygen
to the site of release of erythrogenin in
their kidneys (11) as a result of these
high concentrations of circulating ear-
boxyhemoglobin. Carbon monoxide
not only binds to sites on the hemo¬
globin molecule, which would other¬
wise bind oxygen (thus diluting the
amount of available hemoglobin), but
such binding also affects the affinity of
the remaining binding sites for oxygen,
thus changing the position (P5o) of the
oxygen dissociation curve (8). We cal¬
culated oxygen saturations from meas¬
ured values of Pao2, and pH, using the
P50 actually measured in each patient









Fig. 3. The effect of smoking on red cell mass in
15 patients with COPD treated with domiciliary
oxygen for 12 months.
mined. We thereby calculated the rela¬
tionship between RCM and the arterial
oxygen saturation, expressed as either
Sao2T (including the mean COHb) or
as Sao2A (which ignores the COHb
concentration). The correlation be¬
tween Sao2A and the RCM was only
significant at 5% in the smokers, but
this correlation became significant at
1% when Sao2T was substituted for
Sao2A. Furthermore, the relationship
between either Sao2A or Sao2T was in¬
significant in the nonsmokers who had
very low concentrations of COHb,
despite similar degrees of arterial hy¬
poxemia to that found in the smokers
(table 1). Many of the nonsmokers had
values of RCM that lay within our nor¬
mal range, but of course also had
COHb concentrations that were nor¬
mal. These results would thus support
the proposal that the prevailing degree
of circulating carboxyhemoglobin is an
important determinant of the polycyth¬
emic response.
This notion receives further support
from our studies on patients receiving
long-term domiciliary oxygen therapy.
When this treatment was used to raise
the average arterial Po2 over- 60
mmHg, the hypoxic stimulus to poly¬
cythemia would thus be reduced, as oc¬
curs when high altitude residents return
to sea level. Nevertheless, in seven of
our patients who were treated with
oxygen but who nonetheless continued
to smoke during the 9 h of the 24-h pe¬
riod when they were not receiving oxy¬
gen therapy, the RCM did not decrease
significantly over the course of the year
of oxygen treatment. In contrast, in the
eight patients who did discontinue
smoking, as shown by a decrease in
COHb concentrations, this long-term
oxygen therapy was then associated
with a significant reduction in RCM
(p < 0.001) (figure 2). Similar failures
to reduce packed cell volume by long-
term oxygen therapy in cigarette
smokers have been noted previously
(12). Thus, carbon monoxide inhaled
in cigarette smoke appears to enhance
the polycythemic response to hypoxia
in patients with hypoxic chronic bron¬
chitis and emphysema, but a signifi¬
cant account of the variability in the
RCM still remains unexplained. Exer¬
cise often increases the severity of hy¬
poxemia in these patients (13). Further¬
more, transient episodes of severe, noc¬
turnal hypoxemia have recently been
observed in similar patients with the
'blue and bloated' (Type B, nonfighter)
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pattern of chronic bronchitis and em¬
physema (14), and some of the patients
in whom these observations were made
were included in this present study,.
These significant variations in oxygen
tension could well account for some of
the remaining variability in the poly¬
cythemic response seen in our patients.
In practical terms, our study pro¬
vided further evidence that stopping
cigarette smoking can correct some of
the pathophysiologic abnormalities,
even in those patients who suffer from
a very advanced stage of chronic bron¬
chitis and emphysema. In addition, it
implies that some of the physiologic
benefit to be expected from long-term
oxygen therapy will not be achieved if
the patient continues to smoke at least
some of the time while receiving this
treatment. As a result of these observa¬
tions, we will no longer recommend
this expensive treatment for patients
who have persistently high concentra¬
tions of carboxyhemoglobin despite re¬
peated advice to stop smoking cigarettes.
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Days after glucose tolerance test
Glucose and HBA, values in the 120 days after an oral glucose tolerance test.
•Result differs significantly from baseline value (p<0-05).
concentration of some 2-5 mmol/1 could produce a significant
in-'»!>ee in HbA, concentration of almost 1% of total
haemoglobin and that this increase appeared 10 days after the
hyperglycaemia and values remained high until 30 days later,
then fell to normal by 60 days after the test. These data differ
slightly from those of a similar study2 in which 75 g glucose was
used in that we observed a significant rise in HbA, concentration
earlier.
These findings raise doubts about the validity of using HbA,
concentrations as an index of time-integrated blood glucose
concentration since the blood sugar concentrations of insulin-
dependent diabetics may vary widely and frequently throughout
the day. This criticism would not apply, of course, in un¬
controlled or poorly controlled diabetics, in whom persistent
significant increases in blood glucose concentrations produce a
marked increase in HbA, values. In these circumstances there
F
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is no doubt about the value of HbA, measurement. Perhaps,
however, HbA, measurements are too sensitive in well-controlled
insulin-dependent diabetics and those with mild maturity onset
diabetes since our findings show that a minor transient period
of hyperglycaemia will result in a significant increase in HbA,
concentrations.
It is now established that there is an unstable component of
HbA, (SchifF base fraction) which accounts for the rapid
increase in HbA, values in response to a short-term increase in
blood glucose concentration.3 The microcolumn technique does
not differentiate between unstable and stable (ketoamine)
fractions of HbA,, but an increase in the unstable fraction
would be expected to produce some increase in total HbA,.
We did not observe this during the glucose tolerance test or the
next morning, but possibly the degree of hyperglycaemia might
not have been sufficient to produce this effect. Alternatively we
may have missed the effect occurring later in the day of the test.
The labile fraction is thought to decrease again within six hours,
once normoglycaemia is achieved,1 so it may have disappeared
by the following morning.
We thank Miss Carol Fraser, FIMLS for her invaluable tech¬
nical help, and Miss Hilary Cox for typing the manuscript.
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Carbon monoxide and exercise tolerance in chronic
bronchitis and emphysema
P M A CALVERLEY, R J E LEGGETT, D C FLENLEY
Abstract
The effects of carbon monoxide on exercise tolerance as
assessed by the distance walked in 12 minutes were
studied in 15 patients with severe chronic bronchitis and
emphysema (mean forced expiratory volume in one
second 0-56 1, mean forced vital capacity 1-54 1). Each
subject walked breathing air and oxygen before and
after exposure to sufficient carbon monoxide to raise
their venous carboxyhaemoglobin concentration by 9%.
There was a significant reduction in the walking distance
when the patients breathed air after exposure to carbon
monoxide (p <0 01), and the significant increase in
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walking distance seen after exercise when breathing
oxygen at 2 1/minute via nasal cannulae was abolished if
carbon monoxide had previously been administered.
Thus concentrations ofcarboxyhaemoglobin frequently
found in bronchitic patients who smoke may reduce
their tolerance of everyday exercise, possibly by inter¬
fering with the transport of oxygen to exercising muscles.
Introduction
British cigarettes produce appreciable quantities of carbon
monoxide, which is formed by the incomplete combustion of
tobacco in those cigarettes without ventilated filters. When
inhaled this carbon monoxide readily combines with haemo¬
globin to form carboxyhaemoglobin. Carboxyhaemoglobin
concentration has been related to cigarette consumption,' and
concentrations of 5-15% are common in patients who continue
to smoke (table I). In normal healthy volunteers the maximum
oxygen uptake during bicycle exercise was reduced when the
carboxyhaemoglobin concentration was raised to 20% by
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inhalation of carbon monoxide, but this effect was seen only at
the highest work loads.2 Thus carbon monoxide inhaled from
cigarettes might contribute directly to the reduced exercise
tolerance of patients with chronic bronchitis and emphysema
who continue to smoke. We measured the distance walked on the
level within 12 minutes in 15 such patients to assess their
exercise tolerance before and after they breathed a low concen¬
tration of carbon monoxide sufficient to raise their carboxy-
haemoglobin concentration by 9%.
Patients and methods
We studied 15 outpatients (11 men and four women) with severe
irreversibleairwaysobstruction(mean( ± SD) forced expiratory volume
in one second (FEV,) 0-56±02 1; mean forced vital capacity (FVC)
1-54±0-4 1) who were hypoxic and retaining carbon dioxide at rest
(mean arterial pressure of oxygen 6 83 ±0 65 kPa (51-2 ±4-9 mm Hg),
mean arterial pressure of carbon dioxide 6 33 ±0-7 kPa (47-5 ± 5 3 mm
Hg); mean arterial pH 7-39±0 02) (see table II). All patients were
clinically stable at the time of study, and those who smoked were
asked to stop smoking for 12 hours before each study. All studies
were carried out in the afternoon, the FEV, and FVC being measured
before and at the end of each study. The results in any patient who
showed a change of more than 01 1 in FEV, during the study period
were discarded.
A venous cannula was inserted in the antecubital fossa and blood
withdrawn for estimation of carboxyhaemoglobin concentration on
attendance, during and after inhalation of 0 02% carbon monoxide
from a Douglas bag, and immediately after the end of the final walk.
Carboxyhaemoglobin concentration was measured with an IL 182
Co-oximeter.3 In eight patients we also measured arterial oxygen
saturation non-invasively using a Hewlett Packard HP47201A ear
oximeter before and immediately after the end of the walk. These
values were corrected for the carboxyhaemoglobin concentration.1
The patients walked at their own pace in a level corridor, the
distance walked in 12 minutes (including stops if so desired) being
recorded. All patients wore lightweight nasal prongs, giving either air
or oxygen at a rate of 2 1/minute delivered from a cylinder that was
pushed behind by a technician, who did not know what gas was being
given. Six subjects also wore lightweight electrocardiographic chest
leads, which permitted recording of the electrocardiogram at the end
of the walk. In the other subjects the pulse rate was measured before
and at the end of each walk.
Each subject attended on two afternoons and walked four times
during each afternoon. After spirometry and blood sampling they
walked when breathing 2 1 air/minute, then sat at rest for 20 minutes,
and then walked again breathing 2 1 oxygen/minute. After another 20-
minute rest they inhaled 0 02% carbon monoxide in air from a
Douglas bag through a mouthpiece and noseclip for 20-30 minutes
until their venous carboxyhaemoglobin concentration was 8-12%
above the initial value measured when they arrived for the study. The
two 12-minute walks were then repeated in the same order as before.
At the next visit, seven to 14 days later, the order of breathing air and
oxygen was reversed, both before and after inhaling carbon monoxide.
The results for the two walks were then pooled to eliminate any
training effect and to minimise errors due to fatigue. As carbon
monoxide is eliminated from the blood with a half life of four hours'
it was not possible to repeat the walks with the high carboxyhaemo¬
globin concentrations first.
The results were analysed by the Wilcoxon signed rank test as
normality of distribution could not be assumed. Values were expressed
as mean±SD or as a range.
Results
The initial venous carboxyhaemoglobin concentration when the
patients were breathing air before exercise was 31% (range 11-5-4%),
and this increased to 12-3% (range 9-6-14 9%) after inhalation of
carbon monoxide. There was a tendency for the concentration to fall
during the second period of exercise, so that the mean at the end of
exercise was 10-8% (range 8-5-12-8%). This, however, was a constant
effect and affected equally the walks when patients were breathing air
and when they were breathing oxygen, as the order of walking was
reversed at the end of the second visit. Although the values of FEV,
and FVC were similar (table II), the distance walked when breathing
air varied from 252 to 1075 m in the different patients and these
distances were not significantly correlated with the FEV, or FVC.
When the distance walked by each patient was compared for the
various gas mixtures (figure), breathing 2 1 oxygen/minute increased
the mean distance walked by 53-7 m (p < 0-01) over that walked when
breathing air without a raised carboxyhaemoglobin concentration.
Increasing the carboxyhaemoglobin concentration to 12-3 ±1-4%
reduced the distance walked when breathing air by 42-7 m (p < 0-01).
When patients had a raised carboxyhaemoglobin concentration and
breathed oxygen the mean distance walked increased (as compared
with that when breathing air with a raised carboxyhaemoglobin
concentration) by 79-3 m (p<001). The distance walked when
table I—Mean carboxyhaemoglobin concentrations in 91 patients with chronic bronchitis and emphysema
attending afternoon outpatient clinic*
Carboxyhaemoglobin (%): 0-1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 -13 -14 -15
No of palients: 5 19 13 8596282643 1
•Patients with concentrations up to 3% were probably non-smokers.
table II—Spirometric results, arterial bloodgas tensions, changes in carboxyhaemoglobin concentrations from baseline values after inhalation of carbon monoxide (CO),





















1* 0 5 1-55 7-2 6-3 11-4 830 976 730 870
2 0 45 1-60 6-8 6 5 110 816 809 793 862
3 0 45 1-40 7-5 6-3 10-5 835 874 750 854
4 0 65 1-30 6 1 6-5 10-4 931 937 918 918
5 0 75 2 05 7-7 5-9 9 1 787 827 755 829
6 0 55 1 95 6 3 5-7 8-3 724 738 698 726
7• 0 55 1-25 6 7 5 6 8-7 336 378 210 279
8 0-55 1 20 71 5 9 9 8 725 800 714 772
9* 100 2 00 7 1 5-4 8-7 872 898 830 830
10 0 60 1-40 5-2 6 9 8-8 967 1006 903 955
11» 0-35 0-90 71 6 9 8 0 252 315 168 336
12* 0 50 1 60 6 5 7 6 8-7 1075 1187 1077 1182
13 0-60 210 7-3 61 85 347 555 326 527
14* 0 50 1 80 7-5 5-7 8 0 560 672 558 642
15 0-40 1 00 6-4 7-7 8 2 336 341 260 336
Mean ± SD 0 56 ±0 16 1-54 ±0-4 6 83 ±0 65 6-33 ±0-7 9 2±1 1 694 ±263 754 ±258 646 ±280 728 ±257
•Patients known to be current smokers despite medical advice.
FEV, = Forced expiratory volume in one second. FVC = Forced vital capacity. Po2 = Pressure of oxygen. Pco2 == Pressure of carbon dioxide.
Conversion: SI to traditional units—Po2 and Pco2: 1 kPa=s7-5 mm Hg.




p<0 01 p<0 01 p<0 01
Oxygen Air Air + CO Oxygen + CO
Twelve-minute walking distance, with means ±SD, in 15 patients with
chronic bronchitis and emphysema breathing different gas mixtures.
CO—Carbon monoxide.
breathing oxygen after the carboxyhaemoglobin concentration had
been raised was significantly less than that walked when breathing
oxygen before the concentration was raised (p < 0 05) but was not
significantly different from that walked when breathing air before the
concentration was raised (p>0 1).
The average distance walked did not correlate with the resting
arterial oxygen tension when patients were breathing air or with the
ear oxygen saturation measured either before or at the end of exercising
in the eight patients in whom this was measured. The reduction in
distance walked after breathing carbon monoxide was not related to
the normal smoking habits of the patients, since it occurred in both
current smokers and ex-smokers. The heart rate at the end of the walk
was 100-136 beats/minute, always higher than the 64-88 beats/minute
at rest in each patient. The mean heart rate at the end of exercise,
however, was not significantly different when air or oxygen was being
breathed, before or after the carboxyhaemoglobin concentration was
raised. In three of the six patients in whom an electrocardiogram was
recorded at the end of the walk the ST segment was depressed by
more than 1 mm, but ST depression was not correlated with breathing
any particular gas or with a raised carboxyhaemoglobin concentration.
Discussion
Cigarette smokers are the non-industrial group most heavily
exposed to carbon monoxide," but the concentrations of carboxy¬
haemoglobin in smokers are not considered to produce symptoms.
Acute carbon monoxide poisoning produces symptoms such as
headache, vomiting, and coma only when the carboxyhaemo¬
globin concentration is over 35%. It has been suggested,
however, that chronic exposure to carbon monoxide is associated
with subtler changes in neurological function including an
impaired ability to distinguish between short intervals of time,
which is present even at low carbon monoxide concentrations.7
The carboxyhaemoglobin concentrations reached in our studies
are less than those that reduce maximal oxygen uptake in normal
subjects3 but above those that reduce the duration of bicycle
ergometer exercise in patients with obstructive airways disease."
The 12-minute walking distance is a simple and reproducible
test that correlates well with other subjective and objective
variables of exercise tolerance®13 but is similar to the daily
activities that are within the ability of these disabled patients.
We found that raising the carboxyhaemoglobin concentration
from values found in non-smokers to values seen in patients
who are moderate to heavy smokers reduced the distance that
patients with hypoxic chronic bronchitis and emphysema could
walk in 12 minutes. We confirmed that breathing 2 1 oxygen/
minute by nasal prongs can increase the distance walked by such
patients" and that this effect of oxygen persists after the
carboxyhaemoglobin concentration is raised. The benefit of
oxygen on exercise when the carboxyhaemoglobin concentration
is raised, however, is less than that before the concentration is
raised, and the distance walked when breathing supplementary
oxygen at a high carboxyhaemoglobin concentration is not
significantly different from that covered when breathing air at
the low concentration.
Changes in the oxygen content and oxygen-carrying capacity
of the blood are thus associated with measurable changes in
everyday exercise in these hypoxic patients. Similar increments
in carboxyhaemoglobin concentration in healthy subjects do not
affect oxygen delivery to exercising muscles as the cardiac output
is increased to compensate. Carbon monoxide, however, reduces
the maximal oxygen uptake in healthy people.3 There was a
considerable variation in the distance walked by different
patients, not all of whom showed a dramatic change when the
carboxyhaemoglobin concentration was increased (figure). In
the eight patients in whom ear oxygen saturation was measured
this fell by 3-10% (mean 6-3%) after exercise when breathing
air and by 5-18% (mean 7-6%) after exercise when breathing
air with a raised carboxyhaemoglobin concentration. The fall in
arterial oxygen saturation, however, was not related to the
distance walked. This variable response may arise from different
degrees of physical fitness or from different limitations in the
cardiac output response to exercise, so that the delivery of
oxygen to the exercising muscle could not be maintained in all
patients when the carboxyhaemoglobin concentration was
raised.
These studies have shown that continued smoking may play a
direct part in the reduction of exercise tolerance seen in patients
with severe chronic bronchitis and emphysema. Furthermore,
the resultant raised carboxyhaemoglobin concentration would
negate any benefit on exercise from treatment with portable
oxygen in such patients. Thus even patients with advanced
hypoxic chronic bronchitis and emphysema may derive benefit
from giving up smoking with a reasonable expectation of an
increased exercise tolerance.
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Background: A limited or absent bronchodilator response is used to classify chronic obstructive pul¬
monary disease (COPD) and can determine the treatment offered. The reliability of the recommended
response criteria and their relationship to disease progression has not been established.
Methods: 660 patients meeting European Respiratory Society (ERS) diagnostic criteria for irreversible
COPD were studied. Spirometric parameters were measured on three occasions before and after salb-
utamol and ipratropium bromide sequentially or in combination over 2 months. Responses were classi¬
fied using the American Thoracic Society/GOLD (ATS) and ERS criteria. Patients were followed for 3
years with post-bronchodilator FEV, and exacerbation history recorded 3 monthly and health status 6
monthly.
Results: FEV, increased significantly with each bronchodilator, a response that was normally distrib¬
uted. Mean post-bronchodilator FEV, was reproducible between visits (intraclass correlation 0.93). The
absolute change in FEV, was independent of the pre-bronchodilator value but the percentage change
correlated with pre-bronchodilator FEV, (r=-0.44; p<0.0001). Using ATS criteria, 52.1% of patients
changed responder status between visits compared with 38.2% using ERS criteria. Smoking status,
atopy, and withdrawing inhaled corticosteroids were unrelated to bronchodilator response, as was the
rate of decline in FEV,, decline in health status, and exacerbation rate.
Conclusion: In moderate to severe COPD bronchodilator responsiveness is a continuous variable.
Classifying patients as "responders" and "non-responders" can be misleading and does not predict
disease progression.
Chronic obstructive pulrnonary disease (COPD) is cur¬rently defined by the presence of airflow limitation,measured by the forced expiratory volume in 1 second
(FBV,), that shows little or no improvement after inhaled
bronchodilator drugs.1"3 Selection of the maximum change in
FEV, compatible with a diagnosis of COPD has proved
difficult, but could be important clinically. Approximately 10%
of patients with COPD show a short term spirometric
"response" to a course of oral corticosteroids'1 that is
maintained during subsequent inhaled corticosteroid
treatment.5 This is most likely to occur in those patients with
a substantial (>400 ml) improvement in FEV, after oral
corticosteroids.6 A positive bronchodilator response may
define a different natural history,7 8 while European regulators
now require that COPD patients included in treatment trials
meet the European Respiratory Society (ERS) definition of
irreversible disease. Bronchodilator testing can therefore have
both clinical and regulatory importance.
Several criteria have been proposed to define a significant
bronchodilator response.' Each has tried to encompass the
known variability in FEV, measurements between and within
days'" by including a threshold value to reduce the risk of a
chance finding. However, the approaches adopted differ. The
American Thoracic Society (ATS) and the Global initiative for
Obstructive Lung Disease (GOLD) both use a change of > 12%
of the baseline if this also exceeds 200 ml," 12 while the ERS
recommends a change that is >9% of the predicted FEV,."
Many reports simply quote a percentage change from
baseline, which varies between 12 and 20%.14 The reliability of
these definitions has been challenged previously by data from
the IPPB study15 and in primary care where the patients stud¬
ied had relatively mild disease and the stability of the catego¬
risation was not assessed.' Direct comparisons between the
different criteria and the effect of adding other bronchodilator
drugs on the subsequent response rate have not been reported
in large numbers of stable patients with moderate to severe
COPD. Other factors such as smoking status, atopy, or changes
in treatment may also influence the likelihood of a response."
To determine whether routine bronchodilator testing is a
robust measurement in individual patients already classified
as having "poorly reversible" COPD, we examined data from
the pre-randomisation phase of the ISOLDE (Inhaled Steroids
in Obstructive Lung Disease) study.17 We hypothesised that the
number of patients classified as reversiblewould be influenced
by spontaneous variation in airway calibre and by the use of
additional test drugs, regardless of the choice of threshold for
reversibility. We also tested the effect of atopy, smoking status,
or the withdrawal of inhaled corticosteroids on the response to
inhaled bronchodilators. Finally, we tested the hypotheses
that the size of the bronchodilator response predicted the sub¬
sequent rate of decline in FEV,, health status, or exacerbation
rate over the following 3 years.
METHODS
Patients were recruited from the outpatient clinics of 18 UK
hospital centres. All had a clinical diagnosis and symptoms
compatible with non-asthmatic COPD and met both the ERS
and ATS12 spirometric criteria for this disorder. All were aged
40-75 years and were current or ex-tobacco smokers. Their
baseline post-salbutamol FEV, was at least 0.8 1 but <85%
predicted and all had a ratio of FEV, to forced vital capacity
(FVC) of <70%. At the first visit we excluded from further
follow up those patients whose FEV, improved after inhaled
salbutamol by more than 10% of their predicted FEV,. Other
exclusion criteria included the use of p adrenergic blockers,
regular oral corticosteroids, or co-morbidities likely to reduce
life expectancy below 5 years. Nasal and ophthalmic
www.thoraxjnl.com
660
Downloaded from thorax.bmj.com on March 21, 2012 - Published by group.bmj.com
Calverley, Burge, Spencer, et al
Table 1 Demographic and lung function
characteristics of study subjects
N Mean (SD)
Patients with complete data 660
Pre-salbufamol FEV, (1) 660 1.28 (0.46)
Pre-salbufamol FEV, (% predicted) 660 45.5 (14.9)
Pre-salbufamol FVC (1) 660 2.94 (0.76)
Pre-salbutamol FEV,/FVC 660 0.43 (0.11)
Tlco (mmol/min/kPa)* 556 4.91 (2.10)
Age (years) 660 63.8 (7.0)
Pack years smoked 615 44.6 (32.4)
Current smokers/ex-smokers 314/345 48%/52%
M/F 497/163 75%/25%
Atopic/non-afopic 175/485 27%/73%
Previous use of regular inhaled steroids 353/307 53%/47%
(yes/no
FEV,=forced expiratory volume in 1 second; FVC=forced vital
capacity; Tlco=carbon monoxide transfer factor.
*Narmal range 10.84 (2.52) mmol/min/kPa.
corticosteroids, theophyllines, other oral bronchodilators, and
any inhaled bronchodilators were allowed. All patients gave
their written informed consent before the study, which was
approved by the local ethical committees of the participating
Institutions.
Measurements
All spirometric measurements were made using identical roll¬
ing seal spirometers (Sensormedics 2130D, BVWarwickshire,
UK). Forced expiratory manoeuvres were performed in a
standardised fashion" and the best FEV, and FVC recordings
within 50 ml of each other were accepted. We developed an
intra-centre and inter-centre quality control protocol based on
the criteria used in the Lung Health Study." These were modi¬
fied to accept an FVC in which a volume change of <40 ml in
a 2 second period was not required provided that the forced
expiratory time exceeded 12 seconds. Each spirometric
recording was reviewed centrally and the percentage of tests
meeting the external quality control criteria was fed back to
the study centre to ensure high quality data throughout the
study. Patients were asked to omit short acting inhaled bron¬
chodilators for 4 hours before attendance, and long acting oral
and inhaled agents for 12 hours. If the patient experienced a
respiratory tract infection or exacerbation of COPD requiring
treatment in the 4 weeks before their clinic visit, this was
re-scheduled to provide valid spirometric testing.
Smoking status was assessed using exhaled breath carbon
monoxide (CO) measured after a 20 second breath hold using
a mini Smokerlyzer (Bedfont Technical Instruments Ltd, Kent,
UK). Urinary cotinine was measured by thiocyanate assay in
all patients during the run-in and subsequently in patients
who claimed not to be smoking but had an expired CO level of
>8ppm. Self declared non-smokers were classified as
smokers if their urinary cotinine concentration was >40 mg/
ml and expired CO was > 10 ppm or if the urinary cotinine
value was missing but the expired CO was >10 ppin on more
than two visits.
Atopic status was assessed objectively by skin prick testing
to four common allergens (Aspergillus fumigatus, Dermatopha-
goides pteronyssinus, cat dander, and mixed grass pollen)
togetherwith a positive and negative control. Individuals were
considered to be atopic if they reacted with a wheal of more
than 3 mm in diameter to more than one of these allergens.
Testing for atopy was conducted at the time of the first
attendance.
Study protocol
Patients attended on three occasions at 4 weekly intervals
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Figure 1 Mean (SE) FEV, before and after salbutamol, ipratropium,
and the combination on three occasions at monthly intervals. Note
the differences in pre-bronchodilator values between visits and the
lack of change in post-bronchodilator FEV, after the combination at
visits 1 and 2.
they performed spirometric tests, then received 400 jig
salbutamol via a large volume spacer (Volumatic) and
spirometric tests were repeated after 30 minutes. Ipratropium
bromide 80 |ig was then given via the spacer and spirometric
tests were repeated 30 minutes later. At the next attendance
(VI) the order of the drugs was reversed, while on the third
visit (V2) salbutamol inhalation was immediately followed by
ipratropium and spirometric testing at 30 minutes. After V2,
patients were randomised to receive either fluticasone 500 pg
twice daily via the spacer or an identical placebo. They
attended 3 monthly for repeat spirometric testing as described
at V2 until 3 years of follow up had been completed or they
had withdrawn from the study.
Data analysis and statistical methods
The change in spirometric values after bronchodilation were
expressed as: (a) absolute change (ml); (b) percentage change
from baseline; and (c) change in percentage predicted normal
values. Spirometric values for the normal population used the
ECCS formulae."
Student's t tests were used to test differences from baseline
and differences in mean values between visits. FEV, repeatabil¬
ity was measured using the intraclass correlation coefficient.
The relationship between pre-bronchodilator values and
bronchodilator response was estimated using regression
coefficients." Interactions with smoking status, sex, and atopy
were investigated using analyses of covariance. The rate of
decline in FEV, was derived using the placebo data set only and
was expressed as the change in post-bronchodilator FEV, (ml)
per year. These data were analysed using a random coefficients
mixed effects model as described by Burge et al." Similarly, data
for the change in health status with time and the exacerbation
rate were collected and analysed as described in detail by Burge
et al." All tests were two sided with a 5% level of significance.
Data are expressed as mean (SE) unless otherwise stated.
RESULTS
Study population
Of the 990 patients fulfilling the entry criteria, 751 completed
the 2 month run-in and were randomised, 375 receiving pla¬
cebo. Of the randomised population, 54% had used regular
inhaled corticosteroids before the study. Complete data at all
three bronchodilator assessments were available for 660
patients. The loss of data in the remaining 91 patients was
largely due to delayed assessment because of respiratory tract
www.lhoraxjnl.com
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Figure 2 histograms of the distribution of bronchodilator response
seen in data derived at visit 0 after salbutamol alone.
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Figure 3 Data at the same visit as fig 2 but after salbutamol and
ipratropium and expressed as (A) percentage of predicted FEV,, (B)
absolute change in FEV,, and (C) percentage change from baseline.
infections; these patients did not differ significantly in any
baseline characteristic or prior treatment from those who are
reported here. Details of the study population are presented in
table 1 based on measurements made at V0.
Response to bronchodilator drugs
FEV, and FVC both increased significantly after inhaled sal¬
butamol at VO (mean change in FEV, 128 (4) ml, mean change
Pre-bronchodilator FEV] by change in FEV] (% from baseline)
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Figure 4 Relationship between the response to bronchodilator and
the pre-bronchodilator FEV, at visit 2. (A) Absolute change in FEV, is
unrelated to initial FEV,. (B) Change as a percentage of baseline
FEV, is related to initial FEV, in a curvilinear fashion which persisted
even when the ATS absolute volume criteria were included (C).
in FVC 286 (12) ml). A further significant increase in both
variables occurred after ipratropium (fig 1). The pre-
bronchodilator FEV, at VI was lower than at V0 (p<0.0001),
and the increase in FEV, after ipratropium (the first drug given
at VI) was larger than when salbutamol was given first at V0.
The change in FEV, when ipratropium was added to
salbutamol at V0 was 63 (4) ml, and the change when salbuta¬
mol was added to ipratropium at VI was 39 (4) ml (difference
24 ml, pcO.0001). There were no significant differences in the
mean post-bronchodilator FEV, between VI and V2 or in the
mean bronchodilator response at any visit. The intraclass
correlation coefficient for pre-bronchodilator FEV, was 0.91
and for post-bronchodilator FEV, was 0.93 for the three visits.
The distribution of the change in FBV, expressed as a
percentage of predicted after salbutamol was censored by our
inclusion criteria (fig 2). The distribution became more
obviously normal when data after both salbutamol and ipra¬
tropium were plotted (fig 3A). Similar patterns were seen
when the absolute change in FEV, and percentage change
from baseline were used, although the latter group were
skewed towards apparent responsiveness (fig 3B and C).
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Figure 5 Changes in responder
classification and corresponding
subgroup mean FEV, at each visit
after both bronchodilators using (A)
American Thoracic Society and (B)
European Respiratory Society criteria.
Numbers in circles refer to the total
classified as positive responders at
that visit and those in squares are the
non-responders on the same
occasion. Note that some patients in
the ERS criteria group exhibited a
"response" after both drugs at the first
visit despite being classified as
non-responsive to salbutamol alone.










Influence of baseline FEV, on likelihood of being
classified as responsive
The relationships between the pre-bronchodilator FEV, and
the size of the bronchodilator response expressed in different
ways are shown in fig 4 using data from V2. The change in
FEV,, whether expressed as an absolute value or as a percent¬
age of predicted, was uninfluenced by the pre-bronchodilator
FEV, when measured in absolute units. When the data were
expressed as a percentage change from baseline there was a
clear curvilinear relationship with the pre-bronchodilator
FEV,, best described using a power function (r=0.17,
p<0.0001). This relationship persisted (r=0.44, p<0.0001)
even when patients whose FEV, changed by less than 200 ml
were excluded (fig 4C).
Reproducibilify of the response
The reliability of the patient's responder classification is
shown in fig 5 using data obtained following both broncho¬
dilator drugs. Using the ATS classification, only 103/275 (37%)
of those initially classified as reversible remained so on the
two subsequent visits while 213/385 (55%) of those classified
as irreversible showed equally inconsistent results.
Comparable figures for the ERS classification were 32/149
(21%) initially classified as reversible and 375/511 (73%)
as irreversible. Overall, 52% of patients classified by ATS cri¬
teria and 253/660 (38%) classified using ERS criteria would
be reclassified if tested on a different occasion. There was
a significant association (p<0.0001) between the change
in pre-bronchodilator FEV, between visits and the change
in response classification—that is, an increase in
pre-bronchodilator FEV, between visits was likely be associ¬
ated with reclassification to being irreversible and, conversely,
a fall in pre-bronchodilator FEV, between visits led to
reclassification as reversible. Patients identified as being
consistently reversible by ATS and ERS classifications are
compared in table 2. There were no significant differences
between these groups in the numbers of smokers and atopic
subjects.
Using data obtained at V2 following both bronchodilators,
the absolute change in FEV, was unrelated to smoking status
or atopy. There were no sex differences in the magnitude of
response to bronchodilators. In this study 53% of the popula¬
tion had inhaled corticosteroids withdrawn at screening but
there was no difference in the change in FEV, at V2 between
these patients and those who had not previously received
inhaled corticosteroids.
Table 2 Demographic characferislics of patients consistently reversible and irreversible using ATS and ERS criteria
ATS response ATS no response Difference ERS response ERS no response Difference
(n=103) (n=213) (p value) (n = 32) (n=375) (p value)
Post-bronchodilafor FEV, (1) 1.60 (0.04) 1.35 (0.03) <0.0001 1.70 (0.07) 1.37 (0.02) <0.0001
Change in FEV, (1) 0.34 (0.01) 0.09 (0.01) 0.37 (0.02) 0.13 (0.01)
Change in FEV, (% predicted) 11.17 (0.29) 3.60 (0.21) 13.13 (0.48) 4.60 (0.17)
% women 12 38 <0.0001 25 24 0.9
% smokers 48 47 >0.9 47 48 0.9
% atopic 32 24 0.1 28 24 0.6
% previous regular ICS 61 51 0.1 66 51 0.1
Values are mean (SE).
FEV|=forced expiratory volume in 1 second; ICS=inhaled corticosteroids.
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Bronchodilator response as a predictor of subsequent
disease progression
The mean rate of decline in FEVj in placebo treated patients
was 53 ml per year. We found no relationship between the
absolute or percentage predicted changes in FEV, after
bronchodilator and the subsequent rate of decline in FEV, in
our model which controlled for the baseline post-
bronchodilator data. The mean rate of decline in health status
was unrelated to baseline bronchodilator response (p=0.4).
Bronchodilator response was divided into responders and
non-responders by the median value (170 ml). Decline in
health status was not significantly different between the two
groups (responders 2.8 units/year; non-responders 3.4 units/
year; p=0.3). The annual rate of exacerbations was not
significantly different between the two groups (responders 1.5
exacerbations/year; non-responders 1.5 exacerbations/year;
p=0.6).
DISCUSSION
COPD is now defined using the combination of a clinical his¬
tory and objective evidence of airflow limitation. Data from
this study show that these criteria identify patients with an
accelerated rate of decline in FEV,. However, the distinction
from chronic asthma with limited reversibility remains
difficult, and most treatment guidelines use the spirometric
response to a bronchodilator drug to aid the diagnosis and, in
some cases, to make recommendations about treatment
decisions.12 Previous studies have examined the ability of
bronchodilator testing to differentiate between asthma and
COPD in milder disease and have found no clear distinction
spirometrically between the two.®20 This has not prevented
these criteria being widely recommended in the assessment of
more severe COPD or in the selection of patients for inclusion
in treatment trials."21 In this study we examined the reliabil¬
ity of the bronchodilator response in moderate to severe COPD
defined as "poorly reversible" disease by one set of criteria and
have related it to clinically relevant outcomes. Our data
suggest that the current definitions of bronchodilator revers¬
ibility have significant limitations in established COPD and
may be potentially misleading.
As in the EUROSCOP trial,22 we selected patients with a
<10% change in predicted FEV, after an inhaled p agonist. The
distribution of bronchodilator responses using this criterion
was censored but returned towards normal once the second
bronchodilator drug was added. In these patients we could not
identify a separate population of more responsive patients
however the data were expressed.
Using a second drug, whether ipratropium or salbutamol,
increased the mean FEV, and changed the number of patients
classified as reversible. The group mean change in FEV, after
each drug was reproducible between visits despite the signifi¬
cant fall in pre-bronchodilator FEV, which was probably
related to both the withdrawal of inhaled corticosteroids and
regression to the mean.21 The post-bronchodilator FEV, values
were highly correlated between visits, supporting the use of
this measurement as the principal outcome in longitudinal
studies of the evolution of the disease.
Neither the American nor European definitions were
acceptably reproducible. Over half the patients initially classi¬
fied as reversible by the ATS/GOLD definition would be reclas¬
sified had they attended on another occasion. Likewise, 38% of
those classified by the European criteria changed their appar¬
ent responder statuswith time, despite all being irreversible to
salbutamol alone at the first visit.
A further problem with the ATS and GOLD definitions, but
not with those based on an absolute or percentage predicted
change, is their dependence on the baseline FEV, even when
an initial absolute value of 200 ml is considered a threshold for
this measurement (fig 4C).This may suggest that a substantial
degree of reversibility is present even when the absolute
increase in FEV, is similar to that seen in less severe disease.
The absolute changes in FEV, we saw were similar to that in
much milder disease in the Lung Health Study.13
Our data were uninfluenced by differences in sex, current
smoking status, atopic status, or the prior use of inhaled
corticosteroids. Neither smoking status nor atopy were
over-represented in the patients who showed the most
"consistent" positive responses, suggesting that improvement
in lung function in COPD does not correspond to either an
asthmatic or ex-smoking phenotype. Patients treated previ¬
ously with inhaled corticosteroids did not differ in their
bronchodilator responses from those not so treated. The most
likely explanation for the between day variation in classifi¬
cation is the effect of small fluctuations in bronchomotor tone
as shown by the inverse relationship between pre-
bronchodilator FEV, and the chance of a change in responder
classification. Similar fluctuations in airway calibre have been
noted in other COPD populations and have been related to the
degree of cholinergic tone in the airway smooth muscle.'24
Our model of the rate of decline in FEV, controlled for the
post-bronchodilator FEV, value obtained during the run-in
period. We found no evidence for a relationship between the
change in FEV, after bronchodilators, however expressed, and
the rate of decline in lung function. We confined our analysis
to the placebo treated patients to exclude any confounding
effects of the inhaled corticosteroids. Our data contrast with
those obtained from a more mixed population where only
partial analysis of the FEV, decline was available.7 It
emphasises the difficulty of using measures like a broncho¬
dilator "response" in patients with more severe and structur¬
ally determined airflow limitation. Our results are in keeping
with a long term Danish population study where COPD mor¬
tality was related to both pre-bronchodilator FEV, and the
change in FEV, at study entry, but the latter variable was no
longer significant when the relationship was expressed in
terms of the post-bronchodilator value.25 The failure of the
response to predict future changes in health status or exacer¬
bation frequency is not surprising given the limitations of this
measurement.
We could not, for logistic reasons, include a group receiving
placebo inhalations but felt that the reproducibility of the
FEV, which this assesses has been reported sufficiently
frequently to make this unnecessary." 13 The doses of the
bronchodilator drugs may not have been maximal2'27 or opti¬
mally timed, but these minor differences are unlikely to have
systematically affected our results. This study specifically
addressed the usefulness of classifying patients who are
believed to have COPD on their response to one dose of one
bronchodilator, a common clinical situation. The conclusion
that this is a continuously distributed response susceptible to
the number of drugs used and day of testing suggests that,
even in this group of patients, identifying responder status in
this way is of little practical value. We cannot address whether
this would be true for those with a more substantial broncho¬
dilator response, but the variability in the tail of our response
distribution suggests that it may also be true in these cases.
Our data are not surprising given the day to day variation in
bronchomotor tone and the arbitrary nature of the definitions
adopted. Unfortunately, many clinicians still rely on these
responses to decide whether patients have COPD and what
treatment they should receive, while regulators in Europe and
North America take very different views about the inclusion of
reversibility data in clinical treatment trials. A major purpose
of this study has been to alert them and the regulatory
authorities to the significant limitation of any classification
currently in use. This variability in classification helps to
explain the unreliability of bronchodilator responsiveness as a
predictor of improvement after treatment.23 29 If broncho¬
dilator response data are to be presented in COPD, then the
absolute change in FEV, should be reported without making
prior assumptions about its diagnostic significance.
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ity testing is recommended in all patients
with chronic obstructive pulmonary dis¬
ease (COPD) but does not predict im¬
provements in breathlessness or exercise
performance. Two alternative ways of
assessing lung mechanics—measurement
of end expiratory lung volume (EELV)
using the inspiratory capacity manoeuvre
and application of negative expiratory
pressure (NEP) during tidal breathing to
detect tidal airflow limitation—do relate
to the degree of breathlessness in COPD.
Their usefulness as end points in broncho¬
dilator reversibility testing has not been
examined.
Methods—We studied 20 patients with
clinically stable COPD (mean age 69.9
(1.5) years, 15 men, forced expiratory vol¬
ume in one second (FEV,) 29.5 (1.6)% pre¬
dicted) with tidal flow limitation as
assessed by their maximum flow-volume
loop. Spirometric parameters, slow vital
capacity (SVC), inspiratory capacity (IC),
and NEP were measured seated, before
and after nebulised saline, and at intervals
after 5 mg nebulised salbutamol and
500 gg nebulised ipratropium bromide.
The patients attended twice and the treat¬
ment order was randomised.
Results—Mean FEV„ FVC, SVC, and IC
were unchanged after saline but the
degree of tidal flow limitation varied.
FEV, improved significantly after salbuta¬
mol and ipratropium (0.11 (0.02) 1 and
0.09 (0.02) 1, respectively) as did the other
lung volumes with further significant
increases after the combination. Tidal
volume and mean expiratory flow in¬
creased significantly after all bronchodi-
lators but breathlessness fell significantly
only after the combination treatment. The
initial NEP score was unrelated to subse¬
quent changes in lung volume.
Conclusions—NEP is not an appropriate
measurement of acute bronchodilator re¬
sponsiveness. Changes in IC were signifi¬
cantly larger than those in FEV, and may
be more easily detected. However, our
data showed no evidence for separation of
"reversible" and "irreversible" groups
whatever outcome measure was adopted.
IThorax 2001;56:713-720)
Keywords: chronic obstructive pulmonary disease;
bronchodilator; reversibility; end expiratory lung vol¬
ume; flow limitation
Chronic obstructive pulmonary disease
(COPD) is characterised by airflow limitation
which varies little over several months of
observation or after treatment.12 The assess¬
ment of airflow limitation usually relies on
spirometric testing and, in particular, the
forced expiratory volume in 1 second (FEV,)
which is the usual outcome measure in
diagnostic bronchodilator reversibility testing.3
Although useful diagnostically and prognosti-
cally,4 spirometric abnormalities are poor
descriptors of the severity of breathlessness in
COPD.5 Likewise, significant changes in FEV,
after inhaled bronchodilators are not necessary
for improvement in exercise performance or
dyspnoea to occur.5"7 Two alternative tech¬
niques of measuring lung mechanics relatively
easily are now available. Both are better corre¬
lates of breathlessness than FEV,, but their
reproducibility and sensitivity to change in
response to bronchodilator drugs has not been
assessed—an important consideration if they
are to be of practical value.
The application of negative expiratory pres¬
sure during tidal breathing (the NEP tech¬
nique) is a simple and rapid way of assessing
the presence of flow limitation during tidal res¬
piration which overcomes the problems of gas
compression artefacts and variations in the
preceding volume history of the manoeuvre.8
The degree of tidal flow limitation correlates
with the severity of everyday breathlessness
using the MRC scale.9 One study has reported
that tidal flow limitation was unchanged after a
moderate (400 (ig) dose of inhaled salbutamol
in patients with resting flow limitation,10 but
the effects of higher doses of this drug or other
bronchodilators have not been examined.
Pulmonary hyperinflation during spontane¬
ous breathing is common in advanced COPD,
relates well to the intensity of dyspnoea during
exercise," and can be reproducibly detected
using the inspiratory capacity manoeuvre.12
Inhaled (3 agonists and anticholinergic agents
reduce exercise induced dynamic hyperinfla¬
tion.6 7 Measurements of expired lung volume
such as the forced and relaxed vital capacities
also improve after bronchodilators, suggesting
a fall in residual volume, but how these changes
relate to those in inspiratory capacity (IC) is
less certain.
The major diagnostic difficulties with spiro¬
metric based reversibility testing occur in
patients with a low baseline FEV, where
changes after the bronchodilator drug fall
within the spontaneous reproducibility of the
www. thoraxjnl. com
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measurement.13 In these individuals hyperinfla¬
tion is present at rest and tidal flow limitation is
more likely to be present when the subject is
seated,8 increasing the chance of a positive sig¬
nal using these variables after a bronchodilator
test. Our previous studies have suggested that
acute bronchodilator responsiveness in COPD
is a continuous variable.14We hypothesised that
changes in the degree of hyperinflation and in
tidal flow limitation would be as reproducible
as those in FEV, and would separate potential
responder groups for future treatment trials. To
test this, we have conducted a single blind ran¬
domised placebo controlled trial ofnebulised p
agonists and anticholinergic drugs measuring
both pulmonary hyperinflation and tidal flow
limitation in a group of patients with more
severe COPD than reported previously. Addi¬
tionally, we have measured the relaxed or
"slow" vital capacity to assess whether this
more readily available measurement showed
equivalent sensitivity to change after active
drugs to those seen with the newer measure¬
ments of resting lung mechanics.
Methods
SUBJECTS
Twenty patients (15 men) with severe COPD
participated in the study. All had been cigarette
smokers of >20 pack years, had a clinical
course consistent with the disease, and met the
BTS criteria for diagnosis and classification of
disease severity.15 None had clinical or radio¬
graphic evidence of bronchial asthma, bron¬
chiectasis, or neoplasia, nor of significant
cardiovascular/neuromuscular disease which
would affect their resting sensation of breath-
lessness or their pulmonary function results.
All had been free of respiratory tract infection
for at least 4 weeks. Short acting inhaled bron-
chodilators were omitted for 6 hours, long act¬
ing inhaled bronchodilators were omitted for
12 hours, and oral theophyllines were omitted
for 24 hours prior to testing and caffeinated
beverages were avoided for 6 hours. All were
recruited from the respiratory outpatient clin¬
ics of the University Hospital Aintree and gave
their informed consent to the study which was
approved by our institutional ethics committee.
PROTOCOL
Each patient attended the Pulmonary Physiol¬
ogy Laboratory on two occasions at the same
time of day. At the first visit they were
randomly allocated to one of two groups, A or
B, to determine the order in which they would
receive their bronchodilator drugs. They com¬
pleted a St George's Respiratory Questionnaire
to assess their health status16 and resting
arterial blood gas tensions were measured
seated breathing room air. At each attendance
spirometric parameters were recorded after the
patient had been sitting quietly for at least 5
minutes, followed by measurement of IC and
slow vital capacity (SVC), mean inspiratory
and expiratory mouth pressures, thoracic gas
volume, resting breathing pattern, and finally
NEP testing (see below). Before each test
period the intensity of breathlessness was
graded using a modified Borg category scale"
Hadcroft, Calverley
in response to the question: "How breathless
are you feeling?" Each patient received 2.5 ml
normal saline via a wet nebuliser (Sidestream
Disposable Nebuliser, MedicAid Ltd, UK) at
flow rate of 5 1/min for 5 minutes. After 15
minutes' rest this assessment protocol was
repeated. Patients in group A were then given
5 mg salbutamol via the nebuliser at the same
flow rate as the saline. After a further 15 min¬
utes all measurements were repeated. Group A
subjects finally received 500 pg ipratropium
bromide nebulised as before and then repeated
their measurements 45 minutes later. Patients
in Group B received saline, followed by
nebulised ipratropium with measurements
made after 45 minutes, then nebulised salbuta¬
mol with final measurements made 15 minutes
after this.
On the second day the same protocol was




FEV, and forced vital capacity (FVC) were
measured using a 1 litre dry rolling seal spiro¬
meter (MedGraphics, Minnesota, USA), the
best FEV, and FVC values from reproducible
measurements being reported as recom¬
mended by the ATS.18 " Normal values were
those of the ECSC.20 At the time of their first
visit a maximum flow-volume manoeuvre was
recorded after a period of quiet breathing and
with the equipment software a tidal loop was
positioned relative to the maximal loop using
the IC manoeuvre. The resulting plot was
printed to determine whether the resting tidal
loop exceeded the maximum flow-volume
envelope.
Inspiratory capacity/slow vital capacity
These were measured using the same spiro¬
meter as above. After four normal tidal breaths
the patient inhaled to total lung capacity
(TLC) from their spontaneous end expiratory
lung volume (EELV), paused for 1 second,
then exhaled slowly to functional residual
capacity. This manoeuvre was repeated until
two values corresponded to within 5% of each
other.
Thoracic gas volume/total lung capacity
These were measured in the MedGraphics
constant volume body plethysmograph and
required subjects to pant against a closed
mouthpiece supporting their cheeks. Thoracic
gas volume and TLC were calculated using the
commercial software supporting this equip¬
ment. Knowing the TLC, the EELV could be
determined from the equation:
EELV = TLC - IC
Mean inspiratory and expiratory mouth pressures
These were measured according to the method
of Black and Hyatt.21 Three measurements of
each were made and the best of the three
recorded.
BREATHING PATTERN
After 3-4 minutes of stable breathing a 30 sec¬
ond period of tidal breathing was recorded on
www. thoraxjnl. com
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the NEP circuit (Raytech Instruments, Van¬
couver, Canada) (see below) and displayed on
the computer screen. Inspiratory and expira¬
tory times (Ti, Te), the total time cycle time
(Ttot), and tidal volume (Vt) were measured
using the customised software. The duty cycle
(Ti/Ttot) and mean inspiratory and expiratory
flows (Vt/Ti and Vt/Te) were derived from
these data.
NEP METHOD FOR MEASURING EXPIRATORY FLOW
LIMITATION
The testing method and the protocol used are
similar to those described elsewhere.8 9 22 The
NEP circuit comprised a flanged mouthpiece
in series with a pneumotachograph (Aeromech
Devices, Ontario, Canada) and a Venturi
device (Aeromech Devices), one end of which
was open to the atmosphere, the other
connected to the cone of the heated pneumota¬
chograph (3700 series, Hans Rudolph Inc,
Kansas City, USA). A side port on the Venturi
device was connected via an electrically
operated solenoid valve (Aeromech Devices) to
a source of compressed air using rigid tubing. A
pressure regulator connected to the source of
compressed air could be adjusted to set the
NEP to the required level of -5 cm H20. The
solenoid valve was controlled by a computer
(Raytech Instruments Inc, Vancouver,
Canada) using customised software to activate
the pressure source 0.2 seconds after the onset
of expiration and to remain activated for a pre¬
set period. This period was equal to the length
of tidal expiration of each individual subject.
Airflow was measured from the pressure drop
across the pneumotachograph screen using a
differential pressure transducer (Raytech In¬
struments Inc) calibrated before each subject's
visit with a water manometer. These signals
were amplified, filtered, digitised, analysed,
and displayed on a computer screen. Volume
was obtained by numerical integration of the
flow signal. Flow and volume could be
continuously monitored on screen during the
study, which permitted monitoring of breath¬
ing stability and timing of the NEP test. By
constantly monitoring flow and volume, leaks
could be identified visually.
Procedure
With the patient in a seated position with a
nose clip in place, tidal breathing was recorded
for 30 seconds after acclimatisation and the
duration of tidal expiration was calculated. A
series of test NEP breaths was performed using
an NEP of-5 cm H20 until the patient became
accustomed to the procedure. Each NEP
period was equal to the duration of the
previous tidal expiration and was triggered 0.2
seconds after the onset of expiration. NEP was
only applied once a steady state of tidal breath¬
ing was reached, and when air leaks could be
confidently excluded.
Analysis of flow limitation was made by
superimposing the expiratory limb of the flow-
volume loop in the presence of NEP on the
expiratory limb of the preceding breath. If flow
could be increased by the application of NEP,
then the patient was not flow limited. In
preliminary studies we noted significant breath
to breath variability in flow limitation in some
subjects so only the first pair of breaths at each
measurement was analysed. The degree of flow
limitation was scored according to the amount
by which the two expiratory limbs overlapped
so that the period of flow limitation was
expressed as a percentage of the control breath,
as described elsewhere.8 We then divided these
percentages into three groups (0, 1, and 2)
where 0 = no flow limitation at all during expi¬
ration (0%), 1 = partial flow limitation (>0%
but <100%), and 2 = complete flow limitation
(100%).
STATISTICAL ANALYSIS
Data are expressed as mean (SE) unless other¬
wise stated. Statistical analysis of the physi¬
ological measurements before and after saline,
and each bronchodilator alone and in combi¬
nation was made using analysis of variance
(ANOVA). A p value of <0.05 was taken to be
of statistical significance. Comparisons be¬
tween the same variables on different occasions
were made using the method ofBland and Alt-
man. 95% agreement limits for each pulmo¬
nary function variable after placebo inhalation
were calculated as previously described.23
Comparisons between subgroups defined by
flow limitation were made using analysis of
variance while Borg dyspnoea scores were




Demographic data for the patient population
studied is shown in table 1. They were an eld¬
erly group with severe airflow limitation,
significantly raised lung volumes, and markedly
impaired health status. All individuals had tidal
flow limitation which exceeded the maximum
flow-volume envelope as measured in the body
plethysmograph. However, on NEP testing
when seated, eight individuals had no flow
limitation, six had partial flow limitation, and
six had complete flow limitation at rest. The
demographic features of each of these sub¬
groups are also shown in table 1. NEP testing
was poorly reproducible when repeated within
a few breaths of the first test. Only 12 individu¬
als had a consistent degree of tidal flow limita¬
tion, which worsened in two and decreased in
six. All subsequent NEP data are reported on
the first breath results.
REPRODUCIBILITY
Short term reproducibility data are presented
in fig 1 for the principal flow and volume
measures in the form of Bland-Altman plots.
These demonstrate relatively narrow 95%
agreement limits with no evidence of a
relationship between the baseline value and the
reproducibility of the measurement. The mean
(SE) between day reproducibility (mean of the
differences between each of the baseline meas¬
urements on the two days of testing) of the
FEV„ FVC, IC, and SVC was 0.06 (0.01) 1,
0.23 (0.04) 1, 0.07 (0.04) 1, and 0.16 (0.06) 1,
respectively. The mean change in TLC after
www. thoraxjnl. com
Downloaded from thorax.bmj.com on March 21, 2012 - Published by group.bmj.com
Hadcroft, Calverley
Table 1 Mean (SE) baseline demographic data for the 20 subjects with COPD studied
All (n=20) NEP=0 (n-9) NEP=1 (n=4) NEP=2 (n-7)
Age (years) 69.9 (1.5) 61.4 (7.4) 67.0 (2.0) 73.9 (1.9)
M:F 15:5 7:2 4:0 4:3
BMI (kg/m2) 24.7 (2.5) 25.5 (1.1) 21.6 (1.1) 25.4 (1.8)
FEV, (1) 0.78 (0.05) 0.96 (0.06) 0.61 (0.1)* 0.65 (0.06)*
FEV, (% predicted) 29.6 (2.3) 34.2 (2.4) 20.5 (2.5*) 28.9 (4.8)
FVC (1) 2.26 (0.13) 2.62 (0.19) 1.98 (0.18) 1.95 (0.19)*
FVC (% predicted) 64.6 (3.2) 71.4 (4.0) 51.3 (4.1)* 63.4 (5.7)
FEV,/FVC (%) 35.5 (2.2) 37.6 (2.8) 30.8 (3.3) 35.4 (5.1)
IC (1) 1.65 (0.09) 1.9 (0.2) 1.5 (0.1) 1.4 (0.1)*
SVC (1) 2.65 (0.16) 3.0 (0.2) 2.5 (0.1) 2.3 (0.3)*
TLC (1) 7.48 (0.34) 7.5 (0.5) 8.5 (0.9) 6.9 (0.6)
Pao2 (kPa) 8.75 (0.26) 9.3 (0.4) 8.3 (0.3) 8.3 (0.4)
Paco2 (kPa) 5.52 (0.17) 5.3 (0.2) 5.6 (0.4) 5.8 (0.3)
SGRQ (%) 62.7 (3.3) 62.7 (5.2) 64.7 (7.9) 61.6 (5.9)
BMI = body mass index; FEV, = forced expiratory volume in one second; FVC = forced vital capacity; IC = inspiratory capacity;
SVC = slow vital capacity; RLC = total lung capacity; Pao2J Paco, = arterial oxygen and carbon dioxide tensions; SGRQ = St
George's Respiratory Questionnaire; NEP = negative expiratory pressure; 0 = no flow limitation; 1 = partial flow limitation; 2 =
complete flow limitation.
*p<0.05.
saline was 0.58 L with wide 95% confidence
intervals (-2.04 to +1.79). The NEP data were
less reproducible with 12 subjects remaining
the same, four showing less tidal flow limita¬
tion, and four showing more tidal flow
limitation on repeat testing on the second day.
These changes showed no consistent relation¬
ship with measured IC or breathing pattern.
BRONCHODILATOR RESPONSE
Group mean (SE) bronchodilator responsive¬
ness data are shown in fig 2A and compared
with the changes after saline. Significant
(p<0.001) increases in FEV, occurred after
both salbutamol and ipratropium and a further
significant increase (p<0.05) compared with
the value after a single agent was seen when the
two groups were combined, irrespective of the
order in which they were given. This was also
the case for IC (fig 2B). There were no signifi¬
cant differences in the magnitude of change
after either drug given singly or in combina¬
tion, irrespective of the different timings of the
treatment. Similarly, significant changes in IC,
FVC, and SVC were seen and similar changes












































Mean SVC on two days (I)
Figure 1 Bland-Altman plot ofmean baseline values for each subject on two days plotted against the difference between
the baseline values on the two days. Broken lines represent the mean and 2 standard deviations either side of the mean of
the differences between baseline values. (A) forced expiratory volume in one second (FEV,), (B) forced vital capacity
(FVC), (C) inspiratory capacity (IC), (D) slow vital capacity (SVC). The 95% agreement limits for all measurements
are narrow.
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Nebulised agent
I + S SAL1 SAL2 S I S +1
Nebulised agent
Figure 2 (A) Mean (SE) changes in forced expiratory volume in one second (FEV) after placebo and active drug,
singly and in combination. SAL1 and SAL2 = saline (placebo) on days 1 and 2, respectively, S = salbutamol, I =
ipratropium. Day 1 is the day on which salbutamol was the active drug which was given first (solid lines); day 2 is the day
on which ipratropium was given first (broken lines). (B) Data for inspiratory capacity measured at the same time as the
FEV, and with the same conventions.
assess them (table 2). The FEV,/FVC and
FEV,/SVC ratios were not significantly
changed after either saline or any broncho¬
dilator given singly or in combination. The
number of individuals exceeding the 95% con¬
fidence interval for the measurements after
both bronchodilators are shown in fig 3 where
FEV, and IC data are compared. Using a
change of 12% baseline as representing revers¬
ible disease, on 29 occasions subjects would be
classified as reversible on FEV, criteria while a
change beyond the immediate reproducibility
of the IC test was seen on 27 occasions.
The bronchodilator drugs had a variable
effect on resting tidal flow limitation. Figure 4
shows tidal flow-volume loops in the presence
ofNEP superimposed on the preceding loop in
the absence ofNEP in patient 3. In fig 4A sub¬
ject 3 is non-flow limited before nebulised
salbutamol but in fig 4B flow limitation has
occurred after nebulised salbutamol. Despite
this, expiratory flow increased significantly
Table 2 Mean (SE) changes in respiratory parameters after saline on two days and after salbutamol and ipratropium
alone and in combination on each of the two days tested











































FHV, = forced expiratory volume in one second; FVC = forced vital capacity; IC = inspiratory capacity; SVC = slow vital capacity.
Day 1 represents the day onwhich all subjects received salbutamol first, and day 2 is the day on which the first active drug given was
ipratropium.
*p<0.001 compared with baseline.
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0.6 0.8
Figure 3 Changes in (A) forced expiratory volume in one second (FEV) and (B) inspiratory capacity (IC) after the
combination bronchodilator on both days plotted as the absolute change against the change as a percentage ofbaseline value
with each subjectproviding two data points, one for each day of testing (n-40). r = 0.648for FEV, and r = 0.905for IC.
Two lines have been superimposed on these plots, representing a percentage change of 12% and an absolute change of
200 mlfor FEV, and 213 mlforlC. The value of213 ml represents the group mean increase in IC seen after saline
(placebo) in our study. 200 ml and 12% are the values recommended by the ATSfor satisfaction ofFEV, reversibility
criteria. Few subjects are irreversible using these criteria.
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Figure 4 Negative expiratory pressure (NEP) traces ofa typical subject (subject 3). Flow and volume are plotted against
each other on they and x axes respectively, both in the absence and the presence ofNEP. The arrows denote the points at
which NEP is applied and removed. (A) NEP trace after saline showing no flow limitation at any point during expiration.
(B) NEP trace of the same subject after 5 mg nebulised salbutamol showingflow limitation throughout the whole of
expiration. Despite theflow limitation there is a significant increase in the expiratoryflow rate and in tidal volumefrom
0.79 to 0.89 litres.
after salbutamol. In nine individuals flow limi¬
tation was reduced after the single dose of
bronchodilator and in seven after the combina¬
tion of the two drugs. However, the number of
individuals in whom this occurred was signifi¬
cantly different if the post saline data were used
instead. Of the nine who became less flow lim¬
ited after a single agent, seven became more
flow limited after adding a second broncho¬
dilator and two remained the same. None
became less flow limited after the addition of a
second agent. Post-bronchodilator NEP did
not predict those who showed the greatest
changes in FEV, or IC with bronchodilator
drugs, alone or in combination.
The breathing pattern analysed at rest and
the changes produced by the single and combi¬
nation bronchodilator drugs are shown in table
3. Data for both the P agonists and anticholin¬
ergic drugs were combined as they showed no
significant differences when analysed sepa¬
rately. There were no changes in the timing or
frequency of respiration after any of the
bronchodilator drugs, but there was a signifi¬
cant increase in the tidal volume representing a
rise of 12.7% and 15.5% from the baseline
breathing pattern after single and combination
bronchodilator treatment, respectively. Mean
inspiratory flow (Vt/Ti) did not change after
the bronchodilators but mean expiratory flow
(Vt/Te) showed significant improvements after
each drug singly and in combination, but not
after normal saline. When taken with the
changes in EELV, the resultant changes in
EILV were -0.24 (0.15) 1 and -0.41 (0.19) 1
after the single and combination bronchodila¬
tors, respectively. There were no significant
differences in the measurements of inspiratory
or expiratory muscle strength at any point dur¬
ing the testing, but there was a significant fall in
mean (SE) perceived breathlessness from 3.4
(0.4) to 1.8 (0.3) after the combination
treatment but not after treatment with a single
agent (p<0.05). These changes in resting
breathlessness were not correlated with those
in IC, FEV,, SVC, or any other volume based
derivative.
Discussion
Bronchodilator reversibility testing is an im¬
portant way of excluding a significant asth¬
matic component in patients with COPD but is
relatively ineffective at predicting symptomatic
benefit in severe disease.5 6 Our data, together
Table 3 Mean (SE) changes in breathingpattern after placebo (saline), a single bronchodilator drug (either salbutamol
or ipratropium but with datafrom both days combined, n=40)) and both drugs in combination
Change Change after Change after
Baseline after saline single drug combination
Tidal volume (Vt) (1) 0.69 (0.02) 0.02 (0.02) 0.09 (0.02)* 0.11 (0.02)*
Respiratory frequency (/min) 24.4 (0.85) -0.13 (0.39) 0.38 (0.51) 0.98 (0.58)
Inspiratory time (Ti) (s) 1.01 (0.04) -0.01 (0.02) 0.02 (0.02) 0.03 (0.03)
Total respiratory time (Ttot) (s) 2.6 (0.09) 0.02 (0.04) 0.01 (0.05) -0.06 (0.07)
Ti/Ttot 0.39 (0.01) -0.01 (0) 0.01 (0) 0.41 (0.01)
Vt/Ti (1/s) 0.71 (0.03) 0.03 (0.01) 0.09 (0.02) 0.1 (0.03)
Vt/Te (1/s) 0.46 (0.02) 0.01 (0.01) 0.07 (0.01)* 0.10(0.01)*
*p<0.05.
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with those of others,10 25 suggest that significant
changes in IC and hence pulmonary hyperin¬
flation occur after both P agonists and
anticholinergic drugs. These changes were not
accompanied by reproducible improvements in
tidal airflow limitation nor did the presence of
tidal flow limitation predict the changes in
EELV or dyspnoea occurring after the
bronchodilator. Changes in EELV were paral¬
leled by those in SVC and FVC and were asso¬
ciated with improvements in tidal volume,
which were larger when combination broncho¬
dilator drugs were given. Unlike the NEP
results, all volume related variables showed a
continuous response to bronchodilators with
no sign of a clear break between responders
and non-responders. These data show that
current physiological end points for reversibil¬
ity testing are either insufficiently reproducible
to give a reliable baseline value or are unable to
identify "responder" subgroups, at least in
patients with severe disease.
Our data have a number of strengths and
limitations. Unlike previous studies we have
included both a saline placebo comparison
with our bronchodilator data and a randomised
design. We used doses of bronchodilator high
on the known dose-response relationships to
ensure a maximum effect26 27 and standardised
the volume history and timing of all respiratory
manoeuvres to diminish the effect of variation
in the end expiratory pause on the expiratory
flow rate.28 Our findings are confined to
patients with severe disease (<35% predicted
FEV,), partly because previous studies have
shown more variable degrees of tidal flow limi¬
tation in patients with moderate disease8 and
also because we felt such patients will be the
most likely to be "irreversible". We did not
re-test our patients in the supine posture as we
thought this likely to be impractical in clinical
practice. Our measurements of flow and
volume were very reproducible within indi¬
viduals with a similar short term variability to
that reported in severe COPD7 and in patients
with less marked airflow limitation.29
All of our patients had flow limitation when
assessed conventionally using the maximum
flow-volume envelope and without allowing for
the effects of gas compression. We did not select
them on the basis ofpre-existing tidal flow limi¬
tation but because of the severity of FEV,
assessed on normal spirometric tests. Like other
studies,8 9 we found that true tidal flow limita¬
tion was not present in most patients on NEP
testing. However, despite the advantages of this
type of assessment, we were disappointed to see
that both the immediate and between day repro¬
ducibility of this measurement was inconsistent
in patients of this severity studied in the seated
position. This may reflect the fact that patients
with more severe disease exhibit more dynamic
regulation oftheir EELV than is the case in other
subjects, even though there is no difference in
baseline breathing pattern or IC on the different
days. A variable effect of the small system dead
space or the enhanced contribution of the
abdominal muscles during quiet breathing may
explain why, under some circumstances, the
degree of tidal flow limitation varied. This has
practical problems in terms of establishing a
baseline for individual bronchodilator reversibil¬
ity testing. In contrast, the measurements of lung
volumes were more reproducible, those of FEV,
being within the reported range for this
measurement713 while both SVC and FVC as
well as IC measured from FRC were acceptable
and consistent. The reproducibility of these vol¬
ume based tests was equivalent to that of forced
expiratory manoeuvres and broadly similar
within individuals. Only when two inherently
variable numbers (TLC and IC) were used to
derive a third (EELV) did the variability become
unacceptable. This problem has been noted
previously when using derived lung volumes.30
The effects of the high dose nebulised
bronchodilator drugs were very consistent.
Although the drugs were given at different
times and operate by different pharmacological
mechanisms, there were no significant differ¬
ences between the bronchodilator responses
assessed by changes in IC or in any measure of
expired volume after the P agonist or the anti¬
cholinergic agent. Post bronchodilator values
were fivefold greater than the mean change
seen after nebulised saline. As noted previously
with inhaled ipratropium,7 neither the FEV,/
FVC nor FEV,/VC ratios were affected by high
doses of nebulised bronchodilators, which
suggests that the increase in FEV, resulted pri¬
marily from a fall in the operating lung volume.
Addition of the second drug consistently
produced further improvements in IC and lung
emptying. The volumetric response was con¬
sistently greater than that after a single
bronchodilator alone. Using the data derived
from the short term reproducibility measure¬
ments, 29 of 40 measurements would be
considered reversible on FEV, criteria and 27
on the basis of IC. However, these data do not
show a definite threshold of response and,
when examined over the 2 days of the study, all
subjects showed an improvement in one or
more variable after the combined bronchodila¬
tors. In contrast, the changes in tidal flow limi¬
tation given the variable baseline were very
modest and in keeping with those reported by
Tantucci et at" after a single smaller dose of
inhaled salbutamol in patients with less severe
COPD. The presence of complete tidal flow
limitation did not preclude a relatively large
change in EELV after the combination
bronchodilator in these patients, which con¬
firms that factors other than tidal flow
limitation determine EELV in patients with
advanced COPD. These data are the first to
test directly the alternative hypothesis that a
"poor response" to a bronchodilator is con¬
fined to patients without resting flow limita¬
tion10 31 and, again, no clear pattern of response
was seen.
Changes in the breathing pattern were not
seen after nebulised saline but consistent
improvements in tidal volume did occur after
both anticholinergic and P agonist drugs. This
initial increase in tidal volume amounted to
approximately 50% of the change in EELV
after the single bronchodilator, thereby reduc¬
ing the change in EILV. Larger changes in tidal
volume did not occur when the greater fall in
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EELV was seen after the combination drugs
and on this occasion EILV was also reduced. In
keeping with the data ofBelman et al,6 it was at
this point that the patients recorded a signifi¬
cant fall in the perceived level of resting
breathlessness. The mean inspiratory flow (Vt/
Ti), whether expressed as an absolute value or
as a percentage of the vital capacity, was
unchanged after the bronchodilator drug, sug¬
gesting that resting respiratory drive is well
preserved in these individuals with resting tidal
flow limitation or who are close to this state.
However, we found consistent and highly
significant improvements in mean expiratory
flow after the bronchodilators, irrespective of
the degree of tidal flow limitation. These data
suggest that bronchodilators are acting to
reduce the operating lung volume rather than
resting inspiratory drive, in keeping with previ¬
ous suggestions.31 The changes in EELV after
nebulised bronchodilators were of similar mag¬
nitude to those seen during exercise and to
changes in resting EELV in less severe patients
treated with salbutamol alone.6 We believe that
the improvements produced by the combina¬
tion bronchodilators in our severe patients are
likely to be translated into improved exercise
performance.
The present data confirm the continuity of
the bronchodilator response, however assessed,
compared with placebo and this is seen even in
patients who would be expected to have
irreversible "flow limited" disease by conven¬
tional plethysmographic criteria. The separa¬
tion of patients into "responders" and "non-
responders" on the basis of short term
spirometric changes is unlikely to be accurate
whatever criteria or test is chosen. Despite the
attractions of the NEP technique in objectively
determining tidal flow limitation, it did not add
further useful information when included as an
outcome measure for bronchodilator testing,
nor did it help to classify individuals who were
likely to respond differently to treatment. In
contrast, measurement of the IC was a useful
guide as to when important changes in lung
volume, associated with improvements in rest¬
ing breathlessness, were likely to occur. It was
as simple and reproducible as any of the other
measures commonly reported. The improve¬
ments in EILV seen after a combination ofhigh
dose bronchodilators may explain why some
individuals prefer wet nebuliser treatment to
conventional metered dose inhalers32 as signifi¬
cant improvements in IC occurred even when
the change in FEV, would be considered barely
significant. This technique may prove useful in
assessing patients' suitability for home treat¬
ment with nebulised bronchodilators.
This work was supported in part by a EU collaborative
BIOMEDII grant and The Fazakerley Foundation for Respira¬
tory Research.
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Detection ofexpiratory flow limitation in COPD using theforced oscillation technique.
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ABSTRACT: Expiratory flow limitation (EFL) during tidal breathing is a major
determinant of dynamic hyperinflation and exercise limitation in chronic obstructive
pulmonary disease (COPD). Current methods of detecting this are either invasive or
unsuitcd to following changes breath-by-breath. It was hypothesised that tidal flow
limitation would substantially reduce the total respiratory system reactance (Xrs) during
expiration, and that this reduction could be used to reliably detect if EFL was present.
To test this, 5-Hz forced oscillations were applied at the mouth in seven healthy
subjects and 15 COPD patients (mean±sd forced expiratory volume in one second was
36.8L11.5 % predicted) during quiet breathing. COPD breaths were analysed (n=206)
and classified as flow-limited if flow decreased as alveolar pressure increased,
indeterminate if flow decreased at constant alveolar pressure, or nonflow-limited.
Of these, 85 breaths were flow-limited, 80 were not and 41 were indeterminate.
Among other indices, mean inspiratory minus mean expiratory Xrs (AXrs) and minimum
expiratory Xrs (Xexp,min) identified flow-limited breaths with 100% specificity and sensitivity
using a threshold between 2.53-3.12 cmfLO-s-L"1 (AAVs) and -7.38- -6.76 cmlLO s-L"1
(Xexp,min) representing 6.0% and 3.9% of the total range of values respectively. No
flow-limited breaths were seen in the normal subjects by either method.
Within-breath respiratory system reactance provides an accurate, reliable and
noninvasive technique to detect expiratory flow limitation in patients with chronic
obstructive pulmonary disease.
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Unlike healthy subjects who do not develop expiratory flow
limitation (EFL) even during exhaustive exercise [1], many
chronic obstructive pulmonary disease (COPD) patients are
flow-limited (FL) at rest [2], These patients can only increase
their expiratory flow rate during exercise by allowing their
end-expiratory lung volume (EL) to rise, an energetically
inefficient strategy that is accompanied by severe dyspnoea
that reduces exercise duration [3, 4]. The severity of dyspnoea
in COPD is better predicted by the presence of EFL during
tidal breathing than by the forced expiratory volume in one
second (FEVl) [5, 6]. Thus, a simple method of detecting EFL
during tidal breathing would be a potentially useful clinical
tool. Several noninvasive methods have been proposed to
detect tidal EFL in COPD patients, but each has its limita¬
tions and, to the best of the authors' knowledge, to date none
has been tested against any form of "gold standard" in
spontaneously breathing patients.
In 1993, Peslin et al. [7] reported that some COPD patients
during mechanical ventilation developed large negative swings
in the respiratory system input reactance (Xrs, i.e. the imaginary
part of total input impedance) measured by a forced oscilla¬
tion technique (FOT). Similar behaviour was observed in a
simplified mechanical model of the respiratory system when a
flow-limiting segment was included [8] and in mechanically
For editorial comments see page 187.
ventilated rabbits [9] after intravenous methacholine infusion.
This phenomenon occurs because the linear velocity of gas
passing through flow-limiting segments (choke points) equals
the local speed of wave propagation [10]. Normally the react¬
ance reflects the elastic and inertial properties of the respira¬
tory system but when flow limitation is present, the oscillatory
signal cannot pass through the choke points and reach the
alveoli, producing a marked reduction in the apparent
compliance (and, consequently, a fall in Xrs). These theoretical
and experimental considerations make within-breath reactance
measurement a potentially useful indicator of the occurrence
of tidal EFL in COPD.
The authors hypothesised that the decrease of within-
breath Xrs during expiration would allow the definition of a
sensitive and specific method of determining the presence of
EFL. To confirm this, breaths with and without a decrease in
expiratory flow were studied while alveolar pressure (PA)
increased, an independent way of identifying the presence of
EFL in spontaneously breathing subjects.
Methods
Subjects
Fifteen stable COPD patients and seven age-matched
healthy subjects were studied whose characteristics and lung
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function are shown in table 1. The patients met the standard
diagnostic criteria for COPD [11] and were current or
exsmokers. They omitted their short- or long-acting broncho-
dilators for J: 3 and > 12 h, respectively, before the study.
Spirometry and subdivisions of VL were measured in a
constant-volume body plethysmograph (Medgraphic Auto-
link 1085D, Medical Graphics, St Paul, MN, USA). Predicted
values for flows and volumes were those recomended by the
European Respiratory Society [12]. FOT was applied to the
mouth of each subject while seated, wearing a noseclip and
mouthpiece, during 2-3 min of spontaneous breathing. An
operator firmly supported the cheeks to reduce upper airways
shunt. The study was approved by the institutional research
ethics committee, and written informed consent was given by
each subject.
Measurements
Pressure (Rao) and flow (F'ao) at the airway opening were
measured by a transducer (SCX01, SenSym, Milpitas, CA,
USA) connected to the mouthpiece and by a screen-type
pneumotachograph (4700A; Hans Rudolph, Kansas City,
MO connected to a transducer LCVR, 0-2 cmH20; Celesco
Instruments, Canoga Park, CA). Oesophageal pressure (Roes)
was measured by a pressure transducer (SCX05, Sensym)
connected to a standard balloon-catheter system placed in the
lower oesophagus and filled with 0.4 mL of air. The position
of the balloon was confirmed using the occlusion method [13].
All the signals were sampled at 200 Hz by an analogue-to-
digital and digital-to-analogue board (DAQ-CARD 1200;
National Instruments, Austin, TX) and recorded by a
personal computer. The flow signal was integrated to give
VL. The frequency response of the measuring systems [14] was
flat up to 30 Hz.
Forced oscillations
The experimental set-up for FOT measurement is shown in
figure 1. Healthy subjects and patients were studied while
being oscillated by 5 Hz sinusoidal forcing with a pressure
amplitude at the mouth of ~2 cmH20. The forcing frequency
was chosen based on the preliminary model simulations
presented in the Appendix. The same computer and board
used to sample flow and pressure signals generated the forcing
signal, which was amplified by a power amplifier (Proline
EQ552; Eurosound, Milan, Italy) connected to a 25-cm
diameter loudspeaker (HS250; Ciare, Ancona, Italy) mounted
on a rigid box of ~2 L of internal volume. The pressure
generated by the loudspeaker was transferred from the box
through a connecting tube (22 cm in length, 19 mm in inter¬
nal diameter) to the subject's mouthpiece. A low-resistance,
high-inertance tube (35 mm in internal diameter and 1.5 m in
length) in parallel with the loudspeaker allowed the subjects
to breathe room air without significant loss of forcing
pressure. A bias flow of ~15 L-min"1 reduced the equipment
deadspace to the volume of the pneumotachograph and the
mouthpiece [15].
Detection of expiratory flow limitation by the Mead and
Whittenberger method
The method of Mead and Whittenberger [16] (M-W) of
measuring pulmonary resistance was used to detect EFL
during tidal breathing simultaneously with the application of
forced oscillation. Briefly, the flow-resistive pressure (Rfr;
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equal to Pao-PA) along the tracheobronchial tree was
estimated by subtracting the elastic recoil pressure of the
lung from transpulmonary pressure. During quiet breathing,
elastic recoil pressure is directly proportional to volume. Thus
a signal proportional to volume was subtracted from trans-
pulmonary pressure. The constant of proportionality was
adjusted so that the pressure at zero flow points at the
beginning and end of inspiration were identical. Using zero-
flow points to estimate Pfr the inertial pressure, even if very
small during normal breathing, is neglected. Also lung tissue
resistance, which may introduce a pressure drop between the
pleura and the alveoli, and possible within-breath changes in
upper airway resistance are neglected by the M-W method.
When the Lissajous figure in the Pfr versus flow graphs
(fig. 2a-c) showed a loop where flow decreased during
expiration while Pfr increased the breath was classified as
"flow-limited" (FL; fig. 2c). Conversely, if the expiratory
phase was characterised by a quasi-linear dependence between
Pfr and flow with little or no loop the breath was classified as
"nonflow-limited" (NFL; fig. 2b). In cases where it was not
possible to be certain if flow limitation was present the
breaths were classified as "indeterminate". This occurred in
two different circumstances: when the inspiratory pressure/
flow curve was looped instead of closed (possible errors in
elastic recoil pressure estimation or an expiratory loop
produced by the changes of FL and not by EFL) or when
the expiratory pressure flow curve was characterised by a
clockwise loop in which flow decreased but Pfr did not
simultaneously increase significantly.
Data analysis
Within-breath input impedance (Zin; and thus Xrs) was
determined by using a least squares algorithm [17, 18] taking
advantage of the a priori knowledge of the frequency
spectrum components of the forcing signals. This method
measures the input impedance for every acquired sample
using a moving time window of pressure and flow signals of
0.2 s.
From the quiet breathing tracings, the longest period in
which the breathing pattern was stable and without oesopha¬
geal spasms was selected. Four different indices based on the
anticipated reactance change were used_to detect EFL: 1) the
mean value of Xrs during expiration (Xexp); 2) the minimal
value of Xrs during expiration (Xexp.min); 3) the difference
between the mean value of Xrs during inspiration (Xinsp)
and Xexp (AXrs); and 4) the difference between the maximal
value of Xrs during inspiration (Xinsp,max) and Xexp.min
(Xpeak-to-peak; fig. 3).
Different thresholds were applied to the values of each
index (Aexp, Xexp.min, AArs and Xpeak-to-peak) computed
breath-by-breath. All breaths classified unequivocally by the
M-W analysis as either FL or NFL were used to determine
the sensitivity (the number of detected FL breaths divided by
the total number ofFL breaths) and specificity (the number of
detected NFL breaths divided by the total number of NFL
breaths) of each index. Sensitivity and specificity were cal¬
culated for the range of possible threshold values for each
index in the following way: the total range of values assumed
by an index was subdivided into 100 equally spaced points
to provide a set of possible threshold values with good
resolution. Then sensitivity and specificity were computed for
each of the 100 values. These data were plotted as a function
of the threshold value on the same graph. Areas where
sensitivity and specificity curves were both 100% defined the
optimal range of threshold values. Optimal threshold was
chosen as the midpoint of this range.
Significance of differences of physical characteristics, spiro-
metric data and Xrs indices' values between different groups
was performed by a nonparametric (Mann-Whitney) test.
Data are expressed as mean+SD unless otherwise stated.
Results
Representative Xrs data are presented in the lower panels of
figure 2 where three experimental tracings of Ph and Xrs
obtained during a quiet breath are shown for a control, an
NFL COPD patient and an FL COPD patient. The Pfr versus
flow curve for the same breath is shown in the upper panel.
Clear differences can be observed between the inspiratory and
expiratory reactance in the patient where flow limitation was
present (c and f) but not in the other examples.
In figure 3 the experimental tracings of volume, flow,
pressure, total respiratory input resistance (Rrs) and Xrs are
shown for a representative FL COPD patient. Note that the
Rrs time course, unlike that for Xrs, did not present clear
differences between inspiration and expiration. The within-
breath fluctuations of Rrs were usually wider if EFL was
present than in the absence of flow limitation, a finding
common to most of the breaths studied. These results are in
agreement with the model data presented in the Appendix. Of
the 284 breaths (206 from patients and 78 from controls)
selected, 12 breaths (4%) were discarded because of oesopha¬
geal spasms, spikes in the impedance due to glottis closure or
swallowing, or because they showed an abnormal looping of
the pressure/flow curve. The authors used 85 breaths classified
unequivocally by M-W analysis as FL and 80 as NFL to
determine sensitivity and specificity of the indices. Sensitivity
and specificity plots are presented as function of the threshold
value for each index (fig. 4). All indices had a region where
both specificity and sensitivity were 100% but these regions
Personal
computer
Fig. 1.-Experimental set-up for within-breath impedance measure¬
ment. Fao: flow at airway opening; Rao: pressure at airway opening;
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Fig. 2.-The Mead and Whittenberger graphs (a-c) obtained by plotting the airway opening flow versus the resistive pressure drop (Ffr) during a
single breath. Data from a healthy subject (a and d), a nonflow-limited patient (b and e) and a flow-limited chronic obstructive pulmonary
disease patient (c and f) are shown. The regression lines in a) (m=0.398, R=l/m=2.51 cmHjO-s-L"1) and b) (m=0.102, R=l/m=9.8 cmH2O s-L )
represent airway resistance at breatliing frequency, m being the slope of the regression (airway conductance). In c), expiratory flow limitation ()
is demonstrated by the presence of a region in which airway opening flow is decreasing while Plr is increasing. The lower graphs (d-f) show the
corresponding time courses of Pfr (—■) and respiratory system reactance ( ). The arrows indicate the end of inspiration i.e. time before this
point is inspiration and after is expiration.
had different widths. Total range, optimal range (range of
threshold values in which both specificity and sensitivity were
100%), its percentage of the total range (optimal region) and
the midpoint of the optimal range (optimal threshold) are
shown in table 2 for each index.
The patients were then divided into three groups depending
on the classification of their breaths analysed by the M-W. In
11 patients, all of the breaths were within the same classi¬
fication, but in four patients different breaths were classified
in different categories. However, in these patients there was
always a clear majority of breaths (75% minimum) in the
same category. Thus, six patients were classified as FL during
tidal ventilation, seven patients as NFL and two patients as
indeterminate.
In general, patients with more severe COPD were more
likely to be FL, as would be expected. However, even if the
FL patients presented in average a lower value of FEVl than
NFL (see table 1), the lowest FEVl showed by NFL patients
(25% predicted) was much smaller than the highest presented
by FL patients (41% pred).
Mean values of all the indices for each patient and control
subject are presented in figure 5 as well as the average values
for each group. As expected there was a clear distinction
between the FL and NFL groups with the two indeterminate
patients presenting values similar to the FL patients. Healthy
subjects presented values closer (even if statistically different)
to NFL COPD patients.
The application of the threshold values determined in
COPD patients to the indices computed for the healthy
subjects indicates that in healthy subjects EFL was never
present during quiet breathing, with values for all the indices
clearly separated from the optimal threshold (horizontal
dashed line in figure 5) selected from table 2.
Discussion
The ability to detect EFL reliably and noninvasively during
tidal breathing is of both theoretical and practical value in
patients with COPD. Current techniques all have significant
disadvantages, although more recently developed methods
based on detecting changes in expiratory flow when the
driving pressure is increased are more convenient and simpler
to apply than previous approaches [19, 20], However, even
these methods are limited in the number of breaths that can
be tested and/or by the need to perform a specific respiratory
manoeuvre. Moreover, none has been compared with an
independent method to detect EFL during awake sponta¬
neous breathing subjects
By definition, flow limitation occurs when maximum
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Times
Fig. 3.-Experimental tracing from a representative flow-limited
patient and definition of the indices used to characterise the
respiratory system reactance (Xrs) time course during a single breath,
a) Respiratory volume, b) flow at the airway opening, c) oesophageal
pressure, jl) total respiratory input resistance (Rrs) and d) Xrs
at 5 Hz. Xinsp: mean value of Xrs during inspiration; Xexp: mean
value of Xrs during expiration; Xexp.min: minimum value of Xrs during
expiration; Xinsp.max: maximum value of Xrs during inspiration. Since
reactance was expected to_decrease during expiratory flow limitation,
the difference between Xinsp and Xexp (Airs) and the differ¬
ence between Xinsp,max and Xexp.min (Xpeak-to-peak) was considered.
Indices were defined in two different breaths for clarity. I: inspiration;
E: expiration; Pocs: oesophageal pressure.
expiratory flow is reached on the plateau of the isovolume
pressure/flow curves [21]. Unfortunately this approach is not
suitable for a simultaneous comparison with the measurement
of Xrs. Therefore, flow limitation was defined as a decrease in
-6 -4
Xexp cmHjO-s-L"1
-12 -10 -8 -6
Xexp.min cnnHpO'S-L'1
4 6 8 10 12 14
Xpeak-to-peak cmH20-sl"1
Fig. 4. -Sensitivity ( ) and specificity (—) expressed as percentage
of all the classifiable breaths (80 nonfiow-limited and 85 flow-limited)
are plotted versus the threshold vajues for the four considered indices,
a) Mean expiratory Xrs value (Xexp), b) minimum expiratory Xrs
value (Xcxp.min), c) the difference between mean inspiratory and mean
expiratory Xrs (AXrs) and d) the difference between maximum
inspiratory and minimum expiratory Xrs (Xpeak-to-peak) were consid¬
ered. The shaded bars represent the optimal region in which
sensitivity and specificity are both 100%.
U'ao with an increase in Pfr. This is essentially the same
definition used in the negative expiratory pressure (NEP)
technique; when a negative pressure is applied to the airway
0 2
_ 4 6 8
AXrs cmH20-s-L'1
Table 2.-Total range, optimal range, region width and threshold for respiratory system reactance (Xrs) indices in patients
Index Total range Optimal range Optimal Optimal threshold
cmFUOs-L"1 cmH20-s-L region % cmH20-s-L"'
Xexp -10.5- -0.3 -5.48 -5.38 1.0 -5.4
Xexp,min -16.4- -0.6 -7.38 - -6.76 3.9 -7.1
AXrs -0.8-9.0 2.53-3.12 6.0 2.8
Xpeak-to-peak 0.1-16.7 5.99-6.02 0.2 6.0
Xexp: mean value of Xrs during expiration; Xexp.min: minimum value of Xrs during expiration; AXrs: the difference between Xinsp and Xexp;
Xpeak-to-peak: the difference between Xinsp.max and Xexp.min. Total range of values assumed by indices, optimal range (range of threshold values in
which both specificity and sensitivity were 100%), its percentage of the total range (optimal region) and the midpoint of the optimal range (optimal
threshold) are reported. Indices are as described in the text.
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Fig. 5.-Mean±SD values of the considered indices computed on all
the breaths from a given subject are shown. Control subjects (O),
nonflow-limited (NFL; •), flow-limited (FL; □) and indeterminate
(Ind.) chronic obstructive pulmonary disease patients (■) and
mean+SD of each group (O). a) Mean expiratory respiratory system
reactance (Xrs) value, b) minimum expiratory Xrs value, c) the
difference between mean inspiratory and mean expiratory Xrs (AYrs)
and d) the difference between maximum inspiratory and minimum
expiratory Xrs (Xpeak-to-peak) were considered. In all the graphs, the
optimal threshold value (table 2) is plotted as a horizontal dashed
line.
opening, thereby increasing Pfr, flow limitation is assumed to
be present if expiratory flow does not increase. However, NEP
was not used as a gold standard, as its assumptions have
never been validated by comparison with other physiological
measurements of EFL in spontaneously breathing unsedated
patients. Instead the M-W technique was used; when Pfr
increases and flow decreases, there is a clockwise loop in the
expiratory Pfr/F'ao curve that is not seen during inspiration
(fig. 6a). This method of detecting EFL in each breath has a
number of advantages. It is independent of upper airway
compliance that can potentially influence the results of NEP
measurements. Like NEP it is not influenced by the previous
VL history as it does not require specific respiratory
maneuvers to be performed. However, it is recognised that
it is possible for such a loop to be present when dynamic
compression of airways is combined with volume dependence
of resistance in the absence of choke points, completely
limiting expiratory flow as illustrated in the schematic shown
in figure 6b. In this situation, Xrs would not decrease when,
according to the M-W criterion (and NEP), there was EFL.
Alternatively, choke points could develop in some parallel
fir cmH20
Fig. 6.-Schematic of a) flow-resistive pressure drop (fir) versus flow
diagram in presence of flow-limitation and b) in case of dynamic
compression of airways combined with volume dependence of
resistance in the absence of choke points. In a) the arrow indicates
the onset of expiratory flow limitation. In b) there are three schematic
isovolume pressure/flow curves (thin lines) at 25% (#), 50% (^) and
75% (+) vital capacity (VC). On the same plot a schematic pressure/
flow loop during a tidal breath is also shown (thick line). This last
plot takes into account the increase in resistance as lung volume
decreases. Thus, if the expiration starts for instance at 50% of VC,
the quiet-breathing (QB) loop at the beginning will be very close to
the isovolume pressure/flow curve at 50% VC. Then the lung volume
will decrease, leading to the separation of the QB loop from the 50%
VC isovolume curve and then approaches, for instance, the 25%
isovolume curve at the end of expiration. The schematic was drawn
by hand and the values of 50 and 25% of VC for end inspiration and
end expiration are arbitrary and considered only for clarity.
pathways before expiratory flow was completely limited. If
this were to occur, the authors predict that the forced
oscillations would penetrate to those alveoli where flow was
not yet limited, but would not pass through the choke points
that were established in parallel. This would cause a fall in
Xrs, but not to the extent as would occur when choke points
limited all expiratory flow, while NEP should indicate lack of
flow limitation.
Ideally, the authors would have preferred a gold standard
methodology that only detected complete EFL produced by
choke points. In practice, the comparator used encompassed
the possibility of no flow limitation with volume dependence
of resistance combined with early dynamic compression of
airways insufficient to limit flow and also of partial EFL by
choke points in some parallel pathways but not in others.
Measurement of Xrs is likely to be insensitive to the volume-
dependent effects, sensitive to complete EFL and intermediate
with partial EFL. A false-positive M-W analysis due to early
dynamic compression and volume dependence of resistance



















a) 6 1 this study, the authors have developed indices from Xrs
measurements that detect EFL robustly. From these indices
they were able to identify threshold values, obtained in a
limited number of patients, between which sensitivity and
specificity were 100%. In a larger patient population it is
possible that these thresholds may change somewhat. This
clear separation of values also precluded the use of receiver
operator characteristic analysis.
Although all the indices detected EFL, each had advan¬
tages and disadvantages. AArs presented the clearest separa¬
tion between FL and NFL breaths in the sensitivity-specificity
| \ \ ——. plots (fig. 4). Moreover, this index is less dependent on
■ - ~ baseline airway mechanics being based on a relative change
rather than an absolute value. Indices based on mean values
^tr i are more robust because they are less affected by signal noise,
but must be computed using the whole breath. The index
based on the minimum expiratory Xrs is well suited to study
changes in flow limitation during the breath; the point when
— the actual Xrs value falls below the threshold indicates the
onset of flow limitation that persists until Xrs returns to
values higher than threshold. This index could be used to
detect the VL at which EFL occurred (and thus to auto¬
matically compute, for instance, the percentage of a tidal
breath that is FL) and the relative value of the limiting flow.
In all the analyses the Xrs data was expressed as the
absolute values and the relative changes of reactance rather
than expressing data as a percentage of baseline (i.e. inspira¬
tory Xrs) [9], since the inspiratory Xrs values can range from
slightly positive to negative depending on the mechanical
properties of the respiratory system of the subject. However,
~50 100 150 200 250 the use of physical units should not prevent the application of
RpacmH O-s-L'1 the Xrs thresholds to new patients and data sets. In fact,2 whatever the condition of the patient, the difference between
Fig. 7.-Simulated a) real and b) imaginary part of the input the impedance of the shunt pathway due to airway wall
impedance at 5 (—), 10 ( ), 15 (- - -) and 20 ( ) Hz of a compliance (measured by expiratory Xrs if EFL is present)
lumped parameter model of the respiratory system that includes and the open lung (measured by Xrs during inspiration) is so
airway wall shunting. Real and imaginary parts are plotted versus high (approximately one order of magnitude) that even
peripheral airway resistance (Rpa) that is increased to simulate the differences on airway wall mechanical properties due to
occurrence of expiratory flow limitation. See Appendix 1 for details. intersubject variability or to the disease should only margin¬
ally affect the changes in Xrs during expiration. Moreover, as
would appear as a lack of sensitivity of Xrs indices to detect shown in the Appendix and in figure 7, Xrs is very sensitive to
EFL. As this was never seen over the optimal range of the increase of peripheral airways resistance only at the
threshold values (table 2 and fig. 4), false-positive results with beginning and rapidly reaches a plateau. These observations
this method are probably rare. suggest that the thresholds should only marginally be affected
If partial flow limitation had caused a false-positive M-W by changes in lung and airways mechanics. This is also
analysis that was also detected by Xrs analysis, the sensitivity supported by the 100% sensitivity and specificity obtained
curves in figure 4 would have reached 100% earlier, leading to studying a very heterogeneous patient population (table 1).
a large optimal range. The fact that these ranges were small Finally, even if the oscillatory pressure applied to the subject
for Aexp and Xpeak-to-peak argues against this being a during FOT was very small (<2 cmH20) and with a zero
significant problem. If Xrs analysis were insensitive to partial mean value (as it was a sinusoidal forcing), it is possible that
EFL it would again reduce the test sensitivity, which was not the dead space and the resistance added by the device may
the case. have induced changes in patients' VL and breathing pattern.
The transition from NFL expiration to complete EFL has As a result, the condition of the patients during the measure-
not been carefully studied. Sophisticated modelling combined ments may have been different from baseline spontaneous
with careful physiological measurements during this tran- breathing. However, the amount of dead space and resistance
sition are needed to clarify this issue. The forced oscillation of the device was similar to any measurement system that uses
method can help by giving a quantitative estimate of the pneumotachographs (as NEP or spirometers). Therefore, the
degree of EFL. Xrs should fall as each new choke point effect of FOT on breathing pattern is likely comparable with
develops by an amount dependent on the elastic properties of any other EFL monitoring system.
that part of the tracheobronchial tree subtended by the airway Since changes in Xrs can be due to either EFL or airway
in which the choke point occurs. However, the degree of closure, it is possible that the swing in Xrs may be due in part
Xrs reduction during EFL also depends on the mechanical to the latter phenomenon, affecting the reliability of the
properties of airway walls (which may be hypercompliant in technique to selectively detect EFL. However, as shown in
COPD [22]) and on the location of the choke points. figure 3, the time course of Xrs is not in phase with volume.
Nevertheless, in this study, the intrasubject variability of Typically, Xrs should increase from mid- to late expiration,
airway wall properties or location of choke points did not and at end-expiration is close to its value at end-inspiration,
prevent the definition of a single threshold value (independent This is the expected pattern if Xrs is detecting flow limitation,
from subject characteristics) that reliably indicates the which does not persist to the end of expiration but stops
presence or absence of EFL. before expiratory flow does when pleural pressure falls and
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the airways are no longer dynamically compressed. If airway
closure were occurring, it should increase throughout expira¬
tion and Xrs would continue to fall until end-expiration and
remain low throughout early inspiration before all closed
airway reopened. This behaviour was not observed, since
Xrs starts to return to pre-expiratory values before end-
expiration. This happens as Toes begins to fall (see fig. 3).
The fall in Poes due to pre-inspiratory inspiratory muscle
recruitment necessary to overcome intrinsic positive end-
expiratory pressure can decrease dynamic compression so that
flow limitation is no longer present. It cannot, however, open
airways closed below closing volume as long as VL is still
decreasing. Reopening of closed airways below closing
volume only occurs after inspiratory flow starts and KL
reaches opening volume. Thus, the increase in Xrs toward the
end of expiration must be due to either partial or complete
reopening of choke points.
However, a perfect quantification of flow limitation and
airway closure contributions to Xrs is very difficult in these
circumstances. Nevertheless it is important to underline that it
is impossible to differentiate the impact of airway closure and
EFL during an expiration using any noninvasive monitoring
approaches (including NEP).
These data are in keeping with the theoretical basis for
using the negative swing in Xrs to detect EFL. The Xrs value
at a given frequency results from two opposite contributions:
one negative, related to compliance and one positive related
to inertance. Thus, the observed within-breath changes in Xrs
can be due to either a reduction in the apparent compliance
and/or a decrease of inertance. Lung and chest wall com¬
pliances are functions of volume and not flow, and in the
absence of airway closure in expiration and reopening in
inspiration or the development of choke points during
expiration they should change very little during the respira¬
tory cycle. Inhomogeneities of the time constant can lead to
lower values of Xrs in COPD compared with healthy controls
(as in fig. 2), but, unless airway closure is occurring, inhomo¬
geneities can only contribute for a small fraction of the
changes of Xrs observed in the presence of EFL [23], even if
they decrease substantially during inspiration, as a result of
the dilatation of the peripheral airways. Respiratory system
inertance is mainly due to gas acceleration in the airways [24]
and the mass of the abdomen. At 5 Hz its contribution to
total Xrs is in the order of 0.4 cmH20-s-L"' [25]. The mean
within-breath peak-to-peak difference of Xrs observed in the
FL patients was 10.31 cmH20-s-L"1 (fig. 5d), therefore even
the maximum possible decrease of inertance to zero can
account for only a negligible part (~5%) of the observed
reduction. Thus changes of inertance are unlikely to play a
significant role in the changes in Xrs that were measured.
In summary, these data indicate that the measurement of
expiratory reactance during tidal breathing can reliably detect
breaths that are flow-limited and potentially the time at which
flow limitation begins. A further useful feature of this method
is its ability to identify periods in which total respiratory input
resistance no longer reflects the mechanical properties of the
respiratory system due to the presence of expiratory flow
limitation. This technique is simple to use, sensitive, specific
and noninvasive. The ability to analyse multiple breaths in
different circumstances makes this a useful method in
conditions where flow limitation has been hard to measure,
such as during exercise and in the intensive care unit.
Moreover, this noninvasive technique is particularly suited
to evaluating clinical interventions such as bronchodilator
treatment where it will allow the monitoring ofmore relevant
variables than the forced expiratory volume in one second,
and potentially identify those patients who benefit most from
therapy.
Appendix
To evaluate the impact of the different forcing frequencies
on the Xrs swings observed when passing from FL to NFL
conditions the authors modelled the respiratory system as
a simple lumped parameter model derived from the two-
compartment model proposed by Mead [26]. The model
considers the airways to be compliant structures that
may shunt some of the forced oscillatory flow. The present
model consisted of an airways compartment in series with
parallel alveolar gas compliance and lung-chest wall tissue
compartments.
Airways were modelled as an upper airway resistance
(0.5 cm^Os-L"1), an airway inertance (0.002 cm^O-s^L"1),
an airway wall compliance (0.002 L-cmH20_1) shunt pathway
and a peripheral airway resistance (Rpa) connected as a T
network. The airways compartment (on the Rpa side) leads
to a gas compression compliance (equivalent of 3L of air)
in parallel with the tissues, modelled as a resistance (Rt;
0.5 cmlHO-s'L"1) in series with a compliance (CL.dyn;
0.05 L-cmlLCF1) [25]. Using this simple model, the authors
simulated the effect of the onset of EFL as the increase of Rpa
from a baseline value of 0.5 up to 250 cmH20-s-L_1 [27].
In figure 7, the real and the imaginary part of the Zin
presented by the model are expressed as a function of Rpa. As
soon as Rpa increases the shunt pathway due to the airway
walls compliance affects the total input impedance by
reducing Xrs. Even when this reduction is present at all the
frequencies, the greatest difference is seen at the lowest fre¬
quency. Therefore, to obtain larger Xrs swings from inspira¬
tion to expiration when expiration is flow-limited (and thus
increasing the sensitivity of the indices), the lowest possible
frequency was chosen. Since the quiet breathing signal can
interfere with the estimation ofZin at frequencies below 5 Hz,
5 Hz was used as forcing frequency in this study. This forcing
frequency allows for a time resolution of 0.2 s (i.e. one period
of the forcing signal).
Figure 7 also shows that the real part of Zin is not
monotonic, with an increase at the beginning followed by a
decrease. This suggests that Rrs is not suitable for the
detection of EFL as the same value of Rrs can be measured in
presence of both a mild or a massive increase in Rpa.
This model is an extremely simplified representation of the
respiratory system that considers only one pathway (instead
of several heterogeneous airways) with constant values for the
several parameters instead of considering possible within-
breath variations. The authors accept that the transition
phase between non-EFL to EFL during an expiration is a
complex and heterogeneous phenomenon, both in time and in
the location and the number of pathways involved; therefore
its use is rather speculative. Nevertheless, it was found that
the Xrs values measured at different frequencies (5, 11 and
19 Hz) during EFL in a subset of the COPD patients
frequency are well represented by this model, when Rpa
assumes very high values.
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R.L. Dellaca*, P.P. Pompilio*, P.P. Walker*, N. Duffy*,
A. Pedotii* and P.M.A. Calverley*
ABSTRACT: Bronchodilator drugs produce variable improvements in forced expiratory volume in
1 s (FEVi), but larger changes in end-expiratory lung volume (EELV) in chronic obstructive
pulmonary disease (COPD), which were suggested to be related to the presence of expiratory
flow limitation (EFL) at rest.
We tested this concept in 42 COPD patients (FEVi 42.3 + 13.8% predicted) during spontaneous
breathing before and after 5 mg nebulised salbutamoi. EFL was detected by within-breath
changes in respiratory system reactance measured by a multifrequency forced oscillation
method, while changes in EELV were assessed by inspiratory capacity (IC). Bronchodilation (BD)
increased IC (from 1.8 + 0.5 to 2.1 +0.6 L, p<0.001) and reduced inspiration resistance (Rinsp) at
5 Hz (from 5.1+1.6 to 4.2 + 1.5 cmH20 s L"1, p<0.001). Rinsp identified BD responders with a
discriminative power of 80.1%.
In total, 20 patients were flow-limited before BD. They showed worse spirometry and higher
residual volume, but significant improvements in IC were seen in all patients irrespective of flow
limitation. Changes in Rinsp were confined to flow-limited patients, as were reactance changes. BD
reduced the degree of heterogeneity in the respiratory system, a change best seen with
inspiratory values.
BD has complex effects on lung mechanics in COPD, and EFL affects both this and the
response of some respiratory variables to treatment. However, changes in EELV are consistently
seen, irrespective of the presence of flow limitation at rest.
KEYWORDS: Chronic obstructive pulmonary disease, forced oscillation technique, respiratory
system reactance, within-breath impedance
hronic obstructive pulmonary disease
(COPD) is defined by the presence of
incompletely reversible expiratory air¬
flow limitation (EFL) [1], which occurs at much
lower flows for any given lung volume when
compared with healthy subjects. Initially, flow
limitation is only present during maximal or near
maximal respiratory efforts, but as lung disease
progresses, EFL develops at rest in many, but not
all, individuals [2]. The presence of resting EFL
may identify COPD patients who behave differ¬
ently and who develop dynamic hyperinflation
[3], at least during exercise [4],
Bronchodilator drugs improve lung emptying,
and this leads to variable increases in forced
expiratory volume in 1 s (FEVi), mainly by
reducing lung volume rather than changing the
FEVi/forced vital capacity (FVC) ratio [5].
However, the reproducibility and predictive
value of testing for FEVi reversibility is relatively
poor [6, 7], while the change in resting inspira¬
tory capacity has been shown to be a better
predictor of improvement in exercise perfor¬
mance [8, 9]. Again, patients with EFL have been
reported to show improvements in inspiratory
capacity after bronchodilators [10], which
may relate to an improvement in exercise
performance [11].
Previous workers have used the negative expira¬
tory pressure method to detect EFL [12], but that
study samples a relatively small number ofbreaths
and not all tests are suitable for analysis [2]. We
This article has supplementary material accessible from www.erj.ersjournals.com
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have developed an effort-independent method to determine
flow limitation during tidal breathing using the forced oscilla¬
tory technique to identify within-breath differences in respira¬
tory system reactance [13, 14]. This method allows the
assessment of more breaths, is equivalent to the negative
expiratory pressure approach when both can be recorded [2],
and adds a potential "quantitative" assessment of how close the
patent is to the threshold of EFL [14]. Modelling simulations
based on these data suggest that EFL will influence other
measurements of oscillatory mechanics during expiration, and
this will reduce the sensitivity of expiratory impedance data to
change after interventions, such as bronchodilators. Although
this effect can be identified when within-breath analysis is
performed [13],most published reports of oscillatory mechanics
in COPD only report total respiratory cycle data [15-17].
In the current study, we tested the hypothesis that the changes
in lung volume (specifically inspiratory capacity) and oscilla¬
tory lung mechanics of COPD patients given an inhaled
bronchodilator drug would differ when EFL was present, and
whether this would be unrelated to the presence of reversi¬
bility defined spirometrically. Additionally, we extended our
observations of within-breath impedance using a forced
oscillation method from single to multiple forcing frequencies.
This approach allowed us to testwhether bronchodilator drugs
improve resistance and the intrapulmonary homogeneity of
lung mechanics, avoiding the confounding effects of EFL on
impedance data that would be corrupted when adopting the
conventional multifrequency approach. Finally, we examined
the changes in resting lung and respiratory system mechanics




We recruited clinically stable outpatients who met the
diagnostic criteria for COPD [18] and were either current or
ex-smokers. All patients were using short- and long-acting
inhaled bronchodilators, which were omitted before study for
3-24 h, as appropriate. The study was approved by the
institutional research ethical review committee (South Sefton
Research Ethics Committee, Liverpool, UK), and written
informed consent was given by each subject.
Measurements
Forced expiratory flow, lung volume and subdivisions were
measured by a constant-volume body plethysmograph
(Medgraphic Autolink 1085D; Medical Graphics, St Paul, MN,
USA). All measurements met current standards for acceptable
data quality [19]. We report FEVi, FVC, FEVi/FVC, inspiratory
capacity (IC), residual volume (RV), thoracic gas volume (TGV)
and total lung capacity (TLC) both as absolute values and %
predicted (% pred). Predicted values were those recommended
by the European Respiratory Society (ERS) [20].
We measured breathing pattern and oscillatory mechanics
using previously described methods [13]. Briefly, we recorded
pressure and flow at the airway opening by a transducer
connected to the mouthpiece (PXLA0025DN; Sensym,Milpitas,
CA, USA) and by a screen-type pneumotachograph (3700A,
Hans Rudolph, Kansas City, MO, USA) connected to another
pressure transducer (PXLA02X5DN, 0-2.5 cm; Sensym). All
the signals were sampled at 200 Hz and recorded onto a PC.
The flow signal was integrated to give lung volume, and
volume drift was removed by selecting 2-3 min of stable quiet
breathing and estimating the linear trend on the integrated
signal. This trend was then removed from the traces.
From these signals we measured tidal volume (VT), respiratory
frequency, total cycle duration, inspiratory time, expiratory
time and inspiratory duty cycle (fig. 1). We derived minute
ventilation (V'e), mean inspiratory flow rate and mean
expiratory flow rate from these data.
Forced oscillations
Patients were studied while being oscillated by the following
two different waveforms: 1) a 5 Hz sinusoidal signal, and 2) a
pseudo-random noise (PRN) with three components at 5, 11
and 19 Hz chosen to be non-sum non-difference of order 3 [21].
For both the waveforms, the peak-to-peak pressure amplitude
measured at the mouth was ~l-2 cmH20. In order to have










































FIGURE "1. Examples of a representative experimental tracing of volume and
within-breath multifrequenoy impedance from a chronic obstructive pulmonary
disease patient with the definition of the indices considered in our study, a) Volume
measured by integration of flow at the mouth. b)-d) Within-breath respiratory
impedance (Zrs) at 5 Hz (b), 11 Hz (c) and 19 Hz (d). Each impedance is expressed
as respiratory system resistance (firs, ) and reactance (Xrs, ). The
presence of large within-breath variation of Xrs with more negative values showed
during expiration is a clear sign of the presence of expiratory flow limitation, ft:
inspiratory time; te: expiratory time; ftot: total cycle duration; Vr: tidal volume; Rexp:
mean expiratory resistance; fitot: mean whole-breath resistance; fiinsp: mean
inspiratory resistance; Xinsp: mean inspiratory reactance; AXrs: difference between
Xinsp and Xesp. Xtot: mean whole breath reactance; Xexp: mean expiratory reactance.
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PRN signals, and to keep the total energy of the PRN signal
low, the relative amplitude of the 5 Hz component of the PRN
has been slightly increased.
The experimental set-up for forced oscillation technique (FOT)
measurement was similar to that described previously [13]. The
pressure signal generated by a loudspeaker was transferred
from the box to the subject's mouthpiece through a connecting
tube (22 cm long, 19 mm internal diameter). A low-resistance,
highly inert tube (1.5 m long, 22 mm internal diameter) in
parallel with the loudspeaker allowed the subjects to breathe
room air without significant loss of forcing pressure. A bias flow
of ~15 L-min"1 reduced the equipment dead space to the
volume of the pneumotachograph and the mouthpiece [22]. The
frequency response of the whole measuring system was
assessed up to 30 Hz, as described previously [2], and was flat.
Experimental protocol
Patients attended on one occasion, when all measurements
were made in the same order. Plethysmographic lung volume
measurements were followed by recording oscillatory
mechanics at 5 Hz and breathing pattern with the patients
seated, wearing a nose-clip and with an operator firmly
supporting the cheeks to reduce upper airways shunt [23].
The patients breathed spontaneously through the FOT system
for 1 min, then performed an IC manoeuvre and resumed
spontaneous breathing.
After 10-min rest with the patient disconnected from the
measuring circuit, the FOT measurements were repeated by
following the same sequence of manoeuvres, but with the
multifrequency PRN signal applied.
Next, patients received 5 mg of nebulised salbutamol from an
oxygen-driven Acorns nebuliser (MedicAid, Pagham, UK) and
after 45 min of spirometry, plethysmography and the two FOT
measurements were repeated as described previously.
Data analysis
Within-breath respiratory system input impedance (Zrs) was
determined by using a least squares algorithm taking
advantage of the a priori knowledge of the frequency spectrum
components of the forcing signals [24, 25].
From the complete FOT recording and impedance tracing, we
selected ~10 breaths starting from 45 s after the first IC, to
avoid possible alterations of the breathing pattern after the
manoeuvre. Breaths in which Zrs tracings showed spikes or
oscillations due to swallowing or glottis closure were
discarded. For each breath, the values of several breathing
pattern parameters and Zrs indices were computed and
averaged for all the breaths in each subject and condition.
Within-breath respiratory system resistance (Rrs) was char¬
acterised by the mean values it assumed during inspiration,
expiration and during the whole breath (Rinsp, Rexp and Rtot,
respectively). As the frequency dependence of Rrs is related to
the heterogeneity of airway obstruction [22, 26], we also
computed the difference between Rrs measured at our lowest
and highest frequency (5 and 19 Hz, RS-R19).
Respiratory system reactance (Xrs) was characterised by its
average value during a breath and its within-breath fluctua¬
tions were quantified by computing its average value during
inspiration (Xinsp) and expiration (Xexp). Their difference
(AXrs=Xinsp-Xexp) was used to detect EFL. A breath was
considered flow-limited if AXrs was greater than a threshold
of 2.8 cmHzO-s-L"1, a value that in our previous studies [2,13,
14], enabled identification of flow-limited breaths with very
high sensitivity and specificity. A subject was classified as
flow-limited if the majority of his selected breaths were flow-
limited.
Data are expressed as mean + SD, unless otherwise stated. All
data comparisons were made relative to that individual's
baseline value, although we did conduct an exploratory
analysis of the spirometry data based on the reversibility
criteria recommended by the American Thoracic Society
(ATS)/ERS to identify bronchodilator responsiveness (FEVl
change >12% from the baseline and >200 mL) [27], Significant
differences in the physical characteristics, spirometric data,
and Rrs and Xrs indices values of the different groups were
evaluated using paired or unpaired t-tests, as appropriate. To
allow for the multiple comparisons to be made between
groups, only p<0.01 was considered to be statistically
significant. Our primary outcome was the change in IC after
administration of the bronchodilator. We calculated that a
study with 15 patients would have an 80% chance of showing a
difference of 200 mL at the 5% significance level between the
groups. As we anticipated identifying flow-limited and
nonflow-limited patients, we aimed to recruit 40 individuals
to increase our ability to detect differences between the
subgroups.
RESULTS
The baseline characteristics of the 42 COPD patients recruited
in this study are reported in table 1. All patients performed the
measurements correctly, with no reports of discomfort. From
these patients, a total of 788 breaths were selected and
analysed (408 before and 380 after bronchodilator). In figure 1,
an experimental tracing of volume and multifrequency
impedance data are shown for a representative flow-limited
patient. The presence of flow limitation is clearly shown by the
large decrease of Xrs during expiration compared with
inspiration. Figure 1 also shows that the presence of EFL
affects within-breath variations of Zrs at all frequencies but, as
predicted by the model simulation [13], the intra-breath Xrs
swings decrease in amplitude with increasing frequencies.
The 5 Hz component of the multifrequency forcing gave
similar results to those of the single 5 Hz frequency and,
therefore, in the rest of this study only data recorded during
multifrequency forcing are reported. A full account of the
comparison of the single and multifrequency testing is
presented in the online supplementary material.
Group mean data post-bronchodilator without accounting
for tidal expiratory flow limitation
The lung function, breathing pattern and impedance indices
for the whole patient group, measured after the bronchodilator
are presented in tables 1 and 2. Bronchodilation (BD) produced
statistically significant improvements in all the measured
plethysmographic variables except for FEVl/FVC and TLC
(table 1). There was a significant increase in V'e and a fall in
mean inspiratory and expiratory flow (table 2).
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TABLE 1 Patient characteristics and lung function before
and after bronchodilation (BD)
TABLE 2
Pre-BD Post-BD p-value
Breathing pattern and within-breath input
impedance measured at 5 Hz data for patients
before and after bronchodilation (BD)
Pre-BD Post-BD p-value
Age yrs 63.7±8.4
Sex M/F 21/23 V'e L-min"1 11.036 ±3.465 12.053 ±3.731 <0.001
Weight kg 68.3+21.6 VtL 0.656±0.240 0.711 ±0.244 0.014
Height cm 163.9 ±9.0 fR breathsmin*1 18.1 ±5.6 18.1 ±5.4 0.936
FEVi fi S 1.375±0.473 1.373 ±0.540 0.975
L 1.12±0.39 1.31 ±0.46 <0.001 ftot S 3.747±1.525 3.743 ±1.633 0.968
% pred 42.28 ±13.82 49.08 ±15.87 <0.001 fi/ftot 0.376 ±0.057 0.375 ±0.055 0.723
FEV1/FVC 46.81 ±10.75 46.23 ±11.59 0.510 Vr/fi L s'1 0.500±0.169 0.545±0.167 <0.001
FVC VT/tE L s'1 0.299 ±0.095 0.327±0.108 0.001
L 2.42 ±0.68 2.86±0.76 <0.001 Rinsp 5.1 ±1.6 4.2±1.5 <0.001
% pred 68.69 ±14.26 80.99±15.14 <0.001 Rexp 6.2±2.5 5.8±2.7 0.036
SVC Rtot 5.8±2.1 5.2±2.2 0.001
L 2.60±0.70 2.95±0.83 <0.001 Xinsp -2.3±1.2 -1.8± 1.1 <0.001
% pred 73.01 ±12.64 82.78 ±16.33 <0.001 Xexp -5.3 ±4.3 -3.8±3.3 0.001
IC Xtot -4.3±3.3 -3.1 ±2.5 0.001
L 1.85±0.52 2.09±0.62 <0.001 AXrs 2.9±3.4 2.0±2.5 0.004
% pred 72.95 ±17.94 81.51 ±18.92 <0.001 R5-R19 1.8± 1.0 1.2±0.9 <0.001
RV
L 4.82 ±1.31 4.50± 1.15 <0.001 Data are presented as mean±SD, unless otherwise indicated. Impedance data



















Data are presented as mean + so, unless otherwise indicated. M/F: male/
female; FEVi: forced expiratory volume in 1 s; % pred: % predicted; FVC:
forced vital capacity; SVC: slow vital capacity; IC: inspiratory capacity; RV:
residual volume; TGV: thoracic gas volume; TLC: total lung capacity.
In total, 18 patients met the ATS/ERS criteria for reversibility
of airway obstruction. There were no differences between
responder and nonresponder groups in their baseline plethys-
mographic or oscillatory variables. The changes in plethysmo-
graphic variables post-bronchodilator were similar for the two
spirometrically defined groups, while the oscillometric indices
differed between the responders and nonresponders.
Specifically Rtot and Rinsp at 5 Hz and mean difference in
resistances at 5 and 19 Hz (R5-R19) fell significantly more
(p=0.002, p=0.001 and p=0.002, respectively), while no
differences were seen in Xrs between the groups. The
discriminative power tested by the receiver operated char¬
acteristic curves was greater when Rinsp was used compared
with Rtot (80.1% and 73.5%, respectively) [28]. More details on
lung volumes, breathing pattern and Zrs data for responders
and nonresponders groups are shown in table E4 in the online
supplementary material.
In general, changes in Xrs indices were statistically significant
at all forcing frequencies, while the fall in Rrs only occurred
consistently when measured during inspiration. As a result
Rtot only decreased significantly relative to baseline at 5 Hz
while Rexp did not change significantly at any frequency.
volume; /r: respiratory frequency; fi: inspiratory time; hot: total cycle duration;
fi/ftot: inspiratory duty cycle; Vr/ti: mean respiratory flow rate; VT/(E: mean
expiratory flow rate; fiinsp: mean inspiration resistance; Rexp: mean expiration
resistance; Riot: mean whole breath resistance; Xinsp: mean reactance during
inspiration; Xexp; mean reactance during expiration: Xtot: mean total reactance ;
AXrs: mean difference in reactance; R5-R19: mean difference in resistances at 5
and 19 Hz.
Considering all the patients, Rinsp at 5 Hz was statistically
greater than at 19 Hz both before and after BD. However, it
was possible to identify a subgroup of seven patients in which
this difference was statistically different before BD (p=0.008),
but not after (p=0.204) BD. These patients were, on average,
less obstructed (FEVl was 56.6 + 16.02 % predicted (% pred)
pre- and 66.9 +18.6 % pred post-BD) than the others, enforcing
the concept that R5-R19 can be used as a sensitive index of
heterogeneity in airway obstruction. Indeed, R5-R19 showed a
statistically significant decrease, suggesting that the pattern of
airway obstruction was on average more homogeneous after
BD (table 2, fig. 2).
Effects of expiratory flow limitation on pre- and post-
bronchodilator lung function and impedance
measurements
Of the 42 patients, 20 were flow-limited at rest pre-broncho-
dilator and EFL was present in the majority of breaths studied
both before and after BD (fig. 3).
At baseline, FEVl was clearly lower and RV higher in the flow-
limited patients, but the differences in other plethysmographic
variables did not reach our adjusted significance level.
Of the oscillometric measurements Rinsp, R5-R19 and all the
reactance indices were greater in the flow-limited patients,
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Frequency Hz Frequency Hz
FIGURE 2. Multifrequency impedance spectra for a) mean whole breath resistance (Rtot), b) mean inspiration resistance (Rinsp), c) mean whole breath respiratory
elastance at 5 Hz (Sot) and d) mean inspiratory elastance at 5 Hz (Snsp) in flow-limited (closed symbols) and nonflow-limited (open symbols) patients at baseline before
(circles) and after (triangles) bronchodilation.
with nonsignificant differences being seen in the other
resistance measurements.
Post-bronchodilator, both groups improved in all spirometric
and lung volume variables except for FEVi/FVC and TLC
(table 3, fig. 4a). There were significant decreases in Rinsp and
Rtot in patients with EFL, but not in those without EFL where
the pre-bronchodilator values for these variables were sig¬
nificantly lower (table 3, fig. 4b). Xrs was significantly less
negative after BD at all frequencies in flow-limited patients,
while in nonflow-limited subjects, the change in Xrs was
significant only at high frequencies.
The effect of flow limitation on indices of iung homogeneity
pre- and post-BD
To further investigate the effect of the bronchodilator without
the confounding effect of expiratory flow limitation, we
considered both Rtot and Rinsp, and dynamic elastance (i.e.
Xrs multiplied by -2nf, where / is the forcing frequency) over
the forcing frequencies used in this study (fig. 2). Unlike
patients without flow limitation, EFL patients showed a clear
pattern of frequency dependence that became more evident
when the expiratory phase was excluded. After the broncho¬
dilator, Rrs decreased at all frequencies in nonflow-limited
patients, and the changes were similar whether Rtot or Rinsp
data were selected. By contrast, the change in Rrs was much
more evident (and statistically significant) in EFL patients
when Rinsp was used (fig. 2).
Effects of a bronchodilator on the presence of expiratory
flow limitation
Of the 20 flow-limited patients at baseline, eight patients
became nonflow-limited after BD, while no patient initially
without EFL developed it. The patients where flow limitation
was abolished had nonsignificantly different AXrs values at
baseline and changes in the AXrs after salbutamol compared
with those patients where flow-limitation persisted. There was
no relationship between inspiratory capacity and AXrs changes
overall in the flow-limited patients (r=0.107).
D1SCUSSIOW
The development of expiratory flow limitation during tidal
breathing identifies a group of COPD patients whose ability to
increase their VT to maintain gas exchange is significantly
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FIGURE 3. Relationship between the average value of mean difference in
respiratory system reactance (AXrs) and the percentage of individually classified
flow-limited (FL) breath for each patient before (•) and after (O) bronchodilation.
limited [29]. Inhaling a bronchodilator drug can potentially
have multiple effects in COPD, which may be influenced by
the presence of tidal EFL. These include a reduction in airways'
resistance, an abolition of EFL at that operating lung volume or
a shift in the distribution of choke points within the lung, all of
which can lead to a fall in end-expiratory lung volume that in
turn may lead to the persistence of EFL at rest. We used the
forced oscillation method to identify the presence of expiratory
flow limitation on a breath-by-breath basis, to measure
respiratory system mechanics during tidal breathing and to
quantify the heterogeneity of lung obstruction in COPD. To do
this we used a within-breath multifrequency method that
allowed us to assess the heterogeneity of the obstruction [26,30],
and produced comparable data to that measured using the
single frequency approach. Our data in a more homogeneous
patient group suggest that the response to bronchodilators is
more complex than initially proposed [10].
The effect of the high dose [3-agonist on resting lung mechanics
and breathing pattern we observed in the group as a whole
was similar to that reported in other studies of hyperinflated
COPD patients [5,9,31], with significant increases in FEVl and
inspiratory capacity and falls in RV and TGV. V"e increased, as
did mean inspiratory and expiratory flow rates, compatible
with the decrease in total and inspiratory resistance.
Bronchodilator reversibility defined spirometrically is common
in COPD [32]. Although nearly half of our patients met the
current criteria for a response [27], there was no difference in
the magnitude of the IC change in spirometric responders and
nonresponders, which helps to explain why these tests are only
poorly predictive of the patient's subsequent clinical course
[6, 7, 33]. However, oscillatory mechanics changed differently
in responders and nonresponders, with the Rrs values tracking
the changes in FEVl, unlike the reactance values, which
followed the inspiratory capacity data. A similar discrepancy
between resistance and reactance measurements pattern has
been reported during recovery from COPD exacerbations
























lli I JT 4i
■4r* |I
Rinsp Rexp Rtot Xnsp Xexp Xtot AXrs R5—R19
FIGURE 4. Changes of a) spirometric, plethysmography, and b) impedance
data at 5 Hz induced by bronchodilator in flow-limited (□) and nonflow-iimited (■)
patients at baseline. % pred: % predicted; FEVi: forced expiratory volume in 1 s;
FVC: forced vital capacity; IC: inspiratory capacity; SVC: slow vital capacity; RV:
residual volume; TGV: thoracic gas volume; TLC: total lung capacity; flinsp: mean
inspiration resistance; flexp: mean expiration resistance; fltot: mean whole breath
resistance; Xinsp: mean reactance during inspiration; Xexp; mean reactance during
expiration: Xtot: mean total reactance ; AXrs: mean difference in reactance;
fl5-Ri9: mean difference in resistances at 5 and 19 Hz. #: p=0,04; p=0.05;
+: p=0.001; s: p=0.031.
Resting expiratory flow limitation was present in just over half
the patients. All the breaths studied were consistently
classified, except for eight cases where the degree of EFL
varied from breath to breath and the classification was based
on a majority decision. As expected, flow-limited patients had
worse spirometry and a higher RV with a general tendency for
higher lung volumes, although these differences were less
consistent between groups. Despite this, the response to
bronchodilators was almost identical with similar changes in
flow and volume indices irrespective of the presence of flow
limitation. This does not preclude a different behaviour during
exercise in the patients who were flow-limited at rest, but the
improvement in exercise performance post-bronchodilator has
been consistently related to changes in resting inspiratory
capacity, without reference to whether these occurred in flow-
limited patients [33, 36],
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TABLE 3 Lung function, breathing pattern and impedance data at 5 Hz for patients who were nonflow-limited (non-FL) at
baseline and patients who were FL
Non-FL at baseline p-value FL at baseline p-value Non-FL versus FL
p-va!ue#
Pre-BD Post-BD Pre-BD Post-BD
FEV1
L 1.27+0.43 1.47±0.53 <0.001 0.95±0.27 1.14±0.30 <0.001 0.007
% pred 47.89 ±14.55 54.72 ±17.34 <0.001 36.10± 10.07 43.15 ±11.89 <0.001 0.004
FEV1/FVC % 50.27 ±10.59 50.36 ±11.52 0.504 43.00±9.81 41.90 ±10.24 0.380 0.027
FVC
L 2.54±0.70 2.91 ±0.77 <0.001 2.28 ±0.65 2.80±0.77 <0.001 0.213
% pred 73.22 ±14.64 83.26 ±13.86 <0.001 63.70 ±12.32 78.60 ±16.38 <0.001 0.029
SVC
*"2\. 2.61 ±0.72 2.90±0.83 <0.001 2.59 ±0.70 2.99±0.84 <0.001 0.943
% pred 74.47 ±13.56 82.77±16.16 <0.001 71.40 ±11.68 82.80 ±16.94 <0.001 0.439
ll_»
L 1.85±0.53 2.01 ±0.66 <0.001 1.86 ±0.53 2.18±0.59 <0.001 0.969
% pred 75.72 ±18.47 81.04±19.28 <0.001 69.90 ±17.28 82.00 ±19.02 <0.001 0.299
RV
L 4.29 ±1.21 4.02 ±0.98 <0.001 5.40±1.18 5.04±1.10 0.020 0.004
% pred 216.81 ±57.88 203.69 ±46.28 <0.001 255.00 ±54.92 238.11 ±50.72 0.015 0.035
TGV
L 5.16±1.33 4.93 ±1.24 <0.001 6.14 ±1.49 5.84 ±1.39 0.019 0.030
% pred 172.53 ±33.05 164.73±31.44 <0.001 197.65±35.64 188.28±33.75 0.019 0.023
TLC
L 7.02 ±1.66 6.97 ±1.61 0.261 7.99 ±1.67 7.97 ±1.57 0.747 0.070
% pred 125.46±19.76 124.48±17.33 0.184 138.65±18.38 137.94± 15.73 0.703 0.031
Zrs 5 Hz
Rinsp 4.4±1.2 3.8±1.5 0.014 5.8±1.8 4.6±1.3 <0.001 0.005
Rexp 5.4±1.5 4.9± 1.6 0.032 7.0±3.0 6.9±3.3 0.511 0.038
Rtot 5.0±1.4 4.5 ±1.5 0.024 6.6±2.5 6.1 ±2.6 0.020 0.013
Xinsp -1.7±0.9 -1.5 ± 1.1 0.318 -3.1 ±1.0 -2.2±1.1 <0.001 <0.001
Xexp -2.1 ±1.4 -2.0 ±1.7 0.601 -8.8 ±3.5 -5.8±3.4 <0.001 <0.001
Xtot -1.9 ±1.2 -1,8±1.5 0.527 -6.8±2.9 -4.6±2.6 <0.001 <0.001
AXrs 0.4±0.7 0.4±0.8 0.860 5.7 ±3.0 3.7 ±2.7 0.002 <0.001
R5-R19 1.2±0.7 0.8±0.9 0.019 2.5±0.7 1.6±0.6 <0.001 <0.001
Data are presented as mean +so, unless otherwise stated. Impedance data (fi and X) are expressed as cmH2Os-L~1. BD: bronchodilator; FEV1: forced expiratory volume in
1 s; % pred: % predicted; FVC: forced vital capacity; SVC: slowvital capacity; IC: inspiratory capacity; RV: residual volume; TGV: thoracic gas volume; TLC: total lung capacity;
Zrs: within-breath respiratory system input impedance; flinsp: mean inspiration resistance; fiexp: mean expiration resistance; fltot: mean whole breath resistance; Xinsp: mean
reactance during inspiration; Xexp; mean reactance during expiration: Xiot: mean total reactance; AXrs: mean difference in reactance; fl5-fii9: mean difference in resistances at
5 and 19 Hz. #: the p-values are reported for the paired comparison pre- and post-BD in each group and for the unpaired comparison between non-FL and FL at baseline. All
values in bold are statistically significant.
The changes in oscillatory mechanics noted above were largely
driven by changes in flow-limited patients, presumably because
the fall in lung volume in the nonflow-limited patients
compensated for any improvement in resting resistance or
reactance. The fall in group mean Rrs in the flow-limited subjects
was duemainly to a reduction in Rinsp of the respiratory system.
Multifrequency testing generated large amounts of data, which
have been retained for completeness along with the breathing
pattern data as online supplementary material. In general,
these showed qualitatively similar changes in response to the
bronchodilator to the data measured at 5 Hz. We characterised
the heterogeneity of the lung with an index of the frequency
dependence of resistance, R5-R19. It is possible to identify at
least four different sources of heterogeneity: serial distribution
of airway geometry [37], heterogeneous parallel airway
constriction pattern [38], airway wall shunting [30], and
heterogeneity of alveolar tissue in heterogeneous parenchymal
diseases, such as emphysema [39]. Serial distribution of airway
geometry affects impedance data mainly for frequencies
>100 Hz, providing only negligible contribution at the forcing
frequencies used in this study [40]. Tissue heterogeneity
should not be affected by the administration of BD. As the
frequency dependence of Rrs changed statistically significantly
after bronchodilator application in most of the patients, with
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some of them showing no frequency dependence at all after
BD, the tissue heterogeneity should not be the dominant
mechanism affecting R5-R19. Parallel airway constriction and
airway wall shunting are not easy to differentiate, and it is
likely that they are all together contributing to the definition of
R5-R19.
Between-frequency comparisons showed that nonflow-limited
patients had a relatively homogeneous distribution of resis¬
tance, and their response to the bronchodilator was similar
whether Rtot or Rinsp was plotted. By contrast, flow-limited
patients showed a much greater frequency dependence at
baseline, suggesting a highly heterogeneous pattern of obstruc¬
tion. This pattern was apparently little affected by the
bronchodilator when total Ris was considered. However, a
clear fall in frequency dependence of Ris was evident when
inspiratory data, unaffected by the artefacts due to EFL, were
used. This suggests that BD has a great effect in homogenising
time constants throughout the airway tree in flow-limited
patients, as also supported by the changes in dynamic
elastance with frequency, which are also in agreement with
the model prediction of Lutchen et al. [26].
In some patients, bronchodilators abolished expiratory flow
limitation in all or in the majority of breaths. This has been seen
in other reports [31], although the potential for breath-to-
breath variation in the presence of flow limitation complicates
the interpretation of data when only a few breaths are
sampled, as with the negative expiratory pressure method
for identifying EFL. This subset of patients did not differ either
in their baseline physiological characteristics before testing or
in their degree of within-breath reactance change either before
or after treatment.
Our data have some limitations. All studies were conducted at
rest and seated, and changes in lung mechanics may not
translate to data during exercise, although as already noted
there is a good relationship between resting operating lung
volumes and exercise performance. Oscillatory signals can be
influenced by the shunt compliance provided by the upper
airway in COPD. However, each subject is their own control in
our data before and after the bronchodilator. Changes related
to technical factors, such as the presence of expiratory flow
limitation, provide a plausible explanation for the limited
bronchodilator response previously reported in COPD using
total Zrs data and attributed to upper airway factors [15]. Our
data have been reported using the multifrequency pseudo¬
random noise signal, which might have yielded different
results to previous single frequency oscillation studies.
However, as indicated in the online supplementary material,
any differences seen with the systems are likely to relate to
physiological differences between breath variation in the
degree of flow limitation rather than systematic methodologi¬
cal error. This issue is considered in more detail in the online
supplementary material.
In summary, expiratory flow limitation during tidal breathing
has an important influence on the changes in resting lung
mechanics after bronchodilator drugs in COPD, but it does not
predict the magnitude of the subsequent improvement in
operating lung volume, at least not at rest. Noninvasive
measurements of tidal lung mechanics using the forced
oscillation method are an attractive alternative to more usual
effort dependent tests of pulmonary function and others have
shown that such tests are a sensitive way of detecting
bronchodilator effects in these patients [41]. However, the
change in the total Zrs after a bronchodilator may under¬
estimate the true effects of therapy if expiratory impedance
data are not excluded from the analysis in flow-limited
patients. Despite these limitations, forced-oscillation data add
considerable insight into the way treatment works in COPD
and, as a noninvasive, effort-independent methodology, is well
suited formonitoring patients in clinical settings where reliable
clinical measurement has until now been difficult.
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Bronchodilator reversibility, exercise performance
and breathlessness In stable chronic obstructive
pulmonary disease
J.G. Hay, P. Stone, J. Carter, S. Church, A. Eyre-Brook,
M.G. Pearson, A.A. Woodcock, P.M.A. Calverley
Bronchodilator reversibility, exercise performance and breathlessness in stable
chronic obstructive pulmonary disease. J.G. Hay, P. Stone, J. Carter, S. Church,
A. Eyre-Brook, M.G. Pearson, A.A. Woodcock, P.M.A. Calverley.
ABSTRACT: Partial bronchodilator reversibility can be demonstrated in many
patients with stable chronic obstructive pulmonary disease (COPD), but its
relevance to exercise capacity and symptoms is uncertain. Previous data
suggest that anticholinergic bronchodilators do not improve exercise tolerance
in such patients.
We studied 32 patients with stable COPD, mean age 65 yrs, in a double-
blind, placebo-controlled, cross-over trial of the inhaled anticholinergic drug,
oxitropium bromide; From the within and between day placebo spirometry, we
derived the spontaneous variation in forced expiratory volume in one second
(FEVj) and forced vital capacity (FVC) of this population (FEVj 140 ml; FVC
390 ml) and considered responses beyond this to be significant.
Oxitropium bromide increased baseline FEVj from 0.70 (0.28) / (mean (sd))
to 0.88 (0.36) /. The 6 min walking distance increased by 7% compared with
placebo, whilst resting breathlessness scores fell from 2.0 to 1.23 at rest and
4.09 to 3.28 at the end of exercise after the active drug.
Improvements in walking distances and symptoms were unrelated to changes
in either FEVj or FVC, indicating that routine reversibility testing is not a good
predictor of symptomatic benefit in these patients.
Eur Respir J., 1992, 5, 659-664.
patients, and using the data have examined the rela¬
tionship between short-term bronchodilator response
and changes in both exercise performance and dysp¬
noea, using different reversibility criteria.
Methods
We studied 32 patients in two centres. Chronic
obstructive pulmonary disease was defined as a his¬
tory of continuous breathlessness for more than 12
months together with an FEVj of sl.2 /. Patients with
known cardiac or other respiratory disorders were
excluded, as were those with exacerbations in the last
two months and those taking oral corticosteroids. All
subjects had been shown to have a >15% improvement
in FEVj after inhaled salbutamol at sometime in the
preceding six months and no change was made in their
normal drug therapy during the study. No patient was
receiving oral prednisolone. The mean age (sd) of the
group was 65 (8) yrs, 17 were female, 7 were current
smokers,-21 ex-smokers and 4 nonsmokers. Informed
consent was obtained in all cases and the study pro¬




Regional Dept of Respiratory Physiology
Wythenshawe Hospital, Manchester












Received: July 18 1991
Accepted after revision January 14 1992
Many patients with stable chronic obstructive pul¬
monary disease (COPD) show some reversibility of
their airflow limitation on testing with beta-adrenergic
or anticholinergic drugs [1—3], and some of these
respond to corticosteroids [4-6]. Whilst the benefits
of treatment associated with large changes in pulmo¬
nary function are clear in asthmatic patients [7], the
smaller changes seen with partial reversibility in
COPD are harder to evaluate. In particular, we do not
know whether the improvements in breathlessness or
exercise tolerance are confined to patients whose bron¬
chodilator response exceeds the normal between meas¬
urement variability.
Inhaled anticholinergic bronchodilators appear to be
more effective in older patients with less labile airflow
limitation [2, 8, 9] but, unlike salbutamol, they did not
improve corridor walking distance in a previous study
[10]. We have investigated this unexpected finding in
a double-blind, placebo-controlled, cross-over study
of the effects of the anticholinergic drug, oxitropium
bromide, on corridor walking distance and symptoms.
In addition, we have established the spontaneous
variability of forced expiratory volume in one sec¬
ond (FEV,) and forced vital capacity (FVC) in these
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Each patient attended on four occasions, at the same
time of day, and at least 6 h after any inhaled bron-
chodilator treatment, (oral bronchodilators were discon¬
tinued seven days before entry to the study). All
spirometric measurements were made with the dry
spirometer (Vitalograph UK Ltd) recording the best
FEVj and best FVC of three acceptable traces. Breath-
lessness was assessed by asking the patients "how
breathless do you feel?" and recording the response or
a modified Borg category scale [11]. Six minute
walks (6MD) were performed as described by Butland
et al. [12] with a standardized encouragement during
the walk. On the first two visits, spirometry was
measured before and 15 min after salbutamol 200 pg
or 45 min after ipratropium bromide 40 pg, both given
by metered dose inhaler under supervision. Two prac¬
tice 6 min walks were performed with 60 min rest
between each walk. Breathlessness was assessed
before and immediately after each walk (end-exercise).
On visits 3 and 4, baseline spirometry was recorded
and patients performed a walking test, as previously.
Then, patients received either oxitropium bromide 200
pg or placebo from a metered dose inhaler in a rand¬
omized, double-blind fashion and, after 45 min, spiro¬
metry and the 6 min walk were repeated.
In assessing reversibility, we considered that signifi¬
cant change after a bronchodilator was likely when the
spirometric variable (either FEVj or FVC) increased by
15% from its baseline value and this change exceeded
the 95% confidence intervals for the variable in this
population. Four patterns of response were possible -
an isolated improvement in FEVj but not FVC, in
FVC but not FEVj, in both or in neither. We derived
the spirometric confidence intervals for the population
using the method described by Tweedale et al. [13].
Results are expressed as mean and standard deviation
unless otherwise stated. Comparisons between treat¬
ments have been made using the paired Student's
t-test as part of a general linear model analysis pro¬
gramme; p=0.02 being taken as the lower limit of
significance [14], The modified Borg scale linearizes
the relationship between sensation and other physical
variables within an individual [15]. Changes with¬
in individuals have been compared using both para¬
metric and non-parametric tests (Wilcoxon signed
rank) and no difference was seen between them.
Statistical comparisons of Borg scale data between the
subjects have been made using only non-parametric
tests.
Results
There were no differences attributable to either the
centre in which the study was conducted or to treat¬
ment order for any of the variables assessed. Mean
walking distance increased significantly from 370 (82)
to 401 (75) m between practice days 1 and 2 (p<0.001),
but there was no further increase in baseline walking
distance after day 2. Data describing the natural vari¬
ability of these variables is presented for days 3 and 4
only, in order to exclude any practice effects.
Spontaneous measurement variation
The group mean baseline FEVj were very similar on
days 3 and 4 (0.70 (0.28) I and 0.72 (0.28) /, respec¬
tively). Likewise, baseline FVC was stable at 1.74
(0.60) I and 1.72 (0.72) I on each day. Data describ¬
ing the within and between day variability in spiro¬
metry, walking distance and breathlessness scoring
were derived from measurements on the placebo day,
before and after drug administration as appropriate. In
this population a change of 140 ml in FEVj and 390
ml in FVC was required to exceed the within day 95%
confidence intervals for these measurements. These
values exceeded 15% of the baseline FEVj in these
patients.
Likewise, baseline walking distance and resting
breathlessness scores did not differ between the study
days. The within day variation in walking distance
was 53 m with a between day variability of 78 m.
The non-parametric nature of the breathlessness scor¬
ing across the population makes a similar analysis for
these variables inappropriate but there was no change
in the group mean breathlessness score before and
after placebo walks.
Bronchodilator effects
Group mean spirometry before and after salbutamol,
ipratropium bromide and oxitropium bromide is
reported in table 1, with the individual data inter¬
relationships shown in figure 1. All three drugs
produced a statistically significant bronchodilatation for
the group as a whole but there was considerable vari¬
ation in the size of these responses between subjects
and across the different drugs. Oxitropium bromide
increased group mean 6MD by 27 m, reduced breath¬
lessness at rest scores from 2.02 to 1.23 and end-
exercise scoring from 4.09 to 3.28 (p<0.01 in all cases
compared with pre-drug values and placebo data (fig.
2)). However, the absolute increase in breathlessness
scored during the walks before and after oxitropium
bromide was not different.
In table 2 the characteristics of patients showing
different patterns of bronchodilatation to oxitropium
bromide are summarized. Approximately one third of
the group showed no response spirometrically, one
third responded with changes in both FEVj and FVC
and one third with one or the other. Non-responders
had a lower initial FEVj, higher level of resting
breathlessness and shorter baseline 6MD than complete
responders. Statistically significant improvements
in walking distance and reductions in breathlessness
scores were seen in all three groups, with a similar
absolute change in these variables occurring in the
non-responder and complete responder subgroups.
The absolute change in walking distance was not
dependent on the size of the increase in FEVj but was
inversely correlated with the change in resting breath¬
lessness score, so that the greater the reduction in
dyspnoea, the further the patient walked (r=-0.44,
p<0.01).













Table 1. - Changes in group mean (sd) spirometric variables after
placebo and the three inhaled bronchodilator drugs; each drug was

























*: statistically significant difference at the pcO.OOl level. FEV^ forced expira¬
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Fig. 1. - Individual data showing the interrelationship between the bronchodilator response to oxitropium with: A) 200 pg salbutamol;
and B) 40 pg ipratropium bromide, and the variability of the response with three drugs.
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Fig. 2. - The effect of oxitropium bromide (B) on 6 min walking distance (6MD) and breathlessness scores compared with placebo
(A). Data expressed as group mean (sem). Error bars are included with breathlessness scores as a measure of variability and do not
reflect the statistical treatment of the data. *: significantly different at the 1% level in'the paired comparisons of walking distance, rest
and exercise dyspnoea before and after drug. Ex; end-exercise.
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FEVj + FVC 10 0.80(0.33) 441(101) 0.30(0.12) 0.76 (0.36) 26 (37) -0.6 -1.0
FEVj only 6 0.74(0.29) 417(52) 0.24 (0.02) 0.26 (0.15) 19 (16) -0.6 -1.1
FVC only 3 0.57(0.12) 348 (58) 0.14(0.01) 0.44 (0.02) 15 (48) -0.2 -0.7
Neither 13 0.60(0.16) 358 (100) 0.06 (0.07) 0.19(0.13) 33 (32) -0.7 -1.1
Response criteria are defined by a change (A) in spirometry which exceeds the 95% confidence intervals for short-term
variation in the measure. Responder groups are separated by the presence or absence of changes in FEV; and/or FVC.
Data for the mean (sd) baseline FEV) (/) and 6 min walking distance (6MD, m) are given for each responder group,
as are the mean changes in these variables and breathlessness scores after oxitropium bromide. FEV^ forced expira¬
tory volume in one second; FVC: forced vital capacity.
Discussion
Several studies have demonstrated that patients
with stable COPD can show significant improvements
in spirometry after inhaled |32-agonists [16] or anti¬
cholinergic drugs [17]. Control of bronchomotor tone
in such patients appears to be cholinergically mediated
[18], is subject to day-to-day variation [3, 19] and may
be important prognostically [20]. However, the abso¬
lute changes in spirometry are small, fall within the
spontaneous variation of the measurement [13], and
may not be relevant to symptoms or exercise perform¬
ance. There is no general agreement about the best
way to define clinically relevant spirometric changes
in these patients and whether changes in FVC or peak
expiratory flow are better predictors of improvement.
Most investigators have selected criteria which give the
best discrimination among the study population but this
is not necessarily associated with symptomatic benefit
[5, 6, 21]. We found that patients with stable COPD
show small but significant improvements in breathless¬
ness and corridor walking distance after inhaled
oxitropium bromide but not placebo. These improve¬
ments were not confined to those classified as being
reversible on spirometric criteria, but patients in whom
both FEVj and FVC improved after bronchodilator had
a higher baseline FEVj and a better initial walking
distance.
Methodological problems limit the clinical applica¬
tion of the tests used in this study. Familiarization
with the walking test is an important aspect of trial
design [22] but unlike some other groups we found
that after two pre-study visits there were no signifi¬
cant differences in the pre-drug walking distances.
Quantification of respiratory sensations using visual
analogue or category scaling is increasingly used in the
assessment of treatment [23] and the modified Borg
scale has the advantage of being linearly related to
objective physiological measurements [14, 24], In this
study, breathlessness provided a complimentary end-
point and some individuals (n=ll) walked for a simi¬
lar distance but to a lower level of dyspnoea after
active drug, whilst others (n=5) increased their 6MD
and end-exercise level of breathlessness.
In defining a bronchodilator response, we were able
to use our placebo data to establish the spontaneous
variation of FEVj and FVC in our study population.
We used an identical method to that described by
Tweedale et al. [13] and obtained very similar results,
suggesting a wider applicability for such values [5].
Adoption of different response criteria has a substan¬
tial effect on the numbers considered to be responsive
[25] and we observed three subjects in whom FVC
improved in isolation beyond our confidence limits.
Oxitropium bromide is an anticholinergic drug simi¬
lar to ipratropium bromide and has its maximal bron¬
chodilator effect between 30-90 min after inhalation
[26]. A previous double-blind study of the effects of
ipratropium bromide on exercise tolerance in 24 simi¬
lar patients found no improvement in 12 min walking
distance [10] but the present study is larger, involved
more practice walks before the study days, used a
different drug and quantified symptoms. Comparison
with ipratropium bromide suggests that the dose of
oxitropium bromide used would be higher on the dose
response curve [26] and this may explain the some¬
what greater increases in walking distance that we
found. However, the impact of the active drug on
symptoms was greater than that on walking distance
with a reduction in both baseline and end-exercise
levels of dyspnoea after oxitropium bromide. This
emphasizes the importance of assessing symptoms as
objectively as possible if important drug effects are to
be detected. Although within the short-term reproduc¬
ibility of this measure the change in 6MD was, none¬
theless, statistically significant for the group. A small
change in walking distance alone is of doubtful sig¬
nificance unless accompanied by parallel reductions in
symptoms.
The rapid onset of action of inhaled adrenergic and
anticholinergic bronchodilators has made short-term
reversibility testing with spirometry practical in the
clinic and the laboratory, but the interpretation of such
tests is difficult because of spontaneous variation in
baseline FEVj [3]. Although, all of the study patients
had shown reversibility in FEVj prior to entry, only
half would have been classified as having such revers¬
ibility when studied with our active drug. We did not
find a relationship between baseline FEVj and 6MD,
nor was the change in FEVj predictive of improvement
in walking distance after oxitropium bromide. Revers¬
ibility status, however defined, had no effect on the
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small but statistically significant increases in walk¬
ing distance and reduction in breathlessness which
occurred in these patients'. This suggests that the
FEVj response behaves as a continuous variable and
that for these purposes the separation into "reversible"
and "irreversible" patients is not helpful. These find¬
ings with anticholinergic blockade are similar to those
reported in smaller studies, where patients were
selected for lack of reversibility to |32-agonists [27],
and to a study which shows reduction in breathless¬
ness at rest after bronchodilator in similar COPD
patients [28]. Whether such changes would be present
in patients who do not respond on repeated reversibil¬
ity testing is not known.
Why these effects occur is unclear. The small
degree of bronchodilatation produced by oxitropium
bromide in the central airways [29-31] may be suffi¬
cient to permit better lung emptying during exercise.
Alternatively, improvement may also affect small air¬
way calibre, which might improve exercise tolerance,
as has been suggested with other drugs, in similarly
disabled patients [32], Such an effect may influence
the degree of hyperinflation at rest, reducing the
inspiratory threshold load imposed by positive end-
expiratory pressure (PEEPi), and hence diminish the
perception of breathlessness. The mechanisms under¬
lying this have recently been reviewed [33-35]. Anti¬
cholinergics might affect afferent information from
intrapulmonary stretch receptors but the evidence for
an important role for such a sensation in the percep¬
tion of breathlessness in man, is presently lacking.
Whatever the mechanism, these data show that anti¬
cholinergic therapy can improve symptoms and exer¬
cise tolerance in COPD, even when the changes in
spirometry fall within the expected variability of the
measurement. Whilst tests of bronchodilator revers¬
ibility may help to categorize the patients and select
a group more likely to be steroid responsive [5], fail¬
ure to show a "reversible" response should not pre¬
clude a trial of symptomatic bronchodilator treatment.
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Regional chest wall volumes during exercise in chronic
obstructive pulmonary disease
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Background: Dynamic hyperinflation of the lungs impairs exercise performance in chronic obstructive
pulmonary disease (COPD). However, it is unclear which patients are affected by dynamic hyperinflation
and how the respiratory muscles respond to the change in lung volume.
Methods: Using optoelectronic plethysmography, total and regional chest wall volumes were measured
non-invasively in 20 stable patients with COPD (mean (SD) forced expiratory volume in 1 second 43.6
(11.6)% predicted) and dynamic hyperinflation was tracked breath by breath to test if this was the
mechanism of exercise limitation. Resting ventilation, breathing pattern, symptoms, rib cage and
abdominal volumes were recorded at rest and during symptom limited cycle ergometry. Pleural,
abdominal, and transdiaphragmatic pressures were measured in eight patients.
Results: End expiratory chest wall volume increased by a mean (SE) of 592 (80) ml in 12 patients
(hyperinflators) but decreased by 462 (103) ml in eight (euvolumics). During exercise, tidal volume
increased in euvolumic patients by reducing end expiratory abdominal volume while in hyperinflators tidal
volume increased by increasing end inspiratory abdominal and rib cage volumes. The maximal
abdominal pressure was 22.1 (9.0) cm H20 in euvolumic patients and 7.6 (2.6) cm H20 in
hyperinflators. Euvolumic patients were as breathless as hyperinflators but exercised for less time and
reached lower maximum workloads (p<0.05) despite having better spirometric parameters and a greater
expiratory flow reserve.
Conclusions: Dynamic hyperinflation is not the only mechanism limiting exercise performance in patients
with stable COPD. Accurate measurement of chest wall volume can identify the different patterns of
respiratory muscle activation during exercise.
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Exercise limitation is a major cause of disability inpatients with chronic obstructive pulmonary disease(COPD) and is largely the result of disturbances in the
mechanics of breathing. Tests of airflow limitation at rest
such as forced expiratory volume in 1 second (FEVH are
relatively poor predictors of exercise duration in these
patients.12 The most common explanation for this is that,
unlike healthy subjects, end expiratory lung volume (EELV)
increases during exercise in patients with COPD, decreasing
the inspiratory capacity (IC).2 3 This dynamic hyperinflation
increases the ability of the respiratory system to generate
expiratory flow but limits the maximum tidal volume and
reduces the ability of inspiratory muscles to produce force by
reducing their length, leading to the sensation of breath-
lessness.4 At present few data are available on the time course
of these changes, how the volume change is distributed
between the compartments of the chest wall (rib cage and
abdomen), and what happens in patients who do not show
these changes in lung volume.
EELV is usually measured indirectly from IC, but this is
influenced by the subject's ability to cooperate. It cannot
follow brealh-to-breath variation in lung volume. Integrator
drift, which is multifactorial in origin, also poses a problem.
This problem can be overcome by using optoelectronic
plethysmography (OEP).5 6 OEP is an accurate non-invasive
method for measuring total chest wall volume (Vcw),
ventilation, and respiratory kinematics.7"10 It enables analysis
of chest wall motion and accurately measures changes in the
volume of the different respiratory compartments of the chest
wall in different postures and conditions. Although OEP
cannot measure the absolute lung volume unless the
subdivisions of lung volume are also known, it can measure
changes in volume such as during a tidal breath and can
record breath by breath changes in EELV, as well as its
distribution between the different chest wall compartments.'
A study was undertaken to measure operating chest wall
volumes on a breath by breath basis in patients with clinically
stable symptomatic COPD at rest and during exercise, and
thus to assess how the chest wall changed as dynamic
hyperinflation developed. We hypothesised that an increase
in end expiratory Vcw would be the most important factor




Twenty men with stable COPD diagnosed by accepted criteria
took part in the study.1112 All had been smokers and com¬
plained of exertional dyspnoea. None had clinical or physiolo¬
gical features ofbronchial asthma or a history ofexacerbation in
the previous 6 weeks. There were no co-morbid conditions
limiting exercise. Patients were studied before pulmonary
rehabilitation and were unfamiliar with physiological exercise
testing. Routine bronchodilator drugs were omitted for 4 hours
(short acting) or 12 hours (long acting) before attendance. The
Abbreviations: BMI, body mass index; COPD, chronic obstructive
pulmonary disease; EELV, end expiratory lung volume; EEVcw, end
expiratory chest wall volume; FEF, forced expiratory flow at a
percentage of FVC; FEV], forced expiratory volume in 1 second; FRC,
functional residual capacity; FVC, forced vital capacity; IC, inspiratory
capacity; OEP, optoelectronic plethysmography; Pab, abdominal
pressure; Pdi, transdiaphragmatic pressure; Pga, gastric pressure; Poes,
oesophageal pressure; Ppl, pleural pressure; RV, residual volume; TLC,
total lung capacity; Vab, abdominal volume; Vcw, total chest wall
volume; Vrc, rib cage volume
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protocol was approved by the district research ethics committee
and informed consent was obtained.
Measurements
Subdivisions of lung volumes were measured by body
plethysmography (Medgraphic Autolink 1085D, Medical
Graphics, St Paul, MN, USA) using ATS standards.13 Flow
was measured at the mouth by a screen pneumotachograph
and integrated to display the flow-volume loop from which
FEVi, FVC, and flow indices were derived.
Chest wall kinematics and compartmental volumes were
non-invasively measured by OEP. The principle of this
method is described in detail elsewhere.5 6 Briefly, OEP
measures the change in the complex shape of the chest wall
during breathing by modelling the thoracoabdominal surface
with a large number of points belonging to selected
anatomical reference sites on the rib cage and abdomen.
The three dimensional positions and displacements of each
point are measured by a motion analyser (BTS, Milan, Italy)
based on passive (reflective) markers (plastic hemispheres of
10 mm diameter covered by a thin film of retroreflective
paper) placed on the skin using biadhesive hypoallergenic
tape and special TV cameras operating up to 100 frames per
second synchronised with coaxial infrared flashing LEDs.
After computing and classifying the two dimensional
coordinates of all markers surveyed by at least two TV
cameras, the system determines the three dimensional
coordinates of the different markers by stereo-photogram-
metry. Once the three dimensional coordinates of the points
belonging to the chest wall surface are acquired with
reference to an arbitrary coordinate system, a closed surface
is defined by connecting the points to form triangles (mesh of
triangles) and the volume contained by the surface is
computed using Gauss' theorem. This procedure allows the
direct computation of the volume enclosed by the thoraco¬
abdominal surface approximated by a closed mesh of
triangles. As in our previous studies, we used 89 markers
placed over the chest wall surface and four TV cameras (two
in front and two behind the subject at a distance of 3 m) to
track their movement.
Eight patients were instrumented using standard balloon
tipped catheters connected to pressure transducers (SCX05;
Sensym, Milpitas, CA, USA) for recording oesophageal (Poes)
and gastric (Pga) pressures which were used as indices of
pleural (Ppl) and abdominal (Pab) pressures, respectively.
Transdiaphragmatic pressure (Pdi) was computed as the
difference between Pga and Poes. In these subjects we also
continuously measured flow at the airway opening using a low
dead space (70 ml) pneumotachograph (Medical Graphics).
Breath by breath oxygen consumption and carbon dioxide
production were measured using a fuel cell and infrared
carbon dioxide analyser, respectively, as part of a commercial
exercise system (Medical Graphics).
Pressures and flow signals were synchronised to those of the
motion analyser used for OEP and sent to a personal computer
for subsequent analysis. Oxygen saturation was measured by
pulse oximetry (Biox 3700e, Ohmeda, Louisville, CO, USA).
Protocol
After performing spirometric and plethysmographic measure¬
ments in the body box the subjects were asked to sit on an
electrically braked cycle ergometer. Once acclimatised, quiet
breathing for 3 minutes and a slow vital capacity to
determine chest wall volumes at functional residual capacity
(FRC), total lung capacity (TLC), and residual volume (RV)
were measured. The patients than began pedalling for 3 min
with 10 W increases in workload every subsequent 3 minutes
until exhaustion. Data were collected during the last minute
of each workload, including the subject's subjective assess¬
ment of breathing difficulty and leg fatigue using a 10 point
modified Borg category scale." During both rest and exercise
the subjects grasped handles positioned at mid-sternum
level, which lifted the arms away from the rib cage, so that
lateral markers could be visualised.
Data analysis
Modelling of the chest wall
The chest wall was modelled as if it was composed of two
compartments—rib cage and abdomen. A change in abdominal
volume (Vab) was defined as the volume swept by the
abdominal wall and the boundary between the rib cage and
abdomen along the lower costal margin anteriorly and at the
level of the lowest point of the lower costal margin posteriorly.
Total chest wall volume (Vcw) equalled the sum of rib cage
volume (Vrc) and Vab. The pulmonary and abdominal rib cage
compartments have been combined as Vrc in this analysis.
Comparison between chest wall and
pneumotachographs volumes
As in previous studies in which we assessed the ability of OEP
to measure changes in lung volume,5 7 9 10 we compared
changes in Vcw during inspiration obtained by OEP (AVcw)
with inspired volumes obtained by integration of flow
(AVm), considering the difference between values at the
beginning and end of inspiration. For each instrumented
patient, 5-6 breaths were studied during both quiet breathing
and at their maximal workload during exercise. Data were
then compared by linear regression analysis.
Chest wall, ventilatory pattern and work of
breathing
During quiet breathing and exercise OEP data were used to
measure end expiratory and end inspiratory Vrc, Vab, and
Vcw and the complete ventilatory pattern (including tidal
volume, breathing frequency, minute ventilation, inspiratory
and expiratory times) at each workload. All volumes reported
are the combined mean values over the last minute of each
run (unless otherwise specified). The work of breathing
performed on the lung in the instrumented patients was
calculated as the area enclosed by the Poes-Vcw loops.
Patients were considered to show dynamic hyperinflation
of the chest wall if the end expiratory Vcw increased above its
resting value at maximum workload. Those in whom Vcw
was maintained or reduced were described as euvolumic. This
terminology was the same as that used in other published
papers15 " in which similar patterns of behaviour were found
in healthy subjects in response to an incremental exercise test
with expiratory flow limitation artificially induced by a
Starling resistor.
Statistical analysis
Data are presented as mean (SE) unless otherwise stated.
Differences between anthropometric, spirometric, and exer¬
cise data sets were tested usingWilcoxon and Mann-Whitney
tests for paired and unpaired data, respectively, with a 5%
significance level. To compare chest wall volumes at end
expiration and end inspiration at different workloads
between euvolumic and hyperinflator patients we applied a
repeated measures analysis of variance (ANOVA). This
enabled us to test for an overall difference between work¬
loads (within-subject effect) and between groups (euvolu-
mics v hyperinflators). When ANOVA was significant, post
hoc Fisher's PLSD test was performed to verify the statistical
significance of the differences between pairs of means. For all
tests the significance level was taken as p<0.05.
RESULTS
Baseline anthropometric and pulmonary function data are
shown in table 1. Instrumentation did not influence exercise
performance or the changes in Vcw during exercise.
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Comparison of OEP with pneumotachograph data
The relationship between AVcw (OEP) and AVm (pneumo¬
tachograph) is shown in fig 1. Each data point represents the
mean of 10-15 breaths either during quiet breathing or at
maximum exercise. The linear regression analysis provided
the following equation: AVcw = 1.12 • AVm - 0.08
(12 = 0.92, p<0.0001). Using the same data, the mean (SE)
percentage difference between AVm and AVcw (computed as
(AVm — AVcw)/AVm x 100) was —4.3 (2.5)%. When only
quiet breathing data were considered the equation was AVcw
= 1.16 • AVm + 0.17 (r2 = 0.933, p<0.001) with a mean (SE)
percentage difference of 0.8 (3.2)%; when only exercise data
were considered the equation was AVcw = 0.95 • AVm —
0.15 (^ = 0.92, p<0.001) with a mean (SE) percentage
difference of —9.5 (2.9)%. At rest AVm and AVcw differed by
5 (30) ml, while at maximum workload the difference was
— 100 (29) ml, the AVcw values being larger.
Changes in end expiratory chest wall volume during
exercise
Two patterns of change in Vcw occurred during exercise. End
expiratory Vcw increased by a mean (SE) of 592 (80) ml in 12
patients (five instrumented) and decreased in eight others
(three instrumented; fig 2, right hand panels). End expiratory
Vrc increased significantly by 494 (90) ml in the hyperinflated
patients compared with 46 (148) ml in the euvolumic group
(p<0.05) during unloaded cycling and remained constant
thereafter. End expiratory Vab remained constant in hyper-
inflators throughout exercise with the end inspiratory volumes
rising to accommodate the increases in Vrc (fig 2, left hand and
middle panels). In euvolumic patients the end expiratory Vab
was reduced at the onset of exercise and remained constant
thereafter. The right hand panel of fig 2 shows that the change
in Vcw (that is, the tidal volume) in these patients was almost
entirely the result of the decrease in Vab while end inspiratory
Vcw remained almost constant. In contrast, in the hyperin-
flators end inspiratory Vcw approached the TLC values
measured before exercise and this was accomplished by
increases in both Vrc and Vab.
Resting lung volumes including IC were not significantly
different between the exercise groups nor was the degree of
oxygen desaturation during exercise. Both hyperinflator and
euvolumic patients reported a similar degree of breath-
lessness and leg effort scored at peak exercise. However,
euvolumic patients had significantly higher BMI, pre-exercise
FEVi, FEV^VC ratio, and forced expiratory flows at 25% and
50% of expired volume (table 1).
Flow, pressure, and regional volume relationships
Figure 3 shows the flow-volume and compartmental pres¬
sure-volume relationships of two representative subjects, one
Volume changes by PNT (I)
Figure 1 Comparison of the simultaneously recorded integrated flow at
the mouth (measured by pneumotachograph, PNT) and change in Vcw
(measured by optoelectronic plethysmography, OEP) during quiet
breathing (QB) at rest and at maximum workload during exercise (EX) in
euvolumic patients (closed symbols) and hyperinflators (open symbols).
Each point represents the mean value for each individual. The solid line
is the slope of the regression between the data sets and the dashed lines
are the 95% confidence intervals. The slope of the regression line (equal
to 1.12) reflects the combined effect of gas compression, blood
displacements away from the thorax, and the difference in
thermodynamic conditions (ATPS v BTPS).
hyperinflator (top panels) and one euvolumic (bottom
panels). The hyperinflator had a rightward displacement of
the tidal flow-volume loop at peak exercise with an
expiratory flow profile that had changed little from that
under resting conditions. There was an increase in both rib
cage and abdominal volumes with little change in the shape
of the pressure-volume loop. In contrast, in the euvolumic
patient the expiratory flow was increased during exercise at
close to the resting end expiratory volume with marked
abdominal muscle pressure generation. This pattern was
consistent in all the patients in which it could be assessed.
Exercise capacity, breathing pattern, and respiratory
pressures
Although peak exercise ventilation was the same, hyperinflators
reached a mean (SE) maximum workload of 35.0 (4.8) watts
with an exercise duration of 13.7 (1.4) min, while the
euvolumic patients achieved a maximum workload of 20.0
(4.2) watts and an exercise duration of 8.8 (1.3) min (p<0.05).
The change in end expiratory Vcw was weakly related to the
maximum workload achieved (r2 = 0.216, p = 0.038; fig 4).
Tidal volume and frequency at maximum workload were
similar in the two groups with no significant difference in the
Table 1 Mean (SD) baseline anthropometric and pulmonary function data of study
subjects and subgroups defined by their end expiratory lung volumes during exercise
All (n = 20) Euvolumics (n= 12) Hyperinflators (n = 8)
Age (years) 68.6 (7.0) 65.2 (8.5) 70.9 (5.0)
BMI (kg/m2) 25.5 |2.8| 27.5 (3.0) 24.2 (1.7)*
FEV, (1) 1.28 (0.38| 1.42 (0.43) 1.18 (0.33)
FEVi (% pred) 43.6(11.6) 50.1 (12.2) 39.2 (9.2)*
FVC (% pred) 73.5(16.3) 75.7 (9.8) 72.1 (19.9)
FEVj/FVC (%) 46.0 (8.4) 51.4 (8.5) 42.5 (6.3)*
IC (1) 2.35 (0.44) 2.18 (0.21) 2.46 (0.53)
TLC (% pred) 128.7(18.7) 134.0 (34.1) 125.7(18.7)
FRC 174.2(44.1) 177.6 (58.6) 172.2 (36.0)
RV (% pred) 202.9 (59.6) 210.3 (78.8) 198.6 (48.7)
FEF25% |% pred) 19.1 (10.8) 25.2 (14.5) 15.1 (4.7)*
FEF50x {% pred) 14.8(7.0) 19.0 (9.0) 12.1 (3.5)*
FEF/ra (% predj 17.6 (5.8) 18.5 (7.1) 17.0 (5.1)
*p<0.05, hyperinflators v euvolumics.
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Figure 2 Compartmental and total chest wall volume changes in hyperinflating (upper panels, HY) and euvolumic (lower panels, EU) patients. Open
circles = end inspiration; closed circles = end expiration. Mean values and standard error bars are shown. *p<0.05, "p<0.01, *"p<0.001 vquiet
breathing (QB); fp<0.05, ttp<0 01, tttp<0.001 hyperinflators (HY) veuvolumics (EU).
inspiratory or expiratory times between the subgroups
(table 2).
In the instrumented patients the mean and peak trans¬
diaphragmatic pressure swings remained relatively constant
at rest and during exercise. The mean abdominal pressure
swings at maximum exercise were negative in both groups
and the maximal abdominal pressures were three times
greater in the euvolumics than in the hyperinflators, but the
difference was not statistically significant (table 2).
Although resting and peak exercise oxygen consumption
were similar in both groups, the calculated work of breathing
at the same level of exercise was substantially greater in the
euvolumic patients (p<0.05).
DISCUSSION
When healthy subjects exercise, end expiratory lung volume
falls as ventilation increases—a change seen in young adults"
and in healthy elderly subjects of a similar age to our
patients." Changes in lung volume can be inferred from
changes in IC, but the respiratory response to exercise also
involves the distribution of these volume changes to different
chest wall compartments involving the activity of different
groups of respiratory muscles. Initial studies of Vcw in
patients with COPD used semi-quantitative methods based
on magnetometers and were the first to show that dynamic
hyperinflation occurred during exercise in some of these
patients.113 OEP represents an important technical advance
which has allowed us to define how Vcw changes during
exercise in patients with COPD. As a result, we have
identified two different behaviour patterns in changes to
end expiratory Vcw during exercise.
Studies with externally applied flow resistance in healthy
subjects showed differences in the pattern of response to
exercise, with some maintaining the normal fall in EELV
throughout exercise while others allowed EELV to rise before
stopping.15 In most of our COPD patients end expiratory Vcw
increased with exercise, but in a significant number the
pattern seen in healthy subjects was adopted with reduced
Vab preventing dynamic hyperinflation. In each case the
response of a particular individual was constant and the
differences between groups at each workload were statisti¬
cally significant (fig 2). The hyperinflators reached end
inspiratory volumes close to their resting TLC while the
euvolumic patients had an apparent end inspiratory reserve
when they stopped. The change in end expiratory Vrc
occurred in hyperinflators before loaded exercise began—a
finding previously noted in COPD patients using less
quantitative methods'8 "—and it did not change further in
either group as exercise intensity increased. The effect of
exercise on the abdominal compartment was equally distinct
with end inspiratory Vab increasing in hyperinflators, while
in euvolumic patients the end inspiratory Vab remained
constant but higher abdominal pressure developed to try to
reduce end expiratory Vab (fig 3).
It is not clear why these different responses to exercise
occur. The presence of balloon catheters or breathing via a
mouthpiece did not explain the pattern observed. All patients
had omitted their normal bronchodilator drugs and none had
undergone pulmonary rehabilitation, an intervention which
can modify changes in lung volume during exercise.20 There
was no difference in the oxygen saturation during exercise
and the oxygen consumption, when measured, was similar at
equivalent workloads. Although the BMI differed between
the groups, this is likely to reflect differences in disease
severity, with euvolumic patients having significantly better
spiromelric parameters. Differences in the relative amounts
of emphysema or small airways disease might be relevant,
although the presence of emphysema is not necessary for
dynamic hyperinflation to occur.21
The most likely explanation is a difference between groups
in their resting expiratory flow reserve. The hyperinflators
reported here are very similar to those reported by O'Donnell
and colleagues,21 exhibiting quantitatively similar changes in
end expiratory Vcw using optoelectronic measurement to
www.thoraxjnl.com
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Figure 3 Relationships between tidal flow, chest wall volumes, and pressures in two representative patients, one hyperinflator (top panels) and one
euvolumic (bottom panels). The data represent the composite values during sequential breaths at specific flow, volume and pressure. Solid symbols are
values measured at rest and open symbols are those measured at maximal exercise. In the left hand panels flow at the mouth is related to chest wall
volume (Vcw). The tidal loops of the hyperinflating patient are displaced riahtward during maximal exercise while in the euvolumic patient tidal
expiratory flow is increased without a substantial increase in end expiratoryTung volume (EELV). In the middle two panels the volume of the pulmonary
rib cage (Vrc,p) is related to oesophageal pressure (Poes). These data have been selected as only the pulmonary rib cage is exposed to pleural
pressure.8 In both patients there is an increase in end inspiratory and end expiratory pulmonary Vrc at maximal exercise compared with rest, although
significantly higher end expiratory Poes values were seen in the euvolumic patient. In the right hand panel abdominal volume (Vab) is plotted against
gastric pressure (Pga). With exercise there is little change in the pressure-volume loop of the hyperinflating patient, but a marked shift in the axis of the
loop occurred in the euvolumic patient which suggests a strong recruitment of expiratory muscles acting on this compartment.
those in EELV measured using the IC technique and with
similar impairments in resting spirometry and expiratory
flow. Data from the composite tidal flow-volume loops in our
patients are compatiblewith the presence of resting tidal flow
limitation which is associated with hyperinflation in COPD.22
In contrast, the euvolumic patients were less obstructed and
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Figure 4 Relationship between change in end expiratory chest wall
volume from quiet breathing to exercise (AEEVcw) and maximum
exercise workload reached by euvolumic and hyperinflator patients.
Mean values and standard error bars are shown for the two groups;
*p<0.05.
resting tidal range, as assessed by their maximum pre-
exercise flow-volume loops and the non-invasive data shown
in fig 3. Despite their better inspiratory flow reserve,
euvolumic patients developed high intra-abdominal pressure
rather than permitting EELV to rise as in the hyperinflators.
Whatever the explanation, maintaining a normal end
expiratory lung volume is a poor adaptive strategy. The
calculated work of breathing at end exercise was substan¬
tially higher in the euvolumic patients than in the hyper¬
inflators, confirming that exercise was not limited by poor
motivation in this group. The increase in oxygen consump¬
tion by the respiratory muscles in euvolumic patients
resulting from this increase in work of breathing effectively
competes for a larger share of the whole body oxygen
consumption, reducing the oxygen available to the leg
muscles.2'"23 This may explain why patients who adopted
this strategy, although as breathless as hyperinflators when
they stopped, exercised for less time and reached a lower
intensity of power at equivalent levels of breathlessness.
Measurements of Vcw are normally identical to the volume
change recorded at the mouth during spontaneous breath¬
ing5 710 or that measured in ventilated and paralysed
patients." In our COPD patients there was good overall
agreement between the inspiratory tidal volume and Vcw,
amounting to an error of 0.8% at rest, equivalent to a
difference of 5 ml in the resting tidal volume. This increased
to a 9.5% error at maximal exercise, equivalent to a difference
www.lhoraxjnl.com
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Table 2 Mean (SE) values of exercise performance, breathing pattern, exercise duration, respiratory pressures, energetics
and sensation at rest and maximal exercise (Wmax) for the euvolumic and hyperinflating subjects
All Euvolumics Hyperinflators
Rest Wmax Rest Wmax Rest Wmox
Exercise duration (min) 11.8(1.0) 8.8 (1.3) 13.7(1.4)*
Wmax (watt) 29.0 (3.4) 20.0 (4.2) 35.0 (4.8)*
Breathing frequency (/min) 16.8(1.0) 27.3 (1.6) 18.5 (1.0) 26.9 (3.1) 15.59 (1.49) 27.51 (1.69)
Ti[s| 1.47(0.11) 0.91 (0.06) 1.27(0.06) 0.94(0.10) 1.61 (0.20) 0.90 (0.07)
Te (s) 2.41 (0.18) 1.49 (0.15) 2.03 (0.13) 1.62 (0.35) 2.67 (0.32) 1.40 (0.14)
Minute ventilation (1/min) 12.7|1.0| 37.1 (2.5) 12.7 (0.9) 35.9 (4.2) 12.6(1.6) 37.9 (3.2)
Maximum Ppl (cm H2O) 3.5(1.4) 14.0 (4.6) 4.4 (2.9) 22.6 (8.5) 2.7(1.5) 6.8 (3.4)
Maximum Pab (cm H2O) 5.8 (1.7) 14.2(4.6) 6.7 (3.7) 22.1 (9.0) 5.1 (2.0) 7.6 (2.6)
Work of breathing (cm h^O-l/min) 140(31) 456(132)t 155 (12) 754 (228)f 130 (47) 277 (77)*t
Oxygen consumption (ml/min) 259 (14) 558 (20)t 248 (10) 539 (29)t 267 (25) 570 (29)f
Heart rate (bpm) 86 (5) 104(3) 95(6| 102 (6) 80 (6) 105 (3)
Breathlessness 0.8 (0.3) 4.8 (0.5) 1.1 (0.5) 4.9 (0.9) 0.6 (0.3) 4.8 (0.5)
Leg effort 1.6 (0.5) 5.6 (0.5) 3.1 (0.6) 6.6 (0.8) 0.6 (0.3)* 4.9 (0.5)
To permit comparison between different subjects, Pga data are presented as abdominal pressures (Pab) by subtracting the hydrostatic pressure gradient.
*p<0.05, hyperinflators v euvolumics.
tlO watt.
of 100 ml in the mean tidal volume. This difference is likely
to arise from physiological rather than methodological
factors. The change in Vcw tended to be larger than the
volume change at the mouth and was more marked during
expiration, reflecting the effect of gas compression and also
the shift of blood between thoracic and extrathoracic
regions.15
Our data have clinical implications. They help explain why
spirometry is such a poor predictor of exercise capacity in
individual COPD patients, since those with apparently better
resting values can still be limited by their efforts to reduce
end expiratory Vcw. Evidence from studies at rest in patients
with COPD and with kyphoscoliosis26 suggest that the order
of recruitment of the respiratory muscles during breathing is
an automatic response of the central controller. This
stereotyped behaviour may explain why some patients with
COPD adopt a euvolumic breathing pattern during exercise.
Whether previously euvolumic patients adapt to the onset of
persistent tidal flow limitation and then allow Vcw to rise
remains to be established. Some therapeutic interventions
may work by modifying these volume related exercise
responses. Thus, in healthy subjects, reducing the work of
breathing can increase the oxygen consumption of the
locomotor muscles,24 25 while in patients with COPD the
major effect of supporting ventilation during exercise is to
increase exercise duration in patients with the most marked
abdominal muscle activation.27
In conclusion, exercise limitation in COPD and its
attendant dyspnoea is not necessarily associated with
dynamic pulmonary hyperinflation. Individuals vary in the
strategy of respiratory muscle recruitment that they adopt
and in the resultant change in compartmental chest wall
volume. The reasons for this require further investigation,
and the OEP technique may be helpful in understanding the
effects of treatment on exercise performance in COPD.
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Interferon gamma therapy and pulmonary fibrosis
▲ Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-lb in patients with idiopathic
pulmonary fibrosis. N Engl J Med 2004;350:125-33
n this double blind multinational study, 330 patients with idiopathic pulmonary fibrosis
were randomly assigned to treatment with either subcutaneous interferon gamma-lb
(n= 162) or placebo (n= 168) three times daily for 48 weeks. Interferon gamma-lb had
no significant effect on the primary end point (disease progression or death) compared with
placebo. 10% of patients died in the active treatment group compared with 17% in the
placebo group (p = 0.08). The median time to death or disease progression was 439 days in
the active group and 344 days in the placebo group (p = 0.50). Active treatment was not
associated with any differences in gas exchange, lung function, or conventional quality of
life measures. Exploratory analysis did reveal a greater effect of the active treatment in
reducing mortality in patients with milder disease (parameter > median value of the
group—that is, baseline forced vital capacity (FVC) >62% predicted and carbon monoxide
transfer factor >35% predicted). Active treatment was associated with more frequent
influenza-like symptoms and a higher incidence of pneumonia. However, respiratory
infections were of equal severity and discontinuation rates were similar in the two groups.
This study failed to show any significant effect of interferon gamma-lb on disease
progression, death, gas exchange, lung function, or quality of life in idiopathic pulmonary
fibrosis. Exploratory analysis suggested, but could not confirm, a survival benefit for the
active treatment in patients with milder disease. Due to the limited size and duration of the
trial, a smaller survival benefit cannot be excluded. Further trials are required of adequate
power to answer these questions.
A R L Medford
Clinical Research Fellow and Honorary Specialist Registrar, University of Bristol,
Southmead Hospital, Bristol, UK;
andrew.medford@bristol.ac.ul<
Antirefroviral therapy improves outcome of HIV infected adults with TB
▲ Hung CC, Chen MY, Hsiao CF, et al. Improved outcomes of HIV-1 -infected adults with tuberculosis in the era of highly
active antiretroviral therapy. AIDS 2003;17:2615-22
In this prospective observational cohort study from Taiwan the outcome of HIV infected TBpatients and HIV infected non-TB patients treated with highly active antiretroviraltherapy (HAART) was compared.
A total of 46 TB and 230 non-TB antiretroviral naive patients were included between June
1994 and October 2002. The median duration of antituberculous therapy was 9 months
(range 1-24). Viral clearance (20 of 46 v 107 of 230, RR 0.93 (95% CI 0.65 to 1.34); p = 0.71)
at week 4 of HAART was similar in the two groups, as was the virological failure during
HAART (RR 1.49 (95% CI 0.92 to 2.41); p = 0.14). The CD4 cell count increased in both
groups (71 v 64 x 106 cells/1, p = 0.70). The risk for HIV progression to new opportunistic
illnesses (adjusted RR 1.16 (95% CI 0.764 to 1.77)) and the adjusted hazard ratio for death of
TB patients compared with non-TB patients was also similar in the two groups (1.18 (95% CI
0.65 to 2.32) before HAART era and 0.89 (95% CI 0.57 to 1.69) in HAART era).
This study addresses the important issue of HTV and TB co-infection and shows that TB
does not alter the virological and immunological responses and the clinical outcome when
these patients are treated with HAART and an appropriate antituberculous therapy. The
authors do point out, however, that the rate of multidrug resistant TB was low and few of
these patients were intravenous drug users or homeless, distinguishing them from some
other study populations. They had access to high quality follow up and treatment. Ideally,
we would like to have a situation where we could provide care of an equally high standard to
all patients with HIV and TB co-infection to ensure that these results are widely applicable.
G Rohde
Bergmannsheil, University Hospital, Bochum, Germany;
gernot.rohde@ruhr-uni-bochum.de
www.thoraxjnl.com
Downloaded from thorax.bmj.com on March 21, 2012 - Published by group.bmj.com
Regional chest wall volumes during exercise
in chronic obstructive pulmonary disease
A Aliverti, N Stevenson, R L Dellaca, et al.
Thorax 2004 59: 210-216
doi: 10.1136/thorax.2003.011494
Updated information and services can be found at:
http://thorax.bmj.com/content/59/3/210.full.html
These include:




Email alerting Receive free email alerts when new articles cite this article. Sign up in the
service box at the top right corner of the online article.
Topic Articles on similar topics can be found in the following collections
Collections
Airway biology (858 articles)
Lung function (640 articles)
Notes
To request permissions go to:
http://group.bmj.com/group/rights-llcensing/permissions
To order reprints go to:
http://journals.bmj.com/cgi/reprintform
To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Eur Respir J 2009; 33: 49-60
DOI: 10.1183/09031936.00141607
Copyright©ERS Journals Ltd 2009
Paradoxical movement of the lower ribcage
at rest and during exercise in COPD
patients
A. Aliverti*, M. Quaranta*'#, S3. Chakrafoarti*,







ABSTRACT: Paradoxical inward displacement of the costal margin during inspiration is observed
in many chronic obstructive pulmonary disease patients at rest but its importance is unclear.
The current authors studied 20 patients (forced expiratory volume in one second 32.6±11.7,
functional residual capacity 186 + 32% predicted) and 10 healthy controls at rest and during
symptom-limited incremental exercise. With optoelectronic plethysmography, the phase shift
between pulmonary and abdominal ribcage volumes and the percentage of inspiratory time the
ribcage compartments moved in opposite directions were quantified, using control data to define
the normal range of movement.
Eight patients showed lower ribcage inspiratory paradox at rest (P+), while 12 patients did not
(P-). This was unrelated to resting lung function or exercise tolerance. Total end-expiratory chest
wall volume (EEVcw) increased immediately when exercise began in P+ patients, but later in
exercise in P- patients. This difference in EEVcw was mainly due to a greater increase of end-
expiratory pulmonary ribcage volume in P+ patients. During exercise, dyspnoea increased
similarly in the two groups, while leg effort increased more markedly in the patients without
paradox.
In conclusion, lower ribcage paradox at rest is reproducible and associated with early-onset
hyperinflation of the chest wall and predominant dyspnoea at end-exercise. When paradox is
absent, the sense of leg effort becomes a more important symptom limiting exercise.
KEYWORDS: Chest wall asynchrony, chronic obstructive pulmonary disease, dyspnoea, exercise,
Hoover's sign
n healthy people, inspiration occurs as a
result of the coordinated action of the chest
wall muscles. As the diaphragm flattens, the
incompressible abdominal contents displace the
abdominal wall outwards. The ribcage comprises
two linked compartments: the lung-apposed part
(pulmonary ribcage (RCp)), expanded by inspira¬
tory ribcage muscle action and submitted to
pleural pressure; and the diaphragm-apposed
part (abdominal ribcage (RCa)), expanded as this
muscle contracts and submitted to abdominal
pressure. During inspiration, the expansions of
the abdomen and both ribcage compartments are
in phase, a relationship that persists when the
subject exercises although end-expiratory lung
volume is actively reduced by increased expira¬
tory abdominal muscle action [1],
In chronic obstructive pulmonary disease
(COPD) the situation is different. Here, the
diaphragm is flatter and the respiratory drive is
increased [2]. In this condition, the effectiveness
of the diaphragm is less than in normal subjects
and the expansion of the lower ribcage caused by
diaphragmatic contraction is smaller than in
normal subjects; consequently, it is possible that
an uncoordinated expansion of the two ribcage
compartments occurs, leading to ribcage distor¬
tion [3, 4j. Before the advent of objective
measurements of chest wall volume, clinical
observation had identified patients who exhib¬
ited paradoxical (inward) movement of their
lower ribcage on inspiration [5-8]. Such inspira¬
tory paradoxical motion of the lower ribcage is
common in COPD [7, 8] and has been proposed
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as an aid to diagnosis [9]. However, it has not been quantified
or related to other forms of respiratory behaviour or the
symptoms which limit exercise.
Previously, optoelectronic plethysmography (OEP) has been
used to identify differences in the behaviour of the ribcage and
abdominal compartments of COPD patients during rest and
exercise [10-13], However, the effect of within-breath asyn-
chrony between different ribcage compartments was not
studied. The current authors hypothesised that the presence
of lower ribcage paradoxical movement would relate to the
pattern of the end-expiratory and end-inspiratory chest wall
volume changes during exercise. To test this, the normal range
of lower ribcage paradox was defined by studying a group of
age-matched healthy controls, and then regional chest wall
volumes at rest and during exercise in stable COPD were
measured. Additionally, to investigate the relevance of para¬
doxical lower ribcage movement to exercise undertaken in
daily life, exercise performance and symptoms during self-
paced corridor walking were measured.
METHODS
Subjects
In total, 20 male patients who met the clinical and physiolo¬
gical diagnostic criteria for COPD [14] were studied. All
patients were or had been tobacco smokers, were <75 yrs old
and had a post-bronchodilator forced expiratory volume in one
second (FEVi)/forced vital capacity (FVC) <0.7, a pre-
bronchodilator FEVi <50% predicted and showed <10%
improvement in FEVl after inhaled bronchodilator drugs.
Patients were not known to have paradoxical lower ribcage
movement prior to the study and no specific examination for
the presence of Hoover's sign [5, 6] was undertaken. No
patient had experienced a COPD exacerbation requiring
treatment in the previous 6 weeks. All were treated with
inhaled corticosteroids and long-acting inhaled bronchodila-
tors together with short-acting rescue therapy. In addition, 10
healthy age-matched volunteers were recruited, who followed
the same measurement protocol as follows. Subjects had
normal spirometry for their age and an FEVl/FVC value >0.7.
Protocol
All assessments were made on a single study day. After
clinical review, spirometry and plethysmography lung
volumes were measured in all subjects and repeated in the
COPD patients 15 min after 400 pg salbutamol given via a
spacer device. Each COPD patient performed two 6-min
walking tests with a 20-min rest period between testing. The
first walk was used to familiarise the patient with the test and
only data from the second walk are reported. After a 20-mins
rest, during which the OEP reflective markers were applied,
patients were seated on the cycle ergometer and asked to
execute three slow vital capacity and three FVC manoeuvres
followed by 2 min of quiet breathing (QB), to establish baseline
values for the chest wall volumes. After this, subjects under¬
took the incremental exercise protocol described hereafter.
Subject started pedalling, first unloaded for 2 min and then
with an incremental load of 5 W-min"1 until exhaustion.
The research protocol was approved by the district research
ethics committee (Liverpool, UK) and informed consent was
obtained from each participant.
Measurements
Subdivisions of lung volumes were measured to American
Thoracic Society (ATS) standards in a body plethysmograph
(Medgraphic Autolink 1085D; Medical Graphics, St Paul, MN,
USA). Flow was measured at the mouth by a screen pneumo¬
tachograph and integrated to display the flow-volume loop from
which spirometry and flow indices were derived.
Self-paced corridor walking tests were performed according to
standard protocols with a standardised walking course [15].
Subjects walked at their maximal pace along an elliptical 40-m
course. They were asked to cover as much ground as possible
during the allotted time, while maintaining a steady pace
without running. No encouragement was given, and subjects
were informed each minute of the time remaining. The patients
were allowed to stop, but they could start again, if possible,
within the allocated 6 min. Distance covered in 6 min was
recorded, together with oxygen saturation and heart rate (HR)
from a lightweight pulse oximeter (Pulsox 300i; Konica Minolta
Sensing, Inc., Osaka, Japan). During exercise, subjects were
asked to rate their breathlessness and the sense of leg effort
every minute on a 10-point modified Borg category scale.
Incremental exercise was performed while seated on an
electrically braked cycle ergometer. With the subjects breathing
through a mouthpiece with a nose-clip, breath-by-breath
ventilatory variables were derived from the flow signal
detected by a pneumotachograph system (Medical Graphics).
Oxygen consumption and carbon dioxide production were
measured using a paramagnetic sensor and infrared carbon
dioxide analyser, respectively, as part of an exercise testing
system (Medical Graphics). The flow signal was synchronised
to that of the motion analyser used for OEP and sent to a
personal computer for subsequent analysis. Oxygen saturation
was measured by pulse oximetry (Biox 3700e; Ohmeda,
Louisville, CO, USA) and cardiac frequency was determined
using the R-R interval from a 4-lead ECG. During the exercise
tests, subjects were asked to rate their breathlessness and leg
effort everyminute on the same Borg category scale used in the
walking tests.
Kinematics of the chest wall were measured by OEP (OEP
System; BTS, Milan, Italy). In brief, the volumes displaced by
the three compartments of the chest wall were measured by 89
retro-reflective markers placed on the trunk of the subject
according to precise anatomical reference points. Marker
positions were captured by six TV cameras (three in front
and three behind the subject) operating at 60 frames-s"1 and
synchronised with co-axial infrared flashing LEDs. The three-
dimensional coordinates of the markers were calculated with
stereo-photogrammetry and linked with a mesh of triangles to
create the surface embedding the trunk. The volume of the
trunk enclosed by the surface was obtained through a
computing algorithm based on the Gauss' theorem [16].
The markers (fig. 1) were positioned on approximately hor¬
izontal rows at the following levels: the clavicular line, the
manubrio-sternal joint (angle of Louis), the nipples, the xiphoid
process, the lower costal margin, the umbilicus and the anterior
superior iliac crest. Surface landmarks for the vertical columns
were: themidlines, both anterior and posterior axillary lines, the
midpoint of the interval between the midline and the anterior
axillary line, the midpoint of the interval between the midline
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and the posterior axillary line, and the midaxillary lines. Extra
markers were added bilaterally at the midpoint between the
xiphoid and themost lateral portion of the 10th rib, in the region
overlying the lung-apposed ribcage, and in corresponding
posterior positions. Volume displacement of the chest wall
was calculated by triangulating the surface and integrating the
subtended volume.
Data analysis
Modelling of the chest wall
The chest wall was modelled in three compartments: RCp, RCa
and abdomen (AB; fig. 1). Thus, the total volume (V) displaced
by the chest wall (CW) was calculated as the sum of the
volumes displaced by the individual compartments. Hie
boundaries between the three portions were represented by a
transverse section placed at the level of the xiphoid process
(between RCp and RCa) and another surface positioned at the
level of the lower costal margin (between RCa and AB; fig. 1).
The time-courses of the volume of each region (VRCp, VRCa and
Vab), along with their sum (Vcw) was processed to obtain a
breath-by-breath assessment of both ventilatory pattern and
operational chest wall volumes [1, 4, 16].
Chest wall volume data were standardised for the duration of
each test to allow comparisons between different subjects as a
percentage ofmaximum exercise. Comparisons were also made
using minute ventilation as a percentage of the maximum value
reached and as an absolute value.
Quantitative analysis of the paradoxical movement of the lower
ribcage
The presence of paradoxical lower ribcage motion was
established by comparing the time-courses of VRCp and VRCa.
In each patient, the volume tracings were normalised with
respect to time, in order to allow ensemble averaging over three
reproducible consecutive breaths randomly chosen within the
period of interest (either QB or during exercise at different
levels) and to derive an "average" respiratory cycle at each level
of workload. Inspiratory and expiratory phases of the breathing
cycles were derived from the Vcw signal. From these average
breaths, asynchronous and paradoxicalmotion between the two
ribcage compartments were then assessed by calculating the
following two parameters (fig. 2).
First, the phase shift (0) between VRCa and VRCp, as indicated
by the degree of opening of the Lissajou figure produced when
these two volumes were plotted against each other, was
calculated. This was measured as the ratio of the distance
delimited by the intercepts of the VRCp versus VRCa dynamic
loop on a line parallel to the x-axis at 50% of RCp tidal volume
(m), divided by RCa tidal volume (s), as 0=sirf1(m-s"1), an
approach previously adopted [17]. In this system a phase angle
of zero represents completely synchronous movement of the
compartments and 180° total asynchrony.
Secondly, inspiratory paradox time (IP), defined as the fraction
of the inspiratory time during which the VRCa decreased
(fig. 2), was calculated.
Patients were subdivided into those showing paradox at rest
(P+) and those who did not (P-). This grouping was based on
threshold values of IP and 0, obtained at rest before the various
manoeuvres in the 10 healthy volunteers and defined as values
two standard deviations beyond the respective means. To
confirm the validity of these measurements, three different
breaths were selected under the same workload in both the
control and COPD subjects and the data compared with the
initial estimate. In three COPD patients, the data on the first
incremental test were repeated on a subsequent day to
FIGURE 1. Marker positioning on the a) front and b) back of the subject and c) geometrical models of the chest wall compartments for analysis by optoelectronic
plethysmography, a and b) Borders of the different compartments of the chest wall are shown: pulmonary or upper ribcage (RCp), abdominal or lower ribcage (RCa) and
abdomen (AB). c) The actual triangulation for the different compartments of the chest wall (RCp, RCa and AB). To allow a better understanding, each compartment is
represented slightly shifted in the vertical direction.
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Al/RCa AVRCa AVRCa
FIGURE 2. a-c) Time-courses of the volumes of the upper ribcage, lower ribcage, abdomen and total chest wall (VRCp, VRCa, Vab and Vcw, respectively) during two
consecutive breaths at rest. : boundaries of a single inspiration, d-f) Dynamic loops of change (A) in VRCp versus AVRCa during quiet breathing, averaged on the
respiratory cycle time. Arrows: direction of dynamic loops, a and d) Control subject, b and e) chronic obstructive pulmonary disease (COPD) patient without paradoxical
movement between VRCp and VRCa, c and f) COPD patient with paradoxical movement between VRCp and VRCa. : inspiratory paradox time of the lower ribcage. m: line




determine whether differences in marker position (positioned
by different experimenters) or day-to-day variability in the
subjects' breathing influenced the classification of paradoxical
movement.
As an alternative parameter to 0 for the quantification of the
degree of opening of the Lissajou figure in the VRCp-VRCa plot,
the hysteresivity index (q) was also considered [18]:
q = ((tc • AVRCp • AVRCa/4A)2 -1)"0'5 (1)
where AVRCp and AVRCa are the tidal volumes of the
pulmonary and abdominal ribcage, respectively, and A is the
area bounded by the VRCp-VRCa loop.
In a post hoc analysis, the current authors examined whether
the presence of tidal expiratory flow limitation at rest was
related to the indices of paradoxical lower ribcage movement
and the behaviour of patients during exercise. The flow signal
was integrated to obtain flow-volume loops during rest, forced
expiratory manoeuvres and maximal exercise. To correct the
drift of the volume signal obtained from the integration of the
flow measured at the mouth, the loops were positioned
according to the values of chest wall volume measured at
total lung capacity during inspiratory capacity manoeuvres
performed at rest before tire various manoeuvres during which
the loops to be compared were recorded. Expiratory flow
limitation was considered present at rest when >50% of the
tidal breath met or exceeded the expiratory boundary of the
maximal flow-volume loop [19].
Statistical analysis
Data are presented as mean+SD unless otherwise stated.
Differences between anthropometric, spirometric and exercise
data sets were tested using Wilcoxon and Mann-Whitney tests
for paired and unpaired data, respectively, with appropriate
adjustment for multiple comparisons. To evaluate the influ¬
ence of ribcage paradox and exercise intensity on ventilatory
parameters and operational volumes, a two way ANOVA was
performed. Statistical significance was assumed if the null-
hypothesis was rejected with a probability of p<0.05.
RESULTS
Anthropometric characteristics, spirometry values and sub¬
division of lung volumes are reported in table 1.
Defining the occurrence of paradoxical ribcage movement
at rest
The magnitude of volume change, its timing and the phase
angle relationship of the RCp and RCa regions are shown for
three typical subjects in figure 2, while all the individual VRCa
and VRCp time-courses and VRCp-VRCa loops are presented in
the online supplementary material. Using a difference of at
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TABLE 1 Patient characteristics: anthropometric
characteristics, spirometric values and
subdivision of lung volumes in chronic




















































66 + 7 69 + 6 65 + 7
174 + 6 175 + 6 173 + 7
69 + 14 76 + 16 63 + 11*
22.5 + 3.9 24.6 + 4.3 21.0 + 2.9*
2.9 + 0.78 2.87 + 0.77 2.87+ 0.83
66.0 + 16.5 65.9 + 14.4 66.6 + 17.7
1.0 + 0.3 0.9 + 0.2 1.1+0.4
32.6 + 11.7 28.0 + 6.1 35.6 + 13.6
36.3 + 9.4 31.9 + 5.7 39.3 + 10.4
48.9 + 12.6 43.1 ±7.9 52.7 + 13.9
6.5 + 1.5 6.8 + 0.7 6.2+ 1.7
186.4 + 31.5 189.1 ±24.1 179.1+34.5
5.6 + 1.1 5.7+ 0.7 5.4 + 1.3
239.5 + 48.9 241.2 + 35.5 227.9 + 49.8
8.6+ 1.4 8.6+ 0.9 8.2+ 1.5
125.7 + 15.5 126.7 + 12.2 123.9 + 16.6
66.0 + 7.2 66.0 + 6.0 65.0 + 9.1
188.3 + 15.9 184.3 + 18.2 194.6 + 20.5
3.0 + 0.7 3.0+ 0.7 3.0 + 0.9
68.4 + 12.1 68.2 + 11.1 69.8 + 15.1
1.9 + 0.4 1.8 + 0.5 2.03 + 0.3
61.0+12.3 56.6+ 14.3 64.3+ 9.9
Data are presented as mean± sd, unless otherwise stated. P+: subjects
showing lower ribcage inspiratory paradox at rest; P-: subjects without paradox;
BMI: body mass index; FVC: forced vital capacity; % pred: % predicted; FEVi:
forced expiratory volume in one second; TGV: total gas volume; RV: residual
volume; TLC: total lung capacity; SVC: slow vital capacity; IC: inspiratory
capacity. *: p<0.05 for comparison of P+ with P-.
least two standard deviations above the mean value for the
normal subjects (99% confidence interval) gave a threshold for
the upper limit of normal of 14.0 degrees for phase angle and
20.3% for the IP. When three different breaths were chosen and
the analysis repeated, similar values were obtained and no
individual would have been classified as showing ribcage
paradox, even if only one criterion were used (see online
supplementary material).
Among the COPD patients, eight subjects met both criteria for
paradox (P+) while the remaining 12 did not (P-). Of these,
seven subjects showed no evidence of paradox by either
criteria, four showed only an abnormal phase angle and one an
increased IP (fig. 3a).
Both indices of paradoxical lower ribcage movement lay close
to the upper limit of normal in the P- subjects but were clearly
separate from those in the P+ subjects at rest (p<0.001; fig. 4).
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FIGURE 3. a) Relationship between phase of upper versus lower ribcage (0)
and inspiratory paradox time (IP) of the lower ribcage. b) Relationship between
hysteresivity of upper versus lower ribcage (g) and IP of the lower ribcage. 0:
chronic obstructive pulmonary disease patients; O: control subjects. •••■: thres¬
holds as defined as two standard deviations beyond the mean values observed in
healthy subjects at rest, a) Thresholds 0=14.0° and IP=20.3%, b) thresholds
g=0.061 and IP=20.3%.
phase angle in the COPD patient data was good. No patient
would have been reclassified had different breaths been
chosen. Likewise, no difference was seen among the replicate
data on three different occasions both at rest and during
exercise (see online supplementary material).
When Tj was plotted instead of phase angle against IP to
investigate ribcage paradox (fig. 3b), among the COPD
patients, nine subjects showed values of both IP and r) above
threshold. Of these, eight subjects were previously classified as
P+, and the remaining subject was the one with above-
threshold IP and below-threshold 0.
Tidal expiratory flow limitation
Among the P+ patients, all showed clear evidence of expiratory
flow limitation at rest using the flow-volume criteria (as
aforementioned). Among the P- patients, nine out of the 12
were flow limited and three of these flow-limited patients had
a value of phase angle above the threshold (see online
supplementary fig. E4).
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QB UL Wmax/2 Wmax
FIGURE 4. Mean±SE of a) phase shifts and b) inspiratory paradox times (IP)
during exercise between upper (pulmonary) ribcage and lower (abdominal) ribcage.
•: chronic obstructive pulmonary disease (COPD) subjects showing lower ribcage
inspiratory paradox at rest (P+); O: COPD subjects without paradox (P-); A: control
subjects. QB: quiet breathing; UL: unloaded exercise; Wmax: maximum workload
exercise. *: p<0.05 for comparison of P+ with control; **: p<0.01 for comparison
of P+ with P-; ***: p<0.001 for comparison of P+ with P-; *: p<0.001 for
comparison of P+ with control.
Paradoxical ribcage movement during exercise
The time-courses of the phase angle and IP during unloaded,
half-maximal and maximal exercise are shown in fig. 4. At rest,
the P+ group showed, by definition, higher mean phase angle
and IP than the P- group. During exercise, the phase angle did
not change significantly in the control and the P- groups, but in
the P+ group the phase angle fell at maximal exercise so that
there was no longer any significant difference between tire P+
and the P- groups. The IP patterns, like the phase angle, were
similar throughout for the control and P- groups but, unlike
the phase angle, increased substantially during exercise,
approaching the levels of the P+ group.
Spirometry, lung volumes and exercise performance in
COPD
Tire presence of ribcage paradox was not associated with
statistically significant differences in spirometry or any
measurement of resting lung volume when compared with
patients who did not show this finding. There were no
significant differences in themaximum workload, peak oxygen
consumption achieved, maximum minute ventilation or
breathing pattern between the two groups of COPD patients
(table 2).
Chest wall volumes during incremental exercise
None of the control subjects showed evidence of an increased
end-expiratory total chest wall volume (EEVcw) at end-exercise
relative to their baseline values and all showed an early fall in
EEVcw as exercise began (fig. 5). In contrast, P+ subjects
showed an early increase in EEVcw (fig. 6a) and this was
maintained up to the maximum workload, exceeding the
values of the spontaneous breathing by a mean of 328 mL. In
contrast, P- subjects maintained an EEVcw similar to the
baseline value up to ~50% of maximum workload. EEVcw
slowly rose thereafter, showing a late hyperinflation of 297 mL
at end-exercise, a value similar to that of the P+ subjects (when
volumes were expressed as change from baseline as in
figure 6) but statistically different from the healthy volunteers
(p<0.001). These findings were similar when data where
expressed using minute ventilation either as a percentage of
the maximum or as an absolute value (fig. 6b).
The time-course of the end-expiratory and end-inspiratory
regional chest wall volumes differed significantly between the
healthy subjects and the two COPD groups (fig. 7). In P+, RCp
end-expiratory volumes rose immediately after the onset of
exercise, while this volume increased to a lesser degree in P-
and controls (p<0.001). End-expiratory volumes of RCa
increased during exercise in a similar way in P+ and P-
groups, while in healthy subjects they remained constant up to
~60% of the maximum workload and then increased on
average by 316 mL at end-exercise. In healthy subjects, the Vab
at end-expiration fell significantly throughout the exercise,
while at end-exercise the two COPD groups reached values
identical on average to those measured during QB.
Symptoms and self-paced exercise
Data for the symptom intensity of dyspnoea and leg effort for
both incremental and self-paced exercise and total distance
walked for both P+ and P- patients are presented in table 2,
while the symptoms at rest, the mid-point of exercise testing
and end-exercise are shown in figure 8. The intensity of
dyspnoea reported at end-exercise was similar in the two
groups with both types of exercise. However, the symptom
intensity of leg effort was significantly less in P+ patients
during incremental exercise (p<0.01), with a similar trend in
the self-paced walk test (p<0.05). The difference between
dyspnoea and sense of leg effort severity was statistically
significant in both types of test (p<0.01). Oxygen saturation
and HR data did not show significant differences between P+
and P- groups for either corridor walking or cycling test.
DISCUSSION
Although the movement of the ribcage during the respiratory
cycle normally tracks the change in lung volume, this is not
always the case in patients with obstructive lung disease, as
has been recognised by clinicians for many years [5, 6].
Magnetometer studies have identified different patterns of
behaviour in the upper and lower ribcage [2, 7, 8] but the
present data are the first to provide a quantitative three-
dimensional assessment of the effect of lower ribcage paradox
on chest wall volumes, ventilatory pattern and symptoms at
rest and during exercise. It was observed that COPD patients
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Resting and end-exercise ventilatory pattern and metabolic and cardiac variables
Control COPD
All P+ P-
Rest Peak exercise Rest Peak exercise Rest Peak exercise Rest Peak exercise
Subjects n 10 20 8 12
fn breaths min"1 16 + 4 28 + 5 21+4 31+8 22+ 3 31+7 20+ 5 30 + 9
Vt l 0.67 + 0.12 2.45 + 0.58 0.86 + 0.26 1.42 + 0.36 0.80 + 0.16 1.42 + 0.29 0.89 + 0.30 1.41 ±0.41
V'e L-min"1 11.4 + 2.7 67.40 + 17.20 16.34+ 3.59 40.54 + 8.92 16.65 + 3.25 42.00 + 9.38 16.13+ 3.92 39.58 + 8.89
fi s 1.50 + 0.26 1.04 + 0.19 1.07+ 0.29 0.87+ 0.38 1.03 + 0.27 0.79 + 0.29 1.11+0.32 0.94 + 0.45
Duty cycle % 39.6 + 6.0 46.2 + 2.5 35.6 + 5.4 39.8 + 5.8 34.7 + 5.6 39.4 + 5.3 36.1+5.6 40.1+6.5
V'o2 L min"1 0.33 + 0.10 1.75 + 0.42 0.32 + 0.06 0.78 + 0.19 0.34 + 0.0 0.75 + 0.18 0.31 ±0.07 0.80 + 0.20
V'o2 mLkg"1min"1 4.45 + 1.57 22.73 + 5.02 4.56+1.31 11.08+ 3.16 4.69 + 1.29 10.37 + 2.59 4.48 + 1.37 11.55 + 3.52
V'co2 Lmin"1 0.27 + 0.07 2.19 + 0.59 0.28 + 0.06 0.77+ 0.19 0.30+ 0.05 0.74 + 0.18 0.27 + 0.06 0.78 + 0.21
RER 0.83 + 0.11 1.25 + 0.11 0.87 + 0.07 0.98 + 0.10 0.89+ 0.05 0.99 + 0.10 0.86 + 0.08 0.97 + 0.11
Pet,co2 mmHg 35.5 + 4.3 39.5 + 4.7 29.9 + 5.0 33.3 + 5.9 30.7+ 7.1 35.6+ 7.5 27.6 + 3.3 31.6 + 4.1
Sa,o2 % 97+ 4 96 + 3 93 + 3 93 + 2 95 + 1 93 + 1 92+ 3 92 + 2
Heart rate beatsmin"1 89 + 19 120 + 12 93 + 14 122 + 17 94 + 10 121+4 93+ 20 124+ 18
Dyspnoea 0 + 0.0 4.4 + 3.8 0.7 + 0.2 4.0+ 1.1 0.9 + 0.9 3.9 + 0.8 0.7+ 0.7 4.1+1.2
Sense of leg effort 0+ 0.0 5 + 3.6 0.5 + 0.2 4.3 + 1.6 0.5+ 0.9 3.7 + 1.6 0.5+ 0.77 4.7+ 1.4**
Predominant 0 + 0.0 -0.6 + 0.6 .0.2+ 0.1 -0.3 + 0.2 0.4 + 0.7 0.3 + 1.2 0.2 + 0.4 -0.7+ 0.7**
symptom*
Maximum workload W 153±35 43 + 19 42 + 20 44 + 19
6-min walking 291 + 12 290+93 291+63
distance m
Data are expressed as mean±so. COPD: chronic obstructive pulmonary disease; P+: subjects showing lower ribcage inspiratory paradox at rest; P-: subjects without
paradox; ft: respiratory frequency; Vr: tidal volume; V'e: minute ventilation; fi: inspiratory time; V'o2: oxygen consumption; V'co2: carbon dioxide production; RER:
respiratory exchange ratio; Pet,co2: end-tidal carbon dioxide tension; Sa,o2: arterial oxygen saturation. #: dyspnoea minus leg effort. **: p<0.01 for comparison of P+ with
P-. 1 mmHg=0.133 kPa.
Workload W
FIGURE 5. Mean±se end-expiratory (EE) and end-inspiratory (El) total chest
wall volume variations during exercise, expressed as percentage of the chest wall
volume at total lung capacity (TLC), in chronic obstructive pulmonary disease
(COPD) patients and control subjects. • : COPD subjects showing lower ribcage
inspiratory paradox at rest (P+), El; H: COPD subjects without paradox (P-), El; O:
P+, EE; □: P-, EE; A: control subjects, El; A: control subjects, EE. QB: quiet
breathing; UL: unloaded exercise. ***: p<0.001 for comparison of P+ with P-
(overall data).
with paradox increased their EEVcw as soon as exercise began,
while those without lower ribcage paradox only hyperinflated
their chest wall towards the end of incremental exercise. These
changes were reflected in the symptoms reported during
exercise, with dyspnoea being the major complaint when
paradox was present, irrespective of whether the exercise was
incremental or self-paced. This suggests that different patterns
in the timing of EEVcw change [12] relate to patient symptoms
and can be reliably predicted by ribcage movement assessed
under resting conditions.
In the present study, paradoxical ribcage movement was
defined by quantifying the asynchrony between the two
ribcage regions during inspiration. Tire current authors
followed the model proposed by Ward et al. [20] and used
by others reporting data with OEP [1,4], in which the ribcage is
considered as formed by two subcompartments, i.e. the part
that is apposed to the lung, the RCp, and the part apposed to
the diaphragm, the RCa. Tire boundary between the RCp and
the RCa was defined by a surface identified by a set of markers
placed at the level of the xiphisternum (fig. 1), which does not
change with diaphragm movement. Thus, in COPD patients,
the VRCa may not precisely correspond to the true area of
apposition but is best considered as representing the lower
ribcage where the muscles inserted and acting in that area
differ from those influencing upper ribcage volume.
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FIGURE 6. Mean+sE end-expiratory (EE) and end-inspiratory (El) total chest
wall volume variations during exercise, expressed as chest wall volume variations at
functional residual capacity during quiet breathing (QB) in the chronic obstructive
pulmonary disease (COPD) patients as a function of a) workload and b) minute
ventilation. A: COPD subjects showing lower ribcage inspiratory paradox at rest
(P+), El; A; COPD subjects without paradox (P-), El; 9: P+, EE; O: P-, EE. UL:
unloaded exercise. *: p<0.05 for comparison of P+ with P- (at same level of
exercise); **: p<0.01 for comparison of P+ with P- (at same level of exercise); ***:
p<0.001 for comparison of P+ with P- (overall data).
While previous studies have used changes in the lateral and
antero-posterior dimensions of the ribcage to do this [7, 8], the
present approach was based on the analysis of volume
variation, obtained by integrating the three-dimensional
motion of multiple surface markers. Thus, the current data
are not strictly comparable with those obtained by two-
dimensional analysis of lower ribcage movement alone, and
they provide a description of normal or paradoxical inspira¬
tory motion that includes and integrates changes of dimen¬
sions in multiple directions. A conservative definition of
paradox based on the relative movement of the upper and
lower ribcage regions was used, which was only considered to
be significant when there were changes beyond the normal
range in both the percentage of inspiratory time where
paradox was seen and in the phase angle shift. The latter
index provided a measure of the degree of chest wall distortion
while the former indicated how much of the inspiratory period
was affected. It was possible to classify individuals in a binary
fashion, although the variables themselves are likely to
represent a continuous spectrum of severity as can be seen in
figure 3 and supplementary table El. Each of these measure¬
ments proved relatively reproducible in both healthy subjects
and those with COPD when different breaths were ensemble-
averaged to generate the data. Moreover, differences in
individual operators positioning the markers on different days
did not influence the results, nor did the classification of
resting paradoxical ribcage movement change if different
breaths were used to define it.
When a different index like the hysteresivity of the VRCp-VRCa
loop was considered instead of the phase shift angle, the
classification did not change substantially. Only one patient
who previously showed an increased percentage inspiratory
paradox without an apparently abnormal phase angle shift
would have been reclassified as belonging to the P+ group.
Interestingly, this patient showed relatively early onset of chest
wall hyperinflation during exercise.
The present data were primarily observational rather than
mechanistic. Like the investigators who identified Hoover's
sign clinically [9,21], the current authors found no relationship
between the presence of lower ribcage paradox and resting
lung function. The only significant differences found between
P+ and P- groups were for weight and body mass index,
suggesting that paradox may be commoner as weight
increases. This needs to be confirmed in a larger population
of patients. However, a selective activation of different
respiratory muscle groups might explain the relationship
between the presence of ribcage paradox at rest and the
increased end-expiratory VRCp at the onset of exercise in the P+
subjects. These patients may exhibit an increase in ribcage and
related accessory muscle tonic activation. More detailed
studies to understand the basis of resting paradox defined as
in the present study are now underway. Future experiments
are needed in order to correlate paradoxical movement of the
lower ribcage to diaphragm shape and length of the area of
apposition, as recently proposed by preliminary studies based
on ultrasound [2,22, 23] and magnetic resonance [24] imaging.
Exercise modified the different components of paradox in
different ways. In controls and P- COPD subjects, the phase
angle was unchanged by exercise, while in P+ patients it only
decreased at maximum workload, but even then did not reach
the values seen in the healthy subjects and P- COPD patients.
This result may reflect the increasing volume, and therefore
decreasing compliance, of the RCp as hyperinflation develops,
with a concomitant increase in the mechanical linkage between
the two ribcage portions, hi contrast, in the control and P-
subjects, the percentage of inspiratory paradox time tended to
increase at the onset of exercise and to remain constant
thereafter, approaching levels similar to those seen in the P+
group. This result may be attributed to the insertional action of
the expiratory abdominal muscles on the lower ribcage [1, 4],
even though end-expiratory Vab decreased substantially only
at the onset and during exercise in the healthy subjects (fig. 7).
All the P+ patients showed an early increase of EEVcw. This was
mainly due to the increase of the VRCp, presumably to cope with
the expiratory action of the lower ribcage, which was not seen in
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FIGURE 7. Mean±SEend-inspiratory (a, b, e, f, i and j) and end-expiratory (c, d, g, h, kand I) volume variations of the upper ribcage (VRCp; a-d), lower ribcage (VRCa; e~
h) and abdomen (Vab; i-l) during exercise in the chronic obstructive pulmonary disease (COPD; a, c, e, g, i and k) and control groups (b, d, f, h, j and I). All volumes refer to the
corresponding values at functional residual capacity during quiet breathing (QB). ©: COPD subjects showing lower ribcage inspiratory paradox at rest (P+); O: COPD
subjects without paradox (P-); A: control subjects. UL: unloaded exercise. *: p<0.05 for comparison of P+ with P- (at same level of exercise); **: p<0.01 for comparison of
P+ with P- (at same level of exercise); ***: p<0.001 for comparison of P+ with P- (overall data); #: p<0.05 for comparison of P+ with P- (overall data).
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FIGURE 8. a and b) Dyspnoea, c and d) leg effort and e and f) difference between the two symptoms (dyspnoea minus leg effort) during the 6-min walking test (a, c and
e) and exercise (b, d and f). Data are presented as mean+se. f1: chronic obstructive pulmonary disease (COPD) subjects showing lower ribcage inspiratory paradox at rest
(P+); □: COPD subjects without paradox (P-). Wmax: maximum workload exercise. *: p<0.05 for comparison of P+ with P- (at same level of exercise); **: p<0.01 for
comparison of P+ with P- (at same level of exercise);
p<0.001 for comparison of P+ with P- (overall data).
: p<0.05 for comparison of P+ with P- (overall data); : p<0.01 for comparison of P+ with P- (overall data); !
the P- patients. The early onset of chest wall hyperinflation in P+
patients was unexpected and was not related to the duration of
exercise or the severity of airflow obstruction or baseline
pulmonary hyperinflation. Retrospective classification of the
presence of tidal expiratory flow-limitation showed that all the
eight P+ patients were flow-limited compared with nine out of
the 12 P- patients. None of the P- patients exhibited chest wall
hyperinflation at the onset of exercise. These results suggest that
paradoxical motion rather than the presence of tidal expiratory
flow-limitation determines early chest wall hyperinflation.
Breathlessness and sense of leg effort increased during exercise
in patients with and without ribcage paradox, although the
relative importance of each symptom differed. At the end of
cycle exercise, end-inspiratory Pew, which is not influenced by
gas compression and blood shift effects, approached the critical
inspiratory reserve volume associated with neuromechanical
dissociation [25] in both groups. However, the P+ patients
were less likely to report severe sense of leg effort than the P-
patients, with breathlessness being their principal complaint at
the end of exercise. This is in keeping with previous reports of
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symptom limitation in severe COPD [26], and the predomi¬
nance of effort in P- subjects was replicated during the self-
paced corridor testing. These differences were not related to
degree of oxygen desaturation, peak workload or exercise
duration. The early onset of dynamic hyperinflation of the
chest wall is the most likely explanation for the predominance
of dyspnoea in P+ patients. In P- patients other factors, such as
the onset of peripheral muscle fatigue that limits exercise in
some COPD patients, may have been more important [27],
The present study was designed to identify reliable objective
criteria for the presence of paradoxical lower ribcage movement
and test whether these could be used to predict physiological
differences during exercise in stable hyperinflated COPD
patients. Although the criteria resemble the subjective ones
described by Hoover [6], the current patients were not selected
on the basis of a clinical diagnosis of Hoover's sign and this was
not recorded, to avoid the risk of biasing the results. Other
studies have examined resting lower ribcage movement using
the OEP method in patients clinically defined as having
Hoover's sign, and have reported that Hoover's sign did not
correlate with the level of hyperinflation and, therefore, ribcage
distortion and hyperinflation appear to be independent factors
limiting ventilatory function in stable COPD patients [21].
In conclusion, the present study has shown that abnormal
lower ribcage movement is not just a clinical curiosity but that
it identifies important physiological differences in the chest
wall volumes during exercise and these translate into different
patterns of reported symptoms. The early onset of hyperinfla¬
tion in those with paradox helps to explain why differences
seen in incremental exercise are still present during lower-
intensity self-paced exercise, which relates to the daily activity
undertaken by chronic obstructive pulmonary disease patients.
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ABSTRACT: Exacerbations of chronic obstructive pulmonary disease (COPD) are
associated with worse health and increased healthcare utilisation. The Inhaled Steroids
in Obstructive Lung Disease in Europe (ISOLDE) study in COPD showed a 26%
reduction in the yearly rate of exacerbations in patients treated with fluticasone
propionate (FP) compared to placebo, but did not indicate which patients showed
greatest benefit.
In this study the patients were stratified into mild and moderate-to-severe COPD
using the American Thoracic Society criterion of forced expiratory volume in one
second (FEVl) 50% predicted, and the total number of exacerbations and those
requiring treatment with oral corticosteroids were examined.
There were 391 (195 FP) patients with mild COPD and 359 (180 FP) patients with
moderate-to-severe disease. The exacerbation rate was highly skewed in mild disease,
but more normally distributed in moderate-to-severe disease. FP reduced the overall
exacerbation rate in moderate-to-severe disease (FP median rate 1.47 yr"1, placebo
1.75 yr"1), but not in mild disease (FP 0.67 yr' , placebo 0.92 yr"1). FP use was
associated with fewer patients with ^1 exacerbation-yr"1 being treated with oral
corticosteroids (mild: FP 8%, placebo 16%; moderate-to-severe: FP 17%, placebo 30%).
Effects of fluticasone propionate on exacerbations were seen predominantly in
patients with a postbronchodilator forced expiratory volume in one second <50%
predicted. These data support recommendations in the Global Initiative for Chronic
Obstructive Disease treatment guidelines that inhaled corticosteroids should be
considered in patients with moderate-to-severe chronic obstructive pulmonary disease
who experience recurrent exacerbations.
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Exacerbations in chronic obstructive pulmonary
disease (COPD) are common and associated with sig¬
nificant impairment of health status [1]. Hospitalisation
is relatively frequent [2]. The total cost of treating
exacerbations of COPD in the USA has been reported
to be US$ 1.2 billion, with inpatient and outpatient care
accounting for US$ 32 million and US$ 452 million,
respectively [3],
International guidelines recommend broncho-
dilators as first-line treatment for COPD symptom
control [4-6], since there no evidence to suggest that
such agents slow the progression of the disease [7].
Studies with inhaled corticosteroids have failed to
show a reduction in rate of decline in forced expira¬
tory volume in one second (FEVl) in COPD [8-13].
By contrast, there is evidence to suggest that these
agents may reduce the rate and severity of COPD
exacerbations defined clinically and by the use of
additional treatment [8, 11],
The recent Inhaled Steroids in Obstructive Lung
Disease in Europe (ISOLDE) study, investigated the
effect of inhaled fluticasone propionate (FP) 500 pg
twice daily for 3 yrs on the rate of decline of FEVl
and other clinical outcomes [12]. FP treated patients
had a significantly greater postbronchodilator FEVl
than placebo throughout the trial, although the rate of
decline in FEVl was not altered. FP did reduce the
median yearly exacerbation rate by 25% and signi¬
ficantly reduced the rate of deterioration in health
status. The initial report presented the intention-to-
treat analysis of these data, but did not consider whe¬
ther all patients showed similar treatment benefits. In
this study a post hoc analysis to determine whether
existing criteria for disease severity identifies patients
with a different probability of exacerbating and whe¬
ther the effect of inhaled corticosteroids on acute exacer¬
bations is influenced by disease severity are reported.
Methods
Full details of the study methodology, patient selec¬
tion, efficacy assessments and statistical analyses have
been published previously [12],
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Patients
In brief, the study enrolled current or former smo¬
kers aged 40-75 yrs with nonasthmatic COPD. Patients
were excluded due to the following: they had ever
received a diagnosis of asthma, FEVl improved by
>10% predicted normal following 400 pg inhaled
salbutamol, the postbronchodilator FEVl was <0.8 L
at study entry or they had clinically significant con¬
current medical conditions or a condition likely to
reduce life expectancy to <5 yrs.
Study design
The study used a randomised, double-blind, placebo-
controlled, parallel-group design. It was conducted in
18 hospitals in the UK. All patients provided written
informed consent and the protocol was approved by
each local research ethics committee.
Patients using inhaled corticosteroids discontinued
them and all entered an 8 week-run-in period to ensure
clinical stability and establish the baseline pre- and
postbronchodilator spirometry. After this, patients
were asked to participate in a 2-week trial of oral
corticosteroids (0.6 mg'kg~1-day~1). The majority did
so (85%), but those who did not proceeded directly
into the randomised study. Classification of patient
severity was made using FEVl measurements obtained
before any corticosteroid was given.
Patients were withdrawn from the study if con¬
tinuance was considered detrimental to the patient or
if they required more than two short courses of oral
corticosteroids in any 3-month period or maintenance
oral or inhaled corticosteroid treatment.
Treatment
At the end of the run-in period, patients were ran¬
domised to receive FP 500 pg twice daily via metered-
dose inhaler and Volumatic™ (GlaxoSmithKline,
Greenford, UK) spacer device or an identical placebo.
Randomisation was carried out centrally using a com¬
puter program and treatment allocation codes were
not available to the trialists. Other medication was
continued throughout the study and was equally
distributed in terms of dose of drug and frequency
of use between the treatment groups.
Efficacy
The principal outcome in this analysis was the
number of exacerbations per year. An exacerbation
was defined as "chest problems requiring treatment
with antibiotics and/or oral corticosteroids". It had
been anticipated that, in this 3-yr study the great
majority of exacerbations would be treated by pri¬
mary care physicians and it was judged to be impos¬
sible to set criteria for the diagnosis of an exacerbation
to be used by several hundred primary care physicians.
Exacerbations were recorded by patient self-report at
3-monthly intervals. Treatment of each exacerbation
was recorded, specifically whether the attending
doctor prescribed antibiotics, oral corticosteroids or
both. The physician treating these episodeswas unaware
of the trial treatment the patient was receiving.
Statistical analysis
The results were analysed first in the intention-to-
treat (ITT) population (defined as all patients who
were randomised to treatment and who received at
least one dose of study medication), then in two sub¬
groups, categorised on the basis of the American
Thoracic Society criteria for severity [4] as follows:
mild (postbronchodilator FEVl >50% pred) and
moderate-to-severe (postbronchodilator FEVl <50%
pred).
The exacerbation rate for each patient was calcu¬
lated as the number of exacerbations experienced per
year. If a patient withdrew during the study, the exa¬
cerbation rate was calculated by dividing the number
of exacerbations experienced during the treatment
period by the time spent on treatment. Exacerbations
were analysed as follows: 1) all exacerbations regard¬
less of how treated; or 2) exacerbations treated with
oral steroids, either alone or in combination with
antibiotics. The difference between treatments was
tested using the van Elteren extension to the nonpara-
metric Wilcoxon Mann-Whitney rank-sum test [14].
Study centre was used as a stratifying variable in the
analysis. Confidence intervals (CI) for treatment
differences were calculated by pooling all the treat¬
ment differences using the Hodges-Lehman method
[15]. Stratification by study centre was not considered
in this calculation.
The effect of treatment on the proportion of
patients experiencing one or more exacerbations in
each year of the study (cumulative) was tested using
Fisher's exact test [16], The relationship between treat¬
ment and time to onset of the first exacerbation was
analysed using survival analysis techniques and the
log-rank test (5% significance level). The time to the
first exacerbation was also modelled using Cox's
proportional hazards model [17]. The covariates
considered for inclusion in the model were age,
smoking status, sex, study centre and baseline FEVl.




A total of 751 patients were randomised to treat¬
ment, 376 to FP and 375 to placebo.
Both treatment groups were well matched at base¬
line [12]. The baseline and demographic data were
similar for patients with mild and moderate-to-severe
COPD (table 1). There were small differences between
the two subgroups, with significantly more males than
females with mild rather than moderate-to-severe
disease (85 versus 65%, p<0.0001). The number of
pack-yrs smoked was higher in the moderate-to-severe
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Placebo FP Placebo FP
Subjects n 195 196 179 180
Age yrs 64+7 64+6 63+8 63+8
Male % 81 86 66 63
Smoking history
Pack-yrs 48+36 47+30 39+31 42+30
Current smokers % 38 32 41 41
Exsmokers % 48 51 44 43
Intermittent % 14 17 16 16
Atopy# % 14 13 11 14
FEVi11 L 1.0+0.2 1.0+0.3 1.6+0.5 1.6+0.5
FEVi % pred 39+8 39+8 62+10 62+10
% FEVi reversibility4" 4.1+3.4 4.2+3.4 4.8+3.4 4.6+3.6
Data are presented as mean±SD; FEVi: forced expiratory
volume in one second; FP: fluticasone propionate; % pred:
% predicted; #: atopy defined as positive skin-prick test to
one or more common allergens;11: prebronchodilator FEVi;
+: change in FEVi after bronchodilator expressed as % pred.
There were no significant differences (p>0.05) between the
treatment groups, within each severity category, for any
variable. Except for proportionally more females in the mild
compared to the moderate-to-severe group (p<0.001) and
more pack-yrs smoked in the moderate-severe group.
group than in the mild group (47 versus 41, p<0.01),
but the proportion of continued, mixed and exsmokers
was the same in the two groups (p>0.05).
Onset offirst exacerbation
Kaplan-Meier analysis ofthe ITT population showed
no difference in the time to first exacerbation, p=0.34.
Using Cox's proportional hazards model for the time
of onset of the first exacerbation, the median time in
the placebo group was 136 days versus 164 days in the
FP group (95% CI 0.79-1.09, p=0.35).
Number of exacerbations and withdrawals
Analysis of the total number ofexacerbations showed
no significant difference between the two treatment
groups. During the first year of treatment, 227
patients in the FP group (61%) and 237 in the placebo
group (64%) had at least one exacerbation. Similarly,
290 (78%) and 286 (77%) patients, respectively, expe¬
rienced at least one exacerbation during the 3-yr study
period. During the study, 355 patients were with¬
drawn, 160 in the FP group and 195 in the placebo
group. The most common reason for withdrawal was
frequent exacerbations of COPD; 42 FP patients, 54
placebo patients. Placebo-treated patients were also
more likely to be withdrawn earlier than FP patients
[12]. As a result of the earlier and greater drop-out
rate, placebo patients spent less time in the study (758
patient-yrs) than those treated with FP (840 patient-yrs).
Frequency of exacerbations
The annualised rate of exacerbations ranged from 0
to ^8 yr"1. The distribution was highly skewed in the
mild patients, but more normally distributed in those
with moderate-to-severe disease. Over the 3-yr period,
29% of the mild patients had no exacerbations at all,
but this was seen in only 16% of those with moderate-
to-severe disease (fig. 1). The median exacerbation
rate in the combined treatment groups was signifi¬
cantly lower in the mild patients (0.93 yr"1) compared
to those with moderate-to-severe disease (1.64 yr"1),
p<0.0001.
In the ITT population, there were fewer exacerba¬
tions in the FP-treated group (0.99 exacerbations-yr"1)
compared with placebo (1.32 exacerbations-yr"1),
p=0.026. The significant effect of FP was confined to
the moderate-to-severe group: FP median 1.47 exacer¬
bations-yr"1; placebo 1.75 exacerbations-yr"1, p<0.022
(fig. 2). There was no statistically significant effect in
the mild group (FP median 0.67 exacerbations-yr"1;
placebo 0.92 exacerbations-yr"1, p=0.45). The frequency
of exacerbations in the two patient groups remained
unchanged throughout the 3 yrs of the study. In both
treatment groups, neither the median rate nor the'tail'
0 0-1 1-2 2-3 3-4 4-6 6-8 >8
Annualised rate of exacerbations
Fig. 1.-Frequency distribution for exacerbation rate per year in
patients with a) mild and b) moderate-to-severe chronic obstructive
pulmonary disease. In mild patients the distribution was highly
skewed whereas in moderate-to-severe disease the distribution was
more normally distributed.
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Moderate-to-severe
Disease severity
Fig. 2. -Bar chart of the median rate of exacerbations per year in
placebo (□) and fluticasone propionate (S) treated patients, split
by disease severity (American Thoracic Society criteria). The
Mann-Whitney rank-sum test was used to calculate p-values.
p=0.45;11: p=0.022.
of patients with high numbers of exacerbations pet-
year appeared to lessen.
Exacerbations treated with steroids
In patients with moderate-to-severe disease, 52%
had a corticosteroid-treated exacerbation compared to
30% of the mild group (Fisher's exact test p<0.0001).
The rate of these exacerbations was significantly lower
in FP-treated patients compared to placebo, p<0.001.
FP halved the number of patients having one or more
exacerbations per year in both patient groups (fig. 3).
Reversibility and exacerbations
To test for the presence of subgroups of patients









Fig. 3.-Bar chart of the percentage of patients having ^1
corticosteroid-treated exacerbation-yr"' in placebo (□) and flutica¬
sone propionate (S) treated patients, split by disease severity
(American Thoracic Society criteria). The Mann-Whitney rank-
sum test was used to calculate p-values. p=0.02;11: p=0.01.
post hoc analyses were carried out, dividing patients
into those with greater or less reversibility to
bronchodilator (median split cutting at 170 mL) and
those with greater or less response to prednisolone
(median split cutting at 50 mL). In none of these
subgroups was the effect of fluticasone statistically
significant (p>0.05 in each case).
Discussion
Reducing the number of exacerbations of COPD
is an important goal of treatment and has been
stressed in several treatment guidelines [4-6]. In
patients treated with FP, the rate of exacerbations was
reduced compared to the placebo-treated patients.
This effect was confined to patients with more severe
airflow limitation, since the difference between treat¬
ment groups was not statistically significant in the
milder patients. This could represent a genuine dif¬
ference in efficacy dependent on disease severity or
be a reflection of the smaller number of episodes
identified in mild disease and hence the risk of a Type
2 statistical error, since the proportional reduction
was the same. Support for the latter view comes from
the report of a beneficial effect of inhaled triamcino¬
lone on emergency physician contacts in the recent
large Lung Health Study II in patients with mild
COPD [13].
Not all exacerbations were treated with oral steroids.
Half of the patients with moderate-to-severe disease
received at least one course compared with less than
one third in those with mild disease. The reasons for
this are not clear from the current study, but it is
possible that doctors were more likely to prescribed
oral steroids in patients with worse airflow limitation
or those who appear to have more severe attacks. This
conclusion is supported by data from a large Spanish
community study in which prescription of oral cor¬
ticosteroids was strongly related to the intensity of
dyspnoea [18]. In both severity subgroups, FP halved
the number of patients who needed one or more
courses of oral corticosteroids in a year. In patients
with moderate-to-severe disease it reduced the pro¬
portion of patients requiring oral corticosteroids to
the level of thosewith mild disease treated with placebo.
The median exacerbation rate in the placebo-
treated patients in this study was lJ-patienf'-yr"1.
This is similar to that in a large series of patients
assessed for antibiotic treatment [19] and to the rate of
1.5-patient"'-yr"1 reported in COPD patients with a
similar disease severity in the UK [1], The similarity in
exacerbation rate between the latter study and the pre¬
sent study occurred despite two major differences
between the studies. First, there were differences in defi¬
nition of an exacerbation: increased cough and dys¬
pnoea for ^2 days used by Seemungal et al. [1] and
chest problems requiring treatment with antibiotics
and/or oral corticosteroids used in this study. Secondly,
in the current study details of exacerbations were
recorded retrospectively at 3-month intervals, whereas
Seemungal et al. [1] collected their exacerbation data
prospectively using diary cards. Furthermore, in the
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current study there was also the potential to lose the
effect of patients with the highest frequency of exacer¬
bations because of the study criterion, which required
withdrawal if three courses of oral steroids were
needed in any 3-month period. However, this effect
will have been small, since the tail of the frequency
distribution curve of exacerbations contained only 9%
of patients with an exacerbation rate >4 yr"1, even in
patients with moderate-to-severe COPD (fig. 1).
The frequency of exacerbations was significantly
higher in patients with moderate-to-severe as compared
to mild airflow limitation. Patients with mild disease
had, on average, <1 exacerbation-yr"1 whereas those
with moderate-to-severe disease had >1.5 exacerba-
tions-yr" . Although the frequency distribution of the
exacerbations was skewed towards relatively infrequent
acute episodes, a quarter ofmoderate-to-severe patients
still had >3 exacerbations-yr"1. At the other end of the
spectrum, during the entire 3-yr period, there were no
acute episodes recorded in 16% of the moderate-to-severe
patients who received placebo and 29% in those with
mild disease. These data support the thresholds, based
on FEVl, that are used in a number of treatment guide¬
lines to identify patients at risk of greatermorbidity [4].
The findings of the present study support earlier
data in which, compared with placebo, FP signifi¬
cantly reduced the incidence of severe exacerbations,
defined by the need for hospitalisation [8], however,
FP had no effect on the time to first exacerbation.
This may have been due in part to imprecision in the
capture of the time of the first exacerbation, which in
large measure depended on the patient's recall of the
event when questioned at their 3-monthly visit. The
total number of patients who experienced an exacer¬
bation was also not influenced by FP. One interpreta¬
tion of these observations is that the drug was having
an effect in patients who were prone to recurrent
exacerbations. This view is consistent with the finding
that the treatment effect was most evident in patients
with moderate-to-severe airflow limitation, who were
also the group that had more frequent exacerbations
and were more likely to be treated with courses of oral
steroids in addition to antibiotics.
The parallel-group design of these placebo-controlled
studies permits the conclusion that FP use was asso¬
ciated with a lower exacerbation frequency. The hypo¬
thesis that FP reduces exacerbation frequency can
only be tested directly in a study in which patients act
as their own controls and exacerbation frequency is
measured before and after the introduction of the treat¬
ment. Such a study would require a crossover design
and need either a very large number of patients or long
duration in each arm to ensure adequate power. It is
probably not practically possible to launch such a trial.
In conclusion, this analysis has shown that exacer¬
bations are more frequent in patients with moderate-
to-severe chronic obstructive pulmonary disease, a
quarter of whom may require treatment with anti¬
biotics and/or oral steroids three times in the course of
a year. Fluticasone propionate significantly reduced
both the rate of exacerbations in chronic obstructive
pulmonary disease and the number of exacerbations
treated with courses of oral corticosteroids. This effect
was most apparent in patients with moderate-to-severe
disease. Therefore, patients with moderate-to-severe
chronic obstructive pulmonary disease and a history
of recurrent exacerbations appear to be those most
likely to benefit from this therapy, as proposed in the
recent Global Initiative for Chronic Obstructive Lung
Disease management guidelines [20],
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Relationship between respiratory symptoms
and medical treatment in exacerbations of
COPD
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ABSTRACT: Exacerbations of chronic obstructive pulmonary disease (COPD) can be defined
symptomatically or by healthcare contacts, yet the relationship between these events is unknown.
Data were collected during a 1-yr study of the budesonide/formoterol combination in COPD
patients, where exacerbations, defined by increases in treatment, were compared with daily
records of respiratory symptoms, rescue medication use and peak expiratory flow (PEF).
The relationship between changes in these variables and the medical event was examined
using different modelling approaches. Data from the first exacerbation treated with oral
corticosteroids and/or antibiotics and/or hospitalisation (event based) were available in 468
patients.
Patients exacerbating were significantly more breathless and more likely to report cough than
healthy patients, but did not differ in baseline spirometry. Exacerbations defined by changes in
individual symptoms were only weakly related to event-based exacerbations; however, defined
with 63% of such events being predicted from symptom changes. Changes in rescue medication
use or PEF were poor predictors of event-based exacerbations. The mean peak change in
symptoms was closely related to the onset of therapy.
In conclusion, event-based exacerbations are a valid way of identifying acute symptom change
in a chronic obstructive pulmonary disease population. However, daily symptom monitoring is too
variable using the current diary cards to make individual management decisions.
KEYWORDS: Chronic obstructive pulmonary disease, concurrence, events, exacerbations,
symptoms
Chronic obstructive pulmonary disease(COPD) is a major cause of morbiditya d mortality, and is the only leading
cause of death that is increasing in prevalence [1].
Acute exacerbations of COPD contribute signifi¬
cantly to the individual's disease burden, and an
increased frequency of these episodes may hasten
disease progression and possibly accelerate rate
of decline in lung function [2^4], Acute exacer¬
bations are also associated with a poor prognosis,
with hospital mortality rate ranging from 3-10%
in severe patients [5, 6]. If intensive care unit
admission is required, the rate is substantially
higher, with >30% mortality in patients >65 yrs
of age [7],
To understand the causes and evaluate treatment
that could change the severity or frequency of
exacerbations, a robust and reproducible defini¬
tion of what constitutes an exacerbation is
required. Several approaches to defining an
exacerbation have been proposed and each has
its disadvantages [8]. Tire most commonly used,
and the one recognised most easily by patients
themselves, involves a sustained increase beyond
the normal variability in respiratory symptoms
(dyspnoea, cough, sputum volume and sputum
purulence) [9]. Other symptom-based definitions
have been developed, but none have been
validated in terms of their reliability and respon¬
siveness [2, 10-14], An alternative approach to
definition identifies episodes where symptoms
increase and there is a medical "event", e.g. a
change of therapy (antibiotics or oral corticoster¬
oids) or management (admission to hospital)
[15-19]. This practical definition avoids the
subjectivity of a change in symptoms and usually
requires the involvement of a medical profes¬
sional in the diagnostic process.
Although most clinicians assume that these
approaches are broadly comparable, there has
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not been any direct comparison of events defined using these
different approaches. The hypothesis presented here is that
there would be a consistent increase in one or more key
symptoms in the period around the time of any medical
consultation defined as being an exacerbation. This would
allow identification of discrete episodes that could form the
basis of an automated exacerbation-detection algorithm. These
concepts were tested by retrospectively analysing data
collected as part of a large clinical trial, where event-based
exacerbations were prospectively defined, and in which
patients had recorded daily symptom and peak expiratory
flow (PEF) data using a diary card approach validated in
bronchial asthma [20]. The primary analysis of this clinical trial
data has already been published [18].
METHODS
Study design and patients
The present study utilised data from a 12-month, randomised,
placebo-controlled, parallel-group study of 796 patients with
available data (patients experiencing at least one exacerbation)
in 11 countries (mean age 64 yrs, mean forced expiratory
volume in one second (FEVi) 0.99L, 36% predicted). Subjects
were randomly assigned to take two inhalations b.i.d. of the
following: 9 pg formoterol; 400 pg budesonide; budesonide/
formoterol combination in a dose of 320/9 pg respectively per
inhalation; or placebo [18]. The study included one enrollment
visit, one visit after a 2-week run-in period (visit two) and six
subsequent visits during the treatment period.
Diary cards were distributed at visits one to seven and collected
at visits two to eight. The diaries were carefully reviewed by
the investigator together with the patient. Comments judged by
the investigator to indicate an adverse event were noted in the
appropriate section of the clinical record form.
The diary cards included the following daily recordings: 1)
PEF morning and evening; 2) whether rescue medication was
taken during the 6 h prior to PEF measurement; 3) daytime
COPD symptom scores; 4) night-time awakenings due to
COPD symptoms; 5) intake of study medication morning and
evening; 6) intake of rescue medication and cough medicines
(anti-tussives) morning and evening; and 7) intake of oral
steroids, antibiotics, healthcare contacts and sick-leave related
to COPD symptoms.
A mini-Wright peak flow meter (Clement Clark, Harlow, UK)
and a diary card were dispensed at visit one. The patients were
carefully instructed in the use of the peak flow meter. All
measurements were to be made while standing. Rescue
medication (bricanyl turbuhaler 0.5 mg-dose"1) was not to be
taken for 6 h prior to PEF measurement. The patients were
instructed to perform three manoeuvres twice daily (morning
and evening), the highest value on each occasion being
recorded in the diary. The morning measurement was made
immediately upon rising before taking the study medication.
Similarly, the evening measurement was made before going to
bed and before the evening dose of study medication.
Definitions
Event-based exacerbations
Event-based exacerbations were defined as use of oral
corticosteroids and/or antibiotics and/or hospitalisation for a
worsening in the patient's respiratory symptoms at the
discretion of their usual physician. These events were captured
as severe exacerbations in the original study [18].
Symptom-based exacerbations
Symptom-based exacerbations were defined retrospectively in
a variety of ways (see below) using data recorded daily in
diary cards. Four symptoms (shortness of breath, cough, chest
tightness and night-time awakenings) were each assessed on a
scale of 0-4. The specific questions asked are listed in table 1.
In addition, patients recorded daily use of short-acting (32-
agonist (rescue medication) and morning and evening PEF
values. Diary cards were collected at each visit. Only diary
card data related to the first event-based exacerbation during
the 12-month follow-up are presented in the present study.
The day an event-based exacerbation was deemed to have
occurred (i.e. day 0) was defined as the day on which hospital
admission occurred or drug therapy was initiated, as identified
on the diary card and/or a specific supplementary medicine
record kept by the patient during the study and reviewed at the
regular review visits. The number of symptom-based exacerba¬
tions occurring within 7 days of an event-based exacerbation
was determined. Where overlap was seen, this was classified as
"concurrence" and considered to be the same event. The
maximum level of concurrence was, therefore, 100%.
Descriptive analysis
The event-based exacerbation defined in the clinical study was
used as the "gold standard". The relationship between the
change in symptoms, increased rescue medication use and per
cent predicted morning and evening PEF were compared with
the first event-based exacerbation that occurred. The definitions
used for change in symptoms are described below. Table 1
shows the percentage of days during the run-in phase where the
indicated score was recorded. For each, the average score for
each patient during run-inwas calculated and used as a variable.
This was an exploratory analysis in which statistical assess¬
ment of differences between groups was not appropriate, since
there was no n priori hypothesis to test between the different
classification systems.
Proposed classification systems
Simple symptom, rescue medication and PEF algorithm
Table 2 lists the analyses performed using a simple algorithm
based on symptoms, rescue medication use and change in
morning PEF. Further exploration by varying the time window
for the exacerbation (3, 5 and 7 consecutive days, respectively)
and time lag (28, 14 and 7 days before an event-based
exacerbation, respectively) was also investigated.
Combined symptom scores
The various combined symptom scores explored in these
analyses are also described in table 2. An arbitrary scale was
developed for use in clarifying external rules that would allow
definition of an exacerbation objectively or by automated
means.
Subdivision of patients with event-based exacerbations
In order to examine the relationship between event- and
symptom-based exacerbations, a number of exploratory
EUROPEAN RESPIRATORY JOURNAL VOLUME 26 NUMBER 3 407
DEFINITION OF COPD EXACERBATIONS P. CALVERLEY ET AL.
Baseline aqe and forced vital capacity in one second (FEVi) % predicted normal, and symptoms during run-in
Symptoms Patients with
exacerbation "
Patients with no p-values
exacerbation^
Age yrs 64.1 64.1
FEVi % pred 36.3 39.3
Shortness of breath scores
0 None: unaware of any difficulty 6.8 13.9 <0.001
1 Mild: noticeable during more strenuous activity, e.g. 25.5 29.3
morning exercises, walking more than one block or
up more than one flight without stopping
2 Moderate: noticeable during light activity, such as
making beds or taking out the garbage, walking one
block or up ono flight of stairs, running or jogging
41.7 37.6
3 Marked: noticeable when washing or dressing in the
morninq, after slowly walkinq less than one block or
up to one flight of stairs
21.0 16.7
4 Severe: almost constant, present even when resting 5.0 2.5
Cough scores
n Nl 1 1 .1 ll iQl 1 1 II IrlVVril e 1 if 1 .III IIjl III ly 22 7 26 4 <0 001
1 Rare: cough now and then 34.7 34.8
2 Occasional: less than hourly 27.3 26.2
3 Frequent: one or more times an hour 11.9 10.9
4 Almost constant: never free of cough or feeling free of
the need to cough
3.5 1.7
Chest tightness scores
0 None: unaware of any discomfort 34.7 39.7 0.055
1 Mild: noticeable now and then, but is not bothersome 29.4 31.7
and passes quickly, does not limit activity
2 Moderate: noticeable less than hourly, limits activity
and is aggravated or brought on by moderate activity
22.6 21.6
3 Marked: noticeable one or more times an hour, may be
accompanied by dyspnoea, limits activity and is
aggravated or brought on by normal activity, ouch ao
vvdlkii ly
10.9 10.5
4 Severe: almost constant, accompanied by dyspnoea,
present even when resting and limits all activity
1.7 2.8
Night-time awakening scores'
0 Slept through the night 44.7 44.4 0.57
1 Symptoms caused waking once or early awakening 23.9 26.2
2 Symptoms caused wakening twice or more during the
night (including waking early)
21.1 20.4
3 Symptoms caused wakefulness for most of the night 7.5 6.8
4 Symptoms so severe that patient did not sleep at all 2.7 2.2
Data presented as % unless otherwise stated. per cent of days during the run-in period in which the indicated score was recorded for patients with and without event-
UuogU gacigui baliui io, . dutJ lu i uopiicduiy iyi i lylui 116.
approaches were applied. Patients with event-based exacerba¬
tions were subdivided into different groups according to the
following. 1) Three groups were subdivided according to the
Global Initiative for chronic Obstructive Lung Disease (GOLD)
definitions of severity: moderate stage II, severe stage III and
very severe stage IV. 2) Three groups were subdivided on the
basis of treatment approach, i.e. those receiving antibiotics, oral
corticosteroids or hospitalisation. These groups included all
patients receiving each approach and, therefore, there was
some overlap between the groups.
Occurrence of symptoms, rescue medication and PEF in
exacerbation-free intervals
The median change in symptoms, rescue medication and
morning PEF from baseline to 2 days before an event-defined
exacerbation (day 2) was calculated for the exacerbating
(event-based) patients. This was compared on a daily basis
for all patients to determine what proportion of patients
exceeded the median values for each variable. The intention
was to determine whether patients with an event-defined
exacerbation also exhibited a change in symptoms, rescue
408 VOLUME 26 NUMBER 3 EUROPEAN RESPIRATORY JOURNAL




Simple algorithm Compare the symptom score each day with the If an increase in score of 3*1 is seen for
score 7 days prior to each day 3 consecutive days
Rescue medication use Increase in inhalation of rescue medication One, two or three inhalations more than the number
recorded 7 days earlier fnr 3 consecutive days
Change in PEF PEF measurement Drop of 10%, 15% or 20% in morning PEF
compared with the 7 days before for 3
consecutive days
Combined symptom scores
Combined algorithm Mean of the four symptoms for each day compare Increase in mean score of > 1.0 for 3
each days' moan with that obtained 7 days before conoocutivo dayc
Complex algorithm Mean of the four individual symptom scores, mean Increase in mean score of at least 0.5, 0.75 or 1.0
of last 3 days compared with same function 1 week earlier
Exceeding set mean symptom level Mean symptom value exceeds a set level for 3 Set level: 1.5, 2.0 or 2.5
consecutive days
Exceeding values from 2-week trial Mean symptom level exceeds run-in values for 3 Exceed mean symptom run-in scores by 0.25,
run-in period consecutive days 0.5 or 0.75
PEF: Peak expiratory flow.
values of symptom scores (minimum 0; maximum 4) at
baseline for these patients were as follows: 1) shortness of
breath 1.9; 2) cough 1.4; 3) chest tightness 1.2; and 4) night-time
awakenings 1.0. The remaining 328 patients had a mean age of
64.1 yrs and a mean FEVl % pred of 39.3. The mean symptom
scores at baseline were somewhat lower: 1.6,1.0,1.3 and 1.0 for
the four symptoms, respectively. Table 1 shows the age, FEVl
% pred and symptoms scores separated into two groups, one
experiencing at least one event-based exacerbation and the
other with no event-based exacerbation during the study
period. There was a statistically significant difference in the
symptoms, shortness of breath and cough between the groups
(both pcO.OOl).
Diary cards were well completed. The available number of
records (days with data) averaged 87.8% during the study
period (4 weeks after the day of exacerbation).
Population changes
The four individual symptom scores in the days preceding and
following the first event-based exacerbation are shown in
figure 2. The mean scores for the 468 patients clearly show a
similar pattern across all symptoms, increasing steadily in the
2 weeks prior to an exacerbation and returning to baseline
values ~2 weeks later. This pattern was seen irrespective of the
medication used to treat the exacerbation, with a similar
absolute change in symptom score for episodes treated with
antibiotics alone or with corticosteroids.
Rescue medication use in the days pre- and post-exacerbation
is shown in figure 3. Again, a change was noticed beginning
~2 weeks before an exacerbation, with increasing number of
inhalations, and then a slow return to baseline values.
Morning and evening PEF, expressed as a per cent of the
predicted values, in the days pre- and post-exacerbation are
shown in figure 4. As with the symptom scores, a clear change
medication use or morning PEF in the days prior to an event-
based exacerbation, thereby identifying any variable that was
potentially predictive for an event-based exacerbation.
RESULTS
Of the 796 patients randomised to receive treatment, 468
patients experienced at least one event-based exacerbation, as
defined by episodes requiring antibiotics and/or corticoster¬
oids and/or hospital admission (fig. 1). All patients were
classified in GOLD stages II-IV. The mean age of these patients
was 64.1 yrs and the mean FEVl % pred was 36.3. The mean
FIGURE 1. Event-based exacerbations. O: Antibiotics n=369; •: oral
steroids n=219; : hospitalisation n=25.
EUROPEAN RESPIRATORY JOURNAL VOLUME 26 NUMBER 3 409
DEFINITION OF COPD EXACERBATIONS P. CALVERLEY ET AL.
Day
FIGURE 2. Mean values of symptom scores around the first protocol-defined
exacerbation. •: shortness of breath; ■: cough; ♦: chest tightness; A: night-time
awakening; —: day 0, first day of exacerbations.
Day
FlftllRF 3 Mpviii w^li.iyv nf hiImUm nf ipvri.ip nipHirwlinn ■ leV'.'Ue 11iw.lii/vUii.n•
(day): •: rescue medication (night): —: day 0. first day of exacerbations.
Day
FIGURE 4. Morning peak expiratory flow (PEF) around the first exacerbation.
■ : PEF (evening); •: PEF (morning); —: day 0, first day of exacerbation.
in PEF is seen during the exacerbation, with PEF falling
steadily (decreases in morning PEF of 9.0% and evening PEF of
7.7% being recorded) in the 2-3 weeks before and returning to
baseline values after —1 week.
Individual changes: simple algorithm, rescue medication
and PEF
Simple symptom-based exacerbation calculations
The results of the analyses to identify concurrence between
changes in each of the four individual symptoms and event-
defined exacerbations are shown in table 3. For breathlessness,
660 out of 796 patients experienced a symptom-based exacer¬
bation, as defined by the simple criteria, and 411 of these 660
patients also experienced an event-based exacerbation.
However, only 206 of these 411 exacerbated within 7 days
before and after the symptom-based exacerbation occurred,
meaning that 44% of the event-based exacerbations were also
captured by a change in breathlessness. Assessment of the
other three symptoms showed a similar range of concurrence,
with the change in cough symptoms occurring in 51.7% of the
event-based exacerbations. For all symptoms, varying the time
window to 5 and 7 days, or time lag from baseline to 14 and 28
days, had no notable influence on the results.
Increased use of rescue medication
The lowest condition (an increase of one inhalation for 3
consecutive days) was recorded by almost all patients at some
time-point during the study (table 3). Approximately half of
these were within 7 days of an event-based exacerbation.
Restricting the criteria to two or three inhalations resulted in
fewer symptom-based exacerbations, but also in a considerably
lower percentage of concurrence.
Changes in morning PEF
Assessment of change in morning PEF % pred was only
weakly correlated with event-based exacerbations, with even
Results of analysis of single assessments




Breathlessness 660 411 206 (44.0)
Chest tightness 608 382 182 (38.9)
Cough 649 416 242 (51.7)
Night-time awakening 543 353 149 (31.8)
Any symptom 737 451 330 (70.5)
Increased inhalations
of rescue medication
1 672 424 239 (51.1)
2 469 314 130 (27.8)
3 246 183 65 (13.9)
Fall in morning PEF %
20 235 162 40 (8.6)
15 352 241 63 (13.5)
10 573 373 128 (27.4)
Data presented as n or n (%). PEF: peak expiratory flow.
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the smallest change (10%) resulting in only 27.4% concurrence
(table 3).
Individual changes: combined symptom scores
Combined algorithm
An arbitrary scale was developed for use in clarifying external
rules which would allow definition of an exacerbation
objectively or by automated means. The degree of concurrence
achieved with this score is shown in table 4, for both a 0.5 and
a 0.75 change in combined symptom score (as defined in
table 2). A large number of patients met the criteria defining a
change in symptom score of >0.5, but only 224 of these
occurred in the time frame considered to be the same event as
those described as event-based exacerbations. Increasing the
condition to a change in symptom score of 0.75 selected fewer
patients, but markedly reduced the degree of concurrence.
Complex symptom-based definition
This represents a moving average for 3 days compared with
the average 7 days earlier, the objective being to minimise
individual variation (as defined in table 2). A symptom-based
criteria of an increase in mean symptom score of 0.5 resulted in
almost 60% concurrence (table 4). Changing the criteria to an
increase of 0.75 or 1.0 resulted in fewer symptom-based
exacerbations and also a lower rate of concurrence.
Symptom mean exceeding a set value
Symptom-based events, defined as a mean symptom value
exceeding a 1.5, 2.0 or 2.5 increase for 3 consecutive days,
showed a relatively high degree of concurrence at the lower
levels (table 4). A symptom-based exacerbation, defined as an
increase of 1.5 for 3 days, was seen in almost all patients at










>0.50 639 408 224 (47.9)
>0.75 486 334 154 (32.9)
Increase In mean
symptom score of
>0.50 676 427 279 (59.6)
^ 0.75 539 303 I97 (42.1)
>1.0 387 277 141 (30.1)
Level
2.5 241 175 105 (22.4)
2.0 399 283 190 (40.6)
1.5 557 366 296 (63.3)
Increase over run-in
values
0.75 319 232 138 (29.5)
0.50 422 291 190 (40.1)
0.25 536 348 247 (52.8)
Data presented as n or n (%).
some point, 63.3% correlating with an event-based exacerba¬
tion. Similar results were seen when symptom-based exacer¬
bations were defined as an increase over the run-in period
(table 4).
Effect of COPD severity and therapeutic intervention
Patients with an event-based exacerbation were classified into
groups according to the GOLD definitions of severity (very
severe stage IV: n=158; severe stage III: n=246; and moderate
stage II: n=64) and the pattern of symptoms around the first
event-based exacerbation assessed. While the symptom mean
was seen to increase markedly in the 7-14 days preceding an
event-based exacerbation and decline gradually with resolu¬
tion, no difference in symptom curve was seen between the
three severity groups. Assessment of individual symptoms
showed a similar pattern, with only breathlessness separating
into three distinct peaks at the point of an event-based
exacerbation, with the very severe stage IV patients having
the highest degree of breathlessness and the moderate stage II
patients the lowest.
There was no significant difference in mean symptom scores if
the patients were divided according to treatment (formoterol,
budesonide, budesonide/formoterol combination or placebo).
Occurrence of symptoms, rescue medication and PEF in
exacerbation-free intervals
As shown in figure 5, an increase in symptoms 2 days prior to
an event-defined exacerbation was not seen to be predictive, as
a similar proportion of patients had increased levels without
resulting in an exacerbation. The same was evident for rescue
medication use and PEF levels.
DISCUSSION
Although few clinicians have difficulty in recognising a patient



























FIGURE 5. Mean percentage of days where symptoms, rescue medication
and peak expiratory flow (PEF) exceed the median value for patients with event-
based exacerbations 2 days before their first exacerbation. : no event-based
exacerbation; □: event-based exacerbation.
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definition has been surprisingly difficult and is limited by the
lack of studies where different approaches to defining an
exacerbation have been compared. The present data, relating
event-based episodes to changes in symptom intensity, are the
first where such a comparison has been possible. Although, on
average, symptom intensity peaked around the time therapy
was initiated and declined thereafter. Individual symptom-
based episodes showed only limited agreement with episodes
when the patient sought medical help. Combining the selected
symptoms worsened rather than improved the degree of
agreement between definitions.
There may be several reasons for this surprising finding. The
patients might not have completed their diary cards around
the time of an exacerbation (or have reported only one
symptom of note). This was not the case as judged by the
surprisingly good data completion in the weeks before and
after event-based episodes. Retrospective completion of data
cannot be excluded in some cases, but given the large number
of subjects in different centres it would be surprising if this
systematically biased the results.
The population studied was relatively severe, with an event-
based exacerbation rate of 1.8-yr"1 of those randomised to
placebo and 1.4-yr"1 in those receiving the budesonide/
formoterol combination, in keeping with this severity of
disease [21], All symptoms showed, on average, similar
changes around the time of the event-based episodes and rose
to a similar degree. An increase in the use of rescue therapy
paralleled these changes. The fall in PEF was 4.3% of predicted
normal over the course of the event-based episodes, and was
very similar to that seen when other symptom-based criteria
have been used [22]. However, it was significantly smaller than
the current authors' a priori threshold used to investigate the
value of this criterion. Failure of peak flow to be a reliable
pointer to exacerbations in COPD contrasts with the experience
in asthma [23] and reflects the importance of increases in lung
volumes during such episodes rather than changes in forced
expiratory flow [24]. Detecting changes of this magnitude is
not practical in individual patients and removes the objective
reassurance that PEF data provide when identifying asthma
exacerbations.
The baseline spirometric severity was not related to the mean
symptom change during the episode. Similar absolute changes
in symptoms occurred irrespective of the GOLD stage of
disease. However, the baseline level of symptoms did differ
with GOLD stage, with breathlessness being scored at a higher
level in the initial run-in and during the course of an
exacerbation in those in the lower GOLD stages. This may
explain why such patients are more likely to seek medical
attention when they experience an exacerbation.
The questions selected to monitor with the diary card may
have limited the ability to detect all changes of note. This diary
card was based on the successful model used in studies of
asthma [23] and the present data suggest that it may not be
ideal for use in patients with COPD. However, symptoms such
as breathlessness were reported in just over 60% of event-
based exacerbations, a figure very similar to that seen in
exacerbations reported in one centre in London, UK, where a
different type of scoring was adopted [25]. Future studies
should address the appropriateness of individual questions in
identifying exacerbations and, in particular, whether upper
respiratory tract symptoms associated with viral infections [26]
occur independently of other single symptom combinations.
However, a preliminary report in another large study cohort
where questions regarding cough and sputum were included
may not suggest a better degree of resolution than presented in
the current study [27].
Although, several different objective schemes were devised in
this study for relating exacerbations identified by a change in
therapy to the daily symptom record, the level of agreement
was poor. The choice of a graded diary card suggesting specific
thresholds to be exceeded may have contributed to this. The
approach adopted to identify exacerbations in the on-going
COPD cohort studies was reported by the East London group.
This requires the patient to note a worsening of the symptom
on at least 2 consecutive days, but does not specify by how
much symptoms should deteriorate. There is no standardised
diary card available at present for use in COPD, although
exacerbations can be identified in groups of patients using a
simplified breathlessness, cough and sputum score [28]. More
work to validate these instruments is clearly needed. Better
dating of diary entries using electronic diary cards should
reduce some of the noise in the data. However, more
information is need about why patients attend their physicians
to receive medication and what the doctor is identifying when
treatment is initiated. The present data confirm that these
processes are not captured simply by an increasing intensity of
pre-specified symptoms.
The current data have a number of practical implications. The
difficulty in identifying symptoms or PEF change on the diary
card makes the introduction of individual self-management
plans in COPD difficult, and may explain the limited success of
current approaches to this [29]. Although individually limited,
the pooled data around the exacerbation indicates that the
prodrome may last a little longer than previously suggested
[22], with some patients failing to return to baseline symptoms
within the 4-week window. The average change in total
symptom score was not influenced by the therapy prescribed,
suggesting that medication does not change the nature of an
event where treatment is sought from the doctor, but does
change the number of occasions when this happens.
In conclusion, whether particular aetiologies are more relevant
to specific symptom patterns cannot be addressed in trial data
such as these. However, the close agreement between the
maximal group mean change in symptoms and the onset of
therapy does support the use of event-based criteria as a
simple reflection of the presence of a clinically important event
on average in a chronic obstructive pulmonary disease
population. The relationship between initial symptoms and
the likelihood of future exacerbation may also help in defining
those chronic obstructive pulmonary disease patients where
exacerbation prophylaxis is most likely to be helpful.
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Seasonality and determinants of moderate
and severe COPD exacerbations in the
TORCH study
C.R. Jenkins*, B. Ce!ii#, J.A. Anderson"', G.T. Ferguson*, P.W. Jones5, J. Vestbo^'**,
J.C. Yaites## and P.M.A. Calverley111'
ABSTRACT: We investigated the impact of season relative to other determinants of chronic
obstructive pulmonary disease (COPD) exacerbation frequency in a long-term international study
of patients with forced expiratory volume in 1 s (FEVi) <60% predicted.
COPD exacerbations were defined by worsening symptoms requiring systemic corticosteroids
and/or antibiotics (moderate) or hospital admission (severe). Seasonality effect was calculated as
the proportion of patients experiencing an exacerbation each month.
Exacerbations in the northern and southern regions showed an almost two-fold increase in the
winter months. No seasonal pattern occurred in the tropics. Overall, 38% of exacerbations were
treated with antibiotics only, 19% with systemic corticosteroids only and 43% with both, while 20%
required hospital admission irrespective of the season. Exacerbation frequency was associated
with older age, lower body mass index, lower FEVi % pred and history of prior exacerbations.
Females and patients with worse baseline breathlessness, assessed using the Medical Research
Council (MRC) dyspnoea scale, exacerbated more often (rate ratio (RR) for male versus female
0.7,95% CI 0.7-0.8 (p<0.001); RR for MRC dyspnoea score 3 versus 1 and 2 combined 1.1,95% CI
1.1-1.2 (p<0.001)). The effect of season was independent of these risk factors.
COPD exacerbations and hospitalisations were more frequent in winter.
KEYWORDS: Chronic obstructive pulmonary disease, exacerbations, mortality, seasonal patterns,
TORCH survival study
atients with moderate-to-severe chronic
obstructive pulmonary disease (COPD)
experience on average, two to three exacer¬
bation episodes per year [1,2], Hospitalisation and
COPD-associated mortality account for substan¬
tial treatment and healthcare resource utilisation
costs [2-4]. COPD exacerbations contribute to a
worsening of health-related quality of life over
time [1, 2, 5] and their occurrence predicts the
likelihood of dying [6].
Factors predicting the frequency and slow reso¬
lution of exacerbations include increasing age,
more severe airflow obstruction and a history of
prior exacerbations [7-10]. These data come from
studies of differing size and duration of follow-up
that reported annualised exacerbation rates. Less
attention has been paid to the influence of time of
year on exacerbation occurrence and management.
There is evidence of a seasonal variation in the rate
of hospital admissions for COPD, with more
exacerbations occurring during the winter months
compared with summer [11-13], Exacerbations are
also associated with cooler temperatures [14, 15].
This seasonal variation has been reported predom¬
inantly in countries in northern regions [16, 17],
with little or no similar information available for
either the southern regions or the tropics [18-20].
Furthermore, there is a paucity of information
about seasonal variation in exacerbation rates and
its importance compared with other factors pre¬
dicting exacerbations. The current analysis was
designed to test the impact of seasonal variation
on reported exacerbations in relation to other risk
factors, using data from the prospective, 3-yr
Towards a Revolution in COPD Health (TORCH)
study involving 6,112 patients from the northern
and southern regions and the tropics [21].
METHODS
Patients
Outpatients aged 40-80 yrs with a diagnosis of
COPD, defined in accordance with the European
Respiratory Society (ERS) consensus statement [22],
who were current or ex-smokers with ^ 10 pack-
yrs smoking history were recruited. They had a
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pre-bronchodilator forced expiratory volume in 1 s (FEVl) of
<60% of predicted, with reversibility to 400 gg salbutamol of
<10% of predicted FEV1 and a FEVl /forced vital capacity ratio of
<70% after bronchodilator. Exclusion criteria have been
described previously [21] and included long-term oxygen
therapy at start of the study, or an exacerbation requiring
systemic corticosteroids or hospitalisation during the run-in
period.
Study design
TORCHwas a multicentre, randomised, double-blind, parallel-
group, 3-yr study conducted in 42 countries around the world
[21]. Eligible patients were stratified by smoking status and
were randomised to receive placebo, 50 jug salmeterol, 500 jug
fluticasone propionate or 50/500 jig salmeterol/fluticasone
propionate combination via the Diskus™/Accuhaler™ inhaler
(GlaxoSmithKline, London, UK) (one inhalation twice daily)
for 3 yrs. All patients visited the clinic at 12-weekly intervals;
during these visits, specific enquiries were made regarding
exacerbations or events that required a change in treatment or
hospitalisation by asking the standard questions "Have you had
any (other) medical problems since your last visit/assessment?"
and "Have you taken any new medications, other than those
given to you within this study since your last visit/assess¬
ment?" Exacerbations were recorded as moderate (defined by
worsening symptoms requiring treatmentwith antibiotics and/
or systemic corticosteroids) or severe (defined as those requiring
hospitalisation), and were documented by the investigator as an
adverse event or serious adverse event. Treatment with short
courses of systemic corticosteroids and/or antibiotics as
reported by the patient was recorded on the patient's case
report form. All patients gavewritten informed consent, and the
study was approved by local ethical review boards and
conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines.
Statistical analysis
The number of patients reporting a new exacerbation was
expressed as a proportion of the patients on treatment during
the month in which the exacerbation started. The pattern of
exacerbations was analysed according to geographical location,
based on the locations of the participating centres. Similar
analyseswere conducted for all deaths occurring during the 3-yr
study period. Study populations were grouped into the north¬
ern region (Canada, China, 26 eastern and western European
countries, and the USA), the southern region (Argentina,
Australia, Brazil, Chile, New Zealand and South Africa) and
the tropics (countries lying between the tropics ofCapricorn and
Cancer: Hong Kong, Malaysia, Mexico, Philippines, Singapore,
Taiwan and Thailand).
For seasonal comparisons, in the northern region, we defined
summer as June to August inclusive and winter as December to
February, with the reverse for the southern region. Recruitment
began in September 2000 and the study ended in November
2005. Our investigation of seasonality of exacerbations was
restricted to a 4-yr period (April 2001 to March 2005) when
sufficient numbers of patients were on treatment to reduce the
amount of random variation. For all other analyses, all data
were used.
The number of exacerbations experienced by a patient during
the study was expressed as a rate per year to account for the
differing times on treatment. Exploratory analysis of the
association between exacerbation rates during treatment and
baseline characteristics was performed by modelling the exacer¬
bation rates using the negative binomial distribution (to account
for patient variability), using the logarithm of time on treatment
as an offset variable. Smoking status, sex, region, treatment,
exacerbations in the year prior to study entry (as recalled
retrospectively by the patients or investigators at study entry),
body mass index (BMI), Medical Research Council (MRC)
dyspnoea score, age and baseline FEVl % pred were included
in the model. Rate ratios (RR) with 95% confidence intervals were
calculated for each covariate with all other covariates included in
the model.
RESULTS
Demographic and baseline characteristics of the study popula¬
tion are shown in table 1. Mean+SD age was 65 ±8 yrs and
post-bronchodilator FEVl was 1.23 + 0.4 L. Males comprised
the majority of the study population and >40% of all patients
were current smokers. Nearly 60% of patients had at least one
exacerbation in the year prior to study entry; half of these had
two or more exacerbations.
79% of the study population was recruited from the northern
region, 10% from the southern region and 11% from the tropics.
Overall rates of exacerbations
Overall exacerbation rates per year (moderate or severe) are
shown in figure 1. The distribution was highly skewed; the
majority of patients had between no and two exacerbations per
year, but a few had much higher rates. In total, there were
—13,000 exacerbations. The annual rate for moderate or severe
exacerbations was 1.13 in the placebo group, 0.97 in the 50 gg
salmeterol group, 0.93 in the 500 gg fluticasone propionate
group and 0.85 in the 50/500 gg salmeterol/fluticasone propio¬
nate group.
Pattern of new exacerbations
In the northern and southern regions, but not the tropics, a
seasonal pattern of exacerbations was seen, with a higher
proportion of patients exacerbating in the winter months, which
was consistent over the 4-yr period. Figure 2a and b shows the
raw data of the proportion of patients exacerbating in eachmonth
for the northern and southern regions and the tropics, respec¬
tively. Figure 2c and d represents the same information averaged
into one calendar year. The pattern of exacerbations in the
northern region was mirrored by the pattern of exacerbations in
the southern region (fig. 2a and c). A higherproportion ofpatients
in the southern region reported an exacerbation in any seasonally
adjusted month compared with the northern region (fig. 2c). In
the northern region, 5% ofpatients reported an exacerbation in the
summer compared with 9% in the winter, while in the southern
region, 7% of patients reported an exacerbation in the summer
compared with 12% in the winter (fig. 2c). This seasonal pattern
was seen in all four treatment arms.
Management of exacerbations
The proportion of patients with exacerbations treated with
systemic corticosteroids alone, antibiotics alone or both in the
northern and southern regions is presented in figure 3.
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TABLE 1 Patient demographics and baseline characteristics by region
ITT (efficacy) Northern Southern Tropics
Subjects n 6112 4849 622 641
Age yrs 65.0±8.3 64.8 + 8.3 65.5+8.5 66.5 + 7.3
Males % 76 75 72 89
Current smokers % 43 45 36 36
Post-bronchodilator FEVi L 1.23 + 0.4 1.26 + 0.4 1.16 + 0.4 1.01 ±0.4
Post-bronchodilator FEVi % pred 44.3 + 13.4 45.1+13.2 42.4 + 13.2 40.3 + 14.3
Reversibility % pred FEVi 3.7+ 3.7 3.6 + 3.8 4.0+3.5 3.5 + 3.7
BMI kg m"2 25.4 + 5.2 26.0 + 5.1 24.6 + 4.9 21.7 + 4.1
Exacerbation rate* 1.2 + 1.6 1.2 + 1.5 1.2 + 1.6 1.6 + 2.3
0 exacerbations % 43 43 42 40
1 exacerbation % 25 25 24 24
^2 exacerbations % 32 32 33 36
Data are presented as mean+SD, unless otherwise stated. ITT: intention to treat; FEVi: forced expiratory volume in 1 s; % pred: % predicted; BMI; body mass index,
the 12 months prior to study entry.
Overall, 38% of exacerbations were treated with antibiotics
only, 19% with systemic corticosteroids only and 43% with
both. In the northern region, more exacerbations in the winter
(43%) were treated with antibiotics compared with those in the
summer (37%). This pattern was reversed for exacerbations
treated with systemic corticosteroids (15% in winter but 24% in
summer). A clear seasonal treatment pattern was not seen in
the southern region, possibly due to the smaller number of
patients.
The proportion of all patients who required hospitalisation for
exacerbation in any given month was higher in the winter. For
instance, in the northern region, the highest proportion, in
December (1.9%), was double that reported in the lowest
month (August; 0.9%). However, the proportion of exacerba¬
tions requiring hospitalisation was similar year-round, with a
summer mean of 18.3% and a winter mean of 18.8%. This
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FIGURE 1. Distribution of exacerbation rates per patient per year during the
study. The very high calculated exacerbation rates (>10) were primarily due to
premature drop-out of frequent exacerbators with <6 months follow-up time.
tropics, with a higher proportion of events requiring hospital¬
isation (31.2%) than in the other regions (18.3% in the northern
region and 15.7% in the southern region). Across all regions
20% of exacerbations required hospitalisation.
Factors affecting exacerbation rates
The effect of covariates on the rate of exacerbations during the
study is shown in table 2. Season was a significant covariate
with respect to exacerbation rate. In northern and southern
regions, there were more exacerbations in the winter compared
with the summer. Patients ^75 yrs of age, compared with
patients <55 yrs of age, had 20% more exacerbations (RR 1.2,95%
CI 1.0-1.3; p=0.023). Compared with patientswith amean BMI of
20 to <25 kg-m"2 at baseline, patients with a BMI of ^29 kg-m"2
had 10% fewer exacerbations (RR 0.9, 95% CI 0.8-0.9; p<0.001),
while a low BMI (<20 kg-m"2) was associated with a 10%
increased rate of exacerbations (RR 1.1,95% CI 1.0-1.2; p=0.241).
Low FEVi was also associated with an increased rate of exacer¬
bation (FEVi <30 comparedwith 50% pred: RR 1.9,95%CI 1.7-
2.1; p<0.001). Patients who reported one exacerbation in the
year prior to study entry had a 50% higher rate of exacerbations
while on treatment (RR 1.5, 95% CI 1.4-1.6; p<0.001) and those
reporting two or more exacerbations in the year prior to study
entry had nearly double the rate (RR 1.9,95% CI 1.8-2.1; p<0.001)
compared with patients who reported no exacerbations.
Males had a 30% lower exacerbation rate than females (RR 0.7,
95% CI 0.7-0.8; p<0.001). Increasing severity of dyspnoea, based
on baseline MRC dyspnoea grade, was associatedwith a greater
rate of exacerbations, a grade of 3 having an exacerbation RR of
1.1 (95% CI 1.1-1.2; p<0.001) and grades 4 and 5 having a RR of
1.3 (95% CI 1.2-1.4; p<0.001), compared with grades 1 and 2.
Current smoking was associated with a 10% lower rate of
reported exacerbations than former smoking (0.9 RR, 95% CI
0.8-0.9; p<0.001), after adjusting for other covariates.
Hie reporting of exacerbations differed according to region,
with the rate in the northern region being 20% lower than in
the southern region (RR 0.8, 95% CI 0.7-0.9; p<0.001).
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FIGURE 2. Proportion of patients reporting an exacerbation in the a) northern and southern regions and b) tropics over 4 yrs, and reporting an exacerbation in the
c) northern and southern regions and d) tropics averaged over one calendar year.





The seasonal influence on exacerbation pattern was evident in
all the patient subgroups studied. This is illustrated in figure 4
for FEVi % pred and MRC dyspnoea grade.
Mortality
There were more deaths in the 3 months of winter than the
3 months of summer. In the northern region, 625 of the 4,849
patients died and 180 (29%) of these deaths occurred during
the 3 months of winter in the 3-yr study period, while 135
(22%) occurred in the summer. In the southern region 113 of
the 622 patients died, 42 (37%) during winter compared with
16 (14%) during the summer.
These differences in seasonal mortality were more evident for
COPD-related deaths, which accounted for 41% of all deaths in
TORCH. In the northern region, 79 (34%) of the 235 COPD-
related deaths occurred during winter while 48 (20%) occurred
in the summer. In the southern region, 27 (55%) of these deaths
occurred during winter and four (8%) during the summer.
DISCUSSION
COPD patients and their doctors know that exacerbations
occur commonly in the winter months, but data to establish the
size of this effect have been lacking. Exacerbations defined by
healthcare use, as proposed recently by the American Thoracic
Society (ATS)/ERS task force [23], were more common during
winter. These patternswere consistent from year to year over the
study period and accounted for an almost two-fold increased
risk of exacerbation in winter, in northern and southern region
countries, but not in the tropical countries.
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FIGURE 3. Proportion of patients reporting an exacerbation and treatment received in the a) northern and b) southern regions.
TABLE 2
Factor








5= 75 versus <55
Post-bronchodilator FEV1 % pred
<30% versus ^ 50%
30 to <50% versus ^ 50%
Sex
Male versus female





<20 versus 20 to <25
25 to <29 versus 20 to <25














































Rate ratios (RR) with 95% confidence intervals were calculated for each
covariate with all other covariates included in the model. Multivariate negative
binomial model (each variable adjusted for all the others). FEV1: forced
expiratory volume in 1 s; % pred: % predicted; COPD: chronic obstructive
pulmonary disease; BMI: body mass index; MRC: Medical Research Council.
Thus far, data supporting a seasonal pattern in COPD exacer¬
bations have been derived from smaller studies conducted
mainly in Europe [12-14,16,17], where a seasonal effect has been
reported as part of other analyses. The TORCH study population
comprises data collected over 3 yrs from patients in 42 countries
and, as such, provides sufficient power to extend and support
the previously reported findings. COPD hospital admissions and
deaths increase dramatically in the winter months, as do general
practice visits for respiratory tract infections [14-17], Factors
potentially contributing to this include increased exposure to
viral infections, increased host susceptibility, greater time spent
indoors, reduced physical activity and temperature-related
reduction in lung function. These patterns also relate to lower
weekly mean temperatures, as well as influenza activity and
personal cold exposure factors [24]. The mechanisms by which a
greater risk of respiratory infections occurs in winter are
complex, and include the interaction of temperature and
humidity, changes in human behaviour, exposure to colder air
indoors and outdoors [14^17, 25-28], air pollution, and greater
vulnerability of the local host defence [20, 29].
The seasonal variation was not seen in tropical countries that
are characterised by relatively constant temperatures, with a
mean of ^18°C (^64°F), all year round. In tropical regions,
there is background influenza activity throughout the year
[30, 31], which may contribute to a more stable pattern of
exacerbations throughout the year, as noted in the present
study. Seasonal variations occur with some infections in the
tropics, but may be more closely related to the wet season, air
pressure and relative humidity rather than temperature alone
[17,18,20]. Other factors include outdoor pollution [30-32] and
its interaction with cooler temperatures. Tire tropical countries
in TORCH differ in distance from the equator and meteoro¬
logical characteristics, which produce different seasonal
patterns of respiratory illness between countries [33].
The seasonal variation in the number of exacerbation events was
accompanied by a variation in the treatment of exacerbations.
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FIGURE 4. Proportion of patients reporting an exacerbation in the northern region by a)
grade. % pred: % predicted.
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forced expiratory volume in 1 s and b) Medical Research Council dyspnoea
- <30% pred
- 30 to <50% pred
Antibiotics were used alone or in combination with steroids
more frequently in the winter months compared with summer
in the northern region. The treatment difference may reflect
differences in the way exacerbation patients present in the
winter, but data about seasonal variation in the microbiology of
COPD patients are lacking. In contrast, in the southern region,
both antibiotic and systemic corticosteroid use increased in the
winter, and there was a strong tendency for both to be used
in combination. The reason for these differences cannot be
determined here and requires further study.
More patients were hospitalised due to COPD in the winter
months, although, in absolute terms, the proportion of cases
where this occurred was low. However almost 20% of exacer¬
bations in our large, worldwide population required hospitalisa¬
tion, and this was consistent between the seasons and very
similar to that reported in a smaller US study [34]. Moreover,
the relative proportion of events leading to hospital admission
was unaffected by season, suggesting that the colder wea¬
ther increased the number, rather than the overall severity, of
exacerbations.
Like other researchers, we found that older age, having a lower
BMI, a lower FEVl and a higher incidence of exacerbations in the
previous year all significantly increased the risk of exacerbations
[7-10]. In addition, we found that sex and MRC dyspnoea grade
at study entry, and smoking status are risk factors. Females
report more breathlessness for similar levels of airflow obstruc¬
tion and are more likely to receive treatment for COPD than
males [35,36]. Theymay, therefore, bemore likely to be classified
as having an exacerbation. However, there are also data
indicating that females are at higher risk of being hospitalised
for exacerbations [37], which is unlikely to be due solely to
differential symptom reporting. A higher MRC dyspnoea grade
may identify patients more likely to receive exacerbation
treatment when they present with worsening symptoms.
However, MRC grade also relates to exercise performance and
the degree of activity normally undertaken is a predictor of the
risk of exacerbation [7, 38]. Tine paradoxical observation that
current smokers were less likely to exacerbate than ex-smokers
may not be a chance finding. Potential explanations may be a
healthy survivor effect or the possible beneficial effect of
smoking on sputum clearance [39, 40].
Our data differ in the magnitude of some of the associations
from those reported by Hurst et al. [10] for the Evaluation of
COPD Longitudinally to Identify Predictive Surrogate End-
Points (ECLIPSE) study. We identified almost twice as many
exacerbations as that observational study, which included
more patients with moderate COPD, who were taking more
medication than in our clinical patient population. Moreover,
our study was not confined to Europe, North America and
New Zealand and, unlike ECLIPSE, we did not record the
presence of reflux symptoms. While these factors help explain
some of the differences in predictive capacity, it is reassur¬
ing to see the considerable agreement in the determinants of
exacerbation risk, irrespective of the composition of the study
population. Notably, the seasonal effect on exacerbations occur¬
red independently of all the identified risk factors.
Winter mortality from pre-existing respiratory disease was the
single strongest predictor of excess deaths in a large general
practice-based UK study [41] and pre-existing respiratory disease
increased mortality from cardiovascular but not respiratory
causes. Several other studies have demonstrated excess all-
cause, cardiovascular and respiratory mortality in winter, which
is greater in females thanmales [25-27]. Somewhat paradoxically,
vulnerability to death is increased to a greater extent for a given
fall of temperature in regions with warmer winter temperatures.
This appears to relate to greater personal cold exposure, lack of
indoor heating, failure to dress appropriately for tire cold and
reduced outdoor physical activity [27, 28]. In our population,
possibly due to the limited number ofevents, especially in the sou¬
thern region, we did not see a clear seasonal pattern inmortality.
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There are strengths and limitations of our data. We recorded
data in a standardised way in a large patient population and
carefully identified the time and cause of death [42], This
approach provided adequate statistical power to test for
differences due to region or risk factors. Although we excluded
subjects with known serious comorbidities, including those
dependent on oxygen therapy at entry, we do not believe the
study population and setting bias our main findings. We
recognise that ours was a treatment intervention trial and not
an epidemiological study, and acknowledge the inherent
differences between these two study types. However, the lack
of interaction between any of the treatments used in this study
and the factors identified as predicting exacerbation allowed
us to pool all the data for this analysis, enabling analysis from
>6,000 patients.
Conclusion
In the TORCH trial, tire major burden of exacerbations fell in
the winter months of both northern and southern regions of
the world, which aligns with the perceptions of COPD patients
and their doctors. Furthermore, the risk factors identified in
this study (which, it must be considered, was an interventional
study) may make it possible to prospectively profile an
individual's risk of exacerbating and, thus, allow optimisation
of care to reduce this risk. Further studies to establish the
feasibility of such an approach are warranted.
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BACKGROUND
Although we know that exacerbations are key events in chronic obstructive pulmo¬
nary disease (COPD), our understanding of their frequency, determinants, and effects
is incomplete. In a large observational cohort, we tested the hypothesis that there is
a frequent-exacerbation phenotype ofCOPD that is independent of disease severity.
METHODS
We analyzed the frequency and associations of exacerbation in 2138 patients en¬
rolled in the Evaluation ofCOPD Longitudinally to Identify Predictive Surrogate End-
points (ECLIPSE) study. Exacerbations were defined as events that led a care pro¬
vider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization
(severe exacerbations). Exacerbation frequency was observed over a period of3 years.
RESULTS
Exacerbations became more frequent (and more severe) as the severity of COPD
increased; exacerbation rates in the first year of follow-up were 0.85 per person for
patients with stage 2 COPD (with stage defined in accordance with Global Initiative
for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage
3, and 2.00 for patients with stage 4. Overall, 22% ofpatients with stage 2 disease,
33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more
in the first year of follow-up). The single best predictor of exacerbations, across all
GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype
appeared to be relatively stable over a period of 3 years and could be predicted on
the basis of the patient's recall of previous treated events. In addition to its asso¬
ciation with more severe disease and prior exacerbations, the phenotype was inde¬
pendently associated with a history ofgastroesophageal reflux or heartburn, poorer
quality of life, and elevated white-cell count.
CONCLUSIONS
Although exacerbations become more frequent and more severe as COPD progresses,
the rate at which they occur appears to reflect an independent susceptibility pheno¬
type. This has implications for the targeting of exacerbation-prevention strategies
across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials
.gov number, NCT00292552.)
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SUSCEPTIBILITY TO EXACERBATION IN COPD
The natural history of chronic ob-structive pulmonary disease (COPD) is punc¬tuated by exacerbations— acute worsening
of symptoms. Exacerbations appear to accelerate
the decline in lung function that characterizes
COPD,1'2 resulting in reduced physical activity,3
poorer quality of life,4 and an increased risk of
death,5 and they are also responsible for a large
proportion of the health care costs attributable
to this prevalent condition.6 Consequently, exac¬
erbations are important outcomes in clinical tri¬
als, and their prevention is a key component of
COPD-management strategies.7
Despite the importance of exacerbations, we
know relatively little about their incidence, their
determinants, and their effects in patients with
COPD at various levels of severity. Although exac¬
erbations are generally considered to become more
frequent as the severity of the underlying COPD
increases, the most reliable predictor of exacer¬
bations in an individual patient appears to be a
history of exacerbations.8 There may therefore be
a phenotype of exacerbation susceptibility that in¬
cludes milder forms ofCOPD. However, this theo¬
ry has not been adequately investigated because
our current understanding of COPD exacerba¬
tions and their relationship to disease severity is
based on large intervention studies9'10 or multiple
smaller studies that have used varying definitions
of exacerbation.8 We used data from a large ob¬
servational study to test the hypothesis that there
is a frequent-exacerbation phenotype ofCOPD that
is independent of disease severity.
methods
STUDY DESIGN AND PATIENTS
This analysis was based on data collected as part
of the Evaluation ofCOPD Longitudinally to Iden¬
tify Predictive Surrogate Endpoints (ECLIPSE) ob¬
servational study.11 The study was conducted in
accordance with the Declaration ofHelsinki and
Good Clinical Practice guidelines. All patients
provided written informed consent, and the study
was approved by the relevant ethics and review
boards.
The recruitment criteria included an age of40
to 75 years, a history of 10 or more pack-years of
smoking, a forced expiratory volume in 1 second
(FEVJ of less than 80% of predicted value after
bronchodilator use, and a ratio of FEV1 to forced
vital capacity (FVC) of 0.7 or less after broncho¬
dilator use.
At baseline, patients underwent standard spi¬
rometry after the administration of 400 /xg of in¬
haled albuterol. Computed tomographic (CT) scan¬
ning of the chest was performed to evaluate the
severity and distribution of emphysema (for de¬
tails, see the Supplementary Appendix, available
with the full text of this article at NEJM.org). The
condition of the patients was graded according to
the stages of disease defined by the Global Initia¬
tive forChronic Obstructive LungDisease (GOLD).12
After the baseline visit, patients were followed for
a total of seven visits: at 3 months, at 6 months,
and every 6 months thereafter for 3 years.
The patients' self-reported respiratory symp¬
toms, medications, smoking history, occupational
exposure, and coexisting medical conditions were
documented at study entrywith the use of the well-
established American Thoracic Society-Division
ofLung Disease (ATS-DLD) questionnaire, which
was updated for the purpose of this study.13
Serum and plasma samples were stored at
-80°C until they were analyzed. Details of the
assays are described in the Supplementary Appen¬
dix. Any samples with values below the lower
limit ofquantification were assigned a value that
was half of the lower limit.
A detailed description ofmethods can be found
in the Supplementary Appendix. The study was
conducted in accordance with the protocol, which
is available at NEJM.org.
STUDY OUTCOMES
Exacerbations were a critical outcome. The case
definition ofan exacerbation was a functional one,
based on the decision by a patient's primary cli¬
nician or by study personnel to prescribe antibi¬
otics or systemic corticosteroids, alone or in com¬
bination. Primary clinicians were not given a
specific list of criteria that had to be met for an
event to be classified as an exacerbation, but they
were instructed to base their decision on common
clinical criteria. This case definition therefore met
the criteria for a definition ofhealth care utiliza¬
tion, and the exacerbations we recorded would be
classified as moderate or severe in intensity.14 The
case definition remained the same during the
3 years of active data accrual, and identical criteria
were applied retrospectively when we collected data
from patients on the number ofexacerbations they
had had in the year before study enrollment.
Patient-reported measures at study entry in¬
cluded assessments of dyspnea (made with the use
of a modified Medical Research Council dyspnea
N ENGLJ MED 363:12 NEJM.ORG SEPTEMBER 16, 2010
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(N =293) P Value
Age (yr) 63±7 63±7 64±7 62±7 0.03
Female sex (%) 35 40 32 26 <0.001
Current smoker (%) 36 38 37 28 0.016
Body-mass index-)' 27±6 27±6 26±6 25±6 <0.001
FEV2 after bronchodilator use (liters) 1.35±0.52 1.75±0.45 1.13±0.27 0.72±0.16 <0.001
FEVj after bronchodilator use (% of predicted
value)
48±16 63 ±8 40±6 25±4 <0.001
FEVjtFVC (%) 45±12 53±9 40±9 32±8 <0.001
Distance walked in 6 min (m) 370±121 406±112 357±117 290±119 <0.001
BODE index:): 3.2±2.1 1.6±1.4 4.0±1.6 5.7±1.6 <0.001
Emphysema <0.001
Low attenuation areas (no.) 18±12 12±10 20±12 28±13 <0.001
Extent >5% of total area (%)§ 75 63 82 92 <0.001
Patient-reported outcomes:):
MRC dyspnea score a2 (%) 53 40 59 80 <0.001
CES depression score 11±9 11±9 12±9 13±10 0.002
FACIT fatigue score 35±11 37±10 34±11 32±11 <0.001
SGRQ for COPD, total score 50±20 42±21 54±18 62±16 <0.001
Medication for COPD (%)1
Any long-acting bronchodilator 76 67 83 86 <0.001
Any inhaled corticosteroid 72 60 80 86 <0.001
Any methylxanthine 14 9 16 20 <0.001
Any leukotriene antagonist 3 3 4 3 0.51
Exacerbations
^1 in preceding yr (%) 47 39 52 62 <0.001
>2 in study yr 1 (%) 29 22 33 47 <0.001
Rate in yr 1 (no./patient) 1.21 0.85 1.34 2.00 <0.001
Requiring hospitalization 0.22 0.11 0.25 0.54 <0.001
Requiring oral corticosteroids only 0.14 0.10 0.15 0.21 <0.001
Requiring antibiotics only 0.44 0.37 0.46 0.60 <0.001
Requiring corticosteroids and antibiotics 0.41 0.27 0.47 0.65 <0.001
* Plus-minus values are means ±SD unless otherwise noted. The table includes data for the 56 patients who died (from any cause) during
year 1 of the study; 16 had GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 2 COPD, 26 had GOLD stage 3, and 14 had
GOLD stage 4. FEV! denotes forced expiratory volume in 1 second, and FVC forced vital capacity.
■j" The body-mass index is the weight in kilograms divided by the square of the height in meters.
;j:The BODE index takes into account body-mass index, airway obstruction (as assessed on the basis of FEVJ, dyspnea (as measured with the
Medical Research Council [MRC] dyspnea scale), and exercise tolerance (as measured by a 6-minute walk test); scores range from 0 to 10.
The Center for Epidemiologic Studies (CES) depression scale ranges from 0 to 60, with higher scores indicating more severe depression.
The Functional Assessment ofChronic Illness Therapy (FACIT) fatigue scale ranges from 0 (most severe fatigue) to 52 (least severe fatigue).
Scores on the St. George's Respiratory Questionnaire (SGRQ) range from 0 (good health status) to 100 (poor health status). The MRC
dyspnea scale ranges from 0 (no dyspnea) to 4 (indicating that the patient is too breathless to leave home or becomes breathless when
dressing or undressing) (a score of 4 indicates a minimally important clinical difference).
5 The extent of disease was evaluated by a radiologist.
1 Information on medication was self-reported; patients may have been taking more than one medication.
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scale15), quality of life (St. George's Respiratory
Questionnaire for patients with COPD16), fatigue
(Functional Assessment ofChronic Illness Thera¬
py fatigue scale17), and depression (Center for Epi¬
demiologic Studies depression scale18).
STATISTICAL ANALYSIS
Descriptive data are reported as means ±SD or per¬
centages, as appropriate. Comparisons between
groups for descriptive summaries were performed
with the use ofanalysis ofvariance. The incidence
ofexacerbations was summarized as a per-person
per-year rate. Differences in exacerbations between
groups were analyzed with the use of a nonpara-
metric Kruskal-Wallis test. In the initial explora¬
tion of data, exacerbations were analyzed as an
indicator variable (a patient did have or did not
have an exacerbation during year 1) fitting uni¬
variate models with the use of logistic regression.
Multinomial logistic regression was performed
with the use of PROC CATMOD in SAS, with the
frequency of exacerbations during year 1 classi¬
fied as none, one, or two or more to more fully
characterize the associations between selected
baseline factors and exacerbation frequency. We
defined frequent exacerbations as two or more
exacerbations in a year because this definition co¬
incides with current health care utilization crite¬
ria for frequent exacerbations. For the multivari¬
ate analyses, a stepwise approach was used. All
variables that were explored in the univariate
analyses were considered in the multivariate mod¬
el, with age, sex, smoking status, and body-mass
index included as covariates in all models. A con¬
servative significance threshold of 0.01 was used
to determine the qualification of data for entry
into or deletion from the model. All reported
P values are nominal and two-sided and were not
adjusted for multiple comparisons. Stepwise lo¬
gistic regression was used for analyses involving
patients with very severe COPD (GOLD stage 4).
Biomarker data were log10-transformed before all
regression analyses. All patients who underwent
at least 30 days of follow-up were included in the
regression analyses.
RESULTS
CHARACTERISTICS OF THE PATIENTS
A total of 2164 patients were recruited for the
study, and 2138 patients were enrolled and ob¬




















Figure 1. Association of Disease Severity with the Frequency and Severity
of Exacerbations during the First Year of Follow-up in Patients with Chronic
Obstructive Pulmonary Disease.
Patients with two or more exacerbations during the year were considered to
have frequent exacerbations. An exacerbation requiring hospitalization was
classified as severe. Disease severity was classified according to the stages
of disease defined by the Global Initiative for Chronic Obstructive Lung
Disease (GOLD). P<0.001 for both comparisons.
istics of the patients are reported in Table 1, cat¬
egorized according to the severity of COPD. As
the severity increased, exacerbations were both
more frequent and more severe (Fig. 1). In the first
year of follow-up, the exacerbation rates were 0.85
per person for patients with moderate disease
(GOLD stage 2), 1.34 for those with severe dis¬
ease (GOLD stage 3), and 2.00 for those with very
severe disease (GOLD stage 4). The severity ofdis¬
ease also affected hospitalization in year 1, with
the proportion ofpatients who were hospitalized
increasing with the severity of disease: GOLD
stage 2, 7%; GOLD stage 3, 18%; and GOLD
stage 4, 33%.
FACTORS ASSOCIATED WITH EXACERBATIONS
In univariate logistic-regression analysis, we as¬
sessed factors associated with at least one exac¬
erbation during the first year of follow-up, using
all available baseline assessments in the whole
cohort. The best predictor of an exacerbation in
the first year was a treated exacerbation in the year
before study entry (odds ratio, 4.30; 95% confi¬
dence interval [CI], 3.58 to 5.17; PcO.001). Other
variables significantly associated with exacerba¬
tions are shown in Table 2.
Factors that were independently associated with
exacerbations during the first year of follow-up,
on the basis of a multinomial regression model,
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Table 2. Univariate Associations with the Occurrence ofExacerbations during the First Year of Follow-up.*
Baseline Characteristics Odds Ratio (95% Wald CI) P Value
Demographic and clinical characteristics
Self-reported exacerbation during preceding yr— yes vs. no 4.30 (3.58-5.17) <0.001
BODE index— per increase of 1 point 1.23 (1.18-1.28) <0.001
MRC dyspnea score— 2, 3, or 4 vs. 0 or 1 1.83 (1.54-2.18) <0.001
Distance walked in 6 min — per decrease of 50 m 1.12 (1.08-1.16) <0.001
Post-secondary (or higher) education level— yes vs. no 0.70 (0.58-0.83) <0.001
Fat-free mass index— per increase of 1 point 0.93 (0.90-0.97) <0.001
Sex— female vs. male 1.42 (1.19-1.71) <0.001
Body-mass index— per increase of 1 point 0.98 (0.97-1.00) 0.03
Age— per 10-year increase 1.14 (1.01-1.28) 0.04
Smoking status— current vs. former smoker 0.83 (0.70-0.99) 0.04
Lung function
FEVl— per 100-ml decrease 1.11 (1.10-1.14) <0.001
FEVi— per 5% decrease in % of predicted value 1.15 (1.11-1.18) <0.001
GOLD stage— per increase to next stage 1.74 (1.53-1.97) <0.001
FEVjiFVC— per 1% decrease 1.03 (1.02-1.04) <0.001
FVC— per 100-ml decrease 1.04 (1.03-1.05) <0.001
Emphysema
Per 5% increase in low-attenuation areas 1.16 (1.11-1.20) <0.001
Radiologic score >5%— yes vs. no 1.79 (1.45-2.21) <0.001
Patient-reported outcomes
SGRQ score for COPD — per 4-point worsening 1.10 (1.08-1.12) <0.001
FACIT score for fatigue— per 1-point worsening 1.03 (1.02-1.04) <0.001
CES score for depression — per 1-point worsening 1.03 (1.02-1.04) <0.001
Laboratory values
Platelet count— per increase of 10xl03/mm3 1.02 (1.01-1.04) <0.001
White-cell count— per increase of lxl03/mm3 1.07 (1.03-1.12) <0.001
Neutrophil count— per increase of lxl03/mm3 1.02 (1.01-1.03) <0.001
Biomarkersj
Fibrinogen — mg/dl 1.35 (1.22-1.49) <0.001
High-sensitivity C-reactive protein — mg/liter 1.24 (1.13-1.37) <0.001
Chemokine ligand 18 — ng/ml 1.13 (1.02-1.25) 0.02
Surfactant protein D — ng/ml 1.10 (1.01-1.20) 0.04
Self-reported symptoms and disease history— yes vs. no;i;
Gastroesophageal reflux or heartburn 1.69 (1.38-2.06) <0.001
Wheezing 1.56 (1.31-1.86) <0.001
Osteoporosis 1.74 (1.34-2.27) <0.001
Asthma 1.52 (1.23-1.87) <0.001
Chronic cough 1.20 (1.01-1.42) 0.04
* The full version of this table, including all baseline characteristics, is available in the Supplementary Appendix. Only signifi¬
cant variables are listed. Nonsignificant variables included other clinical data (number of pack-years of smoking), other
laboratory values (percentage of blood eosinophils and hemoglobin), other biomarker data (interleukin-6, interleukin-8,
Clara cell protein-16, and tumor necrosis factor a), and other data on self-reported symptoms and disease history (hyper¬
tension, hay fever, chronic bronchitis or chronic phlegm production, "lung trouble" before 16 years of age, exposure to
chemical fumes or dusts at work, and cardiovascular and sinus disease). BODE denotes body-mass index, (airway) ob¬
struction, dyspnea, and exercise tolerance; CES Center for Epidemiologic Studies; FACIT Functional Assessment of Chronic
Illness Therapy; FEVi forced expiratory volume in 1 second; FVC forced vital capacity; GOLD Global Initiative for Chronic
Obstructive Lung Disease; MRC Medical Research Council; and SGRQ St. George's Respiratory Questionnaire.
"j- The increment for biomarker changes was 1 SD on the log scale.
$ Data on self-reported history are based on subjects' responses to the ATS-DLD questionnaire.
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Table 3. Factors Associated with Increased Exacerbation Frequency in the Stepwise Multivariate Model.-
Factor Number of Exacerbations
P Value for
Overall Model
>2 vs. 0 lvs. 0 a2 vs. 1
odds ratio
(95% CI) P value
odds ratio
(95% CI) P value
odds ratio
(95% CI) P value
Exacerbation during previous yr—
any vs. none
5.72 (4.47-7.31) <0.001 2.24 (1.77-2.84) <0.001 2.55 (1.96-3.31) <0.001 <0.001
FEVX — per 100-ml decrease 1.11 (1.08-1.14) <0.001 1.06 (1.03-1.08) <0.001 1.05 (1.02-1.09) <0.001 <0.001
SGRQ score for COPD— per
increase of 4 points
1.07 (1.04-1.10) <0.001 1.01 (0.99-1.04) 0.38 1.06 (1.03-1.09) <0.001 <0.001
History of reflux or heartburn—
yes vs. no
2.07 (1.58-2.72) <0.001 1.61 (1.23-2.10) <0.001 1.29 (0.97-1.70) <0.005 <0.001
White-cell count— per increase
of lxl03/mm3
1.08 (1.03-1.14) 0.002 1.02 (0.97-1.08) 0.45 1.06 (1.01-1.12) <0.001 0.007
* FEVX denotes forced expiratory volume in 1 second, and SGRQ St. George's Respiratory Questionnaire.
are shown in Table 3. Exacerbations were signifi¬
cantly associated with worsening lung function
(according to post-bronchodilator FEVJ, greater
impairment in health status (quality oflife), a his¬
tory of gastroesophageal reflux, and an increased
white-cell count.
STABILITY OF THE FREQUENT-EXACERBATION
PHENOTYPE
To assess the stability of the frequent-exacerbation
phenotype over time, we first assessed how well
patients' recall of treated exacerbations in the year
before study entry predicted the number of exac¬
erbations in year 1, calculating positive predic¬
tive values and negative predictive values. These
analyses included data from the 1679 patients who
completed all 3 years of the study.
Among the 1318 patients reporting no exacer¬
bation or one exacerbation in the year before en¬
rollment (infrequent exacerbations), 1037 also had
infrequent exacerbations in the first year of the
study (negative predictive value, 79%). Among the
361 patients reporting two or more exacerbations
in the year before enrollment (frequent exacerba¬
tions), 211 also had frequent exacerbations in the
first year of the study (positive predictive value,
58%); 289 of these patients (80%) had at least one
exacerbation. Previous exacerbation frequency as
recalled by patients therefore had a sensitivity of
43% and a specificity of87% for actual exacerba¬
tion frequency in the following year.
We next examined the stability ofexacerbation
frequency between study years 1 and 2. Among
the 1187 patients with infrequent exacerbations
during year 1, a total of 987 had infrequent ex¬
acerbations in year 2 (negative predictive value,
83%). Among the 492 patients with frequent exac¬
erbations in year 1, there were 296 who had fre¬
quent exacerbations in year 2 (positive predictive
value, 60%); 84% of patients with frequent exac¬
erbations in year 1 had at least one exacerbation
in year 2. Thus, exacerbation frequency in the first
year had a sensitivity of 60% and a specificity of
83% for the frequency in the second year.
Among the 1183 patients with infrequent ex¬
acerbations in year 2 of the study, 994 also had
infrequent exacerbations in year 3 (negative pre¬
dictive value, 84%). Among the 496 patients with
frequent exacerbations in year 2, there were 276
who had frequent exacerbations in year 3 (positive
predictive value, 56%).
Over the three-year study period, the pheno-
types for exacerbation susceptibility and resistance
became stronger. Among 296 patients who had
frequent exacerbations in years 1 and 2, there
were 210 (71%) who went on to have frequent
exacerbations in year 3, and among 521 patients
with no exacerbation in year 1 or year 2, a total
of 388 (74%) also had no exacerbation in year 3.
The stability of exacerbation frequency is shown
in Figure 2.
EXACERBATION FREQUENCY ACCORDING TO
DISEASE SEVERITY
Among the 945 patients with moderate COPD, 208
(22%) had frequent exacerbations (two or more
during the first year of the study). (The character¬
istics of patients with moderate COPD are listed
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according to exacerbation frequency in Table 1 in
the Supplementary Appendix.) To further charac¬
terize patients with moderate COPD who had the
frequent-exacerbation phenotype, we repeated the
stepwise multinomial regression analysis, this
time including only these patients. Because there
was a high degree of confounding with sex in
this model, associations were explored for each
sex separately. The results are reported in Table 4.
Exacerbations were significantly more common
in women with moderate COPD than in men with
moderate COPD: 1.02 versus 0.74 exacerbations
per person per year (P<0.001). As in the full co¬
hort, among both men and women, the variable
most strongly associated with exacerbations dur¬
ing the first year of follow-up was a history of
exacerbations. A greater impairment in health sta¬
tus (quality of life) was associated with exacerba¬
tions in the overall cohort of patients with mod¬
erate COPD, but the association was not observed
in the models in which each sex was analyzed
separately.
Among the 293 patients in the study who had
very severe COPD, 138 (47%) had frequent exac¬
erbations (two or more) during the first year of the
study, and 84 (29%) had no exacerbations. (The
characteristics ofpatients with very severe COPD,
categorized according to exacerbation frequency,
are listed in Table 2 in the Supplementary Ap¬
pendix.) In a stepwise logistic-regression analy¬
sis, the patients with very severe COPD who did
not have exacerbations during the 3-year study
period were those who did not have exacerbations
in the year before study entry (odds ratio, 4.53;
95% CI, 2.62 to 7.82; P<0.001). No other variables
were significantly associated with exacerbations,
and in this group of patients, there was no asso¬
ciation between exacerbation frequency and health
status (as assessed with the use of the St. George's
Respiratory Questionnaire). (The characteristics
ofpatients with severe COPD, categorized accord¬
ing to exacerbation frequency, are listed in Ta¬
bles 3 and 4 in the Supplementary Appendix).
DISCUSSION
Using data from the large observational ECLIPSE
cohort, we examined the frequency of exacerba¬
tions among patientswith moderate, severe, or very
severe COPD. We found that one group of pa¬
tients appeared to be susceptible to exacerbations,
irrespective ofdisease severity as defined by spiro-
metric assessment of lung function. This pheno¬
type of susceptibility to exacerbations could be
identified by asking patients about previous ex¬
acerbations and was relatively stable over a 3-year
period.
A range of variables have inconsistently been
associated with exacerbation frequency in previ¬
ous studies.8"10 We have provided robust data from
a single study showing that exacerbations requir¬
ing treatment become more frequent as the se¬
verity of COPD increases. Our study concerns
moderate and severe exacerbations, which are the
most burdensome to patients and health care ser¬
vices, among patients with a wide spectrum of
COPD severity and in whom the underlying dis¬
ease has been comprehensively assessed. Our con¬
servative definition of exacerbation probably un¬
derestimates the frequency of symptom-defined
events.8 Nevertheless, the proportion of patients
with GOLD stage 4 disease who had frequent ex¬
acerbations (two or more annually) was more than
twice the proportion ofpatients with GOLD stage
2 disease who had frequent exacerbations. Our
data also support the view that the consequences
ofexacerbation become more severe with increas¬
ing disease severity. However, differentiating the
severity of exacerbations from the severity of the
underlying disease is complex.
The major determinant of frequent exacerba¬
tions in all GOLD stages ofCOPD severity that we
examined was a history of exacerbations. Our re¬
sults suggest that COPD with frequent exacerba¬
tions is a distinct phenotype that is seen in mod¬
erate and severe stages of disease and that the
incidence of frequent exacerbations increases with
increasing disease severity. We use the term "dis¬
tinct" in reference to a subgroup of patients who
appear to be particularly susceptible to these
events, accepting that exacerbation frequency is
a continuous variable. There is currently much in¬
terest in defining specific phenotypes in COPD
that may have different prognoses or treatment
requirements.19 Our data suggest that the frequent-
exacerbation phenotype can be identified on the
basis of a history of exacerbations, potentially
allowing for appropriate targeting of patients for
interventions and making it possible to selec¬
tively recruit patients for clinical trials. Status
with respect to exacerbation frequency appears
to be relatively stable over time, especially in the
case of patients who do not have exacerbations.
This suggests that the phenotype of frequent ex-
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Figure 2. Stability ofthe Frequent-Exacerbation Phenotype in the 1679 Patients with Chronic Obstructive Pulmonary DiseaseWho Completed
the Study.
The bars at the left show the proportions of patients with no exacerbations, one exacerbation, or two or more exacerbations in year 1.
The bars in the middle show the respective incidence of exacerbations for these patients in year 2; the bars at the right show the respec¬
tive incidence in year 3. The percentages at right denote the proportions ot all patients with no exacerbations, one exacerbation, or two
or more exacerbations. Numbers do not sum to 100 because of rounding.
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Table 4. Factors Associated with Increased Exacerbation Frequency in Patients with Moderate {GOLD Stage 2) COPD, According to Sex.
Factor Number of Exacerbations
Overall
P Value
;>2 vs. 0 lvs. 0 ;>2 vs. 1
odds ratio
(95% CI) P value
odds ratio
(95% CI) P value
odds ratio
(95% CI) P value
Women (N = 376)
Exacerbation during previous year—
yes vs. no
8.89 (4.32-18.29) <0.001 2.28 (1.26—4.11) <0.006 3.90 (1.82-8.34) <0.001 <0.001
History of asthma— yes vs. no 3.38 (1.62-7.05) <0.001 3.00 (1.59-5.66) <0.001 1.12 (0.53-2.38) 0.76 <0.001
Fibrinogen — per increase of 1 SD
on log scale
1.95 (1.28-2.97) <0.002 1.22 (0.85-1.74) 0.28 1.60 (1.03-2.49) <0.04 0.008
Men (N = 569)
Exacerbation during previous yr—
yes vs. no
7.38 (4.44-12.27) <0.001 3.28 (2.09-5.13) <0.001 2.25 (1.30-3.90) 0.004 <0.001
FEV, -— per 100-ml decrease* 1.20 (1.11-1.31) <0.001 1.07 (1.00-1.14) <0.05 1.13 (1.04-1.23) <0.006 <0.001
Chronic wheezing— yes vs. no 2.56 (1.55—4.23) <0.001 1.40 (0.89-2.18) 0.14 1.83 (1.06-3.16) <0.03 0.001
* FEV, denotes forced expiratory volume in 1 second, and NS not significant.
acerbations may best be described as an exacerba¬
tion-susceptibility phenotype, in which persons
with the phenotype are prone to exacerbations as
a result of intrinsic susceptibility and have exacer¬
bations on exposure to particular triggers, such
as respiratory viral infection.20
In the multivariate analysis of data for the en¬
tire cohort, in addition to the association with
previous exacerbations and with greater disease
severity, more frequent exacerbations were associ¬
ated with greater impairment in health status,
a history of gastroesophageal reflux, and an el¬
evated white-cell count. Sex was associated with
exacerbation frequency, but it was confounded
with other variables. It has previously been re¬
ported that patients with frequent exacerbations
may have increased airway inflammation in the
stable state.21 The relationship that we observed
between exacerbation frequency and health sta¬
tus has been noted previously,4 as has the asso¬
ciation of exacerbations with gastroesophageal
reflux.22 In contrast, chronic bronchitis was not
associated with exacerbations in any of our analy¬
ses, despite previous reports that cough and spu¬
tum production are related to exacerbations in
COPD.2325
Among the patients who had moderate COPD,
22% had frequent exacerbations — an important
observation, considering that such patients, who
have relatively mild disease according to FEV1
criteria, may not at present be identified for in¬
terventions to reduce exacerbations. Since mod¬
erate COPD is more prevalent than very severe
COPD,26 the overall burden of exacerbations may
be greater with milder disease. In the group of
patients with moderate disease in our study, ex¬
acerbations were more common among women
than among men, and there were other factors
that varied according to sex. The observation of
sex-based differences in exacerbation frequency is
intriguing, and it is not clear whether the higher
rate of exacerbations among women represents
a real increase in exacerbations, women's height¬
ened awareness of symptoms, or a greater ten¬
dency on the part of women to report such
changes in symptoms to a health care provider.
Regarding features that could suggest airway hy¬
perreactivity, such as wheezing or a history of
asthma, bronchodilator reversibility criteria were
not used as criteria for inclusion or exclusion in
the ECLIPSE study. The question of whether clini¬
cally significant airway hyperresponsiveness is
also a distinct phenotype in COPD requires fur¬
ther study.
Among the patients in the study who had very
severe COPD, 29% appeared to have had resis¬
tance to exacerbations, although some of these
patients may have been unable to recognize an
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exacerbation (which may therefore not have been
reported to their physician for treatment).4'27 This
finding also has potential implications for thera¬
py, in that it may not be necessary to take aggres¬
sive approaches to the prevention of exacerbations
in patients with very severe COPD if they do not
have a history ofsuch events. In our study, patients
with very severe disease who did not have exacer¬
bations did not have any other characteristics dis¬
tinguishing them from patients with exacerba¬
tions except for the fact that they did not report
exacerbations in the preceding year.
Although exacerbation frequency was associat¬
ed with health status across the GOLD stages and
in patients with moderate (stage 2) disease, this
was not true among patients with the most se¬
vere disease (stage 4). Whether this trend reflects
the smaller number of patients with very severe
disease or a survivor effect among patients with
severe disease who were participating in a longi¬
tudinal study cannot be established. Another pos¬
sibility is that in patients with very severe COPD,
the role of exacerbations in compromising health
status is less important than that of the severity
of the underlying disease itself.
The main strength of this analysis is the use of
a large cohort of patients with COPD and a range
of disease severity. Some important negative
findings deserve mention— in particular, the fact
that we did not find an association between smok¬
ing status and exacerbation frequency.4 However,
our cohort was not a population sample but a
sample of symptomatic patients known to respi¬
ratory physicians. Controlled trials have shown
that pharmacotherapy can reduce exacerbations.9'10
We did not focus on medication as a determinant
of exacerbations. Evidence-based treatment of
COPD often includes the use of a history of ex¬
acerbation as an indicator for starting treatment12;
in an observational study, exacerbations are there¬
fore likely to predict treatment— not vice versa.
In conclusion, our study confirms the obser¬
vation that exacerbations become more frequent
and more severe as the severity of underlying
COPD increases and shows that the most impor¬
tant determinant of frequent exacerbations is a
history of exacerbations. This finding supports
the hypothesis that patients who are more subject
to frequent exacerbations, some of whom have
milder disease, have a distinct susceptibility phe-
notype that is relatively stable over time and can
be identified on the basis of the patient's recall
of previously treated events.
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Lung Mechanics and Dyspnea during E^acerbaftians ©f
Chronic ©bstracttiwe Pulmonary Disease
Nicola J. Stevenson, Paul P. Walker, Richard W. Costello, and Peter M. A. Calverley
Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, United Kingdom; and Department of Medicine,
Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
Rationale: Exacerbation of chronic obstructive pulmonary disease
commonly causes hospitalization. The change in lung mechanics
during exacerbation and its relationship to symptoms in spontane¬
ously breathing individuals has not been described.
Objective:We hypothesized that changes in both airflow and lung
volumes would occur during an exacerbation, but that only volume
change would relate to symptomatic improvement.
Methods: Lung mechanics and resting dyspnea were recorded in 22
hospitalized patients during recovery from exacerbation.
Measurements: Spirometry, inspiratory capacity, respiratory system
resistance and reactance, tidal breathing patterns, and expiratory
flow limitation were recorded after nebulized bronchodilator ther¬
apy on the first 3 d after admission, at discharge, and 6 wk postad-
mission (Day 42). Prebronchodilator measurements were taken on
Day 2, at discharge, and on Day 42.
Main Results: Postbronchodilator inspiratory capacity increased 0.23 ±
0.07 L by discharge and 0.42 ±0.1 L by Day 42, FEV, rose 0.09 ±
0.04 and 0.2 ± 0.05 L at discharge and Day 42, respectively, and
FVC increased 0.21 ± 0.08 and 0.47 ± 0.09 L at discharge and Day
42 (all p < 0.05). Consistent reduction in dyspnea was seen as
the exacerbation resolved. Respiratory system resistance, FEV,/FVC,
and expiratory flow limitationwere unchanged throughout, indicat¬
ing that changes in lung volume rather than airflow resistance
predominated.
Conclusions: Improvement in operating lung volumes is the principal
change seen as a chronic obstructive pulmonary disease exacerba¬
tion resolves and increase in inspiratory capacity is a useful guide
to a reduction in dyspnea.
Keywords: breathlessness; inspiratory reserve volume; lung function;
lung hyperinflation
Periodic exacerbations of symptoms are amajor cause ofmorbid¬
ity, mortality, and health care costs in patients with chronic
obstructive pulmonary disease (COPD) (1, 2). They are associ¬
ated with a worse quality of life (3, 4) and a more rapid decline
in both health status (4) and FEV! (5, 6). Most exacerbations
are precipitated by either bacterial or viral infections (7, 8), but
the resulting symptoms relate mainly to altered lung function.
Increased cough, sputum production, and sputum purulence oc¬
cur during exacerbations, but patients identify the most impor¬
tant symptom as being worsening breathlessness (9, 10). Al¬
though changes in lung mechanics are thought to be the major
cause of dyspnea in COPD, we have few data about the time
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course and nature of the change in lung mechanics during the
resolution of an exacerbation in normocapnic patients.
Studies of patients in intensive care units have shown that
the resistive and elastic work of breathing increases significantly
during exacerbations, which leads to a marked increase in intrin¬
sic positive end-expiratory pressure (11,12). How these changes
relate to more familiar measurements of flow and volume or to
changes in symptom intensity in spontaneously breathing sub¬
jects has not been reported, but several mechanisms appear
possible. Increased airway resistance, due to the release ofmedi¬
ators or the direct effect of inflammation reducing airway diame¬
ter, should lessen as the exacerbation resolves and be reflected
by an increase in peak expiratory flow or FEVp However, the
changes reported in these measures during an exacerbation of
COPD are relatively small (13). Tidal expiratory flow limitation
(EFL) is a better indicator of dyspnea severity than is the FEVi
in stable COPD (14), and thus changes in EFL due to airway
narrowing or closure during an exacerbation of COPD might
relate to changes in symptom intensity. The relationship of EFL
to other indices of lung mechanics during exacerbations has not
been reported. However, the factor most likely to explain the
change in symptoms during an exacerbation is a change in op¬
erating lung volume. An increase in end-expiratory lung volume
(EELV) during exercise is the best predictor of symptom inten¬
sity and the degree of exercise limitation (15), and both improve
after administration of a bronchodilator drug (16). During an ■
exacerbation of COPD closure of small airways may occur be¬
cause of mucus plugging, airway wall edema, or inflammation
of lymph follicles, all of which may increase EELV even under
resting conditions (17).
We hypothesized that during the resolution of an exacerba¬
tion of COPD there would be larger changes in lung volume
than in expiratory flow-relatedmeasurements. It proved imprac¬
tical to study the onset of an exacerbation and thus we prospec¬
tively studied patients on admission to hospital and monitored
their subsequent clinical course. To compare patients we stan¬
dardized treatment given and measurement timing as well as
prior bronchodilator therapy. We recorded pre- and post¬
bronchodilator values for spirometry, dynamic lung volumes,
oscillatory lung mechanics, and breathing pattern and tested for
the presence of tidal expiratory flow limitation, relating these
to changes in dyspnea and clinical improvement. Some of the
results of these studies have previously been reported in the
form of abstracts (18-20).
METHODS
Subject Recruitment
Patients were recruited within 24 h of hospitalization. An acute exacer¬
bation was defined as an increase in at least two major symptoms:
dyspnea, sputum purulence, or increased sputum volume, sufficient to
require hospitalization (21). Patients were excluded if they had acute
pneumonia, pneumothorax, atelectasis, or heart failure; had respiratory
acidosis (pH < 7.32); had a coexisting illness that rendered them too
ill to participate; or were unwilling to participate. AH patients had a
diagnosis ofCOPD defined both clinically and physiologically (22) with
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an FEV! less than 80% predicted and an FEV^VC ratio less than 0.7
when enrolled (23). Any patient in whom the FEVt increased by more
than 400 ml after administration of nebulized bronchodilator (24) or
whose lung function improved to within normal values at any test
sessionwas excluded.Written informed consent was obtained from each
patient. The local research ethics committee granted study approval (see
the online supplement for further details).
Inpatient Management of Exacerbation
All patients were managed by a respiratory physician who determined
the time of discharge on clinical groundswithout knowledge of the study
measurements. While hospitalized, patients received regular nebulized
salbutamol and ipratropium bromide (5mg and 0.5mg per nebulization,
respectively) and oral corticosteroids (30 mg daily for 1 wk), and most
patients received antibiotics (usually a broad-spectrum penicillin) as
directed by their clinician.
Study Design
Postbronchodilator assessments were made daily for the first 3 d (Days
1,2, and 3), at discharge and, when possible, on Day 42 (6wk postadmis-
sion). Additional prebronchodilator data were obtained on Day 2, at
discharge, and, when possible, on Day 42. All prebronchodilator tests
were performed in the morning with no bronchodilator therapy for
6 h beforehand. Patients subsequently received nebulized salbutamol
(5 mg) and ipratropium bromide (0.5 mg). Forty-live minutes later, the
tests were repeated. Tests were performed in the same sequence at
each visit and comprised measurement of flow limitation, resting tidal
breathing analysis, measurement of respiratory system resistance and
reactance during tidal breathing, inspiratory capacity (IC), and spirome¬
try (see the online supplement for further details).
Measurements
Spirometry and IC. Spirometry was measured to American Thoracic
Society standards (23), using a pneumotachograph (Jaeger MasterScreen
IOS; VIASYS Healthcare, Hoechberg, Germany). IC was calculated
indirectly by measuring the expiratory reserve volume (ERV) and VC,
also using the same pneumotachograph. Testing was repeated until two
reproducible values within 10% of each other were obtained; the best
being recorded. Predicted IC was derived from combined total lung
capacity (TLC) and FRC predictions. Inspiratory reserve volume (IRV)
was calculated by subtracting Vt from IC.
Measurementoftotal respiratory system resistance and reactance. Re¬
spiratory system resistance at a frequency of 5 Hz (R5) and reactance at
5 Hz (X5) was measured by impulse oscillometry (Jaeger MasterScreen
IOS); the apparatus deadspace was 120 ml. At least five tidal breaths of
the same duration and volume were recorded and the analyzed data
were averaged over this time period. Measurements were repeated until
two values that were within 10% of each other were obtained. The mean
value of these measurements was used for analysis (25).
Tidal breathing and resting expiratoryflow limitation. Resting breath¬
ing was recorded with the pneumotachograph system for 3 min, with
data analyzed during the final minute. Respiratory rate, Vt, inspiratory
and expiratory times and their derivatives,mean inspiratory and expiratory
flow (Vr/inspiratory time [Ti] and VT/expiratory time [Te], respectively),
duty cycle (Ti/total cycle duration [Ttot]), and Ve were calculated.
Negative expiratory pressure during tidal breathing was applied to
detect expiratory flow limitation in the seated patient, as described
previously (26). Breaths were considered flow limited when negative
expiratory pressure did not increase expiratory flow relative to the
preceding untested breath. Flow limitation was also expressed as the
percentage of expired tidal volume affected (FL % Vt).
Assessment of Dyspnea
Before each testing sequence patients were asked to rate the intensity
of their resting breathlessness on a modified Borg scale, in response to
the question: "How breathless do you feel?" (27).
See the online supplement for additional detail on the methods used
to make all these measurements.
Statistical Analysis
Data are expressed as means (SD) for group data or as means ± SEM
when time points or groups are compared. We used a Student / test
and repeated measures analysis of variance to compare differences
in normally distributed data (SPSS version 10.0; SPSS, Chicago, IL),
accepting p < 0.05 as significant. On the basis of the known test-test
reproducibility of inspiratory capacity (26), we needed 14 patients to
detect a 200-ml difference in IC from entry to study conclusion. We
anticipated that we might have a 35% dropout with this protocol and
planned to recruit at least 21 individuals.
RESULTS
Clinical Characteristics of the Study Population
Of 44 patients identified as being potentially eligible over an
18-mo period, 30 entered the study but 7 withdrew during the
early stages because of clinical deterioration (n = 5) or technical
difficulty in completing maneuvers (n = 2). One patient was
excluded as that patient's lung function subsequently returned
to normal. The admission characteristics of the remaining 22
patients are shown in Table 1.
All patients reported symptoms consistent with an acute exac¬
erbation before admission to hospital. Four patients had received
antibiotics and/or oral corticosteroids in the week before admis¬
sion. No patient had been admitted with an exacerbation of
COPD in the preceding 6 wk. Three patients received intrave¬
nous aminophylline and none required ventilation or died. The
median length of hospital stay was 7 d (range, 3-10 d). Two
patients were discharged on Day 3 and their measurements on
Day 3 were also included in the discharge day data. See the
online supplement for sputum microbiological data. Neither the
presence of microorganisms in the sputum nor the treatment
received before admission appeared to influence the changes in
lung mechanics seen during recovery from the exacerbation.
Data for 6 of the 22 patients were not available for Day 42,
either because of recurrent exacerbations of COPD (n = 5) or
because the patient declined to attend for these follow-up studies
(n = 1). Admission data for the 16 patients who returned on
Day 42 are shown in Table 1. Admission characteristics of the
subjects who returned on Day 42 did not differ from those
who did not (Table 1), nor did the data at discharge (data not
presented).
Changes in Lung Mechanics during the Exacerbation
Postbronchodilator spirometry and lung volume. Changes in post¬
bronchodilator spirometry and IC from admission to discharge
and, when available, to Day 42 for all subjects are shown in
Figure 1 and Table 2. Group mean postbronchodilator FEVi
improved by 0.09 ± 0.04 L at discharge (n = 22, p < 0.05) and
by 0.20 ± 0.05 L (n = 16, p < 0.01) by Day 42 relative to the
Day 1 value. Postbronchodilator FVC improved by 0.2 ± 0.08 L
(n = 22, p < 0.05) on discharge and by Day 42 had increased
0.47 ± 0.09 Lfrom the admission value (n = 16, p < 0.001). There
was no change in FEVj/FVC ratio at any stage; for example,
the ratio was 0.49 on admission and 0.48 on Day 42 (p = not
significant). These data were not different if slow vital capacity
data were substituted for the FVC.
IC increased from Day 1, when it was 62 ± 4% predicted at
admission, to 73 ± 4% at discharge (n = 22, p < 0.05), and to
81 ±7% on Day 42 (n = 16, p < 0.01). These values correspond
to. an improvement of 0.23 ± 0.07 L (p < 0.01) by discharge
and 0.42 ± 0.1 L (p < 0.01) by Day 42; see also Table 2. The
change in IC from admission to discharge was related to the
change in FVC (r - 0.47, p < 0.05) but not the change in FEVt.
Respiratory system resistance and reactance. There was no
significant change in respiratory system resistance, R5, through¬
out the study. Thus the R5 fell from 0.65 ± 0.04 to 0.59 ± 0.04
kPa/L/s on discharge, whereas in those in whom it was recorded
on Day 42 the R5 was 0.61 ± 0.2 on admission and 0.58 ± 0.04
on Day 42 (Tables 1 and 2 and Figure 2A).
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TABLE 1. ADMISSION CHARACTERISTICS OF ALL SUBJECTS WHO WERE MONITORED TO
DISCHARGE AND OF THE 16 SUBJECTS WHO COMPLETED 42 DAYS OF FOLLOW-UP
All Subjects Subjects Attending on Day 42
No. subjects (no. males) 22 (9) 16(7)
Age, yr 70 (10.3) 69 (9.9)
Smoking, pack-yr 47 (22.5) 45 (15.5)
Body mass index, kg/m2 21.9(4.8) 22.3 (4.8)
White cell count, x 109/L 11.50(4.36) 11.42 (4.83)
Borg breathlessness score at rest on first assessment 3.7(1.6) 3.9 (1.8)
pH 7.41 (0.05) 7.40 (0.05)
Pa0j, kPa 8.97 (1.40) 8.94 (1.51)
Pac<v kPa 5.02 (0.88) 5.04 (0.99)
FEV,, L 1.03 (0.36) 1.06 (0.40)
FEV,, %pred 46.7 (18.1) 46.8 (19.2)
FVC, L 2.15 (0.57) 2.08 (0.51)
IC, L 1.37(0.43) 1.32 (0.39)
IC, %pred 62.2 (16.3) 59.3 (16.4)
Total respiratory system resistance
Rs, kPa/L/s 0.65 (0.2) 0.61 (0.2)
Xj, kPa/L/s -0.42 (0.16) -0.40 (0.19)
No. subjects with resting EFL 9 7
Definition of abbreviations: EFL = tidal expiratory flow limitation assessed by negative expiratory pressure technique; IC =
inspiratory capacity; Rs = total respiratory system resistance; X5 = total respiratory system reactance.
Values represent means (SD). No statistically significant differences were seen between the groups.
The group mean respiratory system reactance measured at
5 Hz, X5, improved from admission to discharge by 0.11 ± 0.02
kPa/L/s (p < 0.001) and was not significantly different on Day 42
(Table 2 and Figure 2B). From admission to discharge postbron-
chodilator X5 became less negative in 16 subjects (-0.45 ± 0.04
to -0.29 ± 0.04 kPa/L/s) and remained constant in the other
6 patients. There were no significant differences on admission
between patients whose Xs improved over time and those for
whom it did not. The "X5 improvers" had significant improve¬
ments in FEVr (mean change, 130 ml; p < 0.05) and IC (mean
change, 270ml; p < 0.01) whereas the "nonimprovers" did not show
significant improvement (see Table El in the online supplement).
Breathingpattern. The postbronchodilator breathing pattern
at rest did not change significantly during the recovery period
(Table 3). Resting Ve remained relatively high at each test ses¬
sion despite the improvement in other measurements of lung
mechanics. A significant increase in IRV of 0.2 ± 0.1 L (p <
0.05) occurred during the in-hospital period. There was a further
change in outpatient recovery period: on Day 42, IRV increasing
from admission by 0.27 ± 0.64 L (n = 16, p = 0.05).
Tidalflow limitation during exacerbation. On admission, when
seated, 9 of the 22 patients showed EFL, whereas 13 were not
tidal flow limited. EFL resolved in four patients and appeared
for the first time by discharge in . two patients; the remaining 16
patients were unchanged. In EFL, subjects' mean percentage of
FL as a percentage of Vt (FL % Vt) was 44 ± 3% at baseline.
There was no clear pattern of change or improvement in FL % Vt
during recovery.
Bronchodilator Response during Exacerbation
Changes in lung mechanics, breathing pattern, and dyspnea after
nebulized bronchodilators are presented in Table 4. There was a
significant increase in FEVb FVC, IC, and X5 after bronchodilator
administration, accompanied by a fall in dyspnea score and R3.
The increase in FEV; (p < 0.04) and fall in R5 (p < 0.01)
immediately after bronchodilator administration was greater as
the exacerbation resolved. The improvement in IC, FVC, and
Borg score was similar irrespective of the time after admission
that the test was performed.
Breathing pattern was little affected by the bronchodilator,































(Day 1) to discharge (median, Day 7) and postdischarge (Day 42). (B)
Difference in inspiratory capacity (IC) over time from day of admission
(Day 1) to discharge (median, Day 7) and postdischarge (Day 42).
*p < 0.05; fp < 0.01; *p < 0.001, discharge and Day 42 compared
with Day 1. Note that data for Day 42 apply to 16 patients only (see
Tables 1 and 2 for relevant baseline and Day 42 data).
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TABLE 2. CHANGE IN LUNG MECHANICS AND SYMPTOMS OVER THE COURSE OF THE FIRST 3
DAYS OF HOSPITALIZATION, AT THE TIME OF DISCHARGE, AND ON DAY 42
Day 1 Day 2 Day 3 Discharge Day Day 42
No. subjects 22 22 22 22 16
FEV„ L 1.03 ± 0.08 1.08 ± 0.08* 1.08 ± 0.08 1.12 ± 0.09* 1.26 ± 0.10'
FEVi, %pred 47.0 ± 3.9 49.2 ± 4.1* 49.4 ± 4.2 51.2 ± 4.6* 54.8 ± 4.2*
FVC, L 2.15 ± 0.12 2.28 ± 0.2 2.23 ± 0.14 2.36 ± 0.12* 2.54 ± 0.14'
FVC, %pred 76.9 ± 4.8 80.2 ± 4.4 78.0 ± 4.3 83.5 ± 4.1* 86.3 ± 3.1'
FEV,/FVC 0.49 ± 0.03 0.48 ± 0.03 0.50 ± 0.03 0.48 ± 0.03 0.49 ± 0.03
IC, L 1.37 ± 0.1 1.46 ± 0.1 1.43 ± 0.10 1.60 ±0.10' ■ 1.74 ± 0.13'
Borg score 3.73 ± 0.34 3.03 ± 0.34* 3.07 ± 0.30* 2.47 ± 0.24' 2.16 ± 0.30'
Rj, kPa/L/s 0.65 ± 0.04 0.60 ± 0.04 0.65 ± 0.04 0.59 ± 0.04 0.58 ± 0.04
X5, kPa/L/s -0.42 ± 0.03 -0.37 ± 0.04 -0.39 ± 0.04 -0.31 ± 0.03* -0.28 ± 0.04'
Definition ofabbreviations: IC = inspiratory capacity; R5 = total respiratory system resistance; X5 = total respiratory system reactance.
Values represent means ± SEM.
*
p < 0.05, significant difference compared with Day 1.
' p < 0.01, significant difference compared with Day 1.
* p < 0.001, significant difference compared with Day 1.
(+80ml) and Day 42 (+70ml). Expressing the IC as a percentage
of the FVC showed no acute change with bronchodilator admin¬
istration, although the postbronchodilator IC/FVC ratio value
rose from 64% on Day 2 to 68% at discharge. The acute change
in IRV was small on Day 2 but increased by a mean of 120 ml
(p < 0.05) on discharge and by 240 ml (p < 0.05) on Day 42.
Discharge










Figure 2. (A) Difference in total respiratory system resistance (Rs) and
total respiratory system reactance (Xs) over time from day of admission
(Day 1) to discharge (median, Day 7) and postdischarge (Day 42). (B)
Difference in Borg breathlessness scores over time from day of admission
(Day 1) to discharge (median, Day 7) and postdischarge (Day 42).
'p < 0.01; *p < 0.001, discharge and Day 42 compared with Day 1.
Note that data for Day 42 apply to 16 patients only (see Tables 1 and 2
for relevant baseline and Day 42 data).
Relative Change in Resting Breathlessness
and Lung Mechanics
The median resting postbronchodilator Borg breathlessness
score on admission was 4 (range, 0.5-7). There was a fall in
postbronchodilator breathlessness score, relative to Day 1, of
1.7 ± 0.43 units at discharge (p < 0.01) and 2.16 ± 0.4 units on
Day 42 (p < 0.01) with median scores of 2.5 (range, 0-4) and 2
(range, 0-5), respectively (Figure 2B).
Only 16 of 22 patients reported any reduction in resting dys¬
pnea by discharge. These patients had a significantly lower IC
on admission compared with patients not reporting a reduction
in dyspnea (p < 0.01). Both FEVj and IRV were also lower in
this group on admission (both p = 0.05). The degree of resting
dyspnea these patients reported on discharge was similar to that
on admission among the patients whose dyspnea did not improve
over time (see Table E2).
In patients whose Borg score improved during hospitaliza¬
tion, mean FEVj increased by 0.20 ± 0.07 L (p < 0.05), mean
IC by 0.54 ± 0.16 L (p < 0.01), and mean X5 by 0.15 ± 0.04
kPa/L/s (p < 0.01) by Day 42 (n = 11). In contrast, in those
whose dyspnea was unchanged, neither FEVi nor IC increased
significantly (see Table E2). Similar changes were seen in each
of these variables at the time of discharge although these were
generally of a smaller magnitude. By discharge, there was no
significant difference in IC between patients who felt an improve¬
ment in breathlessness and those who did not. The magnitude
of the change in dyspnea from admission to discharge or follow-
up was unrelated to the change in IC or other measured variables.
DISCUSSION
Although exacerbations of COPD are a frequent cause of hospi¬
talization, surprisingly little is known about the physiologic
changes that accompany their resolution and what relationship
these bear to the patient's symptoms. Hypoxia and hypercapnia
have been carefully studied, with the latter relating directly to
lungmechanics (28) and showing a variable resolution over time
(29) and between episodes (30). Our data demonstrate that from
admission to discharge and through the 6 wk after the exacerba¬
tion there was a small increase in FEVb no significant change
in airway resistance or tidal FL, but a significant increase in both
FVC and IC together with an improvement in reactance. In
nonhypercapnic exacerbations, changes in operating lung vol¬
umes rather than either tidal or forced expiratory flow related
to both the resolution of the exacerbation and the change in
breathlessness reported by the patient.
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TABLE 3. BREATHING PATTERN DATA FOR ALL 22 SUBJECTS DURING THE FIRST 3 DAYS OF
HOSPITALIZATION, ON THE DAY OF DISCHARGE, AND ON DAY 42
Day 1 Day 2 Day 3 Discharge Day Day 42
No. subjects 22 22 22 22 16
Vt, L 0.75 ± 0.05 0.76 ± 0.04 0.75 ± 0.04 0.78 ± 0.04 0.83 ± 0.06*
F, min"' 22.15 ± 0.9 23.05 ±1.2 22.78 + 1.4 21.93 ± 1.0 21.6 ± 0.9
Ve, L • min"' 16.8 + 1.5 17.1 ± 0.8 16.71 ±0.9 16.73 ± 0.9 16.1 + 1.5
Ti, s 1.02 ± 0.05 0.99 ± 0.05 1.04 ± 0.07 1.05 ± 0.04 1.12 ± 0.04
Te, s 1.77 + 0.07 1.74 ± 0.08 1.83 ± 0.14 1.79 ± 0.09 1.75 ± 0.08
Vt/Ti 0.77 ± 0.06 0.80 ± 0.04 0.77 ± 0.04 0.75 + 0.04 0.69 ± 0.06
Vt/Te 0.45 ± 0.04 0.45 ± 0.02 0.44 ± 0.02 0.45 ± 0.03 0.45 ± 0.04
Vt/IC 0.57 ± 0.04 0.55 ± 0.03 0.59 ± 0.05 0.52 ± 0.03 0.49 ± 0.05
IRV, L 0.62 ± 0.08 0.71 ± 0.09 0.67 + 0.08 0.82 ± 0.1* 0.97 ± 0.16*
Definition of abbreviations: F = breath frequency; IRV = inspiratory reserve volume; Te = expiratory time; Tr = inspiratory time;
Vt/Te = mean expiratory flow; Vt/Ti = mean inspiratory flow; Vt/IC = ratio of Vt to IC.
Values represent means ± SEM. Statistically significant differences compared with Day 1 are shown.
*
p < 0.05, significant difference compared with Day 1.
A particular strength of this study is the assessment of both
flow- and volume-related measurements at standardized times
and with standardized therapy as the exacerbation resolved.
Treatment before or during admission, including theophylline
use, did not influence lung mechanics, in keeping with another
report (31). All measurements were made at rest and so we
cannot assess the effect of dynamic changes in lung volume that
are likely to occur on exercise in these patients (32). We did not
measure TLC by body plethysmography as this was not possible
in these sick patients. Nonetheless, we believe it unlikely that
TLC increased during recovery and instead either remained
constant or fell. Hence we believe it likely that the change in
postbronchodilator FVC and IC reflects a fall in residual volume
over time. Likewise, the calculated Ve was higher in our patients
than in other studies, which may reflect disease severity of the
patients we studied or the arduous nature of the protocol. How¬
ever, Ve was unchanged with time and is unlikely to influence
the other indices of lung mechanics.
Noninvasive measurements of total respiratory system resis¬
tance and reactance were easy to make, were well tolerated, and
provided information complementary to that obtained from the
change in lung volumes. The accuracy of these data may be
influenced in COPD by the presence of upper airway shunt
compliance (33). This factor does not change acutely, and our
data reported relative to the admission values are likely to be
valid.We have reported data only at 5 Hz as this best reflects total
respiratory system resistance rather than considering frequency
dependence of resistance, a field in which the interpretation of
oscillatorymechanics in COPD remains controversial. TidalEFL
was determined by the negative expiratory pressure technique
in seated subjects. More information might have been obtained
had the subjects been able to lie supine (34), although analysis
of the percentage of each breath showing FL, a potentially more
sensitive descriptor, did not change our results.
The small increase we observed in postbronchodilator FEV!
from admission to discharge is similar to that reported previously
(35). The changes in spirometry were due to an increase in
volume rather than flow as judged by the static FEVj/FVC ratio
throughout the recoveryperiod. This suggests that as the exacerba¬
tion resolved there was an opening of lung units with mechanical
TABLE 4. EFFECTS OF NEBULIZED BRONCHODILATORS ON LUNG MECHANICS, SYMPTOMS, AND BREATHING PATTERN
DURING RECOVERY FROM EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Day 2 Discharge Day 42
Pre Post Pre Post Pre Post
FEV,, L 0.99 ± 0.07 1.08 + 0.08 0.98 ± 0.09 1.12 ± 0.10* 1.04 ± 0.10 1.26 ± 0.11*
FVC, L 2.04 ± 0.14 2.28 ± 0.15* 2.05 ± 0.12 2.36 ± 0.13* 2.18 ± 0.13 2.55 ± 0.15*
IC, L 1.34 ± 0.13 1.46 ± 0.11 1.44 ± 0.12 1.60 ± 0.11* 1.49 ± 0.10 1.74 ± 0.13'
IRV, L 0.65 ± 0.11 0.71 ± 0.09 0.70 ± 0.10 0.82 ± 0.10' 0.73 ± 0.09 0.97 ± 0.14'
Borg score 3.6 ± 0.4 3.0 + 0.4' 2.8 ± 0.2 2.5 ± 0.25' 2.8 ± 0.3 2.15 ± 0.3*
R5, kPa/L/s 0.71 ± 0.04 0.60 ± 0.04* 0.77 ± 0.06 0.59 ± 0.05* 0.79 + 0.05 0.58 ± 0.05*
Xs, kPa/L/s -0.45 ± 0.04 -0.37 ±0.04' -0.50 ± 0.05 -0.31 ± 0.03* -0.51 ± 0.05 -0.28 ± 0.04*
Vt, L 0.68 ± 0.16 0.76 ± 0.16» 0.74 ± 0.19 0.77 ± 0.21 0.72 ± 0.18 0.79 ± 0.24'
F, min-' 23.8 ± 5.8 23.0 ± 5.4 22.0 ± 5.2 22.6 ± 4.8 24.5 ± 6.1 22.0 ± 3.8'
Ti, s 0.97 ± 0.25 0.99 ± 0.24 1.07 ± 0.26 1.03 ± 0.20 0.99 ± 0.28 1.10 ± 0.21'
Te, s 1.67 ± 0.36 1.74 ± 0.39 1.82 ± 0.51 1.73 ± 0.40 1.60 ± 0.37 1.71 ± 0.35
Ve, L ■ min"' 16.2 ± 1.1 1 7.2 + 0.8 16.3 ± 1.3 16.7 ± 0.9 16.9 ± 0.7 16.1 ± 1.3
Vt/Ti 0.75 ± 0.06 0.80 ± 0.04 0.72 ± 0.06 0.77 ± 0.04 0.74 ± 0.03 0.69 ± 0.06
Vt/Te 0.43 ± 0.03 0.45 ± 0.02 0.43 ± 0.04 0.44 ± 0.03 0.46 ± 0.02 0.45 ± 0.04
Definition of abbreviations: F = breath frequency; IC = inspiratory capacity; IRV = inspiratory reserve volume; Rs = total respiratory system resistance; Ti = inspiratory
time; Te = expiratory time; Vt/IC = ratio of Vt to IC; Vt/Te = mean expiratory flow; Vt/Ti = mean inspiratory flow; X5 = total respiratory system reactance.
Values represent means ± SEM. Analysis using paired Student t test comparing pre- and post-bronchodilator values.
*
p < 0.001, significant difference in comparing pre and post results for each day.
1 p < 0.05, significant difference in comparing pre and post results for each day.
* p < 0.01, significant difference in comparing pre and post results for each day.
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properties similar to the lung at admission, as the unchanged
FEVj/FVC ratio reflects the mechanical time constant of the
respiratory system. The IC increase in proportion to the FVC
during the course of the exacerbation is in keeping with this, as
is the relatively constant R5 despite the fall in EELV. Respiratory
frequency was also constant across the study days and did not
seem to be an important determinant of the volume change at
rest.
In our patients, we saw no consistent relationship between
the presence of tidal EFL and the change in either IC or FVC
over time. This might be due to breath-to-breath variation in
the operating lung volume, as has been reportedafter administra¬
tion of nebulized bronchodilators in stable COPD (26), but is
more likely to reflect the change in residual volume over time.
This contribution from a reduced static lung volume helps ex¬
plain why the improvement in postbronchodilator inspiratory
reserve volume occurred without any change in breathing pat¬
tern or respiratory timing.
Total respiratory system reactance became significantly less
negative during recovery. This may in part result from the lower
operating lung volume, but the magnitude of this change is larger
than would be expected if this were the only operative factor.
Taken together with the change in EELV and constant R5, the
data suggest that the "specific conductance" of the respiratory
system was increasing as the patient improved but that individu¬
als opt to reduce operating lung volume rather than to maintain
a higher EELV with lower respiratory system resistance.
This is the first study of the response of patients with COPD
to nebulized bronchodilators during and after an exacerbation.
The large doses used are on the flat part of the dose-response
curve for spirometry (36) and significantly improved FVC and
Borg score at all time points support a relationship between
operating lung volumes and breathlessness. In contrast, signifi¬
cant changes in FEVh IC, and reactance became apparent only
on discharge, becoming larger in thosemonitored to 6 wk postad-
mission. These help explain why spirometric reversibility testing
is unreliable soon after an exacerbation and why tests looking
at FEVj change do not relate well to symptomatic response (37).
Increased breathlessness at rest is a common but not invari¬
able accompaniment ofCOPD exacerbations (13). As in studies
during exercise, Borg dyspnea scores were not normally distrib¬
uted, but for comparison with other data in the literature we
have reported them parametrically (15, 38, 39). Although these
data can be indicative only of the direction of change, not its
magnitude, we found that those patients reporting less breath¬
lessness at the time of discharge and follow-up were the ones
in whom IC and IRV improved significantly over this time, a
change not seen in the smaller number of subjects in whom
dyspnea remained constant. Patients reporting worse breath¬
lessness at admission had significantly worse resting lung me¬
chanics and larger studies will be needed to properly test the
relationship between symptom change during exacerbation reso¬
lution and differentmeasures of lung volume. Mechanically, the
situation at rest during an exacerbation was comparable to that
at maximal tolerated exercise when clinically stable, the change
in postbronchodilator inspiratory capacity of 420 ml from Day 1
to Day 42 being comparable to the volume change reported
during exercise (32, 40).
In summary, in normocapnic patients hospitalized with an
exacerbation of COPD, improvement in operating lung volumes
was related to reduction in dyspnea rather than any index of
expiratory flow; however, it was measured. The impairment in
resting lung mechanics resolved slowly and was not complete at
the time of discharge as determined on the basis of clinical
criteria. The relationship of resting lung mechanics on discharge
to the dynamically regulated lung volume that usually deter¬
mines exercise performance will require further study, as it
may explain the variability in the subsequent clinical course
postexacerbation.
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Hyperglycaemia as a predictor of outcome during
non-invasive ventilation in decompensated COPD
B Chakrabarti,1 R M Angus,2 S Agarwal,2 S Lane,3 P M A Calverley1
ABSTRACT
Rationale: Hyperglycaemia predicts a poor outcome in
Intensive Care Unit (ICU) patients. Whether this is true for
respiratory failure necessitating non-invasive ventilation
(NIV) is not known.
Objectives: To determine whether hyperglycaemia
within 24 h of admission independently predicts outcome
of NIV during acute decompensated ventilatory failure
complicating chronic obstructive pulmonary disease
(COPD) exacerbations.
Methods: Patients with COPD presenting with acute
hypercapnic respiratory failure at University Hospital
Aintree between June 2006 and September 2007 and
receiving NIV within 24 h of admission were studied
prospectively. Random blood glucose levels were
measured before NIV administration.
Results: 88 patients (mean baseline pH 7.25, PaC02
10.20 kPa, and Pa02 8.19 kPa) met the inclusion criteria,
with NIV normalising arterial pH off therapy in 79 (90%).
After multivariate logistic regression, the following
predicted outcome: baseline respiratory rate (OR 0.91;
95% CI 0.84 to 0.99), random glucose >7 mmol/l (OR
0.07; 95% CI 0.007 to 0.63) and admission APACHE II
(Acute Physiology and Chronic Health Evaluation II) score
(OR 0.75; 95% CI 0.62 to 0.90). The combination of
baseline respiratory rate (RR) <30 breaths/min and
random glucose <7 mmol/l increased prediction of NIV
success to 97%, whilst use of all three factors was 100%
predictive.
Conclusions: In acute decompensated ventilatory failure
complicating COPD, hyperglycaemia upon presentation
was associated with a poor outcome. Baseline RR and
hyperglycaemia are as good at predicting clinical
outcomes as the APACHE II score. Combining these
variables increases predictive accuracy, providing a simple
method of early risk stratification.
Non-invasive ventilation (NIV) is an effective
treatment for acute hypercapnic respiratory failure
(AHRF) complicating a chronic obstructive pul¬
monary disease (COPD) exacerbation.1 However,
some patients do not improve with NIV and in
these individuals endotracheal intubation or,
where appropriate, palliation are needed. Several
factors are associated with an increased risk of NIV
failure. In one randomised controlled trial survival
was worse when the initial pH was below 7.3, or if
PaC02 or the respiratory rate (RR) failed to
improve after 4 h of treatment.2 Other factors
retrospectively identified as poor prognostic mar¬
kers include a high APACHE II (Acute Physiology
and Chronic Health Evaluation II) score, radiolo-
gically confirmed consolidation, haemodynamic
instability, impaired consciousness, the presence
of comorbidities, impaired functional status and
metabolic dysfunction.1" NIV is now offered to
patients with COPD presenting with more severe
acidosis than in these early clinical trials and
appears to be effective in improving clinical
outcomes.6 Whether the same risk factors operate
and do so to the same degree is not clear.
In patients with a wide range of conditions
admitted to intensive care, pretherapy hypergly¬
caemia is an independent predictor of a poor
outcome7"10 which may be improved by tight
glycaemic control.1112 A retrospective case note
review of patients hospitalised with COPD exacer¬
bations but not necessarily exhibiting respiratory
failure found an increased mortality and longer
hospital stay in patients with random blood
glucose of 3=7 mmol/l.13 Whether hyperglycaemia
upon presentation influences the outcome of NIV
in acidotic COPD patients is not known nor is its
relationship to other identified poor prognostic
factors. To investigate these relationships we
prospectively collected data about the occurrence
of hyperglycaemia and the risk factors identified
above in an observational study of consecutive
patients with COPD undergoing NIV.
METHODS
Patients
All patients admitted to University Hospital
Aintree between June 2006 and September 2007
with an exacerbation of COPD who received NIV
within 24 h of admission to the Respiratory Failure
Unit (RFU) or ICU were prospectively identified.
AHRF was defined by the presence of worsening of
dyspnoea and an arterial pH <7.35 with a PaC02
>6 kPa. The diagnosis of COPD was made
clinically and confirmed by spirometry whenever
possible." Where spirometry was unavailable, a
senior respiratory clinician confirmed that COPD
was the most likely diagnosis based on the history,
tobacco exposure, examination findings and radi¬
ology. An exacerbation of COPD was defined
according to pre-existing criteria" while pneumo¬
nia was diagnosed when a new infiltrate on the
chest radiograph occurred with one or more of the
following: dyspnoea, cough, sputum production,
fever >38°C, abnormal breath sounds and rales.15
We excluded patients with other respiratory
conditions—for example, chest wall and neuro¬
muscular disease leading to acute on chronic
ventilatory failure, those presenting with acute
cardiogenic pulmonary oedema, those patients
where doxapram was used as an adjunct to NIV,
patients commenced on NIV >24 h following
hospital admission and those with known active
malignancy or a diagnosis of acute or chronic
thromboembolic disease. In addition, patients with
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COPD weaned using NIV postextubation and those unable to
tolerate the mask due to agitation or claustrophobia were
excluded. Details of the local protocol in our institution for
administering NIV during acute exacerbations of COPD are
given in the online supplement.
Protocol and measurements
Before initiating NIV, the RR was measured by a doctor,
together with the arterial blood gases which were repeated at 1
and 4 h post-treatment. Details of the diagnosis, associated
comorbidities, usual medication including oral corticosteroids,
previous lung function and the time from presentation to the
initiation of NIV were recorded together with body tempera¬
ture, haemodynamic status and Glasgow Coma Score (GCS)
pre-NIV. Venous blood was drawn for the measurement of the
blood count (Sysmex XE-2100 automated full blood count
analyser; Sysmex Milton Keynes, UK), routine biochemistry
(AU 2700 automated chemistry analyser; Olympus UK,
Watford, UK) and random glucose levels (hexokinase method,
AU 2700 Olympus). In all episodes, blood samples were taken
on admission to the Emergency Department but before NIV
began—that is, the first blood glucose value that was obtained
on hospital arrival was used. Hyperglycaemia was defined as a
random blood glucose level >7 mmol/1.13 The baseline APACHE
II score was calculated by a single investigator (BC).16
Preadmission comorbidity was assessed using the Charlson
comorbidity index.17 Successful NIV was defined as the
resolution of respiratory acidosis leading to successful weaning
from the ventilator, and no requirement for ventilatory support
for at least a further 48 h. Formal ethical approval for the study
was obtained via the regional ethics committee.
Statistical analysis
Statistical analysis was performed using SPSS 15.0. Data are
presented as mean and SD unless otherwise stated. We used the
independent sample t test to identify significant differences in
continuous variables between patients failing or succeeding
with NIV, and the x2 test for categorical variables. Statistical
significance was defined as a p value <0.05. No "a priori" power
calculation was performed as the relationship between blood
glucose and NIV success in patients with COPD was not
known. The statistical significance of each variable in predicting
the outcome from NIV was initially determined using uni¬
variate logistic regression. Subsequently, baseline variables with
a p value <0.1 were included in a multivariate logistic regression
model which identified the most parsimonious predictors of
NIV outcome. The variables identified from the logistic
regression model were used to construct receiver operating
characteristic (ROC) curves from which we determined the
sensitivity, specificity, and positive and negative predictive
value of these factors. Candidate variables were considered in
isolation and in combination to establish whether they added
additional explanatory power to this analysis.
RESULTS
Of 168 patients receiving NIV for decompensated AHRF, 109
episodes in 92 patients fulfilled the study entry criteria. Two
patients were excluded due to claustrophobia and agitation during
treatment, leaving 107 episodes in 90 patients (fig 1). Thirteen
patients presented with more than one episode of AHRF during
the study period comprising 17 such episodes in total. For those
patients presenting with more than one episode of AHRF during
the study period, the first episode was used for the purposes of the
study, leaving 90 episodes in 90 patients. Random blood glucose
data were available in 88 of these 90 patients, thus leaving 88
episodes in 88 patients for final analysis.
The ceiling of treatment was set at NIV alone in 73% (64/88)
of patients. NIV failed in 16 patients (18%), one patient who
received invasive ventilation surviving to discharge while the
remaining 15 patients died, all of whom had NIV as their ceiling
of treatment. In 11 (12%) patients, COPD exacerbation was
associated with pneumonia but the mortality was not worse in
this subgroup (p = 0.12). NIV was administered in the RFU in
86 patients and in the ICU for the remaining 2 patients.
The baseline demographics of the study population are
outlined in table 1. Spirometry data confirming the diagnosis
of COPD were available for 82 (93%) patients, all recordings being
within a year of the index admission. Details of the six cases
where COPD was diagnosed clinically are provided in the online
supplement. In 16 patients (18%), oral corticosteroids were taken
before admission. Intravenous aminophylline was administered in
24 patients and this did not affect the outcome of NIV (3 NIV
failures received aminophylline p = 0.54; non-significant).
Glycaemia and outcome of NIV
The relationship between hyperglycaemia and outcome from
NIV is summarised in table 2. Hyperglycaemia was present at
baseline in 50% (44/88) of patients whilst 16 (18%) had a pre¬
existing diagnosis of diabetes mellitus. NIV failure was seen in
34% (15/44) of patients where random blood glucose was
s=7 mmol/1 compared with 2% of the group with blood glucose
<6.9 mmol/1 (1/44; p = 0.003). The mean blood glucose level
was higher in patients when NIV failed (9.03 (3.22) mmol/1 vs
7.01 (2.18) mmol/1; t test; p = 0.003). A prior diagnosis of
diabetes mellitus preadmission was not associated with failure
of NIV (table 3), with the mean blood glucose in the 16 patients
with diabetes being 8.03 (4.02) mmol/I compared with 7.23
(2.04) mmol/1 in those without diabetes (p = 0.25 non¬
significant). Of the 44 patients with hyperglycaemia, pneumo¬
nia was noted in 7 (16%) compared with 4 patients (9%) with
normoglycaemia (p = 0.52 non-significant).
When taking only those 82 patients where the diagnosis of
COPD was confirmed by spirometry, the association between
hyperglycaemia and failure of NIV remained. In this subgroup,
NIV was successful in 71 patients and failed in 11. Baseline
hyperglycaemia was present in 41% (29/71) of NIV successes
and 100% (11/11) of NIV failures (p<0.001).
In 72 patients, oral corticosteroids were not taken before
hospital admission and NIV succeeded in 58. In this subgroup,
92 patients receiving NIV
for AHRF
88 studied
Figure 1 Flow diagram illustrating the outcome of patients receiving non¬
invasive ventilation (NIV) for acute hypercapnic respiratory failure (AHRF).
4 excluded
(2 unable to tolerate NIV; blood
glucose not checked in2)
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Table 1 Baseline demographics of the study population Table 2 Relationship between glycaemia and outcome from NIV
Variable Value
Age (years; mean (SD)j, n = 88
Gender, n = 88
FEV, (litres; mean (SD)), n = 82
FVC (litres; mean (SD)), n = 82
Known diagnosis of diabetes mellitus
Glucose level prior to NIPPV initiation, n = 8f
Arterial pH prior to NIPPV initiation, n = 88
Arterial pC02 prior to NIPPV initiation (kPa),
n = 88
Arterial p02 prior to NIPPV initiation (kPa),
n = 88
Calculated bicarbonate (mmol/l), n = 88
Respiratory rate prior to NIPPV initiation
(breaths/min), n = 88
APACHE II score prior to NIPPV initiation,
n = 88






Yes = 16 (18%; 4 prescribed insulin)
No = 72 (82%)
0-6.9 mmol/l = 44 (50%)








Random blood glucose quartile
(mmol/l)
NIV success (no. of
cases)
NIV failure (no. of
cases)
Values are given as mean (SD).
APACHE II, Acute Physiology and Chronic Health Evaluation II; FEV,, forced expiratory
volume in 1 s; FVC, forced vital capacity; NIPPV, non-invasive positive pressure
ventilation.
baseline hyperglycaemia was present in 38% (22/58) of NIV
successes and 93% (13/14) of NIV failures (p<0.001).
Hyperglycaemia was not related to prior oral corticosteroid use.
Of the 16 patients prescribed oral corticosteroids preadmission, 9
(56%) presentedwithhyperglycaemia comparedwith35of72 (49%)
not prescribed oral corticosteroids (p = 0.59; non-significant).
Arterial blood gases and outcome of NIV
The relationships between the baseline pH, subsequent change
in arterial blood gases over 4 h and outcome of NIV are shown in
table 4 and in table 1 online. A baseline pH <7.30 before NIV did
not predict NIV failure, although the relationship between
outcome and presentation with a baseline pH <7.25 approached
statistical significance (p = 0.09). In 84 patients, NIV was still
being used 4 h after initiation (4 patients had died by this stage).
Failure to improve arterial pH compared with baseline after 4 h
NIV treatment was not associated with treatment failure nor was
the inability to normalise pH following 4 h of NIV predictive.
Logistic regression analysis
Of the baseline variables tested, age, blood glucose <7 mmol/l,
baseline RR, APACHE II score, mean baseline arterial pH pre-
NIV and calculated serum bicarbonate level were related to the
outcome of NIV treatment in the univariate logistic regression
(see tables 3, 4). These variables were included in the
multivariate model which identified three statistically signifi¬
cant predictors of NIV outcome: baseline RR (OR 0.91; 95% CI
0.84 to 0.99), random glucose 3=7 mmol/l (OR 0.07; 95% CI
0.007 to 0.63) and APACHE II score on admission (OR 0.75;
95% CI 0.62 to 0.90). The model correctly classified 93% of the
successful outcomes in the sample.
The correlation between random blood glucose and the other
statistically significant associations identifying NIV outcome in
the univariate analysis are shown in tables 2 and 3 online.
Statistically significant correlations were noted between blood
glucose concentration, RR and pre-NIV pH in those patients
where NIV was successful, and with baseline APACHE II score
and pre-NIV pH where NIV failed. The correlations between
0-6 (n = 28) 27 (96%) 1 (4%)
6-6.9 (n = 16) 16 (100%) 0 (0%)
7-8.9 (n = 26) 17 (65%) 9 (35%)
>9 (n = 18) 12 (67%) 6 (33%)
NIV, non-invasive ventilation.
baseline RR and APACHE II index and with pre-NIV pH were
0.25 (p = 0.01) and —0.16 (p = 0.14, non-significant), respec¬
tively, in the whole cohort.
To investigate further the discriminatory power of the three
variables, ROC curves were constructed between RR, APACHE
II index, blood glucose level and the outcome of NIV. For
baseline RR and NIV outcome, the lines for sensitivity and
specificity intersected at an RR of 30/min (area under the curve
0.78; 95% CI 0.62 to 0.94). In terms of APACHE II index, the
point of intersection occurred at 16.5 (area under the curve 0.79;
95% CI 0.66 to 0.91), and with random blood glucose level (area
under the curve 0.76; 95% CI 0.63 to 0.89) the point of
intersection was at 7.3 mmol/l. The sensitivity, specificity, and
positive and negative predictive value of these factors in
predicting a successful outcome is shown in table 4 online.
The combination of baseline RR <30 breaths/min and random
glucose <7 mmol/l increased the prediction of a successful
outcome from NIV to 97%, while the use of all three factors was
100% predictive in this population.
DISCUSSION
NIV represents a significant advance in the management of
acute respiratory failure in patients with severe COPD. The data
in our observational prospective cohort study support this, with
>80% of patients recovering from an episode which a decade
ago would have required invasive ventilation. This success rate
is comparable with that previously reported from an ICU18 and
was not substantially different from a more mixed population
of patients, many without acidosis, admitted to UI< hospitals.19
Patients with COPD managed with invasive ventilatory support
are more likely to die from non-pulmonary causes than
respiratory causes.20 In surgical and medical intensive care
practice hyperglycaemia is a known adverse prognostic mar¬
ker.7 2122 Specific data about hyperglycaemic patients managed
with NIV are limited. A small study suggested that "late
failure" defined by deteriorating gas exchange was more
frequent in patients with an initially raised blood sugar.3 A
larger but retrospective review of a mixed population of
unselected patients with COPD noted longer hospital stays
and greater mortality in patients presenting with hyperglycae¬
mia. However, it was not possible to adjust for the potential
confounding effects of corticosteroids while many of the
diagnoses were based on purely clinical grounds.13
Our study in a well defined patient population found that
hyperglycaemia, even when defined at only one time point,
related to the final outcome irrespective of the diagnosis of
diabetes, use of insulin or prior oral corticosteroid use. In general
the degree of hyperglycaemia observed was modest but it may
still reflect the significant physiological stress associated with
deteriorating gas exchange and worsening lung mechanics,
often accompanied by pulmonary infection. Some patients had
radiological evidence of pneumonia, but this did not explain the
occurrence of hyperglycaemia in most patients nor did it predict
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Table 3 Clinical variables and outcome from NIV: univariate analysis
NIV success
(n = 72) NIV failure (n = 16) OR (95% CI) p Value
Age, n = 88* 68 (10) 77 (9) 0.9 (0.84 to 0.97) 0.006




1.97 (0.62 to 1.97) 0.25 (NS)




0.57 (0.19 to 1.72) 0.32 (NS)
FEV, (litres), n = 82* 0.69 (0.30) 0.60 (0.17) 4.53 (0.19 to 106.4) 0.35 (NS)
FVC (litres), n = 82* 1.67 (0.55) 1.35 (0.48) 3.64 (0.73 to 18.07) 0.11 (NS)
Diagnosis of diabetes
mellitus, n = 16+
12 4 0.6 (0.17 to 2.18) 0.44 (NS)










Time from admission to NIV
administration (h), n = 88*
3.59 (3.85) 1.07 (0.92 to 1.24) 0.40 (NS)
IPAP (cm H20), n = 88* 15.07 (2.17) 15.00 (3.29) 1.01 (0.80 to 1.28) 0.34 (NS)
EPAP (cm H20), n = 88* 5.24 (1.38) 5.63 (1.78) 0.84 (0.58 to 1.2) 0.16 (NS)
APACHE II, n = 88* 14.63 (3.80) 19.19 (4.31) 0.76 (0.65 to 0.89) 0.001
Oral corticosteroid
administered prior to
admission, n = 16+
14 (19%) 2 (13%) 1.69 (0.34 to 8.31) 0.52 (NS)
Charlson comorbidity index,
n = 88*
1.62 (0.73) 1.88 (0.93) 0.78 (0.35 to 1.25) 0.20 (NS)
GCS, n = 88* 14(1) 13(3) 1.21 (0.93 to 1.45) 0.18 (NS)
Pneumonia cases, n = 11 + 7 4 0.32 (0.08 to 1.28) 0.12 (NS)
Baseline RR (breaths/min), 26 (6) 34 (10) 0.86 (0.79 to 0.94) 0.001
n = 88*
Values are given as mean (SD).
*t test.
tx2 test.
APACHE II, Acute Physiology and Chronic Health Evaluation II; EPAP, expiratory positive airway pressure; F, female; FEV,, forced
expiratory volume in 1 s; FVC, forced vital capacity; GCS, Glasgow Coma Score; IPAP, inspiratory positive airway pressure; M,
male; NIV, non-invasive ventilation; NS, non-significant; RR, respiratory rate;
NIV failure. Thus, in our data initial hyperglycaemia had an
independent prognostic value.
Initial observational data suggested a relationship between
the severity of acidosis and the outcome of AHRF in COPD, a
finding supported by subsequent randomised studies.2 23 Our
mean baseline pH was <7.25 in 42% of patients but, unlike the
earlier studies, treatment succeeded in >70% of cases. This may
explain why baseline pH was a poorer discriminant in the patient
population now referred for NIV. In contrast, the initial
respiratory rate was a good measure of treatment response, as
has been seen elsewhere.1 2 5 24 25 A higher RR may reflect
asynchrony of the patient and the ventilator, but it may also be
a marker of a greater intrinsic respiratory load promoting a
shortened inspiratory time and more hypercapnia.26 27 As the
respiratory muscles are unloaded by the effects ofNIV, the RR can
fall, the associated pulmonary hyperinflation lessens along with
the work of breathing and dyspnoea improves.27 We observed a
relationship between the APACHE II score and clinical outcomes,
which was unsurprising as this index incorporates several
variables which independently predicted outcome. However, the
APACHE II score was no better in predicting outcome in our data
than simpler measures such as the initial RR.
Table 4 Outcome from NIV and relationship with arterial blood gas variables: univariate analysis
NIV success (n = 72) NIV failure (n = 16) OR (95% CI) p Value
Baseline pH, n = 88* 7.26(0.06) 7.22 (0.08) 3.96 (1.55 to 5.07) 0.02
Baseline Pa02 (kPa), n = 88* 8.15(2.73) 8.30 (2.31) 0.98 (0.80 to 1.20) 0.87 (NS)
Baseline PaC02 (kPa), 10.20(2.19) 10.20 (2.16) 0.99 (0.78 to 1.28) 0.99 (NS)
n = 88*
Baseline calculated 26.09(3.44) 23.51 (3.69) 1.24 (1.04 to 1.45) 0.014
bicarbonate (mmol/l),
n = 88*
1 h pH, n = 88* 7.29 (0.06) 7.25 (0.09) 1.78 (0.04 to 2.23) 0.03
1 h PaC02 (kPa), n = 88* 8.84 (2.21) 9.50 (2.61) 0.88 (0.68 to 1.15) 0.36 (NS)
1 h Pa02 (kPa), n = 88* 8.77 (2.87) 7.85 (1.64) 1.27 (0.84 to 1.91) 0.26 (NS)
4 h pH, n = 84* 7.32 (0.51) 7.28 (0.90) 4.34 (2.90 to 5.89) 0.14 (NS)
4 h Pa02 (kPa), n = 84* 8.37 (2.39) 7.70 (1.22) 1.27 (0.79 to 1.96) 0.31 (NS)
4 h PaC02 (kPa), n = 84 * 8.19 (1.98) 8.47 (2.07) 0.93 (0.68 to 1.27) 0.66 (NS)
Values are given as mean (SD).
*t test.
NIV, non-invasive ventilation; NS, non-significant.
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Multivariate logistic regression analysis identified three
factors which explained almost all the variance in outcome in
our patient group and which were largely independent of each
other. ROC curve analysis defined threshold values in this
population, which agreed with the conventional level of
elevated blood glucose in the case of hyperglycaemia and which
independently identified an RR of 30/min, the same value used
in the highly discriminant CURB65 score for pneumonia
severity.28 The relative simplicity with which these variables
can be measured suggests that a simple prognostic index can be
developed based on these factors if our findings are validated in
other trials. The presence of RR <30 combined with normogly-
caemia prior to the initiation of NIV carried a specificity of 92%
in predicting success from NIV with a sensitivity of 79%. When
baseline RR <30 was combined with normoglycaemia and
APACHE II index < 16, the specificity increased to 100%. In
essence, the combination of these "favourable" criteria in a
patient with COPD with decompensated ventilatory failure
prior to initiation of NIV predicts a successful outcome. On the
other hand, in terms of predicting failure of NIV, the presence of
an RR s=30/min coupled with hyperglycaemia carried a negative
predictive value of 97% and a sensitivity of 92% (the failure rate
was 55% in this subgroup). We therefore conclude that the
presence of these "unfavourable" criteria in a patient at baseline
does not imply NIV will definitely fail but such patients may
require more intensive and aggressive monitoring as there is a
significantly higher risk of treatment failure in such circum¬
stances. Validation of this model in terms of predicting outcome
from NIV in acute decompensated ventilatory failure is required
in a second cohort of patients.
Our study has some limitations. Although it was a
prospective study, we recorded only one blood glucose value
and this may vary during an acute illness. However, the use of a
threshold value close to the upper limit of normal had
significant discriminatory power when used as a binary
outcome for NIV success. Furthermore, the timing of the
measurement was similar in all cases—that is, upon presenta¬
tion to hospital but prior to NIV initiation. In addition, the
overall sample size of the study was small but did comprise a
relatively homogenous population. We had limited information
about the role of infection in these patients, but again the
predictive variables selected are indirectly linked to the
consequences of infection. In our cohort, acute NIV carried a
relatively low failure rate of 18%. This may reflect the patient
selection criteria used—that is, only patients with COPD
receiving NIV within 24 h of hospital admission were included.
Patients developing decompensated ventilatory failure after a
longer hospitalisation or when complicated by a hospital-
acquired infection probably represent a sicker group carrying a
higher failure rate. Our failure to identify an association with
baseline pH may reflect this focused entry criterion, although
the absolute values are rather lower than in several other series.
The high mortality in patients who failed NIV may reflect both
the severity of the initial presentation and also current UK
practice towards additional supportive ventilation which con¬
tinues to be a topic for debate.29 Our data relate to the first
episode on an admission when the patient was ventilated and to
the outcome of that episode. One individual who recovered
from such an episode subsequently died before discharge, but
overall our mortality is in keeping with other recent reports in
the literature.6 30 Although not all patients had spirometrically
confirmed COPD, the predictive value of hyperglycaemia
remained even after excluding those cases where spirometry
was not performed. Certain factors known to affect tolerance to
Chronic obstructive pulmonary disease
NIV were not measured, such as the degree of mask leak, the
presence of secretions and the ability to remove them. Further
research in these important areas is needed.
In summary, when patients with COPD develop decom¬
pensated ventilatory failure, baseline hyperglycaemia identifies
patients with the greatest risk of failure with NIV, as does an
elevated RR and increased APACHE II index on admission.
Combining these approaches should provide a relatively simple
way of stratifying risk and adjusting management accordingly.
The RR remains an underused measurement which tracks the
patient's progress. Whether changes in blood glucose during
therapy are as helpful remains to be studied. Tight glycaemic
control has its advocates," 12 but careful prospective studies will
be needed before this approach can be recommended in the care of
patients with primary respiratory problems treated with NIV.
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Figure 2 CT scan of the brain showing ring-enhancing lesions in the
right frontoparietal lobe with surrounding oedema and mass effect.
(BAL). The airways were inflamed with inspissated yellow
secretions visible on the left. Histological examination of the
cerebral biopsy specimen was consistent with a cerebral abscess,
but no granulomatous inflammation was identified. All cultures
from the BAL fluid and cerebral abscess were negative.
QUESTION
What further diagnostic technique may aid in pathogen
identification?
See page 92.0.
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Figure 1 Chest radiograph showing left apical consolidation, volume
loss and pleural thickening.
862
Cough, confusion and flaccid paralysis
in a 46-year old man with left apical
consolidation and ring-enhancing
lesions on cerebral imaging
CLINICAL PRESENTATION
A 46-year-old man was admitted with confusion and lower limb
weakness that had developed over 2 weeks. A history of chronic
productive cough was noted. Significantly, 4 years previously he
had been investigated for cough and left apical lung consolida¬
tion. No evidence ofMycobacterium tuberculosis was found at the
time and this was not investigated further. The only other
relevant history was of heavy ethanol intake and self-neglect.
The patient was febrile (38.6°C), confused and unwell. He
had evidence of finger clubbing, poor oral hygiene and signs of
consolidation in the left lung. Early bilateral papilloedema and a
flaccid paralysis in the lower limbs were noted. Admission
investigations identified a raised white cell count of 21.5xl09/l
(neutrophils 19.5). Multiple sputum cultures were negative.
There was no reaction to a Mantoux (5 units PPD) test.
Antibodies to HIV were not detected. A chest radiograph (fig 1)
and CT scan showed left apical consolidation and volume loss.
A CT scan of the brain (fig 2) showed two ring-enhancing
lesions in the right frontoparietal lobe. An MRI scan revealed a
ring-enhancing lesion in the lumbar spine.
Craniotomy and excision of a cerebral lesion was performed,
with concurrent bronchoscopy and bronchoalveolar lavage
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Oral corticosteroids in patients admitted to hospital with
exacerbations of chronic obstructive pulmonary disease:
a prospective randomised controlled trial
L Davies, R M Angus, P M A Calverley
Summary
Background The role of oral corticosteroids in treating
patients with exacerbations of chronic obstructive pulmonary
disease (COPD) remains contentious. We assessed in a
prospective, randomised, double-blind, placebo-controlled
trial the effects of oral corticosteroid therapy in patients with
exacerbations of COPD requiring hospital admission.
Methods We recruited patients with non-acidotic
exacerbations of COPD who were randomly assigned oral
prednisolone 30 mg once daily (n=29) or identical placebo
(n=27) for 14 days, in addition to standard treatment with
nebulised bronchodilators, antibiotics, and oxygen. We did
spirometry and recorded symptom scores daily in inpatients.
Time to discharge and withdrawals were noted in each group.
We recalled patients at 6 weeks to repeat spirometry and
collect data on subsequent exacerbations and treatment.
Hospital stay was analysed by intention to treat and forced
expiratory volume in 1 s (FEV,) according to protocol.
Findings FEV, after bronchodilation increased more rapidly
and to a greater extent in the corticosteroid-treated group:
percentage predicted FEV, after bronchodilation rose from
25-7% (95% CI 21 0-30-4) to 32-2% (27-3-27-1) in the
placebo group (p<0-0001) compared with 28-2%
(23-5-32-9) to '41-5% (35-8-47-2) in the corticosteroid-
treated group (p<0-0001). Up to day 5 of hospital stay, FEV,
after bronchodilation increased by 90 mL daily (50-8-129-2)
and by 30 mL daily (10-4-49-6) in the placebo group
(p=0-039). Hospital stays were shorter in the corticosteroid-
treated group. Groups did not differ at 6-week follow-up.
Interpretation These data provide evidence to support the
current practice of prescribing low-dose oral corticosteroids
to all patients with non-acidotic exacerbations of COPD
requiring hospital admission.
Lancet 1999; 354; 456-60
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SniroducSion
Chronic obstructive pulmonary disease (COPD) is an
important cause of death worldwide and exacerbations of
this disease commonly lead to hospital admission (1250
per year in our 350 000 health district) and increased cost.
The treatment of exacerbations ofCOPD is controversial.
Guidelines1-2 have made recommen-dations about
prescribing, but although there are clear indications for
antibiotic and bronchodilator use, they state that the use
of oral corticosteroids is based on common practice and is
not evidence based.
When given to stable COPD patients, systemic
corticosteroids significantly increase the forced expiratory
volume in 1 s (FEV,) in only 10% of cases,3 whereas
inflammatory-mediator production is not influenced by
this treatment.4 Moreover, continued use of oral
corticosteroids in COPD patients is associated with
corticosteroid myopathy,5 which may be potentially
important for patients with frequent exacerbations who
are treated with these drugs.
Several studies have investigated the outcome of systemic
use of corticosteroids in exacerbations of COPD with
conflicting results. One study of 96 patients suggested that
there was no effect of methylprednisolone in preventing
admission to hospital after 5 h treatment in the emergency
room,6 although a later, randomised double-blind study
found that the readmission rate was lower in patients given
treatment.7 In a randomised controlled trial, Albert and
colleagues8 noted significant improvements in FEV, before
bronchodilation in the first 3 days of admission in 22 patients
given intravenous methylprednisolone, but improvements in
FEV, after bronchodilation were less obvious. In another
randomised controlled trial, 27 patients fit enough for
discharge from the emergency room were followed up.9 The
13 treated patients showed greater improvement in FEV, and
the partial pressure of oxygen in arterial blood than did the
14 untreated patients. The Veterans Affairs Cooperative
study group has completed a study of the effects of high-dose
systemic corticosteroids on exacerbations of COPD.10 The
primary endpoint was treatment failure, rates of which were
signiflcandy lower in the glucocorticoid-treated groups than
in the placebo group.
Most COPD patients admitted with exacerbations in
the UK, New Zealand, and Australia1113 are treated with
30-40 mg oral prednisolone. We investigated the
hypothesis in a prospective, randomised, double-blind,
placebo-controlled trial that in more severe patients, oral
corticosteroids administered in these doses would not
modify the rate of improvement of lung function or
significantly affect the course of hospital stay.
(Patients and methods
Patients
Patients with a diagnosis ofCOPD presenting to the accident and
emergency department ofUniversity Hospital Aintree, Liverpool,
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were eligible for entry into the study if they had a history of
increased breathlessness and at least two of the following
symptoms for 24 h or more: increased cough frequency or
severity, increased sputum volume or purulence, and increased
wheeze. We included patients who were aged 40-80 years, had a
history of at least 20 pack-years of cigarette smoking, and had
physiological evidence of airflow limitation with initial FEV, less
than 70% predicted and FEV,/forced vital capacity ratio less than
75%.'
We excluded patients if they had a personal or family history of
asthma or atopy, uncontrolled left-ventricular failure, clinical or
radiological evidence of pneumonia, received oral corticosteroids
within 1 month of presentation, or if arterial blood pH on
admission was less than 7'26. All patients gave written informed
consent to participate, and the study was approved by the district
ethics committee.
Study design
One investigator (LD) took a detailed medical history and
examined patients at admission. The investigational protocol was
started within 3 h of presentation to the accident and emergency
department. Patients received standard treatment with nebulised
(3-agonist (5 mg salbutamol) and an anticholinergic (500 pg
ipratropium bromide) every 6 h, controlled oxygen therapy, and
oral or intravenous antibiotics at the judgment of the admitting
physician. Any patient who was receiving inhaled corticosteroid
therapy before randomisation was continued on this therapy. In
addition, we randomly assigned patients 30 mg prednisolone
every day for 14 days or identical placebo. Randomisation was
done by the hospital pharmacy according to a table of random
numbers. Packages of treatment were numbered in advance and
used consecutively. All patients, investigators, respiratory
physicians, technicians, and other hospital staff were masked to
treatment status until the end of the study. Study duration was
from the time of admission to the time of discharge and included
a follow-up visit 6 weeks after admission.
On admission, we took blood samples for full blood count,
including absolute eosinophil count, and arterial blood gas
measurement. Sputum was collected for microscopy, culture, and
sensitivity. Spirometry was done daily from admission, before,
and 15 min after 5 mg nebulised salbutamol, by a dry-bellows
spirometer that met the American Thoracic Society and British
Thoracic Society standards." At least three forced expiratory
manoeuvres were obtained on each occasion until two were
within 5%. We compared airflow measurements with European
Steel and Coal Company predicted values.15 We obtained a daily
symptom score, which was calculated from a diary completed by
the patient. Questions were asked about breathlessness, sputum
production, wheeze, mobility, sleep quality, cough, and general
well-being. Patients were asked to score each of the symptoms
from 0 (much better than usual) to 5 (much worse than usual).
We also collected data about potential side-effects of oral
corticosteroids (mood swings, heartburn, and overt
gastrointestinal bleeding), and tested patients' urine daily for
glucose.
On day 5, static lung volume was measured by helium dilution,
and transfer factor by single-breath method (Benchmark
respirometer, PK Morgan, Rainham, Kent, UK). We did skin
tests to eight common allergens. Also on day 5, we used the
St George's respiratory questionnaire to assess patients' usual
health status.16 Patients were asked, "Ignoring this admission,
how has your health been over the last 6 months?" and were
shown a 200 mm visual analogue scale with markings every
20mm from 0 (could not have been worse) to 10 (perfect health)
and asked to point to the number that they felt best answered the
question.
The respiratory physicians in charge of the patients, who were
not investigators, were free to withdraw patients from the study at
any time if they felt clinical improvements were not satisfactory.
We automatically withdrew any patient whose arterial blood pH
fell below 7-26 and treated them with oral corticosteroids and
supportive therapy as required. Patients were free to withdraw at
Figure 1: Trial profile
any time if they were not satisfied with their progress. The
physicians in charge also decided the time at which patients
reached medical fitness for discharge, and it is this date that we
have used. In some patients, the actual time to discharge was
delayed because of social and transport arrangements. On the day
of discharge, a second visual analogue score was recorded for the
answer to, "How do you feel today compared to the day of
admission?" from 0 (verymuch worse) to 10 (verymuch better).
At 6 weeks after admission, we recalled patients to repeat
spirometry before and after 5 mg nebulised salbutamol and to
complete a second St George's respiratory questionnaire and
visual analogue scale score of health perception over the past
6 months. We collected data about treatment at follow-up and
whether patients had required treatment for further exacerbations
from their family physician or the hospital since discharge.
Statistical analysis
We calculated that a sample size of 27 in each group would give
us 80% power to detect a difference of 0-05 L per day in mean
slope between the groups, with an SD of 0-0625. All data were
analysed with Microstat version 1 and SPSS version 8.0. We
calculated means (SE), and used Student's f test, ANOVA, and
ANCOVA to compare normally distributed data, and Wilcoxon's
rank and x2 tests to compare non-normal data.
Results
We screened 246 patients for the study, and 60 met the
inclusion criteria (figure 1). The most common reason for
exclusion was previous treatment with oral corticosteroids
before attending the accident and emergency department.
Of the four patients refusing consent, three declined
because they refused oral corticosteroids after being told
of possible side-effects and one because she did not wish
to participate in a clinical trial.
29 patients were randomly assigned active treatment
and 27 were assigned placebo. Six patients were
withdrawn from the study: five in the placebo group (on
days 1, 2, 3, 6, and 13) and one in the corticosteroid-
treated group (day 11). Only one patient (on placebo) was




















Eosinophil count (X109/L) 018 (0 03) 0 09 (0 03)
Symptom score on admission 26-7 (0-7) 30-5 (0 7)
SGRQ on day 5 72-6 (2 4) 68-5 (7 0)
Percentage predicted FE\li
On admission, before bronchodilation
On admission, 15 min' after bronchodilation
On discharge, before bronchodilation
On discharge, 15 min after bronchodilation
On day of withdrawal, 15 min after bronchodilation









10 7 (4 3)
23-7 (2 9)
SGRQ=St George's respiratory questionnaire. Values are means (SE) or numbers (%).
Patients withdrawn had significantly worse spirometry on admission than those
completing study. *p=0 008. tp=0-004.
Table 1: Baseline characteristics of patients
withdrawn because of respiratory acidosis. During week 1 of
the study, patients in the placebo group were significantly
more likely to be withdrawn than those in the active-therapy
group (p=0-034). Patients withdrawn from the study had
significantly lower percentage predicted FEV, on admission
before (p=0-008) and after bronchodilation (p=0-004) than
those completing the study, but other baseline
characteristics did not differ (table 1).
Of the 50 patients completing the study, 34 were men
and 16 women (mean age 67 years [SE 1-2]; mean
smoking history 55 pack-years [4-5]). These patients had
severe airflow obstruction with mean FEV, before
bronchodilation 0-59 L (95% CI 0-1-2) and mean
percentage predicted FEV, before bronchodilation 24-7%
(21-2-28-2). Samples for arterial blood gas analysis were
taken from all patients. In the 34 patients measured on
air, mean pH was 7-33 (7-19-7-47), partial oxygen
pressure was 8-9 kPa (8-4-9-4), partial carbon-dioxide
pressure was 5-4 kPa (4-9-5-9). Arterial blood gases did
not differ between the two groups. At study entry, all
patients used inhaled or nebulised short-acting P-agonist
therapy, 34 (64%) inhaled or nebulised anticholinergics,
45 (80%) inhaled corticosteroids, 11 (20%) oral




















Eosinophil count (Xl09/L) 0-12 (0 03) 0-24 (0-06)
Symptom score 26 1 (1-1) 27-6 (0 6)




































SGRQ=St George's respiratory questionnaire. Values are means (SE) or numbers (%).
Table 2: Demography of patients on admission
Tifnfijrtinl 6f inBaiTimirtifti
Figure 2: Change in absolute FEV., after bronchodilation from
admission by day of study in active and placebo groups
(according to protocol)
Means (95% CI) are shown.
long-term oxygen therapy, and two (4%) inhaled long-
acting P-agonists. At study entry there were no differences
in previous treatment between groups.
34 patients had purulent sputum on admission,
although only 11 yielded positive cultures (seven
Haemophilus influenzae, two Streptococcuspneumoniae, one
Moraxella catarrhalis, and one Pseudomonas aeruginosa). 52
patients were treated with oral or intravenous antibiotics.
The mean percentage predicted residual volume
measured on day 5 of admission was 181-4% (SE 6-8),
total lung capacity 112-3% (2-0), and single-breath
diffusing capacity 65-3% (3-4), and there were no
differences between groups. No patient had a positive skin
test. There were no deaths during admission. 28 patients
on oral corticosteroids and 22 on placebo completed the
study to the time of discharge, but two died before the 6-
week follow-up visit. Characteristics did not differ
between groups on admission (table 2).
By the time of discharge, percentage predicted FEV,
before bronchodilation had risen from 21-4% (95% CI
16-5-26-3) to 31-0% (26-3-35-7) in the placebo group
(p<00001) and from 27-4% (22-5-32-3) to 38-4%
(32-9-43-9) in the corticosteroid-treated group
(p<0-0001). Percentage predicted FEV, after
bronchodilation rose from 25-7% (21-0-30-4) to 32-2%
(27-3-37-1) in the placebo group (p<0-0001) and 28-2%
(23-5-32-9) to 41-5% (35-8-47-2) in the corticosteroid-
treated group (p<0-0001). Changes in FEV, after
bronchodilation were significantly greater in the
corticosteroid-treated group (figure 2) and these changes
were similar to values before bronchodilation. Until day 5,
FEV, after bronchodilation increased in the
corticosteroid-treated group by 90 mL per day
(50-8-129-2) compared with that in the placebo group of
only 30 mL per day (10-4-49-6; p=0-039). With FEV,
after bronchodilation on admission as a covariate, the
increase until day 5 in the corticosteroid-treated group
remained significantly greater than that in the placebo
group (p=0-048). Improvement plateaued earlier in the
corticosteroid-treated group; by day 5, patients receiving
corticosteroids had increased FEV, after bronchodilation
to 92% of that achieved at discharge, compared with only
85% in the placebo group (p<0-041). Changes in forced
vital capacity were similar to those seen in FEV,.
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Figure 3: Proportion of patients remaining in hospital by day of
admission by treatment group (intention to treat)
Visual analogue scale scores during the admission
period rose significantly in the two groups by a mean of
2-6 (-0-5 to 5-7) in the placebo group and 3-4 (2-8-4-0) in
the corticosteroid-treated group (both p<0-0001).
Decreases in symptom scores were seen in the two groups.
The greatest symptom changes were found in sleep
quality, breathlessness, mobility, and general well-being,
with a trend towards greater improvement in the
corticosteroid-treated group. In both groups, the most
striking changes in symptom scores were seen between
days 0 and 1, and days 1 and 2, with a further
improvement from day 2 to discharge (p=0-01, p=0-005,
pcO-OOOl). There were no reports of change in mood.
Three patients in the corticosteroid-treated group and two
in the placebo group complained of heartburn, but there
were no episodes of overt gastrointestinal bleeding. Six
patients in the corticosteroid-treated group developed
transient glycosuria.
Length of hospital stay was analysed by intention to
treat for all 56 patients in the study. The median length of
stay in patients treated with oral corticosteroids (7 days)
was significantly shorter than in those receiving placebo
(9 days; p=0-027; figure 3).
At 6 weeks, percentage predicted FEV, after
bronchodilation was 39-6% (95% CI 32-5-46-7) in the
corticosteroid-treated group and 33-2% (27-9-38-5) in
the placebo group, which were not significantly different
to discharge values. There was no change in St George's
respiratory questionnaire or visual analogue scale scores
for health perception in the past 6 months in the two
groups. 16 patients had required treatment for further
exacerbations of COPD, nine in the oral corticosteroid
group and seven in the placebo group. 11 patients had
received further antibiotics or oral corticosteroids from
their family physicians, and five had required further
hospital admission, during which they had also received
antibiotics or oral corticosteroids. There was no difference
in exacerbation rate, admission rate, or treatment received
between the two groups. None of age, current smoking or
ex-smoking, eosinophil count, or concurrent treatment
predicted whether further exacerbations might occur
within this 6-week period.
(Discussion
Any treatment that can hasten the resolution and lower
the costs of exacerbations of COPD" '8 is welcomed. Data
from randomised trials in outpatients suggest that oral
corticosteroids can increase the rate of resolution of the
attack, but data have only been seen in short-term
treatment of inpatients and the impact on health costs was
unclear. We found significant differences in the rate of
improvement of FEV, before and after bronchodilation
compared with placebo, which suggests that the effect of
oral prednisolone was more than an indirect effect on
bronchomotor tone. Hospital stays were shorter for patients
treated with prednisolone than for those on placebo.
Oral prednisolone is widely prescribed for exacerbations
of COPD"'13 and was the most common reason for
patients' ineligibility. Similar difficulties have been seen in
other studies.8-9 Ethical constraints prevented us from
extending our study to acidotic patients, although we have
no reason to suppose they would have differed in changes
in FEV,. Likewise, we were obliged by our ethics
committee to offer an open trial of oral corticosteroids to
all patients withdrawn. Thus, we presented hospital stay
on an intention-to-treat basis, but restricted data for FEV,
to the according-to-protocol analysis. This approach
weighs against the corticosteroid-treated group because
the sickest patients probably dropped out first, which
would lead to a subsequent improvement in the rate of
recovery in the placebo group.
We took measurements after high doses of nebulised
agonist to follow the patients' progress. Data in similar
patients suggest that nebulised (3-agonist or
anticholinergics are probably equally effective
bronchodilators during recovery from an exacerbation.19
Even at discharge, our 56 patients remained significantly
obstructed, with a mean percentage predicted FEV, after
bronchodilation of 37-5% (SE 2-0).
Spirometry was done more often than in the outpatient
study and the rate of change of FEV, after
bronchodilation was three times greater in the
corticosteroid-treated group than in the placebo group.
Maximum improvement in FEV, after bronchodilation
was seen by day 5 in the corticosteroid-treated group,
whereas time to plateau in the placebo group was
significantly longer. Since the improvement reached a
plateau at day 4 in the corticosteroid-treated group, the
90 mL per day value (calculated at day 5) may
underestimate the rate of improvement. Similar changes
were seen for forced vital capacity.
Symptom changes showed a similar time course in each
group, and like the outpatients9 showed a trend towards
greater improvement in the corticosteroid-treated group
that did not reach significance. This may reflect the non-
parametric nature of such data, or the need for greater
numbers in the trial. Both groups showed significant
improvements over the admission period that did not
match the changes in FEV,, with substantial changes in
general well-being, sleep quality, and mobility within 48 h
of admission, and much smaller changes in perceived
cough, wheeze, and sputum production.
Our patients were not only physiologically more
severely affected than in other studies, but had a worse
health status than patients admitted with exacerbations in
other UK studies.20-21 Although we reported similar
improvements in health during admission in the two
groups, this similarity did not change during the 6 weeks
of follow-up; spirometry was similar at discharge. At
6 weeks the St George's respiratory questionnaire did not
register any change from that completed at 5 days, which
suggested that either the score changes less in more severe
patients, or recovery from an exacerbation takes longer
than 6 weeks to register. Although improvement in FEV,
after bronchodilation was maintained aL 6 weeks, patients
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treated with corticosteroids had similar morbidity at
follow-up to those receiving placebo, which suggests that
with treatment at 30 mg the initial benefit does not extend
beyond the early stages of recovery from an exacerbation.
Neither the mechanism of the effects of oral
prednisolone nor the selection of patients most likely to
benefit is clear. Despite the absence of any effect on
several cytokines in stable patients,4 other data suggest
that eosinophils and neutrophils are increased in
exacerbations of COPD.22,23 No simple clinical,
biochemical, or physiological marker, including duration
of disease, current smoker or ex-smoker, presence or
absence of acute infection, eosinophil count, and baseline
FEVj, reliably distinguished those patients who responded
from those who did not. Prescription of oral
corticosteroids for all patients may therefore be the most
practical solution.
Our data support the current practice of prescribing
low-dose oral prednisolone to patients with non-acidotic
exacerbations of COPD who require admission to
hospital. Benefits in spirometric improvement are clearly
seen within the first 5 days and are matched by an
improvement in symptoms of well-being, mobility, and
sleep quality. However, the benefits do not extend beyond
hospital discharge and shorter courses may be equally
effective.
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Withdrawal From Treatment as an
Outcome in the ISOLDE Study of COPD*
Peter M. A. Calverley, MD; Sally Spencer, BSc; Lisa Willits, PhD, MSc;
P. Sherwood Barge, MD; and Paul W. Jones, MD; on behalf of the
ISOLDE Study Group
Objectives: To investigate the determinants of patient withdrawal from our study, and the effect
of these withdrawals on the outcome of treatment with inhaled corticosteroids in patients with
COPD.
Design: A double-blind, placebo-controlled, randomized trial.
Setting: Eighteen outpatient centers in the United Kingdom.
Participants: Seven hundred fifty-one patients with stable COPD defined clinically and as
baseline postbronchodilator FEVj S 0.8 L and < 85% predicted, FEV1/FVC ratio < 70%, and
FEVj change after albuterol < 10% of predicted.
Intervention: Random assignment of either 500 [xg bid of inhaled fluticasone propionate (FP)
using a spacer device or an identical placebo inhaler. Treatment was continued for 3 years or
until patients withdrew from follow-up.
Measurements and results: Postbronchodilator FEVj was measured on three occasions before
randomization and every 3 months thereafter. Health status was assessed by the disease-specific
St. George Respiratory Questionnaire (SGRQ) and the modified short-form 36 questionnaire
(SF-36) at baseline and every 6 months. Three hundred thirty-nine patients withdrew, of whom
156 patients received FP. Prescription of frequent courses of oral prednisolone was the most
common reason for withdrawing as specified in the protocol (69 patients in the FP group
withdrew due to respiratory symptoms, compared with 93 patients in the placebo group). This
explained the significantly greater dropout of placebo-treated patients that was most evident
when FEVj was < 50% predicted. Patients withdrawing had a significantly more rapid decline in
health status, measured by both the SGRQ and the SF-36 (p < 0.001). Those withdrawing from
the placebo group had a more rapid decline in FEVX and more exacerbations than the FP-treated
groups. Raseline FEVj was lower in dropouts than in patients completing the study receiving
placebo, but there was no difference between the respective groups receiving FP.
Conclusions: Patients who withdrew from follow-up were those with the most rapidly deteriorat¬
ing health status and lung function. Losing these patients from the final analysis can reduce the
power of a study to achieve its primary end point. (CHEST 2003; 124:1350-1356)
Key words: COPD; exacerbation; fluticasone propionate; patient withdrawal
Abbreviations: FP = fluticasone propionate; ISOLDE = Inhaled Steroids in Obstructive Lung Disease;
SF-36 = modified short-form 36 questionnaire; SGRQ = St. George Respiratory Questionnaire
T n most areas of pulmonary medicine, treatment is
based on the results of carefully conducted, ran¬
domized controlled trials. In diseases such as bron¬
chial asthma, briefperiods of follow-up are sufficient
to evaluate the effect ofmost drugs, including those
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that modify the natural histoiy of the disease.1'2
Treatment trials commonly last from 3 to 12 months;
in addition to conventional outcomes such as changes
in pulmonary function, symptoms, or health status, the
number of patients who withdraw from follow-up and
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their reasons for doing so are reported.3-4 This patient
dropout information provides further useful infor¬
mation about the effectiveness and acceptability of
treatment.
Evaluating therapy in patients with COPD usually
takes longer, although drugs such as long-acting
inhaled @-agonists can modify health status within 16
weeks.5 Changes in disease progression and, partic¬
ularly in the rate of decline of FEV^ are harder to
assess, and should be monitored over at least 3 years.
There is general agreement that it is difficult to do
this in < 3 years, the minimum period chosen in a
series of intervention studies6-9 using inhaled corti¬
costeroids. Maintaining follow-up over 3 years poses
significant problems, as COPD is characterized by
exacerbations of disease that can lead to study
withdrawal from the study. Patientwithdrawal due to
exacerbations is a particular problem when studying
inhaled corticosteroids, as courses of oral corticoste¬
roids are the most effective way of speeding the
resolution of exacerbations10-11; however, if these
courses are administered frequently, the outcome of
the trial may be affected.
Patient withdrawal is not a problem when patients
are studied early in the natural history of the disease
when exacerbations are infrequent.6-7 The Inhaled
Steroids in Obstructive Lung Disease (ISOLDE)
study recruited patients with established disease. To
show a treatment effect, it was important to retain
the patients within the trial for as long as possible.
The intention-to-treat analysis of this study has now
been reported.8 In this article, we examine the
characteristics of those patients who withdrew from
the trial, and the effect the withdrawals had on our
study population and how we analyzed the data. We
believe that these data are relevant to future inves¬
tigators who study patients of a similar severity, in
which patient behavior during long-term follow-up




Details of the trial design and patient recruitment have been
presented previously.8 All patients had a clinical diagnosis of
nonasthmatic COPD, met die established diagnostic criteria for
this disorder,12-13 were aged 40 to 75 years inclusive, and had a
history of current or previous smoking. At baseline, postbron-
chodilator (400 p.g albuterol) FEVj was a 0.8 L and < 85%
predicted, (FEVj/FVC) ratio was < 70%, and die FEVj change
after albuterol was < 10% of predicted. Patients with a clinical
diagnosis of asdima, those requiring any nontrial anti-inflamma¬
tory treatment for lung disease or (3-adrenergic blockers, patients
with a life expectancy < 5 years due to concomitant disease, and
those unable to meet the required standards for spirometry at die
www.chestjournal.org
pretrial visit were excluded. Nasal and ocular topical corticoste¬
roids were allowed, as were methylxanthines and long-acting
inhaled bronchodilators. All patients received albuterol, 200 p,g,
and ipratropium bromide, 80 p,g, as required diroughout the
trial. The protocol was approved by the ediical review committee
of each participating center, and all subjects gave written in¬
formed consent.
Spirometric Measurements (FEVj and FVC)
Measurements were made at the same time of day for each
subject. Short-acting bronchodilators were withheld for 4 h, oral
or long-acting bronchodilators for 12 h, caffeine-containing prod¬
ucts for 4 h, smoking for 2 h, and large meals for 1 h prior to
spirometric measurements. Measurements were made with pa¬
tients in the seated position after 15 min of resting. Spirometry
was performed before bronchodilation, and then 30 min after-
treatment with 80 p,g of ipratropium bromide and 400 pg of
albuterol.
Health Status Measurement
The St. George Respiratory Questionnaire (SGRQ) is a super¬
vised self-administered measure, designed specifically for use in
airways disease.14 It is a 50-item survey from which a total of
three component scores are calculated: symptoms (distress
caused by specific respiratory symptoms), activity (physical activ¬
ities that cause or are limited by breathlessness), and impacts
(social and psychological effects of the disease). The SGRQ is
scored from 0 to 100, where 0 indicates best health and 100
indicates worst health. A change in score of 4 U is consistent with
a clinically significant change in the patient13-16; therefore, an
increase in score indicates worsening health status. The SGRQ
has been shown to be a valid measure of health impairment in
patients with chronic airflow limitation, and to respond to change
with therapy.5-14-17
General health status was assessed using the SF-36, a core
generic measure.18 It is a self-completed questionnaire contain¬
ing 36 questions covering eight health concepts: physical func¬
tion, physical role limitation, mental role limitation, social func¬
tion, mental health, pain, energy/vitality, and health perception.
Two summary components (physical and mental) can also be
calculated by differentially weighting the scales. The SF-36 scales
are scored as a percentage of impairment, with 0 representing
worst health and 100 indicating best health. With this scale, a
decrease in score indicates worsening general health. Its reliabil¬
ity is extensively documented.19
Other Baseline Measurements
Smoking histoiy was validated with exhaled breath carbon
monoxide and urinary cotinine measurements. Smokers were
defined as those currently smoking or with a urinary cotinine
level > 40 ng/mL. Ex-smokers were those who had given up
smoking, and had a urinary cotinine level < 40 ng/mL Gas
transfer was measured using the single-breath method. Skin-
prick tests with diluent control, 10% histamine, and allergen
extracts of Dermatophagoides pteronyssinus, cat dander, mixed
grass pollens, and Aspergillus fumigatus were read at 15 min.
Maximum wheal diameters were measured, and atopy was
defined as a > 3 mm-wheal to at least one allergen extract with
appropriate controls.
Protocol
After completing an 8-week run in period to establish clinical
stability and confirm the postbronchodilator spirometry values on
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three occasions, patients were offered a 2-week trial of oral
corticosteroids (0.6 mg/kg/d) prior to commencing 3 years of trial
medication. Treatment was randomized between 500 p,g of
fluticasone propionate (FP) or an identical placebo bid from a
metered-dose inhaler using a Volumatic spacer device (Allen and
Hanbury; Greenford, Middlesex, UK). The patients re-attended
were followed at 3-month intervals when postbronchodilator
spirometry was recorded, and every 3 months thereafter together
with a detailed account of all new symptoms and disease exacer¬
bations. These exacerbations were defined as worsening of
respiratory symptoms that required treatment with oral cortico¬
steroids or antibiotics and/or oral corticosteroids. Health status
was recorded at baseline and eveiy 6 months thereafter.
Criteria for Withdrawal
Patients were permitted to withdraw at any time during the
study at will or at the discretion of their physician. Reasons for
withdrawal were categorized into those that were respiratory and
related to the underlying COPD and into other medical and
social reasons leading to the discontinuation of follow-up. Pa¬
tients who were treated by their family physician with a course of
oral corticosteroids on three occasions during any 3-month period
were withdrawn as per protocol, automatically considered as a
study dropouts, and offered open-label therapy with inhaled
corticosteroids. Further follow-up of these patients was not
undertaken.
Data Analysis
Patients in whom 3 years of follow-up data were available from
the time of randomization were considered to be completers; all
other randomized patients were classified as noncompleters.
Student t tests were used to analyze differences in mean values
between treatment groups. A Kaplan-Meier plot was used to
compare the time to withdrawal between treatment groups. The
Fisher exact test compared treatment withdrawals by baseline
FEVr A random coefficients hierarchical model, described
elsewhere,8 was used to determine the rates of change in FEVX
and health status for patients who completed the study and those
who withdrew. Data are expressed as mean (SD) unless stated
otherwise stated. Baseline fevj is tire mean of data measured at
4 weeks and 8 weeks of the run-in period. Tests were two sided,
with a 15% level of significance to take into account multiple
comparisons.
Results
Demographic and Baseline Characteristics
The demographic and baseline characteristics of
the patients categorized into those completing and
withdrawing and by treatment allocation are pre¬
sented in Table 1. At the beginning of the study,
there were no significant differences in gender,
atopy, smoking status, or pack-years of tobacco ex¬
posure between any of these groups; however, pa¬
tients who withdrew while receiving placebo were
significantly more likely to have been receiving
inhaled corticosteroids before entry into the trial.
The baseline FEV\ data did not differ between
patients who did and did not withdraw in the FP
group, but was lower in those withdrawing from
placebo. This was different at the 5% significance
level, but did not meet our post hoc criterion for
statistical significance.
Reasons for and Time to Withdrawal
Of the 751 patients randomized, 402 patients
successfully completed the 3-year follow-up, of
whom 220 patients had received inhaled FP. The
most common reasons for withdrawal were respira¬
tory events (n = 69, FP group; n = 93, placebo
group), the majority being frequent exacerbations as
Table 1-—Demographic and Baseline Characteristics*






3 yr Prior to 3 yr 3 yr Prior to 3 yr
Characteristics (n = 220) (n = 156) (n = 182) (n = 193)
Age, yr 63.2 (6.8) 64.5 (7.5) 62.8 (7.1) 64.6 (7.0)
Male gender, % 75 76 71 77
Atopy, % 26 29 24 24
Continuous smokers, % 34 40 38 40
Continuous ex-smokers, % 46 47 46 46
Smoking pack-yr 44.4 (28.8) 44.3 (31.2) 42.7 (31.2) 45.0 (36.7)
Tlco, mmoI/min/kPa 4.95 (2.08) 4.62 (2.04) 5.28 (2.14) 4.38 (2.03)
Kco, mmoI/min/kPa/L 1.02 (0.64) 0.98 (0.66) 1.08 (0.50) 0.90 (0.48)
Previous use of regular inhaled 52 50 t50 t64
corticosteroids, %
Baseline postbronchodilator 1.42 (0.47) 1.43 (0.48) 1.47 (0.50) 1.34 (0.47)
FEV!, L
Baseline % predicted 49.8 (14.9) 51.3(15.1) 52.0 (14.6) 48.2 (15.4)
postbronchodilator FEV!, L
*Data are presented as mean (SD) unless otherwise indicated. Tlco = diffusing capacity; Kco = diffusion coefficient,
tp < 0.01 between identified groups (Fisher exact test).
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Figure 1. Kaplan-Meier plots of the number of patients remain¬
ing in the study in both FP and placebo groups, and patient
survival allowing for withdrawal from all causes.
defined in the protocol. Thirty-five patients with¬
drew due to cardiac events, and 30 patients withdrew
due to the development of a malignancy. Forty-nine
patients either admitted to not taking any study
medication or failed to return for follow-up. The
remaining patients withdrew due to a variety of other
individually infrequent adverse events or for social
reasons. There was no difference in the frequency of
nonrespiratory withdrawals between the two groups
(p > 0.5). The time to withdrawal from all causes in
placebo- and FP-treated patients is illustrated by the
Kaplan-Meier plot in Figure 1. Patients withdrew
steadily throughout the study. At all time points,
more patients withdrew while receiving placebo at
each time point. The median number of exacerba¬
tions during FP treatment was 0.99/yr irrespective of
subsequent withdrawal. In those receiving placebo, it
was 1.05/yr in those completing but 1.69/yr in those
who did not complete the trial (p = < 0.02).
Spirometry and Withdrawal
The study population was separated into two
groups on the basis of an FEVi of < 50% predicted
(American Thoracic Society stage 3). In patients with
a higher FEV1; the number of patients completing
and withdrawing during the study were similar in
patients with a higher FEVi (> 50% predicted), with
46% of tire total withdrawing. When the FEV^ was
< 50% predicted, there was a clear difference be¬
tween the two treatments, with significantly more
patients withdrawing from placebo compared widi FP
treatment (57% vs 38%, respectively; p = 0.0002). The
reasons for withdrawal were similar in each group as a
percentage of the total causes listed, but tire absolute
numbers were lower in the FP-treated patients.
The rate of decline in FEV1 is presented in Fig¬
ure 2. The effect of treatment on the rate of decline
in FEVX was the same in patients who withdrew and
those who completed the study (Table 2, Fig 2);
however, patients who completed the study had a
significantly slower decline in FEV1 than those who
withdrew, irrespective of treatment group (p < 0.02).
Health Status and Withdrawal
Baseline health status data for the SGRQ and
SF-36 were similar in all domains at study entry
irrespective of subsequent withdrawal. The rate of
decline of health status in those withdrawing in the
FP group did not differ from that in the placebo








FP completed: 46 ml/yr
Placebo completed: 51 ml/
FP withdrawn: 74 ml/yr
Placebo withdrawn: 95 ml/
—I 1 1 1 1 1 1 1 1
12 15 18 21 24 27 30 33 36
Months
Figure 2. Mean rate of change of the postbronchodilator FEVj over 3 years in patients receiving
placebo who withdrew and completed the study, and those receiving FP who withdrew and completed
the study.
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Variables (n = 211) (n = 107) p Value (n = 175) (n = 123) p Value
Postbronchodilator FEVj 46 mL/yr (n = 220) 74 mL/yr (n = 119) <0.02 51 ntL/yr (n = 181) 95 mL/yr (n = 144) <0.02
SGRQ total 2.00 2.79 0.4 2.65 6.74 0.0001
SGRQ symptoms 1.15 0.64 0.6 1.99 4.81 0.009
SGRQ activity 2.04 3.86 0.08 3.06 7.02 0.0001
SGRQ impacts 2.21 2.80 0.6 2.63 7.35 0.0001
SF-36 physical function - 1.81 - 2.40 0.6 - 2.82 - 7.10 0.0001
SF-36 physical role - 3.23 - 3.64 0.9 -4.47 - 11.06 0.005
SF-36 pain - 1.25 - 3.55 0.2 - 2.31 - 2.08 0.8
SF-36 health perception - 2.49 - 2.28 0.9 - 2.25 - 7.10 0.0001
SF-36 energy/vitality - 1.22 - 2.43 0.3 - 2.07 -5.59 0.001
SF-36 social function - 1.22 - 2.43 0.3 - 2.07 -5.59 0.001
SF-36 mental role - 4.51 - 6.08 0.6 -5.40 - 7.82 0.4
SF-36 mental health - 0.02 -0.32 0.8 - 0.99 -2.78 0.06
*Data are presented as U/yr unless odierwise indicated.
in SGRQ total, symptoms, and impacts scores of
placebo-treated patients who withdrew was signifi¬
cantly greater than that of placebo completers or the
patients treated with FP (p < 0.01). The total SGRQ
score of patients withdrawing from placebo deterio¬
rated at 6.74 U/yr, equivalent to a clinically notice¬
able deterioration in health status every 8 months
(Fig 3). The rate of change in the SF-36 physical
function and health perception scores in placebo-
treated patients who withdrew was greater compared
to the other three groups (p < 0.001).
Discussion
This is the first prospective COPD study in which
large numbers of patients failed to complete the
intended follow-up period because of nonrandom
withdrawal. Like other studies6-9 of inhaled cortico¬
steroids, our trial did not show a significant effect on
the primary outcome measure, rate of decline of
FEVi; however, patients withdrawing from our study
had a more rapid deterioration in lung function and
health status assessed prior to withdrawal. Loss of
these patients from the trial is likely to have reduced
the power of the investigation to show differences
between groups, and suggests that the effects that
were reported are a conservative estimate of the
impact of treatment.
At randomization, there were no significant differ¬
ences between the treatment groups. During the
trial, almost half the patients withdrew, principally
















s Placebo withdrawn: 6.7 units/yr
FP withdrawn: 2.8 units/yr Placebo completed: 2.7 units/
FP completed: 2.0 units/yr
1 2
Months
Figure 3. Mean rate of change of the SGRQ total score over 3 years in patients receiving placebo who
withdrew and completed die study, and those receiving FP who withdrew and completed the study. An
increase in score represents worsening of health status.
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corticosteroids. This withdrawal due to repeated oral
corticosteroid use was more common in placebo-
treated patients, and explains the different dropout
rates in between the groups. Post hoc categorization
of patients into completers and witlidrawers suggests
an explanation for the different dropout rates in the
FP- and placebo-treatment groups. Placebo-treated
patients who withdrew had a tendency to have a
lower initial FEV, than those who completed 3 years
of follow-up, a finding not seen in FP-treated pa¬
tients. The effect of the inhaled corticosteroid may
have been to allow these more physiologically im¬
paired patients to better cope with exacerbations
better, and avoid treatment with oral corticosteroids.
Although patients who had previously received in¬
haled corticosteroids were no different in other
respects at study entry,8 they were more likely to
withdraw if randomized to placebo, which is in
keeping with other data from the prerandomization
phase of this study.20
The severity of COPD assessed spirometrically
also influenced both the number withdrawing and
the number of exacerbations that occurred. Patients
with worse spirometric findings were more likely to
withdraw and have exacerbations, and this influ¬
enced the ability of treatment to show an effect.
Thus, the effect of FP treatment on respiratoiy
withdrawals was most evident in patients with more
severe disease (American Thoracic Society stage 3,
ie, < 50% predicted FEVT), where 104 patients
withdrew due to respiratoiy causes compared with
the 54 patients in the less severely affected groups.
These data explain the lower frequency of exacerba¬
tions in other trials of inhaled corticosteroids,6''
where the baseline FEVX was higher. Selection of
patients by a specified postbronchodilator FEV, is
therefore likely to be important when exacerbation
frequency is a study outcome. Moreover, the patient
who withdrew were those in whom the FEV: was
declining most rapidly, providing objective confirma¬
tion of their greater disease severity.
Health status measurements, whether disease spe¬
cific or generic, deteriorate in patients with COPD,
and this change is less marked in those treated with
inhaled corticosteroids.21 Our analysis shows that an
important consequence of effective treatment is to
prevent the deterioration in health status in those
who would otherwise withdraw. Thus, the health
status change of patients receiving FP who withdrew
was similar to that in the placebo-treated completers.
Impaired health status is associated with increased
health-care utilization22 and increased numbers of
exacerbations.23 The higher median exacerbation
frequency in those withdrawing while receiving pla¬
cebo suggests that exacerbations contribute to their
accelerated decline in health status, and the protec-
www.chestjournal.org
tive effect of FP arises from the lower number of
exacerbations observed with this drug.
Differential withdrawal from the study might
modify the study outcome. The loss of those patients
with the most rapid decline in FEV, will reduce the
overall power of the study to show a difference. The
"healthier survivor" effect seen in the placebo-
treated but not the FP-treated patients may reduce
the difference between groups in the rate of decline
of FEV! This may be important because, as others,
we used a random effects model to estimate the rate
of decline of FEV1; but this is a conservative ap¬
proach to detecting differences between treatments,
especially if there are differential dropout rates
between treatment groups. A theoretical analysis of
the magnitude of this effect is shown in Figure 3.
Differential dropout rates between treatment groups
is a relevant consideration for other potential dis¬
ease-modifying agents, in which a reduction of exac¬
erbations may also occur and similar problems arise.
Avoiding premature withdrawal is clearly a diffi¬
cult problem in any study in which an active therapy
is compared with a placebo treatment. This is espe¬
cially so when the treatment is already prescribed by
some physicians, and its removal can precipitate an
exacerbation.20 Patients withdrawn should continue
to be followed up even if their medication is
changed, and future trials should consider less rig¬
orous criteria than those used here to determine
when a patient should be discontinued from partic¬
ipating in the study.
Reporting the number ofpatients leaving a clinical
trial provides useful additional information about
treatment effectiveness in bronchial asthma,3'4 and
our data suggests that this is also true for COPD. The
significantly different outcomes in those withdrawing
from active and placebo treatment suggests that an
important clinical effect is occurring. Thus, the
impact of inhaled corticosteroids in COPD may be
rather greater than analyses of individual end points
have so far suggested. These benefits are most
marked in patients with an FEVj < 50% predicted,
and as such are in line with recommendations for
treatment suggested in the Global Initiative for
Chronic Obstructive Lung Disease management
strategy.13
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Effect of tiotropium bromide on circadian variation in
airflow limitation in chronic obstructive pulmonary disease
PMA Calverley, A Lee, L Towse, J van Noord, T J Witek, S Kelsen
Thorax 2003;58:855-860
Background: In chronic obstructive pulmonary disease (COPD), the degree of circadian variation in forced
expiratory volume in 1 second (FEVi) and the influence of anticholinergic blockade is not known.
Tiotropium is a long acting inhaled anticholinergic bronchodilator that increases daytime FEVi in COPD.
We hypothesised that tiotropium would modify the overnight change in FEVi, and this would be unaffected
by the timing of drug administration.
Methods: A double blind, randomised, placebo controlled trial was conducted with fiotropium 18 mg once
daily in the morning (09.00 hours), evening (21.00 hours), or an identical placebo. Patients with stable
COPD (n = 121, FEVi =41% predicted) underwent spirometric tests every 3 hours for 24 hours at baseline
and after 6 weeks of treatment.
Results: There were no significant differences at baseline between the groups. Tiotropium improved mean
(SE) FEVi (over 24 hours) in the morning (1.11 (0.03) I) and evening (1.06 (0.03) I) groups compared
with placebo (0.90 (0.03) I), and nocturnal FEVi (mean of 03.00 and 06.00 hours) in the morning (1.03
(0.03) I) and evening (1.04 (0.03) I) groups compared with placebo (0.82 (0.03) I) at the 6 week visit
(p<0.01). FEV] before morning or evening dosing was similar, while the peak FEVi moved later in the
day with active treatment. The mean percentage change in FEVi from 09.00 hours to 03.00 hours (the
nocturnal decline in FEVi) was -2.8% in the morning group, -1.0% in the evening group, and -12.8% in
the placebo group. The magnitude of the peak to trough change in FEVi w°s not statistically different.
Conclusions: Tiotropium produced sustained bronchodilation throughout the 24 hour day without
necessarily abolishing circadian variation in airway calibre.















Many patients with respiratory disease complain ofsymptoms which are worse during the night or in theearly mor ing. This has been well docu ented in
bronchial asthma'2 but is also reported by patients with
chronic obstructive pulmonary disease (COPD).1"' In patients
with asthma the symptoms have usually been ascribed to a
substantial increase in the normal circadian variation in
airway calibre,6 but data in COPD are less convincing and
have relied on unsupervised home peak expiratory flow
(PEF) recording. Nonetheless, a circadian variation of 16 1/
min per day has been reported in COPD and is substantially
less than in asthmatic subjects.7
There is general agreement that central cholinergic
mechanisms are the major determinants of this variation in
airway calibre.8 However, this has been difficult to test in
man as the duration of action of existing anticholinergic
drugs does not completely span the overnight period.9
Moreover, the side effects of systemically administered
anticholinergic drugs preclude the chronic treatment required
to assess this response, as does their attendant sleep
disruption. Nonetheless, there are data that suggest that
inhaled oxitropium bromide can reduce the overnight fall in
PEF in nocturnal asthma.10
Tiotropium bromide is a new long acting inhaled antic¬
holinergic bronchodilator that improves lung function for
24 hours after once daily dosing. The pharmacological
properties of muscarinic receptor kinetic subselectivity" 12
and prolonged binding to the M3 receptor have been
proposed as explanations for this prolonged duration of
action." An earlier dose ranging study of single dose
tiotropium in patients with COPD showed that, despite
significant bronchodilation, a nocturnal decline in FEV!
occurred approximately 15-19 hours after morning inhala¬
tion of a single dose.14 This change was less marked than that
with placebo, suggesting that morning administration of
tiotropium partially reverses the nocturnal decline in lung
function.
Evening administration of tiotropium has not previously
been evaluated. The time of administration may influence the
pharmacodynamics of some bronchodilators such as theo¬
phylline, with evening administration of certain formulations
having a more pronounced effect on lung function during the
night." Similar time dependent effects of dosing have been
seen with corticosteroids in asthma.1617
In this study we examined whether the circadian variation
in FEV! in patients with COPD was greater than that reported
in healthy subjects, whether it could be abolished or reduced
by sustained anticholinergic blockade in the airways, and
whether the timing of the dose of tiotropium influenced its




All patients recruited were at least 40 years old with a
smoking history of at least 10 pack years and a clinical
diagnosis and spirometric parameters compatible with COPD
as defined by the American Thoracic Society (ATS).18 Their
FEVi/FVC ratio was less than 70% and their absolute FEV,
was 25-65% predicted using the European Community for
Coal and Steel (ECCS) reference values." Patients with a
history of asthma, allergic rhinitis, or atopy, or a total
eosinophil count s=600/mm3 were excluded, as were those
with significant diseases other than COPD. No patient had
experienced an exacerbation of COPD within the preceding
4 weeks. Medications not permitted after the run in phase
were short acting inhaled anticholinergic drugs, long acting
inhaled p agonists, oral P agonists, and theophylline. Use of
www.thoraxjnl.com
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other concurrent medication was required to be stable during
the study period. The protocol was approved by local
institution review boards and informed consent was obtained
from all patients.
Study design
A 6 week, multicentre, randomised, double blind, double
dummy, parallel group design was used. Three treatment
arms were compared: tiotropium 18 pg daily administered at
09.00 hours (Tio-AM), tiotropium 18 pg daily administered
at 21.00 hours (Tio-PM), and placebo. All patients inhaled
the contents of one capsule twice daily (either placebo or
tiotropium, depending on the group). The times of study
administration selected were based on the anticipated
average time that a person might take morning or evening
medication, considering the study design needed to separate
the dose-time interval by 12 hours. Study medication was
administered by a dry powder device (HandiHaler).
After initial screening, patients entered a 7 day baseline
period to ensure clinical stability (no exacerbations). They
attended the clinic where spirometric tests were performed 3
hourly over a 24 hour period, at the end of which they
received their first morning dose of study medication. They
were instructed to take the study medication in the morning
(09.00 hours) and evening (21.00 hours) and to record their
morning and evening PEF throughout the study in a diary
card immediately before administering study medication.
After 6 weeks the patients attended for their second clinic
visit. Spirometric assessment began before the administration
of the evening dose of medication. Patients remained in the
clinic overnight and spirometric tests were again repeated 3
hourly throughout the following day (including overnight
measurements and immediately before the morning dose of
study medication). Patients were awakened for spirometric
testing if necessary.
A continuous 24 ECG (Holter monitor) was recorded
during the patients' stay in the clinic at baseline and at
6 weeks. Analysis of the Holter ECG tapes was performed by
Hertford Medical BV, Maasdam, The Netherlands by inves¬
tigators blinded to the purpose of the study. Adverse events
were monitored throughout the baseline and 6 week
treatment periods.
Study procedures
Baseline spirometric tests were conducted between 08.00 and
12.00 hours. They were conducted in triplicate and met ATS
standards of reproducibility.20 The highest values of FEVi and
FVC from three reproducible tracings were recorded.
Identical portable electronic spirometers (Microlab 3300
Spirometer; Micromedical, Kent, UK) were used for all
measurements at all centres. Home PEF recordings were
made using a Personal Best Peak Flow Meter (Health Scan
Products Inc, Cedar Grove, NJ, USA) and were recorded as
the best of three efforts in the morning and the evening.
Data analysis
The primary end point was the mean change from baseline in
FEVi recorded at 03.00 and 06.00 hours on the morning
following the last dose of study medication on visit 4 (after 42
(3) days of treatment). Baseline FEV, was derived from the
measurements recorded at 03.00 and 06.00 hours before the
administration of the study drug on visit 2 (day 1). The
overall steady state bronchodilator efficacy of tiolropium was
determined by the mean FEVj response measured over a
24 hour time interval on visit 4. The mean FEV! at baseline
was calculated as the mean of the 3 hourly readings
measured over 24 hours from 09.00 to 09.00 at visit 2. The
mean response was defined as the difference between the
mean FEVi at baseline (visit 2) and the mean FEVi at the end
of treatment (visit 4).
The sample size calculation was based on data from
previous studies of the effect of tiotropium on FEVi in
COPD!4 Assuming a standard deviation of 0.17 1 for FEVi,21 a
sample size of 30 patients per treatment group would be
sufficient to detect a difference of 0.15 1 in FEVi between
treatment groups at a 5% level of significance and 90% power
using a two tailed t test.
Data are presented as mean (SD) for the population and SE
for between-group comparisons. Analysis of covariance with
terms for treatment and centre and baseline as a covariate
was used as the statistical model for all efficacy analyses. The
baseline value was included in the analysis of covariance
model as a covariate to adjust for any baseline differences
between treatment groups. Patients were excluded from
individual analysis if adequate data were not available (for
example, missing baseline data). Differences were accepted
as being statistically significant at p<0.05. Circadian varia¬
tion in peak flow and FEVi was calculated as the difference
between the highest and lowest values divided by the mean
of the values available for that period—that is, all FEVi
measurements during the 24 hour period and all PEF
measurements during the week of study. However, the study
was not originally powered to examine circadian variation




Patient baseline features for the three treatment groups are
presented in table 1. The mean age for the groups combined
was 65.8 years, 62% were men, and the group mean FEVi
was 1.08 1 (40.8% predicted). The mean smoking history was
44 pack years, with 62% of the total population being ex-
smokers. The groups did not differ in their pulmonary
function or in their usual pulmonary medication before
randomisation (table 1).
Spirometric parameters
Forced expiratory volume in 1 second (FEVi)
The mean (SE) nocturnal FEVi (mean FEVi at 03.00 and
06.00 hours) for the Tio-AM, Tio-PM, and placebo groups
and the corresponding overall steady state FEV] (mean over
24 hours) values are presented in table 2. The differences
from placebo in both the morning and evening dosing groups
as well as the nocturnal FEVi were statistically significant
(p<0.05) at all time points on day 42. The baseline 24 hour
spirometric recordings showed significant circadian variation
in FEVi in all three patient groups with the highest values
recorded at 09.00 hours on the study day and the lowest
values occurring at either 03.00 or 06.00 hours on the
following morning (fig 1A). The group mean change in
FEVi between 09.00 and 03.00 hours at baseline was:
— 180 ml in Tio-AM, -200 ml in Tio-PM, and —120 ml in
the placebo group, corresponding to 03.00 hour absolute
values of FEVi of 0.88, 0.84, and 0.90 1, respectively. The
mean FEVi over the 24 hour day was 0.96, 0.95 and 0.96 1 for
the Tio-AM, Tio-PM, and placebo groups, respectively. The
mean circadian variation for each group was 33.3%, 35.6%
and 25.9%, respectively. There was considerable intersubject
variability and these values did not differ statistically
between the groups (ANOVA), but in the pairwise compar¬
isons the variation in the Tio-PM group was higher than in
the placebo group (p = 0.03). However, the baseline varia¬
bility before treatment was lower in the placebo group and
this might influence the results.
When the FEVi profile was repeated after treatment,
patients receiving placebo had a lower 24 hour mean FEVi
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Table 1 Demographic characteristics of patients at screening (n = 121)
Tiotropium (pm) Tiofropium (am)
(n = 43) (n = 38) Placebo (n = 40) Total (n = 121)
Men (n) 28 21 26 75
Age (years)* 66.1 (6.6) 64.9 (7.7) 66.5 (9.4) 65.8 (7.9)
Duration of COPD (years)* 10.0 (8.5) 12.3 (12.3) 9.9 (7.9) 10.7 (9.7)
Baseline spirometry:*
FEV, |l) 1.09 (0.38) 1.12(0.45) 1.04 (0.33) 1.08 (0.39)
FEV, (% predicted) 41.8 (14.0) 41.9 (13.5) 38.6 (9.6) 40.8 (12.5)
FVC (1) 2.14 (0.67) 2.19(0.68) 2.15 (0.71) 2.16 (0.68)
FEV,/FVC (%| 51.8(11.0) 50.9(11.0) 49.6 (9.3) 50.8 (10.4)
Total taking pulmonary 41 (95.3%) 36 (94.7%) 37 (92.5%) 114
medication during the
baseline period
Anticholinergic drugs 15 (34.9%) 14(36.8%) 18 (45.0%) 47
Beta adrenergics (inhaled) 34 (79.1%) 34 (89.5%) 35 (87.5%) 103
Beta adrenergics (oral) 3 (7.0%) 4(10.5%) 4 (10.0%) 11
Mucolytic agents 1 (2.3%) 3 (7.9%) 3 (7.5%) 7
Steroid (inhaled) 31 (72.1%) 27 (71.1%) 27 (67.5%) 85
Steroid (oral) 0(0%) 0(0 %) 2 (5.0%) 2
Theophylline 2 (4.7%) 1 (2.6%) 2 (5.0%) 5
*Mean (SD).
(0.91 (0.02) 1) which was statistically lower than at the
baseline visit (0.96 (0.02) 1). On this occasion, the peak value
occurred at 12.00 hours with the minimum FEVt again being
recorded between 03.00 and 06.00 hours on the following
day, corresponding to an absolute FEVi of 0.82 1 (fig IB).
In both tiotropium groups the FEV! increased significantly
at all time points during the 24 hour observation period
compared with placebo (fig IB). In patients treated with
tiotropium the highest FEV! now occurred at 12.00 hours,
but the nadir remained between 03.00 and 06.00 hours.
There was a non-significant trend towards a reduction in the
magnitude of overnight decline in FEVi compared with
placebo when this was expressed as a percentage change
from the mean at 09.00 hours (fig 2), but not as an absolute
change from the mean daily FEVi value (Tio-AM = 60 ml,
Tio-PM = 48 ml, placebo = 56 ml).
Individual maximum variation was calculated as the
difference between maximum and minimum FEVi expressed
as a proportional change from the minimum (100 x
(maximum - minimum)/minimum). At baseline the mean
maximum variation was 41.6%, 46.5%, and 30.2% for Tio-
AM, Tio-PM, and placebo, respectively. After treatment the
mean maximum variation declined in the Tio-AM (34.5%)
and the Tio-PM (37.2%) groups but was similar to baseline in
the placebo group (32.7%).
Forced vital capacity
The pattern of nocturnal FVC (mean FVC at 03.00 and
06.00 hours) and overall steady state FVC (mean over
24 hours) was similar to the FEVi responses, and both
tiotropium groups were statistically better than placebo
(p = 0.0001). The mean (SE) nocturnal FVC for the Tio-AM,
Tio-PM, and placebo groups and the corresponding overall
steady state FVC values are presented in table 3. No
statistically significant differences were seen between the
two tiotropium dosing groups with respect to the nocturnal
FVC (p = 0.61) and overall steady state FVC (p = 0.35). As
with FEVi, the FVC profile after 6 weeks of treatment
showed that both tiotropium groups were consistently better
than the placebo group throughout the 24 hour observation
period.
Peak expiratory flow
The mean morning and evening PEF during the baseline
period were comparable across the three treatment groups
(table 4). The weekly mean morning and evening PEF for
both tiotropium groups was statistically better than for
placebo (p<0.02, fig 3). For both tiotropium groups themean
weekly morning and evening PEF increased after 1 week on
treatment, and remained consistently better than placebo
throughout the 6 weeks of treatment.
Adverse events
COPD exacerbations and upper respiratory tract infection
were more common with placebo than with Tio-AM and Tio-
PM, although the differences were not statistically signifi¬
cant. Exacerbations of COPD and upper respiratory tract
infections were diagnosed by the physician and reported as
adverse events. Eight patients (20.0%) in the placebo group
had a COPD exacerbation compared with four patients
Table 2 Mean* (SE) nocturnal forced expiratory volume in 1 second (FEV,) and overall
steady state FEV, differences between treatment groups a fter 6 weeks of study drug
Treatment Mean (SE) Comparison Difference (SE) p value 95% CI
Nocturnal
FEV,
AM 1.03 (0.03) AM - Placebo 0.21 (0.04) 0.0001 (0.13 to 0.29)
PM 1.04 (0.03| PM - Placebo 0.21 (0.04) 0.0001 (0.13 to 0.29)
Placebo 0.82 (0.03) AM-PM -0.01 (0.04) 0.8529 (-0.09 to 0.07)
Steady state
FEV,
AM 1.11 (0.03) AM — Placebo 0.21 (0.04) 0.0001 (0.13 to 0.29)
PM 1.06 (0.03) PM — Placebo 0.16 (0.04) 0.0001 (0.09 to 0.24)
Placebo 0.90 (0.03) AM-PM 0.05 (0.04) 0.2127 (-0.03 to 0.12)
*Means are adjusted for centre and baseline.
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Figure 2 Proportional nocturnal decline in forced expiratory volume in
1 second (FEVi) at baseline and after 6 weeks of study drug (steady
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Figure 1 Mean forced expiratory volume in 1 second (FEVi) in litres
over 24 hours (A) at baseline and (B) after 6 weeks (steady state) of
tiotropium in the evening (pm), tiotropium in the morning (am), or
placebo.
(9.3%) in the Tio-PM group and one (2.6%) in the Tio-AM
group. Six patients (15.0%) in the placebo group experienced
upper respiratory tract infection compared with three (7.0%)
in the Tio-PM group and one (2.6%) in the Tio-AM group.
There were no differences in other adverse events in the
tiotropium groups compared with the placebo group.
Treatment with tiotropium was not associated with cardiac
rhythm or heart rate abnormalities as assessed by 24 hour
Holter monitoring.
DISCUSSION
Like many other biological variables, airway calibre exhibits a
circadian variation during the 24 hour day with maximum
values occurring around noon and the minimum values in
the early morning.22 This variability is characteristic of
bronchial asthma and is associated with increased levels of
inflammatory mediators in the airways during sleep.16 The
practice of defining variability by changes in morning and
evening PEF has been transferred to patients with COPD
where, contrary to the current definition of "relatively little
variation in airflow calibre",23 several studies have shown
evidence of circadian variation.4 7 24-27 Using the PEF in COPD
is potentially misleading as the measurement is effort
dependent and underestimates the impairment of FEV, in
COPD." Previous reports have significant limitations. They
included only small numbers of patients and did not obtain
measurements during the night.7 24 26 Some failed to include a
control limb when studying bronchodilator effects24 26 or
included patients with substantial degrees of bronchodilator
responsiveness.4 This is the first study to document circadian
variation in FEVi in patients with stable COPD before and
after a long acting inhaled bronchodilator and to include
measurements during the early morning hours when FEV, is
lowest. Our findings have implications both for the mechan¬
isms underlying this process and the interpretation of the
results of treatment trials.
Studies of spirometric tests in normal subjects report a
mean maximum change across the day of 200 ml in FEV,.28
Observations in a large population of healthy individuals
whose FEV, was measured on different occasions between
09.00 and 21.00 hours confirm that the peak values occurred
around midday.29 They suggested that those who are older,
smoke cigarettes, or have some respiratory symptoms show a
more marked fall in FEV, in the later evening. At baseline in
our patients with COPD there was a mean (SE) daily FEV,
change of 286 (17) ml for the whole group with the
maximum value in the late morning and the minimum in
the early hours of the morning. This overall pattern was
reproducible over the 6 weeks in the placebo group although
the 09.00 value tended to be lower, possibly reflecting
differences in the duration of effect of other permitted
medications. The FVC data parallel those for FEV, with no
meaningful difference in the FEV,/FVC ratio throughout the
24 hour day, an observation supportive of consistent effort in
performing the measurements throughout the day. The mean
PEF was lower in the morning than in the evening
throughout the 6 weeks in the placebo treated patients,
varying by 13-17 1/min. These values are similar to those in
the only other study to report patients of similar severity.7
These mean data mask significant between-week and
between-individual variations and highlight the limitation
of using measurements of circadian variation where the
precise time of measurement is not known.
Lower respiratory system resistance in COPD rises sig¬
nificantly throughout sleep, independent of sleep stage30 and,
although polysomnography data were not included in the
present study, our data are compatible with this. Increased
cholinergic tone in the airway smooth muscle is believed to
be a major contributor to this process, but data from the
COPD patients treated with tiotropium indicate that this may
not be the only factor involved. Tiotropium is an effective
inhaled anticholinergic drug which can block methacholine
challenge in patients with asthma for long periods.3' The
mean FEV, value over the 24 hour day increased after
tiotropium and the absolute FEV, was always higher at any
time point after the active drug than the pretreatment
baseline and placebo values. The timing of FEV, variation
also changed, with the highest FEV, occurring between 12.00
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Table 3 Mean* (SE) nocturnal forced vital capacity (FVC) and overall steady state FVC
differences between treatment groups after 6 weeks of study drug
Treatment Mean (SE) Comparison Difference (SE) p value 95% CI
Nocturnal FVC
AM 1.99(0.05) AM - Placebo 0.31 (0.07) 0.0001 (0.18 to 0.45)
PM 2.02 (0.05) PM - Placebo 0.35 (0.07) 0.0001 (0.22 to 0.48)
Placebo 1.68 (0.05) AM-PM -0.03 (0.07) 0.6051 (-0.16 to 0.10)
Steady state
FVC
AM 2.12(0.04) AM - Placebo 0.32 (0.06) 0.0001 (0.21 to 0.44)
PM 2.07 (0.04) PM — Placebo 0.27 (0.06) 0.0001 (0.16 to 0.39)
Placebo 1.79(0.04) AM-PM 0.05 (0.06) 0.3526 (-0.06 to 0.16)
*Means are adjusted for centre and baseline.
and 18.00 hours, a pattern closer to that described in healthy
individuals." Despite this improvement in absolute FEVj, the
difference between the highest and lowest values during the
day was similar after the active drug whenever given and
resembled that reported in normal subjects.22 Whether this is
due to changes in airway calibre in areas not reached by the
inhaler, to different factors modulating airway smooth
muscle activation, or simply differences in the control of
lung volume or secretion clearance as proposed elsewhere'3
cannot be resolved by our study.
The data illustrate some of the problems in interpreting
bronchial reactivity indices in patients with a low baseline
FEV,. If we relate the change in FEVj after tiotropium
administered at 09.00 hours to a specific time point as in fig 2,
reactivity appears to decline even though the absolute change
from maximum to minimum is unaffected. Similar problems
arise when other indices recommended in population studies
are calculated." This emphasises the need to relate such
variables to baseline lung function and helps explain the poor
concordance between PEF changes and other measures of
bronchial reactivity in patients with COPD.35
Although the timing of the dose of some drugs, such as
corticosteroids in asthma,1617 may influence the subsequent
FEV!, this was not seen in these studies with tiotropium in
COPD. The absolute change in FEV2 compared with baseline
appeared smaller than that reported in some larger trials,36
but the changes relative to placebo were similar in
magnitude. Nevertheless, the timing of the measurements
can influence the end points selected. The 03.00 hours value
had a mean difference of 220 ml in the Tio-AM and Tio-PM
groups compared with placebo, while the 09.00 hours value
had a mean difference of 130 and 110 ml, respectively. This
dependence on timing may help explain why patients with
COPD vary in response to the same drug in different studies.
In summary, we have found that circadian variations in
FEV! are present in patients with COPD. This is likely to
contribute to the disturbed sleep seen in such patients and
reflected in their daytime symptoms. Although the absolute
change in FEV! over 24 hours is close to normal, it comprises
a proportionately greater amount of the waking value and
this can complicate the interpretation of the usual measures
of bronchial responsiveness. Our findings show that tiotro-
Table 4 Mean (SE) baseline weekly means for morning
(PEF am) and evening (PEF pm) peak expiratory flow rates
(l/min)
Tiotropium Tiotropium Placebo
pm (n = 40) am (n = 37) (n = 34)
PEF am 209(13) 195(11) 217(15)
PEF pm 225 (12) 205(11) 223 (15)
pium once daily, whether administered in the morning or
evening, results in sustained improvements in spirometric
indices throughout the 24 hours, including improvement in
the early morning nadir in spirometric values, without
necessarily affecting circadian variability.
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Randomised, double blind, placebo controlled study of
fluticasone propionate in patients with moderate to severe
chronic obstructive pulmonary disease: the ISOLDE trial
P S Burge, P M A Calverley, P WJones, S Spencer,J A Anderson, T K Maslen on behalf of the
ISOLDE study investigators
Abstract
Objectives To determine the effect of long term
inhaled corticosteroids on lung function,
exacerbations, and health status in patients with
moderate to severe chronic obstructive pulmonary
disease.
Design Double blind, placebo controlled study.
Setting Eighteen UK hospitals.
Participants 751 men and women aged between 40
and 75 years with mean forced expiratory volume in
one second (FEV,) 50% of predicted normal.
Interventions Inhaled fluticasone propionate 500 pg
twice daily from a metered dose inhaler or identical
placebo.
Main outcome measures Efficacy measures: rate of
decline in FEV, after the bronchodilator and in health
status, frequency of exacerbations, respiratory
withdrawals. Safety measures:morning serum Cortisol
concentration, incidence ofadverse events.
Results There was no significant difference in the
annual rate ofdecline in FEV, (P= 0.16). Mean FEV,
after bronchodilator remained significantly higher
throughout the study with fluticasone propionate
compared with placebo (P < 0.001). Median
exacerbation rate was reduced by 25% from 1.32 a
year on placebo to 0.99 a year on with fluticasone
propionate (P = 0.026). Plealth status deteriorated by
3.2 units a year on placebo and 2.0 units a year on
fluticasone propionate (P = 0.0043). Withdrawals
because of respiratory disease not related to
malignancy were higher in tire placebo group (25% v
19%, P= 0.034).
Conclusions Fluticasone propionate 500 pg twice
daily did not affect the rate of decline in FEV, but did
produce a small increase in FEV,. Patients on
fluticasone propionate had fewer exacerbations and a
slower decline in health status. These improvements
in clinical outcomes support the use of this treatment
in patients with moderate to severe chronic
obstructive pulmonary disease.
Introduction
Chronic obstructive pulmonary disease is a leading
cause ofmorbidity and mortality worldwide,'2 and its
prevalence is rising.3 It occurs predominantly in
tobacco smokers and is characterised by an increase in
the annual rate ofdecline of forced expiratory volume
in one second (FEV,).4 As lung function deteriorates,
substantial changes in general health occur.5 Smoking
cessation reduces the rate ofdecline in FEV, in people
with this disease," but no pharmacological intervention
has been shown to modify the progression of disease
or the associated decline in health status.
In at least 10% of patients with stable chronic
obstructive pulmonary disease FEV, will increase
significantly after oral prednisolone.' A large, retro¬
spective, open study reported a reduction in the rate of
decline of FEV, in those taking oral corticosteroids.8
Recently, two studies over three years of inhaled
budesonide 800 pg in mild to moderate chronic
obstructive pulmonary disease found no effect of treat¬
ment on the rate of decline in FEV,.910 Clinical
outcomes such as exacerbations, however, were
infrequent and health status either showed no benefit
ofbudesonide9 or was not assessed.,0
The inhaled steroids in obstructive lung disease in
Europe (ISOLDE) study was designed to test the effect
of inhaled fluticasone propionate 500 pg twice daily on




Eighteen UIC hospitals participated. Patients were cur¬
rent or former smokers aged 40-75 years with
non-asthmatic chronic obstructive pulmonary disease.
Baseline FEV, after bronchodilator was at least 0.8
litres but less than 85% of predicted normal, and the
ratio ofFEV, to forced vital capacity was less than 70%.
Previous use of inhaled and oral corticosteroids was
permitted. Patients were excluded if their FEV,
response to 400 pg salbutamol exceeded 10% of
predicted normal, they had a life expectancy of less
than five years from concurrent diseases, or they used P
blockers. Nasal and ophthalmic corticosteroids, theo¬
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The protocol was approved by each centre's local
ethical committee and patients provided written
informed consent
Trial design
Patients were recruited between 1 October 1992 and
31 March 1995. Eligible padents entered an eight week
run-in period after withdrawal from any oral or
inhaled corticosteroids. After clinic visits at 0, 4, and 8
weeks (visits 0,1, and 2, respectively) patients were ran¬
domised to receive either fluticasone propionate 500
jig or an identical placebo twice daily administered
from a metered dose inhaler and with a spacer device
by using 10 tidal breaths after each of two actuations.
We used a computer generated allocation schedule
stratified by centre (block size of six). Patients were ran¬
domised sequentially from a list comprising treatment
numbers only. Throughout the trial patients used
salbutamol (100 jig/pufi) or ipratropium bromide
(40 jig/pufi), or both, for symptomatic relief.
Before the double blind phase, and ifnot contrain-
dicated, patients received oral prednisolone 0.6
mg/kg/day for 14 days, after which spirometry was
performed. These data were used to test whether the
acute corticosteroid response could predict those
patients who would benefit from long term inhaled
corticosteroids. During the three year double blind
phase, participants visited a clinic every three months
for spirometry, recording of exacerbations, and safety
assessments.
The primary end pointwas the decline (ml/year) in
FEV, after bronchodilator.About 450 patientswith two
ormore measurements ofFEV, during treatment were
required to detect a treatment difference of 20 ml/year,
assuming a linear decline and a SD of 75 ml/year, with
80% power. Other key end points were frequency of
exacerbation, changes in health status, withdrawals
because of respiratory disease, morning serum Cortisol
concentrations, and adverse events.
Measurements
Spirometry measurements were recorded by well
trained staff using a standardised procedure on new
Sensormedics 2130D spirometers. Quality control
included a computer generated check against the ATS
criteria11 and a central manual check for acceptability
and reproducibility for all measurements, resulting in
standards comparable with the lung health study.12
Visits were rescheduled to four weeks after any respira¬
tory infections or exacerbations of the disease.
An exacerbation was defined as worsening of respi¬
ratory symptoms that required treatment with oral
Start ol run in phase
Eligible patients
(n=990)
Patients withdrawn before randomisation (n=239; 24%)
Failed entry criteria 49
Adverse event 109
C0PD exacerbations 56
Other respiratory conditions 32
Cardiac events 7
Malignant events 4
Other adverse events 10
Non-compliance 7
Failure to return 30
Other 44
Withdrawls (n=160; 43%)






Other respiratory conditions 4
Cardiac events 15
Malignant events 10
Other adverse events 17
Total adverse events 111
Non-compliance 6























Other respiratory conditions 6
Cardiac events 20
Malignant events 20
Other adverse events 14
Total adverse events 131
Non-compliance 9
Failure to return 18
Other 30
Fig 1 Profile of number of patients at each phase of study
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corticosteroids or antibiotics, or both, as judged by the
general practitioner; specific symptom criteria were
not used. Patients were withdrawn from the study if the
number of exacerbations that required corticosteroids
exceeded two in any three month period.
Health status was assessed at baseline and six
monthly thereafter by using the disease specific St
George's respiratory questionnaire (SGRQ)." This
questionnaire is sensitive to changes in treatment." A
change in total score offour or more units represents a
clinically important change in the patient's condition.5
Serum Cortisol concentrations were measured before
randomisation (baseline) and every six months during
treatment. Samples were taken between 8 am and 10
am and were analysed with the ELISA-Boehringer
Mannheim ES700 method.
At each visit patients were quesdoned about smok¬
ing status.Non-smoking was checked with exhaled car¬
bon monoxide and urinary cotinine measurements.
Selfdeclared non-smokers were classified as smokers if
cotinine was >40 ng/ml or carbon monoxide was
>10 ppm at two visits. For analysis padents were
categorised as condnuous smokers, continuous former
smokers, or intermittent smokers during the study.
Statistical analysis
Analyses for each parameter included all randomised
padents with at least one validmeasurement. To use all
patient data we adopted the mixed models approach'5
for the primary analysis of FEV, and total score. This
is the most suitable technique for estimating rates of
change, with allowance for the correlation structure of
repeated measures data. Regression estimates were
adjusted for patient differences in the number of
observations contributing to the model and for
variances within patients.16 Fixed effects were time and
five covariates: baseline value centre, age, sex, and
smoking status. Baseline FEV, was the mean at four
and eight weeks of the run-in period—that is, at least
four weeks after withdrawal of corticosteroids. Subject
effects were assumed to be random. The treatment by
time interaction tested for a differential treatment
effect on the rate of change in FEV, or respiratory
questionnaire score. The model for FEV, also
included a treatmentmain effect to help to account for
the early non-linear treatment changes. Measure¬
ments at the end of the prednisolone trial were
excluded from the model ofdecline in FEV,. FEV, was
also compared by using analysis of covariance after 3,
6, 12, 24, and 36 months to investigate treatment
differences over time.
Patient exacerbation rates were calculated as the
exacerbation number per treatment days and
extrapolated-interpolated to a number per treatment
year.TheWilcoxon rank sum test," stratified by centre-
,tested for treatment differences.
Fisher's exact test compared treatment withdrawals
due to respiratory causes. These included any
non-malignant lower respiratory diseases. Analysis of
covariance compared data on log transformed serum
Cortisol concentration during treatment, adjusted for




Of the 751 patients randomised, 376 received
fluticasone propionate and 375 placebo (figure 1). Dur¬
ing the double blind phase, 160 patients (43%)
withdrew from the fluticasone propionate group and
195 patients (53%) from the placebo group, the
commonest reason being frequent exacerbations of
chronic obstructive pulmonary disease. Mean FEV, at
visit two was 160 ml lower in patients who withdrew
from placebo compared with those who did not
withdraw (1.30 litre v 1.46 litre); patients who withdrew
from fluticasone propionate had a 40 ml higher FEV,
compared with those who did not withdraw (1.44 litre
v 1.40 litre). Treatment groups were well matched at
baseline (table 1).
Changes in FEV,
There was a fall in mean FEV, after bronchodilator
during the the run-in (placebo 75 ml, fluticasone
propionate 65 ml) (fig 2). The effect was greater in
patients who withdrew from inhaled corticosteroids at
run-in (89 ml compared with 47 ml in the steroid naive
group). After oral prednisolone there was a 60 ml (SD
170 ml) improvement in mean FEV, after broncho¬
dilator in both treatment groups. Subsequently mean
FEV, declined gradually in the fluticasone propionate
group whereas in the placebo group it fell within three
months to values before prednisolone treatment
The annual rate ofdecline in FEV, was 59 ml/year
in the placebo group and 50 ml/year in the fluticasone
propionate group (P = 0.16) (table 2). This small differ¬
ence in slopes was uninfluenced by smoking status, age,
sex, or FEV, response to the oral corticosteroid trial.
The predicted mean FEV, at three and 36 months in
Table 1 Baseline characteristics of randomised population. Figures are means (SD)
unless stated otherwise
Placebo Fluticasone propionate
No of patients randomised 375 376
Age (years) 63.8 (7.1) 63.7 (7.1)
Women 97 94
Body mass index (kg/m2) 24.9 (4.7) 24.5 (4.8)
Evidence of atopy* 91 103
Smoked throughout trial 147 137
Former smoker throughout trial 172 176
Smoking pack years at randomisationf 44 (34) 44 (30)
Previous use of regular inhaled corticosteroids 214 192
Lung function at visit 0+:
After salbutamol (400 pg) FEV, 1.40 (0.48) 1.42 (0.47)
As % predicted normal 50.0% (14.9%) 50.3% (14.9% )
Change in FEV, after salbutamol (400 pg) 0.13 (0.10) 0.13 (0.10)
As % predicted normal 4.4% (3.4%) 4.4% (3.5%)
After salbutamol (400 pg) FVC 3.29 (0.80) 3.37 (0.82)
After salbutamol (400 pg) FEV,:FVC 43.0% (11.0%) 43.0% (12.0%)
Baseline (average of visit 1 and 2)§:
FEV, before bronchodilator 1.23 (0.47) 1.25 (0.44)
FEV, after bronchodilator (salbutamo! 400 pg and
ipratropium bromide 80 pg)
1.40 (0.49) 1.42 (0.47)
Respiratory questionnaire total scored 49.9 (17.4) 47.7 (17.6)
FEV,=forced expiratory volume in one second in litres; FVC=forced vital capacity.
"Atopy was defined as being positive response to skin prick testing with common inhalant allergens.
Missing data—placebo: 14; fluticasone propionate: 20.
tMissing data—placebo: 37; fluticasone propionate: 16.
TMissing data—placebo: 4; fluticasone propionate: 3.
§Missing data—placebo: 1; fluticasone propionate: 0.
IScore of zero indicates no health impairment and 100 represents worst possible score. Missing
data—placebo: 8; fluticasone propionate: 7.
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B: Oral corticosteroid trial
C: Double blind inhaled
treatment
linear (P< 0.0001). The respiratory questionnaire
score worsened at a faster rate (P= 0.004) with placebo
(3.2 units/year) than with fluticasone propionate (2.0
units/year).
Withdrawals
More patients in the placebo group than in the flutica¬
sone propionate group withdrew because of respira¬
tory disease that was not associated with malignancy
(25% v 19%, respectively; P = 0.034).
Fig 2 Mean FEV, (litres) after bronchodilator by time from start of
double blind treatment. Numbers reflect patients with valid readings
at each time point. Measurements within four weeks of exacerbation
are excluded. Direct comparisons of FEV, means at each time point
are not possible because fewer patients remained in the study as it
progressed
the fluticasone propionate group was 76 ml and 100
ml higher, respectively, than in the placebo group
(mixed effects model P< 0.001). The analysis of covari-
ance showed that FEV, in the fludcasone propionate
group was higher than in the placebo group by at least
70 ml at each time point (PsO.OOl). There was no sig¬
nificant relation between FEV, response to oral
corticosteroid or fluticasone propionate (P= 0.056).
Exacerbations
The median yearly exacerbation rate was lower in the
fluticasone propionate group (0.99 per year) compared
with the placebo group (1.32 per year), a reduction of
25% in those receiving fluticasone propionate
(P= 0.026).
Health status
At baseline the total respiratory questionnaire score
was not significantly different between treatment
groups (table 1), and it did not change significantly
over the first six months of treatment (placebo: up 1.2
(SD 11.9); fluticasone propionate: down 0.5 (SD11.8);
P = 0.09). Thereafter it increased (that is, health status
declined) over time (figs 3 and 4). This increase was
Safety
Reported events were similar between treatments
(table 3), except for a slightly higher incidence ofevents
related to inhaled glucocorticoid in the fluticasone
propionate group.
There was a significant (PsO.032) yet small decrease
in mean Cortisol concentrations with fluticasone
propionate compared with placebo (table 4). No more
than 5% of patients on fluticasone propionate had
values below die normal range during the study at any
time. No decreases were associated with any signs or




















12 18 24 30 36
Time from start of inhaled treatment (months)
Fig 3 Effect of treatment on decline in health indicated by increasing
total scores on respiratory questionnaire (means (95% confidence
intervals) calculated from analyses of covariance). Numbers at each
assessment indicate number of patients for whom measurements of
health status were available at that visit. Direct comparisons of
respiratory questionnaire scores at each time point are not possible
because fewer patients remained in the study as it progressed





Treatment difference between drug and
placebo (95% CI) P value
FEV, after bronchodilator:
No of patients 325* 339*
Mean change in FEV, ml/year (SE) -59 (4.4) -50 (4.1) 9 (6.0) (-3 to 20) 0.161
Predicted FEV, at 3 months 1.37 1.44 0.076 (0.056 to 0.097) <0.001
Predicted FEV, at 3 years 1.20 1.30 0.100 (0.064 to 0.135) <0.001
Health status:
No of patients 291* 309*
Mean change in questionnaire score (SE) (units/year) 3.17 (0.31) 2.00 (0.29) -1.17 (0.40) (-1.95 to -0.39) 0.004
Annual exacerbation rate:
No of patients 370 372
Mean (SD) rates 1.90 (2.63) 1.43 (1.93)
Median (range) rates 1.32 (0 to 30) 0.99 (0 to 26) -0.3 (-0.4 to 0.0)t 0.026
FEV,=forced expiratory volume in one second in litres.
•Numbers are smaller than randomised population for FEV, and health status because of patient withdrawals, missing assessments, or respiratory infections or
exacerbations (affects FEV, only).
tZero values are possible in 95% confidence intervals with non-parametric analyses that show P values s:0.05 because method of calculation ot confidence intervals
differs from non-parametric test.





Time from start of inhaled treatment (months)
Fig 4 Weighted regressions from random coefficients (mixed) model
(see text) to account for the effect of differences in the number of
observations between patients, with adjustment for baseline
covariates (baseline questionnaire score, age at entry, sex, centre,
and smoking during the study)
Table 3 Number of patients with each category of adverse
events during double blind period
Fluticasone
Placebo (n=370) propionate (n=372)
Serious adverse events:
Any event 148 141











Throat irritation 27 43
Candidiasis of mouth/throat 24 41




* Includes ecchymotic rash (1 placebo patient, 8 fluticasone propionate
patients).
Discussion
Inhaled corticosteroids have been used widely in the
United Kingdom for the empirical treatment of symp¬
tomatic chronic obstructive pulmonary disease, but
evidence to support this practice is limited. Unlike
early reports,1810 our study in moderate to severe
chronic obstructive pulmonary disease found no effect
of corticosteroids on the rate of decline in FEV,—a
finding consistent with two recent budesonide studies
in mild disease."10 Like Euroscop, a study in continued
smokers,10 we found a small improvement in FEV, after
bronchodilator at threemondis, which was maintained
throughout the study. The clinical significance of this
change in airway function is unclear. Our study also
showed no significant relation between corticosteroid
trial response and response to long term inhaled
corticosteroid.
The exacerbation rate for placebo was similar to
that seen in previous reports,™ but for fluticasone pro¬
pionate it was 25% lower. Precise definition ofan exac¬
erbation is difficult in ambulant patients with chronic
obstructive pulmonary disease, but, by using the
operational approach adopted in ISOLDE, reductions
in exacerbation severity were seen in another study of
patients with moderately severe disease treated for six
months with fluticasone propionate.21 During the ISO¬
LDE run-in we also observed that withdrawal of
inhaled corticosteroids was associated with an
increased likelihood ofan exacerbation.22 These obser¬
vations suggest that inhaled corticosteroids do modify
the risk of symptomatic deterioration in chronic
obstructive pulmonary disease.
Assessment of of health status is recognised as an
important additional measurement in patients with
chronic respiratory disease and is a better predictor of
admission to hospital and death within 12 months
than FEV,.23 The baseline respiratory questionnaire
score showed significant impairment, in keeping with
other populations with similar reductions in FEV,.1314
This study shows for the first time that, like FEV,,
health status declines at a measurable rate in patients
with moderate to severe chronic obstructive pulmo¬
nary disease. Fluticasone propionate significantly
reduced this rate of decline, delaying the average time
for a clinically important reduction in health status
from 15 to 24 months. As the respiratory questionnaire
has only a weak correlation with FEV,,5 it must be
reflecting other disease components other than airflow
limitation.
Limitations
Several factors, including disease severity, comorbidity,
and study duration, contributed to the high withdrawal
rate. Patients were also actively withdrawn from the
study and not subsequently followed up if they experi-
Table 4 Morning serum Cortisol concentration (nmol/l) for patients who provided valid data (8 am to 10 am samples only) during
double blind period
Placebo (n=370) Fluticasone propionate (n=372)
Geometric mean* No {%) of patients with Patients Geometric mean No (%) of patients with
Patients with serum Cortisol values below normal range with valid serum Cortisol * values below normal range
Time point valid samples (CVf) (150-700 nmol/l) samples (CVf) (150-700 nmol/l)
Baseline 265 344 (33) 5(2) 265 353 (31) 4(2)
6 months 260 345 (33) 3(1) 272 311 (42) 2(1)
12 months 209 352 (34) 3(1) 238 316 (45) 13(5)
24 months 136 345 (34) 1 (D 160 303 (44) 5(3)
36 months 93 354 (33) 1 (1) 96 310 (35) 4(4)
>1 point during double
blind treatment
299 — 4(1) 331 — 17(5)
* Least squares means from analysis of covariance of log transformed serum Cortisol concentrations were back transformed to give geometric means.
tCV=coefficient of variation (%).
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What is already known on this topic
Inhaled corticosteroids are widely prescribed for
patients with chronic obstructive pulmonary
disease, although there are few studies to support
this
A meta-analysis of three small studies showed
improvements in FEV, with high dose
beclomethasone dipropionate or budesonide but
no benefit from medium dose treatment
In two recent large studies, budesonide in medium
dose produced either no benefit or a small initial
improvement in FEV,
What this study adds
This study measured progressive decline in health
status ofpatients \vitli chronic obstructive
pulmonary disease rather thanjust die FEV,
In patients with moderate to severe disease,
fluticasone propionate 1 mg daily resulted in fewer
exacerbations, a reduced rate of decline in health
status, and higher FEV, values than placebo
treatment
Serious side effects were similar to placebo, topical
side effects were increased
These data provide a rationale for the use of high
dose inhaled corticosteroids in patients with
moderate to severe chronic obstructive pulmonary
disease
enced frequent exacerbations; this is an acknowledged
limitation of the study. The effect of the differential rate
of withdrawal from treatment is difficult to quantify,
nevertheless it is likely to have led to a conservative
estimate ofbenefit with fluticasone propionate.
Reports of adverse events for each treatment were
generally similar, although the incidence of events
related to glucocorticoids was slightly higher in the flu¬
ticasone propionate group. The incidence of fractures
was low (2%) and similar to that reported in
Euroscop.10 No more than 5% of patients on
fluticasone propionate had Cortisol concentrations
below the normal range at any time during treatment
Similar reassuring data have been reported from a two
year placebo controlled study of fluticasone propion¬
ate 500 pg twice daily in adults with mild asthma.21
Conclusions
We found no benefit of fluticasone propionate on the
rate of decline in FEV„ although small improvements
in FEVj were seen. Unlike the two studies in patients
with milder disease, where other clinical outcomes
were less measurable,910 we found that fluticasone pro¬
pionate 500 pg twice daily significantly reduced
exacerbations and the rate of decline in health status.
These data provide a rationale for the current practice
of using use of inhaled corticosteroids at this dose in
patients with moderate to severe chronic obstructive
pulmonary disease.
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Comparing health inequality in men and women:
prospective study of mortality 1986-96
Amanda Sacker, David Firth, Ray Fitzpatrick, Kevin Lynch, Mel Bartley
Abstract
Objectives To study prospectively the differences in
health inequality in men and women from 1986-96
using the Office for National Statistics' longitudinal
study and new socioeconomic classification. To assess
the relative importance of social class (based on
employment characteristics) and social position
according to the general social advantage of the
household to mortality risk in men and women.
Design Prospective study.
Setting England and Wales.
Subjects Men and women ofworking age at the time
of the 1981 census, with a recorded occupation.
Main outcome measures Mortality.
Results In men, social class based on employment
relations,measured according to the Office for National
Statistics' socioeconomic classification, was the most
important influence on mortality. In women, social class
based on individual employment relations and
conditions showed only a weak gradient Large
differences in risk ofmortality in women were found,
however, when social position was measured according
to the general social advantage in the household.
Conclusions Comparisons of the extent of health
inequality in men and women are affected by the
measures of social inequality used. For women, even
those in paid work, classifications based on
characteristics of the employment situation may give a
considerable underestimate. The Office for National
Statistics' new measure of socioeconomic position is
useful for assessing health inequality in men, but in
women a more important predictor ofmortality is
inequality in general social advantage of the household.
Introduction
Social variation in morbidity and mortality in women
whose social position is measured according to then-
own occupation is often found to be less than that of
men.1-4 The extent of social inequality in women's
health is known to be particularly sensitive to tire way
in which inequality is defined and measured.1 5 6 When
women's social position is classified according to the
occupation of their male partners, male and female
health gradients are more similar.7 8 In estimates of
health inequality there is comparatively little discussion
of these apparent sex differences.
It is now possible to study sex differences in health
inequality with distinct validated measures of social
position and advantage, one based on relations and
conditions of employment and the other on material
cultural aspects of lifestyle outside the workplace. The
Office for National Statistics (ONS) has recently
adopted a new measure of social inequality: the ONS
socioeconomic classification, for use in the 2001 census
and official surveys." This measure allocates occupa¬
tions to social classes on the basis ofaspects of thework
situation, in particular the extent to which members of
an occupation have control over their own work and
that ofothers.
The othermeasure is the Cambridge scale,which is
based on general social and material advantage and
lifestyle as reflected in choices of friendship.10"12 Both
measures are being increasingly used in health studies
and have been found to be related to mortality,
morbidity, and health related behaviour.13"18
We aimed to determine whether social gradients in
mortality in women in England and Wales during
1986-96 were less noticeable than in men, andwhether




The ONS longitudinal study is an approximate 1%
sample of the population ofEngland and Wales. Sam¬
pling was begun at the time of the 1971 census when
all those born on any one of four days in the year were
entered into the dataset. The study is regularly updated
to include new members born on any one of the four
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@ Combined salmeterol and fluticasone in the treatment of
chronic obstructive pulmonary disease: a randomised controlled
trial
Peter Calverley, Romain Pauwels, Jorgen Vestbo, Paul Jones, Neil Pride, Amund Gulsvik, Julie Anderson,
Claire Maden for the TRISTAN (TRial of Inhaled STeroids ANd long-acting fi2 agonists) study group*
Summary
Background Inhaled longacting p2 agonists improve lung
function and health status in symptomatic chronic obstructive
pulmonary disease (COPD), whereas inhaled corticosteroids
reduce the frequency of acute episodes of symptom
exacerbation and delay deterioration in health status. We
postulated that a combination of these treatments would be
better than each component used alone.
Methods 1465 patients with COPD were recruited from
outpatient departments in 25 countries. They were treated in a
randomised, double-blind, parallel-group, placebo-controlled
study with either 50 pg salmeterol twice daily (n=372), 500 gg
fluticasone twice daily (n=374), 50 gg salmeterol and 500 gg
fluticasone twice daily (n=358), or placebo (n=361) for
12 months. The primary outcome was the pretreatment forced
expiratory volume in 1 s (FEV,) after 12 months treatment' and
after patients had abstained from all bronchodilators for
at least 6 h and from study medication for at least 12 h.
Secondary outcomes were other lung function measurements,
symptoms and rescue treatment use, the number of
exacerbations, patient withdrawals, and disease-specific
health status. We assessed adverse events, serum Cortisol
concentrations, skin bruising, and electrocardiograms.
Analysis was as predefined in the study protocol.
Findings All active treatments improved lung function,
symptoms, and health status and reduced use of rescue
medication and frequency of exacerbations. Combination
therapy improved pretreatment FEV, significantly more than did
placebo (treatment difference 133 mL, 95% CI 105-161,
p<0-0001), salmeterol (73 mL, 46-101, p<0-0001), or
fluticasone alone (95 mL, 67-122, p<0-0001). Combination
treatment produced a clinically significant improvement in
health status and the greatest reduction in daily symptoms. All
treatments were well tolerated with no difference in the
frequency of adverse events, bruising, or clinically significant
falls in serum Cortisol concentration.
Interpretation Because inhaled long-acting |32 agonists and
corticosteroid combination treatment produces better
control of symptoms and lung function, with no greater risk
of side-effects than that with use of either component alone,
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this combination treatment should be considered for patients
with COPD.
Lancet 2003; 361: 449-56. Published online Jan 28, 2003
http://image.thelancet.com/extras/02art5284web.pdf
See Commentary page 444
Introduction
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity worldwide. It is characterised by
chronic progressive symptoms, airflow obstruction,1,2 and
impaired health status,3 which is worse in those who have
frequent, acute episodes of symptom exacerbation/ The
aim of treatment is to prevent and control symptoms and
exacerbations while improving lung function and health
status.5,6 Any new treatment approach should be judged
against these endpoints.
Inhaled long-acting P2 agonists improve airflow
obstruction, control of symptoms, and health status in
patients with COPD over 3-4 months7"14 and have several
potentially beneficial non-bronchodilatory effects.15 The
role of inhaled corticosteroids in COPD management is less
certain.16 These drugs do not change the rate of decline in
lung function,17-20 but can increase postbronchodilator
forced expiratory volume in 1 s (FEV,),11,1' reduce the
number of exacerbations,17,18 and slow the rate of decline in
health status.17 Whether long-acting P2 agonists and inhaled
corticosteroids in combination will result in treatment
effects that are better than those associated with either drug
alone is not clear. Furthermore, we do not know whether
improvements seen in the short term will be maintained
during sustained treatment. To test our hypothesis, we did
a randomised controlled trial over 1 year of combination




We recruited outpatients with COPD from 196 hospitals
in 25 countries. All patients had a baseline FEV, before
bronchodilation that was 25-70% of that predicted, an
increase of less than 10% of predicted FEV, 30 min after
inhaling 400 pg salbutamol, and a prebronchodilator
FEV,/forced vital capacity (FVC) ratio of 70% or less.21
Patients also had a history of at least 10 pack-years of
smoking (ie, equivalent to 20 cigarettes smoked per day
for 10 years), of chronic bronchitis, at least one episode
of acute COPD symptom exacerbation per year in the
previous 3 years, and at least one exacerbation in
the year immediately before trial entry that required
treatment with oral corticosteroids, antibiotics,
or both.
We excluded patients who had respiratory disorders
other than COPD, required regular oxygen treatment, or
had received systemic corticosteroids, high doses of
inhaled corticosteroids (>1000 (ig daily beclometasone
dipropionate, budesonide, or flunisolide or >500 pg daily
fluticasone), or antibiotics in the 4 weeks before the
2 week run-in period before the trial began.
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Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
Withdrawal after randomisation 140 (39 %) 119 (32 %) 108 (29 %)* 89 (25 %)tt
Age 63-4 (8.6) 63.2 (8.6) 63.5 (8.5) 62.7 (8.7)
Male 269 (75 %) 261 (70 %) 260 (70 %) 270 (75 %)
Current smoker 171 (47 %) 191 (51 %) 198 (53 %) 186 (52 %)
Pack-years smoked 43-4 (22-4) 43-7 (21-9) 41-5 (20-7) 42-0 (22-4)
Previous ICS use 188 (52 %) 183 (49 %) 202 (54 %) 178 (50 %)
Previous LABA use 136 (38 %) 156 (42 %) 148 (40 %) 151 (42 %)
Pretreatment FEVt (% predicted) 44-2 (13-7) 44-3 (13-8) 45-0 (13-6) 44-8 (14-7)
Reversibility (% predicted FEVJ 4-0 (4-5) 3-7 (4-3) 3-7 (3-9) 4-0 (4-7)
Pretreatment FEVt (ml.) 1266 (467) 1245 (452) 1260 (449) 1308 (532)
Postbronchodilator FEVX (mL) 1379 (476) 1346 (463) 1363 (460) 1419 (549)
Pretreatment FVC (mL) 2500 (800) 2386 (751) 2443 (781) 2537 (838)
PEF L/min 243 (89) 235 (90) 246 (90 ) 247 (93)
SGRQ score 47-1 (16-5) 48-7 (17-1) 49-8 (15-8) 47-1 (15-7)
Median use of relief medication per day (range) 2-7 (0-17) 2-9 (0-14) 2-8 (0-15) 2-7 (O-ll)
Mean number awakenings per week 3-5 (5-3) 3-5 (6-1) 3-5 (4-9) 2-8 (4-9)
ICS=inhaled corticosteroids. LABA=longacting ft2 agonist FEV,=forced expiratory volume in 1 s. FVC=forced vital capacity. PEF=peak
SGRQ=St George's Respiratory Questionnaire. Data are number (%) or mean (SD) unless otherwise indicated. *p=0-007 vs placebo,
vs salmeterol.
Table 1: Patients' demographic data and baseline characteristics
expiratory flow.
fp=0-0001 vs placebo. ip~0-033
We obtained approval from local ethics committees at
each participating site, and all patients provided written
informed consent.
Study design
We used a randomised, double-blind, placebo-controlled,
parallel-group design. Recruited patients participated in a
2-week run-in to the trial, a 52-week treatment period
with clinic visits at weeks 0, 2, 4, 8, 16, 24, 32, 40, and
52, and a 2-week post-treatment follow-up.
We used a randomisation schedule generated by the
patient allocation for clinical trials (PACT) program to
assign patients to study treatment groups. Every
participating centre was supplied with a list of patient
numbers (assigned to patients at their first visit) and a list
of treatment numbers. Patients who satisfied the
eligibility criteria were assigned the next sequential
treatment number from the list. Salmeterol and
fluticasone combination (50/500 pg twice daily),
salmeterol (50 pg twice daily), fluticasone (500 pg twice
daily) and placebo were packaged in identical inhaler
devices. Study drugs were labelled in a way to ensure that
both the patient and the investigator were unaware of the
allocated treatment.
During the 2-week run-in, patients stopped taking
regular inhaled corticosteroids or long-acting (32 agonists.
Inhaled salbutamol was used as relief medication
throughout the study, and regular treatment with
anticholinergics, mucolytics, and theophylline was
allowed. All non-COPD medications could be continued
if the dose remained constant whenever possible, and if
their use would not be expected to affect lung function. If
patients had clinically stable symptoms after 2 weeks, they
were randomised to receive one of the following
treatments: 50 pg salmeterol and 500 pg fluticasone in
combination; 50 pg salmeterol; 500 pg fluticasone; or
placebo, all twice daily, for 52 weeks via a multidose dry-
powder inhaler (Diskus or Accuhaler [GlaxoSmithKline,
Greenford, UK]).
The primary efficacy measure was FEV, after patients
had abstained from all bronchodilators for at least
6 h, and from study medication for at least 12 h. Lung-
1974 patients recruited
> 509 patients withdrew
Figure 1: Trial profile
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function tests were done in the clinic: pretreatment FVC3
and postbronchodilator FEVt and FVC were measured at
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Figure 2: Effect of treatment on lung function measurements and
health status
Raw mean changes from baseline are shown. A, prebronchodilator FEV,.
B, postbronchodilator FEV,. C, daily peak expiratory flow. D, health status—
the fall in St George's score represents an improvement in health status.
30 min after inhalation of 400 |lg of salbutamol. All
spirometry measurements were done at the same time of
day for all patients, with the same spirometer. Every
morning, patients used daily record cards to record the
highest of three peak expiratory flow values measured
with a mini-Wright peak flow meter (Clement Clarke
International Harlow, UK) before medication.
Every morning, patients recorded the number of times
they used relief medication, their symptom scores, and
the number of night-time awakenings for the previous
24 h. Symptoms were scored as: breathlessness, 0 (none)
to 4 (breathless at rest); cough, 0 (none) to 3 (severe);
sputum production, 0 (none) to 3 (severe); sputum
colour, 0 (no sputum produced) to 4 (dark yellow or
green).
The occurrence of acute exacerbations of COPD
symptoms was investigated at every clinic visit.
Exacerbations were defined a priori as a worsening of
COPD symptoms that required treatment with
antibiotics, oral corticosteroids, or both. Episodes that
required corticosteroid treatment or hospital admission
were noted separately. Health status was assessed with the
St George's Respiratory Questionnaire at weeks 0, 2, 4, 8,
24, and 52. In the 22 non-English speaking countries we
used a validated translation of this questionnaire.
Adverse event information was obtained at every
clinic visit by recording spontaneously reported
complaints from patients and asking general questions
about medical troubles and concomitant medication.
Morning (0800-1000 h) Cortisol concentrations in serum
were measured after fasting at weeks 0, 24, and 52. At
every visit we noted the number of bruises on the volar
side of the forearms that had a diameter greater than
5 cm. All patients had 12-lead electrocardiography at
weeks 0, 24, and 52, and investigators categorised the
results as normal, abnormal but not clinically significant,
or abnormal and clinically significant.
Statistical analysis
We estimated that a sample size of 300 patients per
treatment group would be needed to obtain data for
250 patients so as to detect a 0-10 L difference in FEV, at
the 5% significance level with 90% power, assuming an
SD of 0-35 L for FEV,. We analysed pretreatment FEV,
using repeated measures analysis.22 Time was included as
a categorical parameter and an unstructured variance-
covariance matrix was fitted with SAS proc mixed
software version 6.12. We also used these methods to
analyse other lung function variables and questionnaire
scores. We analysed log-transformed serum Cortisol
concentrations, morning peak expiratory flow, and mean
symptom score during weeks 1-52 using analysis of
covariance. The number of exacerbations was analysed by
a maximum likelihood Poisson regression, with the
amount of time a patient had had treatment as an offset
variable. Covariates used for analyses, where applicable,
were age, sex, country, baseline value (such as FEV, and
FVC at randomisation), and smoking status. Interactions
of treatment with all covariates were tested for
pretreatment FEV,, exacerbations, and health status
questionnaire scores. For use of rescue medication, the
median data for weeks 1-52 were analysed using the van
Elteren extension to the Wilcoxon rank sum test,23
stratified by smoking status, and the confidence limits
calculated with the Hodges-Lehman method.21 The
number of withdrawals was analysed with the Cochran-
Mantel-Haenszel test, stratified by smoking status, and
time to withdrawal was analysed with Cox's proportional
hazards model.


















































































Data are mean (SE). *p<0-0001 vs placebo; fp=0-0063 vs placebo; ivs combination treatment §p=0-002 vs placebo; 1 p=0-0004 vs placebo; || p=0-013 vs placebo.
Table 2: Effect of 52 weeks' treatment on lung function
Role of the funding source
The study sponsor, GlaxoSmithKline, was involved
together with the principal investigators in the
study design; the collection and analysis of data, which
was made freely available to all the principal
investigators; and the decision to submit the paper for
publication.
Results
We recruited 1974 patients from 196 centres in 25
countries, of whom 1465 received treatment (figure 1).
Demographic data, baseline characteristics, and
compliance did not differ between groups, but the
withdrawal rate did. Significantly fewer patients
withdrew from the combination and fluticasone
groups than from placebo and salmeterol groups
(table 1). The main reason for differences in withdrawal
was presence of adverse events. Patients
in the combination group had a slightly higher mean
prebronchodilator and postbronchodilator FEV, and
fewer mean awakenings per week than did those in
other groups. These minor imbalances in baseline
data were accounted for in the statistical analyses
since both baseline FEV, and mean night awakenings
per week were used as covariates in analyses where
appropriate.
The three active treatments increased pretreatment
FEV, significantly compared with placebo (salmeterol/
fluticasone p<0-0001; salmeterol p<0-0001; fluticasone
p=0-0063; figure 2). This improvement was evident by
week 2 and was sustained throughout treatment. The
rise in FEV, associated with combination therapy was
significantly greater than with either of its components
separately (table 2, figure 2). By week 52, pretreatment
FEV, in the combination group had increased by 10%
compared with 2% in both the salmeterol and
fluticasone groups, and had fallen by 3% in the placebo
group. We noted the same trend for the other lung-
function variables (figure 2). The treatment-by-
smoking-status interaction for prebronchodilator FEV,
was not significant (p=0-134), indicating that the
difference between the treatment groups was unaffected
by whether the participant continued to smoke, or not.
Furthermore, the effects of treatment were not biased
by unbalanced changes in smoking status between the
treatment groups. During the 12-month study period, a
total of 103 patients (6-7% in each treatment group)
changed their smoking habit, with most of these giving
up smoking.
Compared with placebo, all active treatments
significantly reduced the number of exacerbations per
patient per year and the number of exacerbations that
needed treatment with oral corticosteroids (table 3).
The rate of exacerbations fell by 25% in the
combination group (p<0-0001) and by 20% (p=0-0027)
and 19% (p^O-0033) in the salmeterol and fluticasone
groups, respectively, compared with placebo. The
treatment effect was more pronounced in patients
with severe disease (ie, a baseline FEV, <50% of
predicted), who showed a 30% reduction with the
Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
Total exacerbation rate
Mean rate per patient per year (SD) 1-30 1-04* 1-05* 0-97
Treatment ratiof (95% CI) 0-746 0-930 0-925
(0-643-0-865) (0-801-1-080) (0-797-1-073)
pf <0-0001 0-345 0-304
Rate of exacerbations requiring oral corticosteroids
Mean rate/patient/year 0-76 0-54$ 0-50§ 0-46
Treatment ratiof 0-607 0-853 0-925
(0-500-0-736) (0-699-1-039) (0-755-1-133)
pf <0-0001 0-115 0-453
*p=0-003 vs placebo. j;vs combination treatment. tp=0-0003 vs placebo. §p=0-0001 vs placebo.
Table 3: Effect of 52 weeks' treatment on exacerbation rate
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Salmeterol fluticasone combination
Time since randomisation (days)
Figure 3: Cumulative risk of acute exacerbations
combination compared with placebo, as against a
10% reduction in patients who had a baseline FEV, that
was greater than 50% of that predicted. Acute episodes
of symptom exacerbation that required oral cortico¬
steroids were reduced by 39% in the combination group
(p<0-0001), 29% in the salmeterol group (p=0-0003),
and 34% in the fluticasone group (p=0-0001),
compared with placebo. There were no significant
differences between active treatments with respect to
their effect on the rate of episodes of symptom
exacerbation (table 3), time to first exacerbation, or
number of hospital admissions. Figure 3 shows the
cumulative risk of acute exacerbations.
Combination treatment significantly reduced
breathlessness and the use of relief medication
compared with placebo, salmeterol, and fluticasone
(table 4). Median number of days without relief
medication was for placebo 0% (range 0-100%),
salmeterol 3% (0-100%), fluticasone 2% (0-100%),
and combination 14% (0-100%) (p<0-0001 vs
placebo, p=0-004 vs salmeterol, p=0-0003 vs
fluticasone). The number of night-time awakenings
fell significantly in the combination group, compared
with placebo and salmeterol, but not with fluticasone
(table 4). Cough only improved significantly in the
combination group (table 4).
Only the combination group showed a clinically
significant improvement in health status questionnaire
score by week 52. The raw mean changes in health
status total score were -4-3 (SD 10-8) by week 8 and
-4-5 (12-9) at week 52 (figure 2). The change in SGRQ
score in the combination group over 52 weeks at the
end of the study was significantly greater than
that in both the placebo and fluticasone groups
(table 4).
All treatments were well tolerated, and there were
no differences between groups in the number of
patients reporting an adverse event during treatment
(78-81% across all groups), apart from an increased
frequency of oropharyngeal candidosis (placebo
2%, salmeterol 2%, fluticasone 7%, combination
8%). Table 5 shows adverse events that were judged
to be treatment-related. Most patients (S=96%)
had serum Cortisol values that were within the reference
range, or that did not change significantly from
baseline after 24 or 52 weeks of treatment. 13 (4%)
and 11 (4%) patients in the placebo and salmeterol/
fluticasone groups, respectively, had a change from
within to below the reference range, compared with
17 (5%) and 19 (6%) in the salmeterol and fluticasone
groups, respectively. None of these changes was
clinically important. After 52 weeks' treatment,
mean serum Cortisol concentrations rose by 4% in
placebo and 6% in the salmeterol group, whereas
they fell by 1% with fluticasone and by 3% with
the combination treatments. The differences between
fluticasone and placebo were significant at weeks
24 (p=0-035) and 52 (p=0-007), and between combi¬
nation and placebo at week 24 (p=0-020). None of the
changes were associated with any clinical effects or signs
of hypoadrenalism.
We noted skin bruises in a maximum of 22 (6%)
of patients in the placebo group, 20 (6%) in salmeterol,
26 (7%) in fluticasone, and 29 (8%) in the combination
group at any visit. We did not detect any changes
on echocardiograms that could be attributed to
treatment.
Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
SGRQ total score
Adjusted mean 46-3 (0-5) 45-2 (0-4) 45-5 (0-4) 44-1 (0-5)
Treatment difference* (95% CI) -2-2 (-3-3 to -1-0) -1-1 (-2-2 to 0-1) -1-4 (-2-5 to -0-2)
P* 0-0003 0-071 0-021
Symptom scores
Cough 1-44 (0-03) 1-36 (0-03) 1-38 (0-03) 1-35 (0-03)
p* 0-018 0-639 0-340
Breathlessness 1-66 (0-03) 1-59 (0-03) 1-58 (0-03) 1-47 (0-03)
p* 0-0001 0-006 0-010
Sputum production 1-34 (0-03) 1-30 (0-03) 1-33 (0-03) 1-29 (0-03)
p* 0-196 0-687 0-339
Sputum colour 1-36 (0-03) 1-35 (0-03) 1-37 (0-03) 1-32 (0-03)
p* 0-373 0-494 0-250
Median (range) use of relief medications 2 (0-32) 2 (0-14)f 2 (0-11)$ 1 (0-10)
(per day)
p* <0-0001 0-0001 0-0003
Mean number awakenings per week 3-01 (0-21) 2-94 (0-21) 2-45 (0-21)§ 2-31 (0-21)
p* 0-006 0-011 0-591
SGRQ=St George's Respiratory Questionnaire. Data are mean (SE), unless otherwise indicated. A negative value represents an improvement in health status.
*vs combination; fP=0-028 vs placebo; $p=0-010 vs placebo; §p=0-024 vs placebo.
Table 4: Effect of 52 weeks' treatment on health status and symptoms
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Placebo Salmeterol Fluticasone Combination
(n=361) (n=372) (n=374) (n=358)
Any treatment-related event 49 (14%)
Oropharyngeal candidosis 5 (1%)
Candidosis in unspecified site 0
Oral inflammation or nausea and vomiting 8 (2%)
COPD exacerbation 19 (5%)
Cough, breathing disorder,
or lower respiratory infection 6 (2%)
Throat infection or hoarseness 8 (2%)
Headaches, tremor, or vertigo 4 (1%)
Table 5: Treatment-related adverse events
Discussion
Ideally, any new treatment for COPD should improve
one or more of the endpoints outlined in the GOLD
(Global Initiative for Chronic Obstructive Lung
Disease) management protocol2®—symptoms, health
status, and frequency of exacerbation. These effects
should be sustained and better than those of existing
treatments. Many treatment trials in COPD have only
lasted 3-6 months,18,26 or if longer, they have compared
only one active treatment with placebo. Our trial has
compared commonly prescribed agents from different
therapeutic classes for a sufficient time to see changes in
a range of clinically relevant outcomes. Our results
confirm that active treatment is better than placebo. A
combination of different types of treatment produces
benefits across a range of endpoints that translate into a
clinically noticeable benefit for patients, as indicated by
the health status data.
Consistent changes were seen in the pretreatment
FEV,, suggesting a drug effect before the first dose taken
in the day. Both salmeterol and fluticasone produced
small but significant improvements in FEV, in keeping
with previous findings,7'17"18 but combination treatment
was significantly more efficacious than either placebo or
the individual components. Postbronchodilator FEV,
improved after fluticasone, as also noted by
investigators in the ISOLDE study." Patients in the
combination group had the lowest bronchodilator
responsiveness (ie, the change between pretreatment
and post-treatment FEV,), suggesting that part of the
pretreatment effect in patients in the combination group
was caused by the bronchodilatory effects of salmeterol
taken 12 h previously. However, despite this effect,
patients in the combination group had a significantly
higher postbronchodilator FEV, than with either agent
alone. Data for FVC showed much the same trend as
that seen for FEV,, but are more relevant to improved
exercise performance in COPD. Finally, the multiple
daily readings of peak expiratory flow showed a
sustained improvement throughout the year, which was
significantly greater in the combination group, and
evident within 1 week of randomisation. These early
changes in lung function could provide a useful guide to
subsequent patient benefit, but this indicator has not
yet been formally tested.
Improved lung function was associated with
reductions in the number and type of symptoms
recorded in the daily diary cards. Although scores for
cough and sputum did not change greatly,
breathlessness was reduced by both salmeterol and
fluticasone but significantly more so with combination
treatment. Much the same pattern was seen with rescue
treatment, and in the amount of sleep disruption. These
data represent daily recordings for 1 year in every
patient, and confirm the sustained nature of the clinical
benefits. Health status measurement provides an
integrated assessment of the effect of COPD on
46 (12%) 70 (19%) 58 (16%)
5 (1%) 23 (6%) 22 (6%)
2 (<1%) 8 (2%) 1 (<1%)
3 (<1%) 3 (<1%) 4 (1%)
8 (2%) 10 (3%) 9 (3%)
7 (2%) 6 (2%) 3 (<1%)
8 (2%) 16 (4%) 15 (4%)
10 (3%) 2 (<1%) 4 (1%)
patients' health, and has been widely validated.27'28 A 4-
unit reduction in total St George's respiratory
questionnaire score is associated with both subjective
and objective improvement, such as the ability to walk
further and less perceived breathlessness before and
after exercise.12'29,30 This improvement was achieved by
patients in the combination treatment group after
12 months, but not by those who received single-drug
treatment or placebo. The speed of change in health
status was less striking than with lung-function tests but
was still evident by 8 weeks, in keeping with other data
about long-acting (32 agonists.9 The lower than expected
frequency of acute episodes of symptom exacerbation in
patients who received placebo might explain some of
the health status improvement.
All active treatments were associated with a lower rate
of exacerbations than was placebo. Despite differences
in definition, we noted a self-reported exacerbation rate
that was similar to that in other trials—ie, 1-3 per year
with placebo.4,17 Combined treatment reduced the total
exacerbation rate by 25% and exacerbations that
required oral corticosteroids by 39%, which were all
significant changes compared with placebo. Although
these reductions were not statistically significant when
compared with monotherapy, there was a trend in
favour of the combination group which became more
pronounced with increasing COPD severity. Despite
our selection criteria, we saw substantially fewer
exacerbations than expected (46% of patients did not
have such an incident), which significantly reduced the
power of the study to show a difference. The low rate of
acute episodes might be attributable to regression to the
mean in exacerbation number or an effect of improved
care associated with clinical trials, but suggests that a
study of longer duration and with a larger number of
participants would be needed to show a difference. All
active therapies were well tolerated, and there was no
evidence of important cardiac side-effects with
salmeterol, or any unanticipated problems with
fluticasone. There were minor changes in Cortisol
secretion with fluticasone monotherapy and with
combination treatment, which did not differ from those
previously reported.17'18
The reasons why combination treatment proved to
be most effective remain speculative. Results from
research in asthma suggest that long-acting P2
adrenoceptor agonists can enhance the anti¬
inflammatory effect of corticosteroids.31 Although the
absolute changes in lung function induced by
combination treatment in our study were modest, they
did happen rapidly, and were noticeable after 2 weeks.
Such improvements could be sufficient to allow
improvement in exercise tolerance and reduce the
perceived severity of an exacerbation, and hence the
number of episodes reported. Both factors are
important determinants of health status.17'32 The
additional effect of an inhaled corticosteroid on
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postbronchodilator FEV, has been noted before."
(3 receptor numbers can be upregulated with
corticosteroids, and the combination is more effective in
reducing induced interleukin 8 release from airway
smooth muscle." Whether this mechanism is important
in COPD remains to be established
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Error is a grim idea, with connotations of bias,
misjudgment, and increasingly, of liability. Yet the
inadvertent and the fortuitous have given medicine a
number of its great successes. Many of the errors noted in
this Lancet series have centred on lessons practitioners
have learnt from clinical misjudgments. Fewer have come
from public health or population-based endeavours. As
with clinical medicine, these chance occurrences are both
prevalent and underacknowledged.
When ivermectin was first being tested for effectiveness
in onchocerciasis we set out to measure its adverse
reactions when given as mass treatment. The three-year
study was conducted in an endemic area of Malawi using
a double blind, placebo-controlled design. For these
multi-site trials, the World Health Organization had set
explicit criteria for exclusion of subjects from the study.
Because of the potential for ivermectin to cross the blood-
brain barrier in mice, it was thought that persons with a
history of epileptic fits should not receive treatment. This
was an important consideration for us since epilepsy was
quite common in this part of Malawi, and our hospital
ran a heavily patronised outreach service for its
treatment.
Instructions for potential ivermectin recipients were
translated into the vernacular, back translated, and then
pilot tested in a nearby non-study site for comprehension.
Changes were made as necessary to instructions. The
importance of epilepsy as a reason for not participating
was specifically noted in the verbal instructions to
potential participants.
After the first round of treatment it became evident
that almost no one had been excluded from treatment
because of a history of epilepsy. Pursuing this it was
discovered that the specific word used for epilepsy was
not recognised in the study villages even though the
language was the same as in the pilot area where the
instructions had been pre-tested. In a hurried follow-up
we identified some 80 persons with epilepsy who had
been unintentionally treated with ivermectin. Further
investigations in this cohort with a history of epilepsy
revealed that no fits had followed treatment. The cohort
was then followed through the two subsequent annual
treatment rounds during which there was no association
between receiving treatment and having fits. On the basis
of these Malawi findings, a history of epilepsy was
dropped as a reason for excluding treatment in the
subsequent ivermectin mass-treatment programmes for
onchocerciasis. The outcome from this error ofwords has
been that tens of thousands of epileptics living in 37
countries where onchocerciasis is endemic have been
treated regularly as a prevention against this physically
disabling and potentially blinding disease. This is another
reminder that a study may yield important findings aside
from the answering of the original research questions.
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA (G Burnham md)
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ABSTRACT: Lung function in chronic obstructive pulmonary disease (COPD) can be
improved acutely by oral corticosteroids and bronchodilators. Whether clinical
improvement can be maintained by subsequent inhaled therapy is unknown.
COPD patients (n=l,022, mean prebronchodilator forced expiratory volume in one
second (FEVl) 36% predicted) initially received formoterol (9 fig b.i.d.) and oral
prednisolone (30 mg o.d.) for 2 weeks. After this time, patients were randomised to
b.i.d. inhaled budesonide/formoterol 320/9 fig, budesonide 400 fig, formoterol 9 pg or
placebo for 12 months.
Postmedication FEVl improved by 0.21 L and health-related quality of life using the
St George's Respiratory Questionnaire (SGRQ) by 4.5 units after run-in. Fewer
patients receiving budesonide/formoterol withdrew from the study than those receiving
budesonide, formoterol or placebo. Budesonide/formoterol patients had a prolonged
time to first exacerbation (254 versus 96 days) and maintained higher FEVl (99%
versus 87% of baseline), both primary variables versus placebo. They had fewer
exacerbations (1.38 versus 1.80 exacerbations per patient per year), had higher
prebronchodilator peak expiratory flow, and showed clinically relevant improvements in
SGRQ versus placebo (-7.5 units). Budesonide/formoterol was more effective than
either monocomponcnt in both primary variables.
Budesonide/formoterol in a single inhaler (Symbicort®) maintains the benefit of
treatment optimisation, stabilising lung function and delaying exacerbations more
effectively than cither component drug alone or placebo.
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Several randomised, controlled trials have shown that long-
acting, inhaled p2-agonists improve lung function in chronic
obstructive pulmonary disease (COPD) irrespective of disease
severity [1], and improve health-related quality of life
(HRQL) [2, 3], These improvements equal or exceed those
seen with ipratropium [3] or theophylline [4]. Only two studies
have followed the effects of treatment with long-acting,
inhaled p2-agonists over 1 yr [5, 6]. The results confirmed the
effect on spirometry, but the change in HRQL was smaller
than expected.
The role of inhaled corticosteroids (ICS) in COPD is more
controversial. Corticosteroids do not appear to affect the rate
of decline of forced expiratory volume in one second (FEVl)
[7-10]. However, ICS increased postbronchodilator FEVl in
two studies [8, 9], and reduced the severity [11] and frequency
of exacerbations when this end-point could be reliably
assessed [9]. These observations have led to ICS being
recommended for COPD patients with FEV1 <50% predicted
who show a spirometric response [12]. In two 1-yr studies, the
clinical effect of ICS on exacerbations requiring oral steroids
was confirmed [5, 6]; the reduction in exacerbation frequency
was less evident for patients taking ICS alone in the study by
Szafranski et al. [5]. These results may suggest that sicker
patients require more than just ICS in their treatment for
COPD.
For editorial comments see page 874.
Combining a long-acting p2-agonist and an ICS as
maintenance therapy has been very successful in managing
bronchial asthma [13, 14], but less is known about this
treatment strategy in COPD. Lung function (prebronchodi¬
lator FEVl) is improved when these drugs are combined,
compared with monotherapy [15], and recent studies have
found that combining therapies is also associated with fewer
exacerbations and improved HRQL, compared with placebo
treatment [5, 6].
Patients with more severe COPD (Global Initiative for
Obstructive Lung Disease (GOLD) stages III and IV)
frequently experience exacerbations, which impact on their
HRQL [16]. Prolonging the time to exacerbation may delay
the deterioration of the disease and help maintain health
status, an important aim in the treatment of COPD. More¬
over, it can be difficult to separate the improvement in health
status that occurs at the start of a clinical trial, due to closer
medical attention, from the effects of treatment itself, and this
caveat can reduce the power of the study to assess the true
therapeutic effect on this outcome. To address this difficulty,
a clinical trial was conducted in which inhaled formoterol and
oral corticosteroids were administered during a short run-in
period, to ensure that patients' treatment was optimised
before entry into the trial. During the 12-month, randomised
treatment period in patients with COPD, an ICS (budesonide)
and a long-acting p2-agonist (formoterol) given in the same
inhaler were compared with the component drugs given
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separately and with placebo. The primary outcomes were time
to first exacerbation and change in FEVl. Data were also
recorded on HRQL, peak expiratory flow (PEF), symptoms,
use of reliever medication and adverse events (AEs). This
protocol allowed the authors to test a clinically relevant
situation, namely whether the short-term improvement that
follows a period of treatment optimisation can be maintained
over a longer time by inhaled therapy, and to investigate
which drugs change what aspect of patient well-being.
Methods
Patients
Outpatients with COPD (GOLD stages III and IV) [12]
were recruited based on the following criteria: aged ^40 yrs,
COPD symptoms for >2 yrs, smoking history of ^ 10 pack-
yrs, FEVl/vital capacity (VC) < 70% prebronchodilator, FEVl
<50% of predicted normal value prebronchodilator, using
inhaled bronchodilators as reliever medication, ^1 COPD
exacerbation requiring a course of oral corticosteroids and/or
antibiotics 2-12 months before the first clinic visit.
Principal exclusion criteria were: a history of asthma/
seasonal allergic rhinitis before the age of 40 yrs, any relevant
cardiovascular disorders or significant disease/disorder, which
may have put patients at risk or influenced the results of the
study, an exacerbation of COPD requiring medical interven¬
tion within 4 weeks prior to enrolment and/or during run-in,
use ofoxygen therapy, P-blocking agents or nonallowed medica¬
tions. All patients gave written, informed consent and the study
was approved by an Ethics Committee for each centre.
Study design
This was a randomised, double-blind, placebo-controlled,
parallel-group study involving 109 centres in 15 countries or
regions. All medication was from AstraZeneca, Lund,
Sweden, and delivered via a dry powder inhaler (Turbuha¬
ler®; AstraZeneca). During the 2-week run-in, patients
received oral prednisolone (30 mg) o.d. and inhaled formo-
terol (Oxis®) 2x4.5 pg b.i.d., and terbutaline (Bricanyl®)
0.5 mg as needed. Patients were then randomised to 12
months of treatment with either budesonide (Pulmicort®)
2x200 pg b.i.d., formoterol 2x4.5 pg b.i.d., budesonide/
formoterol (Symbicort®; this Turbuhaler® delivers the
same amount of budesonide and formoterol as the corre¬
sponding Turbuhaler® monoproducts) 2x160/4.5 pg b.i.d.,
or placebo (lactose monohydrate) b.i.d with terbutaline
0.5 mg as needed.
Certain medications were allowed, with restrictions, after
randomisation. Courses of oral corticosteroids (maximum 3
weeks per course) and antibiotics were allowed in the event of
exacerbations. Parenteral steroids and/or nebulised treatment
(single injections/inhalations) were allowed at emergency visits.
The following medications were disallowed from recruit¬
ment: inhaled steroids (except the study medication), diso-
dium cromoglycate, leukotriene antagonists or 5-lipoxygenase
(5-LO) inhibitors, bronchodilators (other than study medication
and terbutaline 0.5 mg (Bricanyl®) as needed), antihista¬
mines, any medication containing ephedrine, and (5-blockers,
including eye-drops.
The following medications were withheld prior to recruit¬
ment: short-acting inhaled or oral p2-agonists (6 h before),
inhaled or oral long-acting p2-agonists (48 h), inhaled short-
acting anticholinergics (8 h), inhaled long-acting anticholi¬
nergics (7 days), xanthine-containing derivatives o.d. (48 h),
xanthine-containing derivatives b.i.d. (24 h), leukotriene anta¬
gonists or 5-LO inhibitors (48 h).
Assessments
Patients attended the clinics at recruitment, randomisation
and after 1, 2, 3, 6, 9 and 12 months of treatment. The primary
variables were time to first exacerbation and change in post-
medication FEVl. The secondary variables were number of
exacerbations, time to and number of oral corticosteroid-
treated episodes, morning and evening PEF, slow VC,
HRQL, symptoms, use of reliever medication and AEs.
Exacerbations requiring medical intervention (oral anti¬
biotics and/or corticosteroids or hospitalisation) were recorded
at each visit after randomisation. The time to and number of
exacerbations and oral corticosteroid-treated episodes were
analysed.
Predicted FEVl was calculated at recruitment using
European Respiratory Society (ERS) equations [17]. FEVl
was measured before and 15 min after two inhalations of
terbutaline 0.5 mg and the per cent increase from baseline in
FEVl was calculated. Spirometry (FEVl and slow VC)
measured after study medication and at least 6 h postreliever,
at each clinic visit, met ERS standards [17]. Wherever
possible, spirometry was performed at the same time of day,
using the same spirometer (calibrated on each study day in
accordance with the trademark specification), and supervised
by the same well-trained study staff. Patients were instructed
to rest for 15 min before measurement and spirometry was
performed in a sitting position whilst wearing a noseclip. All
spirometers met or exceeded the American Thoracic Society
recommendations.
Prebronchodilator PEF, measured using a Mini-Wright®
peak flow meter (Clement Clark, Harlow, UK), was recorded
daily in a diary, in the morning and evening as the best of
three attempts before inhalation of the study medication.
The St George's Respiratory Questionnaire (SGRQ) [18]
was used to assess HRQL. Questionnaires were completed at
recruitment, at randomisation, and at 6 and 12 months; a
Total score was calculated. A lower score indicates better
health, while a change of ^4 units indicates the minimal
clinically important difference relevant to the patient [19].
Symptoms of shortness of breath, cough, chest tightness and
night-time awakenings (on a 5-point scale from 0 (none,
unaware of symptoms) to 4 (severe)), as well as use of reliever
medication, were recorded daily in a patient diary. AEs were
monitored at each postrandomisation visit by asking a
standard question.
Analysis
With 150 patients per group, a difference in survival curves
could be detected with 80% power if 66% exacerbated in the
reference group and 50% in the comparative group. Adjusting
for a 35% dropout rate implied ~230 patients per group.
An intention-to-treat analysis was used and all hypothesis
testing was with two-sided alternative hypotheses; p<0.05 was
considered statistically significant. Time to first exacerbation
was analysed using a log-rank test and described further by
hazard rates from a Cox proportional hazards model, with
treatment as factor and stratifying by country. The number of
exacerbations was analysed using a Poisson regression model
(expressed as mean rate i.e. mean number of exacerbations
per patient per year). Treatment and country were used as
factors, time in study as an offset variable, and confidence
intervals were adjusted for overdispersion. Oral corticosteroid
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courses were analysed similarly to exacerbations. The FEYl
and VC end-points were the mean of all available measure¬
ments during the treatment period, analysed in a multi¬
plicative analysis of variance (with logarithm of values) with
treatment and country as factors, and the randomisation
value as a covariate. The mean ratios were presented as per
cent increases. Both primary variables were required to give
statistical significance at the 5% level in order to keep the
overall significance level to 5% in the final conclusion [20],
Differences in subgroup response were addressed using
standard "treatment by subgroup" interaction analyses.
SGRQ was analysed in a similar manner to FEVl but based
on the last available measurement on treatment. Diary-card
variables were also analysed in a similar manner to FEVl but
with an additive model.
Results
Patients
Of 1,141 patients enrolled into the study, 119 (10%)
withdrew during run-in; 26% of these were due to COPD
worsening and 24% due to AEs other than COPD worsening.
Following run-in, 1,022 patients were randomised, of whom
629 (62%) completed the study (table 1). Mean demographic
and baseline characteristics were similar across all treatment
groups (table 2) and correspond in general to GOLD stages
III and IV COPD [12]. After the initial period of treatment
optimisation, the group mean FEVl had increased by
(mean+SD) 0.21+0.32 L and the SGRQ Total score decreased
by 4.5+10.7 units.
Withdrawal from study
The budesonide/formoterol group had a lower risk of
withdrawing from the study compared with the placebo,
budesonide and formoterol groups (table 1). There was no
significant difference in withdrawal rates versus placebo in
either the budesonide group or the formoterol group.
After randomisation, 393 patients withdrew from the study;
193 of these were due to COPD worsening, 72 withdrew
because of AEs other than COPD worsening, and 128 for
other reasons (table 1). Significantly fewer withdrawals due to
COPD worsening were reported in the budesonide/formoterol
Table 1.-Patient flow and withdrawals
B/F B F Placebo Total
Patients enrolled 1141
Patients withdrawn during run-in 119
Patients randomised 254 257 255 256 1022
Patients withdrawn after randomisation** 74 (29) 102 (40) 111 (44) 106 (41) 393 (38)
Patients withdrawn due to COPD worsening11 28 (11) 46 (18) 59 (23) 60 (23) 193 (19)
Patients withdrawn due to adverse event other than COPD worsening 20 (8) 21 (8) 20 (8) 11(4) 72 (7)
Patients lost to follow-up 0(0) 2 (0.8) 3 (1.2) 3 (1.2) 8 (0.8)
Eligibility criteria not fulfilled 4(1.6) 4 (1.6) 4(1.6) 6 (2.3) 18 (1.8)
Other reasons 22 (8.7) 29 (11.3) 25 (9.8) 26 (10.2) 102 (10.0)
Patients completing study 180 (71) 155 (60) 144 (56) 150 (59) 629 (62)
Data are presented as n (% of randomised patients per group) unless otherwise stated. B: budesonide; F: formoterol; COPD: chronic obstructive
pulmonary disease. **: p=0.001 budesonide/formoterol versus placebo, p=0.037 budesonide/formoterol versus budesonide, p<0.001 budesonide/
formoterol versus formoterol, p=0.223 budesonide versus placebo, p=0.950 formoterol versus placebo (Cox proportional hazards model);p<0.001
budesonide/formoterol versus placebo and versus formoterol, p=0.038 budesonide/formoterol versus budesonide, p=0.031 budesonide versus placebo,
p=0.616 formoterol versus placebo (Cox proportional hazards model).
Table 2.-Patient demographic and baseline characteristics (at enrolment, unless otherwise stated)
B/F B F Placebo
Patients randomised n 254 257 255 256
Male % 78 74 75 75
Age yrs 64 (42-86) 64 (41-85) 63 (41-84) 65 (43-85)
Current smokers % 33 39 36 30
Pack-yrs 39 (10-240) 39 (10-150) 38 (10-120) 39 (10-150)
Previous medication % of patients
ICS 47 51 48 46
Inhaled SABAs 52 49 53 48
Anticholinergics 29 30 30 32
Inhaled LABAs 31 30 30 25
Xanthines 37 33 40 36
Inhaled combination of p2-agonist and anticholinergic 16 18 18 22
FEVl L 0.98+0.33 0.99+0.33 1.00+0.32 0.98+0.33
FEV1 % predicted 36±10 36+10 36+10 36+10
FEVl/VC % 42+12 44+12 44+12 44+11
Reversibility % predicted 6+7 6+7 6+6 6+6
Baseline SGRQ Total score at randomisation 48+19 49+18 47+19 48+18
Data are presented as mean (range) or mean+SD unless otherwise stated. B: budesonide; F: formoterol; ICS: inhaled corticosteroid; SABA: short-
acting p2-agonist; LABA: long-acting p2-agonist; FEVl: forced expiratory volume in one second; VC: vital capacity; SGRQ: St George's Respiratory
Questionnaire.
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group compared with the placebo, budesonide and formoterol
groups (table 1).
Exacerbations
Budesonide/formoterol prolonged time to first exacerbation
compared with all other treatments (all p<0.05, log-rank test;
fig. 1). Hazard rate analysis showed that the risk of having an
exacerbation while being treated with budesonide/formoterol
was reduced by 22.7%, 29.5% and 28.5% versus budesonide,
formoterol and placebo, respectively. The exacerbation rate
with budesonide/formoterol was reduced compared with placebo
(23.6%) and formoterol (25.5%) but not with budesonide
alone (13.6%) (table 3). Neither budesonide nor formoterol
affected either measure ofexacerbation compared with placebo.
When the analysis was restricted to oral corticosteroids
given due to exacerbations, the lowest rates were found in the
budesonide/formoterol and budesonide treatment groups
(table 3). Budesonide/formoterol prolonged the time to first
course of oral corticosteroids after randomisation; risk
reductions were 32.7% and 33.8% versus budesonide and
formoterol, respectively (both p<0.01), and 42.3% versus
placebo (p<0.001). Budesonide/formoterol also reduced the
rate of oral corticosteroid courses by 28.2%, 30.5% and 44.7%
Fig. 1.-Kaplan-Meier plot of time to first exacerbation by treatment
group. Log-rank tests of budesonide/formoterol (—) versus budeso¬
nide ( ), p=0.037; budesonide/formoterol versus formoterol ( ),
p=0.002; budesonide versus placebo ( ), p=0.796; formoterol versus
placebo, p=0.490; and budesonide/formoterol versus placebo, p<0.05.
versus budesonide, formoterol and placebo, respectively;
budesonide alone reduced the number of oral corticosteroid
courses compared with placebo but formoterol did not
(table 3).
Lung function
After the optimisation period, the improvement in FEVl
seen during run-in was maintained with budesonide/formo¬
terol treatment throughout the study. In contrast, FEVl
declined greatly and rapidly with all other treatments. This
difference was significant with budesonide/formoterol com¬
pared with placebo (14%), budesonide (11%) and formoterol
(5%), and with formoterol versus placebo (8%), but not with
budesonide versus placebo (2%) (fig. 2).
Changes in VC closely followed those of FEVl. Budeso¬
nide/formoterol and formoterol improved VC versus placebo
(both p<0.001), while budesonide/formoterol also improved
VC versus budesonide (p<0.001). Budesonide/formoterol therapy
was also associated with higher morning PEF compared with
all other treatments, and higher evening PEF compared with
placebo and budesonide (fig. 3).
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Months since randomisation
Fig. 2.-Changes in mean forced expiratory volume in one second
(FEVl) in the four treatment groups from randomisation to the
average of all available measurements during the 12-month treatment
period. Budesonide/formoterol (■) versus budesonide (•), p<0.001;
budesonide/formoterol versus formoterol (□), p=0.002; budesonide
versus placebo (O), p=0.145; formoterol versus placebo, p<0.001;
budesonide/formoterol versus placebo, p<0.001.
Table 3.-Analysis of exacerbations and oral corticosteroid courses due to exacerbations
B/F B F Placebo
Time to first exacerbation
Median number of days
#RR (95% CI) B/F versus other groups"1"
p-value11
Total number of exacerbations
Mean rate per patient per year
RR (95% CI) B/F versus other groups"1"
p-value1'
Exacerbations requiring oral corticosteroids
Mean rate per patient per year
RR (95% CI) B/F versus other groups4"
p-value11
254 178 154














B: budesonide; F: formoterol; RR: rate ratio; CI: confidence interval. #: a RR of0.715 represents a reduction in rate of28.5%; versus placebo; +:
rates from Poisson regression model, RR is hazard ratio from Cox proportional hazards model. *: p<0.05 in favour of budesonide/formoterol; **:
p<0.01 in favour of budesonide/formoterol.
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Fig. 3.-Change in peak expiratory flow (PEF) from randomisation
to the average of all available measurements during the 12-month
treatment period (from daily diary-card data). Budesonide/formoterol
(top line) therapy was associated with a) higher morning PEF versus
placebo (bottom line; 18 L-min"1 difference, p<0.001), budesonide
(line third from top; 15 L-min"1, p<0.001) and formoterol (line
second from top; 7 L-min"', p=0.007). Formoterol versus placebo
p<0.001. b) Budesonide/formoterol therapy was associated with
higher evening PEF versus placebo (14 L-min"1, p<0.001) and
budesonide (12 L-min"1, p<0.001), but not versus formoterol
(5 L-min"1) and this improvement was sustained throughout the
treatment phase. Formoterol was also associated with placebo
(p<0.001).
For both exacerbations and FEVl, interaction analyses
between treatment and sex, smoking status/history, reversi¬
bility or use of ICS at entry, were performed in order to
investigate differences in treatment response. There was no
evidence of heterogeneity in the treatment differences with
respect to the primary variables in any of these categories,
i.e. the results in these groups were consistent with the main
analysis.
Health-related quality of life
Baseline values for the SGRQ Total score were similar in
each group and high, indicating poor HRQL (table 2). At the
end of the run-in period, Total scores had improved by a
mean of 4.5 units (range 3.6^1.8; fig. 4). During the treatment
period, the Total scores fell further in the budesonide/
formoterol group, representing an additional improvement
beyond that achieved during run-in. Treatment with budeso¬
nide or formoterol allowed the initial improvement in HRQL
to be maintained, while HRQL in the placebo group
deteriorated to the original (prerun-in) values (fig. 4). Thus,
Months since randomisation
Fig. 4.-Time course of the change in St George's Respiratory
Questionnaire Total scores relative to first attendance measured at
clinic visits. At 12 months, budesonide/formoterol (■) versus budeso¬
nide (•), p=0.001; budesonide/formoterol versus formoterol (□),
p=0.014; budesonide versus placebo (O), p<0.05; formoterol versus
placebo, p<0.01; and budesonide/formoterol versus placebo, p<0.001.
all active treatments improved the Total score versus placebo,
with the greatest improvement occurring with budesonide/
formoterol (differences at 12 months of -7.5, -3.0 and -4.1
versus placebo for budesonide/formoterol, budesonide and
formoterol, respectively). Similarly, Symptoms, Activity and
Impacts domain scores were each improved by 5=5.5 units
in those patients receiving budesonide/formoterol compared
with the placebo group (p<0.01). In addition, budesonide/
formoterol showed improvements versus monocomponents
in the Activity (changes of -3.6 versus budesonide and -3.5
versus formoterol, both p<0.05) and Impacts (changes of
-5.7 (p<0.001) versus budesonide, and -3.7 (p<0.05) versus
formoterol) domains, but not in the Symptoms domain (-2.8
versus budesonide and -0.6 versus formoterol).
Symptoms
Budesonide/formoterol and formoterol improved the total
symptom score and the individual symptom scores for
shortness of breath, chest tightness and night-time awaken¬
ings compared with placebo. Budesonide also improved the
night-time awakenings score compared with placebo. None of
the treatments significantly improved the cough score. Mean
data for changes from run-in to end of treatment in symptom
scores and differences between groups are shown in table 4.
Use of reliever medication
Budesonide/formoterol significantly reduced the use of
reliever medication by 0.8 inhalations per day versus both
budesonide and placebo (both p<0.001), and by 0.3 inhala¬
tions per day versus formoterol (p<0.05), and formoterol
reduced reliever medication intake by 0.4 inhalations per day
versus placebo (p<0.01). Budesonide alone had no effect on
this variable compared with placebo.
Safety
No further safety issues for budesonide/formoterol were
identified in this study compared with what is previously
budesonide/formoterol in copd
Table 4.-Mean changes from run-in to end of treatment in symptom scores
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Total symptom Shortness of Chest tightnes
score (0-16) breath score (0-4) score (0-4) awaicenmg score (U-4)
B/F versus placebo -0.56 (-0.89—0.24) -0.21 (-0.32—0.10) -0.16 (-0.26—0.05) -0.07 (-0.17-0.03) -0.16 (-0.27—0.05)
p-value <0.001 <0.001 0.004 0.180 0.004
B/F versus B -0.26 (-0.58—0.07) -0.12 (-0.23—0.01) -0.09 (-0.20-0.01) -0.02 (-0.12-0.08) -0.05 (-0.16-0.06)
p-value 0.120 0.040 0.080 0.651 0.361
B/F versus F -0.02 (-0.35-0.30) 0.00 (-0.11-0.11) -0.01 (-0.12-0.09) -0.02 (-0.12-0.08) -0.04 (-0.15-0.07)
p-value 0.891 0.946 0.788 0.705 0.463
B versus placebo -0.30 (-0.63-0.02) -0.09 (-0.20-0.02) -0.06 (-0.17-0.04) -0.05 (-0.15-0.05) -0.11 (-0.21—0.00)
p-value 0.067 0.100 0.238 0.372 0.049
F versus placebo -0.54 (-0.87—0.21) -0.21 (-0.32—0.10) -0.14 (-0.25—0.04) -0.05 (-0.15-0.05) -0.12 (-0.22—0.01)
p-value 0.001 <0.001 0.008 0.335 0.033
Data are presented as mean (95% confidence interval) unless otherwise stated. B: budesonide; F: formoterol.
known for budesonide/formoterol, budesonide and formo¬
terol in COPD and asthma. The mean number of AEs
experienced with budesonide/formoterol was no different
from that with placebo (5, 5, 6 and 5 AEs per 1,000 treatment
days for the budesonide/formoterol, budesonide, formoterol
and placebo groups, respectively), and the most frequently
reported AEs were similar across the treatment groups
(table 5). The lowest number of withdrawals was in the
budesonide/formoterol group (table 1) and the lowest number
of serious AEs other than deaths were in the budesonide/
formoterol and placebo groups (65, 88, 85 and 66 in the
budesonide/formoterol, budesonide, formoterol and placebo
groups, respectively). The number of serious AEs related to
COPD was 40, 40, 55 and 38 in the budesonide/formoterol,
budesonide, formoterol and placebo groups, respectively. The
numbers of deaths were 5, 6, 13 and 5 in the budesonide/
formoterol, budesonide, formoterol and placebo groups,
respectively. Most of the deaths were events related to
COPD and only a few were related to cardiovascular events.
Discussion
Many clinicians manage newly referred COPD patients by
intensifying their treatment, often including a period of oral
Table 5. -The most frequently reported adverse events (AEs)
B/F B F Placebo
Subjects n 254 257 255 256 '
COPD# 48 (19) 62 (24) 73 (29) 79 (31)
Respiratory infection 36 (14) 34 (13) 33 (13) 24(9)
Fever 5(2) 9(4) 11 (4) 2(1)
Dyspnoea 5(2) 5(2) 12(5) 5(2)
Back pain 8(3) 4(2) 6(2) 7(3)
Pharyngitis 7(3) 5(2) 8(3) 5(2)
Chest pain 8(3) 4(2) 6(2) 5(2)
Hypertension 6(2) 9(4) 3(1) 5(2)
Pneumonia 8(3) 5(2) 7(3) 2(1)
Rhinitis 11 (4) 3(1) 6(2) 1 (<0.5)
Dysphonia 5(2) 5(2) 1 (<0.5) 1 (<0.5)
Moniliasis 4(2) 4(2) 2(1) 0(0)
Data are presented as n (%) of patients reporting at least one AE after
the first dose of investigational product unless otherwise stated. B:
budesonide; F: formoterol; COPD: chronic obstructive pulmonary
disease. COPD was reported as an AE only if the COPD symptom
(bronchitis, phlegm, cough, increased sputum production, breath-
lessness, wheeze, dyspnoea) was serious (resulted in death, was
life-threatening, required hospitalisation or prolonged existing hospi¬
talisation, or resulted in persistent or significant disability/incapacity),
or resulted in the patient's withdrawal from the study.
corticosteroid therapy with the hope of selecting individuals
who are "corticosteroid responders". A substantial number of
patients show spirometric improvements with either a p2-
agonist or oral corticosteroids, or both [21]. Unfortunately,
neither the presence of a "positive" or "negative" oral
corticosteroid response in patients with more severe COPD
predicts future response to inhaled therapy [9]. Whether these
improvements in lung function are accompanied by changes
in symptomatic end-points like HRQL has not been studied,
nor has the ability of inhaled drugs to maintain these effects
been assessed, although results from observational studies
suggest that at least ICS may be beneficial [22], This study
shows that significant short-term improvements in lung
function (both FEVl and PEF) and HRQL occur after
optimised treatment with formoterol and oral corticosteroids,
and that these improvements can be maintained for a year
using budesonide and formoterol in the same inhaler.
This is the first study to show that after an intensification
regimen, administration of an ICS and long-acting p2-agonist
in a single inhaler prolongs the time to a first COPD exacer¬
bation, compared with monocomponents. Moreover, these
data add further strong support to recent studies where these
drug treatment classes have been combined and therapy has
initially been withdrawn, rather than optimised, during the
run-in phase [5, 6]. The exacerbation frequency in this study
was almost identical to that reported in the previous study of
budesonide/formoterol in COPD patients of a similar disease
severity [5], and the effects of each treatment were the same in
both studies. In this study, budesonide/formoterol was clearly
better than monocomponents at preventing exacerbations,
while budesonide had a small effect on episodes where oral
corticosteroids were considered necessary. The lack of effect
of formoterol may reflect the more severe nature of the
episodes used as the outcome here (i.e. requiring medical
intervention) rather than the "bad days" used as a surrogate
for exacerbations in other studies [3]. The similarities of the
data presented in this paper to those of Szafranski et al. [5]
indicate that prior treatment optimisation does not influence
this outcome. The more severe disease in the patients studied
(FEVl 36% pred) is the likely explanation of the greater
number of episodes seen here compared with other studies [6,
9], a difference that increases the power of the study to detect
an effect of treatment. The 24% reduction in exacerbations
with budesonide/formoterol compared with placebo may trans¬
late into worthwhile improvements in patient well-being.
Furthermore, the reductions are probably underestimated
since the lowest withdrawal rate occurred in the budesonide/
formoterol group. It is likely that the most severely ill patients
dropped out first, potentially leading to a lower number of
exacerbations in the other groups. To some extent, this bias
applies to lung function and HRQL differences as well.
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Budesonide/formoterol was able to maintain FEVl at the
run-in level over the study year. In contrast, lung function
(both FEVl and PEF) returned to baseline by 1 month in
patients treated with either placebo or budesonide and, as
judged by the PEF data from the daily diary cards, this
change occurred within 2 weeks of randomisation to these
treatments. Numerically, the formoterol data lay between
those of the other treatment limbs, but the values were
significantly smaller than those measured using budesonide/
formoterol. The size of the spirometric changes, comparing
budesonide/formoterol with placebo and individual compo¬
nents, was almost identical to that seen when combination
therapy was introduced after a period of treatment with¬
drawal [5, 6], rather than after the intensification regimen
used here. The PEF data also show that within 2 weeks of
stopping intensified therapy, clinical benefits of treatment
optimisation were diminished in all patients not taking
budesonide/formoterol.
Budesonide/formoterol produced significant improvements
in daily symptom scores compared with placebo, as did
formoterol versus placebo (except for cough, which was
unchanged). The absolute changes were similar to those seen
by Szafranski et al. [5] who used the same questionnaire.
Even modest improvements in symptom scores are likely to
lead to improved mobility and an increased level of activity.
However, there were statistically and clinically significant
differences between treatments in their ability to sustain the
HRQL improvement after optimisation of therapy. Budeso¬
nide/formoterol treatment was associated with the largest
difference in the SGRQ Total score compared with placebo,
which clearly exceeded the minimum clinically important
difference of 4 units [19]. Improvements in Total score
compared with placebo were also clinically important with
formoterol alone, and approached clinical relevance for
budesonide alone. The additional effect of budesonide/
formoterol on HRQL compared with monocomponents is
likely to reflect the lower number of exacerbations experi¬
enced by these patients, since HRQL is known to be worse in
frequent exacerbators [16].
All the active treatments had some positive effect on
HRQL; the change seen over the year in the budesonide
group being almost identical to that seen in the less spiro-
metrically impaired Inhaled Steroids in Obstructive Lung
Disease study patients, who were also studied after an initial
course of prednisolone [9]. Inclusion of an optimised treat¬
ment phase may overcome problems in assessing HRQL in
clinical studies as it reduces the immediate effect of with¬
drawing ICS that has been associated with more frequent
exacerbations [23, 24]. This approach should permit a more
realistic comparison to be made of treatment effect on HRQL
and overcomes the "clinical-trial effect" seen in the placebo
limb of other 1-yr trials [6].
In this study, AEs were monitored by specific enquiry at
each visit. No new safety issues related to treatment with
budesonide/formoterol were identified during 12-months
treatment. The incidence of AEs related to COPD was clearly
lower in the budesonide/formoterol group compared with the
other groups, and overall, a low incidence of hoarseness and
moniliasis was reported.
This study did not collect bone mineral density data,
although the dose of budesonide used did not affect this
variable during 3 yrs of treatment in patients with less
advanced COPD [25], As expected when studying a COPD
population of this severity, a number of deaths occurred. The
number of serious AEs and deaths reported were highest in
the formoterol treatment group and most of these were events
related to COPD. An investigation into the individual causes
of death did not give an explanation for the apparent
difference between the groups, and no increase in mortality
during formoterol treatment without ICS was observed in
a previous study with a similar patient population [5].
Conversely, increased disease severity/mortality has been
reported in some recently published studies with bronchodi-
lators alone [26-28], These observations, together with the
potential seriousness of severe exacerbations, suggest that a
combination of a long-acting bronchodilator and an ICS
may be particularly appropriate in patients with this severity
of COPD.
The reasons for the improved efficacy of budesonide/
formoterol are not yet clear, although corticosteroids can
upregulate the number of |32-receptors on the cell membrane
and p2-agonists may increase the nuclear localisation of
glucocorticoid receptors [29]. It also seems that formoterol
and budesonide in combination are more effective at reducing
proliferation of airway smooth muscle than either drug alone,
as a result of synchronised cellular signalling [30]. Clinically,
each type of drug appears to add something to the combined
effect with the improvement in symptoms, lung function
(FEVl, PEF), and HRQL associated with formoterol being
complemented by the reduction in exacerbations and better
HRQL seen with budesonide. Whether these effects are
merely additive or represent true synergy cannot be estab¬
lished here, but the difference in treatment withdrawal
between the group taking budesonide/formoterol and those
taking the other treatments is likely to be explained by these
multiple beneficial actions.
This study has a number of implications. It provides further
and clearer evidence of the effectiveness of ICS and long-
acting p2-agonists on health status, exacerbations, lung
function (FEVl and PEF) and HRQL, in COPD (GOLD
stages III and IIV), and of their additional clinical benefit
when combined in a single inhaler. Secondly, standardising
therapy for a period before entry into a long clinical trial
allowed greater improvements in HRQL than seen in similar
trials that did not include this run-in treatment. This is a novel
approach that may allow for easier interpretation of this end-
point, and merits further study.
Finally, this study provides evidence that intensifying
treatment in stable chronic obstructive pulmonary disease
may be a useful way of rapidly improving patient well-being
and that this approach merits future study as an alternative to
stepwise increments in treatment intensity.
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ABSTRACT
BACKGROUND
Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic
obstructive pulmonary disease (COPD), but their effect on survival is unknown.
METHODS
We conducted a randomized, double-blind trial comparing salmeterol at a dose of
50 fjbg plus fluticasone propionate at a dose of 500 fig twice daily (combination regi¬
men), administeredwith a single inhaler, with placebo, salmeterol alone, or fluticasone
propionate alone for a period of 3 years. The primary outcome was death from any
cause for the comparison between the combination regimen and placebo; the fre¬
quency of exacerbations, health status, and spirometric values were also assessed.
RESULTS
Of 6112 patients in the efficacy population, 875 died within 3 years after the start
of the study treatment. All-cause mortality rates were 12.6% in the combination-
therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and
16.0% in the fluticasone group. The hazard ratio for death in the combination-ther¬
apy group, as compared with the placebo group, was 0.825 (95% confidence interval
[CI], 0.681 to 1.002; P = 0.052, adjusted for the interim analyses), corresponding to
a difference of 2.6 percentage points or a reduction in the risk of death of 17.5%.
The mortality rate for salmeterol alone or fluticasone propionate alone did not difi
fer significantly from that for placebo. As compared with placebo, the combination
regimen reduced the annual rate of exacerbations from 1.13 to 0.85 and improved
health status and spirometric values (P<0.001 for all comparisons with placebo).
There was no difference in the incidence of ocular or bone side effects. The prob¬
ability of having pneumonia reported as an adverse event was higher among pa¬
tients receiving medications containing fluticasone propionate (19.6% in the com¬
bination-therapy group and 18.3% in the fluticasone group) than in the placebo
group (12.3%, P<0.001 for comparisons between these treatments and placebo).
CONCLUSIONS
The reduction in death from all causes among patients with COPD in the combination-
therapy group did not reach the predetermined level ofstatistical significance. There
were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov
number, NCT00268216.)
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Chronic obstructive pulmonary Dis¬ease (COPD) is a major cause of illness,death, and the use ofhealth care resources
globally.1"3 The disease causes approximately 2.75
million deaths annually, and the number is pro¬
jected to increase.2 Treatment for COPD is focused
on minimizing risk factors, improving symptoms,
and preventing exacerbations.3 With the exception
ofsmoking-cessation programs for patients with
early disease,4 home oxygen treatment for persis¬
tent hypoxemia,5-6 and lung-reduction surgery for
selected patients with emphysema,7 no treatment
has been shown to reduce mortality.
Pulmonary inflammation is prominent in
COPD.8 Antiinflammatory drugs such as inhaled
corticosteroids have little or no effect on the rate
ofdecline of lung function9'10 but may reduce the
frequency ofexacerbations,9 especially when com¬
bined with an inhaled long-acting beta-agonist.11
Retrospective analyses suggest that inhaled corti¬
costeroids reduce the mortality rate among pa¬
tients with COPD12 and that adding a long-acting
beta-agonist might increase this effect.13 We hy¬
pothesized that the combination of the long-act¬
ing beta-agonist salmeterol and the inhaled corti¬
costeroid fluticasone propionate would reduce
mortality among patients with COPD, as com¬
pared with usual care. To test this hypothesis, we
undertook the Towards a Revolution in COPD
Health (TORCH) trial, a double-blind, placebo-
controlled, randomized, parallel-group study com¬
paring salmeterol plus fluticasone propionate
(the combination regimen) with each of the com¬
ponents alone and with placebo over a 3-year
period.
METHODS
Details of the study design and the analysis plan
were published previously.14 The complete study
protocol is in Supplementary Appendix 1, available
with the full text of this article at www.nejm.org.
PATIENTS
We recruited patients who were current or former
smokers with at least a 10-pack-year history. Eli¬
gible patients were 40 to 80 years ofage and had
received a diagnosis ofCOPD, with a prebroncho-
dilator forced expiratory volume in 1 second (FEVJ
of less than 60% of the predicted value,15 an in¬
crease ofFEV, with the use of400 fig ofalbuterol
of less than 10% of the predicted value for that
patient, and a ratio of prebronchodilator FEV1 to
forced vital capacity (FVC) equal to or less than
0.70. For the exclusion criteria, see Table 1 in Sup¬
plementary Appendix 2. All patients gave written
informed consent. The study was approved by lo¬
cal ethics review committees and was conducted
in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines.
STUDY DESIGN
This double-blind studywas conducted at 444 cen¬
ters in 42 countries; center and data auditing en¬
sured the integrity of the data (see the study pro¬
tocol in Supplementary Appendix 1). After a
2-week run-in period, eligible patients were ran¬
domly assigned, in permuted blocks with stratifi¬
cation according to country and smoking status,
to treatmentwith the combination ofsalmeterol
at a dose of 50 fig and fluticasone propionate at
a dose of500 fig (AdvairDiskus, Seretide, Glaxo-
SmithKline) or salmeterol (Serevent, Glaxo-
SmithKline) alone at a dose of 50 fig, flutica¬
sone propionate (Flovent Diskus, Flixotide,
GlaxoSmithKline) alone at a dose of 500 fig, or
placebo, all taken in the morning and the eve¬
ning for 3 years. Study medications were ad¬
ministered as a dry powder with the use of an
inhaler (Diskus, Accuhaler, GlaxoSmithKline).
Inhalers were collected every 12 weeks, and the
number of doses remaining in each inhaler was
recorded to check adherence to the study regimen.
Before the run-in period, all use ofcorticosteroids
and inhaled long-acting bronchodilators was
stopped, but patients could continue other medi¬
cations for COPD.
After randomization, patients were seen every
12 weeks to confirm vital status, record any un¬
scheduled visits to a health care provider, and note
the occurrence ofany adverse events. Postbroncho-
dilator spirometry was performed and health
status was assessed every 24 weeks. An indepen¬
dent safety and efficacy data monitoring commit¬
tee performed safety reviews every 6 months, and
two interim efficacy analyses were performed,
the first after the first 358 deaths had occurred
and the second after a total of 680 deaths had
occurred.
OUTCOME MEASUREMENTS
Vital status was assessed until 3 years after treat¬
ment had begun, regardless of whether the pa¬
tients continued to take study medication. The
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primary end point was the time to death from
any cause by 3 years. An independent clinical end
point committee, whose members were unaware
of the treatment assignments, determined the
primary cause of death and whether death was
related to COPD. The committee used information
obtained from investigators, medical records, and
other data, as available.
Secondary end points were the frequency of
exacerbations, defined as a symptomatic deterio¬
ration requiring treatmentwith antibiotic agents,
systemic corticosteroids, hospitalization, or a com¬
bination of these, and health status, as assessed
according to scores on the St. George's Respira¬
tory Questionnaire.16 Scores are based on a scale
of 0 to 100, with lower scores indicating better
functioning; a change of4 units is generally con¬
sidered clinically relevant. The questionnaire was
administered in the 28 countries where a vali¬
dated translation was available. Lung function
was assessed with the use of postbronchodilator
spirometry. For patients who withdrew from the
study prematurely, all data on exacerbations, health
status, and lung function available at the time ofa
patient's withdrawal from the study were included
in the analysis.
SAFETY EVALUATION
Adverse events and medications were reviewed at
each study visit. Additional information was col¬
lected about any fractures, classified as either
traumatic or nontraumatic, with nontraumatic
fractures considered to be caused by falls from
less than standing height or falls occurring spon¬
taneously. Dual-energy x-ray absorptiometry at the
hip and lumbar spine and slit-lamp examinations
were performed on patients' entry into the study
and annually thereafter in a safety substudy con¬
ducted in the United States and involving 658
patients.
STATISTICAL ANALYSIS
All reported data analyses were prespecified. As¬
suming a 17%mortality rate in the placebo group
at 3 years,17 we estimated that 1510 patients would
be needed for each study group to detect a reduc¬
tion in mortality of 4.3 percentage points in the
combination-therapy group, as compared with the
placebo group (hazard ratio for death, 0.728), at a
two-sided alpha level of 0.05 with 90% power.
Two interim analyses of death from any cause
were planned to assess whether there was over¬
whelming evidence of a benefit from the combi¬
nation regimen, as compared with placebo, or of
harm in any study group; these analyses were
performed by the independent safety and efficacy
datamonitoring committee according to the meth¬
od ofWhitehead.18 As a consequence, the P value
for the primary comparison between the combi¬
nation regimen and placebo was adjusted upward
to conserve an overall significance level of 0.050.
The difference in times to death from any
cause between the combination-therapy group
and the placebo group was analyzed with the use
of the log-rank test (with stratification according
to smoking status) and expressed as a hazard
ratio. We used a Cox proportional-hazards model
as a supportive secondary analysis.
The frequency of exacerbations was analyzed
with the use of a generalized linear model (as¬
suming a negative binomial distribution, which
accounts for variability among patients in the
number and frequency ofexacerbations), with the
number of exacerbations as the outcome and
the logarithm of time during which treatmentwas
received as an offset variable. Total scores on the
St. George's Respiratory Questionnaire and post¬
bronchodilator FEV1 were analyzed as changes
from baseline values with the use of repeated-
measures analysis of covariance (ANCOVA). Esti¬
mated differences between treatments at each
visit were averaged with equal weights to deter¬
mine the overall treatment effect during the 3-year
study period. All efficacy analyses were per¬
formed according to the intention-to-treat princi¬
ple. Comparisons other than those between the
combination regimen and placebo and between
the combination regimen and salmeterol alone
were exploratory.
Times to the first fracture, eye disorder, and
pneumonia were compared among the study
groups in the safety population with the use of
Kaplan-Meier estimates and the log-rank test,
with stratification according to smoking status.
In the safety substudy, bone mineral density for
the total hip and lumbar spine was analyzed by
repeated measures ofANCOVA, and the develop¬
ment of cataracts was analyzed with the use of
logistic regression. (For details of the statistical
analysis, see Supplementary Appendixes 1 and 2.)
The steering committee, made up of six aca¬
demic investigators and two employees of the
sponsor, developed the design and concept of the
study, approved the statistical plan, had full access
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Figure 1. Enrollment of Patients and Completion of the Study.
Adverse events included death during the study period but may not have included deaths occurring after patients withdrew from the
study. The number of patients who underwent randomization and the number of those included in the safety population differ in the
placebo group and the fluticasone group, because one patient who was assigned to placebo received fluticasone propionate for more
than half the study period; this patient was therefore included in the safety population of the fluticasone group and in the efficacy popu¬
lation of the placebo group. In each study group, patients were excluded from the efficacy analysis because during routine site visits and
data audits, data from centers at which there were unacceptable research practices were excluded (see Supplementary Appendix 2). Vital
status for patients included in the efficacy analysis was established at the end of the study, except for one patient in the combination-
therapy group whose data were censored at the last point at which he was known to be alive (day 792).
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* Plus-minus values are means ±SD.
"j'The body-mass index is the weight in kilograms divided by the square of the height in meters.
:j: Exacerbations during the 12 months before screening were self-reported.
I Clinical data are from visit 1 (the screening visit). FEVX denotes forced expiratory volume in 1 second, and FVC forced
vital capacity.
1 Reversibility denotes the change in the FEVX after the administration of 400 pg of albuterol to less than 10% of the pre¬
dicted value for the patient.
| Scores on the St. George's Respiratory Questionnaire are based on a scale of 0 to 100, with lower scores indicating bet¬
ter functioning; a change of 4 units is considered clinically relevant. Data are given for the centers at which the ques¬
tionnaire was administered.
Table 1. Demographic and Baseline Clinical Characteristics ofPatients in the Efficacy Population.-
Placebo Group
Combination-
Salmeterol Group Fluticasone Group Therapy Group
Variable (N = 1524) (N = 1521) (N = 1534) (N = 1533)
Age at enrollment— yr 65.0±8.2 65.1 :8.2 65.0*8.4 65.0*8.3
Male sex— no. (%) 1163 (76) 1160 (76) 1157 (75) 1151 (75)
Body-mass indexf 25.4*5.2 .eft' 25.4±5.2 25.4=5.1 25.4*5.3
Geographic region — no. (%)
United States 345 (23) 346 (23) 348 (23) 349 (23)
Asia-Pacific 188 (12) 189 (12) 193 (13) 188 (12)
Eastern Europe 7.90 (19) 289 (19) 287 (19) 288 (19)
Western Europe 476 (31) 475 (31) 481 (31) 476 (31)
Other 7 7; • 225 (15) 222 (15) j 225 (15) 232 (15)
Current smoker— no. (%) 658 (43) 651 (43) 661 (43) 660 (43)




Inhaled corticosteroid 338 (22) 2.73(18) 306(20) 292 (19)
Long-acting beta-agonist 118 (8) 137(9) 130 (8) 137(9)
Inhaled corticosteroid plus long-acting
beta-agonist
449(29) 413 (27) 414 (27) ?: 435 (28)
Exacerbation — no.;i;
Requiring antibiotics or oral corticosteroids ; 1.0±1.4 1.0*1.4 ff 1.0=1.4 1,0*1.3
Requiring hospitalization 0.2±0.7 0.2±0.6 0.2*0.6 0.2*0.6
Lung function!
Prebronchodilator FEVX —liters 1.12±0.40 1.10±0.39 1.12*0.39 1.12*0.40
Postbrorchodilator FEV. —liters 1 22±0.42 1.21=0.41 1.22*0.41 1.22*0.42
FEVj—% of predicted 44.1±12.3 43.6±12.6 44.1*12.3 44.3*12.3
Reversibility—% of predicted FEVj^ : 3.7±3.7 3.7.t3.9 3.7*3.7 3.6*3.6
Prebronchodilator FEVX:FVC (%) 48.6±10.9 48.7±10.8 48.5*10.7 48.7*10.8
Total score at baseline on St. George's
Respiratory Questionnaire!
49.0*17.4 49.9*16.6 49.5*17.1 48.9*17.4
to and interpreted the data, wrote the manuscript,
and was responsible for the decision to publish
the manuscript. An academic author wrote a draft
of the manuscript; an employee of the sponsor
performed the statistical analysis. The academic
authors vouch for the veracity and completeness
of the data and the data analysis. The sponsor did
not place any restrictions on the academic au¬




Of 8554 patients recruited, 6184 underwent ran¬
domization (Fig. 1). Of these, 72 patients at five
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sites were excluded from the efficacy analysis be¬
cause these sites failed to meet the standards of
the study for Good Clinical Practice and ethical
practices and were closed before the study ended
(see Supplementary Appendix 2). These 72 pa¬
tients were included in the safety analysis, and
a total of 6112 patients were included in the effi¬
cacy population.
Demographic and baseline clinical charac¬
teristics of the efficacy population are shown in
Table 1. The mean age was 65 years, and the
mean value of postbronchodilator FEVj was 44%
of the predicted value. During the year before en¬
try into the study, more than half the patients had
used inhaled corticosteroids, a long-acting beta-
agonist, or both, and 57% of the patients had
reported an exacerbation. The proportion of pa¬
tients who withdrew from the study was signifi¬
cantly higher in the placebo group (44%) than in
the three other groups, and the proportion was
lowest in the combination-therapy group (34%)
(Fig. 2A). The total number ofyears of exposure
to the study drugs was 3678 in the combination-
therapy group, 3238 in the placebo group, 3499
in the salmeterol group, and 3532 in the flutica¬
sone group. The rate of adherence to treatment
was similar in all groups, ranging from 88% to
89% of the prescribed doses taken.
MORTALITY
Vital status was known at 3 years for 6111 of the
6112 patients included in the efficacy population.
There were 875 deaths within 3 years after ran¬
domization. The proportions ofdeaths from any
cause at 3 years were 12.6% in the combination-
therapy group, 15.2% in the placebo group, 13.5%
in the salmeterol group, and 16.0% in the flutica¬
sone group. The absolute risk reduction for death
in the combination-therapy group as compared
with the placebo group was 2.6%, and the hazard
ratio was 0.825 (95% confidence interval [CI],
0.681 to 1.002; P=0.052), corresponding to a reduc¬
tion in the risk ofdeath at any time in the 3 years
of 17.5% (95% CI, -0.2 to 31.9) (all adjusted for
the interim analyses) (Fig. 2B and Table 2).
Prespecified secondary analyses for mortality
were also performed: Cox proportional-hazards
testing yielded a hazard ratio of 0.811 (95% CI,
0.670 to 0.982; P = 0.03) (Table 2); log-rank test¬
ing, stratified according to smoking status and
country of residence, yielded a hazard ratio of
0.815 (95% CI, 0.673 to 0.987; P=0.04) (see Table 2
Figure 2 (facing page). Outcomes.
In the combination regimen, salmeterol was adminis¬
tered at a dose of 50 pg and fluticasone propionate at
a dose of 500 pg twice daily. Salmeterol alone was ad¬
ministered at a dose of 50 pg twice daily, and flutica¬
sone propionate alone was administered at a dose of
500 pg twice daily. Cumulative incidences of discontinu¬
ation of a study drug at 3 years were 43.5% in the place¬
bo group, 36.4% in the salmeterol group, 38.1% in the
fluticasone group, and 33.7% in the group receiving
the combination of salmeterol plus fluticasone propio¬
nate (Panel A). Intergroup comparisons yielded the fol¬
lowing hazard ratios for the discontinuation of a study
medication: 0.69 (95% CI, 0.62 to 0.78, P<0.001) for
the combination-therapy group versus the placebo
group; 0.89 (95% CI, 0.79 to 0.999; P<0.05) for the
combination-therapy group versus the salmeterol
group; 0.86 (95% CI, 0.76 to 0.96; P=0.010) for the
combination-therapy group versus the fluticasone
group; 0.78 (95% CI, 0.70 to 0.86; P<0.001) for the sal¬
meterol group versus the placebo group; and 0.81
(95% CI, 0.72 to 0.90; P<0.001) for the fluticasone
group versus the placebo group. Patients discontinu¬
ing a study medication were included in the mortality
analysis at 3 years but could receive any treatment. In
the analysis for the primary end point of the probability
of death from any cause at 3 years, the risk of death in
the placebo group was 15.2%, as compared with 12.6%
in the combination-therapy group. Salmeterol and flu¬
ticasone propionate in combination reduced the risk of
death at any time during the 3-year study period by
17.5% (P = 0.052) (Panel B). The probability of COPD-
related death at 3 years was 6.0% in the placebo
group, 6.1% in the salmeterol group, 6.9% in the flu¬
ticasone group, and 4.7% in the combination-therapy
group (Panel C). The effect of each study medication
on health status (assessed according to changes in
patients' total scores on the St. George's Respiratory
Questionnaire) and FEVj during the 3-year study peri¬
od are shown in Panels D and E, respectively. Values in
the tables below the graphs represent the numbers of
patients alive (Panel B), the numbers of of patients
alive or dead from non-COPD-related causes (Panel C),
or the number of patients remaining in the study (Panels
A, D, and E). I bars represent standard errors (at ap¬
proximately 1, 2, and 3 years in Panels A, B, and C).
HR denotes hazard ratio.
in Supplementary Appendix 2). There was no
interaction between treatment and age, sex, region
of country, baseline FEV^ categorized by disease
stage according to the Global Initiative for Chron¬
ic Obstructive Lung Disease, body-mass index, or
smoking status. Adjusting for exposure to smok¬
ing (pack-years) did not affect the results.
The risk ofdeath in the salmeterol group and
in the fluticasone group did not differ signifi¬
cantly from that in the placebo group (Table 2).
The risk was similar among patients who died
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Variable Mortalityanalysis No.ofdeathsfr mnycause Probabilityfdeatht3yr—%
Placebo Group
(N=1524) 231
Adjustedprobabilityofdeatht3yr—%f COPD-relateddeaths:!: No.ofdeaths Probabilityfdeatht3yr—%
Salmeterol Group (N=1521) 205
Fluticasone Group (N=1534) 246

















































































































Combinationtherapyvs.pl cebo Combinationtherapyvs.salmeterol Combinationtherapyvs.flutica one propionate Salmeterolvs.placebo , Fluticasonepropi natevs.placebo Combinationtherapyvs.pl cebo Combinationtherapyvs.salmeterol Combinationtherapyvs.flutica e propionate Salmeterolvs.placebo Fluticasonepropi natev .placebo Combinationtherapyvs.placebo Combinationtherapyvs.salmeterol Combinationtherapyvs.flutica one propionate Salmeterolvs.placebo Fluticasonepropi atevs.placebo
Rateio(95%CI) 0.75(0 69-0.81) 0.88(0 81-0.95) 0.91(0 84-0.99) 0.85(0.78-0.93) 0.82(0.76-0.89) 0.57(0.51-0.64) 0.71(0 63-0.79) 0.87(0 78-0.98) 0.80(0.72-0.90) 0.65(0.58-0.73) 0.83(0 71-0.98) 1.02(0.87-1.20) 0.95(0 82-1.12) 0.82(0 69-0.96) 0.88(0 74-1.03)
fortheprimaryendpointa epr vi ed
<0.001 0.002 0.02 <0.001 <0.001 <0.001 <0.001 0.02 <0.001 <0.001 0.03 0.79 0.56 0.02 0.10
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while receiving a study medication (data not
shown) and those who died from COPD-related
causes (Fig. 2C). The risk of death in the combi¬
nation-therapy group did not differ significantly
from that in the salmeterol group, but patients
receiving the combination regimen were less
likely to die than those receiving fluticasone
propionate (hazard ratio for death, 0.774 [95% CI,
0.641 to 0.934]; P=0.007). Overall, 27% of the
deaths were adjudicated as due to cardiovascular
causes, 35% to pulmonary causes, and 21% to
cancer (for other causes of death, see Table 3 in
Supplementary Appendix 2).
EXACERBATIONS, HEALTH STATUS, AND LUNG
FUNCTION
According to our statistical models, the annual
rate of exacerbations was 0.85 (95% CI, 0.80 to
0.90) in the combination-therapy group and 1.13
(95% CI, 1.07 to 1.20) in the placebo group, result¬
ing in a rate ratio for exacerbations of 0.75 (95%
CI, 0.69 to 0.81; P<0.001), which is a reduction of
25% and corresponds to a number needed to treat
of four to prevent one exacerbation in 1 year. An¬
nual rates ofexacerbations in the salmeterol group
and the fluticasone group were significantly lower
than in the placebo group (Table 2). Overall, 26%
of the patients were hospitalized at least once dur¬
ing the 3-year study period. Annual admission
rates were 17% lower in the combination-therapy
and salmeterol groups than in the placebo group
(P<0.03) (Table 2), corresponding to a number
needed to treat of 32 to prevent one hospitaliza¬
tion in 1 year.
Total scores on the St. George's Respiratory
Questionnaire initially improved from baseline in
all groups, with the greatest changes occurring
in the combination-therapy group (mean score at
baseline, 48.7, with a mean reduction of 3.0 units
averaged over 3 years), as compared with the
placebo group (a mean score of48.4 at baseline,
with an increase of 0.2 unit in the placebo group)
(Fig. 2D and Table 3). Similarly, for lung function,
the mean baseline FEVj in the combination-
therapy group was 1.236 liters with an average
increase of 0.029 liter, whereas in the placebo
group, the mean baseline FEV1 was 1.257 liters
and a decrease of0.062 liter. Averaged over 3 years,
the health status (a reduction of 3.1 units in the
score for the St. George's Respiratory Question¬
naire) and spirometric measurements (an increase
in FEVj of 0.092 liter) in the combination-therapy
group were significantly better than in the groups
receiving placebo, salmeterol alone, or fluticasone
propionate alone (Fig. 2E and Table 3).
ADVERSE EVENTS AND SAFETY
Adverse events were reported by 90% of the pa¬
tients in the study, and serious adverse events were
reported by 41% of the patients (Table 4). (For
mortality data for the safety population, see Fig. 1
and Table 4 in Supplementary Appendix 2.) The
most frequently reported adverse event was an
exacerbation ofCOPD. The probability of having
pneumonia reported as an adverse event during
the 3-year study period was significantly greater
among patients receiving a study medication con¬
taining fluticasone propionate: the probabilitywas
19.6% in the combination-therapy group, 12.3%
in the placebo group, 13.3% in the salmeterol
group, and 18.3% in the fluticasone group (P<0.001
for the comparison between both the combina¬
tion-therapy and fluticasone groups and the pla¬
cebo group). Among patients receiving study med¬
ications, there were 8 deaths from pneumonia in
the combination-therapy group, 7 in the placebo
group, 9 in the salmeterol group, and 13 in the
fluticasone group. There was no significant dif¬
ference in the probability of fractures among the
groups (6.3% in the combination-therapy group,
5.1% in the placebo group, 5.1% in the salmet¬
erol group, and 5.4% in the fluticasone group).
There was no excess of cardiac disorders among
patients treated with the combination regimen or
salmeterol alone (reported event rates per study
year, 0.087 in the combination-therapy group,
0.113 in the placebo group, 0.114 in the salmet¬
erol group, and 0.102 in the fluticasone group).
In the safety substudy, there were no significant
differences in bone mineral density or in the num¬
bers of patients in whom cataracts developed be¬
tween the groups receiving active study drugs
and the placebo group (Table 4).
DISCUSSION
In this trial, the reduction in mortality from any
cause in the combination-therapy group, as com¬
pared with the placebo group, did not meet the
predetermined level ofstatistical significance. Dur¬
ing the 3 years of the study, treatment with the
combination regimen resulted in significantly
fewer exacerbations and improved health status
and lung function, as compared with placebo.
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There are two possible reasons why the re¬
duction in mortality in the combination-therapy
group, as compared with the placebo group, did
not achieve statistical significance. The first is
that there is no effect of salmeterol plus flutica¬
sone propionate on survival. In this scenario, the
data would suggest that the observed symptom¬
atic and functional improvement derives from
mechanisms other than those that prolong life.
It could be that mortality is influenced mainly by
factors that are currently unidentified and unre¬
sponsive to therapy with salmeterol plus flutica¬
sone propionate.
The second possible reason, which we believe
is the more likely one, is that salmeterol plus
fluticasone propionate does have an effect on
mortality but that our study was underpowered
to detect this effect. Our power calculations were
based on the Inhaled Steroids in Obstructive Lung
Disease in Europe (ISOLDE) study, and there were
fewer deaths in the placebo group than antici¬
pated.14'17 The TORCH study was designed to have
90% power to detect an effect of 4.3 percentage
points on overall mortality; in practice, we iden¬
tified a reduction of 2.6 percentage points. In ad¬
dition, there was a high withdrawal rate, which
was highest among patients in the placebo group,
who were free to receive active therapy subsequent¬
ly. Furthermore, performing the second interim
analysis so close to the final analysis increased
the threshold required for significance. More stud¬
ies are needed to determine whether either of
these explanations or another explanation ac¬
counts for the primary finding.
Our data on the secondary outcomes are con¬
sistent with and extend previous observations in
studies using combinations of inhaled cortico¬
steroids and long-acting beta-agonists19"21 in show¬
ing that the combination regimen reduced exacer¬
bations significantly, as compared with placebo,
including those exacerbations requiring hospital¬
ization. The combination regimen was also signif¬
icantly better than each of its components alone
in preventing exacerbations, and these benefits
were accompanied by sustained improvements in
health status and FEV,; the values for both were
better at the end of the trial than at baseline.
Unlike previous studies in which reductions in
exacerbations and improvements in health status
have also been reported,19'21 in our study there
was no requirement of exacerbations during the
year before entry into the trial. Furthermore, the
greater number of patients withdrawing from
the placebo group is likely to have resulted in an
underestimation of the effect of the combination
regimen on all the secondary outcomes. Neverthe¬
less, the number needed to treat to prevent an ex¬
acerbation in 1 year was 4, and the number needed
to treat to prevent a hospitalization was 32.
An important safety finding, identified because
the size of the study was sufficient to detect in¬
frequent events, was the excess of patients who
received a diagnosis of pneumonia among those
receiving study medications containing flutica¬
sone propionate. This finding had not been pre¬
viously reported in studies involving the use of
inhaled corticosteroids by patients with COPD.
Since the finding was unexpected, there was no
prospective definition ofpneumonia in the study
protocol (e.g., confirmation on chest radiogra¬
phy). However, this finding was observed in the
different subgroups, which suggests that it may
be an important signal whose mechanism is cur¬
rently unclear and requires further study. The
increase in pneumonia did not appear to repre¬
sent an increase in the number of deaths. As de¬
termined by the independent clinical end-point
committee, among deaths attributed to pneumo¬
nia in patients in the safety population while they
were receiving a study medication, there was one
more death in the combination-therapy group
and six more in the fluticasone group than in the
placebo group.
The increase in oropharyngeal side effects
among patients receiving fluticasone propionate
or the combination regimen was expected, but
there was no evidence of excess cardiac events
among those receiving salmeterol alone or the
combination regimen. The total number of frac¬
tures, including those associated with minimal
trauma or none, did not differ significantly among
the four groups. This finding was in keeping with
the absence ofa significant difference among the
groups in bone mineral density among patients
in the U.S. substudy. The prevalence of cataracts
at baseline in all the study groups was high, but it
was not influenced by treatment during the course
of the study. However, exposure to the study
medications for 3 years may not be long enough
to detect differences in the occurrence of frac¬
tures and eye disorders.
The TORCH study recruited patients with COPD
from around the world, and we think that our
findings can therefore be generalized. The par-
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Table 4. Adverse Events among 6184 Patients in the Safety Population and 658 Patients in the Substudy ofBone Mineral
Density.
Placebo Salmeterol Fluticasone Combination-
Group Group Group Therapy Group
Adverse Event (N = 1544) (N = 1542) (N = 1552) (N = 1546)
Reported during treatment—% of patients
Any event 90 90 90
:
89
Serious event 41 40 42 43
Drug-related event 13 12 vf;\::i9 18 :i:i'
Event resulting in withdrawal or discontinuation of study 24 20 23 18
medication
Total exposure to study medication— yr 3278 3531 3555 ■ 3700
Most commonly reported event during treatment— rate per yr
COPD exacerbation 0.92 0.76 0.78 0.67
Upper respiratory tract infection 0.10 0.08 0.09 0.11
Nasopharyngitis 0.09 0.09 0.10 0.10
Pneumonia 0.04 0.04 0.07 0.07
Bronchitis 0.05 0.05 0.05 0.05
Headache 0.08 0.06 0.06 0.05
Back pain 0.04 0.04 0.04 o.04' .
Sinusitis 0.03 0.03 0.04 0.04
Cough 0.03 0.03 ; ^ 0.04 Ti\ 0-03
Hypertension 0.03 0.03 0.03 0.02
Additional events associated with the use ofcorticosteroids —
rate per yr
Candidiasis 0.02 0.02 0.09 0.07
Dysphoria 0.004 0.005 0.017 0.028
Of specific interest during treatment—% of patients*
Pneumonia 12.3 13.3 18.3-j- ; 19.6:1:
Fractures
Total 5.1 5.1 5.4 6.3
Nontraumatic 1.8 2.5 1.7 1.7
: Eye disorders 3.6 4.3 4.1 5.2 ;
Safety substudy
Cataracts;)
None at baseline— no. of patients/total no. 47/164 41/166 47/163 52/165
Developed during treatment—no. ofpatients/total no. (%) 10/47 (21) 6/41 (15) 8/47 (17) 14/52 (27)
Bone mineral density^
1 lip — no. of patients/total no, 52/164 78/166 65/163 82/165
Change from baseline— %|| -3.1 -1.7 -2.9 -3.2
Lumbarspine—no. of patients/total no. 50/164 76/166 63/163 81/165
Change from baseline— %\\ 0 1.5 -0.3 -0.3
* Probability was calculated by the Kaplan-Meier method.
"j" PcO.OOl for the comparison between the fluticasone group and the placebo group.
:j; P<0.001 for the comparisons between the group receiving salmeterol plus fluticasone propionate and the placebo
group and between the combination-therapy group and the salmeterol group.
S Patients who had cataracts at baseline were not included in the subsequent analysis.
^1 Patients included in the analysis were those for whom measurements of bone mineral density at baseline and at 158
weeks were available.
|| The percentage of change was calculated as [(ratio of bone mineral density at week 158 to the value at baseline) -1]
multiplied by 100.
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ticular strengths of the study are the virtually
complete survival data to 3 years and the inde¬
pendent adjudication of causes of death, which
eliminated between-country variation in death
certification. Although the TORCH study is a large
COPD trial, as compared with studies ofmortal¬
ity associated with other major chronic illnesses
such as cardiovascular disease,22"24 its size is mod¬
est. The results of our mortality analysis should
be viewed in this context. The potential for a
reduction in the risk of death of 2.6 percentage
points among patients treated with salmeterol
plus fluticasone propionate, as compared with
placebo, and the 17.5% reduction in the risk of
death that was identified in the study clearly
merit further investigation in future large, pro¬
spective trials. Until such trials are completed,
our data support the use of salmeterol plus fluti¬
casone propionate in the clinical management
of COPD.
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Effect of Pharmacotherapy on Rate of Decline of Lung
Function in Chronic Obstructive Pulmonary Disease
Results from the TORCH Study
Bartolome R. Celli1, Nicola E. Thomas2, Julie A. Anderson2, Gary T. Ferguson3, Christine R. Jenkins4,
Paul W. Jones5, Jorgen Vestbo6'7, Katharine Knobil2, Julie C. Yates8, and Peter M. A. Calverley9
Wufts University School of Medicine, Pulmonary and Critical Care Division, Caritas-St. Elizabeth's Medical Center, Boston, Massachusetts;
2Respiratory Medicines Centre, GlaxoSmithKline, Creenford, Middlesex, United Kingdom; 3Pulmonary Research, Institute of Southeast Michigan,
Livonia, Michigan; 4Woolcock Institute of Medical Research, Camperdown, New South Wales, Australia; 5Division of Cardiac and Vascular Science,
St George's University of London, London, United Kingdom; 6Cardiology and Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark; 7North
West Lung Centre, Wythenshawe Hospital, Manchester, United Kingdom; 8Respiratory Medicines Centre, GlaxoSmithKline, Research Triangle Park,
North Carolina; and department of Medicine, University Hospital Aintree, Liverpool, United Kingdom
Rationale: Chronic obstructive pulmonary disease (COPD) is charac¬
terized by an accelerated decline in lung function. No drug has been
shown conclusively to reduce this decline.
Objectives: In a post hoc analysis of theToward a Revolution in COPD
Health (TORCH) study, we investigated the effects of combined
salmeterol 50 p,g plus fluticasone propionate 500 pg, either compo¬
nent alone or placebo, on the rate of post-bronchodilator FEV,
decline in patients with moderate or severe COPD.
Methods: A randomized, double-blind, placebo-controlled study was
conducted from September 2000 to November 2005 in 42 countries.
Of 6,112 patients from the efficacy population, 5,343 were included
in this analysis.
Measurements and Main Results: Spirometry was measured every
24 weeks for 3 years. There were 26,539 on-treatment observations.
The adjusted rate of decline in FEVt was 55 ml/year for placebo,
42ml/year for salmeterol, 42ml/yearforfluticasone propionate, and
39 ml/year for salmeterol plus fluticasone propionate. Salmeterol
plus fluticasone propionate reduced the rate of FEV, decline by 16ml/
year compared with placebo (95% confidence interval [CI], 7-25; P<
0.001). The difference was smaller for fluticasone propionate and
salmeterol compared with placebo (13 ml/year; 95% CI, 5-22; P =
0.003). Rates of decline were similar among the active treatment
arms. FEV, declined faster in current smokers and patients with
a lower bodymass index, and varied betweenworld regions. Patients
who exacerbated more frequently had a faster FEV, decline.
Conclusions: Pharmacotherapy with salmeterol plus fluticasone pro¬
pionate, or the components, reduces the rate of decline of FEVt in
patients with moderate-to-severe COPD, thus slowing disease pro¬
gression.
Clinical trial (GSK Study Code SC030003) registered with www.
clinicaltrials.gov (NCT00268216).
Keywords: FEV-,; salmeterol: fluticasone propionate; disease progression
Chronic obstructive pulmonary disease (COPD), a major cause
of morbidity worldwide (1), is characterized by airflow obstruc¬
tion, as determined by the ratio of the forced expiratory volume
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
The decline in FEVX has been accepted as a key marker for
progression of chronic obstructive pulmonary disease
(COPD). To date, smoking cessation is the only interven¬
tion that has conclusively been shown to alter the rate of
decline in FEVi.
What This Study Adds to the Field
This study shows that pharmacotherapy with combined
salmeterol 50 pg plus fluticasone propionate 500 pg, or
either component alone, can reduce the rate of decline of
FEV! in patients with moderate-to-severe COPD, thus
slowing disease progression.
in one second (FEVi) and forced vital capacity (FVC). Disease
progression has been assessed using the rate of FEVi decline,
which is greater than normal in COPD (2, 3). To date, smoking
cessation is the only intervention that has conclusively been
shown to alter the rate of decline in FEVi (4).
While the pathogenesis of COPD is complex, studies suggest
that airway inflammation plays an important role in disease
progression (3, 5, 6). The intensity of inflammation relates to the
degree of airflow obstruction (5), and may result from oxidant-
induced damage. However, neither the antioxidant drug N-acetyl
cysteine nor the nonspecific antiinflammatory effects of inhaled
corticosteroids have been shown to modify the rate of decline in
FEV! (7-11). Meta-analyses of the inhaled corticosteroid (ICS)
studies have yielded conflicting results (12-14). Salmeterol and
other long-acting (3-agonists are highly selective bronchodilators
that have been shown to improve lung function, dyspnea, and
health status in relatively short-term studies (15, 16). However,
their possible long-term effect on rate of decline in FEVi has
never been evaluated. It has recently been shown that the
administration of an ICS combined with a long-acting P-agonist
modifies the expression of inflammation in mucosal biopsies and
sputum of patients with COPD (6), raising the possibility that
this pharmacologic combination could have an effect on the rate
of decline of lung function.
The Toward a Revolution in COPD Health (TORCH) study
investigated the effect of salmeterol/fluticasone propionate
(SFC) and either component alone compared with placebo on
mortality, as well as the impact on the rate of exacerbations,
health-related quality of life, and postbronchodilator FEVi. The
primary efficacy analysis has already been published (17). The
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original report concentrated on the effect of therapy on mor¬
tality as the primary outcome, and presented the mean effect on
lung function over 3 years as a supportive analysis, without
addressing the change in the rate of FEV, decline, a variable
that has been accepted as a reasonable surrogate marker for
disease progression.
Before treatment unblinding, we decided to test the hypoth¬
esis that pharmacotherapy would modify the rate of decline of
postbronchodilator FEV,, compared with placebo. We also
conducted an exploratory analysis of the factors that could af¬
fect FEVj rate of decline, since an association has been re¬
ported between frequency of exacerbation and an increased
rate of decline of FEV], (18, 19). Some of these results have
been previously reported in the form of an abstract (20).
METHODS
Design Overview
Details of the TORCH study design have been published elsewhere
(17, 21). TORCH was a multi-center, randomized, double-blind,
parallel-group, placebo-controlled study. All corticosteroids and in¬
haled long-acting bronchodilators were stopped before the run-in
period, but other COPD medications were allowed. After a 2-week
run-in period, eligible patients were stratified by smoking status and
randomized to receive either SFC 50/500 p.g, salmeterol (SAL) 50 peg,
fluticasone propionate (FP) 500 pig, or placebo twice daily for 3 years
via a Diskus/Accuhaler inhaler (GlaxoSmithKline, Greenford, UK)
(see online supplement).
The primary efficacy endpoint of TORCH was all-cause mortality
at 3 years. Other efficacy endpoints included rate of exacerbations (see
online supplement), health status, and post-bronchodilator spirometry
every 24 weeks.
Setting and Participants
Details of the study settings and patient inclusion and exclusion criteria
have been published previously (17). All patients gave informed
consent and the study was approved by ethical review boards and
conducted in accordance with the Declaration of Helsinki. For this
analysis we included all patients with a baseline and at least one on-
treatment FEV,.
Randomization and Interventions
Full details of the randomization procedure have been reported
previously (17, 21).
Outcomes and Follow-up
In this report, the primary outcome was the rate of post-bronchodilator
FEV, decline. At visit 1 (start of the 2-wk run-in period), the highest of
three acceptable measurements of FEV, was recorded before, and 30
minutes after, inhalation of 400 pg albuterol as recommended by the
ATS (22). Reversibility was calculated as a percentage of the predicted
normal FEV, (23). Patients refrained from using short-acting bron¬
chodilators for at least 6 hours, and long-acting (32 agonists (LABA) for
at least 12 hours, before visit 1. At visit 2 (baseline) and every 24 weeks
thereafter, post-bronchodilator measurements of FEV, were obtained
(before which subjects were not required to withhold their COPD
medication).
Spirometers were regularly calibrated according to manufacturer
recommendations and a calibration log was kept. Lung function data
were reviewed centrally during the study and queried if values differed
significantly in consecutive visits (criteria used for the query are
published in the online supplement). After completion of the study,
the variability of the spirometric values was assessed by analyzing the
variance of individual regression slopes and comparing them with those
obtained in the ISOLDE trial (11), in which spirometric measurements
were the primary endpoint and were closely monitored.
Statistical Analysis
The study was powered on the primary endpoint of all-cause mortality,
as described previously (17,21), and was not formally powered for the
analysis of rate of decline in FEVi.
The effect of treatment on rate of decline of absolute FEV,,
percentage change in a year and as percentage of predicted FEV,
was analyzed using a random coefficients model, including terms for
treatment, time on treatment in years, treatment by time interaction,
and covariates of smoking status, sex, age, baseline FEV,, region (see
Table 2 footnote for countries included in each region), and body mass
index (BMI). This methodology was the same as that used in other
landmark studies, which assessed rate of decline in lung function in
COPD (9-11). To derive the percentage change in a year, the
logarithm of FEV, was analyzed. To eliminate immediate improve¬
ments, the decline was evaluated from 24 weeks onward (the time at
which the first on-treatment measurement was made). The effects of
covariates on the rate of FEV, decline were investigated using this
model as exploratory analyses, including the covariate by time in¬
teraction individually for smoking status, sex, age, baseline percentage
predicted FEV,, region, ethnic origin, BMI, previous exacerbation
history, and baseline St George's Respiratory Questionnaire (SGRQ).
We also tested whether the treatment effect on the rate of decline was
consistent for subgroups by including a treatment-by-covariate-by-time
interaction individually in this model.
A further analysis was performed by calculating individual patient
slopes from the regression analysis of each subject's FEV, values and
applying ANCOVA to these slopes. At least two on-treatment FEV,
measurements were required for this analysis.
In addition, we report exploratory summary statistics of individual
patient slopes categorized by number of exacerbations reported during
the study, and by whether subjects survived or died during the 3 years
of the study. All analyses were performed on an intention-to-treat basis
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Figure 7. Modified patient dispo¬
sition diagram and analyses pop¬
ulations, based on full CONSORT
diagram published in the study
by Calverley and coworkers (17).
FP = fluticasone propionate; SAL =
salmeterol; SFC = salmeterol/flu-
ticasone propionate combination.
Modified by permission from Ref¬
erence 17.
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TABLE 1. BASELINE* CHARACTERISTICS OF SUBJECTS WITH AT LEAST ONE ON-TREATMENT FEV,,
INCLUDED IN THE ANALYSIS OF FEV, DECLINE
Characteristic Placebo (n = 1,261) SAL (n = 1,334) FP (r? = 1,356) SFC (n = 1,392)
Mean age (SD), yr 64.8 (8.2) 64.9 (8.2) 64.9 (8.4) 64.9 (8.3)
Male, n (%) 976 (77) 1,029 (77) 1,026 (76) 1,049 (75)
Mean body mass index (SD), kg/m2 25.5 (5.2) 25.4 (5.2) 25.3 (5.0) 25.4 (5.3)
Current smoker, n (%) 563 (45) 600 (45) 596 (44) 601 (43)
Baseline post-bronchodilator FEV, (SD), ml 1,257 (444) 1,231 (431) 1,233 (437) 1,236 (455)
% predicted post-bronchodilator FEV, (SD) ml 45.0 (13.0) 44.3 (13.3) 44.8 (1 3.3) 44.7 (13.4)
Region, n (%)
United States 271 (21) 290 (22) 299 (22) 312 (22)
Asia Pacific 1 70 (13) 175 (1 3) 177(13) 175 (13)
Eastern Europe 257 (20) 270 (20) 270 (20) 273 (20)
Western Europe 387(31) 410 (31) 412 (30) 433 (31)
Other 176 (14) 189 (14) 198 (15) 199 (14)
Definition of abbreviations: CI = confidence interval; FP = fluticasone propionate; SAL = salmeterol; SFC = salmeterol/
fluticasone propionate combination.
* Baseline was at randomization visit.
using SAS software version 8.2 (SAS Institute, Inc., Cary, NC) on
a Unix platform. For the principal analyses, a threshold for statistical
significance was set at 0.05. For the effect of covariates on the slopes,
which were exploratory analyses, the threshold was set at 0.10.
Role of the Funding Source
Funding for the TORCH study was provided by GlaxoSmithKIine. The
TORCH Steering Committee, comprising six academics and three
representatives of the sponsor, developed the design and concept,
approved the statistical plan, had full access to and interpreted the




A total of 6,112 patients composed the efficacy population of
TORCH. Of these, 5,343 (87%) had at least one on-treatment
FEV, and were included in the decline analysis (Figure 1). The
characteristics of these patients at baseline are shown in Table
1. The number of patients was smaller in the placebo compared
with the active treatment arms because more patients withdrew
within the first 24 weeks from the placebo arm (17% in placebo
compared with 12% in the SAL and FP arms, and 9% in the
combination arm). During the study, 187 (3%) patients took
tiotropium while on study medication (44 [3%] placebo, 62
[4%] SAL, 40 [3%] FP, and 41 [3%] SFC).
Rate of Decline of FEV,
A total of 26,539 on-treatment observations were available for
the analysis. The maximum number of on-treatment measure¬
ments a patient could contribute to the estimation of the rate
of FEV, decline was 6, and 64% of patients contributed this
number. The average number of measurements was 5, with only
19% of patients having 3 or fewer, primarily due to early
withdrawal or death. In the placebo arm, patients withdrawing
before the end of the study had a faster rate of decline (76 ml/
year) compared with those completing the trial (54 ml/year).
The rate of absolute decline of FEV, for each arm is
summarized in Table 2, and that of % predicted FEV] is shown
in Table 3. Figure 2 shows the adjusted means and standard
errors at each visit and fitted lines from the random coefficients
model of FEV]. The rate of decline of FEV, was slowest in
patients on SFC and fastest in those randomized to the placebo
arm. From Week 24 onwards, the adjusted rate of decline in
FEV] was 39 ml/year for SFC, 42 ml/year for both SAL and FP
and 55 ml/year for placebo, a reduction of 16 ml/year with SFC
compared with placebo (P < 0.001), and 13 ml versus placebo
for both FP and SAL (P = 0.003) (Figure 2). These treatment
differences remained when the values were expressed as %
predicted FEV] (Table 3) or as percentage of the baseline value
(where the rate of decline was 3%/yr for SFC, 4%/yr for SAL
and FP, and 5%/yr for placebo). In addition, the analysis of
individual regression slopes produced similar findings. The
standard deviations of individual regression slopes were similar
in all treatment groups ranging from 160 to 180 ml/year. These
values are similar to those observed in the ISOLDE trial
(166 ml/yr for FP and 187 ml/yr for placebo).
Effect of Covariates on FEV] Slopes of Rate of Decline
A slower rate of decline in absolute ml/year was observed in
former smokers, females, patients 65 years and older, and those
with FEV] less than 30% predicted. Patients with a BMI greater
TABLE 2. ADJUSTED YEARLY RATE OF DECLINE IN FEV, BY TREATMENT GROUP
Placebo (n = 1,261) SAL (n = 1,334) FP (n = 1,356) SFC (n = 1,392)
Adjusted rate of decline (SE), ml/yr -55.3 (3.2) -42.3 (3.1) -42.3 (3.1) -39.0 (3.0)
Active treatment minus placebo (SE), ml/yr - 13.0 (4.4) 13.0 (4.4) 16.3 (4.4)
95% CI - 4.3, 21.7 4.3, 21.7 7.7, 24.9
P value - 0.003 0.003 < 0.001
SFC minus components (SE), ml/yr - 3.3 (4.3) 3.3 (4.3) -
95% CI - -5.1, 11.7 -5.1, 11.6 -
P value - 0.441 0.445 -
Definition of abbreviations: CI = confidence interval; FP = fluticasone propionate; SAL = salmeterol; SFC = salmeterol/
fluticasone propionate combination.
Random coefficients model including smoking status, sex, age, baseline FEV], region, body mass index (BM I), treatment, time,
and treatment by time.
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TABLE 3. ADJUSTED YEARLY RATE OF DECLINE IN % PREDICTED FEV, BY TREATMENT GROUP
Placebo (n = 1,261) SAL (n = 1,334) FP (n = 1,356) SFC (n = 1,392)
Adjusted rate of decline (SE), %/yr -1.5 (0.1) -1.0 (0.1) -1.1 (0.1) -0.9 (0.1)
Active treatment minus placebo (SE), %/yr - 0.5 (0.2) 0.4 (0.2) 0.6 (0.2)
95% CI - 0.2, 0.8 0.1, 0.8 0.3, 0.9
P value - 0.002 0.006 < 0.001
SFC minus components (SE),%/yr - 0.1 (0.2) 0.1 (0.2) -
95% CI - -0.2, 0.4 -0.2, 0.4 -
P value - 0.627 0.401 -
For definition of abbreviations, see Table 3.
Random coefficients model including smoking status, sex, age, baseline % predicted FEV,, region, body mass index (BMI),
treatment, time, and treatment by time.
than or equal to 25 showed a slower decline in lung function
(Table 4).The rate of decline in patients from the Asia Pacific
and Eastern Europe regions was slower than that of patients
from the other regional groups. These relationships were pre¬
served when the rate of FEVX decline was expressed as a
percentage change in a year for all of these covariates except
sex, where there was no difference, and in patients with FEVi
less than 30% predicted (see Table El in the online supple¬
ment). In this group of patients, the FEVX declined by 28 ml/
year, compared with 47ml/year for the other patients (Table 4),
but when this change was expressed as a percentage of baseline
(4%/yr) it was within the range of the other groups (4.4%/yr
and 3.3%/yr for 30-49% and & 50% predicted FEVi, respec¬
tively; Table El).
The effect of treatment on FEVi decline was similar irre¬
spective of smoking status, sex, age, baseline FEVi, region of
the world, ethnicity, BMI, previous exacerbations, and baseline
SGRQ. The differences between placebo and the treatment
arms were unaffected by whether the patients had taken ICS or
LABA in the 12 months before the study (Tables E2 and E3).
We observed no association between previous exacerbation
history based on patient recall and FEVi decline (Table 4).
However, there appeared to be an association between number
No. of patients
Placebo 1261 1248 1128 1049 979 906 819
SAL 1334 1317 1218 1127 1054 1012 934
FP 1356 1346 1230 1157 1078 1006 908
SFC 1392 1375 1281 1180 1139 1073 975
Figure 2. Adjusted means at each visit and rate of decline (mi/yr) in
post-bronchodilator FEV-, by treatment (random coefficients model).
The slope over time was calculated from Week 24 to Week 156, as
indicated by the arrows, and was significantly steeper in the patients
receiving placebo versus those receiving active therapies. FP = flutica¬
sone propionate; SAL = salmeterol; SFC = salmeteroi/fluticasone
propionate combination. *P =s 0.003 compared with placebo. Note:
Vertical bars represent standard errors of the adjusted means at each
visit. The number of patients at each clinic visit with FEVi measure¬
ments is shown below the graph.
of exacerbations documented during the duration of the study
and the rate of decline of FEV! (see Table 5), with higher rates
of decline being evident in patients experiencing more exacer¬
bations.
DISCUSSION
COPD is characterized by airflow obstruction, which is usually
progressive (2, 3), and hence, the measured decline in FEV, has
been accepted as a key marker for disease progression and
a target for therapeutic trials. The longitudinal analysis of lung
function from the TORCH data set presented here is the first to
identify significant reductions in FEVj decline in those patients
receiving active treatment.
The normal rate of FEV! decline in healthy subjects is
approximately 30 ml/year (24, 25). The modeled rate of decline
in post-bronchodilator FEVi in patients receiving placebo in
TORCH was 55 ml/year; similar to that seen in the Lung Health
Study 1 (-52 ml) (26), Lung Health Study 2 (-47 ml) (10),
BRONCUS (-54 ml) (7), and ISOLDE studies (-59 ml) (11),
and slightly lower than in EUROSCOP (-69 ml) (9), where the
baseline FEVi was higher and all randomized subjects were
current smokers. We identified a significantly lower rate of de¬
cline in FEVi (by 13-16 ml/yr) in those patients receiving active
therapy. Rate of decline was similar among the three active
treatment arms of the study. Although treatment did not abolish
the accelerated decline in lung function, it did ameliorate it
substantially, decreasing the excess FEVi decline attributable to
historically obtained values in patients with COPD (27).
All three treatments showed improvements in post-broncho¬
dilator FEVi relative to placebo at each visit, but the mecha¬
nism responsible for the effect on rate of decline is not clear, as
all treatments have potentially significant nonbronchodilator
effects (6, 28, 29). Whether the maintenance of airway patency
and reduction in hyperinflation, improvements in mucociliary
clearance, or decreases in airway inflammation contribute singly
or together to produce the observed functional change cannot
be determined in TORCH, and further mechanistic studies are
needed. The results of the forthcoming UPLIFT trial, where
a long-acting bronchodilator drug tiotropium is compared with
placebo with lung function decline as its primary outcome, may
help clarify mechanisms, since tiotropium is a bronchodilator
without primary antiinflammatory action (30, 31).
In the TORCH trial, there were significant reductions in
exacerbations in all treatment arms, with the greatest reductions
observed with the SFC combination (17). This is consistent with
our data, in which treatment decreased the rate of decline in
FEVi and this effect was greatest in patients receiving SFC.
There was an association between exacerbation frequency
documented during the study and FEVi decline, supporting
previous observations (18, 19) (Table 5). However, in patients
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Smoking status P < 0.001
Current (n = 2,630) 2,360 1,300 (457) -55.0 (2.3)
Former (n = 3,482) 2,983 1,191 (424) -36.6 (2.1)
Sex P = 0.027
Female (n = 1,481) 1,263 1,019 (339) -38.5 (3.2)
Male (n = 4,631) 4,080 1,307(448) -46.6 (1.8)
Age, yr P < 0.001
<55 (n = 701) 633 1,473 (542) -51.7 (4.3)
55-64 (n = 1,972) 1,746 1,284 (455) -51.3 (2.6)
65-74 (n = 2,670) 2,323 1,172 (391) -39.5 (2.4)
s 75 (n = 769) 641 1,125 (360) -36.7 (4.7)
% Predicted FEV, P < 0.001
< 30 (t7 = 937) 778 711 (160) -28.4 (4.3)
30-49 (n = 3,019) 2,630 1,114 (264) -47.2 (2.2)
s50 (n = 2,156) 1,935 1,620 (395) -47.0 (2.5)
Region P < 0.001
United States (n = 1,388) 1,172 1,205 (451) -49.4 (3.4)
Asia Pacific (n = 758) 697 1,045 (400) -30.7 (4.2)
Eastern Europe (n = 1,154) 1,070 1,341 (435) -38.2 (3.3)
Western Europe (n = 1,908) 1,642 1,307 (423) -50.9 (2.8)
Other (n = 904) 762 1,178 (441) -48.4 (4.2)
Ethnic Origin P < 0.001
White (n = 5,006) 4,338 1,278 (439) -48.1 (1.7)
Black (n = 95) 83 1,139 (429) -43.4 (1 3.1)
Asian (n = 769) 705 1,046 (400) -30.6 (4.2)
American Hispanic (n = 193) 173 1,107 (468) -22.4 (8.4)
Other (n = 49) 44 1,121 (333) -46.8 (17.4)
BMI P < 0.001
<20 (n = 824) 719 1,024 (393) -51.1 (4.4)
20 to <25 (n = 2,301) 2,003 1,195 (427) -50.5 (2.5)
25 to < 29 (n = 1,642) 1,424 1,316 (440) -42.1 (2.9)
3=29 (n = 1,345) 1,197 1,351 (358) -35.1 (3.2)
Exacerbations in the year before study P = 0.800
0 (n = 2,626) 2,314 1,282 (439) -45.8 (2.3)
1 (n = 1,513) 1,340 1,244 (447) -44.5 (3.1)
3= 2 (n = 1,973) 1,689 1,176 (435) -43.4 (2.8)
Baseline SGRQ Total Score P = 0.122
<38 (n = 1,427) 1,140 1,381 (431) -43.0 (3.3)
38 to < 50 (n = 1,276) 992 1,251 (418) -42.0 (3.6)
50 to <62 (n = 1,135) 964 1,180 (430) -53.0 (3.7)
3= 62 (n = 1,120) 966 1,144 (426) -47.5 (3.9)
Definition of abbreviations: BMI = body mass index; SCRQ = St George's Respiratory Questionnaire.
Random coefficients model including smoking status, gender, age, baseline FEV,, region, body mass index (BMI), prior
exacerbations, treatment, time and treatment by time, and covariate by time (the term for covariate by time was added one at
a time to the multivariate model including all the covariates).
was significantly faster in the placebo group compared with
active treatments (56 ml/yr versus 27-31 ml/yr), which suggests
that the effect of treatment on exacerbations was not the sole
mechanism responsible for the reduced rate of decline with
active treatment.
Our results confirm those of previous studies, which have
shown that smoking status, age, and baseline percent predicted
FEV, affect the rate of lung function decline (32). However, our
data extend these observations in the Lung Health Study
population to patients with more severe COPD. In addition,
we have identified two novel factors associated with FEV,
decline, specifically BMI and region of origin, although these
could also be due to differences in height. Together with already
known variables such as baseline lung function, smoking status,
and exacerbation frequency, they may help explain between-
subject differences in FEV, decline. Lung function declined
TABLE 5. SUMMARY OF INDIVIDUAL FEV, REGRESSION SLOPES BY EXACERBATION RATE
Placebo (n = 1,137) SAL (n = 1,232) FP 500 (n = 1,242) SFC (n = 1,292) Total (n = 4,903)
N Mean Slope SD n Mean Slope SD n Mean Slope SD n Mean Slope SD n Mean Slope SD
Moderate/severe exacerbation
(rate per annum)
0 294 -55.6 184.7 341 -29.3 192.9 309 -30.7 208.2 362 -26.9 225.4 1,306 -34.9 204.4
> 0 to 1.0 421 -59.1 144.9 475 -43.2 128.5 467 -47.8 122.7 499 -42.2 1 35.4 1,862 -47.7 132.9
> 1.0 422 -64.2 213.8 416 -55.3 164.7 466 -52.6 155.4 431 -58.8 170.2 1,735 -57.6 176.8
Definition of abbreviations: FP = fluticasone propionate; SAL = salmeterol; SFC = salmeterol/fluticasone propionate combination.
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least (35 ml/yr) in patients with a BMI of 29 or higher, was
higher in patients with BMI between 25 and 29 (42 ml/yr), but
was greatest in patients with a baseline BMI below 25 (51 ml/yr).
This suggests an important association between systemic con¬
sequences of the disease and disease progression in the lungs
(33, 34), but does not necessarily indicate causality. Interest¬
ingly, patients from the Asia Pacific and Eastern Europe
regions, as well as patients of Asian and American Hispanic
ethnic origins, had a slower rate of decline compared with
Western Europeans and North Americans, even when expressed
as percentage change in FEVr. This may be related to the fact
that patients in Asia Pacific and Eastern Europe had lower
mean FEVj absolute and percent predicted at baseline (Table
E4), thus providing less capacity for FEVj to decline over
time. Alternatively, other factors yet unexplored such as ge¬
netic, socioeconomic, or environmental differences may be
important.
Female patients lost FEVr at a slower rate than that of male
patients, a result similar to that reported in the long-term
follow-up of the Lung Health Study (4). Women who quit
smoking in that study lost an average of 22 ml/year, compared
with men who lost an average of 30 ml/year. In the smokers, the
values were 54 and 66 ml/year, respectively. In this TORCH
dataset, women lost 39 ml/year, whereas men lost 47 ml/year
irrespective of smoking status. This difference disappeared
when the rate of decline was expressed as a percentage change
in a year, with women losing 4.2% versus 3.9% per year for
men. These results suggest that the sex difference was related to
airway size rather than intrinsic biologic differences in the
progression of COPD.
There were some limitations to our study. As in other long-
term COPD trials (35, 36), many patients failed to complete the
study, with significantly more withdrawing from the placebo
limb. Moreover, those withdrawing showed more rapid de¬
terioration in lung function, a finding noted by others (37). This
preferential dropout in the placebo arm of those patients whose
function worsens more rapidly (evidenced by the greater de¬
cline in patients who withdrew early compared with those who
completed) actually minimizes the differences observed in rate
of FEVj decline. In addition, the random coefficients model
(11) gives most weight to patients who complete the trial, and
hence, the differences in lung function decline we report may be
conservative estimates of the true treatment effect. We are
confident that our principal findings are reliable, since they
were consistent whether expressed in ml/year or as percentage
change per year. It has been suggested that changing the usual
therapy of the patient with COPD can influence the results of
interventional studies (38). This was not the case in TORCH,
where prior therapy with ICS or LABA was unrelated to the
beneficial effect of therapy on the rate of FEVr decline.
Another limitation of the study was that the FEV) was not
a primary outcome in this mortality trial. However, postbron-
chodilator lung function was extensively measured, and the
more than 26,000 spirometric assessments obtained over the
3 years of the study provided a unique opportunity to evaluate
how lung function evolved in patients randomized to different
treatments.
A theoretical limitation was the less rigorous monitoring of
spirometry compared with other trials primarily evaluating lung
function decline. However, the standard deviation of our FEVr
measurements was comparable with that in previous studies, in
which spirometry was performed more frequently and using
more rigorous quality control (10, 11). These data suggest that
measuring postbronchodilator spirometry in a larger number of
patients, as in TORCH, compensated for any inherent between-
tests variability in FEVj.
In summary, we have shown for the first time that pharma¬
cologic therapy slows the decline in lung function in patients
with COPD. Given the progressive nature of COPD, halving of
the excess decline in FEVj is likely to be clinically important in
patients such as those who participated in TORCH.
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Articles I
Roflumilast in symptomatic chronic obstructive pulmonary
disease: two randomised clinical trials
Peter M A Calverley*, Klaus F Rabe*, Udo-Michael Coehring, Soren Kristiansen, Leonardo M Fabbrit, FernandoJ Martinez t, for the M2-124 and
M2-125 study groupst
Summary
Background The phosphodiesterase-4 inhibitor roflumilast can improve lung function and prevent exacerbations in
certain patients with chronic obstructive pulmonary disease (COPD). We therefore investigated whether roflumilast
would reduce the frequency of exacerbations requiring corticosteroids in patients with COPD.
Methods In two placebo-controlled, double-blind, multicentre trials (M2-124 and M2-125) with identical design that
were done in two different populations in an outpatient setting, patients with COPD older than 40 years, with severe
airflow limitation, bronchitic symptoms, and a history of exacerbations were randomly assigned to oral roflumilast
(500 pg once per day) or placebo for 52 weeks. Primary endpoints were change in prebronchodilator forced expiratory
volume in 1 s (FEV,) and the rate ofexacerbations that were moderate (glucocorticosteroid-treated) or severe. Analysis
was by intention to treat. The trials are registered with ClinicalTrials.gov, number NCT00297102 for M2-124, and
NCT00297115 for M2-125.
Findings Patients were assigned to treatment, stratified according to smoking status and treatment with
longacting P2 agonists, and given roflumilast (n=1537) or placebo (n=1554). In both studies, the prespecified primary
endpoints were achieved and were similar in magnitude. In a pooled analysis, prebronchodilator FEV, increased by
48 mLwith roflumilast compared with placebo (p<0 • 0001). The rate ofexacerbations that were moderate or severe per
patient per year was 1-14 with roflumilast and 1-37 with placebo (reduction 17% [95% CI 8-25], p<0-0003). Adverse
events were more common with roflumilast (1040 [67%]) than with placebo (963 [62%]); 219 (14%) patients in the
roflumilast group and 177 (12%) in the placebo group discontinued because of adverse events. In the pooled analysis,
the difference in weight change during the study between the roflumilast and placebo groups was -2 • 17 kg.
Interpretation Since different subsets ofpatients existwithin the broad spectrum ofCOPD, targeted specific therapies
could improve disease management. This possibility should be explored further in prospective studies.
Funding Nycomed.
Introduction
Chronic obstructive pulmonary disease (COPD) is
increasing in prevalence; it is associated with periodic
exacerbations, resulting in patient anxiety,1 worsening
health status, lung function decline, and increase in
mortality rate." Effective management involves pharma¬
cological and non-pharmacological treatments.5 Longacting
inhaled bronchodilator drugs ((3, agonists and anti¬
cholinergic drugs) can improve health status and reduce
the frequency of exacerbations, effects that are greater
when longacting fl2 agonists are used in combination with
inhaled corticosteroids." However, there is a need for
further improvement ofCOPD therapy.
Phosphodiesterase-4 (PDE4) inhibition provides a novel
approach to the treatment of COPD. Drugs that inhibit
PDE4 have a wide range of anti-inflammatory actions in
vitro and in vivo.10"12 Roflumilast, a new PDE4 inhibitor,
reduces airway inflammation in COPD, as assessed with
sputum neutrophil and eosinophil counts." However,
although roflumilast improved lung function, it did not
significantly reduce the frequency of exacerbations in
unselected patients with severe COPD.14 The results of a
post-hoc analysis of this study suggested that roflumilast
reduced the rate of exacerbations in patients with severe
airflow obstruction, frequent exacerbations, and those
requiring oral steroids."
To find outwhether PDE4 inhibitors can have any effect
on clinical outcomes in COPD, we tested the hypothesis
that roflumilast reduces the rate of exacerbations




Study M2-124 was done in 246 centres in ten countries,
and study M2-125 was done in 221 centres in eight
countries (webappendix p 12).
Patients
For both studies, we recruited participants from an
outpatient setting if they met inclusion criteria—ie, were
former smokers or current smokers with at least a
20 pack-year history, older than 40 years, and had a clinical
diagnosis of COPD (confirmed with a postbronchodilator
[albuterol 400 pg] forced expiratory volume in 1 s
[FEV,]/forced vital capacity [FVC] ratio <70%) and chronic
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cough and sputum production. Their postbronchodilator
FEVj was 50% or less than the predicted value. All patients
had at least one recorded COPD exacerbation requiring
systemic glucocorticosteroids or treatment in hospital, or
both, in the previous year. Exclusion criteria are shown in
thewebappendix (p 11); use oftheophyllinewas not allowed
from the start of the run-in period.
The studies were approved by local ethical review
committees and done in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines. All
patients provided written informed consent.
Interventions
Each trial had an initial 4-week run-in, during which
patients took a placebo tablet once a day in the morning,
and recorded their use ofshortacting bronchodilator drugs,
and production of cough and sputum on their daily diary
cards (webappendix p 23). In this initial study phase,
patients, but not investigators, were unaware of the
treatment they were assigned to. Patients were then
randomly assigned to oral roflumilast 500 pg once a day or
placebo, taken in themorning for the subsequent 52 weeks,
provided that the total of their cough and sputum scores
was greater than 14 in the week before randomisation, the
haemoccult (guaiac) test during the baseline period was
negative, at least 80% of prescribed placebo tablets were
taken, and patients were clinically stable. Patients could
use shortacting (32 agonists as needed and could continue
treatment with longacting |32 agonists or shortacting
anticholinergic drugs at stable doses. However, inhaled
corticosteroids and longacting anticholinergic drugs were
not allowed during the study. Eligible patients were
stratified according to their use of longacting (32 agonists
and smoking status.
Randomisation and masking
The sponsor generated a randomisation list of patient
random numbers using a pseudorandom number
generator. The investigator used an automated, interactive
voice response system to randomly assign patients. In the
double-blind treatment phase, all individuals involved in
the studies were unaware of treatment assignment—tablets
were identical in appearance. The investigator or anyone at
the study site was prevented from knowing the allocation
sequence with code labelling. The sponsor and clinical
research associate were notified if there was a clinical
reason for an individual's treatment to be unmasked by the
investigatorwith the interactive voice recognition system.
Figure l.Trial profiles ofM2-124 (A) andM2-125 (B)
COPD=chronic obstructive pulmonary disease. *ln the M2-124 study, one patient
was randomly assigned twice and given study medication twice.The first patient
numberwas included in the intention-to-treat and safety analyses, whereas the
second patient numberwas only included in the safety analysis. Four patients
assigned to placebowere given roflumilast instead (at least once) andwere
included in the roflumilast group for safety analyses. In the M2-125 study,
six patients randomly assigned to placebowere given roflumilast instead
(at least once) andwere included in the roflumilast group for safety analyses.
tPatients might have providedmore than one reason fordiscontinuation.
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M2-124 M2-125 M2-124 and M2-125
Roflumilast (n-765) Placebo (n=758) Roflumilast (n=772) Placebo (n=796) Roflumilast (n=1537) Placebo (n=1554)
Age (years)* 64(10) 63(9) 64(9) 64(9) 64(9) 64(9)
Men 540(71%) 538 (71%) 610 (79%) 648(81%) 1150(75%) 1186 (76%)
Cigarette pack-year*t 48 (24) 46 (23) 49(26) 47(24) 48 (25) 47(23)
Smoking status*
Current smoker 365 (48%) 361(48%) 270(35%) 282 (35%) 635 (41%) 643 (41%)
Former smoker 400(52%) 397(52%) 502(65%) 514(65%) 902 (59%) 911 (59%)
Prebronchodilator FEV, (L)t 107(0-4) 1-06 (0-4) 0-95 (0 3) 0-98 (0 4) 1-01 (0-4) 1-02 (0-4)
Postbronchodilator FEV, (L)t 116 (0-4) 1-15(0-4) 1-05 (0 4) 1-07(0-4) 1-10 (0-4) 1-11(0-4)
Prebronchodilator FEV, (% of predictedjt 34-7(10-2) 34-6 (10-3) 31-4(10-1) 32-2 (10-8) 33-0 (10 3) 33-4(10-6)
Postbronchodilator FEV, (% of predictedjt 37-6 (10-7) 37-5 (10-4) 34-6(10-3) 35-3 (10-9) 36-1 (10-6) 36-4(10-7)
Postbronchodilator FEV,/FVC (%)t 43-3 (11 6) 42-7(11-0) 41-2(10-7) 41-3(10-8) 42-3 (11-2) 42-0 (10-9)
COPD severity*;)f[
Severe 486 (64%) 510(67%) 457(59%) 479 (60%) 943 (61%) 989(64%)
Very severe 199 (26%) 184(24%) 264(34%) 256 (32%) 463(30%) 440 (28%)
Body-mass index (kg/m')t 26-4 (5-5) 26-0(5-5) 25-2 (6 2) 25-4(5-9) 25-8 (5 9) 25-7(5-7)
C-reactive protein (mg/L)* 8-1 (14-0) 7-2(12-5) 8-3(14-6) 9-2 (17-6) 8-2 (14-3) 8-2 (15-4)
Concomitant treatment with longacting
P, agonistsjl
378 (49%) 385(51%) 371 (48%) 408 (51%) 749 (49%) 793 (51%)
Concomitant treatment with shortacting
anticholinergics!!
240(31%) 245 (32%) 297(38%) 324(41%) 537(35%) 569(37%)
Concomitant treatmentwith shortacting
P, agonists!!
761(99%) 753 (99%) 769 (100%) 791(99%) 1530 (100%) 1544 (99%)
Pretreatmentwith inhaled corticosteroids** 338 (44%) 335 (44%) 312 (40%) 322 (40%) 650(42%) 657(42%)
Ethnic origin
Asian 1 (<1%) 1(<1%) 174(23%) 179 (22%) 175 (11%) 180 (12%)
Native American 0 1(<1%) 2 (<1%) 1 (<1%) 2 (<1%) 2 (<1%)
Black 11 (1%) 15(2%) 8(1%) 14(2%) 19(1%) 29(2%)
White 737(96%) 732(97%) 559(72%) 568 (71%) 1296 (84%) 1300 (84%)
Other 16 (2%) 9(1%) 29(4%) 34(4%) 45(3%) 43 (3%)
Data are number (%) or mean (SD). FEV,=forced expiratory volume in Is. FVC=forced vital capacity. COPD=chronic obstructive pulmonary disease. *Measurements were taken at the beginning of the run-in
period, tl pack-year=20 cigarettes per day for 1 year. {Measurements were taken at baseline. $Based on the criteria of the Global initiative for chronic Obstructive Lung Disease. {[Percentages do not add up to
100% because patientswith mild or moderate COPD are not shown. |[8asedon whether the patient had used medications at least oncewithin the start and up to the end of the treatment period inclusive.
**Based on whether the patient had used inhaled corticosteroids at least once within the period starting the day after the first visit until the day before randomisation, inclusive.
Table 1: Demographics and baseline characteristics of the intention-to-treat populations in the M2-124 and M2-125 trials
After randomisation, patients were assessed every
4weeks up to week 12 and every 8 weeks thereafter. At each
visit, spirometric measurements were recorded before and
15-45 min after administration of bronchodilator (inhaled
albuterol 400 pg). Additionally, we recorded any new
exacerbations or adverse events, the patient's bodyweight,
adherence to tablets, completeness of the daily diary
records, use of shortacting (32 agonists, and investigator-
administered transition dyspnoea index (TDI),1S and
dispensed study medication.
Study endpoints
The primary endpoints were the change in pre-
bronchodilator FEV, during treatment and the rate of
COPD exacerbations, defined as moderate if they
required oral or parenteral corticosteroids, or severe if
they were associated with admission or death. Key
secondary outcomes included the postbronchodilator
FEV, (change from baseline during treatment), time to
death from any cause, natural log-transformed C-reactive
protein concentration (a possible marker of systemic
inflammation in COPD;16 change from baseline to study
end) and TDI focal score (during treatment). A change
of one unit in the TDI focal score was considered
clinically significant. Additionally, data for the total
number of COPD exacerbations (as defined above
together with episodes treated with antibiotics alone)
and a range of spirometric outcomes were gathered. As
part of a planned health economic analysis (data for
subsequent presentation), patients completed the
Euroquol 5-dimension (EQ-5D) questionnaire, ameasure
ofhealth utility, at each visit.17






































Time (weeks) Time (weeks)
Number at risk* Number at risk*
Roflumilast 765 739 674 633 606 574 547 519 491 Roflumilast 772 740 674 647 611 579 560 547 520
Placebo 758 740 707 678 632 603 571 543 518 Placebo 796 770 740 716 672 643 602 573 541
Figure 2: Probability of treatmentdiscontinuation in roflumilast and placebo groups in trials M2-124 (A) and M2-125 (B)
*Number ofpatients still at risk at the beginning of the respective week; number at risk might be different from the number completing the study because the
protocol allowed patients to finish the study up to 7 days before the end ofweek 52.
Bodyweight was measured with the same scales at each
visit, height was measured with a stadiometer, and body-
mass index (BMI) was calculated. At weeks 28 and 52
after randomisation, blood samples were taken for
routine haematology and biochemistry tests, and an
electrocardiogram (ECG) was done. In study M2-125,
24-h Holter monitoring was undertaken at 19 sites to
identify any arrhythmias.
Statistical analysis
With the exception of the post-hoc investigation of
adverse events and bodyweight, all reported efficacy
analyses were prespecified in the intention-to-treat
population. Data are presented as mean and SD, unless
otherwise indicated. On the basis of an assumption of a
mean exacerbation rate of 1 • 25 per patient per year in the
placebo group and 1-00 in the roflumilast group, and
using a Poisson regression model, with a correction for
overdispersion of2 based on previous data,"we estimated
that 750 patients per treatment group in each trial would
provide 90% power to detect a significant difference
between treatments with a two-sided a level of 0-05. A
negative binominal regression analysis was done to
assess the robustness of the results against the
distributional assumptions.
Data were analysed in the two studies separately and in
a pooled analysis. We analysed changes from baseline in
prebronchodilator and postbronchodilator FEV, using a
repeated-measures analysis of covariance with all data
available for patients during the 52-weelc treatment.18 A
Cox proportional hazard model was used to test for
differences in time-to-event data. For analysis of the
concentrations of C-reactive protein, an analysis of
covariance model was used, with the method of the last
observation carried forward for the log-transformed data
for concentrations.
For the regression models (analysis of covariance,
Cox, and Poisson), the covariates included treatment,
age, sex, smoking status (current or former smoker),
country, and treatment with longacting (5, agonists. In
the Cox analysis, country was included as a stratum. In
the Poisson regression analysis, baseline post¬
bronchodilator FEV, (% of predicted value) was also
included as a covariate. To address the issue ofmultiple
comparisons, a hierarchical hypothesis-testing approach
was adopted. If the primary outcomes were positive, the
key secondary outcomes were tested in the order above.
If a significant difference between treatments was not
obtained for the primary or key secondary outcomes, all
subsequent analyses were considered exploratory. No
interim analyses were done in either study before
unmasking. However, several statistical analyses were
preplanned and done to assess the robustness of the
results with respect to the effect ofdifferential dropouts
and missing data. Adverse events were analysed with
descriptive statistics and 95% CIs for the differences
between treatments.
The trials are registeredwith ClinicalTrials.gov, number
NCT00297102 for M2-124, and NCT00297115 for M2-125.
Role of the funding source
All authors (academic investigators [PMAC, KFR, LMF,
and FJM] and employees of the sponsor [U-MG and
SI<]) had full access to and interpreted the data, and were
responsible for the decision to publish the report. The
sponsor did not place any restrictions on the academic
authors about the statements made in the final report.
Results
Patient recruitment began in February, 2006, and the
studies ended in July, 2008. In the M2-124 study,
1523 patients were randomly assigned and treated
(figure 1A). In M2-125, 1568 patients were randomly
assigned and treated (figure IB). Four patients in
M2-124 and six in M2-125 were given roflumilast rather
than placebo and are included in the treated group for













Roflumilast 764743 667 625 604 571 542 517 499 Roflumilast 772 730 669 637 606 581 558 544 525
Placebo 758 744 694 667 633 600 566 537 521 Placebo 796762 725 708 673 641 601 565 551
Postbronchodilator Postbronchodilator
Roflumilast 757 728 661622 598 569 540 510 497 Roflumilast 769725 666 635 604 577 554 543 525












Figure 3: Prebronchodilator and postbronchodilator forced expiratory volumes in 1 s (FEV,) over 52 weeks in patients in roflumilast and placebo groups in trials M2-124 (A) and M2-125 (B),
and changes in prebronchodilator and postbronchodilator FEV1 over 52 weeks in patients in roflumilast and placebo groups in trials M2-124 (C) and M2-125 (D)
The changes from baseline that could be calculated from the crude means shown in (A) and (B) are different from the changes from baseline (based on adjusted means) shown in (C) and (D): adjusted
means are based on a repeated-measures analysis of covariance, including factors and covariables that might have an effect on the crude means. Error bars are SE. Number ofpatients at risk for the
baseline value (week 0) is not equal to the number of patients in the intention-to-treat population (table 1) because some patients did not have a baseline value according to the definition from the
statistical analysis plan. Two patients in the roflumilast group left the study during the last visit but were classified as non-completers because they did not undergo all investigations; hence the
number ofpatients with FEVi measurements at the last visit is greater than the number of completers in figure IB. *Number ofpatients with data available; number of patients reported here differs
from the number at risk in figure 2 because some patients did not have their lung function measured at the end of the study, whereas others who did not complete the study had their lung function
measured at week 52.
the safety analysis. Table 1 shows the demographic and
baseline characteristics of the patients who took at least
one dose of study medication. The only difference
between the trials was the proportion ofAsian patients.
The mean prebronchodilator FEV, was between 31%
and 35% of predicted value in the different study
subgroups; 40-44% had used inhaled corticosteroids
previously, whereas about 50% used longacting
(12 agonists during the trials (table 1).
Patient withdrawal was similar in the roflumilast and
placebo groups (35% and 31%, respectively, in M2-124,
and 32% and 31%, respectively, in M2-125; figure 1).
However, more patients in the roflumilast group than in
the placebo group withdrew in the first 12 weeks after
randomisation (figure 2A and 2B). Adherence to
treatment was similar in all groups: mean compliance
was 93% (SD 25) in the roflumilast group and 95% (14)
in the placebo group in the M2-124 study, and 93% (16)
in the roflumilast group and 96% (15) in the placebo
group in the M2-125 study.
The primary endpoints were achieved in both studies.
Figure 3 (A to D) shows the FEV, data during the studies;
table 2 shows the summary results. In the pooled analysis,
prebronchodilator FEV, increased from baseline in the
roflumilast group and decreased in the placebo group
(table 2). The postbronchodilator FEV,, a secondary
outcome variable, increased significantly from baseline
with roflumilast compared with placebo in both studies
and in the pooled analysis (table 2). Prebronchodilator
FVC was significantly greater with roflumilast than with
placebo in both studies (table 2). Similar significant
improvements were seen in postbronchodilator FVC and
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M2-124 M2-125 M2-124and M2-125
Roflumilast Placebo Roflumilast vs Roflumilast Placebo Roflumilast vs Roflumilast Placebo Roflumilast vs
placebo placebo placebo
Lung function*
Change in prebronchodilator 46 (8); 8 (8); Difference 39 (18 33(7); -25(7); Difference 58 (41 40(6); -9(5); Difference 48
FEV, (mL) n=745 n=745 to 60); p=0-0003 n=730 n=766 to 75); p<0-0001 n=1475 n=1511 (35 to 62); p<0-0001
Change in postbronchodilator 57(9); 8(8); Difference 49 (26 44(7); -17(7); Difference 61 50(6); -4(6); Difference 55
FEV, (mL) n=729 n=736 to71);p<0-000l n=724 n=764 (44 to 79); n=1453 n=1500 (41 to 69); p<0-0001
p<0-0001
Change in prebronchodilator 68(15); -21 (15); Difference 89 (51 60 (14); -48(14); Difference 108 (75 64(10); -34(10); Difference 98
FVC(mL) n=745 n=745 to 127); p<0-0001 n=730 n=766 to 141); p<0-0001 n=1475 n=1511 (73 to 123); p<0-0001
Change in 76(15); -25(15); Difference 101 (63 58(13); -45(13); Difference 103 (72 67 (10); -35 (10); Difference 101 (77 to
postbronchodilator FVC (mL) n=729 n=736 to 139); p<0-0001 n=724 n=764 to 134); p<0-0001 n=1453 n=1500 126); p<0-0001
Change in prebronchodilator 0-314 0-001 Difference 0-312 0-200 -0-309 Difference 0-510 0-247(0-147); -0-146 Difference 0-393
FEV,/FVC (%) (0 223); (0-219); (-0-262 to 0-886); (0-190); (0-186); (0-061 to 0-958); n=1475 (0-1439); (0-02 8 to 0-758);
n=745 n=745 p=0-2858 n=730 n=766 p=0-026l n=1511 p=0-0350
Change in postbronchodilator 0-488 0-286 Difference 0-202 0-552 -0-115 Difference 0-668 0-517 0090 Difference 0-426
FEV,/FVC (%) (0-211); (0-208); (-0-343 to 0-747); (0-186); (0-182); (0-226 to 1-109); (0-141); (0-138); (0-077 to 0-776);
n=729 n=736 p=0-4674 n=724 n=764 p=0-0031 n=1453 n=1500 p=0-0l69
Change in prebronchodilator 19(5); 2 (5); Difference 17 (3 to 15(5); -10(5); Difference 25 (13 16(4); -4(4); Difference 20
FEF25-75 (mL/s) n=745 n=745 30); p=0-0152 n=730 n=765 to 36); p<0-0001 n=1475 n=1510 (12to29);p<0-0001
Change in postbronchodilator 22(6); 12 (6); Difference 11 (-5 to 21(5); -8(5); Difference 29 (18 21(4); 2(4); Difference 19 (10 to
FEF25-75(mL/s) n=729 n-736 -27); p=0-l809 n=724 n=763 to 40); p<0-0001 n=1453 n=1499 29); p<0-0001
Change in prebronchodilator 6-65 (1-45); 3-58 (1-43); Difference 3-07 0-75(1-45); -3-09(1-41); Difference 3-85 3-69 (1-02); 0-17(0-99); Difference 3-53 (1-01
PEF (L/min) n=745 n=745 (-0-66 to 6-81); n=730 n=766 (0-46 to 7-23); n=1475 n=1511 to 6-04); p=0-0060
p=0-1063 p=0-026l
Change in postbronchodilator 8-08 (1-50); 3-87 (1-48); Difference 4-21 1-93(1-49); -3-14(1-45); Difference 5-07 4-93 (1-05); 0-22 (1-02); Difference 4-72 (2-13
PEF (L/min) n=729 n=736 (0-34 to 8-07); n=724 n=764 (1-60 to 8-53); n=1453 n=1500 to 7-30); p=0-0004
p=0-0328 p=0-0042
Exacerbationsft
Moderate or severe (mean 1-08 1-27 RR 0-85 (0-74 to 1-21 1-49 RR 0-82 (0-71 to 1-14 1-37 RR 0-83 (0-75 to
rate, per patient per year (0-96-1-21); (1-14-1-40); 0-98); p=0-0278 (1-07-1-36); (1-33-1-66); 0-94); p=0-0035 (1-05-1-24); (1-28-1-48); 0-92); p=0-0003
[95% CI]) n=344 n=389 n=373 n=432 n=717 n=821
Severe (mean rate, per 0-11 0-12 RR 0-89 (0-61 to 0-14 0-18 RR 0-77 (0-53 to 0-12 0-15 RR 0-82 (0-63 to
patient per year [95% CI]) (0-07-0-15); (0-09-0-16); 1-29); p=0-5273 (0-10-0-20); (0-13-0-25); 1-11); p=0-l656 (0-10-0-16); (0-12-0-19); 1-06); p=0-1334
n=69 n=8l n=88 n=117 n=157 n=198
Moderate (mean rate, per 0-94 1-11 RRO-84 (0-72 to 1-04 1-27 RR 0-82 (0-71 to 0-99 1-19 RR 0-83 (0-75 to
patient per year [95% CI]) (0-83-1-06); (100-1-25); 0-99); p=0-0325 (0-92-1-18); (1-13-1-42); 0-95); p=0-0075 (0-91-1-08); (1-10-1-29); 0-92); p=0-0007
n=299 n=343 n=325 n=380 n=624 n=723
Treated with systemic 1-10 1-30 RR 0-85 (0-74 to 1-17 1-41 RR 0-83 (0-72 to 1-13 1-35 RR0-84 (0-76 to
corticosteroids, antibiotics, (0-98-1-23); (1-17-1-43); 0-98); p=0-0240 (1-04-1-31); (1-27-1-57); 0-95); p=0-0055 (1-04-1-23); (1-26-1-46); 0-92); p=0-0003
or both (mean rate, per n=336 n=382 n=364 n=4l6 n=700 n=798
patient per year [95% CI])
Median time to first 85-0 71-0 HR 0-88 (0-76 to 73-0 69-5 HR 0-89 (0-78 to 80-0 71-0 HRO-89
exacerbation (moderate or (29 5-185 5) (29-0-152-0) 1-02); p=0-0859 (26-0-195-0) (27-0-169-5) 1-03); p=0-1132 (28-0-190-0) (28-0-160-0) (0-80 to 0-98);
severe; days [IQR]) p=0-0l85
Median time to second 172-0 159-0 (97-0- HR 0-79 (0-64 to 188-0 144-0 HRO-79 (0-65 to 177-0 148-0 HR 0-79
exacerbation (moderate or (102-0-253-0) 229-0) 0-98); p=0-0290 (84-0-281-0) (81-0-239-0) 0-97); p=0-0214 (92-0-262-0) (85-0-236-0) (0-69 to 0-91);
severe; days [IQR]) p=00014
(Continues on next page)
prebronchodilator midexpiratory flow. These changes in
lung function were similar with and without treatment
with longacting P2 agonist (mean prebronchodilator FEV,
increase with longacting (32 agonist, 46 mL [p<0-0001]
and without longacting fi2 agonist, 50 mL [p<0 - 0001]).
In the pooled analysis, the estimated rate of
exacerbations per patient per year that were moderate
or severe was 17% lower in the roflumilast group than
in the placebo group (table 2). These findings were
supported by the negative binomial regression analysis
(data not shown). The difference in rates between
treatments was independent of concomitant longacting
P2 agonist use (p=0-5382, treatment by concomitant
treatment with longacting P2 agonist interaction). The
total number of exacerbations (excluding severe events)
requiring treatment with systemic corticosteroids or
antibiotics, or both, was also lower in the roflumilast
group than in the placebo group (reduction 16%) in the
pooled analysis (table 2). The times to the first and
second episodes ofexacerbations that were moderate or
severe were significantly prolonged (table 2). When the
analysis was restricted to patients who completed the
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Further prespecified secondary analyses
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Data are mean (SE), mean difference (95% CI), or point estimate (95% CI), unless otherwise indicated. n=number of patients with data available (or, for exacerbations, number of patientswith at least one
exacerbation). FEV,=forced expiratory volume in 1 s. FVC=forced vital capacity. FEF=forced expiratory flow. PEF=peak expiratory flow. RR=rate ratio. HR=hazard ratio. TDI=transition dyspnoea index. EQ-
5D=Euroquol 5-dimension. *Least squares means (SE). tEstimated exacerbation rates were based on a Poisson regression model and HRs were based on a Cox proportional hazards model. tSince patients might
have had more than one type of exacerbation, the total ofmoderate and severe exacerbations is different from the total of exacerbations that were moderate or severe.
Table 2: Lung function variables, exacerbations, and other clinical outcomes
trials, similar differences in exacerbation rates were
seen between the groups, although these were not
significant (webappendix p 13).
The preplanned sensitivity analyses confirmed the
robustness of results for the primary endpoints with
respect to the effect of dropouts and missing data
(data not shown).
A total of 84 patients died during the studies. The
mortality rates per year did not differ in the roflumilast
and placebo groups in the M2-124 study (17 [2%] vs
17 [2%]), and in the roflumilast and placebo groups in
the M2-125 study (25 [3%] vs 25 [3%]; hazard ratio for
time to death from any cause was >1 in both
studies; table 2). Baseline concentrations of C-reactive
protein varied widely and did not change significantly
during the study or with treatment. A small improve¬
ment was noted in TDI focal score from baseline
with roflumilast compared with placebo but there
were no differences in total EQ-5D scores (table 2).
Adverse events in the pooled study population were
reported by 1040 (67%) patients in the roflumilast group
and 963 (62%) in the placebo group; serious adverse
eventswere reportedby 301 (19%) and 336 (22%) patients,
respectively. Discontinuations associated with adverse
events were more common in the pooled roflumilast
groups than in the pooled placebo groups (219 [14%] vs
177 [11%]). With the exception of COPD, the most
frequent adverse events leading to discontinuation were
diarrhoea, nausea, and headache in the pooled analysis
(data not shown). The probability ofwithdrawal due to
adverse events in the first 12 weeks was higher in
roflumilast-treated patients (8% in both studies) than in
placebo-treated patients (3% in both studies). The
subsequent probability ofwithdrawal because ofadverse
events was similar between treatments (9% of
roflumilast-treated patients in both studies, and 9% of
placebo-treated patients in both studies).
Vomiting was reported by 17 (1%) patients in the
roflumilast groups and 11 (<1%) in the placebo groups.
More patients in the roflumilast than in the placebo
groups had weight loss (table 3). The mean weight
change was a reduction of 2-09 kg (SD 3-98) with
roflumilast after 1 year and an increase of 0 • 08 kg (3 • 48)
with placebo. The change in weight in the roflumilast
group happened in the first 6 months of treatment and
was attenuated thereafter. Patients in the roflumilast
group reporting diarrhoea, nausea, vomiting, or
headache had greater weight loss than did those not
reporting these symptoms (2-60 kg [3-72] vs
2 02 kg [4-01] ). The largest absolute weight loss with
roflumilast occurred in obese patients (BMI>30;
webappendix p 14). No differences were noted in the
proportion of reported cardiovascular adverse events in
the roflumilast and placebo groups (108 [7%] and
120 [896], respectively). Atrial fibrillation was an
infrequent complication reported by 17 (1%) patients in
the roflumilast groups and 7 (<1%) of those in the
placebo groups. There was no difference between
roflumilast and placebo groups in the occurrence of
rhythm disturbances in 33 and 22 Holter-monitored
recordings, respectively (webappendix p 16). The
incidence of pneumonia or other pulmonary infections
did not increase during treatment with roflumilast (data
not shown).














COPD 70(9%) 82 (11%) -1-76% (-4-90 to 138) 87(11%) 122(15%) -4-26% (-7-74 to -0-78)
Diarrhoea 63 (8%) 26(3%) 4-75% (2-28 to 7-21) 67(9%) 23(3%) 5-70% (3-28to 8-12)
Weight loss 92 (12%) 24(3%) 8-78% (604 to 11-53) 65 (8%) 20(3%) 5-82% (3-46 to 8-18)
Nasopharyngitis 57(7%) 50(7%) 0-79% (-1-91 to 3-49) 35(5%) 47(6%) -1-45% (-3-78 to 0-88)
Upper respiratory tract infection 16 (2%) 21(3%) -0-70% (-2-38 to 0-98) 33(4%) 38 (5%) -0-57% (-2-75 to 1-62)
Headache 26(3%) 17(2%) 1-13% (-0-66 to 2-92) 25(3%) 8 (1%) 2-20% (0-65 to 3-75)
Pneumonia 17(2%) 15(2%) 0-22% (-1-35 to 1-79) 25(3%) 16 (2%) 1-19% (-0-52 to 2-90)
Back pain 27(4%) 22(3%) 0-60% (-l-30to 2-50) 23 (3%) 13(2%) 1-31% (-0-30 to 2-92)
Acute bronchitis 35 (5%) 40(5%) -0-75% (-305 to 1-56) 21 (3%) 24(3%) -0-34% (-2-12 to 1-44)
Nausea 41(5%) 15(2%) 3-34% (1-34 to 5 35) 21(3%) 15 (2%) 0-80% (-0-81 to 2-41)
Hypertension 20 (3%) 28 (4%) -1-11% (-2-99 to 0-78) 18 (2%) 20 (3%) -0-22% (-1-87 to 1-43)
Insomnia 19(2%) 8(1%) 1-41% (-0-04 to 2-86) 18 (2%) 12 (2%) 0-79% (-0-69 to 2-28)
Decreased appetite 21(3%) 2 (<1%) 2-47% (1-13 to 3-81) 15 (2%) 5 (<1%) 1-30% (0-05 to 2-54)
Influenza 27(4%) 18 (2%) 1-13% (-0-70to 2-95) 12(2%) 20(3%) -0-99% (-2-51 to 0-53)
Data are number (%), unless otherwise indicated. Adverse events were reported independently of the investigator causality assessments. Patients might have had more than
one adverse event. COPD=chronic obstructive pulmonary disease, incidence of adverse events in roflumilast-treated patients in study M2-125 is in descending order. tOne
patientwas randomised twice, and included twice in the safety analysis but only once in the efficacy analysis; four patients assigned to placebo were given roflumilast instead
and were included in the roflumilast group for the safety analysis; 765 patients in the roflumilast group and 758 in the placebo group were included in the efficacy analysis.
tSix patients assigned to placebo were given roflumilast instead andwere included in the roflumilast group for safety analysis; 772 patients in the roflumilast group and 796
in the placebo group were included in the efficacy analysis.
Table 3-' Adverse events occurring in at least 2-5% ofpatients in one of the treatment groups
Discussion
Roflumilast reduced exacerbation frequency and induced
consistent and significant improvements in FEV„ both
before and after bronchodilator use. Similar changes
occurred in FVC and midexpiratory flow, suggesting a
general improvement in operating lung volume. These
changes were independent of the patient's smoking status
or use of concomitant medication, such as inhaled
longacting (?2 agonists, and were similar to those reported
in other patient populations with COPD.14"
PDE4 inhibition provides a novel approach to the
treatment of patients with COPD. However, results from
previous studies have shown inconsistent effects ofPDE4
inhibitors on clinically relevant outcomes such as acute
exacerbation frequency, although results from a post-hoc
analysis suggested that roflumilast might be effective in
selected patients with COPD." The results from the
M2-124 and M2-125 studies show that carefully defined
patient groups that are particularly at risk ofexacerbations
benefit from treatment with roflumilast.
The effects of roflumilast in our proposed subgroups,
which should be easily identified clinically, were tested
in these two adequately powered studies with an
identical design, undertaken in two geographically
different populations. Participants in both studies were
preselected for specific characteristics identified from
earlier trials.'" They had substantial airflow limitation
(stages III and IV according to the criteria of the Global
initiative for chronic Obstructive Lung Disease),
documented cough and sputum production as a marker
for persistent airway inflammation,20 and a history of
exacerbations treated in the year before entry into the
study.
Many clinical trials identify patient subgroups that seem
to respond to treatment in a secondary or post-hoc analysis,
which is not confirmed in studies that are better powered.21
In an earlier study, roflumilast did not reduce overall exac¬
erbation rate but decreased the number of exacerbations
requiring oral corticosteroids.14 Data from our two studies
confirmed this finding. Treatment with inhaled
corticosteroids has been shown to prevent exacerbations,
including those that are subsequendy managed with oral
corticosteroids.7'22 The same holds true for treatment with
roflumilast. A direct comparison of the effect of inhaled
steroids or roflumilast on reduction of exacerbations can¬
not be directly assessed with the present data, but is worth
investigation in the future. The rate ofexacerbations in our
placebo-treated patients was higher than in previous
studies, with few episodes being treated with antibiotics
alone, possibly because of our study design and patient
recruitment. As in other 1-year trials in patients with
COPD, roflumilast did not have much effect on episodes
requiring treatment in hospital,21-25 which were infrequent.
In our studies, the number ofpatients needed to treatwith
roflumilast to prevent one exacerbation per year that was
moderate or severe was 5-29 in the M2-124 study and
3-64 in the M2-125 study, irrespective of concurrent
treatment with an inhaled longacting fS2 agonist.
Several secondary outcomes were assessed. Mortality
rate during treatment did not differ between treatments
www.thelancet.com Vol 374 August 29,2009
and was similar to other events during treatment in the
first year ofa large COPD survival trial.7 The concentration
ofC-reactiveproteinwas unaffected by treatment. However,
the use of this marker in cardiorespiratory disease has
been questioned.76 Small but significant improvements in
breathlessness assessed by the investigator-administered
TDI occurred in both studies, but did not reach the agreed
minimum clinically important difference. Whether this
result indicates that the benefit of treatment with roflumi-
last is predominantly on prevention ofexacerbations rather
than improvement of exercise performance, or is a result
of the selection criteria used will require further study.
Since we allowed patients to continue using inhaled
longacting (32 agonists throughout the study, and inhaled
corticosteroids were withdrawn at entry, no conclusions
can be drawn about synergy or interaction between
roflumilast and other drugs; further studies will be needed
to testspecifically the effectiveness ofinhaledcorticosteroids
alone or in combination with roflumilast. Whether the
effects of roflumilast are additive to longacting inhaled
bronchodilators is addressed by Fabbri and colleagues.27
For practical reasons, the effect of roflumilast on
breathlessness was tested rather than assessment of the
global health status. In general, health status improves
when the exacerbation rate falls by the magnitude seen
here,28-7' but confirmation of this association by means ofa
disease-specific instrument is needed for roflumilast.
Changes in health status were not seen in the previous
1-year roflumilast study and the general health measure
EQ-5D did not seem to identify differences in the data.14
The health-care utilisation definition ofexacerbations used
in this study cannot precisely define the duration ofevents
and might miss mild episodes.30"37 In other studies with
daily diary cards, substantially more events have been
identified than in our studies, including many events that
were not treated with corticosteroids or antibiotics. The
results ofa previous study have suggested that mild events
associatedwith increased symptoms and use ofshortacting
P2 agonists could be prevented with roflumilast;1' the
reduction in use of shortacting (I2 agonists that was noted
in our studies supports this finding. Since roflumilast is an
anti-inflammatory drug, we focused on its ability to change
corticosteroid-treated exacerbations. There were fewer
antibiotic-treated episodes than expected, possibly
indicating the way investigators interpreted the study
protocol. Interpretation of the data has been complicated
by the pattern ofpatient withdrawal in these trials, which
differed between treatment groups in the early and late
phases. In general, this pattern would tend to result in a
minimum biological effectofthe active therapy by reducing
the statistical power of the study comparisons. In
accordance with good clinical trial practice, we focused on
recruiting patients likely to adhere to treatment and, thus,
caution is needed when generalising these findings to the
general clinical population.
No significant neurological or cardiac toxicity was noted
with roflumilast. A range of predicted adverse events
occurred with roflumilast that were centrally mediated
(insomnia, nausea, headache, but not vomiting) or
gastrointestinal (predominantly diarrhoea). These were
most evident in the first 4-12 weeks of treatment when
they contributed to the early difference in withdrawal in
both studies. Thereafter, no difference was noted between
treatment groups in the occurrence ofthese adverse events
and the withdrawals associated with them. Patients
reported weight loss more frequently in the roflumilast
groups than in the placebo groups, a finding confirmed by
objective measurements. The mean weight loss of
2 ■ 1 kg (SD 4- 0) over the course ofthe study was greatest in
the first 6 months of roflumilast treatment. Patients
reporting gastrointestinal or neurological symptoms lost
more weight, but weight loss was still seen in patients
without these side-effects. The change in bodyweight was
similar irrespective of initial BMI and might not be an
unwelcome treatment effect in obese patients who showed
the largest absolute weight loss. We did not notice the
occurrence of more pneumonias among patients in the
roflumilast groups than among those in the placebo
groups, whereas pneumonia was reportedmore frequently
with inhaled corticosteroids in studies with similar patient-
years of treatment exposure to our studies.33 This increased
frequency suggests that pneumonia might relate to local
effects of inhaled corticosteroids rather than representing
a general outcome of treatment with anti-inflammatory
drugs in patients with COPD.
Our results from these clinical trials with identical
design that were done in two different populations have
shown that roflumilast, a PDE4 inhibitor, improves lung
function and reduces the frequency of exacerbations in
patients with bronchitic symptoms and severe airflow
limitation. It should be noted that this treatment is not
suitable for all patients because of the presence of class-
related adverse effects that usually arise soon after
initiation of treatment. Nonetheless, these results suggest
that different subsets of patients exist within the broad
range ofCOPD, and that specific therapies might improve
disease management. This possibility should be explored
further in prospective studies.
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The Effect of Helium and Oxygen on Exercise v.
Performance in Chronic Obstructive Pulmonary Disease
A Randomized Crossover Trial
Elizabeth A. Laude, Nicholas C. Duffy, Chloe Baveystock, Beatriz Dougill, Michael J. Campbell, Rod Lawson,
Paul W. Jones, and Peter M. Calverley
Respiratory Medicine, Royal Hallamshire Hospital; Department of General Practice and Primary Care, ScHARR; Biomedical Science, University
of Sheffield, Sheffield; Clinical Sciences, University Hospital Aintree, Liverpool; St. George's, University of London, London; and BOC Ltd.,
Guildford, United Kingdom
Rationale: Breathing supplemental oxygen reduces breathlessness
during exercise in patients with chronic obstructive pulmonary dis¬
ease (COPD). Replacing nitrogen with helium reduces expiratory
flow resistance and may improve lung emptying. Combining these
treatments should be independently effective.
Objectives: Study the effect of changing oxygen or helium concentra¬
tion in inspired gas during exercise in patients with stable COPD.
Methods: In 82 patients (mean age, 69.7 yr; mean FEV,, 42.6% pre¬
dicted), we measured endurance shuttle walking distance, resting
and exercise oxygen saturation, and end-exercise dyspnea (Borg
scale) while patients breathed Heliox28 (72% He/28% 02), Heliox21
(79% He/21% 02), Oxygen28 (72% N2/28% 02), or medical air
(79% N2/21% 02). Gases were administered using a randomized,
blinded, crossover design via a face mask and an inspiratory demand
valve.
Results: Breathing Heliox28 increased walking distance (mean ± SD,
147 ± 150m) and reduced Borg score (-1.28 ± 1.30) more than any
other gas mixture. Heliox21 significantly increased walking distance
(99 ± 101 m) and reduced dyspnea (Borg score, -0.76 ± 0.77)
compared with medical air. These changes were similar to those
breathing Oxygen28. The effects of helium and oxygen in Heliox28
were independent. The increase in walking distance while breathing
Heliox28 was inversely related to baseline FEV, breathing air.
Conclusion: Reducing inspired gas density can improve exercise per¬
formance in COPD as much as increasing inspired oxygen. These
effects can be combined as Heliox28 and are most evident in pa¬
tients with more severe airflow obstruction.
Keywords: chronic obstructive pulmonary disease; exercise capacity;
helium; oxygen
Chronic obstructive pulmonary disease (COPD) is associated
with impaired exercise capacity, which contributes significantly
to a reduced quality of life in these patients (1). Several physio¬
logic mechanisms limit exercise performance in COPD, but ab¬
normal lung mechanics predominate. Unlike in healthy subjects,
end-expiratory lung volume increases during exercise in patients
with COPD (2). This relates to the intensity of self-reported
breathlessness during exercise and is thought to result from
expiratory flow limitation during tidal breathing (3).
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In general, treatments improve lung emptying or decrease
ventilatory requirement during exercise. Bronchodilator drugs
reduce dynamic hyperinflation (4) and surgical lung volume re¬
duction decreases static lung volumes (5). Both increase exercise
capacity. Breathing supplementary oxygen during exercise sig¬
nificantly increases self-paced walking distance (6) and endur¬
ance time during cycle ergometer endurance exercise by reducing
ventilatory demand (7-9). Similar changes occur during pulmo¬
nary rehabilitation where oxygen breathing can increase the
ability to undergo training (10).
An alternative therapeutic approach would be to change the
physical characteristics of the inspired gas by replacing nitrogen
with the lower density gas helium. This should reduce airway
resistance by decreasing turbulent flow (11) and improve respira¬
tory gas exchange (12). This approach has been used with some
benefit in the intensive care unit (13,14), but the use of helium/
oxygen gas mixtures (heliox) to increase exercise capacity has
produced conflicting results in the small numbers of patients
with COPD of varying severity studied (14-18).
We hypothesized that replacing nitrogen with helium would
increase exercise capacity and reduce exercise-induced breath¬
lessness in patients with stable COPD by a mechanism different
to that operating when breathing supplementary oxygen. Hence,
the effects of combining the two treatments would be indepen¬
dent of each other. Because expiratory flow limitation and the
resulting turbulent air flow at high levels of ventilation will be
most marked in those with severe COPD, we also hypothesized
that the effects of changing the gas density would be greatest
in the most severely obstructed patients. To test these hypothe¬
ses, we conducted a randomized, crossover, factorial trial to
allow us to identify the independent contribution of each gas to
dyspnea and exercise capacity improvement and have sufficient
power to carry out subgroup analyses based on disease severity.




We studied patients with a diagnosis of COPD (21) confirmed by an
FENq/FVC ratio less than 0.7, an FEV] less than 80% predicted, and
limited bronchodilator reversibility. All patients complained of exer¬
tional dyspnea, defined by a Borg score (22) after exercise of 3 or more,
and had no history of recent exacerbation. All patients were ex-smokers
who continued their usual medication throughout the study. The proto¬
col was approved by the local research ethics committees, and patients
gave written, informed consent.
Measurements
Spirometry was performed breathing room air using standard criteria
(23). Exercise capacity was determined using the endurance shuttle
walking test (ESW), performed as described previously (24). An incre¬
mental shuttle walking test was performed initially to establish the
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walking speed corresponding to 85% of the estimated peak oxygen
consumption (25). This speed was used for each subsequent ESW. In
all tests, the investigator carried the gas cylinder walking beside the
patient and gave no encouragement. Patients were instructed not to
speak while breathing the gas mixtures and for 2 min afterwards to
avoid unblinding.
Dyspnea at rest and on exercise was rated using the modified Borg
category scale (22) and a 100-mm visual analog scale (VAS). Sao2 and
heart rate were measured continuously with a pulse oximeter (Minolta
PuIseOx3i; DeVilbiss, Wollaston, UK). Values before and 5 min after
breathing the test gas mixture together with the lowest Sa02 and maxi¬
mum heart rate during exercise were recorded. Tympanic temperature
(IVAC Corporation, San Diego, CA) was measured for 5 min at rest,
before and after breathing the gas, and at end exercise.
Test Cases
Patients breathed Heliox28 (72% He/28% 02), Heliox21 (79%
He/21% 02), Oxygen28 (72% N2/28%02), or medical air (79%N2/21%02)
through a non-rebreathing mask and demand valve system (PRU de¬
mand valve; Oxylitre Health Care, Manchester, UK) connected to a
portable cylinder (BC 2 L/200 bar; BOC Ltd., Guildford, UK). The
flow resistance of this circuit was independent of the gas mixture in
use.
Protocol
Patients attended four times (Figure 1). Spirometry, breathing room
air, and baseline dyspnea (VAS and Borg) were assessed at each visit.
At Visit 1, the patients practiced the incremental shuttle walking test
breathing room air and rated their dyspnea with the Medical Research
Council breathlessness scale (26). At Visit 2, the incremental shuttle
walking test was repeated, breathing medical air, to identify the subse¬
quent ESW speed. Patients also performed a practice ESW breathing
medical air. At Visits 3 and 4, patients were randomly assigned to
receive two of the four gas mixtures. Two ESW tests were performed
40 min apart at each visit, one with each test gas mixture.
Statistical Analysis
Data and analyses are presented postrandomized on an intention-to-
treat basis. We used a general linear model for crossover trials, compar¬
ing outcomes within subject and allowing for visit and sequence of
the gases within visits (SPSS, version 11; SPSS, Inc., Chicago, IL).
A Duncan's test for post hoc comparisons was tested for statistical
significance between gases. The distance walked showed an increasing
variance with increasing mean, so data were log-transformed for these
analyses. In addition, exercise results are presented as untransformed
values and geometric means. Results are reported as mean and 95%
confidence intervals (95% CI) for normally distributed data and as
mean and ranges for non-normally distributed variables unless other¬
wise stated.
The study sample size was established from previous studies using
breathlessness as an outcome (27-29), 24 patients per center being
required for full randomization.
RESULTS
Patients
The progress of patients through the study is summarized in
Figure 1, and the characteristics of the 82 patients randomized
to receive the test gases are shown in Table 1. There was no
order or visit effect with the exception of Sa02 that showed a
small within-visit variation.
There was no significant change in FEV1; baseline Borg, or
VAS scores measured while breathing room air before the walk¬
ing test at each visit. Walking distance, breathing medical air,
was reproducible between tests (r — 0.81, p < 0.001). The mean
value for ESW at Visit 2 was 258 m (95% CI, 207-310 m); at
postrandomization, it was 257 m (95% CI, 201-314 m). Breath¬
lessness at end-exercise breathing medical air was also reproduc¬
ible: the mean Borg score at Visit 2 was 4.75 (95% CI, 4.06-5.44);
at postrandomization, it was 4.66 (95% CI, 4.42-4.91).
No adverse effects were reported from breathing heliox gas
mixtures. Tympanic temperature did not change.
Distance Walked
Patients walked significantly further while breathing Heliox28
than with either Heliox21 or Oxygen28 (Table 2). There was no
significant difference between distances walked on Heliox21 and
Oxygen28, but bothwere significantly greater than values breath¬
ing medical air. We used analysis of variance to test for any
interaction between the effects of the different gas mixtures.
None were found, suggesting that the effect of increasing Fi02
was independent of the effect of replacing nitrogen with helium.
Increasing Fi02 from 21 to 28% improved endurance exercise
distance by 30% (95%, CI 18-44%), replacing 79% nitrogen
with 79% helium produced a 29% (95% CI, 17-42%) increase.
Combining the two as Heliox28 led to a 64% (95% CI, 48-81%)
improvement. Data were similar when expressed as percentage
increase in endurance exercise time compared with that of medi¬
cal air; Oxygen28, 32.0% (95% CI, 20.3—43.6%); Heliox21,
36.1% (95% CI, 20.4-51.8%); and Heliox28, 76.3% (95% CI,
51.3-101.3%). Patients continued exercise until they elected to
stop, no data were censored by the investigators.
TABLE 1. CHARACTERISTICS OF THE 82 PATIENTS WITH
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
RANDOMIZED TO RECEIVE THE TEST GASES
Age, yr 69.7 (range, 46-84)
Number 82 (57 male)
FEV„L 1.1(0.4)
FEV,, % predicted 42.6 (15.5)
FVC, L 2.6 (0.8)
Sa02, % at rest 93.9 (2.3)
BMI 25.4 (4.8)
Medical Research Council dyspnea score 3.2 (0.9)
Dyspnea score at rest
Borg 1.8(1.1)
Visual analog score 24.2 (19.0)
Figure 7. Study profile. A flow chart indicating the number of patients
recruited to the study and their subsequent participation.
Definition of abbreviation: BMI = body mass index.
Values are mean (SD).
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TABLE 2. WALKING DISTANCE, DYSPNEA, AND LIMB FATIGUE AFTER EXERCISE TOGETHER WITH OXYGEN SATURATION AT
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Definition of abbreviation: VAS = visual analog scale.
Data are expressed as mean (95% confidence interval). Duncan's test for post hoc comparisons was applied to determine significance between variables. Croups not
sharing the same suffix differ significantly from each other. Groups sharing the same superscripted symbol do not differ significantly. Thus, for distance walked,
Oxygen28 and Heliox21 did not differ from each other, but were different from medical air and He!iox28. Medical air and He!iox28 were significantly different from
each other and from the other two gases.
Exercise capacity (expressed as log distance walked) breath¬
ing medical air correlated with baseline FEVj (Pearson correla¬
tion, r = 0.36), but when breathing Heliox28, this relationship
was lost (r = 0.04). Oxygen28 and Heliox21 showed an interme¬
diate picture (r = 0.32 and 0.25, respectively). The percentage
increase in exercise capacity relative to the distance walked while
breathing medical air is shown in Figure 2 as a box plot. When
breathing Oxygen28 and Heliox21, the improvement relative to
medical air was normally distributed, but there was a skewed
distribution of improvement in walking distance when breathing
Heliox28 (Figure 2). Some patients had a very large percentage
of improvement relative to breathing medical air when breathing
Eleliox28. This observation was compatible with our hypothesis
that patients with more severe obstructionmay show the greatest
benefits.
To explore this, we used analysis of covariance to model the
relationship between baseline FEV, and percentage change in
distance walked for all gases relative to that individual's walking






Figure 2. The percentage of improvement in walking distance breath¬
ing each gas mixture relative to that of patients breathing medical air.
Data are expressed as a modified box and whisker plot with median
and ± 25% boxes. The extremes of the whiskers are at 10 and 90%.
The wide and asymmetric distribution around the response to Heliox28
suggests heterogeneity in the data.
coefficients were used to express the results of this analysis
graphically (Figure 3). The size of improvement with Heliox21
and Heliox28 was negatively correlated with baseline FEVj
(p < 0.001), indicating that patients with more severe airways
obstruction showed the proportionately greatest increase in ex¬
ercise capacity when breathing a gas mixture based on helium
rather than nitrogen. Oxygen28 did not have this effect, a similar
improvement in walking distance occurred irrespective of base¬
line spirometry.
Symptoms
Dyspnea. Patients' dyspnea ratings at end-exercise using the
modified Borg scale were significantly different between all four
gases. Breathing Heliox28 had the lowest score and medical
air the highest (Table 2). The VAS scores gave similar results
although the scores for Heliox21 and Oxygen28 did not differ
significantly (Table 2).
Limb fatigue. Limb fatigue scores at end-exercise were unaf¬
fected by any gasmixture (Table 2). The intensity of the reported
fatigue did not relate to change in distance walked nor was
exercise tolerance limited by limb fatigue.
Oxygen Saturation
Patients were not significantly hypoxemic at rest (Table 1).
Breathing Heliox21 for 5 min at rest did not change oxygen
saturation significantly in these patients. Significant increases
were found with both Oxygen28 and Heliox28, and values with
Heliox28 were significantly higher than Oxygen28 (Table 2).
The minimum oxygen saturation during endurance walking
differed significantly between gas mixtures (Table 2). When com¬
paring the degree of exercise-induced desaturation, values for
medical air (8.8%; 95% CI, 7.6-10.0%) and Heliox21 (7.7%;
95% CI, 6.7-8.8%) were similar, but there was significantly less
desaturation breathing either Heliox28 and Oxygen28 (5.2%;
95% CI, 4.2-6.1%) and (6.2%; 95% CI, 5.1-7.3%), respectively.
Heart Rate
The increase in heart rate induced by the endurance shuttle walk
breathing the four test gases was not significantly different (Table 2).
These values were also similar to that found at Visit 2 breathing
medical air (34.4 beats/min; 95% CI, 30.6-38.1 beats/min).
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Figure 3. Relationship between
baseline FEV, and improve¬
ment in endurance exercise ca¬
pacity breathing the test gases
compared with medical air. Re¬
gression slopes were calculated
from an analysis of covariance
and show the difference be¬
tween the slope with the test
gas and that obtained when
breathing room air. In this
model, the relationship bet¬
ween medical air and FEV,
would have been zero, if plotted.
FEV1 % Predicted
DISCUSSION
This is the first randomized controlled trial to compare the effect
of increasing the inspired oxygen concentration with reducing
inspired gas density on the exercise performance of patients with
stable COPD. In addition, this is the first study to test whether
combining these treatments produces an equivalent or an addi¬
tive effect on exercise duration and dyspnea intensity.
Previous investigators have focused on identifying the under¬
lying physiologic mechanisms that explain improved exercise
performance while breathing increased oxygen concentrations
(8, 9). Those observations have been confirmed in a larger num¬
ber of patients using field exercise testing (30). The situation
with heliox breathing in COPD has been more complicated. A
number of small trials in patients with either mild (18) or very
severe (17) COPD have used heliox either to explore the influ¬
ence of expiratory flow limitation on exercise or as a method
for unloading the inspiratory muscles (31) rather than primarily
to examine its effect on exercise performance. More recently,
in a single-blind randomized trial, Heliox21 was found to increase
cycle endurance substantially (16). Our data in a randomized
double-blind trial confirm the beneficial effect of exercising with
supplementary oxygen and helium gasmixtures alone and in combi¬
nation. These effects were additive in nature, but were influenced
differently by the initial severity of airflow obstruction.
Earlier studies identified two rather different mechanisms by
which oxygen and helioxmightwork, the former reducing lactate
production and diminishing ventilatory drive (8, 9), whereas
the latter increases maximum expiratory flow by reducing the
pressure required to overcome frictional resistance and the de¬
gree of turbulence at high flow rates (16). Higher levels of minute
ventilations during exercise have been reported while breathing
heliox in both normal subjects and patients with COPD (18,32).
Our data confirm that patients exercising at a constant pace
can walk further with a lesser degree of breathlessness when
breathing 28% oxygen or a 21% oxygen/79% helium mixture,
which reduces the gas density by 0.82 kg/m3 (density: Oxygen28,
1.24 kg/m3; Heliox21, 0.42 kg/m3). The improvements in walking
distance and dyspnea were very similar irrespective of the gas
mixture used. When a modest increase of inspired oxygen was
combined with a similar reduction in gas density (density Heliox28,
0.50 kg/m3), a further improvement in walking distance and
reduction in dyspnea occurred.
Distance walked was reproducible and the maximum heart
rate achieved did not differ between tests, suggesting a compara¬
ble degree of cardiac stress on each occasion. However, we noted
more between-subject variation in walking distance in those
whose exercise performance was better preserved. We overcame
this by reporting the data as log walking distance and the geomet¬
ric mean distances walked derived from this analysis were very
different with the different gas mixtures. Raising the inspired
oxygen and Heliox21 both increased walking distance signifi¬
cantly. Combining the two inspired gas changes (Heliox28) in¬
creased the walking distance further and statistical analysis
showed that their effects were independent. This is in keeping
with their acting by independent mechanisms as suggested in
previous mechanistic studies. Both gas mixtures have been
shown to reduce end-expiratory lung volume during exercise,
but the time course of the change in lung volume appears to be
different (16). Whether changes in this measurement explain
the additive effect of combining the two gas modifications should
be established in future studies.
Breathing Heliox21 did not change resting oxygen saturation,
which rose as expected when the inspired oxygen concentration
increased. This change mitigated the degree of exercise-induced
desaturation, but did not abolish it. Despite the increase in walk¬
ing distance, desaturation breathing Heliox21 was significantly
less than during medical air breathing, but this was still worse
than with Oxygen28, which itself was worse than the desaturation
breathing Heliox28. This improvement in exercise-related gas
exchange may reflect better lung mechanics during exercise or
improved oxygen diffusion in the presence of helium (12). In
either case, the consequent reduction in ventilatory drive would
decrease the degree of dyspnea experienced for any given dis¬
tance covered relative to the medical air breathing test.
We observed significant heterogeneity in the response to
treatment, most evident when breathing Heliox28. Because He¬
liox may lessen the effect of expiratory flow limitation during
exercise (32) and because expiratory flow limitation occurs more
frequently in patients with a reduced FEV, (33), we tested
whether the relative improvement in exercise capacity was
related to the baseline FEV, recorded breathing room air. In
our patients, there was only a modest relationship between medi¬
cal air breathing exercise distance and baseline spirometry.
When breathing heliox gas mixtures, particularly Heliox28, the
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correlation between walking distance and spirometry was abol¬
ished, mainly because of a greater degree of improvement in
the exercise performance of patients with the worst lung func¬
tion. When tested in an analysis of covariance model, we found
significant differences between the responses to the different gas
mixtures that were dependent on initial lung function. There
was evidence of a greater proportionate benefit from heliox
mixtures in patients with the worst spirometry. Breathing heliox
does not appear to affect the degree of resting expiratory flow
limitation (14), but its effect on lung emptying and increasing
maximum exercise ventilation may be particularly important in
those patients with the worse lung function who exhibit the
greatest degree of ventilatory limitation on exercise. In contrast,
breathing Oxygen28 produced a similar percentage improve¬
ment in performance irrespective of the initial degree of spiro-
metric impairment, in keeping with its known effects on ventila¬
tion and lactate production.
We adopted a different approach to other studies by using a
standardized endurance exercise test that reflects the conditions
during exercise outside the laboratory, but still shows a good
relationship with endurance exercise testing measured on the
treadmill (23). Although this simpler approach restricted the
data we could collect, it allowed us to study a larger number of
subjects, with a wider range of baseline lung function, on re¬
peated occasions than has been reported previously. This ap¬
proach also avoided the need for recalibrating equipment be¬
tween gases and hence unblinding of the investigators. Although
shuttle walks are reported to have little "learning effect," we
performed two practice tests before the study and used a ran¬
domized protocol to minimize any impact of such effects on the
comparisons between gases. The analyses showed no sequence
or order effects. We did not conduct reproducibility testing to
confirm individual improvements with the heliox mixtures, but
relied on the randomized blinded design to identify significant
changes in group behavior. Expressing our data as walking time
rather than distance might have overcome some of the intrinsic
variation based on baseline performance, but this did not prove
to be the case. We used two different methods of scaling breath-
lessness because there is no clear consensus as to which has the
best measurement properties (34,35). Grant and colleagues (36)
found a clear visit effect with the VAS that was not evident
with the Borg score, which we used as our principal measure of
dyspnea.
Our patients were symptomatic but stable as judged by their
dyspnea scores, spirometry, and exercise performance breathing
medical air. We found no evidence to support the theoretic
concern that the increased thermal conductivity of helium would
reduce body temperature. At an individual patient level, the
changes in oxygen saturation were generally too small to permit
reliable identification of the gases by the investigator. We took
care to avoid unblinding the patient and investigator by ensuring
that the patient did not speak for at least 2 min after the end
of the exercise test. In summary, we believe that there are no
experimental factors that may have influenced our findings.
Our trial and other studies of supplemental oxygen have all
been acute interventions performed under laboratory conditions.
Future studies designed to assess the impact of heliox on daily
activity will need to address technical issues concerning delivery
devices for routine use. In this context, it should be noted that,
despite many years of prescription of ambulatory oxygen, there
is still no randomized controlled trial evidence for its benefit in
daily life. Whether the substantial improvements in exercise
performance and dyspnea seen with Heliox28 will translate into
more effective use of ambulatory treatment remains to be deter¬
mined, as will methods to identify individuals who show consis¬
tent responses to this treatment.
Although the recent American Thoracic Society/European
Respiratory Society guidelines have recognized that COPD is a
preventable and treatable condition (37), it is still regarded by
many as one in which significant improvement is not possible.
Our data show that this is not the case. The changes in endurance
exercise and the reductions in breathlessness we report while
breathing increased inspired oxygen or heliox gas mixtures are
substantial, being at least comparable to those achieved with
current bronchodilator therapy (38), pulmonary rehabilitation,
or even lung volume reduction surgery (39, 40). Recent data
suggest that bronchodilator therapy can enhance the effect of
pulmonary rehabilitation (41), and future studies should examine
whether the same is true if training is undertaken breathing
Heliox28, particularly in patients with severe airflow obstruction
who may have difficulty training effectively.
In selected cases, the availability ofheliox therapy might have
a dramatic impact on daily exercise performance and health
status beyond that possible with ambulatory oxygen alone, pro¬
vided Heliox28 can be administered in a way patients find accept¬
able. Our trial has shown that combining different treatment
approaches, which modify respiratory physiology, is effective
and that reducing inspired gas density by heliox breathing pro¬
vides a further mechanism that can be exploited therapeutically
in COPD.
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Effect of oxygen on recovery from maximal exercise in
patients witn chronic obstructive pulmonary disease
N J Stevenson, PMA Calverley
Thorax 2004;59:668-672. doi: 10.1136/thx.2003.014209
Background: The effects of oxygen on recovery from exercise in patients with chronic obstructive
pulmonary disease (COPD) are not clearly known. A study was undertaken to determine whether oxygen
given after maximal exercise reduced the degree of dynamic hyperinflation and so reduced the perception
of breathlessness.
Methods: Eighteen patients with moderate to severe COPD performed maximal symptom limited exercise
on a cycle ergometer. During recovery they received either air or oxygen at identical flow rates in a
randomised, single blind, crossover design. Inspiratory capacity, breathing pattern data, dyspnoea
intensity, and leg fatigue scores were collected at regular intervals during recovery. At a subsequent visit
patients underwent a similar protocol but with a face mask in situ to eliminate the effects of instrumentation.
Results: When oxygen was given the time taken for resolution of dynamic hyperinflation was significantly
shorter (mean difference between air and oxygen 6.61 (1.65) minutes (95% CI 3.13 to 10.09), p = 0.001).
Oxygen did not, however, reduce the perception of breathlessness during recovery nor did it affect the
time taken to return to baseline dyspnoea scores in either the instrumented or non-instrumented state
(mean difference 2.11 (1.41) minutes (95% CI -0.88 to 5.10), p = 0.15).
Conclusions: Oxygen reduces the degree of dynamic hyperinflation during recovery from exercise but
does not make patients feel less breathless than breathing air. This suggests that factors other than lung
mechanics may be important during recovery from exercise, or it may reflect the cooling effect of both air
and oxygen.
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Breathlessness is the most disabling symptom associatedwith chronic obstructive pulmonary disease (COPD) andits r lief is an important therapeutic goal.1 It is usually
provoked by exertion and the resultant reduction in exercise
capacity is itself a major determinant of impaired health
status in COPD.2 3
Short acting bronchodilator drugs can reduce dyspnoea
and increase exercise tolerance in COPD,4 5 principally by
limiting the increase in end-expiratory lung volume that
occurs in this disease.6 This is most evident in more severe
disease, occurs during self-paced as well as cycle exercise,7
and appears to be secondary to tidal expiratory flow
limitation present before exercise or occurring during it.8
Breathing supplementary oxygen during exercise increases
exercise duration and reduces the intensity of dyspnoea at
any workload.910 These effects occur independently of the
initial arterial oxygen tension and are more evident at higher
flow rates." Reduction in the degree of dynamic hyperinfla¬
tion secondary to a fall in minute ventilation when breathing
oxygen explains most of this improvement in patients with
COPD.
Much less is known about the physiological basis for "as
needed" oxygen therapy in the treatment of breathlessness
occurring at rest or after exercise. Patients with severe COPD
are often advised to use oxygen after exercise to increase the
rate of resolution of their dyspnoea.12 However, the evidence
to support this is conflicting with some studies in favour" but
others against1415 there being any clinically important
benefits.
In this study we hypothesised that giving oxygen at high
flow rates to patients with COPD after exercise would reduce
their degree of dynamic pulmonary hyperinflation and
change their breathing pattern when ventilation was highest
in the first 5 minutes after exercise ceased. As a result, the
overall speed of resolution of their breathlessness would be
increased when breathing oxygen. We anticipated that these
changes would be most evident in patients with tidal flow
limitation at rest where, presumably, the degree of dynamic
lung volume change would be greatest. To test this we
conducted a randomised, single blind, crossover trial compar¬
ing oxygen and room air given at identical flow rates and
measured inspiratory capacity, breathing pattern, and dys¬
pnoea intensity as exercise resolved. To exclude any effect of
the physiological instrumentation, patients repeated the
same protocol without the mouth piece and nose clip but




Patients aged 40-79 years with stable COPD were randomly
recruited from the respiratory outpatient department. COPD
was defined using BTS/ERS criteria and all patients had a
forced expiratory volume in 1 second (FEVi) of <80%
predicted and a ratio of FEVi to forced vital capacity (FVC)
of <70%. Patients were excluded if they had an exacerbation
of COPD, if there had been any change in their medication in
the 4 weeks before the study, or if they were receiving long
term domiciliary oxygen therapy. Patients unable to perform
exercise testing—for example, as a result of neuromuscular
problems or peripheral vascular disease—and those in whom
exercise testing was contraindicated—for example, patients
Abbreviations: FEVi, forced expiratory volume in 1 second; FRC,
functional residual capacity; FVC, forced vital capacity; IC, inspiratory
capacity; MIP, maximal inspiratory capacity; MEP, maximal expiratory
capacity; NEP, negative expiratory pressure; TFL, tidal expiratory flow
limitation; TLC, total lung capacity; Ve, minute ventilation; Vc>2max,
maximal oxygen consumption; Vc02max, maximal carbon dioxide
production; Vr, tidal volume
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with acute coronary syndrome—were not studied. Study
approval was granted by the local research ethics committee
and written informed consent was obtained.
Pulmonary function testing
Spirometric tests were performed using a rolling seal
spirometer (MedGraphics 1070, Medical Graphics, St Paul,
MN, USA) and met established British Thoracic Society
standards. The highest value for FEVi and FVC from three
reproducible tracings was used. Inspiratory capacity (IC) was
calculated as the volume inspired from the patients' end-
expiratory lung volume to total lung capacity (TLC).
Satisfactory technique and reproducibility of IC manoeuvres
for each subject were established initially under resting
conditions and conformed to the methods described by other
workers.6 TLC was assumed to be constant throughout the
exercise and recovery periods. All patients were familiarised
with the exercise testing protocol before the first measure¬
ments were made. When IC was measured during exercise,
the patients were warned that the measurement was about to
be made a few breaths beforehand and then told: "At the end
of the next normal breath, take a deep breath all the way in",
together with verbal encouragement to make a maximal
effort.
Expiratory flow limitation was assessed by applying
negative expiratory pressure (NEP) during tidal breathing
as previously described.16 Expiratory flow limitation was
deemed to be present when the application of NEP did not
result in an increase in expiratory flow during most of
expiration. Maximal inspiratory and expiratory mouth
pressures (MIP and MEP) measured at functional residual
capacity (FRC) and TLC, respectively, were assessed with a
standard mouthpiece and pressure manometer (P K Morgan,
Chatham, Kent, UK). Tidal breathing pattern was recorded
with the patient breathing normally through a pneumota¬
chograph (MedGraphics 1070, Medical Graphics). Computer
software was used to derive timing (frequency, Ti, Te, Ttot),
tidal volume (Vt), mean inspiratory and expiratory flow (Vt/
Ti, Vt/Te), and expired minute ventilation (Ve). Oxygen
saturation (Sao2) was measured using a pulse oximeter
attached to the pinna.
Exercise testing
Patients exercised on an electrically braked cycle ergometer
wearing a noseclip and breathing through a mouthpiece.
Ventilatory data and its derivatives were recorded breath by
breath throughout the test as was oxygen consumption (Vo2)
using a fuel cell and carbon dioxide production (Vco2) with
an infrared analyser. Resting data, including the Borg symp¬
tom scores for breathlessness and leg fatigue, were recorded for
2 minutes before exercise. From 0 W the workload was
increased by 10 W every 2 minutes until symptom limitation.
Borg scores were recorded every 2 minutes during exercise.
Evaluation of dyspnoea and leg effort
Dyspnoea was assessed by the response to the question:
"How breathless do you feel?" and leg fatigue by the
question: "How tired do your legs feel?". Patients were
familiarised with the modified Borg score before testing. They
were asked to point to the Borg scale corresponding to their
current symptom intensity at rest, during exercise, and
during recovery.
Study design
Patients attended on two occasions separated by at least
1 week. At each visit resting Borg scores and oxygen
saturation on air were recorded. Baseline lung function
testing was performed in the same sequence for each patient
at both visits and involved the measurement of flow
limitation using the NEP technique, MIP and MEP, tidal
breathing analysis, IC, and spirometry. Patients were advised
to avoid caffeine and heavy meals for 4 hours before testing.
All machines were accurately calibrated before the test
sequence.
At each visit patients then performed a maximal cardior¬
espiratory exercise test. As soon as exercise stopped, patients
randomly received either air or oxygen (Fio2 0.4) in a single
blind crossover fashion. At one visit the patient remained
instrumented during recovery while at the other visit the
mouthpiece and noseclips were replaced with a Venturi mask
at a flow rate of 10 1/min. Patients were allowed to rest for a
minimum of 45 minutes between exercise tests. When the
patients remained instrumented during recovery, Borg score,
tidal breathing pattern and IC were recorded every 3 minutes
for 15 minutes. When patients were non-instrumented
during recovery, Borg scores were recorded every minute
for 15 minutes. The order of the visits was randomised in
each patient, so patients were randomised to either the
instrumented or non-instrumented state at the first visit with
crossover at the second visit. Oxygen was administered in
random order at both visits.
The study was powered on the assumption that oxygen
therapy would produce a difference of 200 ml in IC by
4 minutes after exercise. This figure was selected as being
equivalent to the minimum difference in IC seenwith isotime
comparisons when patients were receiving 60% oxygen." A
study of 13 patients would have a 90% power to detect such a
difference. We did not power the trial on time to recovery as
we had insufficient prior data to do this, although we
anticipated that a significant change in IC would affect the
recovery time. Likewise, data about the speed of symptomatic
recovery in this patient group was lacking and we accepted
that any change in symptom recovery time that achieved
statistical significance would be of clinical interest in a study
of this size.
Statistical analysis
Descriptive data are expressed as mean (SD) while other
statistical data are expressed as mean (SE). Single paired
comparisons were performed using Student's t tests and non-
parametric data were analysed using the Wilcoxon rank sum
test. Repeated measures data were analysed using summary
measures over time which are expressed as mean (SE) with
95% confidence intervals (CI). When data involved more
than one comparison, ANOVA was used to assess the
significance of differences between the groups, a p value of
<0.05 being accepted as significant for all analyses.
RESULTS
Subjects
Fifty four patients were screened of whom 38 met the study
criteria and 18 agreed to participate. One patient declined to
attend for visit 2, during which recovery was randomly
allocated to be non-instrumented. There were no statistical
differences in baseline pulmonary function between visits
(table 1). No patient was hypoxaemic at rest, although six
patients desaturated during the maximal cardiorespiratory
exercise test—the lowest Sao2 was 88% (range 88-96%) and
the longest period of desaturation was 6 minutes. Patients
who desaturated with exercise had a lower baseline FEVI
than those who maintained their Sao2 constant when
exercising (0.73 (0.09) 1 v 1.26 (0.09) 1; p = 0.01). Four of
the six patients who desaturated also exhibited tidal flow
limitation at rest.
The presence of desaturation during exercise did not
influence the subsequent results of oxygen treatment.
At each of the four cardiorespiratory exercise tests the
mean (SD) duration of exercise (8.02 (0.39) minutes) and
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No of patients 18
Sex (M:F) 12:6
Age (years) 61.2(4.4)
FEVi (litres) 1.08 (0.42)
FEVj (% predicted) 40.28 (15.93)
IC (litres) 2.17(0.64)
IC (% predicted) 86.88 (25.27)
MIP (cm H20) 70.18 (16.47)
MEP (cm H20) 105.28 (21.98)
Sa02 (%) 95.94(1.66)
Resting Borg breathlessness 0.84 (0.87)
score
Resting Borg leg score 1.0(1.12)
TFL 7/18
Values given are mean (SD) of visits 1 and 2.
FEVi, forced expiratory volume in 1 second; IC, inspiratory
capacity; MIP, maximal inspiratory capacity; MEP, maximal
expiratory capacity; TFL, tidal expiratory flow limitation.
Figure 1 Change in minute ventilation (Ve) over time after the end of
exercise when breathing oxygen {open symbols) and breathing air {solid
symbols). No significant difference in Ve was seen between the gas
mixtures.
maximal workload (37.5 (3.98) W) were not significantly
different (table 2). In addition, there was no statistical
difference between tests in the maximum Borg breath-
lessness and leg scores achieved (mean (SD) 5.30 (2.04) and
5.30 (1.94), respectively).
Seven patients had expiratory flow limitation during tidal
breathing at rest in the seated position. FEV, did not differ
significantly between patients with and without flow
limitation (0.88 (0.13) 1 v 1.21 (0.14) 1; p = 0.09). In addition,
Borg breathlessness scores at rest did not differ significantly
between patients with and without flow limitation (0.75
(0.44) v 1.27 (0.28); p = 0.31). In most patients (n= 16) IC
was lower when measured 1 minute after the end of exercise,
reflecting dynamic hyperinflation. The two patients who did
not show evidence of hyperinflation at this time were not
flow limited at rest; however, their baseline FEV2 was not
statistically different from that of patients who exhibited
dynamic hyperinflation.
Ventilation, breathing pattern, and lung mechanics
after exercise
The mean (SD) resting Ve at both visits was 14.46 (5.28) 1/
min. During maximal exercise this increased to 23.68
(4.84) 1/min. The mean (SE) difference in Ve over the
recovery period between air and oxygen was 0.79 (0.58) 1/
min (95% CI -0.71 to 2.29); p = 0.24 (fig 1). Mean (SE)
baseline Vt was 0.75 (0.05) 1 which increased to 0.89 (0.02) 1
at maximal exercise. Breathing frequency was 21.33
(1.18) breaths/min at baseline, peaking at 28.53
(0.70) breaths/min at maximum exercise. Neither Vt nor
breathing frequency was affected by oxygen at any time
during recovery.
At baseline, mean (SD) IC at both visits was 2.22 (0.62) 1.
One minute into the recovery period the mean (SD) IC was
2.01 (0.56) 1. Patients with resting expiratory tidal flow
limitation, as assessed by the NEP technique, did not have
greater dynamic hyperinflation at this point after exercise. By
4 minutes after exercise the IC in the oxygen treated patients
was significantly less than in those breathing air (p<0.01;
fig 2). The mean (SE) difference in IC during recovery
between air and oxygen was -0.27 (0.13) 1 (95% CI —0.60 to
0.07); p = 0.07). The time taken for resolution of dynamic
hyperinflation was significantly shorter when oxygen was
administered (mean difference between treatments 6.61
(1.65) minutes (95% CI 3.13 to 10.09); p = 0.001). This was
true for patients with and without tidal flow limitation at
rest.
The mean (SD) Borg breathlessness score at rest in all four
tests was 0.87 (1.02), rising to 5.30 (2.04) at maximal
exercise. Breathlessness scores fell with recovery. There was
no statistical difference in Borg scores at any time during
recovery between oxygen and air irrespective of the presence
of instrumentation, nor was the time to return to the pre-
exercise level of breathless affected by the gas inhaled (fig 3).
The mean (SE) difference in Borg breathlessness scores over
the recovery period when instrumented was 0.009 (0.12),
(95% CI -0.21 to 0.39); p = 0.47. When non-instrumented,
the mean (SE) difference in Borg score over time was -0.14
(0.007), (95% CI -0.31 to 0.00); p = 0.10. In the instrumented
Table 2 Ventilatory, breathlessness, and leg fatigue data at rest and maximal exercise
for each of the four cardiorespiratory exercise tests
Air with Oxygen with Air with Oxygen with
Test mouthpiece mouthpiece mask mask
Resting Borg breathlessness score 0.97 (0.28) 0.75 (0.25) 1.03 (0.26) 0.74(0.21)
Resting Borg leg score 1.06 (0.31) 1.03 (0.25) 0.94 (0.27) 0.97 (0.26)
Exercise duration (minutes) 8.16 (0.96) 7.07 (0.87) 8.18 (0.95) 8.65 (0.98)
Maximal exercise Borg 5.36 (0.55) 5.17(0.51) 5.26 (0.49) 5.41 (0.51)
breathlessness score
Maximal exercise Borg leg score 5.56 (0.47) 5.19 (0.39) 5.00 (0.50) 5.44 (0.52)
Maximal workload (W) 37.22 (5.53) 32.78 (5.47) 38.23 (5.30) 41.18 (5.55)
Vo2 max (l/min) 0.97 (0.09) 0.94 (0.08) 0.94 (0.08) 0.91 (0.07)
Vc02max (l/min) 0.85 (0.08) 0.82 (0.08) 0.83 (0.07) 0.82 (0.07)
Values are mean (SE).
V02max, maximal oxygen consumption; VC02max, maximal carbon dioxide production.
Statistical analysis between groups was performed using ANOVA. All p values >0.05.
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Figure 2 Change in inspiratory capacity (IC) expressed as a
percentage of predicted value for age and height during recovery from
exercise when breathing oxygen (open symbols) and breathing air (solid
symbols). IC fell after exercise and returned to baseline values during
recovery. It was significantly greater at 4 minutes when breathing
oxygen than when breathing air; *p<0.01. The rate of recovery of IC
was more rapid during oxygen breathing although overall the difference
in IC at all time points was not significantly different.
patients the time taken to return to the baseline dyspnoea
score was not significantly different when breathing
oxygen (mean (SE) difference between air and oxygen
2.11 (1.41) minutes (95% CI -0.88 to 5.10); p = 0.15).
Similarly, when patients were non-instrumented there was
no difference in the time to symptomatic recovery between
gases (mean (SE) difference between air and oxygen 0.47
(0.46) minutes (95% CI —0.51 to 1.45); p = 0.32). However,
the time take for the dyspnoea score to return to the
baseline levels was greater when breathing air through the
mouthpiece than when it was administered from a face
mask (mean (SE) difference 3.94 (1.77) minutes (95% CI
0.20 to 7.69); p = 0.04).
The mean (SD) Borg score for leg effort was 1.00 (1.12) at
rest and increased to 5.30 (1.94) at maximal exercise. Leg
fatigue scores were not statistically different at any point
during recovery when breathing oxygen. In addition, the time
taken to return to baseline scores did not differ when oxygen
or air was administered. The mean (SE) difference between
air and oxygen in the time taken to return to baseline was
0.65 (1.07) minutes (95% CI -1.62 to 2.91); p = 0.55.
DISCUSSION
Although there is good evidence for the clinical benefit of
oxygen administration during exercise in patients with
COPD, equivalent data supporting the use of oxygen to help
breathlessness resolve more rapidly when exercise stops are
scanty.'8 Despite this, most cylinder oxygen in the UK is
prescribed for this purpose and to control acute dyspnoea, an
indication where there is some experimental evidence of
effectiveness." 20 Since the completion of our study further
data have been published showing that oxygen after exercise
does not appear to influence the rate of symptomatic
recovery.15 21 Our data using a more robust trial design
suggest that supplementary oxygen does reduce dynamic
hyperinflation more rapidly than breathing room air after
exercise stops. However, this does not translate into a
significant reduction in the degree of dyspnoea at any time
after exercise, nor does it influence the rate at which
symptoms resolve.
In this study we used a standardised progressive exercise
protocol to produce the same level of breathlessness before
giving either air or oxygen, something not always done in
Figure 3 Borg score for breathlessness before and after exercise in (A)
patients breathing oxygen (open symbols) or air (solid symbols) with
nose clip and mouthpiece and (B) patients breathing from a face mask.
previous studies. The duration of exercise and degree of
metabolic load incurred were similar in each test. The degree
of oxygen desaturation observed during or at the end of
exercise did not influence the subsequent symptomatic
response to oxygen breathing. We measured IC before and
soon after exercise ended to allow time for the inspired gas to
have an effect. As a result, our IC values were somewhat
lower than those recorded at maximum exercise or immedi¬
ately after stopping walking.7 22 As our purpose was to
compare the effect of oxygen and air on dynamic inflation,
we did not relate these data to peak values during exercise.
The need to obtain technically satisfactory measurements
and to record symptom intensity determined the timing of
the measurements during the recovery period. In practice,
most of the change in dynamic hyperinflation and symptoms
occurred 3-6 minutes after exercise ended.
Breathing oxygen (Fio2 0.4, flow 101/min) did not
significantly affect either ventilation or breathing pattern
during the recovery period. The apparent early difference in
ventilation seen in fig 1 was not accompanied by consistent
changes in ventilation at other time points during recovery.
The degree of dynamic hyperinflation was different by
4 minutes after exercise and this probably explains the more
rapid resolution of this phenomenon during oxygen breath¬
ing. As different individuals recover at different times after
exercise ends, it is not surprising that there is more "noise" in
the latter measurements and it is proportionately harder to
demonstrate changes in related variables such as ventilation
and breathing pattern than is the case during endurance
www.thoraxjnl.com
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exercise testing. Nonetheless, oxygen does reduce the degree
of dynamic hyperinflation more rapidly but, in contrast to the
situation during exercise, this does not appear to be the major
determinant of dyspnoea.
Perception of breathlessness and leg effort
Dynamic hyperinflation occurs more frequently in patients
with expiratory flow limitation at rest23 and can be reduced
by oxygen breathing at rest.20 We did not find a clear
association with tidal expiratory flow limitation and the
presence of dynamic hyperinflation 1 minute after exercise in
our patients. This may reflect the onset of flow limitation
during exercise as noted by others.24 In our patients the
presence of resting expiratory flow limitation did not identify
a subgroup more responsive to supplementary oxygen.
The failure of oxygen to affect dyspnoea intensity reflects
the different conditions present after exercise compared with
those during exercise. When patients with COPD exercise
there is a progressive rise in the respiratory drive to breathe
due to metabolic C02 production, increasing blood lactate
concentrations, and changes in arterial blood gas tensions. In
these circumstances any factor that reduces ventilatory
drive—such as supplementary oxygen—will modify the
breathing pattern, improve lung emptying, reduce dynamic
hyperinflation, and lessen dyspnoea. After exercise the
metabolic drive to breathing declines exponentially whatever
gas mixture is inhaled at a speed that is influenced by many
factors including the redistribution of regional blood flow,
lactate metabolism, and any co-existing cardiac dysfunction.
Although changes in dynamic lung volume still occur, their
relative importance is less than the declining central
respiratory drive and does not appear to significantly affect
the intensity of dyspnoea.
Although oxygen did not influence the intensity or rate of
resolution of symptoms, the presence of a mouthpiece and
noseclip did. This may explain some of the differences in
recovery time from exercise previously reported in the
literature. We chose high gas flow rates to ensure that the
optimal effect on dyspnoea was achieved" but, in doing so,
may have provided some relief from dyspnoea with both gas
mixtures, the facial and upper airway cooling effect being
known to reduce dypnoea during exercise in COPD.25
Our data help to explain why oxygen has less effect as
symptomatic treatment than might be anticipated from its
known effects during exercise, and support recently reported
data on this topic.15 Administration of oxygen or compressed
air may be a useful way of providing a source of cooling gas
flow, but other cheaper and more convenient methods of
doing this are worth exploring in future trials. The routine
use of oxygen to aid recovery of symptoms after exercise does
not appear to be warranted.
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Lower limb activity and its
P P Walker,1'2 A Burnett,1 P W Flavahan,1
ABSTRACT
Background: Patients with chronic obstructive pulmon¬
ary disease (COPD) walk less than healthy older people
and their self-reported activity predicts exacerbation risk.
The relationship between lower limb activity and total
daily activity is not known, nor are there any data which
relate objectively assessed daily activity to laboratory
assessments made before and after rehabilitation.
Methods: Lower limb activity was measured by leg
actigraphy over 3 days in 45 patients with moderate to
severe COPD and 18 controls of similar age. Thirty-three
patients with COPD entered an 8-week rehabilitation
programme in which the change in leg activity was
measured and related to other outcomes.
Results: In patients with COPD the mean level of activity
measured by whole body and leg activity monitors was
closely related (r = 0.92; p<0.001), but leg activity was
consistently reduced compared with controls of similar
age (p = 0.001). Mean leg activity, mean intensity of leg
activity and the time that patients spent mobile at home
were all related to forced expiratory volume in 1 s (FEVi)
(r = 0.57, p = 0.001; r= 0.5, p = 0.003; and r = 0.51,
p = 0.002, respectively), but intensity of activity and time
spent mobile were not related. Subjects completing
pulmonary rehabilitation showed significant improvements
in mean activity (p = 0.001) and spent more time moving
(p = 0.014). These changes were unrelated to improve¬
ment in muscle strength or walking distance but
correlated with baseline FEV-| (r = 0.8, p<0.001).
Conclusions: Total daily activity in patients with COPD is
closely related to leg activity which is reduced compared
with controls of similar age. Individuals differ in the time
spent mobile during the day, but subjective and
objectively assessed activity improves after rehabilitation
and is predicted by FEVv The change in activity is
unrelated to improvements in corridor walking and health
status.
Symptomatic chronic obstructive pulmonary dis¬
ease (COPD) is associated with impaired exercise
performance which, in turn, is related to a
reduction in health status1 and mortality.2
Conventionally, this impairment has been docu¬
mented by incremental or endurance exercise
testing often using field exercise tests such as the
6 min walking distance3 or the endurance shuttle
walking test.2 However, exercise testing measures
what an individual is capable of doing rather than
their activity. The level of activity reported by
patients with COPD relates to the risk of
hospitalisation after an exacerbation5 and mortal¬
ity.15 More recently, the availability of reliable
accelerometers has made it possible objectively to
monitor daily activities outside the laboratory.
Patients with COPD are less active than healthy
age-matched controls and spend longer sitting and
lying down,7 while activity improves after a
Chronic obstructive pulmonary disease
determinants in COPD
M A Calverley1
rehabilitation programme irrespective of the exer¬
cise regime used.8
To date, home activity monitoring has reported
total body movements over a 12 h period using a
waist-mounted triaxial accelerometer which, in the
case of the Dynaport system, also reports the type
of activity.9 The amount of total daily activity
resulting from lower limb movement has not been
determined. This is important as patients with
COPD are subject to loss of skeletal muscle mass
which is most evident in the legs,10 and reduced
quadriceps strength predicts both healthcare use"
and future mortality.12
We hypothesised that the degree of leg activity
would be an important determinant of the total
daily activity of patients with COPD. In addition,
leg activity would relate both to self-paced walking
distance and muscle strength and would improve
significantly after pulmonary rehabilitation.
Moreover, we anticipated that the initial degree
of activity impairment would predict the extent to
which activity improved after rehabilitation,
whether this was assessed objectively by activity
monitoring or subjectively by activity question¬
naire. To test these hypotheses, we have mon¬
itored activity simultaneously with a leg-mounted
accelerometer and a Dynaport activity monitor
and subsequently related leg activity to well-




Patients with a clinical and physiological diagnosis
of COPD13 who had not used antibiotics or oral
corticosteroids for at least 6 weeks and who were
referred for pulmonary rehabilitation were
recruited to the study. Medication was individually
optimised before assessment and remained con¬
stant throughout the study. Patients using dom¬
iciliary oxygen, those with unstable cardiac disease,
and those unable to exercise due to musculoskele¬
tal, neurological or vascular disorders were
excluded. All patients provided written informed
consent and the protocol was approved by the local
research ethics committee.
Study protocol
Patients participated in one or more of three study
evaluations.
► Evaluation 1: A subset of patients with COPD
underwent simultaneous leg accelerometry
measurements and total body activity measure¬
ments. These subjects also completed health
status and activity questionnaires.
Evaluation 2: In a second group of patients
with COPD, leg accelerometry measurements
were compared with those of a control group of
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healthy volunteers of similar age and sex. Quadriceps muscle
strength was also recorded.
► Evaluation 3: A third group of patients with COPD
completed leg accelerometry measurements before and after
pulmonary rehabilitation and these leg activity data were
related to standard measures of lung function, exercise
performance, muscle strength and health status.
Before rehabilitation, assessments were performed on two
visits approximately 7 days apart. After rehabilitation, all
assessments were completed on a single visit scheduled no
more than 14 days after completion of the exercise programme.
Each subject performed the same tests in the same order. All
tests were performed before and after rehabilitation with the




Before testing, patients omitted short-acting inhaled broncho-
dilators for 8 h and long-acting P agonists for 12 h. Spirometry,
static lung volumes and single breath carbon monoxide transfer
factor were measured with a rolling seal spirometer (P K
Morgan, Kent, UK) according to American Thoracic Society
guidelines." Static lung volumes were measured by helium
dilution. Predicted values used were those of the European Coal
and Steel Community.15
Heath status and disability questionnaires
Patients completed the St George's Respiratory Questionnaire
(SGRQ)16 and the Hospital Anxiety and Depression (HAD)
questionnaire,17 while self-reported activity was assessed using
the Nottingham Extended Activities of Daily Living (NEADL)
questionnaire.18
Quadriceps muscle strength
Maximum quadriceps strength was measured by isometric
maximum voluntary contraction of the dominant quadriceps
using a custom-built set up. Further details of this are included
in the online supplement. Subjects performed three maximum
voluntary contractions with a rest period of 1 min between
efforts. Maximum quadriceps strength was defined as the peak
value obtained from the three recordings.
Six minute walking test
The tests were performed in accordance with ATS recommen¬
dations19 with two additional practice walks at the initial
assessment. Perceived breathlessness was scored immediately




Leg activity was measured using the Actiwatch Uniaxial
Accelerometer (Cambridge Neurotechnology, Cambridge, UI<).
All recordings were made continuously over three weekdays
with the exception of Evaluation 1 (comparison of whole body
and lower limb activity) where only 2 days were recorded.
Using a lightweight strap, the Actiwatch was positioned just
above the dominant ankle and subjects only removed the device
for bathing and then repositioned the Actiwatch immediately
afterwards. The Actiwatch has an event marker button and
subjects pressed this button on rising in the morning, going to
bed at night and when the device was removed for bathing.
Subjects also documented when and why the activity monitor
was removed. On the rare occasion a subject forgot to press the
marker button, the written record or period of overnight
inactivity was used to determine the actigram. Activity
monitoring was performed before and after rehabilitation with
the same Actiwatch.
The Actiwatch signal is measured 32 times per second and
processed to provide the amount and duration of movement.
This signal is expressed as an activity count which denotes the
amplitude of the signal detected by the accelerometer. A vale of
approximately 25 counts represents gravitational acceleration.
Further details about the technical specifications are given in the
online supplement. Data were expressed as an activity count,
which is the sum of all the epochs within each 30 s period.
Inactivity was expressed as an activity count of zero. Data
extracted for analysis were aggregated over the three daytime
periods and expressed as:
► Mean activity score: average value of each 30 s epoch
throughout the waking day, including all periods of zero
activity.
► Mean intensity of activity: average value of each 30 s epoch
when activity was occurring throughout the waking day
(excludes any period of zero activity).
► Percentage of time mobile: percentage of 30 s epochs
throughout the waking day where an activity score of >1
was recorded; any epoch with a mean activity score of 0 was
labelled immobile, while any epoch with a score of 3= 1 was
active, although a score of 1 represents a very low level of
activity.
Total body activity measurement
The Dynaport Activity Monitor (McRoberts BV, Den Haag,
Netherlands) is a lightweight device containing a triaxial
accelerometer. It has previously been validated for use in
patients with COPD.9 The device consists of a lightweight box
enclosed in a neoprene belt worn anteriorly around the waist.
The box is connected to a leg sensor which is worn around the
upper third of the thigh. The signal recorded by the device
precisely measures the time spent walking, cycling, standing,
sitting or lying, and it also provides a measure of movement
intensity during the recording period. The technical specifica¬
tions of the activity monitor have been detailed previously.21
The Dynaport Activity Monitor provides a measure of overall
activity (movement intensity) and a measure of intensity of
activity (movement intensity during movement). In addition, it
records the proportion of the day during which the subject was
moving (time spent moving). Different activities can be
classified and expressed as the proportion of the day spent
walking, standing, sitting and lying down.
The Dynaport Activity Monitor was fitted and all subjects
were provided with written instructions, spare batteries and an
emergency contact number. The subjects were monitored for
two consecutive days, a time period over which reliable results
have been obtained previously.7Monitoring lasted from rising in
the morning until whatever time in the evening they had
completed their usual daily activities.
Pulmonary rehabilitation
The 8-week outpatient pulmonary rehabilitation programme
consisted of two supervised and one unsupervised 1-hour
exercise session per week. Patients received an individualised
regime of aerobic upper and lower limb exercises which included
peripheral muscle strengthening and whole body endurance
exercises. Further details of the programme are included in the
684 Thorax 2008;63:683-689. doi:10.1136/thx.2007.087130
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Table 1 Baseline characteristics and number of subjects in each study evaluation
Evaluation 1 (subjects Evaluation 2 (normal Evaluation 3 (subjects Evaluations 2 and 3
with COPD who had subjects of similar age with COPD who had (subjects with COPD
concurrent DP and AW who had AW AW measurement who had AW
measurements) measurement) before and after PR) measurement)
No of subjects 12 18 23 33
M:F 9:3 8:10 12:11 17:16
Age (years) 63 (7) 70 (6) 66 (9) 67 (8)
Current:ex:never 3:9:0 5:9:4 5:18:0 7:26:0
smokers
FEV, (I) 1.01 (0.43) 2.5 (0.6) 0.93 (0.32) 0.96 (0.4)
FEV, (%) 33.4 (12.2) 105.1 (17.7) 36.4 (11.6) 38.2 (12)
FVC (I) 2.83 (0.93) 3.3 (0.8) 2.27 (0.46) 2.36 (0.9)
FEV,/FVC 0.36 (0.07) 0.77 (0.04) 0.41 (0.13) 0.42 (0.12)
IC% 73.3 (14.5) NK 71.6 (15.8) 77.6 (20.8)
Quadriceps MVC (N) NK 415 (98) 315 (106) 308 (116)
SGRQ Total 63.4 (16.2) NK 62.1 (13) 62.2 (12.5)
SGRQ Activity 77.2 (19.4) NK 79.1 (13.1) 80.1 (13.7)
NEADL 18.9 (2.3) NK 16.4 (2.7) 15.7 (2.8)
Actiwatch measures:
Mean activity (x103 123 (110) 143 (61) 82 (53) 82 (49)
counts/h)
Mean intensity of 190 (162) 232 (90) 156 (69) 156 (63)
activity (x 103 counts/h)
% of time mobile 63.2 (14.5) 61.4 (11.2) 50 (13.9) 50.8 (15.4)
Data presented as mean (SD).
AW, measurement of leg activity using the Actiwatch accelerometer; COPD, chronic obstructive pulmonary disease; DP, measurement
of whole body activity using the Dynaport activity monitor; FEV,, forced expiratory volume in 1 s; FVC, forced vital capacity; IC,
inspiratory capacity; MVC, maximum voluntary contraction; NEADL, Nottingham Extended Activities of Daily Living Questionnaire; NK,
not known (not recorded in the particular group); PR, pulmonary rehabilitation; SGRQ, St George's Respiratory Questionnaire.
online supplement. Owing to the "rolling" nature of the
programme, subjects who were unable to attend particular
supervised session(s) were able to continue the programme
beyond 8 weeks until they had attended 16 supervised sessions.
Patients who attended 16 sessions were defined as "comple¬
ters".
Statistical analysis
Group data are expressed as mean (SD) and subgroup data as
mean (SE). Statistical analysis was performed using SPSS V.15.0
and Stats Direct 2.6 with significance set at p<0.05; p values are
recorded to three decimal places. Normal distribution was
assessed using the Shapiro-Wilks test and all data were normally
distributed except for the Actiwatch mean activity score and
Actiwatch mean activity score when active. These data were
Table 2 Measurements of activity obtained by the
Actiwatch (leg) and Dynaport (whole body) systems
during the 2 days of recording in 12 patients with chronic
obstructive pulmonary disease (Evaluation 1)
Mean (SD)
Actiwatch
Time spent mobile (% of recording) 63.3 (14.5)
Mean activity score (x103 counts/h) 123 (110)
Mean intensity of activity (x103 counts/h) 190 (162)
Dynaport
Time spent moving (%) 13.5(4.4)
Movement intensity 0.2(0.1)
Movement intensity during movement 1.48 (0.21)
Time spent walking (%) 3.6 (2.8)
Time spent standing (%) 32.1 (15.2)
Time spent sitting (%) 58.7 (17.6)
Time spent lying down (%) 5.3 (4.9)
logarithmically transformed to normalise the distribution.
Paired and unpaired Student t tests were used to detect
differences in group data and Pearson's correlation coefficient
was used to examine the association between individual
parameters. Multiple linear regression analysis was performed
with the primary explanatory variables being change in activity
scores after pulmonary rehabilitation. A model was constructed
to examine the following potential exploratory variables: forced
expiratory volume in 1 s (FEVi) in litres, FEVi percent
predicted, ratio of FEVx to forced vital capacity (FVC), carbon
monoxide transfer factor (Tlco) percent predicted, quadriceps
strength, 6 min walking distance, SGRQ score and NEADL
score. The final model was constructed using a backwards
stepwise procedure; at each step a variable was removed which
reduced the amount of variation accounted for by the least
amount. Using published data, we considered an improvement
in 6 min walk distance of 54 m after completion of pulmonary
rehabilitation to be clinically significant.3 From pilot data we
established that a change in Actiwatch mean activity score of 30
corresponded with similar improvements in walking distance
and an improvement in health status. Based on the change in
these two measures, we established that 24 subjects had to
complete evaluation 3 of the study to detect a difference in
these outcomes with 80% power at a significance level of 5%.
RESULTS
Baseline characteristics
The baseline characteristics of the patients with COPD and
healthy volunteers are shown in table 1.
Evaluation 1: Relationship between leg and whole body activity
in patients with COPD
Fourteen subjects were studied and all completed 2 days
of recording with the Actiwatch. However, Dynaport
Thorax 2008;63:683-689. doi:10.1136/thx.2007.087130 685
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Figure 1 (A) Relationship between measures of mean activity by
Dynaport and Actiwatch devices. (B) Relationship between measures of
intensity of activity by Dynaport and Actiwatch devices.
of activity and all Dynaport activity assessments (table 3 and
fig IB). No relationship was seen between the time spent in
specific positions and the activity levels assessed by the leg
accelerometer. However, the mean number of counts recorded
in each position for each patient was significantly different
between sitting and walking (see table 1 in online data
supplement).
Evaluation 2: Leg activity in patients with C0PD and healthy
volunteers
The patients and volunteers were of similar age and, by
definition, differed in lung function (table 1). Quadriceps
muscle strength was significantly less in the patients with
COPD (difference 107 N, 95% CI 48 to 139; p = 0.001). The
patients spent significantly less of the day mobile (difference
10.6%, 95% CI 3.1% to 18.2%; p = 0.007) and had a lower mean
activity level (difference 61, 95% CI 27 to 96; p = 0.001) and
lower intensity of activity score (difference 77, 95% CI 27 to
126; p = 0.004) than the healthy volunteers. Leg activity
recordings were relatively stable between the days for both
the patients with COPD and the volunteers. The mean (range)
coefficient of variation was 21.6% (2.2-47.4%) for mean activity
score, 15.7% (3.2-42%) for mean intensity of activity and 11.5%
(1.5-31.3%) for percentage of time spent mobile. When different
leg activity measures recorded in the patients with COPD were
compared, mean activity scores were closely related to the mean
intensity of activity (r=0.86, 95% CI 0.73 to 0.93; p<0.001)
with a weaker relationship between the mean activity score and
the percentage of time scored as mobile (r = 0.68, 95% CI 0.44 to
0.83; p<0.001). However, the intensity of activity when
exercising was not related to the amount of time spent mobile
(r = 0.27, 95% CI -0.08 to 0.56; p = 0.122).
measurements were unsuccessful in two patients owing to
unrecognised lack of battery power (both patients) plus
incorrect operation of the device by one patient.
Simultaneously recorded data were therefore available in 12
patients with a mean recording duration of 18.7 (1.5) h.
Mean data for the activity outcomes and body position are
shown in table 2. There was good agreement between the mean
leg activity score recorded by the Actiwatch and the mean
whole body activity level recorded by the Dynaport device
(table 3 and fig 1A), and also between Actiwatch mean intensity
Evaluation 3a: Lower limb activity and laboratory assessments of
exercise capacity
In this evaluation the Actiwatch accelerometer was worn for an
average of 15.7 (0.2) h per day on each of the 3 days of
recording. All functional measurements—lung mechanics, mus¬
cle strength, walking distance or self-completed question¬
naires—were related to each other to a varying degree (see
table 2 in online data supplement). There was a significant or
near significant relationship between measures of leg activity
and many of these variables (see table 3 in online data
Table 3 Correlation between different activity measures obtained from the Actiwatch and Dynaport Activity
Monitor in 12 patients with chronic obstructive pulmonary disease (Evaluation 1)
Actiwatch
Mean activity score
Mean intensity of activity
score Time spent mobile
Dynaport
Time spent moving (%) r = 0.83 r= 0.76 r = 0.48
95% CI 0.48 to 0.95 95% CI 0.32 to 0.93 95% CI -0.13 to 0.32
p = 0.001 p = 0.004 p = 0.118
Movement intensity r = 0.92 r = 0.88 r = 0.35
95% CI 0.72 to 0.98 95% CI 0.63 to 0.97 95% CI -0.28 to 0.77
p<0.001 p<0.001 p = 0.27
Movement intensity during r = 0.81 r = 0.83 r = 0.05
movement 95% CI 0.45 to 0.95 95% CI 0.49 to 0.95 95% CI -0.54 to 0.61
p = 0.001 p = 0.001 p = 0.883
Time spent walking (%) r = -0.42 r= -0.32 r = —0.42
95% CI -0.8 to 0.2 95% CI -0.76 to 0.31 95% CI -0.8 to 0.2
p = 0.171 p = 0.306 p = 0.169
Data recorded are Pearson's correlation coefficient, 95% confidence interval of the correlation and p value.
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Figure 2 Flow chart showing the
outcome for the 33 subjects referred to
the pulmonary rehabilitation (PR)
programme.
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supplement). The mean activity of the legs and the percentage
of time spent mobile were most closely related to absolute FEVj
(r = 0.57, 95% CI 0.28 to 0.76; p<0.001 and r = 0.51, 95% CI 0.2
to 0.73; p = 0.002, respectively). There was a significant
relationship between FEVj percent predicted and mean inten¬
sity of activity when exercising (r = 0.5, 95% CI 0.19 to 0.72;
p = 0.003), although in this case the best univariate correlation
was with Tico (r = 0.6, 95% CI 0.25 to 0.81; p = 0.003). There
was a weak relationship between mean leg activity and the
subjective assessment of activity using the NEADL question¬
naire (r = 0.35, 95% CI 0 to 0.62; p = 0.049).
Evaluation 3b: Lower limb activity and pulmonary rehabilitation
The number of patients participating in and completing the
pulmonary rehabilitation programme is shown in fig 2. The
change in outcome variables after completion of rehabilitation is
presented in table 4. Subjects completing rehabilitation showed
significant improvements in self-paced walking distance, quad¬
riceps strength, breathlessness at rest and peak exercise, health
status and level of anxiety and depression. In general, these
changes exceeded the minimum clinically important difference
and were paralleled by significant improvements in leg activity.
Flowever, the magnitude of change in walking distance and
muscle strength were unrelated to the change in any index of
leg activity.
Improvement in objectively measured leg activity was
positively correlated with baseline FEVi (r = 0.8, 95% CI 0.58
to 0.91; p<0.001, fig 3). The only other baseline variables that
contributed to the improvement in any measure of activity
were 6 min walk distance and NEADL score. Baseline subjective
activity level assessed using the NEADL questionnaire was
related to change in the percentage of time spent mobile
(r = 0.56, 95% CI 0.15 to 0.79; p = 0.006) and mean activity
score (r = 0.47; 95% CI 0.08 to 0.71; p = 0.021) after completion
of rehabilitation. Full details of the relationships between
change in leg activity and baseline variables are shown in
table 4 in the online supplement.
DISCUSSION
Exercise limitation in COPD integrates the effect of many
different aspects of this condition including abnormal lung
mechanics, peripheral muscle dysfunction and altered mood
states. Subjective assessments of exercise limitation range from
simple reporting of activity limited by dyspnoea such as the
MRC dyspnoea scale22 through to more global reporting of
disability such as the SGRQ activity score or NEADL.
Cardiopulmonary exercise testing can define the physiological
limits to exercise, but this and other objective exercise tests
define what the patient can do rather than what they actually
do at home. In comparison, recording accelerometry provides
Table 4 Effect of pulmonary rehabilitation in the 23 subjects with chronic obstructive pulmonary disease who completed all assessments (Evaluation 3)
Mean (SE) difference
Before PR After PR after PR (95% CI) p Value
Quadriceps MVC (N) 312 (20) 334 (23) 22 (31) (9 to 35) 0.002
6MWD (m) 274 (13) 333 (13) 59 (33) (45 to 73) <0.001
Resting Borg score 1.6 (0.2) 0.9 (0.2) 0.7 (1.2) (0.2 to 1.6) 0.008
Peak Borg score 4.6 (0.2) 3.2 (0.3) 1.4 (1.7) (0.7 to 2.1) <0.001
Leg activity
% of time spent mobile 50.0 (2.7) 55.2 (2.6) 5.2 (9.4) (1.2 to 9.3) 0.014
Mean activity score (x103 counts/h) 81.5 (53.2) 117.2 (84.2) 35.7 (49) (14.5 to 56.9) 0.002
Mean intensity of activity score (x10! counts/h) 156 (69.2) 208.5 (123.4) 52.5 (74.2) (20.4 to 84.6) 0.001
Health status
HAD Anxiety 7.2(1) 5.6 (0.6) 1.6 (3.2) (0.2 to 3.0) 0.016
HAD Depression 6.4 (0.6) 4.4 (0.6) 2 (2.2) (1.0 to 2.9) <0.001
SGRQ 62.9 (2.5) 47.8 (2.4) 15.1 (12.5) (8.9 to 19.7) <0.001
NEADL 16.4 (0.5) 18.2 (0.5) 1.8 (1.7) (1.1 to 2.6) <0.001
Data shown are mean (SE).
HAD, Hospital Anxiety and Depression questionnaire score; 6MWD, six minute walking distance (metres); MVC, maximum voluntary contraction; NEADL, Nottingham Extended
Activities of Daily Living Questionnaire; PR, pulmonary rehabilitation; SGRQ, St George's Respiratory Questionnaire.
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Figure 3 (A) Relationship between forced expiratory volume in 1 s
(FEV,) and change in Actiwatch leg mean activity after rehabilitation
(r= 0.8, p<0.001). (B) Relationship between FEV, and change in
Actiwatch leg mean intensity of activity after rehabilitation (r = 0.67,
p<0.001).
insight into how much activity is undertaken. In this report we
have focused on leg activity and confirm that this variable
relates well to whole body activity, distinguishes patients with
COPD from unaffected individuals and responds to rehabilita¬
tion. However, interpreting these data is not necessarily simple,
nor do they simply track changes in the variables we usually
report when assessing a response to treatment.
Leg activity monitoring showed modest day-to-day variability
in patients with COPD and healthy volunteers comparable to
that reported with other systems. There was good agreement
between the activity scores of the Dynaport, a validated whole
body accelerometer, and both the mean activity scores and
mean intensity of activity scores of the leg device. The
differences in daily leg activity of the healthy volunteers and
the patients with COPD are comparable to those reported for
whole body activity,7 and improvements after rehabilitation
suggest that leg actigraphy tracks other outcome measures and
is responsive to intervention. The lack of agreement between leg
activity and position monitoring data with the Dynaport
system probably reflects the strict scoring standards we used
to define mobility. However, we cannot exclude an effect due to
leg movements when seated or lying. The lack of complete
agreement between the two methods means that lower limb
activity monitors cannot be substituted for those measuring
total activity when determining whole body energy expendi¬
ture.23 Despite this, lower limb activity is clearly the major
determinant of whole body activity and, in most circumstances,
lower limb measurement is likely to be an acceptable surrogate
for a whole body system.
Of the three leg accelerometric variables we reported, mean
activity provided an acceptable compromise between both the
percentage of time spent immobile and the mean intensity of
activity during exercise. These latter variables were unrelated in
the patients with COPD, which suggests that the amount of
time spent sitting or lying completely still was determined by
different factors from those determining intensity of lower limb
activity when exercise had to be undertaken. This was reflected
to a degree in the relative lack of relationship between lower
limb activity and conventionally used performance indicators
such as walking distance, quadriceps strength and activity
questionnaires. Although these variables were related, the major
factor determining leg activity was FEVr; patients with better
lung function undertook a greater degree of activity. The
relationship between lung function and walking distance was
much weaker, albeit not dissimilar to published data,2 as was
the relationship between activity and walking distance. Hence,
level of activity does not appear simply to reflect capacity but
may be affected by lifestyle and choice. The subjectively
reported limitation in activity of daily living score was weakly
related to mean level of activity, and similar associations were
seen with other subjective scores. However, unlike objective
activity measures, subjective scores did not relate to measures of
pulmonary function. These data suggest that level and extent of
activity at home are independent measures of function which
can only be approximately assessed using currently available
laboratory physiological outcomes or activity questionnaires.
Pulmonary rehabilitation produced significant improvements
in health status, lower limb muscle strength and exercise
performance that are comparable to the best results reported
with other programmes.24 Significant improvement was seen in
all measures of lower limb activity although, even after
pulmonary rehabilitation, leg activity was still significantly less
than that in age-matched controls. The magnitude of improve¬
ment in measures of functional capacity—such as walking
distance and quadriceps strength—did not predict the change in
leg activity at home, even though both were significantly
greater after rehabilitation.
We initially hypothesised that the most inactive subjects
would have a greater capacity to improve their level of activity
after rehabilitation. In fact, the baseline level of activity was
only weakly related to the improvement after rehabilitation,
which suggests that even active individuals can further increase
their level of activity with an effective rehabilitation pro¬
gramme. Instead, change in leg activity after rehabilitation,
however expressed, was primarily influenced by lung function,
although the pre-rehabilitation 6 min walking distance also
made an independent contribution. Individuals with better
exercise capacity and lung function thus did more at home and
with greater intensity after completing rehabilitation. This is
compatible with the subjective improvement in activity of daily
living. As in previously published reports,25 patients with a
better preserved FEVj but worse perception of activity reported
the greatest subjective benefit. The importance of spirometry as
a predictor of outcome after rehabilitation is not entirely
surprising as previous reports have highlighted the role of
ventilatory capacity in determining improvement in walking
distance after rehabilitation.25"28
The Actiwatch device was to be easy to use, acceptable to
patients and had a low failure rate. As a simple strap-mounted
device, it could be worn under clothing and, with a long battery
life, it could be worn overnight and only needed to be removed
for bathing. In contrast, the Dynaport was technically more
difficult to use and, although light in weight, it was larger and
noticeable. It includes both a waist and a leg strap and hence has
to be removed overnight and during washing. The start-up
procedure needs to be completed each morning and ideally both
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batteries and memory card should be changed daily. In choosing
an activity monitor, the ease of use of the Actiwatch has to be
balanced against the more precise body position activity data
obtained with the Dynaport.
Our data provide further support for the usefulness of
monitoring daily activity at home in patients with COPD and
confirm that simple monitoring of leg movement gives useful
insights into daily activity. The intensity and amount of leg
activity a patient undertakes at home gives rather different
results from those predicted by more conventional measure¬
ments such as walking distance, muscle strength and health
status questionnaires. Understanding why people improve some
forms of activity but not others after treatment and what
determines how much of their improved exercise capacity they
use after rehabilitation is an important area of future research
which will be greatly aided by the availability of valid
monitoring methods such as actigraphy.
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Cardiovascular events in patients with CORD: TORCH
Study results
Peter M A Calverley,1 Julie A Anderson,2 Bartolome Celli,3 Gary T Ferguson,4
Christine Jenkins,5 Paul W Jones,6 Courtney Crim,7 Lisa R Willits,2 Julie C Yates,7
Jorgen Vestbo,8 on behalf of the TORCH Investigators
ABSTRACT
Background Previous studies have suggested that long-
term use of (3 agonists to treat chronic obstructive
pulmonary disease (C0PD) may increase the risk of
cardiovascular adverse events. In this post hoc analysis,
data from the TOwards a Revolution in C0PD Health
(TORCH) study were used to investigate whether use of
the long-acting (32 agonist salmeterol over 3 years
increased the risk of cardiovascular adverse events in
patients with moderate to severe COPD.
Methods TORCH was a randomised, double-blind,
placebo controlled study conducted at 444 centres in 42
countries. Patients (n=B184; safety population) received
twice daily combined salmeterol 50 pig plus fluticasone
propionate 500 pg (SFC), either component alone, or
placebo. Adverse events were recorded every 12 weeks
for 3 years.
Results The probability of having a cardiovascular
adverse event by 3 years was 24.2% for placebo, 22.7%
for salmeterol, 24.3% for fluticasone propionate and
20.8% for SFC. Although a history of myocardial
infarction doubled the probability of cardiovascular
adverse events, the event rates remained similar across
treatment groups.
Conclusion Post hoc analysis of the 3-year TORCH
dataset showed that salmeterol alone or in combination
(SFC) did not increase the risk of cardiovascular events in
patients with moderate to severe COPD.
Chronic obstructive pulmonary disease (COPD) is
now recognised as being a highly prevalent condi¬
tion1 that causes significant morbidity and
mortality,2 and commonly coexists with cardiovas¬
cular disease.3 Cardiovascular events are one of the
leading causes of mortality and hospitalisation in
patientswith COPD, particularly in thosewithmild
to moderate disease.4 5 Moreover, COPD is a strong
risk factor for cardiovascular events, independent of
smoking,3 6 7 and impaired lung function is an
important marker for cardiovascular mortality.8 9
However, it is unclear whether COPD interventions
other than smoking cessation4 can modify the
increased cardiovascular risk associated with COPD.
Recently there has been concern that the long-
term use of inhaled bronchodilators commonly
used in the treatment of COPD, including long-
acting P2 agonist (IABA) and anticholinergic drugs,
may increase the risk of cardiovascular
complications.10-14 However, prospective data
about the relative risk of therapy in patients with
sufficient symptoms to be offered treatment with
these drugs has, until recently, been lacking.
While the 3-year TOwards a Revolution in
COPD Health (TORCH) study primarily
investigated the effect of combination therapywith
the LABA salmeterol (SAL) and the inhaled corti¬
costeroid fluticasone propionate (FP) compared
with placebo on all-cause mortality, other efficacy
outcomes and adverse events (AEs) were also
measured. The primary paper including the
mortality analysis has already been published.15 It
reported that long-term use of SAL or the SAL plus
FP combination (SFC) did not increase the rate of
cardiac death. In view of the continuing concerns
about cardiovascular safety in COPD therapy, we
extended this analysis (post hoc) to consider the
occurrence of cardiovascular AEs and serious
adverse events (SAEs) in the TORCH study. We
also explored the factors that might determine the
incidence of cardiovascular events in these patients.
Some of these results have previously been
presented in abstract form.16
METHODS
Patients
Details of patient eligibility and study entry criteria
have been published previously.15 Eligible patients
were current or former smokers aged 40—80 years
with a prebronchodilator forced expiratory volume
in 1 s (FEVi) <60% of the predicted value and
a ratio of prebronchodilator FEVi to forced vital
capacity (FVC) of <0.70. The only exclusion
criterion with respect to comorbidities was that
subjects were considered unlikely to die of some¬
thing other than COPD in the subsequent 3 years.
Design overview
The study design has been described in detail
previously.15 17 TORCH was a multicentre, rand¬
omised, double-blind, parallel-group, placebo
controlled study conducted at 444 centres in 42
countries. After a 2-week run-in period, eligible
patients were stratified by smoking status and
randomised to receive either SFC 50/500 pg, SAL
50 pg, FP 500 pg or placebo twice daily for 3 years
via a Diskus/Accuhaler inhaler (GlaxoSmithKIine,
Greenford, UK). Full details of the randomisation
procedure have been reported elsewhere.15 17
The primary efficacy end point of the TORCH
study was all-cause mortality. Other end points
were rate of COPD exacerbations, health-related
quality of life, lung function and AEs. After
randomisation, patient visits occurred every
12 weeks to record any AE. At each visit the subject
was allowed to spontaneously mention any
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problems, then the investigator asked the following standard
questions: (1) 'Have you had any (other) medical problems since
your last visit/assessment?' and (2) 'Have you taken any new
medicines other than those given to you within this study since
your last visit/assessment?' An AE was defined as any unfav¬
ourable and unintended sign (including a clinically significant
abnormal laboratory finding), symptom or disease temporally
associated with the use of the blinded study product, whether or
not it was considered to be related to that product.
SAEs were those that resulted in any of the following
outcomes: (1) death; (2) an immediate risk of death; (3) hospi¬
talisation or prolongation of an existing hospitalisation; or (4)
any other important medical event which, in the opinion of the
investigator, jeopardised the subject's health. An independent
safety and efficacy data monitoring committee performed safety
reviews of all SAEs every 6 months. Causes of death were
independently adjudicated in a standardised fashion by a clinical
end point committee.18
Cardiovascular safety evaluation
Cardiovascular AEs were classified based on the Medical
Dictionary for Regulatory Activities (MedDRA) Version 8.1
terms. MedDRA is the AE classification dictionary endorsed by
the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH). All events in the cardiac disorders system organ class
plus selected events from the vascular disorders and nervous
system disorders system organ classes were included (table 1).
Further analysis was also conducted on the subset of ischaemic
events and on events related to stroke (table 1). No specific
information was collected about whether patient-reported AEs
had been objectively verified.
Subjects receiving medications commonly used to treat
cardiovascular disease were identified; these medications were
selected from dictionary groupings (listed in table 1).
Statistical analysis
The study was powered for its primary all-cause mortality end
point and was not formally powered to detect differences in
numbers of AEs between treatments.
Table 1 List of MedDRA system organ class (SOC) high-level group
terms (HLGT) used for analysis of cardiovascular events, ischaemic
cardiovascular events and stroke events, and list of cardiovascular
medications included in the analysis
Cardiovascular events Ischaemic events
► Cardiac disorders (SOC) ► Ischaemic coronary artery
- Coronary artery disorders disorders
- Cardiac arrhythmias ► Coronary artery disorders NEC
- Heart failures ► Heart failures NEC
- Cardiac disorder signs and symptoms ► Right ventricular failures
- Myocardial disorders ► Left ventricular failures
- Cardiac valve disorders ► Cardiomyopathies
- Pericardial disorders ► Pericardial disorders NEC
► Nervous system disorders (SOC) ► Non-infectious pericarditis
- Central nervous system vascular disorders Stroke events
► Vascular disorders (SOC) ► Central nervous system
- Arteriosclerosis, stenosis, vascular vascular disorders (HLGT)
insufficiency and necrosis
- Aneurysms and artery dissections
- Embolism and thrombosis
Cardiovascular medications
► ACE inhibitors ► Antiarrythmics
► Angiotensin II antagonists ► Cardiac glycosides
► Antihypertensives ► Adrenergic and dopaminergic
► Beta blockers agents
► Calcium channel blockers ► Organic nitrates
NEC, not elsewhere classified.
The safety population included all patients who took at least
one dose of study medication. The number and proportion of
patients reporting a cardiovascular AE over the 3 years were
summarised by treatment group. To correct for differential
treatment exposure between the treatments, the rate of cardiac
events per 1000 treatment years was calculated by dividing the
total number of AEs by the total number of years patients were
exposed to study treatment, then multiplying by 1000. On-
treatment deaths were defined as any death occurring up to
14 days after patients stopped their study medication.
The time to first cardiovascular AE was compared between
treatment groups using Kaplan—Meier estimates and the log-
rank test, stratified by smoking status; Kaplan—Meier cumula¬
tive incidence curves were also generated. Statistical significance
was set at p<0.05.
RESULTS
Study population
Of 8554 patients with COPD recruited, 6184 were randomised
and evaluated for safety (figure 1). This included 72 patients
from five sites excluded from the published efficacy analyses.15
One subject was randomised to placebo but took FP for the
majority of the treatment period and was analysed with the FP
group-
Demographic and baseline patient characteristics were
balanced across treatment groups (table 2). The mean age was
65 years, 76% were male, mean smoking history was 48 pack-
years and baseline postbronchodilator FEVi was 44% of
predicted. At baseline, 7% of patients reported a history of
previous myocardial infarction (MI), 41% were taking cardio¬
vascular medications and 60% were taking short-acting anti¬
cholinergic drugs. Use of the long-acting anticholinergic
tiotropium bromide during the study was low (3%) and was
similar across treatment groups. Of the 187 subjects receiving
tiotropium, over half took it for 12 weeks or less.
The proportion of patients who withdrew from the study was
highest in the placebo group (44%) and lowest in the SFC group
(34%) (SAL 37%, FP 39%). The total number of patient-years of
exposure to the study drugs was 3278 for placebo, 3531 for SAL,
3555 for FP and 3700 for SFC.
Cardiovascular AEs
The proportion of patients who experienced a cardiovascular AE
or cardiovascular SAlE during the study was similar across
treatment groups (17—20% and 10—12%, respectively) (table 3).
When expressed as the number of events per 1000 treatment
years, the rate of cardiovascular AEs was 142 in the placebo
group and 110 in the SFC group. The probability of patients
having a cardiovascular AE by 3 years was lowest for SFC
at 20.8% (24.2% for placebo, 22.7% for SAL and 24.3% for FP;
figure 2A; table 3). The probability of patients having a cardio¬
vascular SAE by 3 years was lowest for SFC at 12.5% (15.4% for
placebo, 13.6% for SAL and 14.7% for FP; table 3).
The proportion of patients experiencing an ischaemic cardio¬
vascular AE was similar across treatment groups (9—11%;
table 4). The rate of ischaemic cardiovascular AEs per 1000
treatment years was 68 for placebo, 70 for SAL, 62 for FP and 54
for SFC. The probability of patients having an ischaemic cardio¬
vascular AE by 3 years was lowest for SFC at 11.3%, 14.6% for
placebo, 13.4% for SAL and 13.8% for FP (figure 2B and table 4).
The proportion of patients with a stroke-related AE over
the 3-year course of the study was similar in each treatment
group (3% placebo, 2% SAL, 3% FP and 3% SFC). The rate of
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Figure 1 Patient flow. *The number of
patients who underwent randomisation
and the number of those included in the
safety population differ in the placebo
group and the fluticasone propionate
group because one patient who was
assigned to placebo received
fluticasone propionate for more than
half the study period; this patient was
therefore included in the fluticasone
propionate group for the safety
analysis. AE, adverse event.
stroke-related AEs per 1000 treatment years was 17 for placebo,
13 for SAL, 16 for FP and 12 for SFC.
The likelihood of experiencing a cardiovascular AE was unaf¬
fected by gender and current smoking status (table 5). Patients
who were on cardiovascular medications at baseline (figure 3),
reported a previous MI (figure 4), were older or had lower
baseline FEVj (table 5) had a higher probability of having
a cardiovascular AE. There were no significant differences
between treatments in the likelihood of an event being reported,
nor was there consistent evidence for an interaction between
treatment and spirometrically-defined disease severity with
respect to cardiac events (see table 1 in online supplement) . In
patients who had previously had an MI, the likelihood of having
a cardiovascular event over 3 years was 54.4% on salmeterol
compared with 49.1% with placebo (p =0.51) and 44.1% with
SFC (p=0.051 relative to salmeterol (figure 4B and table 5).
Table 2 Patient demographic and baseline characteristics of the safety population
Placebo Salmeterol FP SFC
Variable (n= 1544) (n =1542) (n =1552) (n =1546)
Age at enrolment, years 65.1 (8.1) 65.2 (8.2) 65.1 (8.4) 65.0 (8.3)
Male gender, n (%) 1175 (76) 1176 (76) 1169 (75) 1164 (75)
Body mass index, kg/m2 25.5 (5.2) 25.4 (5.2) 25.3 (5.1) 25.4 (5.3)
Postbronchodilator FEV], % predicted 44.1 (12.2) 43.6 (12.6) 44.1 (12.3) 44.3 (12.4)
<30%, n (%) 215 (14) 261 (17) 223 (14) 246 (16)
30—< 50%, n (%) 786 (51) 750 (49) 785 (51) 735 (48)
2:50%, n (%) 543 (35) 531 (34) 544 (35) 565 (37)
Geographical region, n (%)
USA 348 (23) 351 (23) 350 (23) 352 (23)
Asia Pacific 188 (12) 189 (12) 193 (12) 188 (12)
Eastern Europe 297 (19) 296 (19) 293 (19) 293 (19)
Western Europe 478 (31) 475 (31) 481 (31) 477 (31)
Other 234 (15) 231 (15) 234 (15) 236 (15)
Current smoker, n (%) 664 (43) 657 (43) 666 (43) 667 (43)
Pack-years smoked 48.6 (27.0) 49.3 (27.7) 49.2 (28.5) 46.9 (26.5)
Previous C0PD treatment, n (%)*
ICS alone 346 (22) 278 (18) 310 (20) 295 (19)
LABA alone 118 (8) 138 (9) 133 (9) 137 (9)
ICS + LABA 453 (29) 417 (27) 416 (27) 437 (28)
Neither ICS nor LABA 557 (36) 634 (41) 629 (41) 623 (40)
Previous Ml, n (%) n=1543 n=1541 n=1552 n=1545
0 1432 (93) 1427 (93) 1460 (94) 1443 (93)
1 91 (6) 93 (6) 79 (5) 83 (5)
>2 29(1) 21 (1) 13 (<1) 19(1)
Baseline CV treatment, n (%)f 608 (39%) 630 (41%) 630 (41%) 662 (43%)
Baseline short-acting anticholinergics, n (%) 926 (60%) 921 (60%) 943 (61%) 925 (60%)
Data are mean (SD) unless otherwise indicated.
CV, cardiovascular; FEV,, forced expiratory volume in 1 s; FP, fluticasone propionate; ICS, inhaled corticosteroid; LABA, long-acting p2
agonist; Ml, myocardial infarction; SFC, salmeterol/fluticasone propionate combination.
*Self-reported in the 12 months prior to screening.
fSee list in table 1.
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Table 3 Summary of all cardiovascular AEs and SAEs
Placebo Salmeterol FP SFC
(n =1544) (n= 1512) (n= 1552) (n= 1546)
All CV AEs
Patients with CV AE, n (%) 281 (18) 287 (19) 306 (20) 267 (17)
Rate* of CV AE (no of events) 142 (466) 141 (496) 130 (462) 110 (405)
Probability! of CV AE by 24.2 22.7 24.3 20.8
3 years, %
Hazard ratio 95% CI p Value
SFC vs placebo 0.83 0.70 to 0.98 0.031
Salmeterol vs placebo 0.96 0.82 to 1.13 0.629
FP vs placebo 1.00 0.85 to 1.18 0.994
CV SAEs
Patients with CV SAE, n (%) 176 (11) 168(11) 180 (12) 160 (10)
Rate* of CV SAE (no of events) 75 (245) 66 (234) 66 (236) 57 (209)
Probabilityf of CV SAE by 15.4 13.6 14.7 12.5
3 years, %
Hazard ratio 95% CI p Value
SFC vs placebo 0.81 0.65 to 1.00 0.046
SAL vs placebo 0.89 0.72 to 1.10 0.268
FP vs placebo 0.94 0.76 to 1.15 0.542
*Rate=number of events per 1000 treatment years.
fKaplan—Meier probability.
AEs, adverse events; CV, cardiovascular; FP, fluticasone propionate; SAEs, serious adverse
events; SFC, salmeterol/fluticasone propionate combination.
However, the pattern of risk in other groups was inconsistent
with salmeterol-treated patients having a similar incidence of
events to patients treated with FP, as identified by their use of
previous cardiac therapies (figure 3B). Patients who were taking
short-acting anticholinergic treatment at baseline had a higher
probability of cardiovascular events (table 5); however, these
patients also had lower baseline percentage predicted FEVj. The
pattern of cardiovascular events was similar across treatment
groups irrespective of baseline anticholinergic use.
Cardiovascular deaths
There were 882 deaths (14%) during the 3-year study period,
including those both on and off study treatment (see table 2 in
online supplement). Of these, 239 were due to cardiovascular
causes as adjudicated by the clinical end point committee. For
placebo, 71 deaths (4.6%) were due to cardiovascular causes
compared with 45 (2.9%) for SAL, 61 (3.9%) for FP and 62 (4.0%)
for SFC. There were 468 deaths while on treatment, of which
172 were due to cardiovascular causes. For placebo, 47 (3.0%)
deaths were due to cardiovascular causes compared with 33
(2.1%) for SAL, 43 (2.8%) for FP and 49 (3.2%) for SFC.
DISCUSSION
COPD is not simply a lung disease19 but is associated with an
increased likelihood of complications outside the lungs. Support
for this concept comes from recent studies that have shown
significantly increased pulse wave velocity, independent of
smoking status and other risk factors, in patients with stable
COPD. 0 In these circumstances it is no surprise that cardio¬
vascular morbidity and mortality is high in COPD.
Both (3 agonists and antimuscarinic agents, the main classes of
bronchodilator drugs used to treat COPD, have the potential to
precipitate cardiac rhythm disturbances and other cardiac
events; however, this has not been regarded as important in
clinical practice until recently. Unfortunately, unlike the situa¬
tion for cardiovascular disease, most studies of drug treatment in
COPD have been relatively brief (si year) and have only













Time to cardiovascular AE (weeks)
No. of patients
Placebo 1544 1231 1074 974 883 805 521
SAL 1542 1293 1150 1036 946 878 593
FP 1552 1323 1175 1074 981 884 565
SFC 1546 1364 1226 1127 1039 963 644
B
Time to ischaemlc cardiovascular AE (weeks)
No. of patients
Placebo 1544 1257 1109 1021 939 866 571
SAL 1542 1319 1201 1099 1 019 953 643
FP 1552 1347 1215 1127 1037 958 615
SFC 1546 1387 1260 1178 1100 1035 702
Figure 2 Cumulative incidence of (A) all cardiovascular adverse events
and (B) ischaemic cardiovascular adverse events. Full details of the data
presented in (A) and (B) including statistical testing are shown in tables
3 and 4, respectively. Vertical bars represent standard errors. AE,
adverse event; FP, fluticasone propionate; SAL, salmeterol; SFC,
salmeterol/fluticasone propionate combination.
contribution to the systematic reviews in this field, at least as far
as patients receiving treatment for symptoms are concerned. As
the TORCH study was conducted in a patient group likely to be
prescribed inhaled LABAs, the TORCH dataset addresses some
of the problems inherent in these earlier analyses. The current
analysis provides generally reassuring results about the cardio¬
vascular safety of inhaled LABA treatments in patients with
COPD.
TORCH is the largest and longest prospective trial to examine
the role of an inhaled LABA and an inhaled corticosteroid in
COPD. Half of the >6000 patients were randomised to a regime
containing SAL and, allowing for dropouts, this provides 7231
patient-years of exposure to these agents. Over the 3 years,
approximately 1 in 5 patients experienced a cardiovascular AE.
The event rate was lowest in those receiving SAL in combination
with FP and not different from those patients treated with
placebo or with LABA monotherapy. A SAE requiring hospital¬
isation and new cardiovascular ischaemic events were approxi¬
mately half as common as the total cardiovascular event rate,
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Patients with ischaemic 166 (11) 166 (11) 167 (11) 144 (9)
<
30 -CV AE, n (%)
Rate* of ischaemic CV AE 68 (224) 70 (240) 62 (222) 54 (199) o
(no of events) nj>
Probability! of ischaemic 14.6 13.4 13.8 11.3 o 20 -
CV AE by 3 years, % c03
Hazard ratio 95% CI p Value "5 15-
SFC vs placebo 0.76 0.61 to 0.95 0.016
>•
10 -
Salmeterol vs 0.93 0.75 to 1.16 0.531 ja
placebo 43o 5-
FP vs placebo 0.93 0.75 to 1.15 0.477 CL
n -
No prior CV medication
*Rate=number of events per 1000 treatment years.
fKaplan—Meier probability.
AEs, adverse events; CV, cardiovascular; FP, fluticasone propionate;
SEC, salmeterol/fluticasone propionate combination.
but there was a similar pattern across treatment groups. Seven
percent of patients had a history of previous MI. In this group
the cardiovascular event rate, as would be expected, was higher.
Again, no trend was seen for more AEs in those patients rand¬
omised to treatment with SAL in combination with FP.
However, the data for SAL alone are inconclusive, possibly due
to the small sample size in this smaller subgroup of patients.
Unlike other COPD studies, TORCH developed a rigorous
methodology for determining the likely cause of death which
was adjudicated by an expert panel blinded to the study medi¬
cation. Moreover, there was effectively complete follow-up of
the vital status of all patients 3 years after randomisation. In
this data set, the patients randomised to LABA alone had the
Table 5 Kaplan—Meier probability of a cardiovascular adverse event
by 3 years by subgroups
Placebo Salmeterol FP SFC
N (n= 1544) (n= 1542) (n = 1552) (n= 546)
Age
<55 706 13.2 12.5 13.4 13.4
55-64 1988 20.2 18.8 20.7 17.4
65-74 2706 26.6 24.8 26.9 22.1
>75 784 39.2 34.9 35.4 32.9
Sex
Male 4684 24.4 23.0 24.0 20.7*
Female 1500 23.4 21.9 25.3 21.0
Smoking status
Current 2654 22.2 22.0 22.4 20.5
Former 3530 25.8 23.3 25.9 20.9*
Baseline FEV,
<30% 945 25.8 32.1 26.7 23.5
30—<50% 3056 25.7 20.7 25.4 23.4
>50% 2183 21.7 21.7 21.8 16.2*
Baseline CV treatment
Yes 2530 33.5 30.3 30.4 27.9*
No 3654 18.3 17.6 20.2 15.4
Prior Ml
Yes 419 49.1 54.4 41.0 44.1
No 5762 22.2 20.2 23.3 19.1
Baseline short-acting anticholinergics
Yes 3715 25.2 24.0 25.6 22.0
No 2469 22.7 21.0 22.4 18.9
*p<0.05 versus placebo.
CV, cardiovascular; FEV,, forced expiratory volume in 1 s; FP, fluticasone propionate;
Ml, myocardial infarction; SFC, salmeterol/fluticasone propionate combination.
Placebo (n = 936)
SAL (n = 912)
FP (n = 922)
SFC (n = 884)
24 48 72 96
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Figure 3 Cumulative incidence of all cardiovascular adverse events in
patients who (A) did not receive or (B) did receive cardiovascular
medication (listed in table 1) in the 12 months prior to screening. Full
details of the data presented in this figure including statistical testing are
shown in table 5. Vertical bars represent standard errors. AE, adverse
event; CV, cardiovascular; FP, fluticasone propionate; SAL, salmeterol;
SFC, salmeterol/fluticasone propionate combination.
lowest rate of cardiovascular death while those who received
placebo had the largest number of events. The number of on-
treatment deaths, analogous to data included in earlier COPD
studies, showed a similar pattern across treatments.
A range of predictable factors increases the cardiovascular event
rate including higher age, a history of previous cardiac disease and
worse lung function. None of these factors interacted with
treatment to identify a specific 'at-risk' group. Somewhat
surprisingly we saw no difference in event rate between current
and ex-smokers, which may reflect our study entry criteria or
possibly the nature of cardiovascular disease in patients with
COPD. We did not control for the use of inhaled anticholinergic
drugs although, when used, this was predominantly ipratropium
as tiotropium was not available in most countries until
TORCH was nearing completion. In those patients treated with
an anticholinergic agent, there was a suggestion of a somewhat
higher cardiovascular event rate but these patients also had lower
baseline lung function. The association seen is therefore likely to
represent the confounding influence of disease severity, an issue
that has made interpretation of previous studies of COPD
therapy particularly difficult. Patients in GOLD stage 4 receiving
salmeterol appeared to have more cardiac events, although the
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Time to cardiovascular AE (weeks)
Time to cardiovascular AE (weeks)
Figure 4 Cumulative incidence of all cardiovascular adverse events in
patients who (A) had not experienced or (B) had experienced
a myocardial infarction prior to study entry. Full details of the data
presented in this figure including statistical testing are shown in table 5.
Vertical bars represent standard errors. AE, adverse event; FP,
fluticasone propionate; Ml, myocardial infarction; SAL, salmeterol;
SFC, salmeterol/fluticasone propionate combination.
differences between treatment groups were not significant. This
finding is at odds with the lower than average reported incidence
of events with salmeterol in GOLD stage 3 and probably reflects
the lower sample size in the GOLD stage 4 population with
correspondingly widened confidence intervals for these data.
Our study has strengths and some limitations. We monitored
our patients regularly throughout the 3-year study, but events
were self-reported rather than being in response to a prede¬
termined diagnostic list. We did not undertake ECG or echo-
cardiographic evaluations at the study outset and there was no
requirement to provide objective documentation of the nature of
any new cardiovascular episode. However, we did include
patients with a history of cardiovascular disease provided it was
not thought that this was the main cause for their symptoms or
that they were likely to die from this during the study. This is an
important difference from earlier studies where more restrictive
eligibility criteria were applied. As in other large COPD studies,
for example UPLIFT21 and TRISTAN,22 patients randomised to
placebo tended to withdraw more frequently than those rand¬
omised to active therapy, probably reflecting their deteriorating
condition. Thus, patients continuing in the placebo arm of our
on-treatment analysis represent a relatively fitter group of
patients with COPD. Despite this, we saw no suggestion that
patients on treatment were more likely to experience adverse
cardiovascular problems. Finally, we lack data about whether the
use of these agents increases the risk of cardiovascular events
during an acute exacerbation. Recent literature reviews have
failed to report any association between use of high-dose
(3 agonists and risk of arrhythmias in this setting.23
For some of our data the SFC combination appeared to be
associated with important reductions in the incidence of adverse
cardiovascular events. Although this difference may simply have
been due to chance, other biologically plausible mechanisms
exist which can account for this effect. It has been suggested
that inflammation occurring in COPD might directly promote
vascular damage24 and this may be reduced when airway
inflammation is decreased, as has been demonstrated with
a LABA/inhaled steroid combination.25 Our data cannot address
this hypothesis, but this concept is supported by recent obser¬
vations from a large database study that patients who used
inhaled corticosteroids were less likely to experience cardiovas¬
cular deaths than those who received bronchodilators alone.12
This is consistent with the general conclusions of the TORCH
study that there was a reasonable (but not conclusive proba¬
bility that combination treatment with SAL plus FP prolongs
life in COPD. An alternative explanation for the effect of SFC on
cardiovascular outcomes may be its relative efficiency in
preventing exacerbations of COPD which are associated with
elevations in troponin T and a raised cardiac infarction injury
score, at least in hospitalised patients.26 27 Further studies will
be needed to address whether these potentially important
mechanisms best explain the observed data.
In summary, in this large prospectively collected dataset, the
occurrence of new cardiovascular AEs was no more frequent in
patients treated with a LABA than in those treated with placebo.
In addition, we saw some evidence that the combination of
a LABA and an inhaled corticosteroid might offer a degree of
cardioprotection. These data from patients with moderate to
severe COPD provide reassurance that our current use of inhaled
LABA therapies is not harmful to cardiovascular health.
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COPD
Reported Pneumonia in Patients
With COPD
Findings From the INSPIRE Study
Peter M. A. Calverley, MB; Robert A. Stockley, MD, DSc; Terence A. R. Seemungal, PhD;
Gerry Hagan, MD; Lisa R. Willits, MSc; John H. Riley, MD; andJadwiga A. Wedzicha, MD;
on behalfofthe Investigating New Standardsfor Prophylaxis in Reduction of
Exacerbations (INSPIRE) Investigators
Background: Pneumonia is an important complication of COPD and is reported more often in
patients receiving inhaled corticosteroids (ICSs). Little is known about the clinical course and
factors predisposing to pneumonia in patients with COPD. We investigated patient characteris¬
tics and symptoms occurring before pneumonia reports in the Investigating New Standards for
Prophylaxis in Reduction of Exacerbations (INSPIRE) study.
Methods: This was a 2-year, double-blind, double-dummy parallel study of 1,323 patients random¬
ized to salmeterol/fluticasone propionate 50/500 jxg bid (SFC) or tiotropium 18 |xg once daily
(Tio). Raseline demographics, including serum C-reactive protein (CRP) levels, were measured,
and daily record cards (DRCs) were completed.
Results: We identified 87 pneumonia reports from adverse event records (SFC = 62; Tio = 25) in
74 patients (SFC = 50; Tio = 24), compared with 2,255 exacerbations (SFC = 1,185; Tio = 1,070). Pneu¬
monia was more common in patients with severe dyspnea and in those with a baseline CRP level
> 10 mg/L. Numbers of de novo pneumonias (events that were not preceded by symptoms ofan exac¬
erbation) were similar between treatment groups, but pneumonia was more likely after either a
treated or untreated unresolved exacerbation in patients receiving ICSs (SFC = 32; Tio = 7). Similar
results were seen when analysis was confined to radiologically confirmed events.
Conclusions: Pneumonia is much less frequent than exacerbation in COPD. The excess of events
with ICS treatment appears to be associated with protracted symptomatic exacerbations. Earlier
identification and treatment of these events to prevent pneumonia merits further investigation.
Trial registry: ClinicalTriaIs.gov; No.: NCT00361959; Study No.: SC040036; URL: clinicaltrials.gov
CHEST 2011; 139(3):505-512
Abbreviations: BDI = baseline dyspnea index; CRP = C-reactive protein; DRC = daily record card; HCU = health-care
use; HR = hazard ratio; ICS = inhaled corticosteroid; INSPIRE = Investigating New Standards for Prophylaxis in Reduction
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"Pneumonia is the sixth leading cause of death and
-®- die leading cause ofdeath from infectious disease.1'2
Multiple sets of treatment guidelines for pneumonia
exist,35 and their implementation has significantly
reduced morbidity and mortality of the disease.6 8
Patients with pneumonia commonly present with
one or more symptoms, such as cough, fever, chills,
fatigue, dyspnea, rigors, and pleuritic chest pain
with or without respiratoiy signs. Chest radiograph
enables a definitive diagnosis of pneumonia to be
www.chestpubs.org
made, although guidance differs as to whether this
investigation is mandatory.9 The diagnosis of COPD
exacerbations includes episodes in which cough,
For editorial comment see page 483
sputum, and breathlessness are major symptoms.10
Without a chest radiograph, distinguishing between
pneumonia and a COPD exacerbation can be difficult.
Patients with COPD are at greater risk of developing
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pneumonia than the general population,11-12 and
patients with COPD who are hospitalized with pneu¬
monia fare worse than patients without COPD.13 A
database review suggested that using inhaled corti¬
costeroids (ICSs) increases tire risk of hospitalization
with pneumonia,14 but this may be confounded by dis¬
ease severity, as ICS/long-acting (3-agonists (LABAs)
are recommended for patients with recurrent exacer¬
bations.15 Two large prospective randomized con¬
trolled trials identified an increased risk of physician-
reported pneumonia in patients receiving treatments
containing the ICS fluticasone propionate.16-17 This
finding was confirmed using a lower dose of ICS18-19
but was not seen in an analysis of trials using budes-
onide.20 In the Toward a Revolution in COPD Health
(TORCH) study, only limited information was available
about tire clinical course of the pneumonias reported.21
In the Investigating New Standards for Prophylaxis
in Reduction of Exacerbations (INSPIRE) study,
patients recorded their symptoms on daily record
cards (DRCs) throughout the 2-year study. This pro¬
vided a unique opportunity to study the temporal
relationship between common patient-reported respi¬
ratory symptoms and the occurrence of physician-
reported pneumonia in a carefully characterized group
of patients with COPD.
As hospitalization rates due to pneumonia did not
differ in patients treated with placebo or bronchodi-
lators alone,1619 we hypothesized that treatment with
ICS would influence the type and duratioir of the
symptoms preceding clinical diagnosis of pneumo¬
nia and that patients with pneumonia would differ
in their baseline characteristics from those without
pneumonia. To test these ideas, we reviewed patient
DRCs to determine whether any distinctive patterns
of symptoms were associated with pneumonia.
Materials and Methods
The study methodology and primaiy outcomes of the INSPIRE
study have been published.17-22 Patients were randomized to
Manuscript received January 4, 2010; revision accepted June 8,
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receive salmeterol plus fluticasone propionate 50/500 pg bid
(SFC) or tiotropium bromide 18 pg once daily (Tio) in a 2-year,
multicenter, double-blind, double-dummy parallel study.
Baseline measurements included age, sex, smoking status, FEVj
(before and after 400 pg salbutamol), health status using the
St. George's Respiratory Questionnaire (SGRQ),23 modified
Medical Research Council (MRC) breathlessness score, base¬
line dyspnea index (BDI),24 prior exacerbation histoiy, and prior
ICS use. At randomization, FEVj, SGRQ, and BDI were col¬
lected,17 blood was taken, and CRP was measured in serum by
Quest Diagnostics using a high-sensitivity nephelometry assay.
Patients attended at 2 and 8 weeks postrandomization and then
every 3 months for a total of 2 years. The study was approved by
local ethics review committees and was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines.
Outcomes
No a priori definition ofpneumonia existed in the study proto¬
col and episodes were identified from adverse event reports
of pneumonia (reported pneumonias), bronchopneumonia, and
lobar pneumonia. Pneumonia reports defined as serious adverse
events (those that were fatal, life threatening, or resulted in
hospitalization) were reviewed by a physician to determine if a
chest radiograph was used in the diagnosis and whether it con¬
firmed the features of pneumonia. The start and resolution of a
pneumonia event (ie, duration) was determined by the study-site
investigator.
Daily Record Cards
Patients recorded increased symptoms of cough, breathless¬
ness, colds, wheeze, and whether they had a fever and/or sore
throat in the previous 24 h in their DRC. Sputum color and vol¬
ume were scored as described previously.25 A change in sputum
color or volume was defined as an increase of at least one unit
from baseline (median during run-in) with a minimum value of
three for sputum color and one for sputum volume.
Symptom-defined exacerbations were determined using DRCs.
Thesewere identified as an acute worsening of two or more major
symptoms (dyspnea, sputum volume, or purulence) or one major
symptom and a minor symptom (sore throat, wheeze, colds, fever,
increased cough) for at least 2 consecutive days.10-26 Health-care
use (HCU) exacerbations15 were those treated by oral corti¬
costeroids and/or antibiotics or those in which the patient was
hospitalized. An untreated exacerbation was a symptom-defined
exacerbation wherein the case report form showed no medical
intervention. An exacerbation was considered resolved when asso¬
ciated symptoms returned to normal for 5 consecutive days. The
day of resolution of the exacerbation was the day on which the last
symptom of the exacerbation was stated in the DRC.
For all pneumonia reports, the DRC was analyzed for 35 days
before and 21 days after diagnosis. Initially, the number ofpatients
reporting an increase in a specific symptom on each day was
plotted. Subsequently, the occurrence of a COPD exacerbation
as defined above was related to the onset of the pneumonia event
identified from the adverse event report. These data were reviewed
in a random order by four physician members of the Steering
Committee (P. M. A. C., R. A. S., T. A. R. S., J. A. W.) who were
blinded to treatment allocation in order to define the relationship
between symptom onset and the report of die pneumonia.
In this post hoc analysis, two complementary approaches to
classifying the progression of events were adopted: a rule-based
approach or a pattern-based approach. The rule-based approach
involved the independent application ofone of three prespecified
definitions of the events preceding a pneumonia diagnosis:
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pneumonia following HCU exacerbation, pneumonia following
an untreated exacerbation, or de novo pneumonia (few symptoms
before the event onset and no prior exacerbation).
Discrepant categorizations between physicians were reviewed
jointly and a consensus reached. Full definitions for the rule-
based approach and a description of the pattern-based approach,
which was used to further characterize the prodrome, are pre¬
sented in e-Appendix 1.
Statistical Analysis
The time to first pneumonia was compared between treatments
using a Cox proportional hazards analysis adjusted for smoking
status, age, sex, disease severity (% predicted FEVj), and countiy.
The effect of different baseline predictors of pneumonia was
investigated using the same model adjusted for treatment, smok¬
ing status, age, sex, disease severity, and countiy, with additional
covariates of previous exacerbation histoiy, BMI, baseline SGRQ
total score, modified MRC score, baseline dyspnea index score,
and CRP. Kaplan-Meier plots were generated for time to first
pneumonia event and for three predefined ranges of baseline
CRP.27 The effects of different predictors of pneumonia were
summarized by hazard ratios (HRs) and 95% CI. No formal statis¬
tical analysis was conducted for the descriptive data relating symp¬
toms to pneumonia diagnosis.
Results
In the 1,930 patient-years of evaluable postran-
domization data there were 2,255 HCU exacerbations
(1,185 SFC; 1,070 Tio) and 5,152 symptom-defined
events (2,720 SFC; 2,432 Tio). Pneumonia events
were reported by 74 patients on 87 occasions (SFC:
50 patients, 62 events; Tio: 24 patients, 25 events
(Fig 1, Table 1). The estimated on-treatment proba¬
bility ofhaving pneumonia by 2 years was 9.4% in the
SFC arm and 4.9% in the Tio arm. The I1R for time
to first pneumonia was 1.94 (95% CI, 1.19-3.17) for
SFC vs Tio (P = .008) (Fig 2). Restricting the analysis
DRC review
23 events
figure 1. Reported pneumonia events in the Investigating New
Standards for Prophylaxis in Reducing Exacerbations (INSPIRE)
Study (Consolidated Standards of Reporting Trials [CONSORT]
diagram). *Three events widiin 1 week of randomization; one eventexcluded as within 2 weeks of another event. fTwo events within
1 week of randomization. DRC = daily record card; SFC = salme-
terol/fluticasone propionate 50/500 pg bid; Tio = tiotropium 18 pg
once daily.
www.chestpubs.org
Table 1—Number ofPatients with Reported Pneumonia
Events





Patients 41 (6) 19 (3)
Events" 52 19
Fatal pneumonia
Patients 3 (<1) 0
Events 3 0
All pneumonia 62 25
Duration, mean (SD), d 19.4 (19.8) 23.0 (21.7)
<1 wk 4(6) 0
1 to < 2 wk 26 (42) 9(36)
2 to < 3 wk 15 (24) 10 (40)
3 to < 4 wk 5(8) 1(4)
S:4 wk 12 (19) 5(20)
Data are expressed as No. (%) unless otherwise noted. SFC = salmeterol/
fluticasone propionate 50/500 pg bid; Tio = tiotropium bromide 18 pg
once daily.
"Patients can have more than one event.
to the 50 radiographically confirmed events did not
change this conclusion (HR, 1.98%; 95% CI, 1.04-3.76;
P = .037).
Of the 87 reported pneumonias, 71 episodes in
60 patients were identified as serious adverse events
(SFC: 41 patients; Tio: 19). A chest radiograph was
performed for 64 (90%) serious events, and 50 showed
the presence of infiltrates, consistent with the diag¬
nosis of pneumonia. Three patients in the SFC arm
who were hospitalized with pneumonia died.
The duration of all reported pneumonias is sum¬
marized in Table 1. Within the first 2 weeks, 48% of
SFC-reported and 36% of Tio-reported pneumo¬
nias resolved. Approximately 20% of reported pneu¬




SFC 50/500 656 549 510 490 469 450 426 415 150
Tio 18 664 543 497 468 442 426 405 387 136
Time to event (weeks)
Figure 2. Time to first pneumonia. See Figure 1 legend for expan¬
sion of abbreviations.
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Table 2—Review ofSymptoms
Pneumonia Events SFC (n = 658) Tio (n = 665)
Total, self-reported 58 (34) 23 (13)
(radiographically confirmed)
Rule classification
De novo 22(10) 16 (10)
HCU exac 16(11) 3(2)
Untreated exac 20 (13) 4(1)
Pattern classification
De novo 15 (7) 11 (7)
Resolved HCU exac 4(1) 0(0)
Resolved untreated exac 2(0) 3(0)
Unresolved HCU exac 17 (12) 4(2)
Unresolved untreated exac 15(11) 3(2)
Insufficient data 5(3) 2(2)
A total of 47 radiologically confirmed events are included (numbers in
parentheses), as three events confirmed as being pneumonic in nature
occurredwithin 7 days of randomization andwere believed unlikely to
be related to randomizedtherapy. Exac = exacerbation; IICU = health¬
care use. See Table 1 legend for expansion of other abbreviations.
Symptoms Associated With Pneumonia Events
A general increase in patient symptoms prior to a
reported pneumonia was observed independent of
treatment arm. There was an increase in reported
sputum volume and cold symptoms at pneumonia
onset with SFC, whereas fever was more common in
pneumonias in the Tio group (e-Figure 1).
Exacerbations and Pneumonia
DRC completion rate was 98% overall, 91% in the
5 weeks before a pneumonia diagnosis and 70% dur¬
ing the reported pneumonia. Five reported pneu¬
monias occurring within 1 week of randomization
(SFC = 3; Tio = 2) and two reports in one patient
within 5 days of each other (SFC) were considered a
single event and were excluded. This left 81 reported
pneumonias for further characterization, although
seven (9%) had insufficient DRC data for character¬
ization using the pattern-based approach. e-Figure 2
shows examples of the DRC data in three pneumonia
categories using the rule-based approach. This analy¬
sis (Table 2) identified 22 and 16 de novo reported
pneumonias in the SFC and Tio arms, respectively,
16 HCU exacerbations that preceded the reported
pneumonias in the SFC group (7 antibiotic treated;
1 corticosteroid treated; 8 both) and 3 in the Tio group
(1 of each treatment group). Similarly, 20 untreated
exacerbations preceded reports of pneumonia in the
SFC group vs 4 in the Tio group. Pattern-based
approach results were consistent with those of the
rule-based approach. When this analysis was confined
to events in which there was known radiologic abnor¬
mality and which occurred more than 7 days after
randomization to trial treatment (Table 2), an even
clearer picture emerged with identical numbers of
de novo events in each group but more unresolved
exacerbations among pneumonias in the SFC-treated
patients.
Predictors ofthe Risk ofPneumonia in Patients
With COPD
The baseline demographics of die treatment groups
were similar irrespective of the subsequent occur¬
rence of pneumonia (Table 3). Table 4 summarizes
the frequency of reported pneumonia by different
subgroups. Among 550 patients from Eastern Europe,
41 (8%) had at least one pneumonia reported, com¬
pared with 33 (4%) of 773 patients from Western
Europe.
Covariate analyses (Table 5) showed pneumonia
was significantly more likely in patients with baseline
CRP > 10mg/L vs < 3 mg/L (P = .004), a difference
that became more apparent over time (Fig 3). After
adjustment for other predictive factors, patients with
a BDI of 0 to 4 had an estimated increased risk of
pneumonia at any time during the 2-year study of 131%
Table 3—Baseline Characteristics ofPatients with Pneumonia Events
Pneumonia No Pneumonia
Characteristic SFC (n = 50) Tio (n = 24) SFC (n = 608) Tio (n = 641)
Age.y 64(8) 6S (6) 64(8) 64 (8)
Men, % 86 96 81 83
BMI, kg/m2 25(4) 25(7) 26 (5) 25(5)
Current smokers, % 28 50 38 38
Prebronchodilator FEVj," L 1.03 (0.25) 1.16(0.31) 1.05 (0.30) 1.06 (0.31)
Postbronchodilator FEW" L 1.12 (0.27) 1.21 (0.27) 1.11 (0.30) 1.13 (0.31)
Postbronchodilator FEVj, % predicted" 37 (8) 41 (7) 39 (8) 39 (9)
SGRQ total score" 53 (16) 58(14) 50 (18) 52 (17)
Prior ICS use, % 52 38 48 52
Patients with at least one exacerbation in previous 12 mo, % 92 92 85 88
Patientswith at least one moderate/severe exacerbation in previous 12 mo, % 74 75 72 73
Data are expressed as mean (SD) unless otherwise noted. ICS = inhaled corticosteroid; SGRQ = St. George's Respiratory Questionnaire. See
Table 1 legend for expansion of other abbreviations.
aTaken at screening.
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Table 4—Patients With Pneumonia Events by Subgroup
Subgroup SFC (n = 658) Ho (n = 665)
Region
Western Europe 23/384 (6) 10/389 (3)
Eastern Europe 27/274 (10) 14/276 (5)
Smoking status
Current 14/247 (6) 11/254(4)
Former 36/411 (9) 12/411 (3)
Age
<65 22/311 (7) 8/315 (3)
>65 28/347 (8) 16/350 (5)
Sex
Male 43/533 (8) 22/556 (4)
Female 7/125 (6) 1/109 (< 1)
% Predicted FEVj at
screening
<30% 11/100(11) 2/103 (2)
>30% 39/558 (7) 22/562 (4)
Prior exacerbation
0 13/182 (7) 6/182 (3)
1 14/196 (7) 9/193 (5)
>2 23/280 (8) 9/290 (3)
BMI
<20 3/75 (4) 2/69 (3)
20 to < 25 23/244 (9) 17/271 (6)
25 to < 29 13/206 (6) 3/185 (2)
>29 11/133 (8) 1/140 (< 1)
SGRQ at screening
<40 11/168 (7) 2/157 (1)
40 to < 55 17/200 (9) 7/181 (4)
>55 19/251 (8) 13/287 (5)
CRP
<3 17/275 (6) 7/279 (3)
3-10 16/219 (7) 8/225 (4)
>10 15/113 (13) 6/113 (5)
MRC score
0-2 36/435 (8) 13/406 (3)
3-4 14/223 (6) 11/259 (4)
BDI
0-4 20/190 (11) 8/225 (4)
5-6 17/287 (6) 8/268 (3)
>7 12/175 (7) 7/158 (4)
Data are presented as No. of patients with pneumonia/No. in sub¬
group (%). BDI = baseline dyspnea index; CRP = C-reactive protein;
MRC = Medical Research Council. See Table 1 and 3 legends for
expansion ofother abbreviations.
compared with those with a BDI of 5 to 6 (P = .01)
and of 117% compared with those with a BDI of s 7
(P = .06).
Discussion
Our data provide important new insights into the
relationships of respiratory symptoms used to define
COPD exacerbations and the occurrence of physician-
diagnosed pneumonia.We found that reported symp¬
toms increased prior to pneumonia. Patients receiving
the ICS/LABA combination were more likely to have
had an unresolved exacerbation before a pneumonia
www.chestpubs.org
Table 5—HRsfor Predictors ofPatients
with Pneumonia
Covariate Comparison HR 95% CI
Smoking status Current vs former 1.02 0.58-1.78
Age.y a 65 vs < 65 1.57 0.91-2.70
% Predicted FEVj a 30 vs < 30 0.83 0.42-1.63
Previous exacerbations 1 vs 0 1.25 0.61-2.55
a 2 vs 0 1.14 0.55-2.33
BMI, kg/m2 20 to < 25 vs < 20 1.39 0.56-3.44
25 to < 29 vs < 20 0.85 0.31-2.34
a 29 vs < 20 0.97 0.33-2.83
SGRQ 40 to <55 vs<40 0.89 0.41-1.97
a55 vs<40 0.74 0.32-1.68
CRP, mg/L 3 to 10 vs < 3 1.43 0.75-2.72
> 10 vs < 3 2.60 1.36-5.00
MRC 3-4 vs 1-2 0.75 0.39-1.42
BDI 0-4 vs 5-6 2.31 1.23-4.35
0-4 vs a 7 2.17 0.98-4.78
HR = hazard ratio. See Table 3 and 4 legends for expansion of other
abbreviations.
diagnosis. Bisk factors, including increased CRP
levels, were associated with increased risk of pneu¬
monia but did not explain the greater propensity of
ICS-treated patients to report pneumonia.
Like the TORCH study, pneumonia was not an
anticipated adverse event when the INSPIRE study
began, and no specific measures were taken to cap¬
ture diagnostic information. If pneumonia involved a
hospital visit, and chest radiographs were performed
(64 cases), 78% were radiographically consistent with
the diagnosis of pneumonia. Even allowing for this
lower rate of radiographically confirmed events and tire
differential withdrawal on Tio, there was a statisti¬
cally significant difference in the risk of experiencing
pneumonia in patients receiving SFC. However, the
duration of tire pneumonia and pattern of resolution
(identified from the DRC) were similar between
treatment groups. Although three subjects in tire SFC
arm of the study died of pneumonia, the overall
mortality was statistically significantly lower than
widr tiotropium,17 and the death rate from pneumonia
was not different from placebo in the larger TORCH
study.21
The DRCs had few missing data, at least up to the
time of diagnosis of the pneumonia and/or hospital¬
ization. The symptoms recorded reliably identify
COPD exacerbations.26 These DRC data enabled us
to use two related approaches to explore the rela¬
tionship between exacerbations and pneumonia in
a blinded analysis. Patients who received SFC were
more likely to meet our a priori criteria for a treated
or untreated exacerbation prior to pneumonia diag¬
nosis than those receiving Tio. The pattern-based
analysis supported this but also suggested that one-
half tire pneumonias during SFC treatment were asso¬
ciated with an ongoing or unresolved exacerbation.
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Time to event (weeks)
Figure 3. Kaplan-Meier plot of time to first pneumonia event by
baseline C-reactive protein levels.
Regional differences in the reporting of pneumo¬
nia existed; whether this reflects local diagnostic
custom requires a larger study to confirm. Increased
breathlessness during daily activity at baseline and
having a higherCRP at randomizationwere clearly pre¬
dictive of subsequent pneumonia risk. Breathlessness
is also associated with a poor prognosis independent
of lung function,27 whereas CRP is increased in
other chronic diseases and may indirectly reflect the
effect of comorbidity28; also, CRP is an indepen¬
dent marker of poor prognosis and hospitalization
in COPD.29 The CRP thresholds were based on the
cardiovascular literature.30 However, data from pneu¬
monia studies have shown that high CRP levels at
hospitalization predict 30-day mortality, whereas a
CRP > 9.6 mg/dL on day 3 of a community-acquired
pneumonia predicts late treatment failure.31-32 Our
data in patients with clinically stable COPD suggest
a CRP > 10 mg/L may be a marker of pneumonia
risk. Whether this reflects the presence of comorbidi¬
ties or of systemic inflammation secondary to the lung
disease remains unanswered. However, these risk
factors were similar in each treatment group and did
not explain the greater number ofpneumonia reports
with SFC.
Why might unresolved exacerbations be associated
with pneumonia in ICS-treated patients? Incorrect
diagnosis of pneumonia is possible, but unlikely, as
most episodes were confirmed radiographically and
the difference between Tio and ICS/LABA treatment
persisted when the analysis was restricted to radio-
graphically confirmed events. ICS use may lead the
patient to delay appropriate therapy, enabling intra-
bronchial sepsis to progress more peripherally. This is
possible, as there were few episodes in which Tio-
related pneumonias were preceded by an untreated
exacerbation. Inadequate antibiotic treatment might
lead to some exacerbations progressing to a pneumonic
illness, but this appears unlikely, as there were more
exacerbations treated with antibiotics in the patients
receiving SFC than in those receiving tiotropium
(0.85/y vs 0.69/y, respectively).17 Other possibilities
include an effect of ICS on the patient or the infec¬
tive organism, which may lead to persistent or slowly
resolving infection. Detailed mechanistic studies
and further clinical trials are needed to test these
explanations.
Our data have limitations. Like the TORCH trial-
ists, we did not expect to see an excess ofpneumonias
during treatment, so the definition of these events
was less robust than those for exacerbation, our pri¬
mary clinical outcome measure. However, our find¬
ing of a difference in the number of events and in the
preceding exacerbation history was robust, no matter
how the data were subdivided. There were fewer
pneumonia events than in the longer TORCH study,21
and tire data only applied to individuals who remained
in the study at the time of the pneumonia. Informa¬
tion about the severity, microbiology, pneumococ¬
cal vaccination, and the appropriateness of therapy
received for the reported pneumonia is limited.
Indeed, 16 pneumonia report patients received no
antibiotics and in 34 cases antibiotics were accompa¬
nied by an oral corticosteroid. Our DRCs have been
validated for COPD exacerbations rather than pneu¬
monia, but we know of no comparable study in which
symptoms have been prospectively recorded before
pneumonia has developed. Given the overlap between
symptoms of an exacerbation and pneumonia in
COPD, we believe our data remain relevant, even
though we have not captured all possible symptoms
that might lead to a pneumonia diagnosis. Some of
the reported and unreported events might have been
pneumonias that then persisted, although the asso¬
ciated symptoms of those events did not suggest this
and the difference between treatments still requires
an explanation. Our approach was descriptive, and its
objectivity was maximized by considering all symp¬
toms before classifying them as exacerbations and
relating these to the diagnosis ofpneumonia. In these
circumstances, post hoc statistical comparisons are
not appropriate and have not been reported. Finally,
our data relate only to fluticasone propionate and
may not apply to other inhaled corticosteroids,
such as budesonide. Whether there is a relationship
between budesonide use and pneumonia is currently
disputed.20-33 We know of no equivalent data about
the occurrence of prolonged symptomatic COPD
exacerbations in patients with COPD treated with
budesonide or of studies comparing the relative effec¬
tiveness of the different bronchodilator-corticosteroid
combination products. In these circumstances, a deci¬
sion about which drug to use will rely on individual
clinical judgment of the relative risks and benefits of
therapy.
In summary, the clinical path prior to pneumonia
diagnosis in patients with COPD can be markedly
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different. Some patients develop symptoms immedi¬
ately prior to presentation, whereas others are diag¬
nosed after a more protracted period of symptoms.
In the INSPIRE study, these latter events are mainly
seen in patients receiving ICS. Clinicians using ICS
in COPD should be alert to the possibility of pneu¬
monia developing, especially when an exacerbation
is slow to recover. Future studies will be needed to
define whether more active intervention in these cir¬
cumstances can prevent these infrequent but poten¬
tially important events.
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e-Appendix 1.
Definition of a pneumonia
The Steering Committee defined three types ofpneumonia event before reviewing the daily record card (DRC) data,
o Pneumonia following health care utilization (HCU) exacerbation: an episode preceded by an HCU
exacerbation that continues up to start of the event or resolved < 5 days before the event
o Pneumonia following untreated exacerbation as identified by symptom definitions: an episode preceded by a
symptom-defined exacerbation that continues up to start of the event or resolves < 5 days prior to the event but with
no associated HCU exacerbation within 5 days of event
o De novo pneumonia: abrupt onset and more than 5 days from any symptomatically defined exacerbation. This
may be preceded by occasional unsustained symptoms that do not meet the a priori definition of an exacerbation.
Definition of a prodrome event
A prodrome was defined in this study as the symptoms up to 35 days prior to the pneumonia event. Using this
system six types of pneumonia reports were defined as described,
o HCU exacerbation which resolved prior to pneumonia
o HCU exacerbation which was unresolved at the onset of the pneumonia
o Untreated exacerbation which resolved prior to pneumonia
o Untreated exacerbation which was unresolved at the onset of the pneumonia
o De-novo - No consistent pattern of symptoms prior to pneumonia
o Insufficient data to characterize the pneumonia
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